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PS 1-1 ASSESSMENT OF LONG-TERM IMPACT OF BEDAQUILINE-CONTAINING
REGIMENS ON BURDEN OF DRUG-RESISTANT TUBERCULOSIS IN INDIA, A
STATE TRANSITION MODEL ANALYSIS
Applied Health Economics (AHE)
Abela Mpobela Agnarson1, Vandita Gupta2, Lalit Raute2, Ravi Potluri3, Hitesh Bhandari4, Amit
Dhir4, Amit Kumar4, Chrispin Kambili5, Laurent Metz1 and Gunnar Mattson1, (1)New
Brunswick, NJ, (2)Mumbai, India, (3)New York, NY, (4)Gurugram, India, (5)Raritan, NJ
Purpose: To assess the impact of bedaquiline-containing regimens on the incidence, prevalence,
and mortality burden of drug-resistant tuberculosis (DR-TB) in India, following the 2018 update
of the World Health Organization (WHO) guidelines for the treatment of DR-TB that has
prioritized the use of bedaquiline in DR-TB treatment regimens.
Method:
A state transition model that allows patient flow and interaction between three disease states (TB
susceptible, latent TB, and active TB) and between drug-sensitive (DS) and DR-TB patients was
developed in MS Excel. Model inputs were sourced from published literature or were derived to
calibrate the model with metrics published by WHO. Future changes including faster and more
accurate diagnosis, the introduction of shorter regimens leading to improved adherence were
built in to estimate the baseline forecast over the period 2020 through 2040, without the
introduction of bedaquiline.
The model was then used to assess the impact of enhanced utilization of bedaquiline-containing
regimens on the incidence, prevalence and mortality of DR-TB in India through 2040 in two
scenarios differing in the treatment success rate of the regimens, 61%, and 80%, as compared to
46% success rate with standard-of-care treatment. A peak share of 95% for bedaquiline-based
regimens was considered to be attained by 2024; 50% of such use was in the form of shorter
regimens.
Result: In the baseline scenario without bedaquiline, the model predicts annual incidence of DRTB to decline by 1% to 10% in each five-year period from 2020 to 2040, prevalence by 3% to
11% and mortality by 7% to 16% (Table 1). Compared to the baseline, adoption of bedaquilinebased regimens resulted in a considerable drop in these metrics; the cumulative drop in incidence
over the 2020-2040 period increased by a further 70% and 123% respectively in the two success
rate scenarios, prevalence by 60% and 106% respectively, and mortality by 48% and 85%
respectively (Table 1).
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Conclusion: The study assesses increased adoption of bedaquiline-containing regimens for DRTB treatment to significantly reduce DR-TB burden in India, and provides added value to
evidence-based DR-TB public health policy. The use of bedaquiline-containing regimens lessens
DR-TB related illness and deaths, and potentially cuts down the chain of transmission.
Table 1
PS 1-2 OBTAINING STATE-SPECIFIC COSTS FOR ECONOMIC MODELLING IN
HEPATITIS C: A RETROSPECTIVE COSTING STUDY
Applied Health Economics (AHE)
Alexander Haines, MSc, Toronto Health Economics and Technology Assessment (THETA)
Collaborative, Toronto, ON, Canada, Zhan Yao, IC/ES, Toronto, ON, Canada, Hla Hla Thein,
MD, MPH, PhD, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada,
Toronto, ON, Canada, William W. L. Wong, PhD, School of Pharmacy, University of Waterloo,
Kitchener, ON, Canada and Murray D. Krahn, MD, MSc, FRCPC, University of Toronto and
University Health Network, Toronto General Hospital Research Institute, Toronto Health
Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada
Purpose: The most cited Canadian cost estimates used in hepatitis C (HCV) modelling studies
are phased-based. This broad estimation of cost is not best suited for Markov modelling that uses
more granular detail with regards to how HCV progresses. This study aimed to estimate the cost,
to the Ontario healthcare payer, of nine HCV-related health states: no cirrhosis, compensated
cirrhosis, decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), HCC & DC, liver
transplantation, liver related death, other death, and cured HCV.
Method: We performed a retrospective costing study using administrative health data from
databases held at the Institute for Clinical and Evaluative Studies (IC/ES). We identified
individuals with chronic HCV using Public Health Ontario laboratory data. Time from HCV
diagnosis until the end of follow-up was allocated to nine mutually exclusive health states. States
were defined using a validated set of diagnosis, procedure and death codes. Direct medical costs
were calculated for each state based on resources utilized whilst spending time in said state.
Result: Our results identified (n=48,239) individuals diagnosed with chronic HCV. The
following is the average 30-day cost calculated for each health state presented alongside the
frequently cited Canadian phased-based cost estimates by Krajden et al (2010).
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Conclusion: Our estimates are significantly higher than previous Canadian HCV estimates, but
congruent with other published Ontario and international costs. Our study also provides a more
detailed estimation of costs for HCV models that utilize a state-based approach. For example,
individuals with advanced liver disease have a single cost estimate using the phased-based
approach. Now they have five estimates based on the type of advanced liver disease they have,
ranging from $1,487 to $8,753 per 30 days. This will improve the accuracy of economic
evaluations used to evaluate strategies that tackle HCV.
PS 1-3 ASSESSING THE COST-EFFECTIVENESS OF LENVATINIB AS A FIRSTLINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN
CANADA
Applied Health Economics (AHE)
John J. Kim, Thomas McFarlane, BScPhm, PharmD, Stephen Tully, PhD and William W. L.
Wong, PhD, School of Pharmacy, University of Waterloo, Kitchener, ON, Canada
Purpose: In Canada, both lenvatinib and sorafenib are approved as first-line therapy for
unresectable hepatocellular carcinoma (HCC) but only sorafenib is publicly funded through
provincial special access programs. The objective of this study is to determine the comparative
cost-effectiveness of lenvatinib and sorafenib as a first-line therapy for unresectable HCC in
Canada.
Method: A state-transition model of unresectable HCC from a Canadian health care system
perspective was developed in the form of a cost-utility analysis. The model time horizon was five
years and the analyses were performed following the guidelines for economic evaluation by the
Canadian Agency for Drugs and Technologies in Health (CADTH). The efficacy of the model
was informed by a global phase 3, open-label, non-inferiority trial (REFLECT). Costs and
utilities were obtained from published literature. Probabilistic sensitivity analysis, deterministic
sensitivity analysis, and subgroup analysis, using overall survival hazard ratios with stratification
factors adjusted by baseline characteristics, were performed to test the robustness of the model.
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Effectiveness was measured in quality-adjusted life years (QALYs) and cost was measured in
2018 Canadian dollars.
Result: Lenvatinib dominated sorafenib in the base case analysis with an incremental cost of $23,719.34 and incremental effectiveness of 0.132 QALY, indicating a dominance due to greater
effectiveness at a lower cost. A probabilistic sensitivity analysis of 10,000 replications indicated
that lenvatinib remains a cost-saving measure in 64.87% of the simulations and cost-effective
76.12% of the time at a willingness-to-pay (WTP) threshold of $50,000. However, lenvatinib
failed to dominate sorafenib when the cost of sorafenib was decreased by 57%. Further analysis
of 15 patient subgroups outlined in the REFLECT trial showed that in all subgroups, lenvatinib
was cost-saving in at least 49% of the simulations and cost-effective at a WTP of $50,000 in at
least 67% of the simulations. Results of the subgroup analyses did not change the conclusion of
the study (Table 1).
Conclusion: Our analysis showed that lenvatinib was more effective at a lower cost than
sorafenib indicating that lenvatinib may be a cost-saving measure in patients with unresectable
HCC in Canada. However, it is important to consider that lenvatinib may fail to remain a costsaving measure if a significantly cheaper generic sorafenib becomes available in Canada.
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PS 1-4 COST-EFFECTIVENESS OF IMMEDIATE VENTRICULAR ASSIST DEVICE
IMPLANTATION IN PEDIATRIC HEART FAILURE PATIENTS
Applied Health Economics (AHE)
Anton L.V. Avanceña, MS1, David M. Peng, MD2, Josie Lee1, Kurt R. Schumacher, MD2,
Ming-Sing Si, MD2 and David W. Hutton, PhD1, (1)University of Michigan School of Public
Health, Ann Arbor, MI, (2)C.S. Mott Childrenʼs Hospital, Ann Arbor, MI
Purpose:
Pediatric patients with end-stage heart failure have demonstrated improved survival when
implanted with ventricular assist devices (VADs), particularly as a bridge to transplantation.
However, questions remain about the optimal timing of VAD implantation due to concerns about
adverse effects and costs. In this cost-effectiveness analysis, we compare immediate VAD
implantation compared to a watchful waiting approach using optimal medical management with
continuous inotropic therapy.
Method:
Using a Markov model, we simulated a cohort of pediatric patients with dilated cardiomyopathy,
a common cause of heart failure. We used a monthly cycle and twenty-year time horizon. We
estimated cost and benefits (in terms of quality-adjusted life years [QALYs]) from a healthcare
perspective discounted at 3% per year. Transition probabilities, costs, and utility weights were
taken from published and gray literature, which we supplemented with expert opinion where
there were gaps. We calculated the incremental cost-effectiveness ratio (ICER) and performed
one-way and probabilistic sensitivity analyses (PSA) using 10,000 Monte Carlo simulations to
understand the impact of parameter uncertainty in the main findings. Cost variables were
assigned gamma distributions, while transition probabilities and utilities were assigned beta
distributions.
Result:
In a base case analysis, the incremental costs and benefits of immediate VAD implantation
compared to medical management was $221,269 (2017 US$) and 0.21 QALYs, respectively,
resulting in an ICER of $1.04 million per QALY. One-way sensitivity analysis found that the
discount rate, the probability of heart transplantation among patients on VAD and medical
management, and the cost of VAD implantations exerted the most influence on the ICER, though
varying any of the parameters to their lowest and highest values did not bring the ICER close a
$100,000 per QALY willingness-to-pay (WTP) threshold. The PSA showed a 3% chance of
immediate VAD implantation to be cost-effective at a WTP of $500,000 per QALY and a 36%
chance at $1 million per QALY.
Conclusion:
Though VADs provide a net health benefit, immediate implantation is not likely to be a costeffective strategy compared to medical management based on commonly used ICER thresholds.
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Future research can explore the cost-effectiveness of immediate VAD implantation in patients
with other causes of heart failure in children.
PS 1-5 COST-EFFECTIVENESS OF ANTICOAGULANT AGENTS FOR TREATMENT
OF CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM
Applied Health Economics (AHE)
Shuchi Gulati, MD, Zizi Elsisi, BPharm, Smruti Deoghare, MRes and Mark Eckman, MD, MS,
University of Cincinnati, Cincinnati, OH
Purpose: Cancer-associated thromboembolism (CAT) afflicts up to 20% of cancer patients,
resulting in a more than 2-fold increased mortality compared to those without CAT. While low
molecular weight heparin (LMWH) has been the standard treatment for CAT, more recently
several direct oral anticoagulants (DOACs) have been tested in randomized controlled trials.
However, these agents have not all been compared head-to-head. The objective of our study was
to examine the cost-effectiveness of DOACs compared to the traditional LMWH.
Method: We constructed a 9-state Markov transition decision model to examine strategies of 1)
LMWH, 2) Apixaban, 3) Edoxaban, and 4) Rivaroxaban for the treatment of CAT. Data sources
included MEDLINE searches, bibliographies from relevant articles in English language, and
Center for Medicare/Medicaid Services 2018 data. We used a lifelong time horizon and a
healthcare system perspective. Outcomes measure included effectiveness measured in qualityadjusted life years (QALYs) and costs measured in 2019 U.S. dollars.
Result: Apixaban dominated all other strategies by being less costly and more effective than
LMWH or the other DOACs. All relative risks and hazard ratios were compared with LMWH.
One-way sensitivity analyses were conducted to examine the impact of uncertainty in selected
parameter values (relative risks, hazard ratios, costs of different agents, age and utilities). 1)
Apixaban remained cost-saving, unless the hazard ratio for recurrent VTE on Apixaban exceeded
3.8. It remained cost-effective with an incremental cost-effectiveness ratio (ICER) <
$50,000/QALY up to a hazard ratio 4.08. 2) Apixaban remained cost-saving till the relative risk
for major bleeding exceeded 1.58 and it remained cost-effective (ICER < $50,000/ QALY) up to
a relative risk of 1.61. However when the relative risk for major bleeding exceeded 1.7, the ICER
exceeded $150,000/QALY. 3) Apixaban remained cost saving as long as its monthly cost
remained under $270; it was no longer cost-effective (ICER > $50,000/ QALY) when its
monthly cost exceeded $299
Conclusion: Treatment of CAT with Apixaban is both more effective and less costly than the
current mainstay of CAT treatment, LMWH.
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PS 1-6 HEALTHCARE COST ATTRIBUTABLE TO BRONCHIOLITIS: A
POPULATION-BASED MATCHED COHORT STUDY IN ONTARIO, CANADA
Applied Health Economics (AHE)
Beate Sander, PhD1, Hong Lu, MSc, PhD2, Chenthila Nagamuthu2, Erin Graves2, Jeffrey
Kwong, MD, MSc, CCFP, FRCPC2, Yaron Finkelstein, MD3 and Suzanne Schuh, MD3,
(1)Toronto Health Economics and Technology Assessment (THETA) Collaborative, University
Health Network, Toronto, ON, Canada, (2)ICES, Toronto, ON, Canada, (3)The Hospital for Sick
Children, Toronto, ON, Canada
Purpose: To determine attributable healthcare costs in infants with bronchiolitis from the
Ontario Ministry of Health and Long-Term care perspective.
Methods: Using a matched-cohort incidence-based cost-of-illness approach, we identified
infants <12 months of age who presented to an emergency department (ED) or were admitted to
a hospital with acute bronchiolitis (International Classification of Diseases 10th Revision [ICD10-CA] code J21 or J12.1) between April 1, 2003 and March 31, 2014, in linked populationbased Ontario administrative data. We assigned the first instance of ED visit/hospitalization or
physician visit occurring within two days prior to the ED visit/hospitalization as the index date.
We propensity-score matched unexposed subjects (infants without bronchiolitis) to exposed
subjects 1:1. Variables included sex, age (days), neighborhood income quintile, rurality, presence
of complex chronic conditions, gestational weeks at time of birth, small-for-gestational-age
status, and pre-index healthcare cost deciles. We calculated mean attributable 1-year costs (2018
Canadian Dollars). We calculated 95% confidence intervals (95%CI) using a generalized
estimating equation (GEE) model. We stratified costs by age group, sex, neighborhood income
quintile, rurality, presence of complex chronic conditions and premature birth.
Results: We identified 58,375 infants with bronchiolitis. Mean age was 154 days (standard
deviation=±96.6) , majority were male (61%), and tended to live in the lowest income quintile
neighborhood (26%) in urban centers (87%). Four percent had at least one complex chronic
condition. Almost 90% were born at term and did not meet the threshold for low birth weight.
Total mean 1-year costs attributable to bronchiolitis were $4,313 per patient (95%CI: $4,148,
$4,477). Inpatient hospitalizations represented the highest cost burden [$2,847 (95%CI: $2,712,
$2,982)], followed by physician services [$610 (95%CI: $594, $627)], ED visits [$562 (95%CI:
$556, $567)], other health care costs [$259 (95%CI: $222, $297)], and drug costs [$35 (95%CI:
$27, $42)]. Mean attributable 1-year costs were higher among infants <3 months of age [$5,536
(95%CI: $5,216, $5,856)], with at least one complex chronic condition [$17,530 (95%CI:
$14,683, $20,377)], or premature birth [$5,509 (95%CI: $4,927, $6,091)].
Conclusions: Bronchiolitis in infants is associated with increased healthcare costs, with higher
costs persisting at 1-year post index date. High quality cost data is critical for strategic healthcare
planning and the economic evaluation of potential intervention strategies to support sound health
policy decision-making.

E8

Medical Decision Making 40(1)

PS 1-7 COST-EFFECTIVENESS ANALYSIS OF A PHARMACIST-LED
ANTIMICROBIAL STEWARDSHIP PROGRAM AT A TERTIARY TEACHING
HOSPITAL IN ETHIOPIA
Applied Health Economics (AHE)
Gebremedhin Beedemariam Gebretekle1, Makeda Semret2, Stephen Mac3, Damen Haile
Mariam4, Teferi Gedif Fenta1, Workeabeba Abebe5, Tinsae Alemayehu5, Wondwossen
Amogne5, Michael Libman2, Cedric Yansouni2 and Beate Sander6, (1)Social and Administrative
Pharmacy Unit, School of Pharmacy, Addis Ababa University, Ethiopia, Addis Ababa, Ethiopia,
(2)J.D. MacLean Centre for Tropical Diseases and McGill University, Montreal, Canada,
Montreal, QC, Canada, (3)Toronto Health Economics and Technology Assessment (THETA)
Collaborative, Toronto, ON, Canada, (4)School of Public Health, Addis Ababa University, Addis
Ababa, Ethiopia, (5)School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia,
(6)Institute of Health Policy, Management and Evaluation, University of Toronto; Toronto
Health Economics and Technology Assessment (THETA) Collaborative, University Health
Network; Institute for Clinical Evaluative Sciences; Public Health Ontario, Toronto, ON, Canada
Purpose: Antimicrobial stewardship (AMS) significantly reduces inappropriate antibiotics use
and improves patient outcomes. In low-resource settings, AMS implementation may require
concurrent strengthening of clinical microbiology capacity, requiring additional investments. We
assessed the cost-effectiveness of a pharmacist-led AMS program compared to usual care in a
tertiary care hospital in Ethiopia.
Method: We developed a Markov cohort model to assess the cost-utility of pharmacist-led AMS
with concurrent strengthening of clinical microbiology capacity compared to usual care from a
“restricted societal” perspective in a mixed inpatient population. Primary outcomes were
expected life years, quality-adjusted life years (QALYs), costs (US$2018), and the incremental
cost-effectiveness ratio (ICER). We used a lifetime time horizon and discounted health outcomes
and cost at 3%. Data were derived from a prospective observational study of blood stream
infections among patients hospitalized at Tikur Anbessa Specialized Hospital, Ethiopia,
supplemented by the published literature. We assessed parameter uncertainty using deterministic
and probabilistic sensitivity analyses.
Result: Pharmacist-led AMS dominated usual care, i.e., AMS was associated with an expected
incremental gain of 0.0387 QALYs at lower expected cost (incremental cost: $81.51) compared
to usual care. Findings were sensitive to medication cost, infection-associated mortality and
AMS-associated mortality reduction. Probabilistic sensitivity analysis demonstrated that
Pharmacist-led AMS was likely to be cost-effective compared to usual care at 1xGDP/capita per
QALY.
Conclusion: Our study indicates that pharmacist-led AMS can result in improved health
outcomes and substantial healthcare cost savings, demonstrating its economic advantage in a
tertiary care hospital despite greater upfront investments in a low-resource setting.

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E9

PS 1-8 IDENTIFYING A RISK THRESHOLD FOR ANTIBIOTIC RESISTANCE IN
PATIENTS HOSPITALIZED WITH COMMUNITY ACQUIRED PNEUMONIA: A
DECISION ANALYTIC MODEL
Applied Health Economics (AHE)
Phuc Le, PhD, MPH and Michael Rothberg, MD, MPH, Cleveland Clinic, Cleveland, OH
Purpose:
Community acquired pneumonia (CAP) is a common cause of hospitalization, morbidity and
mortality. Clinical guidelines recommend empiric therapy with a beta-lactam plus a macrolide,
and antipseudomonal beta-lactam (for Gram- organisms) plus vancomycin (for Gram+) for
patients at high risk for resistant organisms. The decision to broaden coverage must balance
increased efficacy with drug toxicity—primarily acute kidney injury (AKI) and Clostridium
difficile infection (CDI) —but no threshold for “high risk” has been defined. We created a
decision model to identify a risk threshold for antibiotic resistance at which the benefits of
broader spectrum regimens outweigh the harms.
Methods:
We included patients aged ≥18 years hospitalized for CAP. Our decision model had two
components: a decision-tree representing events within 30 days of hospitalization and a lifetime
Markov model. We compared quality-adjusted life years (QALYs) of 4 antibiotic strategies: a
macrolide plus 3rd generation cephalosporin (CAP therapy), CAP therapy plus vancomycin,
piperacillin/tazobactam, and piperacillin/tazobactam plus vancomycin. The model tracked
admission to ICU, and antibiotic adverse events including CDI, AKI, chronic dialysis, and death.
Probability of Gram+ or Gram- bacteria resistant to CAP therapy were varied from 0% to 10% to
identify a threshold for treatment with either vancomycin or piperacillin-tazobactam. We
assumed vancomycin was 100% effective against Gram+ bacteria and piperacillin-tazobactam
was 88% effective against Gram- bacteria. Patients with bacteria resistant to the antibiotic chosen
had a higher risk of being admitted to the ICU, inhospital mortality, and 30-day readmission than
those having sensitive bacteria. The risk of AKI and CDI varied by antibiotic class. Patients
experiencing AKI were at increased risk for dialysis and death. QALYs were discounted at 3%
per year.
Results:
In the base-case assuming a 1% risk of resistance, CAP therapy was the best strategy with 4.96
QALYs gained compared to broader spectrum regimens. In threshold analysis,
piperacillin/tazobactam was preferred if the probability of Gram- resistance exceeded 5.36%, and
vancomycin if the probability of Gram+ resistance exceeded 3.59%.
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Conclusions:
For most adult patients hospitalized with CAP, a macrolide plus 3rd generation cephalosporin is
the optimal regimen. Broader spectrum antibiotics improve outcomes for only a small portion of
patients at high risk for resistant organisms.
PS 1-9 COST-EFFECTIVENESS OF EMPIRIC TREATMENT STRATEGIES FOR
SUSPECTED UNCOMPLICATED URINARY TRACT INFECTIONS IN THE
EMERGENCY DEPARTMENT SETTING
Applied Health Economics (AHE)
Raphael Sherak, MPH, Albert Einstein College of Medicine, Bronx, NY, Bryan Hayes,
PharmD, Massachusetts General Hospital, Boston, MA, Allison Portnoy, MSPH, Harvard T.H.
Chan School of Public Health, Dept. of Global Health and Population, Boston, MA, Jane Kim,
PhD, Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston,
MA, USA., Boston, MA and Ankur Pandya, PhD, Center for Health Decision Science,
Department of Health Policy and Management, Harvard T.H. Chan School of Public Health,
Boston, MA
Purpose: Urinary tract infections (UTIs) are the 9th most common reason for Emergency
Department (ED) visits in the United States (US) and are a leading source for ED antibiotic
prescriptions. Clinicians must balance the efficacy of various antibiotic options against their
side-effect profiles, as improperly treated UTIs can progress to a kidney infection, while
overtreatment exposes patients to unnecessary risks and costs. Clinicians may delay initiating
treatment for 72 hours for the results of a urine culture to confirm the UTI diagnosis and detect
any antibiotic resistance. The Infectious Disease Society of America (IDSA) recommends
discontinuing the empiric usage of Ciprofloxacin at local resistance rates greater than 10%.
Method: We built a decision tree model to compare the following interventions for suspected
UTIs in the ED including empiric treatment with: (1) Nitrofurantoin; (2) Ciprofloxacin; (3)
Cephalexin; (4) Trimethoprim-Sulfamethoxazole; (5) Fosfomycin; or (6) waiting for urine
culture result. Model input parameters were estimated from published sources. In the model,
patients return to the ED if they fail initial treatment and are able to switch treatment strategies if
their urine culture demonstrates resistance to their initial treatment. Patients with urine culture
results are prescribed the most cost-effective antibiotic that their infection is sensitive to (at a
willingness-to-pay [WTP] of $100,000/quality-adjusted life year [QALY]). Costs (health care
sector perspective) and QALYs were projected over a one-year time horizon from the initial ED
visit.
Result: Nitrofurantoin (strategy 1) and Ciprofloxacin (strategy 2) resulted in costs of $33.43 and
$36.55 and effects of 0.99897 and 0.99899 QALYs respectively. All other strategies had higher
costs and lower effects (i.e., strongly dominated). The incremental cost-effectiveness ratio for
Ciprofloxacin vs. Nitrofurantoin was $131,300/QALY. In probabilistic sensitivity analyses,
Nitrofurantoin was the most cost-effective option 36% of the time followed by Ciprofloxacin
(31%) and Cephalexin (28%) at a WTP of $100,000/QALY. In a scenario with no antibiotic
resistance, Ciprofloxacin was the only non-dominated strategy. At a probability of resistance
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greater than 3.1%, Ciprofloxacin ceases to be the most cost-effective strategy at a WTP of
$100,000/QALY.
Conclusion: Only 1 of 5 antibiotics (Nitrofurantoin) recommended for the treatment of UTIs
proved cost-effective at a willingness to pay of $100,000/QALY. Our results suggest a far lower
threshold for the discontinuation of empiric usage of Ciprofloxacin than the IDSA.
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PS 1-10 CAN WE ESTIMATE THE ECONOMIC VALUE OF POPULATION
GENOMIC SCREENING? CHALLENGES IN ESTIMATING BRCA1/2 CARRIERS’
UPTAKE OF RISK-REDUCING SURGERIES IN GENERAL POPULATIONS
Applied Health Economics (AHE)
Jing Hao, PhD, MD, MS, MPH1, Dina Hassen, MPP1, David Veenstra, PharmD, PhD2,
Gregory Guzauskas, MSPH, PhD2, Marc Williams, MD1, Josh Peterson, MD, MPH3 and Susan
Snyder, PhD, MBA1, (1)Geisinger, Danville, PA, (2)The Comparative Health Outcomes, Policy,
Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, WA,
(3)Vanderbilt University, Nashville, TN
Purpose:
Estimating the economic value of population-level genomic screening is of considerable policy
significance given the interest in broadly implementing precision medicine. Population screening
is likely to focus on CDC Tier 1 conditions, which include hereditary breast and ovarian cancer
syndrome (HBOC), Lynch syndrome, and familial hypercholesterolemia. A key driver of value
is clinicians’ and patients’ uptake of recommended actions based on test results, yet current
estimates of uptake are based entirely on high-risk populations with a personal or family history
of the condition. The purpose of this study was to estimate the adoption of risk-reducing
surgeries among an average risk population found to have BRCA 1/2 variants, and to inform a
cost-effectiveness model.
Method:
We reviewed electronic health record (EHR) data from a retrospective female population of
BRCA1/2 carriers without a personal history of breast or ovarian cancer (unaffected) enrolled in
Geisingerʼs MyCode Health Initiative. MyCode is a population genomic screening program
where adult volunteers undergo exome sequencing and receive medically actionable results. The
study cohort had at least 1-year post-return of results follow up. Overall uptake of risk-reducing
mastectomy and oophorectomy was measured for the 1st year post-return of results and further
stratified by age, variant in BRCA1 or BRCA2, family history of breast and ovarian cancer, and
whether BRCA mutation status was previously known.
Result:
We identified 59 patients as the study cohort out of a total 50,726 MyCode participants. The
median age was 52 (24-90); 64% with a family history, 24% without, and 15% with missing
family history information. Mastectomy and oophorectomy uptake during the 1st year of follow
up was 3.5% and 11.8%, respectively. Stratified uptake results are detailed in Table 1.
Conclusion:
Published literature based on high-risk unaffected female BRCA1/2 carriers indicate that in the
1st year post-genetic testing, the uptake of mastectomy and oophorectomy was about 10% and
30-45% respectively, approximately 3 times that seen in the MyCode population. We conclude
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that the uptake of risk-reducing surgery may be lower in women ascertained through population
genetic screening. However, studying uptake at the population level is challenging because of
differences in risk profiles, e.g. age, family history, socioeconomic status and other population
characteristics, and the need of larger sample size from more population genomic screening
programs.
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PS 1-11 INCORPORATING PERSONALIZED RISK PREDICTION INTO CLINICAL
DECISION SUPPORT: A RANDOMIZED CONTROLLED TRIAL FOR POSTMASTECTOMY BREAST RECONSTRUCTION
Decision Psychology and Shared Decision Making (DEC)
Mary Politi, PhD, Washington University, St. Louis, MO, Clara Lee, MD, MPP, The Ohio State
University, Columbus, OH, Sydney Philpott-Streiff, MPH, Washington University in St. Louis,
School of Medicine, St Louis, MO, Randi Foraker, PhD, MA, FAHA, Division of General
Medical Sciences, Washington University in St Louis, School of Medicine, St Louis, MO,
Margaret Olsen, PhD, MPH, Division of Infectious Disease, Department of Medicine,
Washington University in St Louis, School of Medicine, St Louis, MO, Corinne Merrill, BSN,
RN, CCRN, Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington
University in St Louis School of Medicine, St Louis, MO, Yu Tao, MS, Division of Public
Health Sciences, Department of Surgery, Washington University in St Louis, School of
Medicine, St Louis, MO and Terence Myckatyn, MD, Division of Plastic and Reconstructive
Surgery, Department of Surgery, Washington University in St. Louis, School of Medicine, St
Louis, MO
Purpose: Although numerous decision aids have been developed in research settings, their
implementation in practice remains limited. Incorporating personalized risk prediction into
clinical decision support might encourage engagement by patients and clinicians in decision aid
implementation. Post-mastectomy breast reconstruction is a preference-sensitive choice with a
high rate of complications, particularly for immediate reconstruction. We evaluated a web-based
breast reconstruction decision aid, BREASTChoice, which incorporates personalized risk
prediction, patient education, values clarification, and a one-page summary for use at the pointof-care.
Methods: Adult women with stages 0-III breast cancer considering post-mastectomy breast
reconstruction were randomized to BREASTChoice or enhanced usual care (EUC). Patients
completed surveys before and after surgery. We assessed clinical and implementation outcomes,
including: breast reconstruction knowledge, decisional conflict, decision quality, patient
activation, shared decision-making, preferences, type and timing of surgery, tool usability, and
consultation length.
Results: 376 patients were screened; 120/172 (69.8%) eligible patients enrolled. Their mean age
was 50.7 years (range 25-77). Most were Non-Hispanic White (86.3%) and had a college degree
(64.3%). 90% chose to complete BREASTChoice at home, before the visit. Adjusting for health
literacy and provider, BREASTChoice users had higher knowledge than EUC (84.6% vs. 58.2%
correct; p<0.001). Those using BREASTChoice were more likely to know that reconstruction
typically requires more than one surgery, delayed reconstruction lowers oneʼs risk, and implants
may need replacement (all ps<0.002). BREASTChoice participants felt more confident
understanding reconstruction information (p=0.009). There were no differences between groups
in decisional conflict, decision process quality, shared decision-making, preferences, type or
timing of surgery, (all ps>0.05), or consultation length (mean=29.7 minutes (BREASTChoice) vs.
30.0 (EUC); p>0.05). BREASTChoice had high usability (mean score=6.3/7). Participants
completed BREASTChoice in about 27 minutes. Clinicians described BREASTChoice as highly
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relevant and useful, particularly given the personalized risk profile. They suggested EHR
integration to better support shared decision-making at the point-of-care.
Conclusions: BREASTChoice may improve breast reconstruction decision quality by improving
patients’ knowledge and providing personalized risk estimates. Future work should focus on
incorporating BREASTChoice directly into the EHR to facilitate point-of-care decision support.
This process could help further engage both clinicians and patients in discussing breast
reconstruction.
PS 1-12 A 1-QUESTION METHOD FOR DISENTANGLING ABSOLUTE VERSUS
RELATIVE GIST RISK PERCEPTIONS: EVIDENCE FROM A LARGE SAMPLE OF
THYROID CANCER PATIENTS
Decision Psychology and Shared Decision Making (DEC)
Brian J. Zikmund-Fisher, PhD1, David Reyes-Gastelum, MS1, Ann Hamilton, PhD2, Kevin
Ward, PhD, MPH3 and Megan Haymart, MD1, (1)University of Michigan, Ann Arbor, MI,
(2)University of Southern California, Los Angeles, CA, (3)Emory University, Atlanta, GA
Purpose: Assessing patient risk perceptions is difficult. Most measurement approaches either
rely on numerical estimates of absolute risk (which are subject to numeracy-related biases) or use
subjective rating scales (which are impossible to categorize as accurate). We sought to improve
clarity by asking patients with elevated gist risk perceptions to clearly state whether they
perceive themselves at increased risk relative to others versus at substantially higher absolute
risk.
Methods: We developed a single question that asked patients with well differentiated thyroid
cancer to categorize their perceptions of their future mortality risk into one of 3 categories: (a)
“similar” to the risk of friends their age without thyroid cancer, (b) higher than friends’ risk, but
“very small”, or (c) higher than friends’ risk but “significant.” We administered this question as
part of a larger survey of thyroid cancer patients identified through the SEER registries in
Georgia and Los Angeles. Here, we present a multinomial logistic regression analysis exploring
associations between question responses and patient demographic characteristics (while
controlling for disease characteristics) among the 2305 patients with low (<5% 10-yr) mortality
risk.
Results: Overall, 70% of low risk thyroid cancer patients categorized themselves as having
similar risk as disease-free others, 24% described their risk as higher but very small, and 6%
described their risk as significant. In multinomial logistic regression analyses that controlled for
disease status (tumor and lymph node classification) and used the similar risk group as reference,
younger patients were much more likely to categorize themselves as having elevated relative risk
but very small absolute risk (Age 18-44: Relative Risk Ratio (RRR)=1.91, t=3.59, p<.001; Age
45-54: 1.96, t=3.64, p<.001 vs. age 65-74 group). By contrast, age was not a predictor of beliefs
of being at significant risk. Instead, male patients (RRR=1.64, t=2.39, p=.02 vs female), Hispanic
patients (RRR=2.37, t=3.62, p<.001 vs. White), Asian patients (RRR=2.15, t=2.43, p=.02 vs.
White), and patients with lower education levels (≤HS: RRR=2.33, t=3.34, p<.001 vs. ≥ College)
were all more likely to report elevated absolute risk perceptions.
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Conclusions: A simple, 3-response question appears effective at categorizing patients’ gist risk
perceptions in both relative and absolute terms without resorting to numerical estimation. These
perceptions appear substantially related to individual characteristics such as age, gender, race /
ethnicity, and education.
PS 1-13 DECISION-MAKING NEEDS, CHALLENGES, AND OPPORTUNITIES
AMONG HEALTH CARE PROFESSIONALS SUPPORTING INFANT FEEDING
CHOICES: A QUALITATIVE INVESTIGATION INVOLVING EXPERT INTERVIEWS
Decision Psychology and Shared Decision Making (DEC)
Sarah Munro, PhD, University of British Columbia; Centre for Health Evaluation and Outcome
Sciences, Vancouver, BC, Canada, Julie Sou, MSc, Centre for Health Evaluation and Outcome
Sciences, Vancouver, BC, Canada and Nick Bansback, PhD, School of Population and Public
Health, University of British Columbia; Centre for Health Evaluation and Outcome Sciences,
Vancouver, BC, Canada
Purpose:
Although on balance, human milk confers more health benefits in comparison to formula,
breastfeeding may not be the optimal choice for a given family at a given time. Shared decisionmaking (SDM) can improve patient-centred care for infant feeding choices. We aimed to identify
the decision-making needs, challenges, and opportunities among health care professionals
supporting infant feeding choices.
Method:
In-depth, one-on-one, one-hour interviews were conducted with health care professionals
(registered and public health nurses, physicians, midwives, lactation consultants, and dieticians)
in British Columbia, Canada, who had expertise in supporting families’ infant feeding decisions.
Interviews explored participants’ perceptions of SDM, including: examples of infant feeding
decisions; barriers and facilitators to engage in SDM for infant feeding; learning needs for
integrating new skills; and patients’ infant feeding decisional needs. Participants were sought
through third-party recruitment and snowball sampling. Data collection and analysis were
concurrent and involved the following stages: open coding for analytic ideas to pursue; constant
comparison of data; focused coding to identify and organize codes into batches of similar or
related phenomena; and theoretical coding to synthesize the data into categories.
Result:
Analysis of interviews with 28 health care professionals highlighted that participants
misunderstood that SDM is a shared process, not necessarily a shared final decision. Participants
engaged in information exchange to learn how to support each parent to reach breastfeeding
goals. Information exchange did not aim to assist each parent to gain clarity about their values or
consider feeding options that match what matters most to them. Participants demonstrated skills
in other techniques that may complement an SDM approach, such as trauma-informed care and
motivational interviewing. Our analysis identified three critical time points where an SDM
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approach may better support infant feeding choices: 1) before pregnancy when parents are
considering options and making plans, 2) during the early postpartum in hospital where
decisional conflict may be high as parents' choices are put into practice and feeding challenges
arise, and 3) from hospital discharge to 6 months in primary and community care, when parents
adjust to the reality of feeding their infant.
Conclusion:
Health care professionals engage in some components of SDM to achieve their breastfeeding
health promotion objectives, but there is room for improvement to decrease bias and improve
values-informed decision-making.
PS 1-14 DOES A LUNG CANCER SCREENING DECISION AID IMPROVE
KNOWLEDGE OF SCREENING HARMS AND BENEFITS AND DOES KNOWLEDGE
AFFECT INTENT TO SCREEN?
Decision Psychology and Shared Decision Making (DEC)
Stephen Clark, MD, Chapel Hill, NC, Alison Brenner, PhD, Cecil G Sheps Center for Health
Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, Daniel
Reuland, MD, MPH, UNC Department of Medicine, Chapel Hill, NC and Michael Pignone, MD,
MPH, UT-Austin Dell Medical School, Austin, TX
Purpose: The USPSTF recommends shared decision making to help patients understand the
benefits and harms of lung cancer screening (LCS), and Medicare requires a decision aid to
facilitate this discussion. Whether decision aids improve knowledge of benefits and harms and
how improved knowledge relates to screening intention is unknown. We examined the effect of a
LCS decision aid on knowledge in a screen-eligible population (current or former smokers who
quit less than 15 years ago, aged 55-80 with >30 pack-years of smoking) and evaluated how
changes in knowledge relate to screening intention.
Method: We conducted a web-based survey of screen-eligible participants recruited though
national online panels, and performed a single group pre-post experiment using a previously
developed and validated, brief (3 minute) multi-media LCS decision aid. Participants answered
10 previously validated questions about key potential benefits and harms of screening, including
over-diagnosis. Respondents then indicated their intention to screen (1-4 scale; 1=not likely,
4=very likely).
Result: Among 269 USPSTF-eligible respondents who began the survey, 185 (62.5%)
completed it. Respondents were 56.2% female, 80.5% white, 60.5% current smokers, 30.3% high
school degree or less, 62.2% annual income < $50,000, and 73.0% Medicare, Medicaid or
military insurance. Baseline knowledge was low and increased following decision aid viewing:
(mean pre-decision aid knowledge score 2.8 vs 5.4 post-decision aid, diff 2.5, 95%CI 2.1, 2.9,
p<0.001). Proportions of respondents able to correctly identify the likelihood of benefiting from
screening increased after decision aid viewing (pre 16.2% vs. post 39.5%, p<0.001), as did the
proportion who accurately estimated the likelihood of being overdiagnosed with screening
(25.4% vs 46.0%, p<0.001). Screening intentions post-decision aid were mixed, with 22.2% “not
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likely” to pursue screening, 26.5% “very likely”; mean intent 2.6 ± 1.1. Those not likely to
pursue screening had higher mean post-decision aid knowledge and higher mean pre-post
knowledge change than those who were very likely (mean post knowledge 6.0 vs 4.8, diff 1.2,
95%CI 0.2, 2.2, p=0.016; mean pre-post difference 3.2 vs 1.8, diff 1.5, 95%CI 0.5, 2.4, p=0.003).
Conclusion: A brief decision aid substantially increased knowledge about benefits and harms of
LCS. Screening intentions were heterogeneous, as expected for a preference-sensitive condition.
Participants expressing the least intention of screening had higher knowledge scores than those
with the greatest intent.
PS 1-15 MEASURING SHARED DECISION MAKING: UNDERSTANDING SHARED
DECISION MAKING ACROSS CLINICAL CONDITIONS AND TOPICS.
Decision Psychology and Shared Decision Making (DEC)
Ha Vo, MPH1, KD Valentine, PhD1, Suzanne Brodney, PhD, RD2, Floyd Fowler, PhD3, Michael
Barry, MD2 and Karen Sepucha, PhD2, (1)Massachusetts General Hospital, Boston, MA,
(2)Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA,
(3)Center for Survey Research, University of Massachusetts, Boston, Boston, MA
Purpose:
To extend our understanding of the performance of the Shared Decision Making (SDM) Process
scale and determine whether and how the scores vary by clinical context, type of decision, and
item content.
Method:
Secondary data analysis was conducted across 7 large retrospective and prospective studies of 14
clinical conditions totaling 9021 responses. Verbiage, content, and number of items varied by
study and condition. Given the variety of items, both a short and a long version of the SDM
Process scale are compared here. Short scales (4-5 items) contained about one item for each of
the four basic concepts (providing options, discussing pros, discussing cons, and gauging
patients’ preference); long versions (5-8 items) contained all items from the short version as well
as additional option, pro, con, or preference items. Summed scores added items together. Short
and long versions were scaled to range from 0-4. We examined scores across different clinical
context for different decisions (cancer screening, medication and surgical), conditions
(symptomatic and non-symptomatic), and item content (additional preference or information
items).
Result:
When all conditions are combined, the average SDM Process score was similar for both long and
short versions (Mshort=2.09, SDshort=1.25; Mlong=2.07, SDlong=1.24). However, SDM Process
scores did differ by condition. Patients considering screening had lower SDM Process scores
across versions (M=1.60, SD=1.14) than those considering either medications (M=2.20,
SD=1.25; p<.001) or surgery (M=2.21, SD=1.24; p<.001). Patients with non-symptomatic
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conditions showed lower SDM Process scores across versions (M=1.82, SD=1.21) than those
with symptomatic conditions (M=2.22, SD=1.25; p<.001). When investigating potential
differences between the long versions of the scale, we found that long versions that contained
additional preference questions had lower process values (M=2.03, SD=1.25) as compared to
those whose additional items were made up of option, pro, or con items (M=2.14, SD=1.22;
p<.001).
Conclusion:
SDM Process scores showed resilience to coding changes. SDM Process scores varied by
decision type (e.g. screening vs. surgery), as well as by condition experience (e.g. symptomatic
v. non-symptomatic). Overall, there is considerable room for improvement in SDM across these
conditions. Further, SDM Process scores were lowered when additional preference questions
were included, suggesting that the current version (in which 3/4 of the score is based on
informational elements) may be underweighting discussion of patient goals and concerns.
PS 1-16 TESTING A SINGLE-ITEM IMPLICIT CAUSALITY TASK TO MEASURE
PERCEIVED AGENCY IN SHARED DECISION MAKING
Decision Psychology and Shared Decision Making (DEC)
Julia Nolte, MS, Valerie F. Reyna, PhD and Corinna Loeckenhoff, PhD, Cornell University,
Ithaca, NY
Purpose:
Implicit causality tasks can be used to assess causal attribution in contexts where self-reports are
unreliable. Here, we test whether a single-item implicit causality task can measure how people
ascribe agency in shared decision making contexts. Although patients typically welcome shared
decision making, not all patients might perceive themselves as active agents of the decision
process. This is especially true for older adults who are accustomed to more paternalistic
decision making models. In a direct comparison, we hypothesize that older adults will ascribe
less agency to patients and more agency to physicians than younger adults do.
Method:
Fifty-four younger adults (18 – 30 years, M = 25.78, SD = 3.01) and 70 older adults (60 – 88
years, M = 70.49, SD = 8.96) completed an implicit causality task as part of an hour-long
laboratory-based study. Participants evaluated whether the sentence “The doctor gave the patient
information because...” (or “The patient was given information by the doctor because...”) would
continue with “the doctor” or “the patient”. Choosing “the doctor” indicates ascribing agency
to the physician, whereas choosing “the patient” ascribes agency to the patient. In addition,
participants reported their preferred and actual role in shared medical decision making as well as
their self-efficacy and experience choosing healthcare plans.
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Result:
As intended, responses did not differ between the active-voice and the passive-voice version of
the sentence. Seventy-five participants (60.5%) chose “the patient”, whereas 49 participants
(39.5%) chose “the doctor”. Contrary to our hypothesis, age groups were equally likely to select
“the doctor” or “the patient”, indicating that there are no age differences in perceived patient
agency. In addition, choosing either of the two responses was not linked to ideal or experienced
engagement in shared decision making, participants’ experience choosing healthcare plans, or
their health-related self-efficacy.
Conclusion:
A single-item implicit causality task seems insufficient to capture perceived patient agency in
shared decision making contexts. As task wording was focused on information-acquisition, it is
possible that our task was more suitable to assess perceived agency in informed decision making
rather than shared decision making contexts.
PS 1-17 EXPLORING LAY PERCEPTIONS OF THE CAUSES OF CONFLICTING
SCIENTIFIC CLAIMS
Decision Psychology and Shared Decision Making (DEC)
Nathan Dieckmann, PhD, Oregon Health & Science University; Decision Research, Portland,
OR and Branden Johnson, PhD, Decision Research, Eugene, OR
Purpose: There has been increasing attention to understanding how lay citizens explain and act
on conflicting scientific claims. Within the health arena, these conflicts typically take the form of
competing, or disputing, advice about what is healthy or safe. We conducted a series of large,
national survey studies examining lay citizens’ perceptions of the causes of scientific disputes.
We also examined the impact of several individual difference factors including science
knowledge, perceived credibility of science, and political ideology on these perceptions.
Method: We report results from three large, national online experiments (N~2000 across
studies). Participants were randomly assigned to different scientific dispute topics. In this
presentation, we focus on the health-related topics of 1) the risks and benefits of marijuana, 2)
advice about dietary salt intake, and 3) the use of nanotechnology for improving health.
Result: Public perceptions as to why scientists disagree on these topics were grouped into three
main categories: 1) Process/Competence: Some scientists are more competent than others, 2)
Interest/Values: Personal interests or social forces are biasing some scientific claims, and 3)
Complexity/Uncertainty: Conflicting claims are the result of the complexity and uncertainty
inherent in the topic. We find that the perceived likelihood of these different explanations varied
across topic. There was also a complex set of individual-level predictors that accounted for
variability in these explanations including having heard of scientific disputes in the past, caring
about the topic, general science knowledge, perceived credibility of science, and political
ideology.
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Conclusion: These results are important because they describe the causal attributions that lay
people are likely to make when confronted with conflicting health information. The perceived
causes of conflicting health information can have implications for ongoing trust in the
scientific/health community as well as the concrete actions taken in response to specific health
advice (e.g., one may act differently if the conflict is perceived to be caused by biased, selfinterested scientists vs the complexity of the topic under study). We discuss the implications of
these results in the context of communicating health-related scientific claims in the presence of
conflicting evidence.
PS 1-18 THE IMPACT OF A PHYSICIANʼs RECOMMENDATION AND GENDER ON
INFORMED DECISION MAKING
Decision Psychology and Shared Decision Making (DEC)
Marie Eggeling, Master of Science1, Martina Bientzle, Dr.1, Anna-Lea Meinhardt, Master of
Science2 and Joachim Kimmerle, Professor1, (1)Leibniz-Institut fuer Wissensmedien, Tuebingen,
Germany, (2)University of Tuebingen, Tuebingen, Germany
Purpose:
In the context of shared decision making, both the statements and the external properties of the
attending physician can play an important role. This randomized controlled study examined the
influence of physicians’ recommendations and their gender on the decision-making process in a
preference-sensitive situation.
Method:
Participants put themselves in a hypothetical scenario in which they suffered from a rupture of
the anterior cruciate ligament (ACL). They received general information on the ACL and on
possible treatment options (surgery vs. physiotherapy). They were explicitly informed that both
options showed the same treatment success in the medical research literature and that this was
therefore a preference-sensitive decision situation. Subsequently, participants indicated their
decision for a treatment option, perceived decisional conflict, and their attitude toward the
treatment options. Then they were randomly assigned to one of four conditions in a 2
(physicianʼs recommendation: surgery vs. physiotherapy) x 2 (physicianʼs gender: female vs.
male) design. They listened to an audio track of a medical consultation with a female or male
voice. Here they received further information about the treatment options and the doctorʼs
recommendation for one of those options. Participants then indicated again their decision,
perceived decisional conflict, and attitude. They also assessed the physicianʼs professional
competence.
Result:
We found that the participants changed their decision in the direction of the physicianʼs
recommendation and that their attitude toward the recommended treatment became more
positive. Decisional conflict decreased more strongly if the physicianʼs recommendation was in
line with the initial decision of the participants than if they were not in line. We found no
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influence of the physicianʼs gender on participants’ decision, their decision conflict, or their
attitude toward the treatment options.
Conclusion:
This research indicates that physicians should be careful with recommendations when aiming for
shared decisions, as they might influence patients even if the patients have been made aware that
they should take their personal preferences into account. This could be particularly problematic if
the recommendation is not in line with prior preferences, as this may lead to an increased
decisional conflict. The female physician was assessed just as competent as the male physician,
indicating that at least in our relatively young student population gender stereotypes do not play
a big role.
PS 1-19 GRADE-INFORMED GUIDELINE PANEL DISCUSSIONS CHANGE
PARTICIPANTS’ VIEWS REGARDING PROPOSED PRACTICES
Decision Psychology and Shared Decision Making (DEC)
Robert M. Hamm, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK
and Benjamin Djulbegovic, City of Hope, Duarte, CA
Purpose: North American medical societies review research supporting proposed guidelines for
treatment in particular situations. The GRADE working group recommended principles
appropriate for assessing evidence, which have been used by several medical societies’ guideline
panels. We seek to learn how these panel meetings affect individual members’ views of the
GRADE dimension quality of various proposals, how the individuals’ assessments influence the
groupʼs assessment, and whether the assessed GRADE dimensions affect the panel
recommendations.
Method: The 2017 meetings of several American Society of Hematology guideline panels were
studied. Each panel addressed several proposed guideline recommendations related to one topic.
Panel members were surveyed for their individual assessments of several proposed
recommendations before and after the panel meeting, for comparison with the panelʼs consensus
recommendations. Before the meeting, panelists rated each proposal on 4 GRADE dimensions,
using 4-point or 5-point appropriately labeled scales, and made a recommendation on a 5-point
FOR/AGAINST scale. The panel meeting produced consensus recommendations on the same
scale. Although the GRADE dimensions were systematically discussed during the meeting, no
consensus ratings were available for analysis. After the meeting, panelists rated 10 GRADE
dimensions and restated their recommendations.
Differences between recommendations at different times were analyzed using Lee and Yates’
(1992) decomposition of the mean squared difference. Agreement between the recommendations
was analyzed using Brunswikʼs decomposition of the correlation.
Result: The mean recommendation, over all the questions considered, was near the neutral
midpoint of the 5-point scale, while the GRADE dimension means, before and after meeting,
varied. The correlations between recommendations at different times are: PreMeeting and
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Consensus, -0.017; PreMeeting and PostMeeting, 0.173; Consensus and PostMeeting, 0.740. The
decomposition of the Mean Squared Difference showed that it was almost entirely due to the
2*(1-ra)*SDx* SDy term, for every comparison. Brunswik Lens Model analysis showed that
individual and consensus recommendations were highly predictable from the GRADE criteria;
the benefit-harm balance criterion was the strongest predictor.
Conclusion: Participating in the panel discussion had a large effect on individual panelists’
assessments of the proposed guideline recommendations. Their recommendations after the
meeting correlated substantially more with the meetingʼs consensus recommendations than with
their pre-meeting recommendations. There was no relation between the pre-meeting
recommendation and the panel meeting consensus, which shows the powerful effect of the
meeting discussions.
PS 1-20 AWARENESS OF FAMILY HISTORY AND ALCOHOL CONSUMPTION AS
RISK FACTORS FOR BREAST CANCER AMONG WOMEN AGED 15-44 YEARS IN
UNITED STATES
Decision Psychology and Shared Decision Making (DEC)
Jaya Khushalani, PhD, MHA, MBBS, Jin Qin, Donatus Ekwueme, Ph.D. and Arica White,
Centers for Disease Control and Prevention, Atlanta, GA
Purpose:
Awareness of the link between breast cancer and known risk factors such as family history and
alcohol consumption may help modify health behaviors which can reduce breast cancer risk over
the lifetime. This study aims to examine the awareness of the link between breast cancer and risk
factors (alcohol and family history) among young women in the United States, stratified by
socioeconomic characteristics and presence of risk factors.
Method:
Data from all female respondents to the National Survey of Family Growth (NSFG) 2011-2015
aged 15-44 years without a personal history of cancer (n=10,940) were used to examine
awareness of two risk factors for breast cancer, positive family history of breast cancer and
alcohol consumption, by presence of risk factors and by socioeconomic characteristics. Chisquare tests were used to test differences in awareness of perceived risk by presence of risk
factors and by socioeconomic characteristics such as age, race/ethnicity, education, poverty
level, health insurance, marital status and rurality.
Result:
Prevalence of positive family history, non-binge, and binge drinking was 30%, 29%, and 31%,
respectively. Awareness of positive family history as a risk factor for breast cancer was 88%,
whereas for alcohol consumption it was 25%. Awareness of family history as a risk factor was
higher among women with positive family history of breast cancer compared to those without,
whereas current drinkers had lower awareness than those who did not drink. Racial/ethnic
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minority women and those with lower education and income had lower awareness of family
history as a risk factor. Awareness of alcohol consumption as a risk factor for breast cancer was
<30% across all socioeconomic groups.
Conclusion:
Only one in four women aged 15-44 years was aware that alcohol is a risk factor for breast
cancer despite high prevalence of binge and non-binge alcohol consumption. Awareness of
alcohol as a risk factor for breast cancer was low across all socioeconomic characteristics and
was lower among current drinkers compared to non-drinkers. Awareness of positive family
history as a risk factor was high overall but varied by socioeconomic characteristics. Evidencebased interventions to increase risk awareness and decrease excessive alcohol use among young
women may be needed to reduce the risk of developing breast cancer.
PS 1-21 LUNG CANCER SCREENING: ASSOCIATIONS OF SHARED DECISION
MAKING AND ROLE CONCORDANCE WITH PATIENT-REPORTED OUTCOMES
Decision Psychology and Shared Decision Making (DEC)
Donald Sullivan, MD, MA, MCR1, Liana Schweiger, MD1, Anne Melzer, MD2, Santanu Datta,
PhD, MBA3 and Christopher Slatore, MD, MS4, (1)Oregon Health & Science University,
Portland, OR, (2)Minneapolis VAHCS Pulmonary Section, Minneapolis, MN, (3)Duke
University School of Medicine, Durham, NC, (4)VA Portland Health Care System, Center to
Improve Veteran Involement in Care, Portland, OR
Purpose: Lung cancer screening (LCS) using annual low-dose computed tomography (LDCT) is
recommended and must include shared decision making (SDM) for Medicare reimbursement.
We sought to characterize the presence of SDM and decision-making role concordance and
associated patient outcomes during LCS encounters.
Methods: Prospective, observational study of patients undergoing LCS at three medical centers
with established programs. All patients were eligible for LCS, but some declined a LDCT. Two
sites required patients to be evaluated by trained screening coordinators and complete a decisionmaking interaction using a decision aid, while use of a decision aid was optional at the third site.
After the decision-making encounter, but before the LDCT (if applicable) patients completed the
baseline survey which collected decisional and communication measures. Exposures: SDM
(actual shared-control) and preferred-actual role concordance via the Control Preferences Scale;
outcome measures: decisional conflict scale, Patient-Centered Communication (PCC)
instrument, Consumer Assessment of Healthcare Providers and Systems assessment tool for
communication quality (CAHPS), and patient rating of LCS discussion question. Logistic
regression modeling adjusted by patient demographics, smoking status, and site was used.
Results: Among 410 patients, mean age was 65 years (SD5.5), 347 (85%) were white and male,
188 (48%) were married, and 229 (57%) were current smokers. Regarding decision making role,
patients preferred “patient-controlled”, “provider-controlled” and “shared-control” 43%, 12%,
and 45% of the time, respectively. Patient-reported actual role in decision making was shared for
39% of encounters. Preferred-actual role was concordant for 307 (82%) encounters. SDM was
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not associated with decisional conflict (Adjusted Odds ratio (AOR)=1.02, 95% CI:0.61-1.73),
patient-reported quality of physician communication (AOR=1.28, 95% CI:0.77-2.12), CAHPS
positive assessment (AOR=1.20, 95% CI:0.67-2.16) or positive provider rating (AOR=1.42, 95%
CI:0.81-2.50), or patient rating of the LCS discussion (AOR=1.20, 95% CI:0.71-2.03). Preferredactual role concordance had similar non-significant findings, however, concordance was
associated with a CAHPS positive assessment (AOR=2.33, 95% CI:1.13-4.80).
Conclusions: Among eligible patients considering LCS at centers with established programs,
neither SDM nor role concordance was associated with decisional conflict, quality
communication, or positive provider assessments. Role concordance was associated with a
CAHPS positive assessment. Mandates for enhanced communication using decision aids and
shared decision making may not improve patient-reported experiences during LCS. More
patient-clinician resources are needed to engage in high-quality communication and to study the
effects of SDM approaches.
PS 1-22 MHOMR: AN AUTOMATED MORTALITY PREDICTION TOOL TO
IDENTIFY PATIENTS WITH UNMET PALLIATIVE CARE-RELATED NEEDS
Decision Psychology and Shared Decision Making (DEC)
Pete Wegier, PhD1, Leah Steinberg, MD MA1, Jeff Myers, MD MSEd1, Ellen Koo, MSc2,
Stephanie Saunders, MA1, Allison Kurahashi, MEd1, Bhadra Lokuge, MHS1, Ramona Mahtani,
MD1, Sarah Kawaguchi, MD1, Emily Lovrics, RN MN1 and James Downar, MD MHSc3,
(1)Sinai Health System, Toronto, ON, Canada, (2)University Health Network, Toronto, ON,
Canada, (3)The Ottawa Hospital, Ottawa, ON, Canada
Purpose:
A fundamental obstacle to improving palliative and end-of-life care is the need to reliably
identify patients with unmet palliative care-related needs. Recent work has shown patients with
terminal illness diagnoses (e.g., cancer) have the highest likelihood (88%) of receiving palliative
and end-of-life care, compared to organ failure or frailty diagnoses (44% and 32%, respectively).
This suggests a significant proportion of non-cancer patients are failing to be identified as
appropriate for palliative and end-of-life care. We evaluated the feasibility of an automated tool
to identify patients with a high risk of mortality in the next year and to prompt treating
physicians to consider a palliative approach to care and reduce the identification burden faced by
clinical staff.
Method:
We created a model (the modified Hospital-patient One-year Mortality Risk; mHOMR) to
identify patients having an elevated mortality risk based only on data available when patients
were admitted to hospital. An application was created based on the model to automatically pull
the required data from the EHR for all patients admitted to the general internal medicine (GIM)
service of two hospitals in Toronto, Ontario. To determine whether patients had unmet palliative
care-related needs, we approached patients identified by the model and asked them to complete a
symptom severity scale and a measure of readiness to engage in advance care planning.
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Results:
Patients (N = 201) identified by the model were primarily non-cancer—only 36% had a cancer
diagnosis, while 37% had end-stage organ failure and 20% had a frailty-related condition.
Patients had a median length of stay of 6 days and 93% of patients survived to discharge. We
found that 90% of those identified by the model had an unmet palliative care-related need—
either a severe symptom, or a desire to discuss advance care planning with a physician, or both—
and that patients with higher mortality risks had more severe symptoms (see figure for
distributions per 100 GIM admissions).
Conclusions:
Our model is a feasible way for the accurate and automated identification of patients at elevated
risk of mortality in the next year and those who may have unmet palliative care-related needs.
This automated approach may be effective for the identification of patients appropriate for a
palliative approach to care.

PS 1-23 APPLYING THE GLOBAL PATIENT-REPORTED OUTCOME MEASURE TO
THE RESULTS OF A CLINICAL TRIAL
Decision Psychology and Shared Decision Making (DEC)
Carole Wiedmeyer, MBA1, Liana Fraenkel, MD, MPH2, Zhenglin Wei, MS3, Christine
Ramsey, PhD2, Kaleb D. Michaud, PhD4, Tuhina Neogi, MD5, William Nowell, PhD1, Shilpa
Venkatachalam, PhD1 and David Broniatowski, PhD3, (1)Upper Nyack, NY, (2)Yale University,
New Haven, CT, (3)Washington DC, DC, (4)Division of Rheumatology & Immunology,
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE,
(5)Boston University, Boston, MA
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Purpose: There is no standard method to compare the combined benefits and adverse events
(AEs) experienced by individual patients. We developed GPROM – the Global Patient-Reported
Outcome Measure – to enable such comparisons. GPROM classifies patients into 1 of 6 levels
ranging from 1= Major improvement and no, mild or manageable AEs to 6= Little or no
improvement and irreversible serious AEs. Here, we present the results of applying GPROM to
existing clinical trial data, demonstrating how the combination of benefit and AE information
may help patients and their doctors select treatments.
Methods: We obtained data from the GO-FORWARD study, comparing methotrexate,
golimumab, and combined therapy options. In this trial, patients on stable doses of methotrexate
were randomized into four regimens: 1) methotrexate + placebo (Group 1; n=133), 2) 100mg of
golimumab + placebo (Group 2; n=133), 3) methotrexate + 50 mg of golimumab (Group 3;
n=89), and 4) methotrexate + 100 mg of golimumab (Group 4; n=89). We assigned each
participant a GPROM score using individual-level trial data. Because the GO-FORWARD study
was not powered to draw statistical conclusions, GPROM scores were compared qualitatively
across treatments.
Results: Combined therapy (Groups 3 and 4) had the highest average benefit score (1=29.17,
2=26.39,3=33.88, 4=34.34). Methotrexate + placebo (1=2.30) was found to be have more
severe AEs than other treatments (2=2.03; 3=1.99, 4=2.09). GPROM scores across groups are
illustrated in Figure 1. Combined therapy groups had better GPROM scores (3=2.34, 4=2.32)
compared to those receiving either methotrexate + placebo or golimumab + placebo (3=2.56,
4=2.55), indicating that a greater proportion of patients on combined treatment experience
greater benefit with fewer AEs.
Conclusions: GPROM results demonstrate the ability to represent patients’ global experiences
on treatment. Consistent with prior trial results, GPROM scores indicate the superiority of
combined therapy over single agents.
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PS 1-24 VALIDATION OF A MEASURE OF TRUST IN THE SURGEON
Decision Psychology and Shared Decision Making (DEC)
Suzanne Brodney, PhD, RD1, Karen Sepucha, PhD1, Floyd Fowler, PhD2, KD Valentine, PhD1
and Michael Barry, MD1, (1)Division of General Internal Medicine, Massachusetts General
Hospital, Boston, MA, (2)Center for Survey Research, University of Massachusetts, Boston,
Boston, MA
Purpose:
The impact of shared decision making and patient decision aids on factors that may drive
medical-legal risk, including trust and regret, have received little attention. Improving trust and
reducing regret should mitigate malpractice risk. Having reliable and valid trust measures is
necessary to document the level and importance of trust in the patient-provider relationship. The
aim of this project is to develop and validate a measure of trust in the surgeon.
Method:
Focus groups and cognitive interviews were conducted to learn how people who had a hip or
knee replacement or back surgery in the past 2 years understood what it means to have trust in
your surgeon. Questions were adapted from a published survey. Based on collective feedback, a
revised question set was compiled. A 14-item version was tested using a web-based platform to
achieve a national sample of 300 respondents aged 30 and older who had one of the procedures
in the past 2 years. 11-item and 5-item versions were evaluated using average scores based on
previous qualitative work and the Pearson correlation coefficients. To evaluate construct validity,
we hypothesized that higher trust scores should be correlated to higher Shared Decision Making
Process (SDMP) and lower Decision Regret Scale scores. Ceiling effects were evaluated by
dichotomizing scales into top achievable scores versus all other scores.
Result:
Of the 300 participants, 32% had hip surgery, 33% had knee surgery and 34% back surgery. The
mean age was 53 years, 45% female, 80% white, and 36% had a high school degree or less. We
examined the 14-item version by condition but combined the data, which were similar across
conditions. Pearson correlation coefficients were analyzed (11-item: 0.430-0.709, 5-item: 0.5790.709). The correlation between the 5-item and 11-item total trust scores was 0.96 (p<0.01). The
scores of the 11-item and 5-item versions were positively correlated with participants’ SDMP
scores (0.425 and 0.406, respectively, both p=0.01), and negatively correlated with Decision
Regret scores (-0.502 and -0.477, respectively, both p=0.01). The 11-item version included 25%
with a top score and the 5-item version included 35%, suggesting some ceiling effect with both
scales.
Conclusion:
A 5-item trust scale was found to be well correlated with other measures and was found to have
construct validity with some ceiling effects.
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PS 1-25 HEALTH BURDEN ATTRIBUTABLE TO CARBAPENEMASE-PRODUCING
ENTEROBACTERIACEAE INFECTIONS: A SYSTEMATIC REVIEW
Health Services, Outcomes and Policy Research (HSOP)
Stephen Mac, Institute of Health Policy, Management and Evaluation, University of Toronto,
Toronto, ON, Canada, Dalton R. Budhram, Queenʼs University, Kingston, ON, Canada, Joanna
M. Bielecki, BSc, MISt, Toronto Health Economics and Technology Assessment (THETA)
Collaborative, Toronto, ON, Canada, Samir N. Patel, PhD, Public Health Ontario, Toronto, ON,
Canada and Beate Sander, PhD, Toronto Health Economics and Technology Assessment
(THETA) Collaborative, University Health Network, Toronto, ON, Canada
Purpose: Carbapenemase-producing Enterobacteriaceae (CPE) are a subgroup of carbapenemresistant bacteria that pose a significant global health threat. We conducted a systematic literature
review on the health-related quality of life (HRQoL), health outcomes, and long-term sequelae
attributable to CPE infection.
Method: We followed PRISMA reporting guidelines and published our review protocol on
PROSPERO (CRD42018097357). We searched four electronic databases: Medline, Embase,
CINAHL and the Cochrane Library between January 2008 and May 2018 for concepts related to:
CPE, quality-of-life, complications, and mortality. We included primary studies with a
carbapenem-susceptible control group, conducted in Organization for Economic Co-operation
and Development countries. We excluded studies that were not published in English, used an
inappropriate control, or reported inappropriate outcomes. Quality appraisal was completed using
Joanna Briggs Institute checklists. We qualitatively summarized the most frequently reported
sequelae and conducted a meta-analysis on in-hospital mortality using a random-effects model.
Result: We identified 8,671 publications from which 17 studies met the eligibility criteria for
inclusion into the review. All studies reported health outcomes, none reported HRQoL. Most
studies were conducted in teaching or university-affiliated hospitals (76%), from Europe (65%),
and used case-control designs (53%). Mortality was the most commonly reported consequence of
CPE-infections, with in-hospital mortality as the most often reported outcome (62%). Our metaanalysis (n=5 studies) estimated a risk difference of the in-hospital mortality rate of 0.25 (95%
CI, 0.17 – 0.32). Duration of antibiotic therapy (range, 4-29.7 days vs. 1-23.6 days) and length of
hospital stay (range, 21-87 days vs. 15-43 days) were relatively higher for CPE-infected patients
compared to carbapenem susceptible patients. Overall, most studies (82%) met over 80% of their
respective quality appraisal criteria.
Conclusion: Health outcome studies associated with CPE infection are focused on short-term
(e.g. in-hospital) outcomes; long-term sequelae and quality-of-life are not well studied. Future
opportunities exist for longer follow-up to assess the clinical outlook for CPE infections.
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PS 1-27 COST-EFFECTIVENESS OF INTERVENTIONS TO INCREASE HPV
VACCINATION COVERAGE
Health Services, Outcomes and Policy Research (HSOP)
Jennifer Spencer, MSPH, PhD, Department of Health Policy and Management, Harvard T.H.
Chan School of Public Health, Boston, MA, Noel T. Brewer, PhD, Department of Health
Behavior, Gillings School of Global Public Health, The University of North Carolina at Chapel
Hill, Chapel Hill, NC, Justin Trogdon, PhD, Department of Health Policy and Management,
University of North Carolina, Chapel Hill, NC, Tamera Coyne-Beasley, MD, MPH, FAAP,
FSAHM, University of Alabama-Birmingham, Department of Pediatrics, Birmingham, AL and
Stephanie B. Wheeler, PhD, MPH, Department of Health Policy and Management, University of
North Carolina at Chapel Hill, Chapel Hill, NC
Purpose: HPV vaccination offers substantial benefits for cancer prevention, yet uptake remains
well below national targets. To achieve widespread reduction in HPV cancer incidence, it is
important to identify cost-effective interventions for increasing HPV vaccination coverage.
Methods: We developed a dynamic infection simulation model of HPV transmission and
progression to estimate HPV cancer incidence over a 50-year period. The model assumed a onetime, statewide implementation of three alternative interventions: centralized reminder/recall for
HPV vaccination, school-located HPV vaccination, and the Center for Disease Control and
Preventionʼs Assessment, Feedback, Incentives, and eXchanges (AFIX) program. Previous
studies provided estimates of intervention reach, effectiveness, and per-person cost from a state
government perspective. Outcomes were additional individuals vaccinated, cancers averted, and
quality-adjusted life years (QALYs) gained. We used probabilistic sensitivity analysis to assess a
range of plausible outcomes associated with each intervention. We used the standard
willingness-to-pay (WTP) threshold of $50,000 per QALY gained to establish cost-effectiveness
and discounted costs and QALYs at 3%. We conducted probabilistic sensitivity analyses.
Results: All three interventions are cost-effective relative to no intervention. AFIX would
increase vaccine uptake at the lowest cost per QALY gained of $257 relative to no intervention
(total program cost $64,855, $14 cost/person vaccinated, $758/cancer case averted). Statewide
implementation of centralized reminder/recall would further increase vaccine uptake at an added
cost of $8,426 per QALY gained relative to AFIX (total cost $972,825, incremental cost
$396/individual vaccinated, $45,880/cancer averted). School-located vaccination would have the
largest projected increase in vaccine uptake, with the largest total cost of $3,018 per QALY
gained relative to centralized reminder/recall (cost $3.1 million, $176/individual vaccinated,
$9,311/cancer averted). These estimates were sensitive to changes in intervention effectiveness,
with school-located vaccination showing the widest uncertainty in both costs and benefits.
Conclusion: Three established interventions for increasing HPV vaccine uptake were costeffective at standard WTP thresholds. AFIX visits are a low-cost and efficient intervention, but
both centralized reminder/recall and school-located vaccination could achieve further gains for
higher costs. Policymakers seeking to increase HPV vaccine coverage should consider tradeoffs
between feasibility, total cost and intervention effectiveness as well as their definition of
“value”- particularly the willingness to pay for increased coverage and reduced cancer incidence.
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PS 1-28 "MANY VIEWS ON VALUE" OF NATIONAL CANCER INSTITUTESPONSORED RANDOMIZED TRIALS
Health Services, Outcomes and Policy Research (HSOP)
Van Nghiem, PhD, MSPH1, Riha Vaidya, PhD1, Dawn L. Hershman, MD2, Michael LeBlanc,
PhD1, Scott D. Ramsey, MD, PhD1, Charles D. Blanke, MD3 and Joseph M. Unger, PhD, MS1,
(1)Fred Hutchinson Cancer Research Center, Seattle, WA, (2)Columbia University Medical
Center, New York, NY, (3)Oregon Health & Science University, Portland, OR
Purpose: National Cancer Institute Clinical Trial Network (NCTN) groups serve a vital role in
identifying effective new antineoplastic regimens. We aimed to examine clinical impact,
scientific impact, outcomes of primary endpoints, and their association among NCTN trials.
Methods: We evaluated phase III cancer clinical treatment trials which SWOG Cancer Research
Network coordinated or participated in (1980-2017) under the NCTN program. We included
completed trials with published primary articles reporting primary endpoints (positive vs.
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negative). A practice influential (PI) trial was defined as one with verified influence on National
Comprehensive Cancer Network (NCCN) clinical guidelines or U.S. Food and Drug
Administration (FDA)-approved package inserts. We selected trials with primary articles
published ≥5 years for the scientific impact analysis, in which the annual citation count for
primary articles was obtained from Google Scholar. We estimated the overall rate of PI trials and
trends over time. We compared characteristics between PI and non-PI trials. Generalized
estimating equations (GEE) were used to examine the association between scientific impact and
clinical impact of the trials (alpha=0.05). The total federal investment supporting the trials was
determined in 2017 dollars.
Results: In total, 182 trials comprising 148,028 patients were studied. We identified 79 PI trials
(43.4%); 73 influenced NCCN guidelines, 12 influenced FDA new drug approvals, and 6
influenced both. The rate of PI trials was 72.3% (47/65) among positive trials and 27.4%
(32/117) among negative trials. Thus 40.5% (32/79) of PI trials were based on negative studies,
half of which (16/32, 50.0%) reaffirmed standard of care over experimental therapy. Among 164
trials included in the scientific impact analysis, the best-fit GEE model suggested a PI trial had
an annual citation count 2.8 times higher than a non-PI one (p<0.001) (Figure). For a PI but
negative trial, the annual citation count was 2.1 times higher than a positive but non-PI one
(p<0.005). PI and non-PI trials had similar key characteristics in study design. The total federal
investment in conducting the trials was $1.36 billion, a rate of $7.5 million per study, or $17.2
million per PI trial.
Conclusions: Both positive trials and negative trials influenced guideline care and new drug
indications. Scientific impact reflects clinical impact of the trials. NCTN trials contribute
clinically meaningful, cost-effective evidence to guide patient care.
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PS 1-29 DIFFERENCES IN CASE-MIX ADJUSTMENT MODELS FOR INDIVIDUAL
EQ-5D DOMAINS IN HOSPITAL COMPARISONS: A SUBSTUDY OF THE MR
CLEAN TRIAL
Health Services, Outcomes and Policy Research (HSOP)
Arvind Oemrawsingh, MD1, Nikki van Leeuwen, PhD2, Olvert Berkhemer, MD PhD3,
Diederik W.J. Dippel, MD, PhD4 and Hester F. Lingsma, PhD2, (1)Department of Public Health,
Erasmus Medical Center, Rotterdam, Netherlands, (2)Department of Public Health, Erasmus
University Medical Center, Rotterdam, Netherlands, (3)Department of Radiology, Academic
Medical Center, Amsterdam, Netherlands, (4)Department of Neurology, Erasmus University
Medical Center, Rotterdam, Netherlands
Purpose:
One of the potential applications of patient-reported outcome measures (PROMs) is
benchmarking hospitals However, there is a scarcity of experience and knowledge about
appropriate case-mix adjustment for PROMs. The aim of this study was to develop case-mix
adjustment models for quality of life after acute ischemic stroke and to compare estimated
hospital performance without and with adjustment for case-mix.
Method:
A secondary analysis was performed with the MR CLEAN randomized control trial data (20102015) of patients diagnosed with acute ischemic stroke at 12 stroke centers. Case-mix adjustment
models for Quality of Life, specifically the 5 individual EQ-5D domains (mobility, self-care,
usual activities, pain/discomfort and anxiety/depression) were developed by testing 14 candidate
predictors in univariable proportional odds regression models. The final case-mix models
combined predictors selected from the univariable analysis with p-values below the Akaike
Information Criterion (equivalent to p<0.157 for 1 degree of freedom) for each domain. Model
performance was assessed with the c-statistic. Using random effect models, unadjusted and
adjusted random effect estimates for each stroke center were compared to study the influence of
case-mix adjustment in benchmarking.
Result:
We included 336 patients. Common predictors for all individual EQ-5D domains were
hypertension, peripheral arterial disease and pre-stroke disability. Mobility (8 predictors), selfcare (11 predictors) and usual activities (9 predictors) had more significant predictors than
pain/discomfort (5 predictors) and anxiety/depression (4 predictors). C-statistics for case-mix
adjusted models were 0.61 (anxiety/ depression), 0.66 (pain/ discomfort), 0.68 (usual activities),
0.69 (mobility) and 0.71 (self-care). Estimated performance of individual stroke centers changed
to some extent between unadjusted and adjusted analysis for mobility, self-care and usual
activities (‘physical’ domains) as opposed to pain/ discomfort and anxiety/depression
(‘psychological’ domains).
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Conclusion:
We identified more predictors for ‘physical’ EQ-5D domains than for ‘psychological’ domains.
The final case-mix models for the 5 domains indicated poor to moderate predictive power;
models for ‘physical’ domains performed better. As a result, case-mix adjustment did affect the
estimated hospital performance on the ‘physical’ domains but not on the ‘psychological’
domains. This suggest that the ‘psychological’ outcome is less influenced by patient
characteristics albeit missing important candidate predictors might also be a potential reason.
External validation of the case-mix adjusted regression models needs to be conducted before
being used for valid hospital comparisons.
Figure
PS 1-30 ESTIMATING THE HEALTH BENEFITS OF INCREASING CERVICAL
CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER
EARLY DETECTION PROGRAM AMONG LOW-INCOME WOMEN IN THE U.S
Health Services, Outcomes and Policy Research (HSOP)
Lisa Pollack, PhD, MPH, Division of Public Health Sciences, Department of Surgery,
Washington University School of Medicine in St. Louis, St. Louis, MO, Mei-Chuan Hung, PhD,
Leidos Inc., Atlanta, GA and Su-Hsin Chang, Ph.D., Division of Public Health Sciences,
Department of Surgery, Washington University School of Medicine, St. Louis, MO
Purpose: The National Breast and Cervical Cancer Early Detection Program (NBCCEDP)
provides free cervical cancer screening to low-income uninsured and underinsured women aged
21-64 years. However, only 6.5% of eligible women received screening between 2010 and 2012.
This study estimated the health benefits gained in terms of life years (LYs) saved and qualityadjusted life expectancy (QALE) gained if cervical cancer screening by the NBCCEDP increased
to reach more eligible women.
Methods: Data from the Surveillance, Epidemiology, and End Results 18 registries, 2000-2013,
were used to estimate life expectancy for women with cervical cancer. Data from Medical
Expenditure Panel Surveys, 2008-2012, were used to derive quality-of-life utilities in order to
estimate QALE. Data from the NBCCEDP, 2010-2013, for women aged 18-64 years were used
to obtain cervical cancer stage distribution (no cancer, pre-cancer, local, regional, and distant)
from NBCCEDP-funded Papanicolaou tests results. For this analysis, we refer to these women as
screened. LYs saved and QALE gained/100,000 women were estimated and used to predict
additional health benefits gained if screening by the NBCCEDP increased from 6.5% up to 10%,
15%, 20%, and 25% of the eligible women.
Results: Overall, per 100,000 women screened by the NBCCEDP, 1,731 LYs were saved and
1,608 QALE were gained. By race/ethnicity, non-Hispanic white women experienced the most
LYs saved and QALE gained/100,000 women screened (LYs=1,926, QALE=1,780), followed by
Hispanic women (LYs=1,921, QALE=1,667) and non-Hispanic Black women (LYs=1,506,
QALE=1,300). If the proportion of eligible women screened by the NBCCEDP increased, an
estimated 382,730 (90% CI: 365,430-400,130) additional women would be screened if
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NBCCEDP screening increased from 6.5% to 10%, and 2,015,780 (90% CI: 1,972,5302,059,280) additional women would be screened if screening increased to 25% participation
level. Furthermore, the estimated health benefits would range from 6,626-34,896 LYs saved and
6,153-32,407 QALE gained (Figure 1).
Conclusions: We quantified the health benefits of increasing NBCCEDP cervical cancer
screening in low-income women eligible for the program in terms of LYs saved and QALE
gained. The reported estimates demonstrate that screening a higher percentage of eligible women
in the NBCCEDP would yield more health benefits. Estimates reported in this study provide
useful information to help guide cancer control programs to effectively plan and implement
evidence-based interventions that expand cervical cancer screening among medically
underserved, low-income women.
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PS 1-31 COSTS AND OUTCOMES ASSOCIATED WITH DISCONTINUING A
ROUTINE HIV SCREENING PROGRAM IN A HIGH VOLUME JAIL
Health Services, Outcomes and Policy Research (HSOP)
Angela Hutchinson, PhD, MPH1, Madeline Adee2, Chava Bowden2, Andew Margolis, MPH3,
Mingli Qi2 and Ann Spaulding, MD, MPH2, (1)Centers for Disease Control and Prevention,
Atlanta, GA, (2)Emory University, Rollins School of Public Health, Atlanta, GA, (3)Atlanta, GA
Purpose:
Incarcerated populations have elevated HIV infection rates that are up to 10 times greater than
the general US population in high-prevalence areas. Fulton County Jail (FCJ) is a high-volume
jail in Atlanta, GA which ranks fourth among cities in annual number of new HIV diagnoses.
Beginning in 2010, a CDC-funded demonstration project at the FCJ supported nurse-led, pointof-care routine, rapid HIV screening of entrants. The program was later sustained with funding
from the local health department. After 2017, the health department discontinued funding and
HIV testing at FCJ was limited to clinician-initiated conventional tests. After the initiation of the
routine screening program, 4% of the jail census was found to be HIV-infected (known positives
and those identified through screening). After routine screening ended, the proportion of the jail
census with an HIV diagnosis fell to 3%, possibly representing unidentified HIV. We assessed
the impact of eliminating routine screening in FCJ on HIV diagnoses, and compared costs,
outcomes, and cost-effectiveness of routine screening versus clinician-initiated testing.
Method:
We used a published mathematical model to estimate the cost-effectiveness of HIV screening
from a health system perspective. HIV infections averted because of serostatus awareness and
viral suppression were estimated assuming HIV diagnoses were delayed 3.2 years without a
routine jail screening program. Costs, outcomes, and other model inputs were estimated from the
FCJ testing programs and the published literature. Key parameters included lifetime treatment
costs ($441,700), annual treatment costs ($15,800), 50% of persons with HIV on treatment, and
40% virally suppressed.
Result:
Routine screening from March, 2013 to February, 2014 tested 17,035 persons and identified 89
new HIV infections (Table). From January to December, 2018, the clinician-initiated program
tested 3,689 persons and identified 17 new HIV infections. Compared to clinician-initiated
testing, routine screening yielded an additional 72 new HIV infections, 5 estimated HIV
transmissions averted, 21 QALYs gained, and was cost-saving. Program costs for the routine
screening could increase 10-fold and still remain cost-effective compared to clinician-initiated
testing at the $50,000 per QALY threshold.
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Conclusion:
Routine screening was cost-saving compared to clinician-initiated testing even with greater costs
for screening and earlier treatment. Public health policy makers should consider initiating and
sustaining funding for cost-effective programs such as routine HIV screening in jails located in
high prevalence areas.

PS 1-32 CHARACTERIZING LONGITUDINAL PATTERNS OF TYROSINE KINASE
INHIBITOR ADHERENCE IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC
MYELOID LEUKEMIA
Health Services, Outcomes and Policy Research (HSOP)
Samantha Clark, MHS1, Zachary Marcum, PharmD, MS, PhD2 and Aasthaa Bansal, BS, PhD2,
(1)The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Seattle, WA,
(2)The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University
of Washington, Seattle, WA
Purpose:
Although the introduction of tyrosine kinase inhibitors (TKIs) in the early 2000s represented a
watershed moment in chronic myeloid leukemia (CML) treatment, it is estimated that only 70%
of patients with CML are adherent to TKIs. We conducted a latent profile analysis (LPA) to
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determine whether groups of patients with CML exhibit distinct adherence trajectories, and, if so,
which patient characteristics are predictive of membership in these groups.
Method:
Using the Truven Health MarketScan Commercial and Medicare Supplemental Databases (20072017) and Area Health Resource Files (2017-18), newly diagnosed CML patients with at least
two TKI prescriptions were identified and relevant covariate values extracted. Proportion of days
covered (PDC) per 30-day interval was used to calculate adherence over the 12-month follow-up
period. An LPA incorporating these PDC estimates was conducted to identify distinct patterns of
TKI adherence. Identified trajectories were then grouped into four clinically relevant categories
and predictors of membership in these categories determined via multinomial logistic regression.
Result:
A seven-class LPA model with 3⸰ polynomial terms was selected based on multiple specification
criteria. From this model, four broader distinct adherence categories emerged: never adherent
(group 1), initially non-adherent becoming adherent (group 2), initially adherent becoming nonadherent (group 3), and stable adherent (groups 4, 5, 6, and 7) (Figure 1). Results from the
subsequent multinomial logistic regression (using the “stable adherent” group as the baseline)
indicated that younger age was significantly associated with membership in all three non-stable
adherent groups (1, 2, and 3). Membership in the non-stable adherent groups was further found
to be significantly related to female sex, greater monthly financial burden, fewer comorbidities,
fewer concomitant medications, living outside the northeast region, and a longer duration from
diagnosis to treatment.
Conclusion:
To our knowledge, this is the first study using LPA methods to describe longitudinal TKI
adherence and examine determinants of membership in these groups. Results suggest that there
are multiple distinct patterns of TKI adherence and that sociodemographic and clinical
characteristics may be used to predict membership in broader, clinically meaningful groups of
TKI adherence. Incorporating this information on dynamic medication adherence into healthcare
systems could help inform the timing and targeting of intervention strategies, subsequently
increasing the value of TKI therapy through improved patient prognosis and reduced costs.
PS 1-33 THE IMPACT OF REDUCED COPAYS ON PRIMARY AND SECONDARY
ADHERENCE TO HORMONAL THERAPY FOR OLDER BREAST CANCER
PATIENTS: MULTI-STATE ANALYSIS
Health Services, Outcomes and Policy Research (HSOP)
Aaron WInn, PhD, MPP1, Nicole Fergestrom, MS2 and Joan Neuner, MD, MPH2, (1)Medical
College of Wisconsin, Milwaukee, WI, (2)Milwaukee, WI
Purpose: Several large randomized controlled trials have clearly documented the survival
benefit of hormonal therapy (HT); however, many women fail to initiate (primary non-
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adherence) or among those who are initiate they fail to remain adherent to medication (secondary
non-adherence). Prior studies have found that costs impact secondary non-adherence to
medications, but have systematically failed to examine primary non-adherence. To estimate how
primary and secondary adherence was impacted by reducing copays for medications by the
introduction of generic HTs.
Method: We examined monthly adherence to HT using the proportion of days covered (PDC)
for women diagnosed with stage 1-3 breast cancer between 2008-2009 using SEER-Medicare
data after then ceased active treatment (surgery, radiation or chemotherapy). We followed
patients for up to five year or until they were censored due to insurance disenrollment or having
evidence of cancer recurrence. We examined adherence for 1 year before and up to 4 years after
generic HT was available. We compare women whose copays would change and those whose
would not due to the receipt of cost-sharing subsidies before and after generics were introduced
using a difference-in-difference analysis. To examine primary and secondary non-adherence we
use a multi-state model with 4 states (Never used, Low adherence (PDC<0.80), Adherent
(PDC≥0.80), and Former User). Additionally, we used the model to simulate the expected time a
person is adherence to the drug, effectively combining the results for the primary and secondary
adherence components. We implemented the multi-state model using a clock forward approach.
We used a Cox proportional hazard model and adjusted for demographic and clinical factors.
Result: We identified 38,626 women with breast cancer after they ceased active treatment. We
find that reduced copays results in faster initiation of treatment (hazard ratio (HR)=1.11;
95%CI=1.04-1.19; p-value < 0.01), among adherent individuals, reduced copays results in being
less likely to have low adherence (HR=0.68; 95%CI=0.62-0.75; p-value < 0.01) and less likely to
stop taking medication adherent (HR=0.49; 95%CI=0.42-0.57; p-value < 0.01). Among
individuals with low adherence, they are less likely to stop taking the HT (HR=0.65;
95%CI=0.57-0.82; p-value < 0.01).
Conclusion: This study finds that both primary and secondary non-adherence were positively
impacted by reduced copays.
PS 1-34 HEALTH GAINS AND FINANCIAL PROTECTION FROM HUMAN
PAPILLOMAVIRUS (HPV) VACCINATION IN ETHIOPIA
Health Services, Outcomes and Policy Research (HSOP)
Allison Portnoy, MSPH1, Dawit Desalegn, MD2, Jane J. Kim, PhD3 and Stéphane Verguet,
PhD1, (1)Harvard T.H. Chan School of Public Health, Dept. of Global Health and Population,
Boston, MA, (2)Addis Ababa University, Addis Ababa, Ethiopia, (3)Center for Health Decision
Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Boston, MA
Purpose:
High out-of-pocket (OOP) medical expenses for cervical cancer can lead to risk of catastrophic
expenditure or medical impoverishment in many low- and middle-income countries. There are
32 million women over the age of 15 at risk of cervical cancer in Ethiopia, but cervical cancer
screening coverage is 0.8%. An evaluation of both the health gains and financial risk protection
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benefits, and their distributional consequences across socioeconomic groups, from routine human
papillomavirus (HPV) vaccination will be critical to support cervical cancer prevention in this
setting.
Method:
We used a multiple modeling approach that captures HPV transmission, cervical carcinogenesis,
and population demographics to project health and economic outcomes associated with routine
HPV vaccination in Ethiopia. Costs included vaccination and operational costs in US$2015 over
2018-2118 and cervical cancer costs over the lifetimes of the current female population in
Ethiopia. Health outcomes included number of cervical cancer cases and deaths. We estimated
household OOP expenditures averted (assuming 34% of health expenditures are financed by
OOP), cases of catastrophic expenditures averted, and cases of poverty averted by HPV
vaccination. These cases averted depended on individual income (relying on GDP per capita of
Ethiopia as a proxy [$768 in US$2017], distributed by income quintile according to the
lognormal distribution and a Gini coefficient), disease incidence, health-care use, and OOP
payments. Catastrophic expenditures are defined as 10% of individual income and the number of
poverty cases averted is measured as the number of individuals who no longer fall below the
international poverty line ($1.90 per day).
Result:
Our analysis shows that, per dollar spent by the Ethiopian Government, routine two-dose HPV
vaccination could avert up to 200 cervical cancer deaths per $100,000 spent. Additionally,
routine two-dose HPV vaccination could avert 32,000 cases of catastrophic expenditure at 40%
coverage or 60,000 cases at 80% coverage, assuming 100% vaccine efficacy. At 80% vaccine
efficacy, HPV vaccination could avert 44,000 cases of catastrophic expenditure at 80% coverage.
Approximately 30% of health benefits accrue to the poorest quintile whereas 50% of financial
risk protection benefits accrue to the poorest quintile.
Conclusion:
Our approach incorporates financial risk protection into the economic evaluation of routine HPV
vaccination in Ethiopia. This understanding can help policymakers in decisions regarding
continued routine HPV vaccination and cervical cancer control.
PS 1-35 ALTERNATIVE APPROACHES TO QALY ESTIMATION WITHIN
STANDARD COST-EFFECTIVENESS MODELS: LITERATURE REVIEW,
FEASIBILITY ASSESSMENT, AND IMPACT EVALUATION
Health Services, Outcomes and Policy Research (HSOP)
Elizabeth Brouwer, MPH1, Eunice Kim1, Phoebe Wright1 and Josh Carlson, MPH, PhD2,
(1)University of Washington, Seattle, WA, (2)The Comparative Health Outcomes, Policy,
Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, WA
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Purpose: The use of the conventional QALY has been a topic of continued debate since its
inception. Alternative approaches have been proposed but most haven’t been comprehensively
evaluated. Our objective was to identify alternatives to the conventional QALY, characterize
them in terms of implementation feasibility, and evaluate the impact of implementing the
feasible options in a contemporary set of 9 cost-effectiveness models developed as part of the
Institute of Clinical and Economic Reviews reports.
Methods: We conducted a literature review to identify alternatives. Our search strategy
combined keywords relating to QALYs, methodology alternatives, and cost-effectiveness in
Pubmed, EconLit, Web of Science, and Medline. Articles were included if they discussed an
alternative or adjustment to the conventional QALY. Alternatives were abstracted and
characterized according to type, data availability, calculation burden, and overall implementation
feasibility. The subset of feasible alternatives, i.e. sufficient data and methodology consistent
with incorporation into standard modelling approaches, were evaluated according to two
outcomes: 1) change in within model intervention rankings by absolute QALYs and 2) change in
intervention rankings across all models by incremental QALYs.
Result: Our search identified 31 articles discussing 13 alternatives. The subset of feasible
alternatives were using patient preference data, equity weighting according to: baseline utility,
fair innings, and proportional QALY shortfall, and the equal value of life-years-gained approach.
Only the patient preference data and the equal value of life-years-gained approaches had an
impact on the within model rankings, which was relatively minor. Larger impacts were observed
when looking across models with baseline severity weighting and patient preference data having
the biggest impacts.
Conclusion: The impact on model outcome rankings varied by alternative with the largest
impacts observed for baseline severity weighting and using patient preference data. While the
identified approaches seek to improve on perceived QALY shortcomings, each comes with its
own limitations. Further research will evaluate the potential impact on decision making.

PS 1-36 CLINICAL PATHWAYS AND HEALTH CARE COSTS IN NON-METASTATIC
CASTRATION-RESISTANT PROSTATE CANCER: LINKING MEDICAL RECORDS
AND HEALTH ADMINISTRATIVE DATA
Health Services, Outcomes and Policy Research (HSOP)
Steven M. Carcone, MSc1, Karen E Bremner, BSc2, Welson Ryan3, Nicholas Mitsakakis, PhD4,
Lusine Abrahamyan, MD, MPH, PhD3, Alice Dragomir, PhD5, Ivan Yanev, MSc6, Antonio
Finelli, MD, MSc7 and Murray Krahn, MD, MSc, FRCPC3, (1)Toronto Health Economics and
Technology Assessment (THETA) Collaborative, Toronto General Hospital Research Institute,
University Health Network, Toronto, ON, Canada, (2)Toronto General Hospital Research
Institute, University Health Network, Toronto, ON, Canada, (3)Toronto Health Economics and
Technology Assessment (THETA) Collaborative, Toronto, ON, Canada, (4)Institute of Health
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Policy, Management and Evaluation, Toronto, ON, Canada, (5)Research Institute of the McGill
University Health Center, Montreal, QC, Canada, (6)The Research Institute of the McGill
University Health Centre, Montreal, QC, Canada, (7)University of Toronto and University
Health Network, Division of Urology, Department of Surgery, Toronto, ON, Canada
Purpose: Incidence, prevalence and costs of advanced prostate cancer (PCa), including nonmetastatic castration-resistant PCa (nMCRPC), are important information for policy makers
facing reimbursement decisions for new PCa treatments. The primary objectives of this study
were to describe pathways and transition probabilities to nMCRPC and estimate health care
resource use and costs for PCa.
Method: Patients were recruited from ambulatory clinics at two cancer centers in two Canadian
provinces [Ontario (n=195) and Quebec (n=210)]. We developed an algorithm, based on
validated health state definitions and using data from chart reviews, to allocate each patientʼs
observation time into the 15 discrete health states of our PCa state transition model, from PCa
diagnosis to death. Graphical representations were employed to understand patient-level state
trajectories, and debug the time-allocation algorithm. Individual-level clinical and health state
data for the Ontario patients were linked to health care administrative data to estimate resource
utilization and direct medical costs (2018 CAD) for each health state, unadjusted and adjusted
for covariates (initial treatment, age, comorbidity).
Result: The algorithm appropriately allocated each patientʼs observation time into health states,
verified by the graphical representations. We identified 33 distinct pathways leading to
nMCRPC. The most frequent was: watchful waiting--androgen deprivation therapy--nMCRPC
(n=18). The median survival from entering the nMCRPC state was 1593 days (95%CI = 1261,
2060). Mean total costs per 30 days for each of the 15 health states ranged from $364 (posttreatment surveillance) to $4,359 (MCRPC). Inpatient hospitalization, physician services, and
cancer clinic visits accounted for most of the total cost in all health states except later disease
stages. Drug costs represented an increasingly higher proportion of total expenditures in later
stages of PCa. The best-fitting model for adjusted costs included age and comorbidity as
covariates, but not initial treatment. Estimated mean costs increased within each health state,
with increased age and comorbidity.
Conclusion: This study provides new insights into the prognosis and costs of late stage PCa. Our
chart review data linkage methods were time-consuming and costly but achieved estimations of
individual-level true resource use and costs for clinical PCa health states. Our graphical
representational approach to portray patient pathways has potential clinical and research
applications. Our estimated costs provide input for health economic models for policy-making
and decision-making about PCa treatments.
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PS 1-37 MEDICARE PART B SPENT 1.9 BILLION DOLLARS ON FIVE COSTINEFFECTIVE DRUGS IN 2018
Health Services, Outcomes and Policy Research (HSOP)
Karen C. Smith, BA, Harvard Graduate School of Arts and Sciences, Cambridge, MA and
Ankur Pandya, PhD, Center for Health Decision Science, Department of Health Policy and
Management, Harvard T.H. Chan School of Public Health, Boston, MA
Purpose: To estimate 2018 Medicare Part B spending on cost-ineffective drugs
Method: We conducted a budget impact analysis of cost-ineffective drugs (incremental costeffectiveness ratio [ICER] ≥$200,000/quality-adjusted life-year [QALY]) from the Medicare Part
B perspective. We used the Tufts Cost-Effectiveness Analysis (CEA) Registry to identify CEAs
of cost-ineffective drugs covered by Medicare Part B. We included CEAs that were published
between 2010 and 2015 for the US setting, had a study quality rating ≥5 (out of 7), and reported
an ICER ≥$200,000/QALY. This resulted in 13 CEAs covering drugs with ICERs ranging from
$220,000/QALY to $2,600,000/QALY. We used available literature to estimate the 2018
population age ≥65 with the disease for which the drug is cost-ineffective. We assumed that 66%
of patients age ≥65 were enrolled in Medicare Part B and that these patients paid 20% of
treatment costs (co-insurance). We used published literature to estimate utilization rates for each
drug within the patient population. We used July 2018 Medicare Part B fee schedules and
published adherence rates to estimate per-patient average annual spending on each drug. We
calculated total spending in 2018 by multiplying the number of Medicare Part B patients using
the drug by the average annual cost of the drug. We excluded five CEAs for which necessary
data were not available in published literature. When there were multiple published estimates in
the literature, we used the lowest one so as to err on the side of underestimating total spending.
Therefore, these results should be considered a lower bound of spending on these drugs.
Result: Medicare Part B and patients spent $2.3 billion on five cost-ineffective drugs for eight
diseases. Medicare Part B spent $1.9 billion, which was 6% of Medicare Part B drug-specific
spending. Among the five cost-ineffective drugs, 51% of spending was on ranibizumab. If the
cost-effective alternatives were used instead of the cost-ineffective drugs, Medicare would save
$1.7 billion.
Conclusion: A widely-cited article by Schwartz et al. (JAMA Int Med, 2014) estimated that in
2009 Medicare spent $1.9-8.5 billion on 26 health services that do not improve health (“no-value
care”). We estimate that in 2018 Medicare Part B spent $1.9 billion on five cost-ineffective drugs
(“low-value care”). To maximize health, this spending should be reallocated to cost-effective
care (“high-value care”).
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PS 1-38 UTILIZATION PATTERNS AND COSTS OF BREAST CANCER GENE
(BRCA) TYPE 1 AND 2 TESTING AND PROPHYLACTIC SURGERIES IN KOREAN
WOMEN: 2010-2017
Health Services, Outcomes and Policy Research (HSOP)
Sung Mo Son, Seoul, Korea, Republic of (South)
Purpose: A study to investigate the impact of health coverage on decision patterns of BRCA
mutation testing and prophylactic surgeries related to breast and/or ovarian cancers.
Method: A total of approximately one hundred and sixty million claims, 1) women in high-risk
pools tested for both BRCA1 and 2 from 2010 to 2017 and 2) the uptake of family history (FH)based screening by women from 2016 to 2017, was collected from Health Insurance Review &
Assessment Service (HIRA)ʼs health insurance claims data, and the retrospective study was
performed. The annual trend, rate and cost in use of both BRCA1 and 2 tested patients and rate
in different age groups were observed before-and-after the approval of health coverage related to
BRCA testing by National Health Insurance Service (NHIS): the insurance reimbursement of
prophylactic salpingo-oophorectomy (RRSO) of BRCA mutation positive was decided in 2012
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and both prophylactic-reducing mastectomy (RRM) and FH-based screening were introduced in
2016 for the first time in Korea. Also, the utilization patterns and costs of BRCA 1 and 2 tested
patients who undergone prophylactic surgery were estimated. Recurrent cases after 2009 and
ongoing treatment cancer patients prior to 2010 were excluded in the targeted analysis of 2010 to
2017ʼs claims data. All statistical analysis was performed with SAS software (version 9.4, SAS
Institute Inc., Cary, NC, USA)
Result: The uptake numbers of high-risk pool-based BRCA testing have rapidly increased with
the average annual growth of 48.2% from 2012 to 2017, which coincides with a clarification of
insurance reimbursement of RRSO related to BRCA testing in 2012. And FH-based BRCA
testing has shown 37.1% increase within two years, coinciding with the new insurance coverage
expansion of RRM and FH-based testing in 2016. The proportion of women using FH-based
testing was 64.6% and high-risk pool-based BRCA tested women was 96.1%.
Conclusion: The health coverage expansion has impacted the dramatic increase in use of BRCA
testing, and there could be a series of additional reasons other than reducing the financial burden:
optimizing clinical decision making or strategies for both clinician and patient, benefiting family
and relatives, increased professional society recommendations, guidelines, scientific evidence,
education and awareness. Additional health economic assessment, such as cost-effectiveness
analysis, is needed to determine the appropriateness of resource allocation.
PS 1-39 PREDICTING PATIENT-LEVEL ANTIBIOTIC ADHERENCE
Health Services, Outcomes and Policy Research (HSOP)
Isabelle Rao, MS1, Adir Shaham, MS2, Amir Yavneh, MS2, Dor Kahana, MS2, Gabriel Chodick,
PhD, MHA3, Itai Ashlagi, PhD1, Dan Yamin, PhD2 and Margaret L. Brandeau, PhD1,
(1)Department of Management Science and Engineering, Stanford University, Stanford, CA,
(2)Department of Industrial Engineering, Faculty of Engineering, Tel Aviv University, Tel Aviv,
Israel, (3)Maccabi Health Services, Institute of Research and Innovation, Tel Aviv, Israel
Purpose: Low antibiotic adherence is a leading problem in developed countries, accelerating
antibiotic resistance and causing a substantial health and economic burden. Past adherence
studies have used relatively homogeneous, small-scale samples. We sought to exploit data from
electronic medical records (EMRs) and demographic data at large scale to predict whether a
patient will purchase a prescribed antibiotic.
Method: We analyzed primary data of a historical cohort from electronic medical records of
250,000 random patients from Maccabi Healthcare services from 2007-2017, representing the
Israeli population. We performed a behavioral pattern analysis to identify adherence patterns
related to each individual patient, the patientʼs socio-demographic environment, the prescribing
physician, and the type of antibiotic. Then, we used machine learning algorithms – in particular,
random forest, logistic regression, neural networks, XGBoost, and naïve Bayes methods – to
conduct a predictive modeling analysis that converted the behavioral insights into a prediction of
the patientʼs purchasing behavior for a specific prescription. We split the data into training,
validation, and test sets by treating each year once as a test set, its previous year as the validation
set, and the rest of the past years as training years.
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Result: A total of 1,815,977 prescriptions were provided by 5988 physicians, for 30 distinct
antibiotic medications, over the 11-year period. Approximately 82% of these prescriptions were
purchased. Behavioral pattern analysis identified medication type, patient and social
characteristics, and physician specialty as the most significant factors affecting antibiotic
purchasing behavior. A simple predictive model based solely on a patientʼs previous antibiotic
purchasing behavior achieved an AUC (average area under the receiving operating characteristic
curve) of 0.564. The model with the best performance achieved an AUC score of 0.684, with the
most important features being the physicianʼs adherence proportion, the proportion of adherence
to the specific medication overall and by age group, the patientʼs historical adherence proportion,
and the adherence proportion of the patientʼs clinic.
Conclusion: Analysis of large-scale patient data can help identify the probability that a patient
will purchase a prescribed antibiotic medication. Such analysis could be used to provide realtime predictions to physicians, who can then counsel the patient about medication importance.
More broadly, in depth analysis of patient-level data can help shape the next generation of
personalized intervention strategies.
PS 1-40 CHANGES IN DIAGNOSIS FOR PNEUMONIA AT VA EMERGENCY
DEPARTMENTS.
Health Services, Outcomes and Policy Research (HSOP)
Barbara Jones, MD, MSc1, McKenna Nevers, MS2, Patrick Alba, MS2, Tao He2, Elizabeth
Rutter, MD3, Makoto Jones, MD4, Adi Gundlapalli, MD PhD5, Charlene Weir, PhD6 and
Matthew Samore, MD7, (1)University of Utah, Salt Lake City VA Health System and SLC
"IDEAS" Center of Innovation, Salt Lake City, UT, (2)University of Utah, Salt Lake City, UT,
(3)University of Utah Dept of Emergency Medicine, Salt Lake City, UT, (4)VHA Salt Lake CIty
and University of Utah, Salt Lake City, UT, (5)IDEAS SLC VA Healthcare System, Salt Lake
City, UT, (6)Department of Biomedical Informatics, School of Medicine, University of Utah,
Salt Lake City, UT, (7)Division of Epidemiology, University of Utah School and VA SLC
"IDEAS" Center of Innovation, Salt Lake City, UT
Purpose: To examine temporal and facility differences in the alignment between initial and final
diagnosis for pneumonia in a population of patients hospitalized from the emergency department.
Method: In a retrospective analysis of encounters at VA Emergency Departments (EDs) with
chest imaging (chest X-ray or computerized tomography) between 2006-2016, we examined
yearly and facility differences in the alignment between initial diagnosis of pneumonia –
identified by natural language processing of clinical notes or ED-assigned ICD-9 or 10 codes –
versus final diagnosis of pneumonia – identified by hospital discharge ICD code – among
hospitalized patients. We calculated positive predictive value (PPV) and sensitivity using 2x2
contingency tables, treating the initial diagnosis as the “test” and final diagnosis as an imperfect
reference standard for true disease. We examined relationships between diagnostic alignment and
ED volume (annual number of visits), ED length of stay, and frequency of CT scans.
Result: Between 2006-2016, 3.98M ED encounters with chest imaging occurred and resulted in
1.7M hospitalizations. 179,682 were initially diagnosed with pneumonia, and 118,969 received a
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final discharge diagnosis for pneumonia, with an overall sensitivity of 69% and PPV of 46%.
The overall proportion of visits with an initial diagnosis increased from 7% to 8% of all
encounters. Sensitivity increased over the study period from 67% to 72%; PPV decreased from
50% to 43%. The number of annual visits per facility increased (2,533 to 3,852), and ED median
length of stay among hospitalized patients increased (3 to 4.5 hours). We observed variation in
diagnostic alignment across facilities (lowest versus deciles of PPV: 35% versus 60%;
sensitivity: 60% versus 78%). Higher-volume facilities demonstrated a non-significantly lower
PPV (Figure). We observed no significant relationship between facility rates of diagnostic
alignment and diagnostic workup including CT scans, ABGʼs and lactate, or 30-day mortality.
All reported differences were statistically significant (p<0.001).
Conclusion: Among a national population of Veterans hospitalized from the ED, changes
between initial and final diagnosis for pneumonia were common. The threshold for the initial
diagnosis of pneumonia in hospitalized patients has decreased over time, and may be related to
increasing ED volume and length of stay.
PS 1-41 POINT-OF-CARE ORAL CYTOPATHOLOGY TOOL FOR ORAL LESION
CHARACTERIZATION: DECISION ANALYSIS OF APPLICATION IN PRIMARY
CARE
Health Services, Outcomes and Policy Research (HSOP)
Stella Kang, MD, MSc1, Rahul Mali, MBBS, MPH1, Alexander Kerr, DDS2 and John McDevitt,
PhD3, (1)new york, NY, (2)NYU College of Dentistry, New York, NY, (3)NYU College of
Dentistry, new york, NY
Purpose:
To compare test-and-treat strategies for patients with potentially malignant oral lesions (PMOLs)
with versus without use of a new point-of-care oral lesion cytopathology test (POCOCT), using
life expectancy (LE).
Method:
We constructed a state-transition model that incorporated patient age, sex, and grades of
dysplasia with differential progression to cancers to compare diagnostic and treatment strategies
for management of patients with PMOLs in the primary care setting. The base case was 60-yearold men with asymptomatic oral lesions. Strategies compared included: 1) usual care with no
routine oral cavity screen; patients are usually detected at symptomatic stages and treated with
surgery; 2) routine oral cavity screening; all patients with PMOLs are treated based on biopsy
results with surgery if positive for dysplasia or malignancy; 3) routine oral cavity screening and
biopsy for all PMOLs, surgery if positive for moderate or severe dysplasia or malignancy,
surveillance for mildly dysplastic lesions; 4) A point-of-care testing strategy (POCOCT), with
biopsy for results of dysplasia and malignancy; 5) POCOCT with biopsy only for moderately or
severely dysplastic or malignant lesions (and surgery for biopsy positivity), and surveillance for
mild dysplasia; 6) POCOCT with biopsy/surgery only for higher grade moderate dysplasia,
severe dysplasia and malignancy and surveillance of lower grade moderate dysplasia and mild
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dysplasia; 7) POCOCT with biopsy/surgery only for severe dysplasia and malignancy, with
moderate or mild dysplasia undergoing surveillance.
Result:
The strategy of using POCOCT, and having only lesions showing moderate/severe dysplasia and
cancer referred for biopsy while mild dysplasia underwent surveillance, had the highest LE of
20.52 life-years (+8.5 days) compared with the next most favorable strategy of routine oral
cavity screening and biopsy of all lesions without use of POCOCT. The POCOCT strategy
extended life expectancy 53 days compared with usual care (no screening). Sensitivity and
specificity of POCOCT affected favorability when values were lower than reported in a clinical
trial. Model results were also sensitive to rates of malignant transformation of mild dysplasia and
metastatic disease rates.
Conclusion:
Use of a new point-of-care device, validated in a clinical trial, extends life expectancy when
compared with biopsy of all PMOLs. The device may guide triage to biopsy for early cancer
detection and without sacrifice in life expectancy when mild dysplasia is observed, mitigating
risks of overtreatment.
PS 1-42 THE NATURAL HISTORY OF DUCHENNE MUSCULAR DYSTROPHY IN
THE CORTICOSTEROID ERA: A SYSTEMATIC REVIEW OF STUDIES FROM
CANADA AND THE US
Health Services, Outcomes and Policy Research (HSOP)
Alison M. Deighton, BASc1, Shelagh M. Szabo, MSc1, Renna Salhany, PharmD2, Meagan
Harwood, MPH1, Jean K. Mah, MD, MSc3 and Katherine L. Gooch, PhD2, (1)Broadstreet
HEOR, Vancouver, BC, Canada, (2)Sarepta Therapeutics, Cambridge, MA, (3)University of
Calgary, Calgary, AB, Canada
Purpose: Duchenne Muscular Dystrophy (DMD) is a severe progressive myopathy characterized
by early loss of ambulation (LOA) and reduced life expectancy. Corticosteroids (CS) have been
observed to delay disease progression. As new treatments emerge, understanding the CS-treated
natural history is important; however, few large cohort studies exist and a synthesis of available
outcomes data is lacking. The objective was to summarize data on age at LOA and death from
CS-treated patients with DMD.
Method: A systematic review was conducted using MEDLINE and EMBASE. This analysis
focused on studies with a minimum sample size ≥50 CS-treated DMD patients from the US and
Canada. Outcomes included mean or median age at, and the percentage experiencing, LOA and
death. Some studies reported estimates from mixed CS-treated and untreated samples.
Result: Of 5,637 records identified, 14 studies reported age at LOA, and 7 studies reported age
at death (2 of which also reported on LOA). Estimates of mean age at LOA, reported in 5
studies, ranged from 9.5 (% with LOA not reported (NR) in n=112) to 12.5 (LOA in 68% of
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n=75) years. Median age at LOA, reported in 10 studies, ranged from 10.0 (LOA in 67.4% of
n=85 [mixed CS]) to 14.0 (% with LOA NR in n=94) years. When mixed CS-treatment samples
were excluded, the range was 12.0 (n=63) to 14.0 (n=94) years (% with LOA NR). Mean age at
death, reported in 3 studies, ranged from 18.1 (in 11% of n=101) to 20.0 (in 13% of n=437)
years. Mean age at death from 3 separate studies specifically enrolling ventilated and nonambulatory patients, ranged from 27.3 (n=25) to 30.4 (n=108) years (% deaths NR); and was
26.0 (47.4% of n=114) years in one study reporting on DMD-related cardiomyopathy. Details of
CS treatment will be presented.
Conclusion: Natural history studies among CS-treated patients from Canada and the US report
that LOA on average occurs at the beginning of the second decade, and death at the third decade
of life. Limitations include: a) mean ages are reported from only a subset experiencing the
outcome; b) variable inclusion criteria reduce comparability of estimates; and c) small sample
sizes with short follow-up impact accuracy. As factors such as genotype variability are presently
unaccounted for, meta-analysis may improve estimate precision.
PS 1-43 AGE- AND TIME- TRENDS IN HARMFUL ALCOHOL USE IN CHINA:
PROJECTING BURDEN AND THE POTENTIAL FOR INTERVENTION BENEFIT
Health Services, Outcomes and Policy Research (HSOP)
Kyueun Lee, Stanford University, Stanford, CA, Joshua Salomon, Ph.D., Center for Health
Policy and Center for Primary Care and Outcomes Research, Stanford, CA and Jeremy D.
Goldhaber-Fiebert, PhD, Stanford Health Policy, Centers for Health Policy and Primary Care
and Outcomes Research, Stanford University, Stanford, CA
Purpose:
Heavy drinking increases the risk for over 200 diseases and injuries. China has seen surges in
total alcohol consumption in recent decades. Currently there is little research illuminating
demographic patterns and trends in high-risk drinking. Such information is necessary for
projecting future burdens of chronic disease and mortality. This study characterizes age- and
time-trends in harmful alcohol use, makes projections through 2027 of these behaviors and
resulting health impacts, and considers potential benefits of targeted mitigation policies.
Methods:
We simulated the change in heavy drinking over time in each cohort (born between 1903-1997)
using a 4-state Markov model (never-heavy drinker, heavy drinker, former heavy drinkers, and
dead). We calibrated cohort- and age-specific rates of initiating or resuming heavy drinking and
of quitting heavy drinking to age- and time-specific prevalence patterns estimated from 18 years
of data from the Chinese Health and Nutrition Surveys. We used Bayesian calibration to
characterize these rates and their uncertainty. We projected the future prevalence of heavy
drinking and age-specific mortality patterns through 2027. To quantify the potential benefits of
mitigation policies, we made counterfactual projections where such policies (1) halted initiating
or resuming heavy drinking or (2) forced quitting heavy drinking among target age groups.
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Outcomes were the average reduction in age-adjusted prevalence and total deaths averted
through 2027.
Results:
Across birth cohorts, rates of initiating or resuming drinking increased in the teens and twenties
and then declined in later ages. Quitting was highest in younger ages, declined through middle
age before rising in later ages. While age-specific patterns were similar, the rates¡¯ magnitudes
differed markedly by birth cohort (Figure Panels A). Given these patterns, we project that heavy
drinking prevalence for males aged 16 and older in 2015 will decline from 7.1% to 5.2% by
2027, due to declines in all age groups except men age 65+. Both mitigation policies have
substantial potential to accelerate the decline in prevalence and avert deaths, especially with the
largest incremental benefits when the interventions expanded to males aged mid-40s and 50s.
(Figure Panels B).
Conclusions:
Capturing age and temporal trends in risky drinking behavior enables future projections of
morbidity and mortality by birth cohort. Such information supports decision makers to target
policies to groups with the largest potential to benefit.
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PS 1-44 THE COST-UTILITY OF MEASLES-MUMPS-RUBELLA IMMUNIZATION
STRATEGIES DURING A MUMPS OUTBREAK
Applied Health Economics (AHE)
Kikanwa Anyiwe1, David Naimark2, Oliver Baclic3, Vinita Dubey4, Marina Salvadori5, Man
Wah Yeung3, Matthew Tunis3 and Beate Sander6, (1)Institute of Health Policy, Management
and Evaluation, University of Toronto; Toronto Health Economics and Technology Assessment
(THETA) Collaborative, University Health Network, Toronto, ON, Canada, (2)Institute of
Health Policy, Management and Evaluation, University of Toronto; Toronto Health Economics
and Technology Assessment (THETA) Collaborative, University Health Network; Division of
Nephrology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, (3)Centre for
Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa,
ON, Canada, (4)Dalla Lana School of Public Health, University of Toronto; Toronto Public
Health, Toronto, ON, Canada, (5)Schulich School of Medicine and Dentistry, Western
University; Department of Paediatrics, Childrenʼs Hospital at London Health Sciences Centre,
London, ON, Canada, (6)Institute of Health Policy, Management and Evaluation, University of
Toronto; Toronto Health Economics and Technology Assessment (THETA) Collaborative,
University Health Network; Institute for Clinical Evaluative Sciences; Public Health Ontario,
Toronto, ON, Canada
Purpose: To assess the cost-utility of measles-mumps-rubella (MMR) immunization strategies
during a mumps outbreak.
Methods: We performed a cost-utility analysis from a healthcare payer perspective to assess the
economic attractiveness of providing an additional MMR vaccine dose to contacts of cases
during a mumps outbreak, relative to no additional dose (status quo comparator). We constructed
a dynamic parallel trials microsimulation Markov model to simulate transmission during a
mumps outbreak. The model structure was informed by mumps natural history and transmission
patterns, and was based on a susceptible-infected-recovered (SIR) infectious disease
conceptualization. The model simulated 1000 hypothetical individuals, representative of the
Canadian population. We modelled transmission during a one-year mumps outbreak; resultant
mumps health-related outcomes and disease costs were modelled over a lifetime time horizon.
We considered primary outcomes of mumps cases averted, life years, quality-adjusted life years
(QALYs), health system costs, and the incremental cost-effectiveness ratio (ICER). QALYs and
costs were discounted at 1.5 percent annually. We evaluated cost-utility relative to a $50,000 per
QALY threshold. We conducted two-dimensional simulation to capture individual-level
variability and parameter uncertainty in sensitivity analysis.
Results: The total mumps outbreak size was larger in the absence of MMR immunization,
relative to the outbreak observed when contacts of mumps cases received a vaccine (i.e., 60 vs.
34 mumps cases). Provision of an additional outbreak dose of MMR vaccine to contacts of ill
individuals averted 26 cases of mumps. Outbreak immunization resulted in per-person increases
in mean life years (50.17 vs. 50.04 LYs; Δ0.13 LYs gained) and mean quality-adjusted life years
(23.24 vs. 23.18 QALYs; Δ0.06 QALYs gained), relative to no outbreak intervention. With a
mean per-person intervention cost of $104.44, providing an outbreak dose of MMR vaccine had
an ICER of $1,721.50 per QALY gained, relative to no additional immunization. At a cost-
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effectiveness threshold of $50,000 per QALY, 87% of the second-order iterations fell below the
selected threshold.
Conclusions: Findings indicate cost-effectiveness of MMR immunization during a mumps
outbreak relative to no intervention. Findings align with existing health economic evaluations
investigating the cost-effectiveness of outbreak immunization programs.
PS 1-45 DO DECISION AIDS FACILITATE SHARED DECISION MAKING
CONVERSATIONS IN UROGYNECOLOGY?
Patient and Stakeholder Preferences and Engagement (PSPE)
Felisha Marques, MPH, Kevan Josloff, MPH, Kristin Hung, MD, May Wakamatsu, MD and
Karen R. Sepucha, PhD, Massachusetts General Hospital, Boston, MA
Purpose:
The goal of this pilot study was to examine the efficacy and acceptability of four decision aids
(DAs) in Urogynecology.
Method:
This before-after study enrolled patients at the time of their visit with a Urogynecologist to
discuss treatment for pelvic organ prolapse, stress urinary incontinence, or overactive bladder.
The four DAs were worksheets that elicited patients’ goals, and pros and cons of each option. In
the control arm, the visit was conducted per usual care, without a DA. In the intervention arm,
providers were encouraged to use the DAs to help guide counseling during the visit. Patients and
providers were surveyed after the visit. Patient surveys included questions on treatment
preference, condition specific knowledge questions, SURE, CollaboRATE, and Shared Decision
Making Process (SDM) scales. The provider surveys assessed perception of the decision making
process, and the length of the visit.
Result:
66/71 eligible patients were recruited (33 in each arm). Patients were on average 59 years old,
80% were white, and 63% had a college degree. The demographics did not differ between arms
(all p s>0.46). In the intervention arm, providers reported using the DAs in 24 of 33 interactions
(73%). The reason for non-use was the DA was not appropriate for the patientʼs clinical
condition. Patients in the intervention arm had higher knowledge scores compared to the control
(72% v. 60%, p=0.06). Patients in the intervention arm reported more Top Scores on the SURE
scale (91% v. 73%, p= 0.11) and on the CollaboRATE scale (75% v. 52%, p= 0.07). The SDM
Process scores were similar for both groups (Intervention=3.2, Control=3.2, p=0.96). Patients in
the intervention arm were more likely to have a clear treatment preference (85% v. 67%,
p=0.08). Additionally, the percentage of visits rated “normal length” by providers was similar
(Intervention=70%, Control=76%, p=0.78.).
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Conclusion:
This pilot found that use of short in-visit DAs for pelvic organ prolapse, stress urinary
incontinence, and overactive bladder was acceptable to Urogynecologists. Furthermore, the DAs
resulted in higher knowledge scores and communication ratings, and less decisional conflict,
although the results were not statistically significant due to the relatively small sample size. A
larger study is warranted to examine the impact of these tools on decision quality as well as
treatments choices in a broader patient population.
PS 1-46 DEVELOPMENT OF A PREFERENCE BASED SINGLE INDEX FOR THE VR12 IN CANADA
Patient and Stakeholder Preferences and Engagement (PSPE)
Nick Bansback, PhD, School of Population and Public Health, University of British Columbia;
Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, Brendan Mulhern,
MRes, Centre for Health Economics Research and Evaluation, University of Technology
Sydney, Ultimo, NSW, Australia, Richard Norman, PhD, Curtin University, Perth, WA,
Australia, Logan Trenaman, PhD, Centre for Health Evaluation and Outcome Sciences,
Vancouver, BC, Canada, Rebecca Metcalfe, BA Hons., MA, University of British Columbia,
Vancouver, BC, Canada, Richard Sawatzky, RN, PhD, Trinity Western University, Langley, BC,
Canada, John Brazier, BA, MSc, PhD, The University of Sheffield, Sheffield, United Kingdom,
Donna Rowen, PhD, University of Sheffield, Sheffield, United Kingdom and David GT
Whitehurst, PhD, Simon Fraser University, Burnaby, BC, Canada
Purpose:
To estimate Canadian population-based preference weights for the Veterans Rand 12-item (VR12), a widely used patient reported outcome measure.
Method:
Members of the Canadian general population were recruited to complete a web survey in English
or French. All participants completed 10 discrete choice experiment (DCE) questions, comprised
of two VR-12 health states. Based on previous consideration of the measurement properties of
the VR-12, health states were developed using eight questions: moderate activities; accomplish
(physical); accomplish (emotional); pain; calm and peace; energy; downhearted and social
activities. One additional attribute related to length of life, termed ‘life-years,’ was also included,
resulting in 9 attributes in total. Cognitive interviews and pilot testing helped develop the survey
and instructions which facilitated responses to a total of 200 unique DCE pairs. Results were
modelled using conditional and latent class logit regression, where each dimension level was
interacted with duration, with the coefficients used to estimate a preference index such that full
health and death were valued at 1 and 0, respectively.
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Result:
Three thousand, three hundred and eighty completed the survey with 8% completing in French.
Respondents were broadly representative of the Canadian population in terms of age, gender and
geographical location. The models found that ‘feeling downhearted all of the time’ and ‘pain
interfering with normal work all the time’ were the primary drivers of utility weights (0.29 and
0.25 respectively). 12% of respondents were identified to provide inconsistent responses, but
their exclusion did not change results meaningfully. Latent class models identified heterogeneity
in preferences, but no clear patterns defined class membership.
Conclusion:
The results of this study facilitate the derivation of utility values based on Canadian preferences
for the VR-12 instrument. These can be used to calculate QALYs for economic evaluation, and
single indices to facilitate comparisons between populations. Limitations of the study include the
utilization of an online sample requiring a cognitively demanding task, which likely limited the
inclusion of the preferences of some marginalized groups. Further analysis will look to deriving
estimates for the SF-12 and how preference heterogeneity can be better incorporated.
PS 1-47 THE FIRST PRENATAL VISIT: AN OPPORTUNITY FOR IMPROVE
SHARED DECISION-MAKING FOR PATIENTS’ USE OF PRENATAL GENETIC
TESTS
Patient and Stakeholder Preferences and Engagement (PSPE)
Ruth Farrell, MD, MA1, Christina Collart1, Madelyn Pierce1, Richard Frankel, PhD2,
Brownsyne Tucker Edmonds, MD, MPH, MS2, Uma Perni, MD1, Edward Chien, MD3, Marissa
Coleridge, MS, CGC1 and Susannah Rose, PhD1, (1)Cleveland Clinic, Cleveland, OH, (2)Indiana
University School of Medicine, Indianapolis, IN, (3)MetroHealth Medical Center, Cleveland,
OH
Purpose: Discussions at the first prenatal visit set the stage for patients to make informed
decisions about their genetic testing options. Yet, these initial discussions can be some of the
most challenging given the nature of such discussions, increasing complexity of the testing
options, and logistics of the first prenatal visit. We conducted a study to examine the nature and
content of the discussions that take place at the onset of prenatal care to gain a better
understanding of how to structure shared decision-making and support patients’ informed
choices about prenatal genetic screens and diagnostic tests.
Method: We conducted direct observations of 84 audio-recorded initial prenatal outpatient visits
to examine the nature and content of the discussions about prenatal testing that take place at the
first prenatal visit. Transcripts of the audio-recordings were doubled coded using a context
checklist to identify terms and concepts as outlined by professional organizations. Continuous
measures were summarized using means and categorical factors were analyzed using Fisherʼs
Exact tests using SAS.
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Result: Discussions placed emphasis on trisomy 21 (83.1%) compared to trisomy 18 (56.6%)
and 13 (49.4%). Discussions about diagnostic testing placed greater emphasis on amniocentesis
as an option compared to chorionic villus sampling (44.6% vs. 20.8%). There was limited
discussion of how to prepare patients to interpret screen results and contextualize post-screen
options. Just over half of the visits (50.6%) included discussion of post-test options for a positive
result. There was little discussion about a false positive result (25.3%), with providers in practice
> 10 years less likely to address this concept (p = 0.002). No other associations by provider years
in practice or training, or by patient characteristics (age, parity) were noted. Overall, there was
little discussion of the detection rate of cell free DNA screening (cfDNA) (28.9%), false negative
results (4.8%), or the concept of positive predictive value (1.2%). Values and preferences as they
related to testing were discussed in only 43.4% of the visits.
Conclusion: The growing availability of genomic-based tests introduces challenges to
addressing the decision-making needs of pregnant patients. These data demonstrate an
opportunity to structure shared decision-making discussions in early pregnancy to support
patients’ informed, values-based decisions about an expanding array of prenatal testing options.
PS 1-48 HEALTH PREFERENCE RESEARCH IN EUROPE: A REVIEW OF ITS USE
IN APPROVAL, REIMBURSEMENT, PRICING DECISIONS
Patient and Stakeholder Preferences and Engagement (PSPE)
Axel Mühlbacher, PhD1, Janine A. van Til, PhD2 and Christin Juhnke, B.Sc., M.A.1,
(1)Hochschule Neubrandenburg, Neubrandenburg, Germany, (2)University of Twente,
Enschede, Netherlands
Purpose: HTA and regulatory decisions involve value judgements. As patient groups, industry,
and regulatory agencies conduct more preference studies to quantify these judgements, a better
understanding of the methods and practices is needed. Currently, there is no systematic mapping
of the use of preference data in Europe.
Methods: This study examines European decision makers’ consideration and use of quantitative
preference data. A mixed method approach was used based on a systematic literature review,
survey and subsequent interviews with decision makers and experts, to identify the use of
quantitative preference data by all relevant HTA bodies and regulatory authorities of the EU
member states, and to identify key standards and guidelines.
Results: Preference data utilization was identified in 22 countries and at a European level.
Within the survey, a total of 62 survey responses were received. Many respondents reported that
their agencies were responsible for supporting more than one type of decision, with 69.0%
supporting approval decisions, 64.3% supporting reimbursement decisions, 61.9% supporting
pricing decisions, and 64.2% supporting guideline development. The most prevalent use (19
countries) was citizen/general population preferences, collected using time-trade off or standard
gamble methods to inform health state utility estimation. Preference data was also used to: 1)
value other impact on patients; 2) incorporate non-health factors into reimbursement decisions;
and 3) estimate opportunity cost. Pilot projects were identified (6 countries and at a European
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level), with a focus on multi-criteria decision analysis methods and choice-based methods to
elicit patient preferences.
Conclusions: While quantitative preference data support reimbursement and pricing decisions in
most European countries, there was no utilization evidence in European-level marketing
authorization decisions. Much of this use of preference data can be understood within the
standard framework of economic analysis adopted by many HTA agencies; either in in the form
of: standard ways to estimate QALYs; ways to broaden the impacts of technologies captured in
the QALY; or ways to weigh health gain with other decision-making criteria, such as disease
severity or innovativeness.
PS 1-49 PREFERENCES REGARDING BIOMEDICAL PREVENTION OF BACTERIAL
SEXUALLY TRANSMITTED INFECTIONS AMONG GAY, BISEXUAL AND OTHER
MEN WHO HAVE SEX WITH MEN
Patient and Stakeholder Preferences and Engagement (PSPE)
Theresa H.M Kim, PhD, MSc, IWK Health Centre, Halifax, NS, Canada, Darrell Tan, MD
FRCPC PhD, St Michaelʼs Hospital, Toronto, ON, Canada, Laura Anne Fusca, BSc, Dalla Lana
School of Public Health, University of Toronto, Toronto, ON, Canada, Troy Grennan, MD MSc
FRCPC DTM&H, BC Centre for Disease Control, Vancouver, BC, Canada, Mark Hull, MD, The
University of British Columbia, Division of Infectious Diseases, Department of Medicine,
Vancouver, BC, Canada, Ann Burchell, PhD, St. Michaelʼs Hospital, Toronto, ON, Canada and
Ahmed M. Bayoumi, MD, MSc, University of Toronto, Toronto, ON, Canada
Purpose: Novel biomedical strategies, such as routinized screening and antibiotic-based
prophylaxis, for preventing bacterial sexually transmitted infections (STIs) among gay, bisexual
and other men who have sex with men (gbMSM) will be maximally effective if there is targeted
high uptake. We conducted a discrete choice experiment (DCE) to determine participants’
preferences and tradeoffs regarding delivery of sexual health services among gbMSM.
Method: We recruited gbMSM who were at increased risk for STIs from sexual health clinics.
Each participant completed a DCE questionnaire consisting of 12 choice sets, each with two
alternatives. Attributes and levels were: distance to the clinic (1km, 3km, 5km, 7km, 9km, or
11km), type of health care setting (family doctorʼs office, sexual health clinic, or hospital-based
specialist clinic), type of provider (physician or nurse), hours of operation (business, evening, or
weekend hours), and type of testing (nominal or anonymous). We analyzed results using mixed
logistic regression and calculated how much further individuals would travel in order to receive a
preferred service and evaluated heterogeneity by examining the predicted standard deviation of
attribute coefficients.
Result: Of 424 participants, 54% were white and the median age was 31 (interquartile range
[IQR] 26 to 39). Participants reported a median of 6 (IQR 3 to 13) male sexual partners in the
preceding six months. We excluded 24 participants who had all missing data or gave invariant
responses. Participants preferred receiving care in a sexual health clinic over a family doctorʼs
office (willing to travel an extra 1.64km; 95%CI 0.80 to 2.47) or a hospital-based specialist clinic
(1.84km; 95%CI 0.99 to 2.68). Participants were willing to travel an extra 0.76km (95%CI 0.23

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E57

to 1.29) to see a physician rather than a trained sexual health nurse and were willing to travel an
extra 4.80km (95%CI 3.76 to 5.84) to obtain anonymous testing results compared to nominal
testing. Participants were indifferent regarding clinic hours. We observed the greatest
heterogeneity in preferences for anonymous testing and receiving care at an STI clinic.
Conclusion: Anonymous STI testing is an important aspect of care for many gbMSM, although
preferences varied considerably. Our results have important implications for optimal planning
regarding the number, type, and location of STI services in a city.
PS 1-50 MAPPING PATIENT PREFERENCES TO CONTRACEPTIVE TREATMENT
CHOICE WITH THE USE OF A SHARED DECISION-MAKING AID
Patient and Stakeholder Preferences and Engagement (PSPE)
Shirley Y. Jiang, BS1, Sylvia Lambrechts, MPH, MA2, Meghana Munnangi3, Lorna Kwan,
MPH1, Mona Abutouk4, Christopher S. Saigal, MD, MPH1 and Aparna Sridhar, MD MPH1,
(1)David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA,
(2)Department of Medicine, UCLA Health, Los Angeles, CA, (3)Emory Rollins School of Public
Health, Atlanta, GA, (4)UC Davis School of Medicine, Sacramento, CA
Purpose:
Contraceptive choice is a highly preference-based decision. This analysis describes the
concordance of elicited patient preferences around outcomes of various types of contraceptives
with contraceptive choice. Concordance of preference with treatment choice is viewed as a
hallmark of decision quality.
Methods:
A web-based decision aid (DA) that provides contraceptive education and patient preference
elicitation using conjoint analysis was used to support womenʼs contraceptive choice in a high
volume academic obstetrics/gynecology clinic. 106 women of reproductive ages 18-49 who had
made an appointment for contraceptive consultation and had not yet made a contraceptive choice
were invited to review the DA prior to their consultation. The DA used quantified preferences
generated from conjoint analysis in a personalized decision analysis, which also incorporated
patient clinical factors that stratified possible outcomes and side effects. A report was
subsequently generated that ranked in order both the patientʼs values and their highest expected
value contraceptive methods. A latent class analysis was performed to determine whether
subgroups of preferences elicited by the DA could map to contraceptive methods ultimately
chosen by patients, including long-acting reversible contraceptives (LARC) vs. non-LARC and
hormonal vs. non-hormonal.
Results:
Of the 106 women in this analysis, 44% chose LARC and 93% chose a hormonal method. These
women were grouped into two preference “profiles” using latent class analysis. Profile 1 was
most concerned about pregnancy and persistent pain/cramping from birth control. Profile 2 had
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relatively lower concerns about pregnancy and persistent cramping, and higher concerns about
treatment intensity, control of contraception, and delay in fertility if discontinued. When
comparing Profiles 1 and 2, 56% vs. 41% chose LARC (p= 0.1794), and 100% vs. 91% chose a
hormonal method (p= 0.1946). In a multivariate logistic regression controlling for age, race,
marital status, and employment, Profile 1 was found to be 2.16 times more likely than Profile 2
to select LARC, however this was not significant (95% CI 0.84, 5.57).

Conclusions:
Our cohort of women clustered into two specific preference profiles, which seem to align with
the decision to choose LARC. However, preference cluster was not associated with treatment
choice for LARC after adjusting for clinical factors. In future studies, physician recommendation
can be studied as a factor that may impact the relationship between preferences and treatment
choice.
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PS 1-52 A NOVEL DECISION TREE ALGORITHM TO IMPROVE CLASSIFICATION
FOR IMBALANCED RARE EVENT OUTCOMES
Quantitative Methods and Theoretical Developments (QMTD)
Yao-Chi Yu1, Liang Wang1, Jr-Shin Li, Ph.D.1 and Su-Hsin Chang, PhD2, (1)Department of
Electrical and Systems Engineering, Washington University in St. Louis, St. Louis, MO,
(2)Division of Public Health Sciences, Department of Surgery, Washington University in St.
Louis, St. Louis, MO
Purpose: Decision tree is commonly used for classification. Prediction of imbalanced outcomes,
such as rare medical adverse events, is challenging due to the much smaller number of failure
cases than success cases. We aimed to develop a novel classification tree algorithm to counter
the imbalance data and to improve prediction accuracy.
Method: We developed an optimal transport (OT) distance-based, multi-way node splitting
decision tree learning algorithm for binary-labeled imbalanced data. Optimal Transport (OT)
distance seeks the most efficient way of transforming one probability distribution to another. At
each split, probability distributions of positive and negative class labels were constructed based
on categorical values of a given feature. During tree growth, OT distance of each feature with the
greatest OT distance was selected to grow the branch. In addition to a single decision tree, we
further developed an OT distance-based random forest consisting of OT-based decision trees. To
evaluate the algorithm performance in comparison to the standard algorithms, i.e., Classification
and Regression Tree (CART) and random forest, we used two datasets as examples: A)
immunotherapy dataset (imbalance ratio of treatment success over failure 3.73, n=90, 7 features)
from the UCI machine learning repository; and B) liver transplant dataset (imbalance ratio of
graft survival over failure  30-d after transplant 16.53, n=29,182, 33 features) from the Organ
Procurement and Transplantation Network.
Result: Using the OT distance-based decision tree, the area under the receiver operating
characteristic curve (AUROC) increased from 0.6612 (standard CART) to 0.7754 in example A,
and increased from 0.5088 (standard CART) to 0.5987 in example B. Using the OT distancebased random forest, AUROC increased from 0.7176 (standard random forest) to 0.9014 in
example A and increased from 0.5445 (standard random forest) to 0.6426 in example B.
Conclusion: We demonstrated that the OT-distance based decision tree learning algorithms
achieved better predictive power over standard tree-based algorithms using two examples.
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PS 1-53 DEVELOPMENT AND VALIDATION OF MICROSIMULATION MODELS
FOR PREDICTING COLORECTAL CANCER SCREENING BENEFITS IN EUROPE
Quantitative Methods and Theoretical Developments (QMTD)
Andrea Gini1, Maaike Buskermolen1, Carlo Senore2, Ahti Anttila3, Dominika Novak Mlakar4,
Piret Veerus5, Erik Jansen, MSc1, Nadine Zielonke1, Sirpa Heinavaara3, Nereo Segnan2, Harry J.
de Koning, MD, PhD1 and Iris Lansdorp- Vogelaar, PhD1, (1)Department of Public Health,
Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands, (2)AOU Città
della Salute e della Scienza, CPO Piemonte, Torino, Italy, (3)Finnish Cancer Registry, Helsinki,
Finland, (4)National Institute for Public Health, Ljubljana, Slovenia, (5)National Institute for
Health Development, Tallinn, Estonia
Purpose: To support European countries in improving their colorectal cancer (CRC) screening
programmes, the EU-TOPIA consortium has developed an online user-friendly tool
(https:\\miscan.eu-topia.org) for allowing European researchers and policymakers to simulate
future benefits of CRC screening using the Microsimulation Screening Analysis-Colon
(MISCAN-Colon) model. In this study, we describe the development and external validation of
four country-specific decision models that, along with the previously published Dutch MISCANColon model, form the basis of this web tool.
Methods: We quantified four MISCAN-Colon country-specific model versions, one each for
Italy, Slovenia, Finland, and Estonia using data from national health institutions (i.e. age-specific
CRC incidence, stage distribution, and survival observed in the period before the implementation
of CRC screening programs). Subsequently, the models were externally validated using the best
available evidence for screening effectiveness in their European region. Published evidence,
respectively, from Northern, Southern, and Eastern Europe were selected for validating the
Finnish/Estonian, Italian, and Slovenian model. We selected the Screening for COlon REctum
[SCORE] trial and the Florentine fecal immunochemical test (FIT) screening study for Italy; the
Norwegian Colorectal Cancer Prevention [NORCCAP] trial and the guaiac fecal occult blood
test (gFOBT) Finnish population-based study for Estonia and Finland. As no published evidence
was found from Eastern Europe, an external validation for the Slovenian model was not
performed. In validating the models, primary outcome was CRC mortality reduction due to
screening.
Results: The four models reproduced country-specific CRC incidence rates and stage
distributions in the pre-screening period. However, models for Italy, Estonia, and Slovenia
overestimated CRC incidence rates among individuals aged 85 years or older (Table 1,
calibration). The Italian model replicated CRC mortality reductions observed in Italy (SCORE
trial and Florentine FIT study). Both Estonian and Finnish models replicated CRC mortality
reductions observed in the NORCCAP Trial and in the Finnish gFOBT study (Table 1, external
validation). CRC mortality reductions were predicted slightly larger than those observed (except
for NORCCAP trial), but consistently within the corresponding 95% confidence intervals.
Conclusions: Our findings corroborate the MISCAN-Colon model reliability, which can
represent an additional tool for policymakers and researchers, aimed to support policy-making on
quality-assured population-based screening for CRC in Europe.
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PS 1-54 PRACTICAL CONSIDERATIONS FOR THE EFFICIENT COMPUTATION OF
THE EXPECTED VALUE OF SAMPLE INFORMATION TO PRIORITIZE
RESEARCH IN HEALTH CARE
Quantitative Methods and Theoretical Developments (QMTD)
Natalia R. Kunst, MSc, Department of Health Management and Health Economics, Faculty of
Medicine, University of Oslo, Oslo, Norway, Edward C.F. Wilson, PhD, Health Economics
Group, Norwich Medical School, University of East Anglia, Norwich, United Kingdom,
Fernando Alarid-Escudero, PhD, Drug Policy Program, Center for Research and Teaching in
Economics, Aguascalientes, AG, Mexico, Gianluca Baio, PhD, University College London,
London, United Kingdom, Alan Brennan, BSc, MSc, PhD, Health Economics and Decision
Science, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield,
United Kingdom, Michael Fairley, MS, Department of Management Science and Engineering,
Stanford University, Stanford, CA, David Glynn, PhD, University of York, York, United
Kingdom, Jeremy D. Goldhaber-Fiebert, PhD, Stanford Health Policy, Centers for Health Policy
and Primary Care and Outcomes Research, Stanford University, Stanford, CA, Christopher
Jackson, PhD, MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom,
Hawre Jalal, MD, PhD, University of Pittsburgh Graduate School of Public Health, Pittsburgh,
PA, Nicolas A. Menzies, PhD, Harvard TH Chan School of Public Health, Dept. of Global
Health and Population, Boston, MA, Mark Strong, PhD, School of Health and Related Research
(ScHARR), University of Sheffield, Sheffield, United Kingdom, Howard Thom, PhD, University
of Bristol, Bristol, United Kingdom and Anna Heath, PhD, The Hospital for Sick Children,
Toronto, ON, Canada
Purpose: Value of information (VOI) can quantify the expected value of a specific study that
generates new data. For policy-makers, VOI can guide decisions about the design of future
studies. Historically, a computationally expensive Monte Carlo estimation method for the
Expected Value of Sample Information (EVSI) has restricted its use in study design. Recently,
four methods have overcome this barrier to make EVSI more feasible and accessible. We have
compared these methods to provide good practice recommendations for EVSI computation.
Method: In November 2018, members of the Collaborative Network for Value of Information
(ConVOI) surveyed the developers of four EVSI approximation methods, published in Strong et
al. [1], Menzies [2], Jalal and Alarid-Escudero [3], and Heath et al. [4], to identify the strengths
and limitations, inputs, analyst skills and software required to perform the VOI analyses with
each method.
Result: Table highlights the strengths and limitations for these four methods. All methods
require a probabilistic sensitivity analysis (PSA) from a decision-analytic model. One method reruns this model to estimate EVSI. Analysts must master at least one of the following skills:
regression modeling, likelihood specification, and Bayesian modeling. All methods are
programmed in the statistical computing language R, while two utilize online applications to
display or calculate EVSI.
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Conclusion: We provide a practical guide to EVSI approximation. Our results inform choices
about the best method for a given application and allow analysts to determine the method that is
most appropriate for their skills.

Characteristic
Strengths
Estimates EVSI for complex studies with many outcomes
Requires only PSA
Uses non-parametric regression
Estimates EVSI for different study sizes with
same computational cost
Quantifies uncertainty in EVSI
Limitations
Requires accurate EVPPI estimation
Requires study data simulation
Requires simulated study data summarized in a lowdimensional summary statistic
Struggles if proposed study has >5 outcomes
May provide inaccurate EVSI for specific proposed
studies/previous data

Strong Menzies Jalal Heath

X
X
X

X
X

X
X
X
X

X

X
X
X

X
X
X

?

X
X

X
X

X

[1] M. Strong, et al. Medical Decision Making, 35(5):570–583 (2015)
[2] N. Menzies. Medical Decision Making, 36(3):308–320 (2016)
[3] H. Jalal and F. Alarid-Escudero. Medical Decision Making, 38(2):174–188 (2018)
[4] A. Heath et al. Medical Decision Making. In press.

PS 1-55 HEALTH YEARS IN TOTAL (HYT): A NEW HEALTH OBJECTIVE
FUNCTION FOR COST-EFFECTIVENESS ANALYSIS
Quantitative Methods and Theoretical Developments (QMTD)
Anirban Basu, PhD, Josh Carlson, MPH, PhD and David Veenstra, PharmD, PhD, The
Comparative Health Outcomes, Policy, Economics (CHOICE) Institute, School of Pharmacy,
University of Washington, Seattle, WA
Purpose: Despite the important advantages of quality-adjusted life-year (QALY), distributional
issues generated by the use of QALY present a critical challenge that has resulted in the
exclusion of its use in some public decision making (e.g. US Medicare) on health care in the US.
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There is tremendous pushback in the use of QALYs from patient groups and some state
legislatures in the US. Alternatives to QALY (such as Equal Value of Life, EVL) have not
gained traction as their use raises other efficiency issues. For example, EVL fails to recognize
quality of life gains during added years of life. We present a new effectiveness metric for CEA,
Health Years in Total (HYT), that overcomes both the distributional issues raised by QALYs and
the efficiency challenges of EVL.
Methods: The HYT framework fundamentally separates life-expectancy changes and quality of
life changes in an additive scale.

We provide conceptual and theoretic arguments for use of HYT and illustrate their performance
against QALYs and EVL using several example. We also present methods to calculate HYT in a
CEA model, derive CEA thresholds for HYT corresponding to the QALY–based thresholds in
the US, and study the policy implications for the use of HYT using recently published
technology evaluations.
Results: The HYT framework overcomes the issues around QALYs and EVLs across all of the
examples studied. Its calculation in decision analytic models are fairly straightforward.
Identifying the percentiles for $50K/QALY, $100K/QALY and $150K/QALY in the distribution
of $/QALY ratios in the US, we infer the corresponding threshold for HYT to be $34K/HYT.
$72K/HYT and $89K/HYT respectively.
Applying them to selected Institute of Clinical and Economic Review (ICER)ʼs reports on costeffectiveness of alternative interventions we find that HYT alters the relative rank of
technologies, favoring life extending technologies more that only QOL enhancing ones,
compared to QALY-base ranking. Of the forty-one technologies studied by ICER, one
technology falls below the lower threshold for HYT but not for QALYs, fifteen technologies fall
above the upper threshold for HYT but not for QALYs.
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Conclusions: The HYT framework may provide a viable alternative to both the QALY and the
EVL; its application to diverse healthcare technologies and stakeholder assessment are important
next steps in its development and evaluation.
PS 1-56 OBESITY PARADOX FOR PATIENTS WITH CHRONIC KIDNEY DISEASE:
A DECISION ANALYSIS
Quantitative Methods and Theoretical Developments (QMTD)
Rashikh Choudhury, MD1, Dor Yoeli, MD2, Hunter Moore, MD, PhD2, Gerard Hoeltzel, MD3,
Akshay Pratap, MD4, Kristoffel Dumon5, Kendra Conzen, MD4 and Trevor Nydam, MD2,
(1)University of Colorado, DENVER, CO, (2)University of Colorado Hospital, Aurora, CO,
(3)University of Pennslyvania, Philadelphia, PA, (4)University of Colorado, Aurora, CO,
(5)University of Pennsylvania, Philadelphia, PA
Purpose: Obesity has been associated with both a paradoxical improvement in survival among
ESRD patients as well as with increased progression of chronic kidney disease. Thereby, the
optimal weight management strategy for obese CKD patients is unknown.
Methods: A Markov, decision analytic state transition model was created to simulate the life of
3,000 obese patients with CKD stage 3b, as they progressed to ESRD, transplantation, or death.
Life expectancy following conservative medical weight management, Roux-en-Y Gastric Bypass
(RYGB) and Sleeve Gastrectomy (SG) were estimated. Base case patients were defined as being
55 years old and having a pre-intervention BMI of 40 kg/m2. Sensitivity analysis of initial BMI
was performed. All Markov parameters were extracted from literature review and expert opinion.
Results: RYGB and SG were associated with improved survival for patients with a preintervention BMI of > 39.6 kg/m2. Compared to medical weight management, base case patients
who underwent RYGB gained 10.4 months of life, and gained 8.1 months of life following SG.
Conclusion: Balancing the progression of CKD with the paradoxical improved survival while in
ESRD for obese patients requires selective use of weight management strategies. RYGB and SG
improved survival for CKD patients with Class III obesity, but not for patients with Class I and
Class II obesity. As such aggressive weight loss interventions should be reserved for patients
with Class III obesity, while more conservative methods should be offered to those with Class I
and II obesity.
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PS 1-57 A NOVEL METHOD FOR ASSESSING FEASIBILITY OF GENERATING
REAL-WORLD DATA BASED CONTROL GROUPS
Quantitative Methods and Theoretical Developments (QMTD)
Wei-Jhih Wang, MS, The Comparative Health Outcomes, Policy, and Economics (CHOICE)
Institute, Seattle, WA, Aasthaa Bansal, BS, PhD, The Comparative Health Outcomes, Policy,
and Economics (CHOICE) Institute, University of Washington, Seattle, WA, Caroline Bennette,
PhD, Flatiron Health, New York, NY and Anirban Basu, PhD, The Comparative Health
Outcomes, Policy, Economics (CHOICE) Institute, School of Pharmacy, University of
Washington, Seattle, WA
Purpose:
One must replicate retrospective trial data using real world data (RWD) to demonstrate that
RWD can be used to generate control arms for single-arm trials. However, often we only have
summary but not individual data from retrospective trials. Correlations that exist among baseline
covariates in RWD may be different from trial data, and a different correlation structure would
affect outcomes, especially if the outcomes data generating process includes effect modifiers or
non-linear models. To address this issue, we develop an iterative algorithm combining copulas
with propensity score methods that can simulate individual-level trial data in control arms using
published trial summary data and individual-level RWD.
Method:
We developed an algorithm that iteratively uses copula and resampling, which are based on the
estimated propensity score for likelihood of enrollment in a clinical trial given participants’
characteristics, to approximate the true potential correlation matrix of participants’
characteristics in the trial and generates individual-level trial data accordingly. The validation
was performed using Monte-Carlo simulation with several scenarios. Finally, we applied an
outcomes model, trained in real-world data as a function of baseline characteristics, to predict
outcomes using the simulated individual-level trial data and compared to actual trial results.
Result:
Across all of our scenarios, we found that the algorithm was successful in closely reproducing
the joint distribution of baseline characteristics in the trial data using only summary data from
trial and the real-world data. For example, in a scenario with two continuous variables (age and
logarithm of income), estimated correlation of covariates in a trial (-0.17) is very close to that in
the true trial (-0.21), while the correlation of covariates in the real-world data is 0.04. In addition,
compared to using the naïve correlation from RWD, using estimated correlation of the trial from
our algorithm is able to closely predict outcomes (mean = 3,568, SD=799) for the true clinical
trial (mean = 3,570, SD= 810).
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Conclusion:
We develop an iterative approach useful to generate external control groups using RWD when
only trial summary data is available. Future work will illustrate this method in an actual trial
setting. This method can also be used for other applications, e.g. to assess the generalizabilityof
clinical trials given participants’ characteristics, from past trials where only summary data are
available.
PS 1-58 COMPARING THE PERFORMANCE OF STATISTICAL ADJUSTMENT
METHODS BY RECOVERING THE EXPERIMENTAL BENCHMARK FROM THE
REFLUX TRIAL
Quantitative Methods and Theoretical Developments (QMTD)
Luke Keele, PhD, University of Pennsylvania, Philadelphia, PA, Stephen O'Neill, PhD,
National University of Ireland Galway, Galway, Ireland and Richard Grieve, PhD, London
School of Hygiene and Tropical Medicine, London, United Kingdom
Purpose:
To contrast the performance of a variety of statistical adjustment methods for the estimation of
average treatment effects by recovering an experimental benchmark from the REFLUX study.
Methods:
REFLUX was a multicentre randomised controlled trial (RCT) (N=357) that contrasts the
effectiveness of laparoscopic surgery with medical management for patients with GastroOesophageal Reflux Disease (GORD). The study design also included data collection for an
observational preference-based treatment contrast (N=453). Primary outcomes is a EQ-5D is a
standardised measure of health status taken at 3 months. We use the average treatment effect
from the RCT act as a benchmark against which to compare estimates obtained by applying a
variety of methods to the observational component of the study. We applied a variety of
adjustments for observed confounders including regression methods, matching and weighting
methods, and machine learning based methods including random forests based methods and an
ensemble using a Superlearner. For each method, we estimated the ATE and associated
confidence interval, and calculated the discrepancy with the RCT estimate.
Results:
The estimated treatment effect was quite sensitive to the choice of statistical adjustment method.
Stata based matching methods were unable to recover the experimental benchmark. Methods
based on random forests and propensity score weighting produced estimates that did not
significantly differ from the experimental benchmark.
Conclusions: We find important variation in which statistical adjustment methods recover an
experimental benchmark. Our results suggest analysts should implement multiple adjustment
strategies as a robustness check.
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Figure 1: Estimated difference between estimated causal effect and experimental benchmark
with 95% confidence intervals by statistical adjustment method.

PS 1-59 META-MODELLING FOR POLICY SIMULATIONS WITH MULTIVARIATE
OUTCOMES
Quantitative Methods and Theoretical Developments (QMTD)
Huaiyang Zhong, MS1, Golnaz Eftekhari Yazdi, MSc2, Jianing Wang, MS2, Shayla Nolen,
MPH2, Benjamin P. Linas, MD, MPH2, Margaret L. Brandeau, PhD1 and Joshua Salomon,
Ph.D.3, (1)Department of Management Science and Engineering, Stanford University, Stanford,
CA, (2)Section of Infectious Disease, Department of Medicine, Boston Medical Center, Boston,
MA, (3)Center for Health Policy and Center for Primary Care and Outcomes Research, Stanford,
CA
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Purpose: A metamodel is a simplified approximation of the relationships between inputs and
outputs in a simulation model. A challenge in metamodeling for policy analysis is that there are
often multiple correlated outputs of interest: for example, costs and effects of different policy
choices. We develop a framework for metamodeling that accommodates multivariate outcomes,
and we compare alternatives for the choice of the base learning algorithm.
Methods: To generate metamodels for multivariate outcomes, we combined two algorithm
adaptation methods – multi-target stacking (MTS) and regression chain with maximum
correlation chain (RCCC) – together with different base learners including linear regression
(LR), elastic net (EN) with second-order terms, Gaussian process regression (GPR), random
forests (RFs), and neural networks (NNs). We optimized the integrated models using variable
selection and hyperparameter tuning. We compared approaches in terms of model accuracy,
efficiency, and interpretability. To illustrate the framework, we used inputs and outputs from an
individual-based decision analytic simulation model of testing and treatment strategies for
chronic hepatitis C virus in correctional settings. The training data set included 2,000
simulations, each summarized by 37 input variables and 60 output variables (5 economic and
health outcomes for 6 alternative strategies measured over 2 time horizons).
Results: The output variables from the simulation model were heavily correlated (average
rho=0.58). Without multioutput algorithm adaptation methods, in-sample fit (measured by R2)
ranged from 0.881 for LR to 0.987 for GPR. Inclusion of multioutput algorithm adaptation
methods increased R2by 0.004 on average across all base leaners, and variable selection and
hyperparameter tuning added 0.009. In terms of model efficiency, simpler models such as LR,
EN, and RF required minimal training and prediction time. GPR had short prediction time, but
the training time was heavily affected by the size of the training dataset. NN had the longest
training and prediction time. For model interpretability, LR and EN have clear advantages, but
we also consider methods for improving interpretability of other models.
Conclusions: This study provides a framework for metamodeling in policy analyses with
multivariate outcomes of interest. While the advantages and disadvantages of specific learning
algorithms may vary across different modeling applications, we expect that the general
framework presented here will have broad applicability to decision analytic models in health and
medicine.
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PS 1-60 VALIDATING A NOVEL COLORECTAL CANCER NATURAL HISTORY
MICROSIMULATION MODEL: THE COLORECTAL CANCER AND ADENOMA
INCIDENCE MICROSIMULATION MODEL (CRC-AIM)
Quantitative Methods and Theoretical Developments (QMTD)
Andrew Piscitello, MAT1, Michael Matney, MS2, Leila Saoud2, Marcus Parton2, Bijan J. Borah,
Ph.D.3, Paul Limburg, MD, MPH2 and Harald Rinde, MD, MBA4, (1)EmpiriQA LLC, Long
Grove, IL, (2)Madison, WI, (3)College of Medicine, Mayo Clinic, Rochester, MN, (4)Monaco,
Monaco
Purpose: Describe the development and validation of the Colorectal Cancer and Adenoma
Incidence Microsimulation model (CRC-AIM), a programmable CRC model that provides a
platform for collaborative simulation analyses.
Methods: We utilized the Cancer Intervention and Surveillance Modeling Network (CISNET) as
a foundation for CRC-AIMʼs formulas and general assumptions, with the addition of novel
submodels and recalibrated parameters to fill gaps and discrepancies from publicly available
information, to analyze natural history outcomes of CRC. To validate CRC-AIM, we compared
its outputs to those from CISNET models. Analyses included adenoma and CRC prevalence and
incidence, proportion of clinically-detected CRC cases that had a precursor adenoma lesion
present within 10 and 20 years of diagnosis, adenoma dwell time, probability of transition from
adenoma to CRC, prevalence of preclinical CRC and adenomas, location and size distribution of
adenomas, incidence by age and stage distribution of clinically-diagnosed CRC cases,
cumulative probability of developing and dying from CRC by age, and cumulative probability of
developing CRC by presence and absence of an existing adenoma/preclinical CRC at age 55.
Results: Overall, our modeling results aligned closely with CISNET model outputs, particularly
CRC-SPIN. CRC-AIM produces a cumulative probability curve of developing CRC between the
age of 40 and 100 that is nearly identical to the CISNET models until age 85, after which CRCAIM estimates more CRC. Similarly, CRC-AIMʼs cumulative probability curve of dying from
CRC between the age of 40 and 100 is nearly identical to the CISNET models until age 80, after
which CRC-AIM estimates more CRC deaths. This is likely due to the type of life table used in
the models. CRC-AIM uses cohort life tables to simulate deaths from other causes, while the
CISNET models use period life tables. The greater cumulative probability of dying from CRC
after age 80 was due to CRC-AIMʼs orthogonal CRC survival methodology.
Conclusions: We developed and validated a CRC natural history microsimulation model, CRCAIM, that provides a readily accessible platform for future, collaborative studies to simulate the
impact of previously under-explored parameters of CRC screening, surveillance, and costeffectiveness, as well as for rigorous sensitivity analysis of key model inputs and modifications
to the natural history process itself.
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PS 2-1 MANAGEMENT STRATEGIES FOR SMALL ASYMPTOMATIC
INTRACRANIAL ANEURYSMS: A COST-EFFECTIVENESS ANALYSIS
Applied Health Economics (AHE)
Clark Veet, MD1, David Panczykowski, MD2, Natasha Parekh, MD, MS1, Kenneth Smith, MD
MS3 and Spiros Blackburn, MD2, (1)University of Pittsburgh, Pittsburgh, PA, (2)University of
Texas, Houston, TX, (3)University of Pittsburgh School of Medicine, Pittsburgh, PA
Purpose: Small, asymptomatic unruptured anterior circulation intracerebral aneurysms (UIAs)
are increasingly diagnosed. Active surveillance of small UIAs utilizing magnetic resonance
angiography (MRA) is the current recommended strategy. However, the efficacy, costs, and
optimal follow-up interval for long term UIA surveillance has not been evaluated, and the costeffectiveness of potential management strategies is unclear.
Methods: We developed a Markov cost-effectiveness model simulating a cohort of patients with
small (< 7 mm) UIAs diagnosed at age 50 years evaluating strategies of observation, immediate
operative treatment, or yearly MRA surveillance with UIA growth prompting operation.
Outcome measures were quality-adjusted life-years (QALYs), lifetime medical costs (2015
US$), and incremental cost-effectiveness ratios (ICERs). Cohorts were followed for 10 yearly
cycles, with death and disability modeled as lifetime disutilities, taking a health system
perspective and discounting 3%/yr. Model parameter values were obtained from medical
literature and surgical databases. Cost-effectiveness analysis and deterministic and probabilistic
sensitivity analyses were performed.
Results: Observation was the least costly and effective strategy. Compared to observation,
yearly MRA surveillance gained 0.49 QALY and costed $10,697 more, or $21,600/QALY
gained. Compared to yearly MRA surveillance, immediate operation costed $43,880/QALY
gained. At a $100,000/QALY willingness-to -pay threshold, immediate surgery was preferred
over MRA surveillance, with screening intervals ranging from 0.25-10 years. Annual MRA
surveillance was preferred at $100,000/QALY only if surgical complication rates were >11.8%
(base case 6%), annual rupture risk with no growth was <0.7% (base 1.1%), or patient age at
diagnosis was >62 years. At $100,000/QALY willingness-to-pay threshold, immediate surgery
was the preferred strategy in 64.2% of probabilistic sensitivity analysis iterations, compared to
34.4% for surveillance and 1.3% for observation (Figure 1).
Conclusion: Immediate surgical intervention is an economically reasonable initial management
strategy for small UIAs, but is sensitive to patient age, surgical complication rate, and risk of
aneurysm rupture. Institutional and surgeon-specific operative complication metrics should be
considered in guiding patients with small anterior circulation aneurysms to immediate surgery
vs. surveillance.
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Figure 1: Cost Effectiveness Acceptability Curve for Management of Small, Unruptured
Intracerebral Aneurysms in 50 year old

PS 2-2 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF BACTERIAL
WHOLE GENOME SEQUENCING SURVEILLANCE COMPARED TO STANDARD
OF CARE IN DETECTING HOSPITAL OUTBREAKS
Applied Health Economics (AHE)
Praveen Kumar, University of Pittsburgh, Pittsburgh, PA, Alexander J Sundermann, University
of Pittsburgh School of Medicine and Graduate School of Public Health, Pittsburgh, PA, Elise M
Martin, Department of Medicine, Division of Infectious Diseases, University of Pittsburgh
Medical Center, Pittsburgh, PA, Graham M Snyder, Infection Prevention and Hospital
Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, PA, Lee H Harrison,
Infectious Diseases Epidemiology Research Unit, University of Pittsburgh School of Medicine
and Graduate School of Public Health, Pittsburgh, PA and Mark S. Roberts, MD, MPH,
University of Pittsburgh School of Medicine, Pittsburgh, PA
Purpose: The Enhanced Detection System for Healthcare Associated Transmission (EDS-HAT)
is a novel infection prevention (IP) program that uses bacterial whole genome sequencing
(WGS) surveillance and electronic health record data mining to rapidly identify hospital
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outbreaks and their routes of transmission. The objective was to develop a method to assess the
potential cost-effectiveness and budget impact of EDS-HAT compared to Standard of Care
(SoC), which involves reactive performance of WGS in response to suspected outbreaks.
Methods: We used two K. pneumoniae outbreaks that occurred during 2011-2016 to assess the economic value of a molecular typing based IP program from the perspective of UPMC, an adult
medical/surgical tertiary care hospital. We used the transmission network of an outbreak to
estimate incremental cost per infection averted for EDS-HAT. The number of infections averted
depends on the time at which an outbreak signal is received, the effectiveness of intervening
against transmission routes (the effectiveness was considered 100% for intervening against
instruments and 30% for units) and the amount of time needed to implement the corrective action
(Figure 1). The major route of transmission in these outbreaks was contaminated instruments
followed by the shared unit as a route.
Results: The preliminary results suggest that out of 48 hospital acquired infections, 25.5
(scenario 1) to 35.5 (scenario 2) infections could have been averted with EDS-HAT given earlier
identification of the outbreak and depending on the type of intervention against instruments.
Assuming that EDS-HAT would have 50% higher costs, the discounted incremental cost per
infection averted ranged from a net saving of $3,980 (scenario 1) to $7,680 (scenario 2). A
higher number of infections were averted when an instrument was the dominant route compared
to a shared unit. The budget impact was a saving of $100,750-$271,000 because higher IP
program costs of EDS-HAT were offset by savings in infection treatment costs. The most
sensitive model parameters were the effectiveness of intervening against a unit and the cost of
running the IP program and treating infections.
Conclusions: The proposed economic analysis is a useful tool to examine the potential costeffectiveness and budget impact of any molecular typing based IP program. For these outbreaks,
EDS-HAT was found to be a cost-saving and more-effective program than SoC given earlier
identification of the outbreaks.
PS 2-3 EXAMINING THE COST-EFFECTIVENESS OF EMPIRICAL PASSIVE
PERSONALIZATION WITH P2Y12 INHIBITORS IN PATIENTS WITH ACUTE
CORONARY SYNDROME
Applied Health Economics (AHE)
Kangho Suh, PharmD, MS1, Anirban Basu, PhD1, Kelley Branch, MD, MS2 and Josh Carlson,
MPH, PhD1, (1)The Comparative Health Outcomes, Policy, Economics (CHOICE) Institute,
School of Pharmacy, University of Washington, Seattle, WA, (2)Division of Cardiology,
University of Washington, Seattle, WA
Purpose: Passive personalization (PP) refers to physicians individualizing use of treatments by
learning which medication works best for an individual patient through repeated use and
experience. The objective of this study was to estimate the potential cost-effectiveness of
empirical PP compared to universal clopidogrel or newer P2Y12 inhibitors for the secondary
prevention of major cardiac adverse events.
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Method: A hybrid model (1-year decision-tree followed by lifetime Markov model) was
constructed to estimate costs and outcomes for acute coronary syndrome patients after
percutaneous intervention. Inputs for the first year of the model were based on a comparative
effectiveness study we completed using an instrumental variable approach with IBM®
MarketScan® data. We found patients who initiated treatment as determined by their physicians
through the PP approach had better effectiveness (i.e. lower probability of major adverse
cardiovascular events [MACE]) at one year of follow-up compared to universal treatment with
clopidogrel. Universal treatment with the newer antiplatelet agents resulted in the lowest
probability of MACE. However, the newer agents are more costly and believed to be associated
with higher risk of adverse events.
In accordance with clinical guidelines, patients were assumed to take their P2Y12 inhibitor for
one year and then transitioned to a lifetime model. Transition probabilities and health state
utilities were informed using sources from the literature. We used a healthcare sector
perspective, discounted costs and outcomes at a rate of 3%, and adjusted costs to 2019 USD. We
measured lifetime costs, life years (LYs), quality-adjusted life-years (QALYs), and incremental
cost-effectiveness ratio (ICER).
Result: Empirical PP resulted in 11.63 LYs, 9.92 QALYs, and $72,402 total costs; universal
clopidogrel resulted in 11.59 LYs, 9.84 QALYs, and $72,670 total costs; universal newer P2Y12
inhibitors resulted in 11.67 LYs, 10.00 QALYs, and $73,325 total costs. Treatment with
universal clopidogrel was dominated. Compared to empirical clinical practice, treatment with
universal newer P2Y12 inhibitors resulted in an ICER of $11,144/QALY. These results were
robust in one-way and probabilistic sensitivity analyses.
Conclusion: Universal treatment with newer P2Y12 inhibitors, as advocated by current clinical
guidelines, is a cost-effective approach compared to current clinical practice. Future studies
assessing the potential cost-effectiveness of a more personalized approach to treatment, such as
pharmacogenetic-guided therapy, would be beneficial.
PS 2-4 EARLY PROSTATE CANCER DETECTION AFTER A PREVIOUS NEGATIVE
BIOPSY: MRI, BIOMARKER, OR SYSTEMATIC BIOPSY? A COSTEFFECTIVENESS ANALYSIS.
Applied Health Economics (AHE)
Douglas Cheung, MD, MBA1, Amanda Hird, MD1, Diana Magee, MD, MPH1, Nathan Perlis,
MD, MSc2, Antonio Finelli, MD, MSc2 and Girish Kulkarni, MD, PhD2, (1)University of
Toronto, Toronto, ON, Canada, (2)University of Toronto and University Health Network,
Division of Urology, Department of Surgery, Toronto, ON, Canada
Purpose: To evaluate the clinical and cost-effectiveness of incorporating MRI and biomarker
testing versus standard of care (routine biopsy) for the detection of clinically significant prostate
cancer (PCa) in the setting of early PCa detection after an initial negative prostatic biopsy.
Methods: A two-dimensional Markov microsimulation model (Figure 1) was constructed to
incorporate patient-level characteristics known to be clinically important in prostate cancer (age,
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comorbidity status, prostate specific antigen [PSA], digital rectal examination, and family
history) and memory across disease states. Following comprehensive literature review, patient
covariates were drawn from representative distributions of large population datasets, and test
performance was calibrated to available randomized controlled trial data outcomes if not directly
reported by the trials. After index intervention, patients were followed in quarterly surveillance
states where they could re-present, progress, or die from competing risk mortality.
The primary outcome was clinically significant PCa detection and total costs. Other outcomes
included time to diagnosis, number of clinically insignificant cases (overdiagnosis), biopsies
avoided, complications, PCa progression, and competing risk mortality. A 5- to 10-year horizon
with a focus on PCa detection rates was considered the most clinically relevant to capture the
incremental benefit of these interventions.
Results: Across 5 years, MRI improved the detection of clinically significant PCa over routine
biopsy (31.68% versus 26.25%; +5.43% absolute improvement), but at higher cost ($2,379.44
versus $2,238.48; +$140.96 per patient). This yielded an ICER of $2,595.95 per clinically
significant cancer detected. PHI and PCA3 testing yield lower detection rates (20.80% and
23.31%, respectively) at lower cost ($2,156.01 and $2,108.81).
In secondary outcome analyses, the majority of cancers were detected earlier in the MRI arm
(6.96 months decreased time to diagnosis) with a modest decrease in PCa progression (-0.69%).
35.9% of index biopsies were spared, including -0.87% biopsy-related complications. These
results were maintained across a 10-year time horizon and varying intervention thresholds.
Conclusions: MRI improved the absolute detection of clinically significant PCa, and was
associated with an ICER of $2,595.95 per clinically significant cancer detected and a 7-month
earlier detection benefit.
Figure 1. State Transition Diagram of Health States
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PS 2-5 ANALYTIC PERSPECTIVE MATTERS: THE COST-EFFECTIVENESS OF
EARLY INTERVENTION IN PSYCHOSIS
Applied Health Economics (AHE)
Saadia Sediqzadah, MD, SM, Harvard TH Chan School of Public Health, Boston, MA, Allison
Portnoy, MSPH, Harvard T.H. Chan School of Public Health, Dept. of Global Health and
Population, Boston, MA, Jane J. Kim, PhD, Center for Health Decision Science, Harvard T.H.
Chan School of Public Health, Boston, MA, USA., Boston, MA and Ankur Pandya, PhD, Center
for Health Decision Science, Department of Health Policy and Management, Harvard T.H. Chan
School of Public Health, Boston, MA
Purpose: First episode psychosis is an early sign of primary psychotic disorders including
schizophrenia in young adults. Early intervention treatment programs have demonstrated clinical
efficacy including reduced hospitalization and improved employment rates but there has been
limited research evaluating cost effectiveness. We projected the health benefits, healthcare and
societal costs, incremental cost effectiveness, and incremental net monetary benefits (iNMB) of
early intervention in psychosis versus standard psychiatric care in the US.
Methods: We evaluated two clinical strategies, “early intervention” (a specialized clinic
focusing on both medication management and psychosocial support) versus “standard care” (a
general psychiatry clinic focusing on medication management alone), for 20-year-old males with
a recent diagnosis of a first episode of psychosis. We developed a decision-analytic Markov
model (Panel A) to project discounted (3% annual rate) lifetime quality-adjusted life years
(QALYs) and costs using healthcare and societal perspectives using a cost-effectiveness
threshold of $100,000/QALY. Model input parameters were derived from the published
literature including a 2018 meta-analysis of 10 trials comparing early intervention to standard
care, and US Census data for productivity benefits (only included in the societal perspective).
Results: Patients in the early intervention strategy had approximately 4 less hospitalizations and
3 more years of employment relative to standard care over the course of their remaining life
expectancy. From a societal perspective, early intervention was dominant (cost-saving while
producing more QALYs compared to standard care). Panel B shows one-way sensitivity analysis
results with threshold values (where iNMB=$0) of: $16,500 for the annual costs of early
intervention clinic (base-case value= $15,000); $11,300 for the standard care clinic (base-case
value=$12,800); and effectiveness (relative risk) of early intervention on employment of 1.01
(base-case value=1.13, 95% CI 1.03-1.24). From a healthcare perspective, early intervention had
an incremental cost-effectiveness ratio of $198,500/QALY.
Conclusions: Early intervention in psychosis was shown to reduce the number of
hospitalizations and increase employment rate for this vulnerable patient population. Using a
societal perspective, early intervention is cost-saving; therefore, our findings advocate for
increased access to early intervention for young adults in the US. However, when considerations
are limited to the healthcare sector, our analysis shows that early intervention does not meet
conventional standards for cost effectiveness in the US, underscoring the importance of
including productivity benefits in the societal perspective.
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PS 2-6 THE COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVES IN
LOW SURGICAL RISK PATIENTS: A TALE OF TWO RANDOMIZED CLINICAL
TRIALS
Applied Health Economics (AHE)
Derrick Tam, MD, University of Toronto, Toronto, ON, Canada, Stephen Fremes, MD MSc,
Sunnybrook Health Sciences Centre, Toronto, ON, Canada, Mario Gaudino, MD, Weill Cornell
Medicine, New York, NY and Harindra C. Wijeysundera, MD, PhD, Schulich Heart Center,
Sunnybrook Health Sciences Center, Toronto, ON, Canada
Purpose: To compare the cost-effectiveness of two different transcatheter aortic valve
replacement (TAVR) devices against surgical aortic valve replacement (SAVR) in low surgical
risk patients from the recently published Placement of AoRtic TraNscathER valves 3
(PARTNER 3) and CoreValve Low Risk Trials for severe, symptomatic, aortic stenosis.
Methods: A cost-utility analysis from the Canadian healthcare system payerʼs perspective was
undertaken comparing balloon-expandable (BE) TAVR, self-expandable (SE) TAVR to SAVR
in low surgical risk patients (predicted 30-day mortality <4%). A fully probabilistic Markov
cohort model was constructed to estimate differences in costs (2019 Canadian dollars) and
effectiveness (quality-adjusted life years [QALYs]) over a life-time time horizon, discounted at
1.5%/annum with 30-day cycle lengths. Health states included: alive/well, permanent stroke,
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paravalvular leak ≥moderate, new pacemaker, rehospitalization, and death. A network metaanalysis of the PARTNER 3 and Corevalve Low Risk trial was performed to establish a common
comparator (SAVR) for the efficacy inputs of early mortality, complication rates, and late
mortality/stroke. For the base case, event rates in the SAVR arm were calculated by aggregating
findings from both trials. Cost inputs were from the Canadian Institute for Health Information,
and utilities were obtained from the published literature. Incremental-cost effectiveness ratios
(ICER) were calculated. Sensitivity analyses were conducted on event base rates for SAVR using
the results from the individual trials.
Results: In the base-case analysis, after discounting, the total lifetime costs in the BE TAVR, SE
TAVR, and SAVR arms were $37,330±4724, $39,660±4862, and $34,583±6731 respectively
and total lifetime QALYs gained were 9.15±3.23, 9.13±3.23, and 9.05±3.19 respectively. The
ICERs for BE TAVR and SE TAVR against SAVR were $27,196/QALY and $59,641/QALY
respectively. In the base-case, SE was extendedly dominated by BE. There was substantial
uncertainty, with only 53% and 58% of 10,000 models iterations showing BE to be the preferred
option at willingness-to-pay thresholds of $50,000/QALY and $100,000/QALY respectively.
The ICER was robust to changes in event base rates for SAVR– BE TAVR remained the most
cost-effective approach when PARTNER 3 and Corevalve LR trial event rates were applied in
the sensitivity analyses.
Conclusions: In this first head-to-head comparison of BE TAVR, SE TAVR, and SAVR in low
surgical risk patients, BE TAVR is likely the most cost-effective approach in treating aortic
stenosis.
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PS 2-8 MODEL-BASED EFFECTIVENESS AND COST-EFFECTIVENESS OF
PERSONALIZED SELECTION STRATEGIES FOR ADJUVANT CHEMOTHERAPY
IN STAGE II COLON CANCER
Applied Health Economics (AHE)
Gabrielle Jongeneel1, Marjolein JE Greuter1, Felice N van Erning2, Miriam Koopman3,
Geraldine R Vink4, Cornelis JA Punt1 and Veerle MH Coupe1, (1)Amsterdam UMC,
Amsterdam, Netherlands, (2)Netherlands Comprehensive Cancer Organisation, Eindhoven,
Netherlands, (3)University Medical Center Utrecht, Utrecht, Netherlands, (4)Netherlands
Comprehensive Cancer Organization, Utrecht, Netherlands
Purpose: To evaluate the (cost-)effectiveness of personalized strategies to improve the selection
of stage II colon cancer patients for adjuvant chemotherapy.
Methods: For all analyses, we used the ‘Personalized Adjuvant TreaTment in EaRly stage coloN
cancer’ (PATTERN) model. Patient-level data from the Netherlands Cancer Registry, three
observational studies and scientific literature were used for model quantification. Based on trial
data, a hazard ratio for treatment effect of 0.73 was applied for all treated patients in the model.
Treatment duration was set at 6 months based on current guideline recommendations. Six
selection strategies were evaluated; 1) no adjuvant chemotherapy, 2) adjuvant chemotherapy for
all patients, 3) Dutch guideline recommendations (patients with MSS status and pT4 stage
receive treatment) assuming observed adherence, 4) Dutch guideline recommendations assuming
perfect adherence, 5) a biomarker-only strategy (patients with MSS status combined with a
BRAF and/or KRAS mutation receive treatment) and 6) a biomarker plus pT4 stage strategy.
The no adjuvant chemotherapy strategy was considered as the reference. Outcomes were colon
cancer deaths per 1,000 patients and total discounted costs and quality-adjusted life-years
(QALYs) per patient (pp). Analyses were done from a societal perspective. An ICER below
50,000 €/QALY was considered cost-effective.
Results: The reference strategy resulted in 115.4 colon cancer deaths per 1,000 patients, 7.969
QALYs pp and total costs of €26,109 pp (Table 1). Strategies 2 to 6 were more effective (89.9115.0 colon cancer deaths per 1,000 patients and 7.970-8.074 QALYs pp) and more costly
(€26,679-€41,000 pp). In an incremental analysis, ICERs ranged between 103,025 €/QALY and
161,704 €/QALY. Varying adherence rates, treatment effect, discount rates and drug costs over
plausible ranges led to similar results. When treatment duration was reduced to 3 months, which
is currently under discussion in the Netherlands, ICERs varied from 66,252 €/QALY to 82,106
€/QALY.
Conclusion: Selection strategies in which (part of the) patients received chemotherapy were
more effective and more costly compared to no chemotherapy. Based on the Dutch willingnessto-pay threshold, none of the evaluated strategies was cost-effective compared to the no
treatment strategy. However, when the willingness-to-pay threshold is set at 80,000 €/QALY,
which is not exceptional in cancer treatment, the perfect adherence to the Dutch guideline and
biomarker-only strategies would be cost-effective when treatment duration is reduced to 3
months.
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PS 2-9 CATALOGUE OF AGE AND MEDICAL-CONDITION-SPECIFIC
HEALTHCARE COSTS IN THE US TO INFORM FUTURE COSTS CALCULATIONS
IN COST-EFFECTIVENESS ANALYSIS
Applied Health Economics (AHE)
Boshen Jiao, MPH and Anirban Basu, PhD, The Comparative Health Outcomes, Policy,
Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, WA
Purpose: This study aims to estimate annual age and medical-condition-specific healthcare costs
per capita among those who are living at a certain age (survivors) and the cost attributable to
death itself for those who die at that age (decedents) in the United States to inform future costs
calculations in cost-effectiveness analysis.
Method: The analyses for survivors were based on 2015 and 2016 Medical Expenditure Panel
Survey (MEPS) data. The age-specific costs were estimated using locally weighted runningmean smooth (bandwidth=0.8) for all survivors stratified by sex and by ten priority medical
conditions. In order to obtain sufficient sample size for decedents, data from 2008-2016 MEPS
were pooled to estimate the incremental medical costs associated with death using a propensity
score method. We first ran a complementary log regression in which death (indicator for
alive/dead) was regressed on demographic and socioeconomic variables, aggregated international
classification of diseases (ninth revision) conditions and selected interactions and polynomial
terms. Then a quadratic regression was performed with medical costs as the outcome and age,

E82

Medical Decision Making 40(1)

age squared, death and interaction terms between death and each of the two age variables as the
predictors. In the regression, the survivors received a weight equal to the odds predicted by the
previous complementary log regression and the decedents received a weight of one. All the cost
values were adjusted to 2018 US dollars. Cost estimates were calibrated using split sample
analyses. Uncertainty in cost estimated were obtained via bootstrap.
Results: The future medical costs per capita tended to be greater in older and female survivors
(see the figure below). At 85 years old and above, the average costs reached $9,697 (95%
confidence interval [CI]: $9,327, $10,099) for all survivors, $10,257 (95% CI: $9,702, $10,836)
for female and $8,996 (95% CI: $8,466, $9,574) for male. Survivors with stroke consumed more
medical care for most of the age categories than the other medical conditions (see the figure
below). Cost of death was estimated to be $11,886 (95% CI: $10,177, $13,594) at 85 years old
and above, and appeared to decline with age.
Conclusion: The US catalogue of healthcare costs among survivors and decedents can facilitate
calculations of future costs in cost-effectiveness analysis as recommended by the Second Panel
on Cost-Effectiveness in Health and Medicine.
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PS 2-11 EMERGENCY DEPARTMENT SCREENING AS A CORE COMPONENT OF
POPULATION-BASED HEPATITIS C CONTROL: A COST-EFFECTIVENESS
ANALYSIS
Applied Health Economics (AHE)
Andrew Mendlowitz, MBiotech, HBSc1, David Naimark1, William W. L. Wong, PhD2,
Camelia Capraru, MD3, Jordan J. Feld, MD, MPH4, Wanrudee Isaranuwatchai, PhD5 and Murray
Krahn, MD, MSc, FRCPC6, (1)University of Toronto, Toronto, ON, Canada, (2)School of
Pharmacy, University of Waterloo, Kitchener, ON, Canada, (3)Toronto Center for Liver Disease,
University Health Network, Toronto, ON, Canada, (4)Toronto Centre for Liver Disease,
University Health Network, Toronto, ON, Canada, (5)Centre for Excellence in Economic
Analysis Research, The HUB, Li Ka Shing Knowledge Institute, St. Michaelʼs Hospital,
Toronto, ON, Canada, (6)Toronto Health Economics and Technology Assessment (THETA)
Collaborative, Toronto, ON, Canada
Purpose: The World Health Organizationʼs (WHO) strategy to eliminate hepatitis C virus
(HCV) by 2030 recognizes the need for interventions that identify at-risk populations most
affected by infection. The emergency department (ED) has been suggested as a potential setting
for HCV screening. The purpose of this study was to explore the health and economic impact of
HCV screening in the ED setting.
Method: We used a microsimulation model to conduct a cost-utility analysis evaluating
strategies including: (1) no screening (status quo); (2) screening and subsequent treatment of the
general ED patient population; and (3) screening and subsequent treatment of ED patients born
between 1945 and 1975. The analysis was conducted from a healthcare payer perspective over a
lifetime time horizon. Two scenarios representing different ED seroprevalence estimates were
examined in both Canadian and US healthcare settings. Outcomes were expressed as qualityadjusted life years (QALYs) and 2018 Canadian dollars (CAN$). For the US healthcare setting
analysis, costs were reported in 2018 US dollars (US$). Model parameters were obtained from
literature and a pilot ED HCV screening initiative at Toronto Western Hospital in Toronto,
Canada. Deterministic sensitivity analyses were performed on seroprevalence and linkage to care
parameters to examine their effects on model outcomes.
Result: For birth cohort screening, in the reference (1.8%) and high seroprevalence (11.1%)
scenario, in comparison to no screening, one liver-related death was averted for every 123 to 760
patients screened. For general population screening, for both scenarios, one liver-related death
was averted for every 147 to 831 patients screened. Birth cohort screening was cost-effective at
cost-effectiveness thresholds greater than CAN$26,000/QALY and US$43,000/QALY. General
population screening was cost-effective at cost-effectiveness thresholds greater than
CAN$20,000/QALY and US$32,000/QALY.
Conclusion: Innovative approaches to HCV screening will be necessary to reach the targets set
by the WHO for HCV elimination. ED screening may represent an effective and cost-effective
component of population-based strategies to eliminate HCV. Further studies are warranted to
explore the feasibility and acceptability of this approach.
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Fig 1. Cost-effectiveness of ED HCV screening over a range of 1945 to 1975 birth cohort
seroprevalence measures.

Reference lines represent varying seroprevalence measures obtained from published HCV
observational studies in different ED settings. Shaded regions represent the 95% confidence
intervals around each line of best fit.

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E85

PS 2-14 REDUCED CERVICAL CANCER SCREENING FREQUENCY IN HUMAN
PAPILLOMAVIRUS VACCINATED, HIV-INFECTED WOMEN: A COSTEFFECTIVENESS ANALYSIS
Applied Health Economics (AHE)
Jamie Cohen, MS, Harvard T.H. Chan School of Public Health, Boston, MA, Nicolas A.
Menzies, PhD, Harvard TH Chan School of Public Health, Dept. of Global Health and
Population, Boston, MA and Jane J. Kim, PhD, Center for Health Decision Science, Harvard
T.H. Chan School of Public Health, Boston, MA, USA., Boston, MA
Purpose: Human papillomavirus (HPV) vaccination presents an opportunity to reduce the
frequency of cervical cancer screening. We conducted a cost-effectiveness analysis to identify
the level of efficacy that would be required to relax screening intensity in perinatally HIVinfected women vaccinated against HPV in South Africa.
Methods: We developed a microsimulation model of HPV infection and cervical carcinogenesis
in an HIV-positive population. Disease dynamics were represented by transitions between
mutually exclusive health states, including genotype-specific HPV infection, grade of pre-cancer,
and stage of cancer. We assumed all women in the model were infected with HIV at birth and
received a completed 3-dose course of the HPV vaccine at age 9. We grouped HPV genotypes
into four categories: 1) low-risk, 2) 16/18, 3) 31/33/45/52/58, and 4) other high-risk. We
calibrated the model to South African epidemiologic data using simulated annealing to search the
parameter space and weighted least squares to score the output. For each of our best-fitting
parameter sets, we simulated 1 million HPV-vaccinated girls and compared current screening
guidelines to 5 strategies that relaxed screen intensity. We performed these analyses varying
screen ages, screen frequency, and considered 14 genotype-specific vaccine efficacy scenarios.
Costs included cancer screening, diagnosis and treatment. Health outcomes included cancer
cases and disability-adjusted life years (DALYs) averted. We conducted a cost-effectiveness
analysis to determine the optimal screening strategy at different willingness to pay (WTP)
values.
Results: We found that the cost-effectiveness of screen intensity was sensitive to genotypespecific vaccine efficacy and WTP (see Figure 1). Using the bivalent vaccine, which protects
against genotypes 16 and 18, we found that at a WTP of $1,000 per DALY averted it would be
cost-effective to extend the screen interval to every 5 years and end screening at age 60, as long
as vaccine efficacy is above 80%. At any WTP above $1,000 and any vaccine efficacy below
80%, current guidelines remained optimal. Using the nonavalent vaccine, which protects against
five additional high-risk genotypes, the vaccine could be as low as 70% effective and still allow
for a reduction in screen intensity.
Conclusion: This analysis suggests that under certain vaccine efficacy assumptions, it could be
cost-effective to relax screening frequency. These results motivate the collection of data to
conclusively understand HPV vaccine efficacy in HIV-infected women.
PS 2-15 PREVENTION AND CONTROL OF DENGUE AND CHIKUNGUNYA IN
COLOMBIA: A COST-EFFECTIVENESS ANALYSIS
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Applied Health Economics (AHE)
Anneke Claypool, MS1, Margaret L. Brandeau, PhD1 and Jeremy D. Goldhaber-Fiebert, PhD2,
(1)Department of Management Science and Engineering, Stanford University, Stanford, CA,
(2)Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes Research,
Stanford University, Stanford, CA
Purpose: Dengue and chikungunya are emerging viruses spread by Aedes aegypti and Aedes
albopictus mosquitos. Both are prevalent in Colombia. Ongoing efforts aim to develop vaccines
for both diseases. Dengvaxia, a dengue vaccine, was approved by the FDA in May 2019 despite
increasing infection severity in some children. In addition to vaccines, prevention measures
include mosquito vector control measures such as insecticide spraying. We assess the
effectiveness and cost-effectiveness of these measures using a multi-disease model to capture
both their direct and indirect effects.
Methods: We developed a dynamic human-and-mosquito transmission cohort model of
chikungunya and dengue, calibrated to disease-specific incidence and deaths in Colombia (June
2014- December 2017) using a directed search algorithm. We compared benefits and costs of
dengue vaccine with 20% coverage and 60% efficacy, a chikungunya vaccine with 20%
coverage and 60% efficacy, an insecticide with 10% efficacy, and multi-intervention portfolios.
After following individuals over their lifetime, we calculated infections, deaths, disabilityadjusted life years (DALYs), and costs (2015 USD) of each intervention portfolio employing a
3% annual discount rate.
Results: Model calibration produced 150 realistic parameters sets that closely matched diseasespecific incidence and deaths in Colombia. The dengue vaccine averted an expected 115,320
symptomatic dengue infections, 3,557 DALYs, and 107 deaths. The chikungunya vaccine
averted an expected 73,323 symptomatic chikungunya infections, 2,576 DALYs, and 14 deaths.
Insecticide averted an expected 117,553 symptomatic dengue infections, 116,764 symptomatic
chikungunya infections, 7,547 DALYs, and 131 deaths. Portfolios had greater (but sub-additive)
benefits. In 150 model runs, insecticide was the preferred intervention in 43 cases and the status
quo was preferred in 107 cases (See Figure). The expected incremental net monetary benefit for
a willingness-to-pay of $18,132 (3x GDP per capita) was -$117.9 (CI: -187.8, -67.8) for the
dengue vaccine, -$85.6 (CI: -161, -17.8) for the chikungunya vaccine, and -$22.5 (CI: -143.2,
230.8) for insecticide.
Conclusions: Moderately effective interventions for dengue and chikungunya delivered at
relatively low coverage levels can provide health benefits, but not cost-effectively. While
estimates of health benefits from insecticides may be too low given their effects in reducing Zika
and yellow fever not captured by the model, more effective interventions delivered more broadly
are likely required to provide good value for money in this context

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E87

PS 2-17 INDIVIDUAL AND PUBLIC PREFERENCES FOR HEALTH STATES: WHAT
CAN BE LEARNED FROM TIES IN EQ-5D-5L TIME-TRADE-OFF VALUATION
STUDIES?
Patient and Stakeholder Preferences and Engagement (PSPE)
Nathan McClure, MSc1, Feng Xie, PhD2 and Jeffrey Johnson, PhD1, (1)University of Alberta,
Edmonton, AB, Canada, (2)McMaster University, Hamilton, ON, Canada
Purpose: The Canadian EQ-5D-5L valuation study elicited health state preferences using timetrade-off (TTO, i.e., cardinal response) and discrete-choice-experiment (DCE, i.e., ordinal
response) tasks. It was not uncommon for a respondent to give more than one health state the
same TTO value (i.e., tie); however, development of the value set involves aggregating
responses, identifying differences in health utility scores (HUS) between any two health states,
which can be small (e.g., 0.0001). This raises the question: how do differences in HUS represent
the stated health preferences of individuals?
Method: Data from the EQ-5D-5L Canadian valuation study (N=1073) was used. In all
analyses, the explanatory variable used pairwise differences in EQ-5D-5L HUS. First,
participants' TTO responses were transformed into pairwise comparisons to yield ordinal TTO
responses. Then, three logistic regression models were used to construct curves representing the
average probability that participants consider a pairwise comparison between health states to be a
tie, worse or better difference. Second, the predicted probabilities from the ordinal TTO
responses were compared to predictions from DCE responses using a linear model. Lastly, the
average pairwise differences in participants’ observed TTO values were stratified according to
their ordinal TTO responses to determine how the value of (small) differences in EQ-5D-5L
HUS differs from participants’ stated preferences.
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Result: Probability curves show that HUS differences near 0 have as much as 30.6% probability
of representing a tie. Differences in EQ-5D-5L HUS of -0.054 (95% Confidence Interval: -0.067
to -0.045) and 0.047 (0.037 to 0.066) maximized the sensitivity (0.78-0.81) and specificity (0.770.80) of discriminating a transition to a worse and better health state, respectively. When ties
were included in the ordinal TTO responses, the slope coefficient of predicted probabilities
regressed on DCE probabilities were 0.72-0.80; however, if ties were excluded, the slope
coefficient increased to 0.98-1.00. Small differences in HUS of +/-0.03 to +/-0.07 had average
TTO differences of +/-0.18, and +/-0.36 whether ties were included or excluded, respectively.
Conclusion: Differences in EQ-5D-5L health utility scores, particularly small differences, are
not uniformly representative of individuals’ stated preferences, which consist of ties, better or
worse differences. Therefore, the significance of a small difference is ambiguous, lending
support to the idea of a minimally detectable or important difference for decision-making.
PS 2-18 WOMENʼs PRIORITIES AND PREFERENCES FOR MANAGEMENT OF
PREGNANCY HYPERTENSION
Patient and Stakeholder Preferences and Engagement (PSPE)
Rebecca Metcalfe, BA Hons., MA1, Mark Harrison, PhD2, Joel Singer, PhD1, Mary Lewisch3,
Anna Hutfield, MBA1, Laura Magee, MSc, FACP, FRCPC, MD4 and Nick Bansback, PhD5,
(1)University of British Columbia, Vancouver, BC, Canada, (2)Faculty of Pharmaceutical
Sciences, University of British Columbia, Vancouver, BC, Canada, (3)Patient Partner, BC,
Canada, (4)Kingʼs College London, London, United Kingdom, (5)School of Population and
Public Health, University of British Columbia; Centre for Health Evaluation and Outcome
Sciences, Vancouver, BC, Canada
Purpose:
In response to new clinical guidance recommending ‘tight control’ (i.e., antihypertensive therapy
to a target blood pressure of 135/85mmHg) for pregnancy hypertension, this study aimed to:
assess womenʼs priorities and preferences for management of pregnancy hypertension; identify
preference predictors; and explore womenʼs decisional needs.
Method:
An online survey was developed using semi-structured interviews, focus groups and patient
partner input. The survey included four components: demographic information; information
provision and knowledge assessment; a seven-item Case 2 best-worst scaling (BWS) task; and a
decisional needs assessment. Pregnant women were recruited via an online sample. All question
responses were analyzed descriptively. Latent class analysis of BWS responses identified
treatment priority subgroups. T-tests were used to assess the relationship between knowledge and
treatment preference. Logistic regression was used to identify predictors of treatment preference
(i.e., less-tight control (LTC) vs. tight control (TC)).
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Result:
We recruited 183 pregnant individuals to the study. More than one quarter of respondents
reported current or past pregnancy hypertension. Latent class analysis identified three distinct
groups of treatment priorities: “Equal Prioritizers” – 62% of the sample; “Early Delivery
Avoiders” – 24% of the sample; and “Medication Minimizers” – 14% of the sample. Participants
were evenly divided on treatment preference, with 49% preferring TC and 51% preferring LTC.
Mean knowledge scores were higher for those who preferred TC to LTC (4.5 vs. 3.4 out of 7; p =
0.001). Multivariable logistic regression found the odds of preferring TC were greater among
those with: higher knowledge scores; Caucasian ethnicity; and a university education or
professional qualification. Participants reported diverse decisional needs. 60% of participants
preferred individualized compared to average information. Most participants preferred to make
the final treatment decision themselves, with (48%) or without (22%) their physicians’ input.
Conclusion:
Our research found that womenʼs priorities for management of pregnancy hypertension are
heterogeneous, that women are divided about preferred treatment, that knowledge predicts
treatment preference, and that preferences for decisional supports are diverse. These findings
emphasize the importance of an individualized approach to treatment recommendations that
considers patient values and preferences.
PS 2-19 CAN THE EQ-5D CAPTURE HEALTH OUTCOMES IN A DEGENERATIVE
RARE DISEASE? AN INTERNATIONAL STUDY
Patient and Stakeholder Preferences and Engagement (PSPE)
Norah Crossnohere, MHS, Johns Hopkins University Bloomberg School of Public Health,
Baltimore, MD, Ryan Fischer, Parent Project Muscular Dystrophy, Hackensack, NJ, Andrew
Lloyd, DPhil, Acaster Lloyd Consulting Ltd, London, United Kingdom, Lisa Prosser, PhD,
University of Michigan Medical School, Ann Arbor, MI and John F P Bridges, PhD, The Ohio
State University College of Medicine, Columbus, OH
Purpose: To explore the validity and feasibility of the generic health-related quality of life
(HRQoL) measure EQ-5D in assessing health status for an international rare disease community.
Methods: A community-engaged survey conducted in partnership with patient organizations in
Australia, Belgium, Canada, the Netherlands, United Kingdom, and United States documented
HRQoL in Duchenne muscular dystrophy (DMD), a degenerative neuromuscular disorder.
Participants included adults and parents/caregivers of adults or children with DMD. HRQoL was
assessed using the EQ-5D (3L, 3LProxy, YProxy1), visual analogue scale (VAS), and validated
disease-specific functional measures (PUL-PROM, ambulatory [yes/no]). EQ-5D index scores
were obtained from the US value set. Construct validity, criterion validity, and responsiveness
were explored by comparing index scores to functional measures, and across VAS and patient
age. Likert-type scales assessed participant endorsement of the EQ-5D as easy to answer and
understand, and reflective of true health. Having at least 75% of respondents agree with these
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items served as evidence of minimal-burden and content validity. Floor and ceiling effects were
defined as the proportion of respondents in the best (11111) and worst (33333) health states.
Results: Of 245 surveys initiated, 201 (82%) completed the EQ-5D. Most participants were from
the US and UK (73%). Patient age raged from 1- 48 years. A quarter of participants were adults
with DMD (24%). Mean EQ-5D index was higher for ambulatory (0.63) than non-ambulatory
patients (0.30) (P>0.001), and was negatively associated with upper limb impairment (P<0.001).
Index was positively associated with VAS rating (P<0.001) and negatively associated with
patient age (P<0.001). EQ-5D met/exceeded 75% benchmarks for ease of understanding,
answering, and reflecting true health (P<0.001). Less than 1% of respondents demonstrated
ceiling and floor effects.
Conclusions: Results demonstrate the acceptability of the EQ-5D as a measure of HRQoL
across the natural history of DMD. This finding challenged existing thought within the DMD
community, where there was initially reticent towards the generic measure given the pediatric
onset and degenerative outcomes of DMD, in addition to uncertainty in how to account for
wheelchair use when assessing mobility. Treatment advances in rare diseases necessitate the
documentation of HRQoL to inform health technology assessment, pricing, and reimbursement.
Exploring the ability of EQ-5D to detect modest, yet meaningful, improvements in health from
first generation therapies presents an ongoing hurdle.
PS 2-20 DISPARITIES IN HEALTH UTILITIES AMONG HEPATITIS C PATIENTS
RECEIVING CARE IN DIFFERENT SETTINGS
Patient and Stakeholder Preferences and Engagement (PSPE)
Yasmin Saeed, BScPhm1, Kate Mason2, Arcturus Phoon3, Josephine F Wong, MD3, Jeff Powis,
MD4, Jordan J. Feld, MD, MPH5, Zeny Feng, PhD6, Nicholas Mitsakakis, PhD7, Karen E
Bremner, BSc3, Murray Krahn, MD, MSc, FRCPC3 and William W. L. Wong, PhD8, (1)Leslie
Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, (2)Toronto Community
Hepatitis C Program (TCHCP), Toronto, ON, Canada, (3)Toronto Health Economics and
Technology Assessment (THETA) Collaborative, Toronto, ON, Canada, (4)Michael Garron
Hospital, Toronto, ON, Canada, (5)Toronto Centre for Liver Disease, University Health
Network, Toronto, ON, Canada, (6)Department of Mathematics and Statistics, University of
Guelph, Guelph, ON, Canada, (7)Institute of Health Policy, Management and Evaluation,
Toronto, ON, Canada, (8)School of Pharmacy, University of Waterloo, Kitchener, ON, Canada
Purpose:
To compare health utilities in two populations of chronic hepatitis C virus (HCV) infected
patients: patients receiving HCV care at academic hospital-based clinics, and socioeconomically
marginalized patients receiving HCV care through a community-based HCV program.
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Methods:
We recruited patients from 3 hospital-based clinics at the University Health Network (UHN) and
3 community-based sites of the Toronto Community Hepatitis C Program (TCHCP) in Toronto,
Ontario, Canada.
UHN is a network of research and teaching hospitals. TCHCP is a community-based program
that provides HCV treatment, support, and education to marginalized patients who have
difficulty accessing mainstream healthcare due to barriers such as low income, substance use,
and mental health issues.
We elicited EQ5D-3L utilities from patients and collected sociodemographic and clinical
information.
A regression model examined whether observed differences in utility between settings remained
after adjusting for age, sex, liver disease severity, and Charlson Comorbidity Index (CCI). A
second model examined whether socioeconomic factors accounted for any differences found.
Results:
We recruited 211 eligible patients (UHN:113; TCHCP:98). Hospital patients were more likely to
be older (mean age:57 vs 51), female (46% vs 32%), and cirrhotic (32% vs 22%). Community
patients had more comorbidity (mean CCI:1.3 vs 1.1), unemployment (87% vs 61%), history of
injection drug use (88% vs 48%), and history of mental health issue(s) (79% vs 51%).
Unadjusted mean±standard error utilities were substantially lower in community patients
(community: 0.722±0.209; hospital: 0.806±0.195; Wilcoxon rank-sum p=0.0002) (Table 1).
Multivariable regression showed that this disparity between settings persisted after adjusting for
age, sex, liver disease severity, and CCI (community coefficient=-0.075, p=0.018) (Table 1).
The secondary regression model demonstrated that much of the difference could be explained by
disparities in utility associated with unemployment (coefficient=-0.092, p=0.007) and a history
of mental health issue(s) (coefficient=-0.106, p=0.001) (Table 1).
Conclusions:
Although HCV disproportionately affects marginalized individuals, a large portion of research is
conducted in academic hospital settings which may not reflect the population living with
hepatitis C. Cost-utility analyses informed by hospital-based utility studies may over- or
underestimate the benefits of HCV screening and antiviral therapy. Longitudinal research on the
impacts of antiviral therapy on utilities in marginalized populations is needed, as well as research
on the costs and utilities associated with providing mental health and employment services
alongside antiviral therapy.
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PS 2-22 PATIENT DECISION APPRAISAL IN STAGE III COLORECTAL CANCER
TREATMENT
Decision Psychology and Shared Decision Making (DEC)
Ana De Roo, MD1, Arden Morris, MD MPH2, Paul Abrahamse, MA3, Amber Trickey, PhD MS
CPH2 and Sarah T. Hawley, PhD, MPH4, (1)Department of Surgery, University of Michigan,
Ann Arbor, MI, (2)S-SPIRE Center, Department of Surgery, Stanford University, Stanford, CA,
Stanford, CA, (3)University of Michigan, Ann Arbor, MI, (4)University of Michigan, Ann Arbor
VA Health System, Ann Arbor, MI
Purpose:
Although colorectal cancer (CRC) is the 3rd most common cancer in the US and its management
requires patients to understand complex information and treatment options, the decision making
process for CRC treatment is not well-studied. To inform this gap, we evaluated patient-reported
treatment decision appraisal in a diverse, population-based sample of Stage III CRC patients.
Method:
We conducted a survey of all incident Stage III CRC cases in the Surveillance Epidemiology and
End Result registries of Georgia and Detroit between August 2011 and March 2013. The primary
outcome was patient-reported treatment decision appraisal. The survey assessed patients’
decision regret (2 questions) and decision satisfaction (2 questions), each on a 5-point Likert
scale (“Strongly disagree” to “Strongly Agree”). The 4 items were scaled, and factor analysis
indicated the 4 items reflected one factor (Cronbachʼs alpha 0.82), representing a continuous
measure of overall treatment decision appraisal (0-5, from low to high decision appraisal).
Patient-level covariates included age, race, education, marital status, gender, income, health
literacy (high vs. low), trust in providers (high vs. low), presence of surgical complications,
study site, and preferred level of decision involvement (patient-led, shared, physician-led). We
performed ANOVA, chi-square tests, and linear regression of all covariates to identify
associations with decision appraisal.
Result:
Among 894 respondents, mean decision appraisal was 3.95 (SD 0.75). In bivariate analysis,
decision appraisal was lower among patients who a) preferred shared decision making (3.86
shared versus 4.20 physician-led and 4.02 patient-led, p<0.001), b) reported low trust in their
oncologist (3.34 versus 4.10, p<0.001) or surgeon (3.42 vs. 4.07, p<0.001), and c) had low health
literacy (3.80 vs. 4.17, p<0.001). In multivariable analysis, low decision appraisal was associated
with low trust in providers (oncologist (-0.60, p<0.001); surgeon (0.34, p<0.001)), low health
literacy (-0.28, p<0.001), and a preference for shared decision making (reference: patient-led DM
(-0.19, p=0.01).
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Conclusion:
Low treatment decision appraisal was associated with low trust in providers and low health
literacy, both actionable targets for improvement. The finding that low decision appraisal was
associated with a preference for shared decision making suggests that perhaps patients who have
clear decision making preferences (either patient- or physician-led) may appraise the process
more positively. Further work to evaluate the treatment decision making process in this
important population is warranted.
PS 2-23 IMPROVING DECISION MAKING BY DEVELOPING AND VALIDATING A
WEB BASED PATIENT DECISION AID FOR STAGE I-II NON-SMALL CELL LUNG
CANCER.
Decision Psychology and Shared Decision Making (DEC)
Iva Halilaj, MSc, Arthur Jochems, PhD, Cary Oberije, PhD, Janita van Timmeren, MSc,
Relinde Lieverse, MSc and Philippe Lambin, PhD, Maastricht University, Maastricht,
Netherlands
Purpose: Studies indicate that the majority of early-stage non-small cell lung cancer (NSCLC)
patients find it important to be involved in treatment decision making, however, some
participants experienced decision conflict (40%) and feel uninformed (36%) (Mokhles et al,
2018). We therefore developed a patient decision aid (PDA) for stage I-II NSCLC patients that
informs and empowers patients to help decide between stereotactic radiotherapy (SBRT) and
surgery. The aim of this study is to test the proof-of-concept PDA in a group of doctors and IT
specialists.
Method: The PDA, that was developed based on the International Patient Decision Aid
Standards (IPDAS) (http://ipda.herokuapp.com/lung), was evaluated by 18 IT specialists and 7
doctors. For this purpose, we adapted a previously published questionnaire (Petersen et al, 2019).
We assessed the user friendliness and content of the tool. The questionnaire contained 40
multiple-choice questions. Answers were given on a 5-point Likert Scale, that ranged from
strongly disagree to strongly agree. Additionally, there were 3 open questions, and one question
about the general evaluation of the application, for which a 10-point scale was used. We
performed a descriptive analysis of the responses.
Result: Both IT specialists and doctors agreed that the PDA gives information and could help
patients to participate more in SDM. 85% of the doctors were satisfied with PDA and assessed
the information in the tool as correct. 71% of them agreed that this application would help
patients to make an informed decision, improve the healthcare quality. They answered that, if
available, they would recommend this tool to their patients. 57% believe that this tool will
facilitate the patient-doctor communication. Simultaneously, 61% of IT specialists agreed that
the tool is nicely designed, 39% suggested improving the interface. 83% agreed that the tool
works well. 50% agreed that there is no need for help to go through the tool, 44% of them
disagreed.
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Conclusion: We developed a PDA for stage I-II NSCLC. The positive results from the
evaluation of IT specialists and doctors show the potential of using the PDA in clinical practice.
Currently we are improving the tool based on respondents’ suggestions. As a next step, the PDA
will be tested by patients, which will open up the way for setting up a prospective
implementation study in clinical practice.

PS 2-25 USING SINGLE-ITEM GIST MEASURES OF CATEGORICAL RISK AND
BENEFIT PERCEPTION TO PREDICT RESULTS OF ALCOHOL ABUSE
SCREENING
Decision Psychology and Shared Decision Making (DEC)
Bridget Hayes, M.A., Valerie F. Reyna, PhD, Pratik Vadlamudi and David Garavito, MA,
Cornell University, Ithaca, NY
Purpose: Fuzzy Trace Theory (FTT) predicts that health decisions often depend on simple,
categorical perceptions of the gist of benefits and risks. Building on FTT scales used in other
health domains, we tested the utility of two single-item measures of categorical risk and benefit
perception to predict positive screens for alcohol abuse on the AUDIT (Alcohol Use Disorders
Identification Test).
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Method: Two samples of college students (n=2028 and n=2025) responded to the World Health
Organizationʼs 10-item AUDIT during the summer before college and in the fall of freshman
year. AUDIT is a validated measure that assesses drinking patterns and history of drinking
consequences. AUDIT scores above 7 constitute a positive screen for alcohol abuse. Participants’
perceptions of the overall gist of the risks and benefits of drinking alcohol were elicited with a
response scale of “none,” “low,” “medium,” or “high.”
Result: AUROC analysis was performed on each item separately to determine cut-off scores for
overall accuracy (treating Type I and II errors similarly) before assessing sensitivity and
specificity. Across the two samples and two measurement occasions, a positive screen on the
categorical benefit item (i.e. “medium” or “high”) predicted a positive screen on AUDIT with
sensitivity ranging from .623 to .751, specificity ranging from .761 to .842, and overall accuracy
ranging from .760 to .803. Results were similar across genders. A positive screen on the
categorical risk item (i.e. “none” or “low”) predicted a positive screen on AUDIT with sensitivity
ranging from .476 to .532, specificity ranging from .606 to .684, and accuracy ranging from .583
to .667. Combining the categorical risk and benefit items into a single measure slightly improved
specificity and accuracy compared to the measure of categorical benefit alone, but reduced
sensitivity.
Conclusion: Lifetime frequency of alcohol dependence is estimated as 1 in 5, and dependence
peaks in young adulthood. Applying FTT, a simple question about the gist of the benefits of
drinking performed remarkably well in identifying high-risk drinkers (based on convergent
validity). High-risk drinking appears to be better predicted by benefit perception than risk
perception in these samples. A single-item measure of categorical perception of benefits related
to drinking alcohol predicts a positive screen on a validated screening test, with sensitivity and
specificity approaching the level of common clinical tests.
PS 2-26 DID WE MAKE THE RIGHT DECISION? PARENTS NAVIGATION OF
CRITICAL TREATMENT DECISION(S) FOR THEIR FETUS/NEONATE DIAGNOSED
WITH A LIFE-THREATENING CONGENITAL HEART DEFECT
Decision Psychology and Shared Decision Making (DEC)
Rebecca Delaney, PhD1, Nelangi Pinto, MD, MS1, Elissa Ozanne, PhD1, Heather Coulter,
M.Ed2, Louisa Stark, PhD2, Michelle Karasawa, M.S.1, Angira Patel, MD, MPH3, Mary
Donofrio, MD4, Michelle Steltzer, MSN, APRN, CPNP, AC/PC3, Mingfen Xu, M.S.N.5 and
Angela Fagerlin, PhD6, (1)University of Utah, Salt Lake City, UT, (2)University of Utah Health
Center for Clinical & Translational Science, Salt Lake City, UT, (3)Ann & Robert H. Lurie
Childrenʼs Hospital of Chicago, Chicago, IL, (4)Childrenʼs National Health System,
Washington, DC, (5)Duke University School of Medicine, Durham, NC, (6)University of Utah /
Salt Lake City VA, Salt Lake City, UT
Purpose: Parents of a fetus/neonate diagnosed with a complex, life-threatening congenital heart
defect (cCHD) must make unexpected and challenging medical decisions choosing between
termination, palliative/comfort care, or surgery. The purpose of this qualitative study is to
understand parental experiences and decision-making processes surrounding the initial treatment
decision.
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Method: Parents of a fetus/neonate diagnosed with cCHD from four sites across the U.S.
(Chicago, Durham, Salt Lake City, and Washington, DC) were recruited 6 months to 5 years
post-diagnosis. Ten focus groups, lasting approximately 2 hours, were conducted with parents of
a child with cCHD who chose termination or palliative care (5 groups) or surgical intervention (5
groups) to gain insight into experiences around diagnosis, treatment decisions, outcomes, and
daily life. Participants (n=56) were, on average, 34 years old (range= 20-52 years; SD=5.1), 45
were female and 11 were male; 89% identified themselves as White. Focus groups were audiorecorded, transcribed, coded by independent raters and content analyzed to identify prominent
themes.
Result: Key guiding principles in the decision-making process differed among parents. Some
parents reported that their “gut feelings” or religious or spiritual beliefs guided treatment
decisions; while others focused on measurable outcomes (e.g., survival rates). The impact on
quality of life for the child, their other children, and family was another key factor in decisions.
The main barriers parents reported regarding the decision-making process included: 1) difficultly
processing information under emotional circumstances, 2) the need to learn exceedingly complex
information in a short amount of time, and 3) challenges finding quality information. Parents also
reported inconsistencies in treatment options providers discussed, with little to no discussion for
some options and other options presented that did not align with parents’ values.
Conclusion: Parents have trouble processing and understanding important information to make
complex treatment decisions, especially in their distressed state. There is also variability in how
parents make treatment decisions and how treatment options are presented by providers.
Therefore, we believe that the development of decision support tools and strategies would benefit
parents to ensure that they are informed and help them navigate the challenging decision-making
process. Future work should include developing decision support tools that address barriers to
decision making and help identify parents’ values as a method for improving the medical
decision-making process for cCHD.
PS 2-28 MAPPING INFORMATION SEARCH AND EVALUATION STRATEGIES
USING A DIGITAL DECISION AID FOR REPRODUCTIVE HEALTH CLIENTS
Decision Psychology and Shared Decision Making (DEC)
Sakawrat Kitkuakul, Master Degree1, Raphael Gotlieb, Master Degree2 and Dana L. Alden,
PhD1, (1)University of Hawaii at Manoa, Honolulu, HI, (2)McGill University, Montreal, QC,
Canada
Purpose: This study mapped information search and evaluation strategies used by reproductive
health (RH) clients while they reviewed contraceptive methods arrayed in a digital matrix as part
of a simulated decision aid (DA) experience. Participants could rate up to five contraceptive
methods on attribute importance and utility in preparation for consultation with their provider.
Mapping user search/evaluation strategies is critical to developing information presentations that
match RH clients’ decision making styles.
Methods: Female panel members (n=169, 18-35, US residents) reviewed a digital DA comprised
of a 5x5 matrix with five method attributes (e.g., contraceptive method convenience) listed
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vertically and five method categories listed horizontally (e.g., barrier methods; see Figure).
Following their own preferred strategy, participants searched and assigned importance scores (010) for each attribute and utility scores (1-10) for each contraceptive category. Unknown to
participants, customized background software, developed for this study, tracked
search/evaluation strategies. Other measures of interest were time spent using the DA matrix and
perceived ease of use.
Results: Two distinct search/evaluation models emerged. Approximately 65% of participants
engaged in compensatory processing, first rating the five attribute importance weights (e.g.,
assigning a score of 7 out of 10 on ‘protects against STIs’) and then, vertically rating utilities for
each of five methods on some or all attributes (e.g., assigning a score of 8 out of ten on ‘protects
against STIs’ for barrier methods). The other 35% used non-compensatory processing in which
they rated one or two attribute importance weights and then, horizontally rated the utilities of
most or all five methods for those attributes only. Compensatory processers spent more time
searching/evaluating (6 minutes/48 seconds versus 5 minutes/45 seconds, p<.01) and evaluated
the DA more positively (4.4 versus 4.1, p<.04).
Conclusion: As self-directed, digital DAs become more prevalent, understanding RH clients’
interactions with matrices and other information arrays is increasingly important. In this study, a
majority of RH clients evaluated methods vertically one at a time, forming weighted importance
X utility averages (compensatory). However, a substantial percentage focused on one or two
most important attributes horizontally across methods and did not attend to substantial amounts
of matrix information (non-compensatory). Mapping such strategies facilitates development of
DA architecture that effectively prepares RH clients (and potentially patients in general) for
shared decision making.
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PS 2-29 IMPROVING THE NAVIGATION DESIGN OF A DIGITAL DECISION AID
FOR SURROGATE DECISION-MAKERS OF CRITICALLY ILL TRAUMATIC BRAIN
INJURY PATIENTS USING EYE TRACKING TECHNOLOGY: A SINGLE-MASKED
RANDOMIZED STUDY
Decision Psychology and Shared Decision Making (DEC)
Javad Norouzi Nia, MBA1, Soussan Djamasbi, PhD1, Bengisu Tulu, PhD1, Andrew Aberdale,
B.S.1, Christopher Lee, MS2 and Susanne Muehlschlegel, MD, MPH3, (1)User Experience and
Decision Making Lab, Foisie Business School, Worcester Polytechnic Institute, Worcester, MA,
(2)University of Massachusetts Medical School, Worcester, MA, (3)Department of Neurology,
University of Massachusetts Medical School, Worcester, MA
Purpose: Shared decision-making has been recommended by major professional critical care
societies for surrogate decision-making in the ICU to reduce decisions incongruent with patient
values and preferences and decisional conflict. We converted a paper-based goals-of-care
decision aid (DA) in critically-ill TBI patients to a digital DA. We aimed to apply eye-trackingtechnology in a single-masked randomized study to understand the effects of and optimize the
DA navigation design to facilitate information processing.
Methods: We created two digital DAs: (1) an unmodified conversion of the paper-DA with
horizontal, top-justified static navigation (control) vs. (2) a vertical, left-justified navigation with
page subsections and page completion checkmarks (experimental), which encourages users to
view pages in order. Sixteen healthy participants were randomly assigned to the two groups (n=8
per group) and navigated through the DAs, while remaining masked to the DA assignment
(control vs. experimental). We compared user disorientation and usability using validated scales,
and eye movements (fixation and saccades) recorded with eye-tracking-technology. Betweengroup comparisons were performed using t-tests after confirming a normal distribution of the
data. Impact of navigation on usability was assessed with linear regression, adjusting for
disorientation (System-Usability-Score= b0+ b1*Disorientation).
Results: Disorientation was significantly less in the experimental DA (mean 6.5 vs. 5.2;
p=0.005; smaller values indicating increased disorientation) with no difference in usability (mean
System-Usability-Scale scores 81 vs. 78; p=0.64; scores >72 indicating good usability [score
range 0-100]). Regression analysis revealed a significant association between disorientation and
usability (p=0.01), with disorientation explaining 31% of the variation in System-UsabilityScores (adjusted R2=0.31). Eye-tracking measurements revealed longer average fixation per page
in the experimental DA (mean 0.24 sec vs. 0.23 sec; p=0.03) and a higher ratio of information
processing to search per page (fixation-duration over total duration of both fixations and
saccades on a page; mean 0.89 vs. 0.88; p=0.0003).
Conclusions: Our small randomized study using eye-tracking-technology suggested that the
experimental navigation design significantly improved the navigation experience of our digital
DA resulting in less disorientation and participants spending less time searching and more time
processing the information. While there was no difference in subjective usability, we found a
significant association between improved navigability and higher usability.
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PS 2-32 IMPACT OF A LARGE U.S. GOVERNMENT NUTRITION PROGRAM ON
UNDER-FIVE NUTRITION IN SUB-SAHARAN AFRICA: AN EVALUATION OF FEED
THE FUTURE
Health Services, Outcomes and Policy Research (HSOP)
Theresa Ryckman1, Margot Robinson2, Courtney Pedersen2, Jay Bhattacharya, MD, PhD3 and
Eran Bendavid, MD, MS4, (1)Department of Health Research and Policy, Stanford University,
Stanford, CA, (2)Stanford University School of Medicine, Stanford, CA, (3)Stanford University,
Stanford, CA, (4)Stanford Health Policy, Centers for Health Policy and Primary Care and
Outcomes Research, Department of Medicine, Stanford University, Stanford, CA
Purpose: Malnutrition is the single greatest risk factor for child morbidity and mortality
globally, and yet there are few evaluations of any large multi-country nutrition programs in the
literature, with global nutrition experts highlighting a need for more evidence on what works,
especially at scale, to inform policy decisions. We performed an econometric analysis of the
impact of Feed the Future (FTF), a large multi-country nutrition and agriculture program, on
nutritional outcomes in Sub-Saharan Africa (SSA).
Methods: We analyzed data from 118 Demographic and Health Surveys and Multiple Indicator
Cluster Surveys conducted in 12 FTF focus countries and 21 non-FTF countries in SSA between
2000 and 2017. We estimated FTFʼs impact on stunting, a key indicator of child nutrition, as our
primary outcome. A child is considered stunted if their height-for-age z-score is more than two
standard deviations below a reference median. Secondary outcomes included wasting (low
weight-for-height) and underweight (low weight-for-age). We used a difference-in-differences
statistical model that compares the experience of children in FTF countries after the programʼs
implementation to children before FTFʼs introduction and children in non-FTF countries,
controlling for relevant covariates, time-invariant national differences, and trends over time
common to all countries.
Results: Our final data set consists of data on a total of 883,309 under-five children: 388,052
observations from FTF countries and 495,257 from non-FTF countries. 39% of children in our
sample were stunted, 10% were wasted, and 23% were underweight. Children in FTF focus
countries exhibited a 2.4 [0.6-4.2] percentage point greater decline in stunting, a 1.7 [0.2-3.2]
percentage point greater decline in wasting, and a 2.4 [0.8-4.1] percentage point greater decline
in underweight levels after FTFʼs implementation, compared to non-FTF countries. We estimate
that the program has resulted in approximately one million fewer children stunted, wasted, and
underweight to date.
Conclusions: FTFʼs activities were followed by improvements in three standard measures of
undernutrition. We could identify no other valid hypothesis for improvements occurring during
this time period unique to FTF countries. This finding highlights the effectiveness of a large,
country-tailored program focused on the underlying determinants of undernutrition (such as
agriculture and food security), which has important implications for decisions regarding nutrition
policy in low-resource settings.
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Figure 1: Adjusted undernutrition outcomes before and after FTFʼs implementation

PS 2-33 PERSONALIZED DIABETES SCREENING RECOMMENDATIONS WITH
CONSIDERATION OF HBA1C TEST HISTORY, AGE, AND BMI
Health Services, Outcomes and Policy Research (HSOP)
Chou-Chun Wu and Sze-chuan Suen, PhD, Daniel J. Epstein Department of Industrial and
Systems Engineering, University of Southern California, Los Angeles, CA
Purpose:
There is strong evidence that diabetes is underdiagnosed in the US -- the CDC estimates
approximately 25% of diabetic patients are unaware of their condition. To encourage timely
diagnosis of at-risk patients, we develop screening guidelines stratified by BMI, age, and prior
test history to provide more personalized screening frequency recommendations that do not
impose costs beyond our willingness to pay values.
Method:
We develop a Partially Observed Markov Decision Processes (POMDP), a widely used
reinforcement learning model in machine learning. This framework is ideally suited for solving
sequential decision-making problems with uncertainty, which we have here. Every six months,
we need to recommend to the physician whether to screen her patient, given the patientʼs
characteristics and test history. This is further complicated by two sources of uncertainty: the
true diabetic state is not observable, and the screening test (HbA1c) results may not be perfect.
The model framework assumes the physician has an estimate of the patientʼs health state (nondiabetic, prediabetic, or diabetic) at each period and updates her beliefs about the patientʼs health
given expected disease progression and observed test results. We solve the POMDP to identify a
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policy that provides the optimal action (screen or wait) at every six months from age 45 to 90
that that maximizes the patientʼs discounted lifetime net monetary benefit (NMB).
Result:
We show that given risk factors and history of inspection results our medical decision framework
can generate patient-specific screening guidelines. We conclude that the current screening
policy, which is to screen above ages 45 every one to three years, is suboptimal. We find that
individuals with BMI < 25 should be screened roughly every year between ages 65 and 85 while
individuals with BMI ≥ 25 should be screened roughly every six months between ages 50 and
85.
Conclusion:
Our model finds that earlier and more frequent screening for all BMI groups would be justified
with typical willingness-to-pay values. We estimate that this optimal screening policy would
increase NMB by $2000-$4000 per patient compared to the status quo at a willingness-to-pay of
$50,000/QALY.
PS 2-34 ESTIMATING HEALTH BURDEN ATTRIBUTABLE TO LABORATORYCONFIRMED LYME DISEASE IN ONTARIO, CANADA: A POPULATION-BASED
MATCHED COHORT STUDY USING HEALTH ADMINISTRATIVE DATA
Health Services, Outcomes and Policy Research (HSOP)
Stephen Mac1, James Jung2, Alexander Kopp2, Gerald Evans, MD3, Eleanor Pullenayegum,
PhD4, Samir N. Patel, PhD5 and Beate Sander, PhD6, (1)Institute of Health Policy, Management
and Evaluation, University of Toronto, Toronto, ON, Canada, (2)Institute for Clinical Evaluative
Sciences, Toronto, ON, Canada, (3)Queens University, Kingston, ON, Canada, (4)Program in
Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada,
(5)Public Health Ontario, Toronto, ON, Canada, (6)Toronto Health Economics and Technology
Assessment (THETA) Collaborative, University Health Network, Toronto, ON, Canada
Purpose: Lyme disease (LD) is the most commonly reported vector-borne disease in North
America, with incidence rates having increased 14-fold in Canada since 2010. The objective of
this study is to estimate health outcomes attributable to laboratory-confirmed LD in Ontario,
Canada, using health administrative data.
Method: We used a previously created LD cohort of laboratory-confirmed cases between Jan 1,
2006 and Dec 31, 2013 from provincial laboratory and reportable diseases databases, linked to
population-based health administrative data. Infected subjects were hard-matched 1:3 to
uninfected subjects on age ±1 year, sex, index date ± 30 days, and the logit of the propensity
score from a regression on rurality, neighbourhood income quintile, and comorbidities 2-years
prior to index date. We used ICD-10 and Ontario Health Insurance Plan billing codes to identify
emergency department visits, physician billings and hospitalizations related to LD sequelae: skin
rashes, carditis, arthritis, facial palsy, cognitive sequelae, polyneuropathy or meningitis, and
physical sequelae (e.g. myalgia, arthralgia, nausea and vomiting, headaches, vertigo). We looked
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back 1-year pre-index date to exclude sequelae reported prior to confirmed LD infection, and
followed subjects until March 31, 2017. We compared proportion of sequelae using a chi-square
test, and calculated relative risk (RR) ratios.
Result: The matched cohort consisted of 655 laboratory-confirmed LD subjects meeting the
cohort inclusion criteria. Mean age at index date was 44.45 + 20.09 years; 51.0% (n=334) were
female. Balance was assessed and most standardized differences were < 0.1. In comparison to
uninfected subjects, LD subjects had increased RR (95% CI) to develop arthritis 1.26 (0.90–
1.76), carditis 1.04 (0.80–1.34), cognitive sequelae 1.11 (0.79–1.57), skin rashes 1.49 (1.052.12), facial palsy 9.98 (4.57–21.79), physical sequelae 1.18 (1.03–1.34), polyneuropathy or
meningitis 4.59 (2.57–8.22), and have multiple sequelae 1.29 (1.10–1.51). Upon LD cases, males
had increased RR of facial palsy, 2.20 (1.01-4.78) and decreased RR to develop physical
sequelae, 0.77 (0.62–0.96) when compared to females.
Conclusion: Laboratory-confirmed LD is associated with increased risk of several physical and
neurologic sequelae. Further investigation of probable LD cases and increased sample size is
warranted to understand LD clinical outlook, including risk factors for sequelae. High-quality
health outcomes data attributable to LD is important for disease history models, intervention
evaluations, and health policy decision-making.
PS 2-35 SEPSIS SURVIVORS EXPERIENCE A SHORT-TERM—BUT NOT LONGTERM—REDUCTION IN SELF-RATED HEALTH COMPARED TO MATCHED
CONTROLS: A RETROSPECTIVE COHORT STUDY USING THE US HEALTH AND
RETIREMENT STUDY
Health Services, Outcomes and Policy Research (HSOP)
Matthew R. Carey, MBA1, Hallie C. Prescott, MD, MSc2, Theodore J. Iwashyna, MD, PhD2,
Michael E. Wilson, MD3, Angela Fagerlin, PhD4 and Thomas S. Valley, MD, MSc2,
(1)University of Michigan Medical School, Ann Arbor, MI, (2)Division of Pulmonary and
Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor,
MI, (3)Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN,
(4)University of Utah / Salt Lake City VA, Salt Lake City, UT
Purpose: Sepsis is a leading cause of mortality and functional disability among the elderly
though less is known about the long-term impact of sepsis or associated intensive care unit (ICU)
admission on self-rated health.
Methods: We used 2004-14 US Health and Retirement Study (HRS) data with linked Medicare
claims to identify individuals aged 65+ who had a sepsis admission in the two years following a
baseline HRS survey. A cohort of individuals who were not hospitalized from their baseline HRS
surveys to the time of matching was matched to patients whose first hospitalizations postbaseline survey were for sepsis using 1:1 nearest-neighbor matching without replacement on
demographics, hospitalizations prior to the baseline HRS survey, and comorbidities. Patients
with sepsis were then subdivided into those admitted to the ICU and those who were not. Thus,
we identified three analysis groups: non-hospitalized, non-ICU sepsis, and ICU sepsis. Cox
proportional hazard models were used to compare mortality rates across the groups. Self-
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reported health status was measured on a five-point Likert scale, with lower numbers indicating
better health. Differences between baseline and follow-up self-rated health were compared across
the groups for survivors from each time period for which survey data were available using multilevel modeling techniques with a random intercept to account for differences in baseline selfhealth scores.
Results: A total of 2,286 individuals were included for analysis. Non-hospitalized and sepsis
cohorts were well balanced across covariates. As expected, mortality was higher for both the
non-ICU sepsis (hazard ratio 1.19 [1.06,1.34], p=0.003) and ICU sepsis (hazard ratio 1.68
[1.47,1.91], p<0.001) cohorts compared to the non-hospitalized cohort. At the time of the first
follow-up interview in year two, both non-ICU and ICU sepsis admissions were associated with
worse self-rated health compared to the non-hospitalized cohort (impact on non-ICU sepsis=0.14
[0.03,0.26], p=0.012; impact on ICU sepsis=0.30 [0.14,0.45], p<0.001). In years 4-10, non-ICU
and ICU sepsis were not associated with worse self-rated health scores compared to the nonhospitalized cohort or their own baseline scores (Figure 1).
Conclusions: Four years after hospitalization, there was no difference in self-rated health
between sepsis survivors and non-hospitalized adults, regardless of the severity of sepsis.
Patients and clinicians should take into account that short-term declines in quality of life may be
temporary after surviving sepsis.
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PS 2-36 ESTIMATED MORTALITY RATES AMONG TREATED AND UNTREATED
VETERANS WITH OPIOID USE DISORDER IN THE VETERANS HEALTH
ADMINISTRATION
Health Services, Outcomes and Policy Research (HSOP)
Jack H. Ching, BSE, Stanford Health Policy, Stanford University, Stanford, CA, Jodie A.
Trafton, PhD, Program Evaluation and Resource Center, Office of Mental Health and Suicide
Prevention, VA Palo Alto Health Care System, Menlo Park, CA, Jeremy D. Goldhaber-Fiebert,
PhD, Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes
Research, Stanford University, Stanford, CA, Douglas K. Owens, MD, MS, VA Palo Alto Health
Care System, Palo Alto, CA and Joshua A. Salomon, Ph.D., Center for Health Policy and Center
for Primary Care and Outcomes Research, Stanford University, Stanford, CA
Purpose:
While receipt of methadone and buprenorphine treatment are associated with significantly lower
all-cause mortality for patients with opioid use disorder (OUD), initiating or discontinuing either
treatment is associated with higher mortality risks relative to maintaining stable treatment. We
used a simulation model to characterize the length of time that patients need to remain on
treatment in order to realize mortality benefits.
Method:
We developed a compartmental model to simulate Veterans seen in the Veterans Health
Administration (VHA) for OUD. The five compartments were based on MAT status: not
receiving MAT, receiving treatment in a licensed methadone treatment clinic, or receiving
office-based treatment with buprenorphine, oral naltrexone, or injectable extended-release
naltrexone. Monthly transitions between each compartment accounted for the inflow of Veterans
newly diagnosed with OUD, differential rates of treatment initiation and discontinuation for each
treatment type, all-cause mortality, as well as elevated mortality risks during treatment transition
periods. We used a Bayesian approach to calibrate the rate of new OUD diagnoses, as well as
rates of treatment initiation, retention, and all-cause mortality to fit quarterly targets based on
VHA treatment volumes and observed mortality between 2017-2018. We derived relative risks
of all-cause mortality in the first month of initiating and the first month after discontinuing
buprenorphine and methadone treatment from the literature.
Results:
Our model-based estimates of all-cause mortality rate for Veterans with OUD not receiving
MAT was 58.06 per 1000 person-years, significantly higher than those who remained in
buprenorphine (5.25 per 1000 person-years) and methadone (10.96 per 1000 person-years)
treatment beyond one month. During the first month of treatment, the all-cause mortality was
6.39 and 22.10 per 1000 person-years for buprenorphine and methadone respectively. During the
first month after treatment discontinuation, the all-cause mortality was 40.96 and 61.23 per 1000
person-years for buprenorphine and methadone respectively. Due to the significantly lower allcause mortality rate while receiving either treatment, being on buprenorphine or methadone
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treatment for relatively short periods can be beneficial over not receiving treatment at all, despite
elevated mortality risks associated with treatment transitions.
Conclusion:
Efforts focused on expanding coverage of MAT should focus on MAT initiation as well as
retention of those patients already engaged in MAT, in order to maximize health outcomes for
patients with OUD.

PS 2-37 NAFLD SIMULATOR: AN INTERACTIVE SIMULATION TOOL FOR LONGTERM OUTCOMES OF NON-ALCOHOLIC FATTY LIVER DISEASE
Health Services, Outcomes and Policy Research (HSOP)
Ozden Dalgic, PhD1, Sumeyye Samur, PhD1, Kathleen Corey, MD, MPH2, Emily Bethea, MD3,
Wanyi Chen, PhD1, Rohit Loomba, MD, MHSc4 and Jagpreet Chhatwal, PhD1, (1)Institute for
Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston,
MA, (2)Harvard Medical School, Boston, MA, (3)Liver Center and Gastrointestinal Division,
Massachusetts General Hospital, Boston, MA, (4)University of California San Diego, La Jolla,
CA
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Purpose: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease
worldwide, with an estimated prevalence ranging from 25% to 40%. Non-alcoholic
steatohepatitis (NASH), an aggressive form of NAFLD, is projected to become the leading
indication of liver transplantation in the US by 2020. Several potential drugs for NAFLD/NASH
treatment are in early stages of development; however, long-term outcomes of these treatments
will not be known for decades. Our aim was to predict long-term outcomes of NAFLD/NASH
and develop an open-access, interactive tool for patients and providers that help them understand
the long-term adverse outcomes associated with NAFLD.
Methods: We developed an individual-level state-transition model to simulate the life course of
NAFLD patients as they progressed through the different stages of the natural history. Transition
probabilities were derived from published meta-analyses, observational studies, and clinical
trials. Unknown model parameters were estimated through calibration process—we used
simulated annealing for calibration such that model-predicted 20-year survival (equivalent to
139,163 person-years data) matched closely with the outcomes of a large observational study.
Using the calibrated model, we generated 10 million simulated NASH patient profiles and their
outcomes, which were then used it to create an interactive, web-based tool, NAFLD Simulator.
NAFLD Simulator allows users to enter patient demographics and current NAFLD stage, and
predicts survival, mortality due to liver, non-liver, and background and causes, cumulative risk
of hepatocellular carcinoma and cirrhosis.
Results: Figure 1 compares the estimated outcomes for a 50-year old patient having NASH
fibrosis stages F1, F2, F3 and F4. For instance, the 10-year survival in patients with NASH F1,
F2, F3, and F4 was 93%, 91%, 86%, and 69%, respectively. The 10-year non-liver-related
mortality in these patients was 2%, 4%, 8%, and 12%, respectively; and the corresponding liverrelated mortality was 0%, 0.01%, 0.06 and 13.5, respectively. The model also estimated the 10year risk of developing hepatocellular carcinoma increases from 0.6% to 8.8% if patients
progress from F3 to F4 stage.
Conclusions: NAFLD Simulator can closely replicate the outcomes of a large observational
study and provides an innovative platform to disseminate the long-term risk associated with
NAFLD and NASH to patients and providers.
Figure 1: Outcomes from microsimulation model of a 50-year old patient for NASH fibrosis
stages F1, F2, F3 and F4.
PS 2-38 THE PITTSBURGH INFANT BRAIN INJURY SCORE: A COSTEFFECTIVENESS ANALYSIS
Health Services, Outcomes and Policy Research (HSOP)
Kathleen Noorbakhsh, MD1, Rachel Berger, MD, MPH1 and Kenneth Smith, MD, MS2,
(1)Childrenʼs Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA,
(2)University of Pittsburgh, Pittsburgh, PA
Purpose: Abusive head trauma (AHT) is the leading cause of traumatic brain injury death in
infants; 30% of children with AHT are initially misdiagnosed, which leads to increased
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morbidity and mortality. The Pittsburgh Infant Brain Injury Score (PIBIS) is a validated tool to
identify infants at high AHT risk who are most likely to benefit from brain imaging. This study
evaluates the cost-effectiveness of PIBIS compared to other AHT detection strategies.
Method: We performed a Markov decision analysis from a healthcare perspective to estimate
the cost-effectiveness of AHT screening strategies. Infants enter the model with or without mild
AHT. Screening strategies include clinical judgment alone, universal head computed tomography
(CTH), and PIBIS followed by CTH (PIBIS/CTH). Given increasing availability of rapid
magnetic resonance imaging (rMRI) for AHT, universal rMRI versus PIBIS followed by rMRI
(PIBIS/rMRI) were also considered. PIBIS score of ≥2 was the imaging criterion (sensitivity
93%, specificity 53%). Correctly diagnosed individuals undergo medical treatment and are
assumed to no longer be at risk; misdiagnosed individuals are at risk for re-injury with associated
death or disability. Individuals are followed for one year. Outcomes included quality-adjusted
life-years, costs and incremental cost-effectiveness ratios.
Result: PIBIS/CTH was preferred, with universal CTH costing $134,000/QALY and universal
rMRI costing >$270,000/QALY gained in incremental analyses. Clinical judgement and
PIBIS/rMRI were dominated. In one-way sensitivity analyses, PIBIS/CTH remained the
preferred strategy over universal CTH if: radiation-induced brain cancer risk was >8.6
cases/10,000 CTH (base case 10/10,000), lifetime disutility associated with brain cancer was
>8.5 QALY (base 9.9), CTH specificity was <98.7% (base 98%), or AHT probability was <3.3%
(base 3%). Probabilistic sensitivity analyses show PIBIS/CTH was favored in 58% of model
iterations at a $100,000/QALY acceptability threshold.
Conclusion: PIBIS/CTH for AHT is economically reasonable compared to alternative strategies.
Current recommendations recommend vigilance in high-risk infants; some advise universal CTH
in those with high-risk features. Minimal historical changes in AHT rates suggest low clinical
judgment efficacy and minimal adoption of universal CTH. PIBIS offers a more cost-effective
screening strategy than clinical judgement alone with reduced radiation exposure in this
vulnerable population. Universal CTH could be favored in higher risk infants (≥3.3% AHT risk)
or if lower CTH-associated brain cancer risk can be assumed.
PS 2-39 WHO RECEIVES OPIOIDS DURING AN ACUTE MEDICAL
HOSPITALIZATION?
Health Services, Outcomes and Policy Research (HSOP)
Kaitlin Keenan, BS1, Michael Rothberg, MD, MPH2, Shoshana Herzig, MD, MPH3, Simon
Lam, PharmD, RPh4, Vicente Velez, MD, FACP, FHM2 and Kathryn Martinez, PhD, MPH2,
(1)Cleveland Clinic Lerner College of Medicine, Cleveland, OH, (2)Cleveland Clinic,
Cleveland, OH, (3)Division of General Medicine, Beth Israel Deaconess Medical Center,
Boston, MA, (4)Department of Pharmacy, Cleveland Clinic, Cleveland, OH
Purpose: Nearly half of medical inpatients receive opioids. As few guidelines exist regarding
recommended use of opioids, physicians often use their own discretion in determining which
patients receive them. The objective of this study was to identify patient characteristics
associated with opioid receipt during an acute medical hospitalization.
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Method: This is a retrospective observational study of patients at Cleveland Clinic Hospitals in
2016 of patients with an acute medical hospitalization who reported pain. Prior opioid use was
defined as any opioid prescription 30 days prior to hospitalization. Opioid receipt was defined as
any opioid prescription during the hospitalization and analyzed dichotomously. Patient
characteristics included age, gender, race, and smoking status. Clinical characteristics included
maximum pain score, history of chronic pain or psychiatric diagnosis, and prior opioid use.
Differences in the odds of opioid receipt were assessed using mixed effects logistic regression,
accounting for clustering by discharging physician. The model was then stratified by prior opioid
receipt.
Result: The sample included 15,478 patients; 70% white and mean age was 69 years; 60% had a
chronic pain history and 35% had prior opioid use. Seventy-two percent received opioids. In the
overall mixed effects model, opioid receipt was associated with male gender (OR: 1.12, 95% CI:
[1.02 – 1.23]), maximum pain score (OR per point: 1.53, CI: [1.50 - 1.56]), chronic pain history
(OR: 1.32, CI: [1.20 – 1.46]), and prior opioid use (OR: 3.09, CI: [2.74 – 3.49]). Black patients
were less likely to receive opioids than whites (OR: 0.57, CI: [0.51 – 0.64]). Patients with a
history of a psychiatric diagnosis were less likely to receive opioids than without (OR: 0.73, CI:
[0.66 – 0.80]). In the model stratified by prior opioid use, there was no difference by race in the
odds of opioid receipt for those with prior use, but among opioid-naïve patients, blacks were less
likely to receive opioids than whites (OR:0.47, CI: [0.38 -0.59]).
Conclusion: Physician decision making for opioid prescribing is influenced by clinical and nonclinical factors. Controlling for clinical indications, black patients were less likely to receive
opioids than white patients, especially if they didn’t have a prior opioid use history. Clearer
guidelines regarding opioid prescribing are needed to help physicians make evidence-based
decisions for appropriate pain management for all patients.
PS 2-40 IVACAFTOR TREATMENT FOR G551D CYSTIC FIBROSIS PATIENTS IS
NOT COST-EFFECTIVE IN THE US HEALTH CARE SYSTEM SETTING
Health Services, Outcomes and Policy Research (HSOP)
Kael Wherry, MS, Division of Health Policy and Management, University of Minnesota,
School of Public Health, Minneapolis, MN, Ian O. Williamson, M.B.A., School of Public Health,
University of Minnesota, Minneapolis, MN, Richard H. Chapman, PhD, Institute for Clinical and
Economic Review, Boston, MA and Karen M. Kuntz, ScD, Division of Health Policy and
Management, University of Minnesota School of Public Health, Minneapolis, MN
Purpose: Cystic fibrosis (CF) is a rare genetic disease affecting over 30,000 people in the US.
There is no cure for CF and until recently, treatment has targeted symptoms of the disease and
not the disease-causing genetic defect. Ivacaftor is included in a new class of breakthrough drugs
targeting the genetic defects of CF and was approved for the US market in 2012. We sought to
estimate the long-term cost-effectiveness of ivacaftor in the US G551D CF population (about 5%
of patients) from a payer perspective.
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Method:
We developed an individual-level microsimulation model that followed a cohort of US CF
patients with the G551D mutation over a lifetime. We used percent predicted forced expiratory
volume in 1 second (ppFEV1) as the primary indicator of lung function and treatment effect. Our
microsimulation included individual heterogeneity in ppFEV1decline over time. The primary
outcome of interest was quality-adjusted life years (QALYs). We also compared unadjusted life
years, count of acute pulmonary exacerbations, and count of lung transplants over a lifetime
between patients treated with ivacaftor plus best supportive care and patients treated with best
supportive care alone. We used a 3% discount rate and conducted one-way and probabilistic
sensitivity analyses to test the impact of various model inputs and uncertainties.
Result:
We found a substantial increase in QALYs, life years, and treatment costs over a lifetime for
patients treated with ivacaftor plus best supportive care versus best supportive care alone.
Discounted results for ivacaftor were 22.65 QALYs and $8,751,053 in total lifetime costs
compared to 15.92 QALYs and $2,267,869 lifetime costs for the best supportive care alone arm.
The incremental cost-effectiveness ratios (ICERs) were $958,683 per QALY and $1,486,780 per
life year gained. Based on the ivacaftor price used in this analysis, a 73% discount is required to
make ivacaftor cost-effective at $150,000 per QALY. Results from the probabilistic sensitivity
analysis (PSA) indicated a 0% chance that ivacaftor was cost-effective at a willingness-to-pay
(WTP) threshold of $500,000 per QALY.
Conclusion:
Our findings indicate substantial benefits associated with ivacaftor treatment at a substantial
increase in lifetime cost of care among US CF patients with the G551D mutation. The high cost
of ivacaftor treatment prohibited cost-effectiveness at or near commonly accepted WTP
thresholds.
PS 2-41 HEALTH MASS INDEX: OBESITY METRICS TO REFLECT HEALTH
RATHER THAN GROWTH
Health Services, Outcomes and Policy Research (HSOP)
Enrique Saldarriaga, MS, BS and Anirban Basu, PhD, The Comparative Health Outcomes,
Policy, and Economics (CHOICE) Institute, Seattle, WA
Purpose: To develop an alternate functional form of weight and height, denoted as the Health
Mass Index (HMI), that can be better proxies for underlying health.
Method: We conduct a literature review to identify a set of health outcomes that are most
proximally associated to unhealthy levels of weight: prediabetes, diabetes, hypertension, high
cholesterol, coronary heart disease, and any cancer. A Structural Equation Model (SEM) with a
latent variable, deterministically loaded by W and G, was fit to the NHIS 2017 Adults sample, a
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nationally representative cross-sectional dataset, using simultaneous equations estimation.
Assuming Hk denotes a vector of health outcomes, and θ the log(HMI), we define:
Hkij= αk0+αk1·Xij+αk2·θij+εkij
θij= ρ1j·log(Wij) + ρ2j·log(Gij)
Where i denotes individuals and j gender; X represents the matrix of demographic and
socioeconomic cofounders. Coefficients ρ1 and ρ2 are shared across all health outcomes and
hence provide with the estimation for the powers in HMI. We normalize ρ1=1 across all health
outcomes and allow to vary. We implement the analysis through a 5-fold cross-validation
method to select the best model between a constrained (ρ2j=2, as in Body Mass Index (BMI)) and
an unconstrained (ρ2j unfixed) one. We prefer the model with the smallest average prediction
error across all left-out subsets. If unconstrained model is selected, we pool data across 5 folds to
obtain our final estimates of ρ2j.
Result: The unconstrained model was the preferred one due to better prediction properties. We
found a ρ2j of 2.4 (95% CI 2.7, ) for males and 2.6 (95%CI 3.0, 2.2) for females. We found
evidence that the HMIʼs coefficient for height is statistically different than the BMIʼs, implying
better representation of underlying health. We did not find significantly different estimates
between genders, and therefore, propose a function form of (Weight/Height2.5) to represent the
HMI.
Conclusion: HMI represents a functional form of weight and height that is slightly different than
BMI and is a better proxy for health measures that are epidemiologically linked to weight gain.
Future research should ascertain whether HMI is better able to address health-related
confounding issues in treatment effect estimation. Furthermore, optimal cut-offs for HMI to
represent obesity categories must be derived. We hope researchers will further explore the
potential of HMI to impact research in obesity-related disease and healthcare services.
PS 2-42 PERSONALIZED INTER-DONATION INTERVALS TO MANAGE RISK OF
IRON-RELATED ADVERSE EVENTS IN REPEAT BLOOD DONORS
Health Services, Outcomes and Policy Research (HSOP)
W. Alton Russell, MS, Management Science and Engineering, Stanford University, Stanford,
CA, David Scheinker, PhD, School of Medicine, Stanford University, Stanford, CA and Brian
Custer, PhD, Laboratory Medicine, University of California San Francisco, San Francisco, CA
Purpose: Individual biology, behavior, and donation frequency contribute to high variability in
repeat blood donors’ risk of iron-related adverse outcomes, which include deferral for low
hemoglobin, giving blood when body iron stores are already low (ferritin < 20 ng/ml for women;
< 30 ng/ml for men) and giving blood when iron stores are already absent (ferritin < 12 ng/ml).
We test how well machine learning can predict risk of iron-related adverse outcomes. Accurate
predictions could be used to develop personalized inter-donation intervals that minimize the risk
of adverse outcomes while maintaining an adequate blood supply.
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Method: Using a public use dataset from the REDS-II Donor Iron Status Evaluation (RISE)
study, we defined donor profiles with hemoglobin, donation history, and questionnaire responses
regarding diet, reproductive health indicators, demographics, and measures of iron status. We
used these donor profiles and donors’ inter-donation intervals to estimate risk of adverse
outcomes at next donation attempt. We performed our analysis both with and without ferritin and
soluble transferrin receptor (sTfR), which U.S. blood centers do not routinely measure. We
trained ensemble multi-class prediction algorithms on 2,543 donations, and we assessed
performance on a hold-out test set of 620 donations. We then used our model to generate risk
profiles for the 620 test set donations. These profiles showed the estimated risk of adverse
outcomes as a function of days since last donation, varied from 56 to 250 days.
Result: While variability in individual donor risk profiles was observed, estimated risk of any
adverse outcome at 250 days was lower than at 56 days for all test set donations. Overall AUC
was 0.76 (with ferritin and sTfR) and 0.72 (without). Both models were best at predicting
hemoglobin deferral (one-vs-all AUC 0.89 with ferritin and sTfR; 0.87 without). Including
ferritin and sTfR improved the ability to predict donations from low-iron donors (AUC 0.79 vs.
0.74) and donations from absent-iron donors (AUC 0.64 vs. 0.57).
Conclusion: Machine learning can effectively predict donors’ risk of iron-related adverse events,
even without ferritin and sTfR. Personalizing inter-donation intervals could protect blood donors
without unduly threatening the adequacy of the blood supply. Further study is needed to ensure
results generalize beyond the RISE study population.
PS 2-43 HEPATOCELLULAR CARCINOMA SURVEILLANCE IN THE ERA OF NEW
HEPATITIS C ANTIVIRAL TREATMENTS: A VALUE OF INFORMATION
ANALYSIS
Health Services, Outcomes and Policy Research (HSOP)
Gizem S. Nemutlu, PhD1, Peter Mueller, PhD1, Qiushi Chen, PhD2, Turgay Ayer, PhD3,
Naveed Janjua, PhD4, Fasiha Kanwal, MD, MSHS5 and Jagpreet Chhatwal, PhD1, (1)Institute for
Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston,
MA, (2)Department of Industrial and Manufacturing Engineering, Penn State University,
University Park, PA, (3)H. Milton Stewart School of Industrial and Systems Engineering,
Georgia Institute of Technology, Atlanta, GA, (4)School of Population and Public Health,
University of British Columbia, Vancouver, BC, Canada, (5)Department of Medicine, Baylor
College of Medicine, Houston, TX
Purpose: The treatment landscape for chronic hepatitis C has changed with the availability of
direct-acting antivirals; 95-100% of patients with hepatitis C can now be cured. However,
virological cure of hepatitis C does not eliminate the risk of hepatocellular carcinoma (HCC) in
individuals with advanced fibrosis and cirrhosis. The value of routine HCC surveillance in this
population is widely debated; long-term data on HCC incidence in these individuals is lacking.
Our objective was to evaluate the value for future research on HCC surveillance in individuals
who were cured of hepatitis C.
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Method: Using a validated discrete-event microsimulation model of the natural history of HCC,
we conducted a value of information (VOI) analysis. Model parameters were estimated from
published sources and clinical trial data. We estimated the cost-effectiveness of routine HCC
surveillance under different surveillance durations (5, 10, 15, 20, 25, and 30 years) and
performed a VOI analysis informed by the population-level expected value of perfect
information (pEVPI) to determine the value of future research. The population-level values were
estimated for the number of individuals cured of hepatitis C who had advanced fibrosis or
compensated cirrhosis and would be undergoing HCC surveillance until 2040.
Result: Figures 1a and 1b show the pEVPI and the cost-effectiveness acceptability frontier of the
cost-effective HCC surveillance strategy at different willingness-to-pay (WTP) thresholds with
the current information in individuals with cirrhosis and advanced fibrosis, respectively. In
individuals with compensated cirrhosis, routine surveillance for 20 years was cost-effective at
$100,000 WTP threshold. The pEVPI at this threshold was $402 million. In individuals with
advanced fibrosis, no surveillance was the cost-effective strategy at all WTP thresholds. The
pEVPI at $100,000 WTP threshold was $358 million.
Conclusion: Routine HCC surveillance provides a good value in individuals with cirrhosis who
were cured with new antivirals; however, surveillance is not cost-effective in individuals with
advanced fibrosis. The VOI analysis implies that future research could potentially be worthwhile
if the fixed cost of research is less than $402 million in individuals with compensated cirrhosis
and $358 million in individuals with advanced fibrosis.
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Figure 1. Cost-effectiveness acceptability frontier and expected value of perfect information over
a range of values for the willingness-to-pay threshold
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PS 2-44 PROJECTION OF PREVALENCE AND MORTALITY ASSOCIATED WITH
ALCOHOL-RELATED LIVER DISEASE IN THE UNITED STATES FROM 2016 TO
2050
Health Services, Outcomes and Policy Research (HSOP)
Jovan Julien, MS1, Turgay Ayer, PhD1, Emily Bethea, MD2, Elliot Tapper, MD3 and Jagpreet
Chhatwal, PhD4, (1)H. Milton Stewart School of Industrial and Systems Engineering, Georgia
Institute of Technology, Atlanta, GA, (2)Liver Center and Gastrointestinal Division,
Massachusetts General Hospital, Boston, MA, (3)Division of Gastroenterology and Hepatology,
University of Michigan, Ann Arbor, MI, (4)MGH Institute for Technology Assessment, Boston,
MA
Purpose:
After remaining stable for over three decades, the number of alcohol-related cirrhosis deaths
started increasing in the United States (US) in 2006. Our study aims to project temporal trends in
alcoholic liver disease (ALD) and mortality in the US up to the year 2050 while accounting for
potential changes in drinking patterns.
Methods: We developed a Markov-based, multi-cohort, state-transition model of the high-risk
drinking (HRD) patterns and natural history of ALD. Health states in our model characterized
individuals by onset of drinking and disease progression. Disease progression rates and other
unobserved parameters were calibrated to cohort studies involving heavy drinkers (n=701),
patients with cirrhosis due to ALD (n=466), and publicly available comprehensive national
surveys on alcohol use.
Results: We validated our model by showing that it closely reproduced the observed trends in
alcohol-related cirrhosis deaths from 2001-2016, as reported by the US National death registry.
The validated model projected that the mortality from cirrhosis is expected to reach 64,400 in
2050 (a 128% increase from 2017). The model projected that a return to HRD reported by
NESARC Wave I (30% decrease from current rate) would result in a 7% decrease in mortality
from 2020-2050, while an increase by the same rate increases ALD mortality 30% from 20202050. Additionally, we project the impact of drinking rate changes including a 30% increase in
HRD, a return to 2001 HRD levels (30% reduction), and a 50% reduction in HRD. The model
projects an intervention targeting a 50% reduction in HRD is necessary to maintain mortality
rates consistent with 2016 figures.
Conclusion: The burden of liver cirrhosis is projected to increase over the next 31 years due to
ALD. While the drinking culture of young adults forebodes an increase in alcohol related
cirrhosis mortality in the long-term, interventions that target a return to 2001 levels of HRD
would have limited effect in arresting mortality increases from 2020-2050 due to the population
bubble of the “baby boomer” generation. Further evaluation on the effect of intervention
strategies on the long-term disease trends in ALD is necessary to address this growing public
health problem.
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* The lower border of shaded region indicates the reported annual mortality and the region itself
represents up to 50% underreporting of mortality due to ALD.

PS 2-45 COST-EFFECTIVENESS OF INTERVENTIONS TO PREVENT PLAGUE IN
MADAGASCAR
Health Services, Outcomes and Policy Research (HSOP)
Giovanni Malloy, Stanford University Department of Management Science & Engineering,
Stanford, CA, Jason Andrews, MD, MS, Stanford University School of Medicine, Stanford, CA,
Margaret L. Brandeau, PhD, Department of Management Science and Engineering, Stanford
University, Stanford, CA and Jeremy D. Goldhaber-Fiebert, PhD, Stanford Health Policy,
Centers for Health Policy and Primary Care and Outcomes Research, Stanford University,
Stanford, CA
Purpose: Plague (Yersinia pestis) remains endemic in certain parts of the world. An outbreak in
Madagascar in 2017 resulted in 2,417 cases and 209 deaths, with 68% of these cases occurring in
the Analamanga region. To improve future response efforts, we sought to assess the costeffectiveness of plague control interventions recommended by the World Health Organization
(WHO), including antibiotic treatment with doxycycline and distribution of malathion pesticide.
Methods: We developed an SEIR dynamic compartmental model of the spread of plague
between interacting populations of humans, rats, and fleas, calibrated to the outbreak in
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Analamanga, Madagascar. We used the model to assess the following interventions alone and in
combination: additional antibiotic treatment with doxycycline, mass distribution of doxycycline
prophylaxis, and distribution of malathion. We assessed how value depends on intervention
timing – on day 1 (immediate), day 65 (early), or day 95 (late) – and coverage level – ranging
from 0% to 100% of eligible individuals. Using costs in 2017 US dollars, effectiveness measured
in quality-adjusted life years (QALYs), and a 3% discount rate, we calculated the incremental
cost-effectiveness of each intervention.
Results: Estimated cumulative bubonic and pneumonic cases and deaths from the calibrated
model were within 10% of the WHO reported values. For interventions on the cost-effectiveness
frontier for an immediate intervention (Figure 1), costs ranged from $2.25 million – $13.68
million and QALY gains ranged from 2,480 – 3,364. Using a willingness-to-pay of $1350 (the
per capita GDP in Madagascar), the cost-effective intervention was mass prophylaxis of
doxycycline enrolling around 9,000 new people/day (40% eventual coverage). For interventions
on the cost-effective frontier for an early intervention, costs ranged from $2.65 million – $9.90
million, QALY gains ranged from 1,099 – 2,032, and no intervention was cost-effective. For
interventions on the cost-effectiveness frontier for a late intervention, costs ranged from $3.43
million – $8.22 million, QALY gains ranged from 64 – 81, and no intervention was costeffective.
Conclusions: Our research highlights the potential for a cost-effective mass doxycycline
prophylaxis intervention to prevent future large-scale plague outbreaks in Madagascar. Our work
also highlights the importance of intervention decision timing: early intervention is more
effective and cost-effective than later intervention. Our work has the potential to influence future
plague outbreak response strategy in Madagascar and elsewhere.
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PS 2-46 PREDICTING THE EFFECTIVENESS OF INTERVENTIONS FOR
INFECTIOUS DISEASE CONTROL: THE ROLE OF MODEL STRUCTURE
Quantitative Methods and Theoretical Developments (QMTD)
Giovanni Malloy, Stanford University Department of Management Science & Engineering,
Stanford, CA, Jeremy D. Goldhaber-Fiebert, PhD, Stanford Health Policy, Centers for Health
Policy and Primary Care and Outcomes Research, Stanford University, Stanford, CA, Eva A.
Enns, MS, PhD, Division of Health Policy and Management, University of Minnesota School of
Public Health, Minneapolis, MN and Margaret L. Brandeau, PhD, Department of Management
Science and Engineering, Stanford University, Stanford, CA
Purpose: Many infectious disease policy decisions hinge on estimates of magnitudes and rates
of intervention impacts. These impacts are often estimated using dynamic transmission models.
We aim to characterize how the choice of model can influence estimates of intervention impacts
over both short- and long-term time horizons.
Methods: We characterize dynamic transmission models along two dimensions: 1)
homogeneous vs. heterogeneous levels of individual risk behaviors; and 2) contact network vs.
mass-action mixing model of transmission. We define the reference model as a contact network
with heterogeneous risk levels. We use this model to simulate the long-term equilibrium disease
prevalence. We then define simpler models on one or both dimensions, calibrating to the same
long-term equilibrium prevalence as the reference model. We conduct a structural sensitivity
analysis considering an intervention with 100% coverage that reduces the probability of
transmission per contact by 50%. We measure long-term intervention impacts over 5,000 days.
Results: The stable equilibrium disease prevalence of the mass-action mixing model with
heterogeneous risk levels reaches 0% by 5,000 days (Panel 1), while that of the network model
with heterogeneous risk levels reaches 0.9% (Panel 2). The mass-action mixing model predicts a
larger magnitude of intervention impact because an intervention affects the entire population
uniformly. Each model reaches stable disease prevalence at different rates: the mass-action
mixing model with heterogeneous risk reaches an overall disease prevalence of under 0.01%
after 1,550 days, whereas the network model with heterogeneous risk reaches an overall disease
prevalence of 0.9% after 4,450 days. The rate of intervention impact is slower in the network
model because the intervention must propagate via individuals. Finally, 5,000 days after
intervention, in the mass-action mixing model the prevalence among both risk groups decreases
by 100% and in the network model, prevalence among high-risk individuals decreases by 95%
and among low-risk individuals decreases by 89%.
Conclusions: Despite producing equivalent results in the absence of intervention, different
models can lead to different estimates of magnitudes and rates of intervention impact. Our results
highlight the importance of choices regarding model structure and complexity when estimating
intervention impacts. By abstracting away the underlying contact network structure, simpler
mass-action mixing models can greatly overestimate the population health impacts of
interventions as well as the speed of those impacts.
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PS 2-47 EVALUATING BIAS AND VARIANCE ACROSS METHODS FOR
MICROSIMULATION MODEL VALIDATION
Quantitative Methods and Theoretical Developments (QMTD)
Jinyi Zhu, MPH, Center for Health Decision Science, Harvard T.H. Chan School of Public
Health, Boston, MA and Ankur Pandya, PhD, Center for Health Decision Science, Department
of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA
Purpose: In statistical modeling, the performance of a predictive model can be optimistically
biased when simply estimated on the original sample that was used to develop the model. Several
advanced methods, including the bootstrap, have been developed to correct for this bias in model
performance. However, in simulation modeling, these validation methods have been underused
and understudied. We aimed to compare the relative performance of different model validation
methods using a stroke microsimulation model.
Methods: We first developed a data generating process (DGP, a stroke microsimulation model)
to approximate the observed data from the Atherosclerosis Risk in Communities Study. We then
generated 1,000 random samples of size 500 from this DGP as “observed data” to reflect
constructing microsimulation models with individual-level datasets. For each random sample, we
evaluated the relative performance of four model validation methods: 1) Apparent performance
(estimate model performance in the original sample in which the model was developed and
calibrated), 2) Split-half, 3) Cross-validation (50%), and 4) Bootstrap methods for bias-corrected
performance. The true performance of the model was determined in an independent dataset
(n=100,000) generated using the same DGP. Model performance was measured by the sum
squared distance between the predicted and observed (i.e., Kaplan-Meier estimates) survival
curves for all-cause mortality (t=1-25 years).
Results: Apparent performance resulted in pessimistically biased estimates of model
performance but had low variance (RMSE=0.0057). The bootstrap bias-corrected estimates had
similar variance and were nearly unbiased. Estimates from split-half (RMSE=0.0156) and crossvalidation (RMSE=0.0129) methods were both highly biased and uncertain (Figure). Overall, the
bootstrap methods achieved the lowest mean squared error among all four methods
(RMSE=0.0046).
Conclusions: Apparent performance in simulation models can be pessimistically biased when
strong external evidence (e.g., life tables for background mortality probabilities) is brought in to
construct the model, a phenomenon not observed in the development and validation of purely
individual-level dataset-based risk prediction models. Validation methods using hold-out
samples as test sets (e.g. split-sample and cross-validation) can result in both high bias and
variance, as only part of the sample is used for model development and the other part for
validation. Using the full sample for model development while correcting for bias with
bootstrap-based methods should be considered good practice for developing and validating
microsimulation models based on individual-level datasets.
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PS 2-48 NUMERICAL METHODS FOR ADAPTIVELY DETERMINING CYCLE
LENGTH IN COHORT STATE-TRANSITION MODELS
Quantitative Methods and Theoretical Developments (QMTD)
Mauricio Lopez-Mendez, Masters, Brown University, School of Public Health, Providence, RI,
Fernando Alarid-Escudero, PhD, Drug Policy Program, Center for Research and Teaching in
Economics, Aguascalientes, AG, Mexico and Rowan Iskandar, PhD, Center for Evidence
Synthesis in Health, Brown University, Providence, RI
Purpose: Using a fixed cycle length (CL) in cohort state-transition models (cSTMs) may
introduce bias since events occurring at higher rates may necessitate shorter CL compared to
those with lower rates. We introduce methods borrowed from numerical analysis for simulating
cSTMs with adaptive CL and evaluate potential biases from having fixed CL.
Methods: We re-formulated cSTMs as a system of ordinary differential equations (ODEs) due to
their equivalence in representing the average cohort dynamics. We solved the system of ODEs
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using Euler and Runge-Kutta-Fehlberg (RKF45) methods, two commonly-used methods for
fixed and adaptive CL, respectively. The Euler method assumes constant derivative values at the
beginning of each pre-specified time-step. In contrast, RKF45 adaptively determines the CL by
choosing an approximate derivate such that the solution at the next time-point lies within a
specified error. As a case study, we used a published cSTM of breast cancer evaluating the
benefits and harms of adjuvant chemotherapy accounting for treatment induced toxicity in terms
of gains in life expectancy (GLE) for different time horizons: 10-year, 20-year, and 50-year. We
performed a full factorial design (FFD) for distant cancer recurrence and treatment-induced
toxicity rates, which are two key parameters to simulate scenarios with events occurring at
different time-scales. We evaluated the performance of each method by computing the bias on
the treatmentʼs effectiveness defined as the percentage difference in GLE compared to the gold
standard (exact solution of the system of ODEs by solving its characteristic equation).
Results: Under a fixed CL of 365 days, the cSTM and Euler methods produced equivalent biases
in GLE (50-year) of 0.41% and 0.40%, respectively. The RFK45 produced a lower bias of 0.05%
using an adaptive CL with an average of 344 days. Numerical methods generated considerably
lower biases than cSTM for shorter time horizons. FFD indicates that when recurrence and
toxicity rates are varied to their extreme values (2.25 times bigger and 0.025 times smaller,
respectively), the ratio of biases (RoB) of the methods (cSTM/RFK45) is considerably larger
(RoB=72) compared to base-case rate values (RoB=8.4).
Conclusion: Using an adaptive CL when simulating cSTMs may reduce bias in key clinical
outcomes driven by competing events operating at different time-scales compared to a fixed CL.
We suggest using an adaptive CL whenever possible.
PS 2-49 HOW MUCH SHOULD WE KNOW ABOUT SEX? FINDING RELEVANT
INFORMATION ABOUT SEXUAL BEHAVIORS USING COST-EFFECTIVENESS
ANALYSIS
Quantitative Methods and Theoretical Developments (QMTD)
Szu-Yu Zoe Kao, MA, Karen M. Kuntz, ScD and Eva A. Enns, MS, PhD, Division of Health
Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN
Purpose:
Mathematical models used to evaluate interventions to address sexually transmitted infections
(STIs) are often parameterized with aggregate sexual behaviors, such as the number of sexual
partners in the past year (annual degree). However, these cumulative measures may be consistent
with substantially different relationship dynamics, with implications for STI spread. In particular,
concurrency (proportion of population with multiple partners) and turnover (number of new
casual partners per year) are important measures of relationship dynamics not uniquely
determined by annual degree, but that influence STI spread. This study is to evaluate how costeffectiveness analysis (CEA) conclusions vary by level of sexual behavior information that
inform concurrency and turnover while calibrating sexual networks.
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Methods:
We simulated sexual networks for a heterosexual population aged 15-24. We developed three
calibration scenarios with increasing levels of information: (1) annual degree distribution alone;
(2) annual degree and relationship duration; and (3) annual degree, duration, and concurrency.
Some sexual relationship parameters and targets were derived from the 2015-2017 National
Survey of Family Growth (NSFG). For each scenario, we conducted a Bayesian calibration to
obtain a joint distribution of concurrency and turnover consistent with the calibration targets. For
each parameter set, we simulated a dynamic sexual network and the spread of chlamydia. We
then conducted a cost-effectiveness analysis (CEA) of different partner management
interventions to prevent chlamydia transmission, including partner notification (PN), expedited
partner therapy (EPT), and a combination strategy using EPT for current partners and PN for past
partners (EPT-PN).
Results:
All the calibration scenarios fit the annual degree distribution well (Figure, top panels).
However, different scenarios resulted in varying ranges of concurrency and turnover (Figure,
bottom panel). In scenario 1, concurrency and turnover ranged from 0% to 22% and from 0.15 to
0.68 partners a year, respectively. As more information was included, concurrency and turnover
shifted to lower levels with reduced uncertainty. At a willingness-to-pay of $100,000/QALY, the
most cost-effective strategy was PN in scenario 1, but EPT-PN in scenarios 2 and 3.
Conclusions:
Compared to aggregate number of sexual partners, relationship duration and concurrency are
more difficult to collect in conducting surveys. However, more detailed information about sexual
behaviors could be valuable because it might change recommended partner management
intervention for the sexual partners of STI patients.
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PS 2-50 DEVELOPMENT AND CALIBRATION OF A DYNAMIC HIV
TRANSMISSION MODEL FOR SIX US CITIES
Quantitative Methods and Theoretical Developments (QMTD)
Xiao Zang, MSc1, Emanuel Krebs, M.A.1, Jeong Eun Min, MSc1, Ankur Pandya, PhD2,
Brandon Marshall, PhD3, Bruce R. Schackman, PhD4, Czarina Behrends, PhD5, Daniel Feaster,
PhD6, Bohdan Nosyk, PhD1 and Localized HIV modeling study group, (1)Health Economic
Research Unit at the BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, (2)Center
for Health Decision Science, Department of Health Policy and Management, Harvard T.H. Chan
School of Public Health, Boston, MA, (3)Brown University School of Public Health, Providence,
RI, (4)Department of Healthcare Policy & Research, Weill Cornell Medical College, New York,
NY, (5)Department of Healthcare Policy and Research, Weill Cornell Medical College, New
York, NY, (6)Department of Public Health Sciences, Leonard M. Miller School of Medicine,
University of Miami, Miami, FL
Purpose: Heterogeneity in HIV microepidemics across US cities necessitates locally-oriented,
combination implementation strategies to prioritize resources according to the greatest public
health benefit. We calibrated and validated a dynamic, compartmental HIV transmission model
to establish a 25-year projection (2016-2040) of a status quo treatment scenario, holding constant
current levels of HIV care and prevention services for six US cities.
Method: Built off a comprehensive evidence synthesis, we adapted and extended a previouslypublished HIV model to replicate the transmission, progression and clinical care for the HIV
microepidemics in Atlanta, Baltimore, Los Angeles (LA), Miami, New York City (NYC) and
Seattle. For each city, we identified a common set of 17 calibration targets between 2012-2015
and used the Morris Method to select the most influential free parameters for calibration. We
then applied the Nelder-Mead algorithm to iteratively calibrate the model to derive 2,000 subsets
of best-fitting parameters out of 10,000 randomly generated initial sets. Finally, model
projections were internally validated with a series of robustness checks, externally validated
against published external estimates of HIV incidence, while the face validity of a selection of
25-year projections were assessed by a Scientific Advisory Committee.
Result: We documented our process for model development, calibration and validation to
maximize its transparency and reproducibility. Application of the Morris Method resulted in 52
unique and 176 total selected free parameters across cities. The projected model outcomes
demonstrated a good fit to calibration targets, with a mean goodness-of-fit ranging from 0.0174
(NYC) to 0.0861 (Atlanta). A majority of incidence predictions were within the uncertainty
range for 5/6 cities (ranging from 21% (Miami) to 100% (NYC)), demonstrating good external
validity. The face validity of the long-term projections were confirmed by our Scientific
Advisory Committee, showing that the rate of HIV infections per 100,000 would decrease in
Atlanta (from 45 [95% CI: 43-51] to 37 [33-41]), NYC (from 31 [31-32] to 15 [12-17]) and
Seattle (from 15 [14-16] to 10 [8-14]), remain stable in LA (33-34 [27-38]), while increasing in
Baltimore (from 27 [26-28] to 33 [27-35]) and staying the highest in Miami (102 [81-120]).
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Conclusion: This extensive model calibration and validation exercise provides a basis for
assessing the incremental value of further investments in HIV combination implementation
strategies tailored to each urban HIV microepidemics.
PS 2-52 CALIBRATION TO CROSS-SECTIONAL DATA WHEN BIRTH COHORT
TRENDS EXIST AS EXEMPLIFIED BY MODELS OF HEAVY DRINKING IN CHINA:
CONSISTENCY WITH CALIBRATION TARGETS DESPITE MARKEDLY
DIFFERENT PARAMETERS AND FUTURE PROJECTIONS
Quantitative Methods and Theoretical Developments (QMTD)
Kyueun Lee, Stanford University, Stanford, CA, Joshua A. Salomon, Ph.D., Center for Health
Policy and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA
and Jeremy D. Goldhaber-Fiebert, PhD, Stanford Health Policy, Centers for Health Policy and
Primary Care and Outcomes Research, Stanford University, Stanford, CA
Purpose:
Calibration infers parameter values that generate model estimates consistent with observed data,
enabling credible future projections and policy evaluation. Current modeling studies frequently
employ cross-sectional data as calibration targets, assuming no cohort trends in risk behaviors or
disease natural history. Using the example of high-risk drinking in China, we illustrate how this
assumption can lead to drastically different calibrated parameters, future burden projections, and
intervention effect estimates when compared to calibration that employs cohort-specific
parameters.
Methods:
We modeled heavy drinking among Chinese men using a 4-state Markov model: never-heavy
drinkers, heavy-drinkers, non-heavy drinkers, and dead. For birth cohort (BC) calibration, we
used longitudinal data (1993-2011) from Chinese Nutrition and Surveys as targets and calibrated
age-specific rates of initiating/resuming and stopping drinking in each cohort. Cross-sectional
(CS) calibration used 1-year cross-sectional data as targets. We measured each calibration
methodʼs performance (sum of squared errors, SSE) to predict heavy drinking prevalence in
2015. We also compared the change in prevalence when a mitigation policy halted a birth
cohortʼs initiation and resumption of heavy drinking from 2015 through 2027 using BC- or CSderived parameters.
Results:
Both BC and CS calibration methods generated age-specific heavy drinking prevalence
concordant with past observations. Notably, the scale and age-patterns of quitting rates differed
between BC and CS calibration (Panels A1, A2). BC calibrated models performed better in
projecting prevalence in 2015 (SSE = 0.62) than CS calibration for any year (SSE varying from
0.80 to 7.58). While CS calibration for the most recent year had better fit than CS calibration for
other years, temporal proximity did not monotonically predict projective validity (Panel B). All
the models that used CS calibration estimated intervention effects that were >2 times larger than
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with BC calibration (Panel C) because BC calibration projected slowly declining prevalence
even in the absence of intervention. Notably, even CS calibration to 2011 data, which had
projective validity similar to BC calibration, projected substantially larger policy effects (Panel
C).
Conclusions:
Calibration to cross-sectional data is often necessitated when cohort-specific data are
unavailable. Even when cross-sectional calibration generates estimates consistent with past and
near future observations, it can still produce divergent future projections and intervention effect
estimates when secular trends exist. If cross-sectional calibration is necessary, cohort
assumptions should be carefully evaluated.
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PS 3-1 POINT-OF-CARE DIAGNOSTIC TESTS FOR INFLUENZA IN THE
EMERGENCY DEPARTMENT: A COST-EFFECTIVENESS ANALYSIS
Applied Health Economics (AHE)
Stephen Mac1, Ryan O'Reilly2, Neill Adhikari, MDCM, M.Sc.3, Robert Fowler, MDCM, M.Sc.2
and Beate Sander, PhD4, (1)Institute of Health Policy, Management and Evaluation, University
of Toronto, Toronto, ON, Canada, (2)Institute of Health Policy, Management and Evaluation,
Toronto, ON, Canada, (3)Sunnybrook Research Institute, Toronto, ON, Canada, (4)Toronto
Health Economics and Technology Assessment (THETA) Collaborative, University Health
Network, Toronto, ON, Canada
Purpose: Influenza virus causes annual epidemics of acute respiratory illness globally and
remains a high public health priority. Our objective was to assess the influenza point-of-care
diagnostic tests’ impact on health outcomes in patients admitted to emergency department (ED)
with influenza-like illness (ILI) and to determine the cost-effectiveness from a Canadian
healthcare payer perspective.
Method: We developed a decision-analytic model to simulate care pathway and disease history
for patients admitted to the ED with ILI at a mean age of 65 years. The model was informed by
data from the literature, and seasonal influenza and cost data from Canada. We compared the
following test/treat strategies: batch polymerase chain reaction (PCR), rapid influenza diagnostic
tests (RIDT), digital immunoassays (DIA), nucleic acid amplification tests (NAAT), clinical
judgement, no test/treat everyone, and no test/don’t treat anyone. We followed patients over their
lifetime and reported health outcomes (appropriately treated influenza cases, adverse events,
mortality), quality-adjusted life years (QALY), costs in 2017 Canadian dollars, net health benefit
(NHB), and incremental cost-effectiveness ratio (ICER). We conducted extensive deterministic
sensitivity and scenario analyses.
Result: In the base-case simulating seasonal influenza, the most cost-effective strategy was to
treat everyone without diagnostic tests, as demonstrated in the cost-effectiveness plane (Figure
1). The treat everyone strategy resulted in 15.0470 expected QALYs and $644 per patient, but
inappropriately treated 86% of ILI patients, and resulted in adverse event rate of 0.04721. The
NHB at $50,000/QALY for diagnostic test strategies increased as test sensitivity increased; the
order of preferred strategies was: PCR (Treat until results available), NAAT, DIA, RIDT and
clinical judgement. When comparing PCR (Treat) to Treat Everyone, the ICER was
$541,876/QALY (incremental cost and effect of $29, and 0.00005 QALYs, respectively). Order
of cost-effectiveness remained consistent through sensitivity analysis of tests’ sensitivity and
specificity. As disutility of adverse events increased to 0.2, the most cost-effective strategy was
PCR, followed by NAAT.
Conclusion: Based on our model, treat everyone was the most cost-effective strategy for patients
admitted to ED with ILI when treating with oseltamivir due to decreased time to treatment and
avoided diagnostic costs. Evidence from this study can support influenza clinical management
and decision-making.
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Figure 1. Cost-effectiveness plane for diagnostic test and treat strategies for influenza

PS 3-2 THE COST OF EARLY ONSET OF COGNITIVE IMPAIRMENT AND
DEMENTIA AMONG PEOPLE LIVING WITH HIV/AIDS
Applied Health Economics (AHE)
Hsin-Yun Yang, MS, Department of Pharmaceutical and Health Economics, School of
Pharmacy, University of Southern California, Los Angeles, CA and Sze-chuan Suen, PhD,
Daniel J. Epstein Department of Industrial and Systems Engineering, University of Southern
California, Los Angeles, CA
Purpose:
Prior studies have documented that people living with HIV/AIDS (PLWHA) are at higher risk of
acquiring cognitive impairment/dementia, but few studies have quantified the magnitude of this
effect and no studies have examined the costs of this phenomenon. Here, we identify the relative
risk of cognitive impairment (CI)/dementia among PLWHA and find the excess healthcare
expenditures of PLWHA due to cognitive impairment/dementia.
Method:
We used medical claims data between 2007-2016 from de-identified Clinformatics Data Mart
(OptumInsight, Eden Prairie, MN). We excluded enrollees without complete demographic or
diagnostic information as well as enrollees with less than 1-year enrollment. We also excluded
people who enrolled at an age younger than 50 years old. People living with HIV/AIDS were
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identified by ICD-9 or ICD-10 codes. We ran a logistic regression to identify odds ratios for
PLWHA, from which we calculated their relative risk of CI/dementia.
We then used a validated, published microsimulation model – the Future Elderly Model (FEM) –
to project the future healthcare expenditures for our PLWHA cohort. To do so, we first created
an initial cohort to reflect the characteristics of our PLWHA cohort. We then adjusted the health
state transition probabilities by including the relative risks of developing CI/dementia and death
for PLWHA. We then simulated future healthcare expenditure (Medicare and out-of-pocket
costs) under these HIV-specific risks.
Result:
We find that PLWHA in our dataset have earlier onset of CI/dementia (see Figure 1). From our
regression calculations, we find that the relative risk of CI/dementia for PLWHA is statistically
significant at 1.66 after controlling for age, sex, race, income, smoking, alcohol/substance abuse,
obesity, and chronic disease comorbidities. With no excess HIV-specific mortality, this increased
risk for CI/dementia would result in $3,858 additional average annual total healthcare
expenditures per person compared to an individual without HIV ($42,065 for HIV+ versus
$38,207 for HIV-). In sensitivity analyses, we find that, with this relative risk of CI/dementia,
costs continue to be higher for PLWHA even with high levels of competing mortality (relative
risk of death above 3).
Conclusion:
Our findings suggest that the risk of CI/dementia is significantly higher for PLWHA, and this
can generate substantial healthcare expenditures as PLWHA age.
PS 3-3 PREVENTING GROUP B STREPTOCOCCUS (GBS) DISEASE IN MOTHERS
AND INFANTS IN CANADA: A COST-UTILITY ANALYSIS
Applied Health Economics (AHE)
Marina Richardson, Institute of Health Policy, Management and Evaluation, University of
Toronto; Toronto Health Economics and Technology Assessment (THETA) Collaborative,
University Health Network, Toronto, ON, Canada, David Naimark, University of Toronto,
Toronto, ON, Canada, Natasha Crowcroft, Public Health Ontario, Toronto, ON, Canada,
Deshayne Fell, University of Ottawa, School of Epidemiology and Public Health, Ottawa, ON,
Canada, Shaun Morris, Division of Infectious Diseases, Hospital for Sick Children, Toronto, ON,
Canada, Kellie Murphy, Mount Sinai Hospital, Toronto, ON, Canada and Beate Sander, Institute
of Health Policy, Management and Evaluation, University of Toronto; Toronto Health
Economics and Technology Assessment (THETA) Collaborative, University Health Network;
Institute for Clinical Evaluative Sciences; Public Health Ontario, Toronto, ON, Canada
Purpose: Colonization with Streptococcus agalactiae, commonly referred to as Group B
Streptococcus (GBS), during pregnancy puts infants and mothers at risk of infection. The
standard of care is to screen women for colonization at 35 to 37 weeks of pregnancy and if
positive, treat with intrapartum antibiotic prophylaxis (IAP). Candidates for a GBS vaccine are
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currently in development. The purpose of this analysis was to assess the cost-effectiveness of
GBS prevention strategies in mothers and infants comparing: 1. Vaccinate all pregnant women at
20 weeks of pregnancy; 2. Screen all pregnant women at 36 weeks, and if positive, provide IAP;
and 3. Combined vaccination/screening + IAP.
Method: We developed a Markov, parallel group, dynamic population, microsimulation model,
simulating 100,000 Canadian pregnant women. The primary outcomes were the number of cases
of early onset disease (EOD) and late/ultra-late onset disease (LOD/ULOD) per 1000 live births,
cases of maternal GBS disease, life years (LYs) gained, quality adjusted life years (QALYs)
gained, and incremental cost-effectiveness ratio (ICER). We assumed a one-time vaccination for
women at 20 weeks’ gestation with a base-case cost of $75.00 CAD and assumed a peak vaccine
efficacy of 85% for mothers and 64% for infants (at birth) for preventing GBS disease. Waning
of vaccine-derived maternal antibodies was modeled for both the mother and infant. We used a
lifetime time horizon, 1.5% discount rate for LYs, QALYs, and costs, and conducted the analysis
from the public health care payer perspective. We validated the model against reported data and
conducted sensitivity analyses to assess parameter uncertainty.
Result: Our initial results suggest that vaccinating all pregnant women was the most costeffective strategy with an ICER of $14,483.90/QALY. The combined vaccination/screening +
IAP approach was dominated by the vaccinate only strategy and the screening + IAP strategy
(standard of care). There were 0.048 more cases of EOD and 0.113 fewer cases of LOD/ULOD
per 1000 live births with vaccinating all pregnant women compared to standard of care.
Conclusion: Preliminary results suggest that vaccination is a cost-effective strategy. Our
analysis will help inform future GBS vaccine implementation decision-making. Model inputs
and assumptions should be revisited as new data become available.
PS 3-4 COST-EFFECTIVENESS OF SPINAL MANIPULATION, SUPERVISED
REHABILITATIVE EXERCISE, OR HOME EXERCISE FOR SPINAL PAIN IN THE
UNITED STATES USING AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS
APPROACH
Applied Health Economics (AHE)
Brent Leininger, DC, MS1, Gert Bronfort, DC, PhD1, Roni Evans, DC, MS, PhD1, James
Hodges, PhD2, Karen M. Kuntz, ScD3 and John Nyman, PhD3, (1)Integrative Health &
Wellbeing Research Program, Earl E. Bakken Center for Spirituality & Healing, University of
Minnesota, Minneapolis, MN, (2)Division of Biostatistics, School of Public Health, University
of Minnesota, Minneapolis, MN, (3)Division of Health Policy and Management, University of
Minnesota School of Public Health, Minneapolis, MN
Purpose:
Estimate the cost-effectiveness of spinal manipulation, supervised rehabilitation exercise, and
home exercise for spinal pain using individual patient data meta-analysis (IPDMA).
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Method:
We estimated incremental cost-effectiveness ratios (ICERs) from both the societal and healthcare
perspectives using cost and clinical outcome data collected alongside eight randomized clinical
trials performed in the U.S. We used a two-stage approach to IPDMA using random-effect
models to estimate ICERs and quality-adjusted life years (QALYs) as the effectiveness measure.
Costs and QALYs from trials comparing similar interventions were combined and bootstrap
methods were used to calculate cost-effectiveness acceptability curves.
Result:
The analyses included 1,739 participants (60% female) with individual pooled analyses ranging
from 380 to 650 participants (2 to 4 trials depending on the interventions compared). On average,
supervised rehabilitation exercise led to higher societal costs relative to home exercise ($3390;
95% CI $1658 to $5121) or spinal manipulation ($1288; 95% CI $77 to $2499) with small gains
in QALYs (0.002 to 0.003), and ICERs above $400,000 per QALY. Adding supervised
rehabilitation exercise to home exercise also resulted in an ICER above $400,000 per QALY.
Spinal manipulation resulted in higher societal costs compared to home exercise ($677; 95% CI $601 to $1956) and a small increase in QALYs (0.003; 95% CI -0.021 to 0.027), with an ICER
of $226,000 per QALY. Adding spinal manipulation to home exercise led to lower societal costs
(-$931; 95% CI -$3,667 to $1,804) and a small increase in QALYs (0.007; 95% CI -0.005 to
0.020). The probability that adding spinal manipulation to home exercise is cost-effective is
above 0.80 if society is willing to pay $100,000 or more per QALY. Adding spinal manipulation
to supervised rehabilitation exercise led to an additional $340 in societal costs (95% CI $214 to
$465) and a small increase in QALYs (0.01; 95% CI -0.002 to 0.022) with an ICER of $34,000
per QALY. Results from the healthcare perspective were similar, the only important difference
being a reduction of the ICER for spinal manipulation compared to home exercise from
$225,000 to $87,000 per QALY.
Conclusion:
Adding spinal manipulation to home exercise or supervised rehabilitation exercise is likely a
cost-effective approach for managing spinal pain. Supervised rehabilitation exercise alone or in
addition to home exercise is not likely cost-effective.
PS 3-5 SHOULD DENTAL INSURERS IMPLEMENT COMPREHENSIVE SCHOOLBASED CARIES PREVENTION PROGRAMS?
Applied Health Economics (AHE)
Shulamite S. Huang, PhD, New York University College of Dentistry, New York, NY
Purpose: Despite strong evidence supporting the clinical efficacy of dental prevention, fewer
than 15% of US children accessing dental care receive topical fluoride or sealants. Prior work
has suggested insurers reimburse for school-based caries prevention programs (SCPPs) to 1)
increase uptake of clinically effective dental prevention, 2) avoid issues of dentists’ financial
incentives, and 3) avert costs for downstream restorative care for tooth decay. However, no
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economic evaluations of SCPPs have examined the private dental insurerʼs perspective. Hence,
we examine the cost-effectiveness of SCPPs from a private dental insurer perspective and
contrast with a societal perspective.
Method: We use a Markov simulation model to estimate the net costs and increased quality of
life across different types of SCPPs. The model is an extension of Griffin et al.ʼs (2016) model
used to evaluate SSPs, adapted to include outcomes for all posterior teeth instead of only
permanent first molars. To allow for comparability with earlier studies, we assess quality of life
using disability-adjusted life years to account for the disease burden of experiencing toothaches.
Costs are measured in 2014 U.S. dollars. We compare CariedAway, a comprehensive SCPP,
relative to school-based sealant-only programs (SSPs) and a default scenario of no SCPP within
the school. Program resource costs are derived from prior work. Probabilistic, 1-, and 2-way
sensitivity analyses are included for robustness. This includes 2-way sensitivity analyses for
CariedAway program costs vs. dental coinsurance for fillings.
Result: From a societal perspective, the CariedAway program is unambiguously cost-saving and
cost-effective relative to SSPs (net cost: -$261.45 per child) and no-SCPP (net cost: -$239.77 per
child). However, CariedAway is cost-effective relative to SSPs from a private dental insurerʼs
perspective only if 1) coinsurance for restorative care is low, 2) the percentage of the school
population that is privately insured is high, and/or 3) CariedAway program costs are low.
Otherwise, SSPs dominate CariedAway, and both SCPPs dominate no-SCPP from a private
dental insurerʼs perspective given the average coinsurance for a basic filling (20%).
Conclusion: Private dental insurers may have a financial incentive to directly implement SCPPs,
but the type of SCPP implemented may not be societally optimal unless CariedAway program
costs are lowered or subsidized.
PS 3-6 IS IT THE PATIENT OR IS IT THE DISEASE – THE (IL)LOGICAL
REPERCUSSIONS OF APPLYING EQUITY WEIGHTS TO OUTCOMES WHEN
MAKING DECISIONS BASED ON COST EFFECTIVENESS
Applied Health Economics (AHE)
Doug Coyle, PhD, School of Epidemiology and Public Health, University of Ottawa, Ottawa,
ON, Canada
Purpose:
In many jurisdictions, discussions have focussed on whether reimbursement criteria for health
interventions should be more favourable towards specific patient populations: e.g. patients with
cancer or rare disease. It has been suggested that this could be achieved through equity weighting
of outcomes such as QALYs. In the decision to apply equity weights a choice must be made
between whether the application is specific to decisions relating to the disease (Scenario A) or
decisions relating to the patent with the disease (Scenario B). The objective of this study is to
examine the impact of implementation of equity weights in both scenario and the implications of
their application.
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Method:
The application of equity weights is consistent with making particular funding decisions subject
to a higher cost-effectiveness threshold (i.e. treatments which meet the criteria for an increased
equity weighting would be funded with a higher incremental cost-effectiveness ratio than
currently acceptable). This will necessarily lead to a reduction in the supply side cost
effectiveness threshold for those treatments not meeting this criteria. For both of the above
scenarios, the study identifies situations where the application of equity weights with respect to
rare disease may give confusing or illogical repercussions.
Result:
Under Scenario A, it can be demonstrated that paradoxically a patient that has both a rare and
common condition could now accrue less benefits at a higher cost to the payer. This can occur
when the benefits obtained from treating the common disease are greater than treating the rare
disease and at lower cost. The incremental cost per QALY gained for treating the common
disease may no longer meets the reduced supply side threshold; yet treating the rare disease
meets the new higher threshold.
Under Scenario B, funding of a treatment for a common disease may be restricted only to those
with a rare disease; even when treating other patients with the same disease is less costly and
more effective. This can occur, similar to above, when the benefits from treating the patient
without the rare disease are greater and at lower cost.
Conclusion: As discussions continue with respect to applying equity weights and adopting
differential funding criteria for different patient populations it is important that these (il)logical
and potentially inequitable repercussions are recognised.
PS 3-7 USING MACHINE LEARNING TO ASSESS HETEROGENEITY IN COSTEFFECTIVENESS STUDIES OF HEALTH PROGRAMS
Applied Health Economics (AHE)
Mikael Svensson, PhD and Carl Bonander, PhD, University of Gothenburg, Gothenburg,
Sweden
Purpose: Traditionally, economic evaluation of health programs (e.g. cost-effectiveness
analyses) report results based on differences in average cost and average benefit between
programs. The focus on "average effects" overlook the fact that for many health programs the
costs and benefits will differ in important ways across the population of interest. When
heterogeneity is assessed it is typically done by splitting the population of interest in sub-groups
based on pre-determined (or, more problematic, ex-post) sub-groups based on health, economic
and/or demographic characteristics. It is well known that this poses a number of problems when
analyzing individual-level data; e.g. multiple hypothesis testing, lack of power, and the fact that
we often don't know what characteristics drive heterogeneity. The purpose in this study is to
apply and demonstrate how modern machine learning methods can be used to ex-post assess
heterogeneity while minimizing the risk of spurious findings, power problems, etc.
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Method: We use data from a randomized controlled trial (RCT) carried out at the Sahlgrenska
University hospital in Gothenburg (Sweden) in patients with peripheral arterial disease (PAD).
Patients were randomly assigned to vascularization (invasive treatment) or best medical therapy
(non-invasive treatment). We estimate the cost-effectiveness of the invasive treatment compared
to the non-invasive treatment by comparing the costs and quality adjusted life years (QALYs)
between the two options. We use a causal forest forests approach developed to assess
heterogeneity in treatment effects and extend the method to assess heterogeneity in the costeffectiveness of treatments.
Result: We find that the average cost-effectiveness of the invasive treatment is very poor, using
Swedish as well as international thresholds to determine cost-effectiveness. However, the results
from the causal forest approach shows that there is significant heterogeneity with respect to the
baseline severity of the disease among the patients. The results indicate that the invasive
treatment may be cost-effective for patients with a very severe PAD.
Conclusion: We demonstrate how machine learning techniques can be used to assess
heterogeneity in the cost-effectiveness of health programs, and e.g. serve as a more detailed input
on reimbursement and coverage decisions by moving beyond the "one-size-fits-all" approach of
only looking at the average cost-effectiveness.
PS 3-8 COST-EFFECTIVENESS OF COMBINING PROCALCITONIN AND RAPID
MULTIPLEX RESPIRATORY VIRUS TESTING FOR SEVERE ACUTE
RESPIRATORY INFECTIONS IN ELDERLY PATIENTS
Applied Health Economics (AHE)
Wan-Ting Hsu, MSc, Harvard University, Boston, MA, Chien-Chang Lee, MD, ScD, National
Taiwan University Hospital, Taipei, Taiwan, Allison Portnoy, MSPH, Harvard T.H. Chan School
of Public Health, Dept. of Global Health and Population, Boston, MA and Jane Kim, PhD,
Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA,
USA., Boston, MA
Purpose:
Antibiotic treatment is overused among elderly patients who present to the emergency
department (ED) with severe acute respiratory infection (SARI). Previous studies have
demonstrated that combining serum procalcitonin test and rapid point-of-care (POC) molecular
respiratory virus tests could reduce antibiotic prescriptions; however, the cost-effectiveness of
this strategy has not been evaluated.
Method:
We conducted an economic evaluation to determine the cost-effectiveness of combining
procalcitonin and rapid POC molecular respiratory virus testing in elderly patients with SARI.
Effectiveness data were retrieved from a prospective controlled trial performed at two medical
centers in Taiwan. Cost data were extracted from the National Health Insurance Research
Database of Taiwan. The base case assumed a 65-year-old patient with SARI over a 30-day time
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horizon. A Markov Chain Monte Carlo micro-simulation was performed to simulate 5,500
patients, and an incremental cost-effectiveness ratio (ICER) was calculated to measure costeffectiveness. The willingness to pay (WTP) per QALY was set to be $25,004 based on the
Taiwan gross domestic product (GDP) per capita. A sensitivity analysis was performed using 0.5
to 3 times GDP per capita. Additional sensitivity analyses were conducted to examine the
robustness of the model. All costs were adjusted to 2018 U.S. dollars; costs and QALYs were
discounted at a 3% annual rate.
Result:
Compared with procalcitonin test alone (ICER: $8,110 per QALY gained), the combined
procalcitonin and rapid POC test strategy was associated with lower effectiveness and higher
costs. For all examined WTP thresholds, procalcitonin test alone showed the highest incremental
net monetary benefit. Sensitivity analysis found that combining procalcitonin and POC test
strategy is cost-effective given a utility gain of combination test strategy greater than or equal to
0.042 per QALY and a cost of the rapid POC test below $200 (current reimbursement level: $68
for existing similar tests). The results were most sensitive to parameters in: utility of viral
pneumonia, utility of bacterial acute exacerbation, utility of bacterial pneumonia, and age.
Conclusion:
In elderly patients with SARI, procalcitonin test alone was the most cost-effective strategy.
Results of our analysis provide a reference for the reimbursement price of this new test.
PS 3-9 TARGETING OF THE DIABETES PREVENTION PROGRAM LEADS TO
SUBSTANTIAL BENEFITS WHEN CAPACITY IS CONSTRAINED
Applied Health Economics (AHE)
Natalia Olchanski, MS, David van Klaveren, PhD, Joshua T. Cohen, PhD, John B. Wong, MD,
Robin Ruthazer, MPH and David M Kent, MD, MS, Tufts Medical Center, Boston, MA
Purpose: Approximately 84 million people in the US have pre-diabetes, but only a fraction of
them receive proven effective therapies to prevent type 2 diabetes. Intensive lifestyle
intervention underlying the National Diabetes Prevention Program (DPP) requires significant
resources for individuals to participate and successfully make lasting changes over time. We
estimated the value of prioritizing individuals at highest risk of progression to diabetes for
treatment, compared to non-targeted treatment among individuals meeting inclusion criteria for
DPP.
Methods: Using microsimulation to project outcomes in the DPP trial population, we compared
intensive lifestyle modification to usual care. We further compared a strategy of prioritizing the
intervention to those at highest risk progressing to diabetes with a non-targeted strategy,
assuming either unlimited or limited program capacity and resources for participant retention.
We modeled the individualized risk of developing diabetes and projected diabetic outcomes to
yield lifetime costs and quality-adjusted life expectancy, from which we estimated net monetary
benefits (NMB) for lifestyle versus usual care, assuming a base case willingness to pay of

E136

Medical Decision Making 40(1)

$50,000 per quality-adjusted life year. A key contribution over previous analyses is that we
accounted for effect modification of intervention effectiveness by individual diabetes risk. To
estimate efficacy beyond randomized clinical trial follow up, we developed two alternative
scenarios – a conservative, or short-term treatment effect scenario, which assumes that
interventions provide reduction in hazard of diabetes onset only in the initial 4 years; and a
second, more optimistic, long-term treatment effect scenario assuming a constant hazard
reduction for diabetes onset over time.
Results: Compared to usual care, lifestyle modification conferred positive benefits and reduced
lifetime costs for all eligible individuals. If however, only 20% of the population could actually
receive treatment – either due to capacity or resource constraints, when prioritizing individuals
based on their diabetes risk, rather than treating a 20% random sample, the difference in NMB
ranged from $14,000 to $18,000 per person (Figure).
Conclusions: When capacity and resources for participant retention are constrained, and only a
subset of the eligible population can be treated, prioritizing active diabetes prevention to patients
at highest risk could improve health outcomes and reduce costs compared to providing the same
intervention to a similar number of patients with pre-diabetes without targeted prioritization.
Figure:
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PS 3-10 FUTURE RESEARCH PRIORITIES—A VALUE-OF-INFORMATION STUDY:
USING VALGANCICLOVIR FOR THE TREATMENT OF GLIOBLASTOMA
MULTIFORME
Applied Health Economics (AHE)
Kari M. Mentzer, MA, University of Minnesota School of Public Health, Minneapolis, MN and
Karen M. Kuntz, ScD, Division of Health Policy and Management, University of Minnesota
School of Public Health, Minneapolis, MN
Purpose: Valganciclovir is a potentially effective therapy for the treatment of glioblastoma
multiforme (GBM); however, no randomized controlled trial (RCT) has been completed to verify
effectiveness or measure patient quality of life. We calculated expected value of perfect
information (EVPI) to establish an upper bound of the cost of conducting future research, and the
expected value of partial perfect information (EVPPI) to inform the economic feasibility of
conducting an RCT or an observational study of patient utility.
Methods: We developed a Markov model to compare GBM treatment with valganciclovir plus
standard of care (SOC; resection radiation therapy and temozolomide) to SOC alone. All
parameters were assigned distributions derived from clinical trials and other research. The
analysis was from the societal perspective, using a lifetime horizon, with one-month cycles.
EVPI was calculated by sampling across all parameter distributions. EVPPI was calculated by
sampling from the distributions of utility and efficacy in outer-loop simulations, and holding
those values fixed while the remaining parameters were varied in inner-loop simulations.
Population EVPIs were derived using the estimated new cases of adult GBM occurring each
year, assuming a 75% eligibility rate, and evaluating the costs over a 5-year period (n=16,650).
A 5-year period is a likely minimum horizon for new GBM treatment development. We used a
willingness-to-pay (WTP) threshold of $100,000 per quality-adjusted life year (QALY) and
discounted future costs and population estimates by 3%.
Result: In the base-case analysis, SOC was the most cost-effective strategy, with a probability of
51.7% of being cost-effective. EVPI was $6,218 for the individual and $103.5 million for the
population. EVPPI for patient utility was $34.55 for the individual and $575,257 for the
population. Individual EVPPI for knowing the effectiveness of valganciclovir was $2431, with a
population value of $40.5 million.
Conclusion: Results show conducting an observational study of patient quality of life would not
provide enough information to be economically advantageous. However, the predicted
population EVPPI for the effectiveness of valganciclovir ($40.5 million) is more than the
average combined costs of typical phase 2 & 3 oncology trials ($33.3 million). This suggests
further analysis (estimated value of sample information, and trial costs specific to GBM) should
be undertaken to confirm the VOI of an RCT using valganciclovir for GBM treatment.
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PS 3-11 THE ECONOMIC BURDEN OF VANCOMYCIN RESISTANT
ENTEROCOCCUS (VRE) BACTEREMIA: A POPULATION-BASED MATCHED
COHORT STUDY IN ONTARIO, CANADA
Applied Health Economics (AHE)
Jennie Johnstone, MD PhD1, Cynthia Chen, MSc2, Emily Shing2, Kwaku Adomako, MSc2, Gary
Garber, MD2 and Beate Sander, PhD3, (1)Mt. Sinai Hospital, Toronto, ON, Canada, (2)Public
Health Ontario, Toronto, ON, Canada, (3)Toronto Health Economics and Technology
Assessment (THETA) Collaborative, University Health Network, Toronto, ON, Canada
Purpose: To determine attributable healthcare costs for VRE bacteremia from the Ontario
Ministry of Health and Long-Term care perspective.
Methods: We conducted a population-based matched cohort study of hospitalized patients with
confirmed VRE bacteremia in Ontario, Canada. Subjects with VRE bacteremia (i.e., exposed)
were identified from the provincial Patient Safety Public Reporting dataset between January
2009 and December 2013 and linked to population-based Ontario administrative data. The index
date corresponded to the admission date. Infected subjects were hard matched to up to three
unexposed subjects based on age, sex, pre-index cost, exposure time and propensity score.
Propensity score variables included rurality, neighbourhood income quintile, hospital type, and
resource utilization bands. Subjects were followed until December 31, 2018. We calculated mean
attributable 1-year costs (2018 Canadian Dollars).
Results: We identified 217 exposed subjects and matched 199 exposed to 581 unexposed
subjects. In the exposed group, mean age was 62.5 (SD 16.5, median 64) years, the majority
were male (61.3%), urban residents (90%), among the low to medium income quintiles (66.2%),
very high user of the healthcare system (77.4%) and admitted to a teaching hospital (74.9%).
Mortality for exposed subjects was 69% within 1 year, and 78% within 3 year, versus 35% and
50% for unexposed subjects, respectively. Mean attributable 30-day, 1-year, and 3 year costs
were $27,513, $390,837, and $1,172,733, respectively. Inpatient hospitalizations represented
>90% of the attributable cost burden throughout.
Conclusions: VRE bacteremia is associated with increased healthcare costs, extending well
beyond the index hospitalization.
PS 3-12 PROVIDER RECOMMENDATIONS AND LUNG CANCER SCREENING –
PATIENT PREDICTORS AND IMPLICATIONS
Decision Psychology and Shared Decision Making (DEC)
Jeff DeWitt, PhD1, Joseph Leishman, MPH1, Angela Fagerlin, PhD2 and Tanner Caverly, MD,
MPH1, (1)Ann Arbor VA Center of Clinical Management Research (CCMR), Ann Arbor, MI,
(2)University of Utah / Salt Lake City VA, Salt Lake City, UT
Purpose: To examine the strength of lung cancer screening recommendations that eligible
patients report receiving from their providers and explore the implications of such
recommendations on patient-reported outcomes.
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Methods: From October 2016 to January 2019, LCS-eligible patients at 8 Veteran Affairs
medical centers across the U.S. were mailed a survey after being offered LCS. The survey
measured patients’ report of whether they received a recommendation and how strongly it was
made, as well as the following: knowledge and opinions regarding screening harms and benefits,
satisfaction with the screening discussion, Decisional Conflict Scale (DCS), Medical MaximizerMinimizer Scale (MMS), and demographics. We calculated each patientʼs risk of developing
lung cancer using a validated lung cancer risk model. Although our primary analyses examined
lung cancer risk continuously, we also used a risk threshold from prior work to dichotomize lung
cancer risk into “high-benefit” (LCS recommended even for medical minimalists) and
“preference-sensitive” (best recommendation highly-dependent on patient preferences).
Associations were tested via linear regression.
Results: 1,099 patients returned completed surveys (~35% response rate across sites). The
sample was 89% male, 70% white, 38% high school educated or less, with mean age of 65.5 (SD
= 6.2). Table 1 displays the distribution of recommendations for High Benefit and Preference
Sensitive patients. While lung cancer risk was not associated with patient reports of providers’
recommendations, the patientʼs general approach to healthcare was predictive - medical
maximizers were more likely to report a stronger recommendation to screen (b = 0.23, 95% CI =
[0.10, 0.36], p < .001). Receiving a stronger recommendation to screen was also associated with
patient reports of LCS being more effective, less harmful, and a better choice overall. In
addition, those receiving any type of recommendation felt more positive about the decisionmaking process across all measures and reported less decisional conflict.
Conclusions: Patient reports of provider recommendations for LCS suggest: 1) Providers
calibrate recommendations according to their patientʼs general healthcare orientation more than
their individual risk of developing lung cancer; or 2) The same recommendation may be
perceived stronger/weaker as a function of the patientʼs underlying healthcare tendency. Further
understanding why recommendations are made for LCS is important because they may affect
patients’ opinions regarding harms and benefits, as well as their overall satisfaction with the
decision process.
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PS 3-13 RISK LADDER, TABLE, OR TEXT? IDENTIFYING STRATEGIES FOR
EFFECTIVELY COMMUNICATING PERSONALIZED RISK AND RISK REDUCTION
INFORMATION FOR MULTIPLE DISEASES
Decision Psychology and Shared Decision Making (DEC)
Erika A. Waters, PhD1, Julia Maki, PhD1, Ying Liu2, Nicole Ackermann, MPH1, Chelsey
Carter2, Hank Dart2, Deborah Bowen3, Linda Cameron4, Graham A. Colditz, MD, DrPH5 and
Imagine Health, (1)Washington University School of Medicine, St. Louis, MO, (2)Saint Louis,
MO, (3)Seattle, WA, (4)Merced, CA, (5)Division of Public Health Sciences, Department of
Surgery, Washington University School of Medicine, St. Louis, MO
Purpose: Most personalized risk assessment tools provide information about the risk of
developing only one disease; few provide personalized estimates of how oneʼs risk could differ
given engagement in a health behavior. We tested three strategies for communicating
personalized risk and risk reduction information for five diseases.
Methods: We stratified recruitment so 50% +/-5% of the sample (N=500) were from
racial/ethnic minority groups. Community residents ages 30-64 who exercised <150 mins/week
and had <= 1 (for men) or 2 (for women) comorbidities were randomly assigned to view a risk
ladder, table, or alphanumeric text that conveyed personalized risk estimates for heart disease,
stroke, diabetes, and breast (women) and colon cancer. Participants also viewed conditional risk
estimates for >180 mins/week of exercise and completed a survey. Primary outcomes were
physical activity intentions, verbatim knowledge, and liberal and strict gist knowledge. “Gist
knowledge” was defined as determining whether physical activity was beneficial for overall
health. “Liberal gist” required that participants detect between-category change (e.g., “high” risk
lowers to “medium” with activity). “Strict gist” required detection of within-category change as
well (e.g., “high” risk lowers with activity but remains within the “high” category).
Results: ANCOVAs (one for each primary outcome) showed no main effect of communication
format on intentions or verbatim knowledge, but they revealed main effects on liberal (p=.005)
and strict (p=.03) gist knowledge. Post-hoc contrasts showed the risk ladder elicited higher strict
gist knowledge than text (b=0.40, p=.009). However, the ladder elicited lower liberal gist
knowledge than either text (b=-0.40, p=.03) or table (b=-0.61, p=.001). Exploratory sequential
mediation analyses found the beneficial effect of ladder on strict gist knowledge led to higher
perceived risk and then higher intentions (b=.02, 95% CI .002-0.4). However, the detrimental
effect of ladder on liberal gist knowledge led to lower perceived risk and then lower intentions
among white (but not minority) participants (i.e., moderated sequential mediation, b=.04, 95% CI
-.08- (-.01)). There was also a beneficial effect of table (vs. text) on intentions through higher
response efficacy (b=.10, 95% CI .01-.21).
Conclusion: The effects of risk communication formats on knowledge and intentions vary by
format and population. This study demonstrates that the “best” format for communicating
multiple disease risks depends on the communication goal (e.g., informing vs persuading) and
target audience.
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PS 3-14 IMPROVING SHARED DECISION-MAKING IN LATINO MEN WITH
PROSTATE CANCER: A THEMATIC ANALYSIS
Decision Psychology and Shared Decision Making (DEC)
Joaquin Michel, B.S.1, Jorge Ballon, B.S.1, Sarah Connor, MPH CHES2, Mark S. Litwin, MD
MPH3, Christopher S. Saigal, MD, MPH4 and Dana (Dane) L. Alden, PhD5, (1)Department of
Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, (2)Department of
Urology, UCLA School of Medicine, Los Angeles, CA, (3)Department of Urology, David
Geffen School of Medicine at UCLA; UCLA Fielding School of Public Health; UCLA School of
Nursing, Los Angeles, CA, (4)David Geffen School of Medicine at University of California Los
Angeles, Los Angeles, CA, (5)University of Hawaii at Manoa, Honolulu, HI
Purpose: Multiple studies have shown that digitally-mediated decision aids help prepare patients
for decision making with their provider. However, few studies have investigated whether
decision-support preferences differ between non-English- and English-speaking ethnic
populations in the US, especially among the underserved Latino men with limited literacy or
numeracy. With a goal of identifying patterns of health information seeking and willingness to
use digital decision aids, we conducted 20 in-depth interviews with older, underserved Latino
men who had recently received a prostate cancer diagnosis at a county hospital in California.
Method: Over a 6-month period, a bilingual team member conducted semi-structured, in-depth
telephone interviews with 12 Spanish-speaking and 8 English-speaking Latino men. Following
transcription of taped interviews, 2 external bilingual professionals translated the Spanish
speakers’ interviews. Using a coding protocol developed by the team, 2 bilingual members
jointly analyzed the transcripts for emerging themes. Coder agreement exceeded 80%.
Differences were resolved through discussion.
Results: Thematic differences between groups with different language skills emerged from the
analysis. Almost all respondents engaged in online health information seeking using cellphones,
perceived a paternalistic patient-provider relationship, and expressed willingness to use a
hypothetical digital decision aid if recommended by their provider. English speakers reported
higher digital technology use for general medical and urological search purposes. They also more
frequently indicated family involvement in digital search related to their condition and preferred
self-guided, web-based decision aids. In comparison, Spanish speakers reported lower digital
technology knowledge/use and preferred family-involved, coach-guided, paper and visual
decision aids. English speakers reported substantially higher levels of formal education.
Conclusion: Preferences regarding the use of digital technology to inform prostate cancer
treatment decision-making among underserved Latino men varied depending on preferred
primary language. This was associated with level of formal education. Effective preparation of
underserved Latino men with prostate cancer for shared decision-making requires consideration
of alternative approaches depending on preferred primary language and associated factors such
as years of formal education.
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Figure 1. Thematic Analysis
PS 3-15 PATIENT-CENTERED CARE IN THE CONTEXT OF MEDICAL MANDATES
Decision Psychology and Shared Decision Making (DEC)
Bryan Wallace1, Monica Edwards1, Daniel Matlock, MD, MPH2 and Chris Knoepke, PhD,
MSW, LCSW3, (1)University of Colorado School of Medicine, Aurora, CO, (2)University of
Colorado School of Medicine, Division of Geriatrics, Aurora, CO, (3)Adult and Child Center for
Health Outcomes Research and Delivery Science, University of Colorado School of Medicine,
Aurora, CO
Purpose: Clinician attitudes towards improving the patient-centered aspects of care are critical
to understanding the success of shared decision making (SDM) implementation efforts. As a
recent example, CMS began requiring the use of evidence-based decision aids as a precondition
for reimbursement for implantable cardioverter defibrillator (ICD) placement. This study
describes responses to the mandate, attitudes towards patient-centered care in the context of the
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mandate, and elements of decision-making interventions that clinicians believe would be
necessary for success.
Methods: As part of an NIH-sponsored R01 regarding SDM with patients considering ICD
therapy, we are interviewing clinicians involved in the ICD care process (MDs, nurses,
administrators) about existing attitudes and experiences surrounding implementation of SDM
during the pre-intervention phase. We are continuously qualitatively analyzing these interviews
using a grounded theory deductive approach to develop a framework for understanding clinician
perspectives. As data are described, they will be contextualized according to provider type, site
characteristics, and other demographic indicators to highlight qualitative comparisons between
groups. All analyses are being conducted using Dedoose analytic software.
Results: As this project is ongoing, we have currently gathered and analyzed 10 interviews and
we anticipate including 15 more over the next three months. Initial analyses revealed three
topical areas: 1) the CMS mandate itself, 2) desire among ICD care teams to improve patientcentered care; and 3) desired qualities of new SDM interventions. Clinicians are generally aware
of the mandate, but are afraid of SDM interventions becoming “another box to check off” rather
than adding value to patient-clinician interactions. Similarly, clinicians express that ICD care
teams generally support improving patient decision making, but there is discordance around who
owns the decision making process (general cardiology vs. specialty care). The primary desired
qualities highlighted by clinicians are: the time that SDM would take, when tools would be
delivered to the patient, and how easily SDM tools could be codified into regular clinic
procedure.
Conclusion: Decision support for patients considering defibrillators is both a timely and
important topic, as new CMS mandates require SDM for reimbursement. Clinicians stated that to
be successful, a new SDM intervention would need to save time, be delivered before the clinic
appointment, and be easily systematized in clinic procedures.

E144

Medical Decision Making 40(1)

PS 3-16 THE ASSOCIATION BETWEEN PATIENT-PROVIDER COMMUNICATION
AND COLON CANCER SCREENING
Decision Psychology and Shared Decision Making (DEC)
Kristin Maki, PhD, University of Texas MD Anderson Cancer Center, Houston, TX
Purpose:
This study examines whether there is an association between patient-provider communication,
electronically-mediated communication channels, and colorectal cancer screening.
Method:
This study utilizes data from the Health Information National Trends Survey 5, Cycle 2
(collected in 2018). The outcome variable is dichotomized to reflect whether an individual has
had a colonoscopy, sigmoidoscopy, or stool blood test to check for colon cancer. Key
independent variables include whether participants’ health professionals gave them a chance to
ask questions; gave attention needed for feelings/emotions; involved them in decisions as much
as they wanted; made sure they understood what was needed to take care of their health;
explained things for understanding; spent enough time; and helped deal with feelings of
uncertainty. Additionally, the study assessed whether the participants had used an electronic
device to look for health or medical information; used email to communicate with a healthcare
provider (or office); track health care charges and costs; and look up medical test results.
Demographics and other health-related variables were included. The data were analyzed with
hierarchical logistic regression using AM Statistical Software, which accounts for the study
design features including cross-sectional weighting and the cluster variable.
Result:
Individuals who were diagnosed with colon cancer and those who were less than 50 years old
were excluded, leaving 2237 individuals in the present study. The overall model is significant (F
[29, 70] = 75.27, p < .001). After controlling for the variables mentioned above, participants who
said they were involved in decisions as much as they wanted were twice as likely to have been
screened (β = 0.71, p = 0.005, OR = 2.03); as were those who said the healthcare provider spent
enough time (β = 0.67, p = 0.016, OR = 1.96). Finally, those who had sent or received a text
to/from a healthcare provider were 5 times as likely to have been screened (β = 1.69, p = 0.014,
OR = 5.39).
Conclusion:
This studyʼs findings suggest that being involved with decision-making, having healthcare
providers spend enough time, and having new forms of communication such as texting are
important factors for patients. Specifically, these factors were associated with an increased
likelihood of having completed colon cancer screening. Future research will benefit from further
examining patient-provider communication in this context.
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PS 3-17 PREFERENCE ASSESSMENT TOOL REDUCES SURGICAL RATES IN THE
TREATMENT OF LUMBAR HERNIATED DISC
Decision Psychology and Shared Decision Making (DEC)
Richard Hwang, BS1, Aaron Reyes, BA1, Sylvia Lambrechts, MPH, MA2, Christopher S.
Saigal, MD, MPH2, Lorna Kwan, MPH2, Haoyue Zhang1, Crystal Cisneros, BS1, Langston
Holly, MD1, John Cabri, BS1, Adam Pena2 and O. Kenrik Duru, MD, MSHS1, (1)David Geffen
School of Medicine at University of California Los Angeles, Los Angeles, CA, Los Angeles,
CA, (2)David Geffen School of Medicine at University of California Los Angeles, Los Angeles,
CA
Purpose: To evaluate the effect of a preference assessment tool on treatment decisions for
patients with a lumbar herniated disc.
Method: An electronic patient decision aid (PDA), that includes automated preference
assessment, was provided to patients who were seeking treatment for a herniated disc at L4-L5
and/or L5-S1 at a single large academic institution from 2016 to 2018. Patients who completed
the PDA prior to consultation with a spine surgeon or physiatrist were included in the analysis.
Rates of elective surgery, corticosteroid injections, and non-invasive treatment (i.e. physical
therapy, home exercise program, medications) at 6 months from the consultation visit were
collected using CPT codes and chart review. A usual care cohort was established from 2015 to
2016, prior to the implementation of the PDA.
Result: 154 patients completed the PDA (PDA group), while 136 patients were included in the
usual care group for these analyses. The combined groups had a mean age of 47 years, with 139
females (48%), and were mostly Non-Hispanic white (64%). 132 patients consulted with a spine
surgeon while 158 consulted with a physiatrist. Of the patients who consulted with a spine
surgeon, patients in the PDA group were significantly less likely to pursue elective surgical
treatment and more likely to pursue non-invasive treatment compared to patients in the usual
care group (surgery: 26% vs 47%, steroid injections: 15% vs 12%, non-invasive treatment: 59%
vs 41%; p=0.04). Treatment decisions among patients seen by a physiatrist were similar between
the PDA and usual care groups (surgery: 1% vs 2%, steroid injections: 33% vs 38%, noninvasive treatment: 66% vs 60%; p=0.71).
Conclusion: Automating preference assessment using a software-based PDA prior to
consultation was associated with a decrease in the use of elective surgery for lumbar herniated
discs. By decreasing the rates of surgery, the use of decision aids with automated preference
assessment may help reduce the costs of care in the treatment of lumbar herniated discs.
PS 3-18 EXPLAINING EQUIPOISE: A RANDOMIZED TRIAL OF SHARED DECISION
MAKING AS PART OF CLINICAL TRIAL CONSENT
Decision Psychology and Shared Decision Making (DEC)
Ellen A. Lipstein, MD, MPH1, Maggie Breslin, MDes2, Cassandra M. Dodds, MA1, Michael
Kappelman3, Peter Margolis1 and William Brinkman1, (1)Cincinnati Childrenʼs Hospital Medical
Center, Cincinnati, OH, (2)The Patient Revolution, New York, NY, (3)Chapel Hill, NC
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Purpose:
By definition clinical trials represent a situation of medical equipoise, making decisions about
participation ideal for shared decision making (SDM). We hypothesized that integrating SDM
into the consent process of a clinical trial would improve participants’ trial-specific knowledge
and decisional uncertainty, as well as positively impact trial recruitment.
Method:
Using patient-centered design methods we developed a SDM tool to be used by physicians
introducing a clinical trial to families. This tool was tested in a cluster-randomized trial nested
within a pragmatic trial comparing 2 treatment approaches in pediatric Crohnʼs disease.
Physicians and research coordinators at sites randomized to the intervention arm were trained in
tool use via webinar and video. Aside from the SDM tool, recruitment and consent materials
available to sites did not differ between study arms. In both study arms, after reviewing consent
materials, participants completed a knowledge questionnaire and the uncertainty subscale of the
decisional conflict scale.
Result:
238 participants at 43 sites participated in the trial, with data available from 211 participants.
26% of families approached at control sites and 31% at intervention sites consented to participate
in the clinical trial (p=0.28). 91% of participants in the intervention arm reported having been
shown the decision tool. There were no differences in knowledge between study arms, although
overall 4% of participants did not understand randomization, 3% did not understand blinding and
8% did not understand other treatment options. Mean decisional uncertainty scores were 93.8
and 93.2 (p = 0.68) in the control and intervention arm, respectively. Retrospectively, research
coordinators from most intervention sites reported that the SDM tool was more often used by a
research coordinator than by a physician.
Conclusion:
Use of a SDM tool to introduce the purpose and procedures of a pragmatic clinical trial was
associated with a numerical increase in participation rates. The full potential of our intervention
may not have been achieved as it was designed to be utilized by treating physicians but was
frequently presented by research coordinators not directly involved in the care of potential
participants. As such, in this sample with high decisional certainty and knowledge, the SDM tool
did not impact participant understanding of the trial or decisional uncertainty. Nevertheless, this
study demonstrates the feasibility of integrating SDM into clinical trial consent.
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PS 3-19 DID PHYSICIANS ENGAGE PATIENTS IN SHARED DECISION MAKING
ABOUT PROSTATE CANCER SCREENING IN THE ERA OF A USPSTF GRADE D
RECOMMENDATION?
Decision Psychology and Shared Decision Making (DEC)
Teri Malo, PhD, MPH1, Renee M. Ferrari, PhD, MPH1, Stephen Clark, MD2, Kim Bird, MSc1,
Alison Brenner, PhD1 and Daniel Reuland, MD, MPH2, (1)UNC Lineberger Comprehensive
Cancer Center, Carrboro, NC, (2)UNC Department of Medicine, Chapel Hill, NC
Purpose: From May 2012—May 2018, the United States Preventive Services Task Force
(USPSTF) recommended against using the prostate-specific antigen (PSA) test to screen men
ages 55-69 years for prostate cancer. The USPSTF elaborated: “physicians should not offer or
order PSA screening unless they are prepared to engage in shared decision making [SDM] that
enables an informed choice by the patients.” We assessed recorded clinical encounters for the
presence of key SDM elements about PSA-based prostate cancer screening.
Method: We searched a database of transcribed encounters from a national physician panel for
conversations occurring June 2012—April 2018 between primary care physicians and patients
ages 55-59. We chose this age range, rather than the full range of 55-69, in an effort to capture
conversations about initiating screening. We searched transcripts electronically for keywords
relevant to prostate cancer screening, then manually reviewed to identify conversations about
PSA-based screening. Two authors independently coded transcripts for the following SDM
elements: presenting “screening” and “no screening” as valid options (i.e., equipoise) and
discussing potential harms of screening. Equipoise was scored as: 0=behavior not observed;
1=perfunctory attempt to perform the behavior; 2=behavior performed at baseline skill level;
3=behavior performed to good standard; 4=behavior performed to high standard. Coding
discrepancies were resolved by consensus.
Result: We identified 30 encounters about PSA-based screening. In 13 of 30 (43%) encounters,
PSA was ordered prior to the visit and results were given without further discussion. The
remaining 17 of 30 (57%) included additional screening-related dialogue. Two conversations
(2/17; 12%) conveyed equipoise about PSA-based screening at a baseline skill level or higher.
The average equipoise score was 0.47 (range: 0-3). In 5 (29%) conversations, the physician
mentioned the controversy around PSA-based screening; however, discussion of screening harms
such as sequelae of overdiagnosis and overtreatment (incontinence, erectile dysfunction,
infection, bleeding) was observed in only 3 (18%) conversations.
Conclusion: Despite a USPSTF recommendation against offering or ordering PSA-based
screening without SDM, many physicians ordered PSA ahead of a visit and provided results
without evidence of discussion. A small number of physicians mentioned the controversy around
PSA-based screening; thus, it appears the USPSTF recommendation may have changed the way
some physicians discuss screening with patients. However, key elements of SDM were generally
absent from conversations.
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PS 3-20 DOES GIVING THE DOCTOR A DOCUMENT TEMPLATE WITH THE
PATIENTʼs OWN VALUES AND PREFERENCES WHEN MAKING DECISIONS
ABOUT STARTING MEDICATION IMPROVES SHARED DECISION MAKING?
Decision Psychology and Shared Decision Making (DEC)
Seiji Bito, MD, MSHS1, Tomomi Iioka, MS1 and Atsushi Asai, MD, PhD, MBioeth2, (1)NHO
Tokyo Medical Center, Toyko, Japan, (2)Tohoku University, Sendai,, Japan
Purpose: Although there are several decision-support tools for empowering patients at Shared
Decision Making (SDM), their effectiveness is limited. We have developed a document template
for patients to describe their own values and preferences, whilst making a decision with their
physician. We investigated if decision conflicts, decision process and the patientʼs final decision
could be positively influenced by giving the written document to her/his physician.
Method: We examined a comparative study before and after a control period and an intervention
period. Study targets were patients who were in a situation where their physicians were
considering the commencement of any new antihypertensive, antihyperlipid or diabetes agents.
For study intervention, there was a single-sheet template that provided spaces to describe the
following; patientʼs worry; expectation of outcomes; expectation for health providers; self-care
plan; things they want to be avoid. The documented template was attached to the patientʼs
electronic medical record. A chart review of the medical record after 3 months after registration
examined the content of the decision and the degree of agreement between the physicianʼs
recommended option at the patient registration and the decision actually made. We also
compared the mean values of the Decision Conflict Scale (DCS) and the Decision Regret Scale
(DRS) two months after the registration.
Result: Eighty-five controls and 67 intervention groups participated in the study. The mean
value of the DCS in the control and intervention groups was 35.3 ± 12.2, 38.9 ± 17.1 (p = 0.19)
and 21.8 ± 12.6, 22.0 ± 14.5 (p = 0.96) for the DRS. Three months after registration, the
percentage of those who started the drug, those who did not start, and those who delayed their
decision to start in the control group were 39%, 49%, and 11%, respectively. While in the
intervention group, it was 47%, 28%, and 24%, respectively (p = 0.015). Seventy-five percent of
controls and 89% of the intervention group were in agreement with the recommendations that
their physicians had in mind regarding the decision to take medications at the time of the
patientʼs registration.
Conclusion: Submitting written documents with patientʼs values to his/her physician in advance
of a clinical decision making may enhance the dialogue process on SDM and may encourage the
patient to listen to his/her physicianʼs professional opinion.
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PS 3-21 MEASURING SHARED DECISION MAKING IN ONCOLOGY:
PSYCHOMETRIC PROPERTIES OF THE ISHARE-PATIENT AND ISHAREPHYSICIAN QUESTIONNAIRES
Decision Psychology and Shared Decision Making (DEC)
Hanna Bomhof-Roordink, MSc1, Fania R. Gartner, PhD1, Nanny van Duijn-Bakker1, Trudy Van
der Weijden, PhD, MD2, Arwen H. Pieterse, PhD1 and Anne M. Stiggelbout, PhD1, (1)Medical
Decision Making, Department of Biomedical Data Sciences, Leiden University Medical Center,
Leiden, Netherlands, (2)Maastricht University, Maastricht, Netherlands
Purpose:
Questionnaires to assess shared decision making (SDM) often focus on physician behavior, but
SDM requires patient behavior as well. Strong ceiling effects are also generally seen. We
developed the iSHAREpatient and iSHAREphysician questionnaires to assess SDM in oncology,
which include both physician and patient behaviors and assume a formative measurement model
(Bomhof-Roordink et al., submitted). Behaviors relate to several domains. Example items
include “The physician provides balanced information”; “The patient considers what is most
important to him in the context of treatment options”. We aimed to determine construct validity
(both questionnaires) and test-retest reliability (iSHAREpatient only).
Methods:
Physicians from six Dutch hospitals approached consecutive cancer patients for participation,
following a decision-consultation, and completed the iSHAREphysician, the Control Preferences
Scale (CPS), and the SDM-Q-Doc for each consultation, and the Ideal Patient Autonomy Scale
(IPAS) once only. After the consultation patients completed the iSHAREpatient, the SDM-Q-9,
the CPS, the Decisional Conflict Scale (DCS), and age, gender and education. Patients
completed the iSHAREpatient again 1-2 weeks after the first assessment. We formulated a priori
hypotheses at sum and domain score levels, e.g., the iSHAREphysician should correlate >.30
with the SDM-Q-doc, and iSHAREpatient domain ‘Preferences&Deliberation’ should correlate
>.30 with the DCS ‘Values Clarity’-subscale. Reliability was assessed using ICC.
Results:
Sixty-two physicians (52% male, mean age 45+10) rated 154 consultations using the
iSHAREphysician; and 130 patients (55% male, mean age 67+12) completed the
iSHAREpatient. We excluded physicians and patients with the highest score on all 15 items
(acquiescence bias, n=20 (11%) resp. 29 (22%)).
Sum scores (range 0-100) were still high: 74.8+16.8 (Phy) and 80.1+20.3 (Pat), as were scores
on the overarching domains (range 0-5): Choice Awareness (Phy 3.7+1.2; Pat 3.9+1.5),
Information Exchange (Phy 3.8+0.8; Pat 3.7+1.1), Preferences&Deliberation (Phy 3.5+ 1.0; Pat
4.0+1.2), and Decision (Phy 4.0 + 1.0; Pat 4.4+1.1). Test-retest reliability was moderate
(ICC=0.69, n=84). Hypotheses regarding correlations (construct validity) were confirmed for
SDM-Q-9, SDM-Q-Doc, and DCS, not for IPAS. Other results will be presented.
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Conclusions:
The iSHARE questionnaires provide more extensive information than the commonly used SDMQ-9 and SDM-Q-Doc, but still show high acquiescence, and high scores overall. If we disregard
the low correlations with the IPAS, which is about ideals, not practice, we showed good
construct validity.
PS 3-22 POSITIVE ATTITUDES TOWARDS A DECISION AID FOR LEFT
VENTRICULAR ASSIST DEVICES
Decision Psychology and Shared Decision Making (DEC)
Daniel Matlock, MD, MPH1, Monica Edwards2, Jocelyn Thompson, MA3, Colleen
McIlvennan, DNP, ANP4, Russell Glasgow, PhD2, Megan Morris, PHD, MPH5, Matthew Wynia,
MD, MPH2, Diane Fairclough, DrPH, MSPH2, Bridget Mosley, MPH2 and Larry Allen, MD,
MHS4, (1)University of Colorado School of Medicine, Division of Geriatrics, Aurora, CO,
(2)University of Colorado School of Medicine, Aurora, CO, (3)University of Colorado School of
Medicine, Adult and Child Center for Health Outcomes Research and Delivery Science, Aurora,
CO, (4)University of Colorado School of Medicine, Division of Cardiology, Aurora, CO,
(5)ACCORDS, University of Colorado, Aurora, CO
Purpose: The left ventricular assist device (LVAD) is now more common than heart transplants
for people dying from end-stage heart failure. Although patients’ chances of survival are
markedly increased with an LVAD, the LVAD poses many risks – including stroke, serious
infection, bleeding – and major lifestyle changes. Our prior work found that a decision aid for
LVADs significantly increased both patient knowledge and values-choice concordance. The goal
of the next phase is to implement the decision aid at as many of the 178 LVAD programs in the
United States as possible. In order to better understand how ready LVAD programs are to use the
decision aid, we conducted a national survey.
Methods: In April and May 2019, the survey was distributed using four professional society list
serves that specifically target heart failure clinicians including physicians, nurses, and social
workers. The survey was sent electronically twice over a month period. Questions included
attitudes towards LVAD decision making, barriers to adoption based on domains from the
Diffusion of Innovations theory, and demographics about the respondent and their program. All
respondents received a $20 gift card.
Results:
Currently, 530 individuals from 125 different LVAD sites have completed the survey, with 63
LVAD sites having more than one responder. Among respondents, 15.1% are physicians, 23.2%
are advanced practice providers (e.g. physician assistants or nurse practitioners), 40.6% are
registered nurses, 12.6% are social workers, and 8.5% identify as other, such as an LVAD
educator or coordinator. Overall, attitudes towards shared decision making and a decision aid
were overwhelmingly positive (Table). However, nearly half of the respondents feel that they
can fully inform patients without a decision aid and worry that a decision aid would not capture
the complexity of the decision.
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Conclusions: The overwhelmingly positive attitudes towards shared decision making are
encouraging that the decision aid for LVADs could be implemented nationally. However, some
beliefs about the decision aid being unnecessary or inadequate in informing patients may be a
barrier to broad implementation. This suggests the decision aid may be better adopted if used as
part of a larger shared decision-making conversation with clinicians to enhance discussions and
not as a standalone tool.
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PS 3-23 VALIDATION OF A 3-ITEM BEHAVIOR CHANGE OUTCOME (BCO)
MEASURE
Decision Psychology and Shared Decision Making (DEC)
Suzanne Brodney, PhD, RD1, Floyd Fowler, PhD2, KD Valentine, PhD1 and Michael Barry,
MD1, (1)Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA,
(2)Center for Survey Research, University of Massachusetts, Boston, Boston, MA
Purpose: To develop a short measure of how much patients were engaged in managing their
chronic conditions, we assessed the relationship of their answers to three questions to physicians’
rating of their patients’ self-management effectiveness for type 2 diabetes.
Method: Based on qualitative work to identify issues central to patient engagement in managing
their conditions, we field tested a three-question series with 600 patients from a national online
consumer panel who were managing diabetes or obesity. To test the validity of these items in
clinical practice, we surveyed physicians from three primary care practices and their diabetic
patients. Each physician completed an online survey for a randomly generated list of up to 15
diabetic patients to determine eligibility. For those eligible, the physician answered two
questions 1) how well the physician thought the patient was managing his/her diabetes, and 2)
how much effort the physician thought the patient was putting in. Each patient was mailed a
survey that included demographics and the three-question series: 1) how much things you do in
daily life affect your diabetes, 2) how much confidence you have to manage your diabetes, and
3) how involved you are in the decisions to manage diabetes. Descriptive statistics and Pearson
correlation coefficients were used to assess the patient and physician items. Generalized
Estimating Equations were used to predict how well the physician thought the patient was
managing their diabetes and their effort.
Result: 35/39 physicians completed an eligibility review of 509 patients. 388/509 eligible
patients were sent a survey and 243 (63%) completed the survey. Correlations among the three
patient-reported items ranged from -0.01 to 0.45. A 3-item composite Behavior Change Outcome
(BCO) measure was constructed by summing responses. The BCO score was a significant
predictor of physicians’ ratings of how much effort patients devoted to condition management
but didn’t predict physicians’ ratings of how effective patients were. Perhaps not surprisingly, it
was the patients’ A1C levels that best predicted physician ratings of effectiveness. BCO was not
associated with A1C (r=0.02).
Conclusion: Patients’ BCO scores predicted physicians’ ratings of patient effort in diabetes
management and appears to be a good measure of patient engagement in condition management.
Further assessment is needed to understand how it relates to how effectively patients manage
their conditions.
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PS 3-24 THE IMPACT OF AN INTENSIVE OUTPATIENT CLINIC ON MEDICALLYCOMPLEX PATIENTS’ DECISION MAKING OUTCOMES
Decision Psychology and Shared Decision Making (DEC)
Brittany Sisco-Taylor, PhD1, Angela Fagerlin, PhD2, Peter Weir, MD1, Bernadette Kiraly, MD1
and Elissa Ozanne, PhD1, (1)University of Utah, Salt Lake City, UT, (2)University of Utah / Salt
Lake City VA, Salt Lake City, UT
High-risk, high-need patients—sometimes referred to as “super-utilizers”—have complex
medical and social needs that can make engagement in medical decision making and disease
management difficult. The University of Utah Health Intensive Outpatient Clinic (IOC) is a
standalone clinic that implements interdisciplinary, team-based care for a group of medicallycomplex patients with poorly managed chronic illnesses. Although the effects of these types of
clinics on patients’ utilization, costs, and health have been studied, their impacts on patients’
decision making outcomes is unknown. This is the first study to examine capacity for decision
making and care experiences within this vulnerable patient population.
Purpose: We examined: 1) the IOCʼs impacts on high-risk, high-need patients’ self-efficacy in
their disease management and their trust and communication with their care team; and 2) the
extent to which patients’ individual characteristics predict 6-month improvements.
Method: Participants were 36 patients who joined the IOC between July 2017-August 2018, and
who received care in the clinic for at least 6 months. Patients completed online surveys upon
joining the IOC and again at 6 months. Self-efficacy to manage disease (Self-Efficacy Scale),
trust in physician (Patient Trust Scale), and patient-physician communication (Modified Picker
Survey) were collected at both time points. Paired t-tests examined mean differences in scores
across the 2 time points. Multivariate linear regressions tested the extent to which patient
individual differences—preferences for more or less medical care (Medical MaximizingMinimizing), age, gender, ethnicity, race, education, and subjective numeracy (Subjective
Numeracy Scale)—predicted 6-month improvements, after adjusting for baseline scores.
Result: Participants were ages 21-64 (Magebaseline=45 years; SD=11.74; 61% female; 72% white;
14% Hispanic/Latino). IOC patients significantly improved in their ratings of self-efficacy for
disease management (t(35)=2.25, p=.031), trust in care team (t(33)=2.77, p=.009), and
communication with care team (t(35)=5.40, p<.001) from before intervention to after 6 months of
clinic care. No patient characteristics significantly predicted 6-month improvements.
Conclusion: Over 6 months of care in the IOC, patients showed improved confidence in their
ability to self-manage disease and their ratings of trust and communication with the care team.
These patient-reported outcomes have implications for the quality of decision making and
continuity of care in this vulnerable population that, over time, could help to explain cost-savings
and patient health improvements.
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PS 3-25 A MIXED METHODS STUDY TO EXPLORE THE RELATIONSHIP
BETWEEN THE MEDICAL MAXIMIZER-MINIMIZER SCORE AND PATIENTS’
INTENTION TO TAKE A CARDIAC STRESS TEST AFTER EXPOSURE TO A
DECISION AID
Decision Psychology and Shared Decision Making (DEC)
Ashley Bucher, MPH, Penn State College of Medicine, Hershey, PA and Andrew Foy, MD,
Penn State Hershey Medical Center Heart and Vascular Institute, Hershey, PA
Purpose:
The medical maximizer-minimizer score (MMS) measures patients’ general preferences to seek
or avoid medical care. We sought to understand how MMS relates to emergency department
(ED) patients’ intention to take a cardiac stress test after exposure to a video-based decision aid
(DA).
Method:
Participants were ED patients with chest pain who were being considered for cardiac stress
testing prior to discharge. Participants first completed the MMS questionnaire. They then
watched a 6 minute, non-biased video that provided education in audio-visual format on the 30day risk of major cardiovascular events and potential benefits and risks of cardiac stress testing
prior to discharge. Following the video they scored their intent to take a stress test on a 7-point
Likert scale and participated in semi-structured interviews about their decision making process.
MMS and intent-to-test scores were correlated using Pearson correlation coefficient and R2.
Interviews were transcribed verbatim, then analyzed using an iterative process of coding,
categorization and thematic development using NVivo software and a health belief model
interpretive lens. Quantitative and qualitative data were triangulated to arrive at an interpretation
of the results.
Result:
Sixty participants aged 30 to 80 years (mean 55; 63% female) were enrolled. MMS scores were
normally distributed with an average score of 4.6 (+/- 0.8). MMS was mildly associated with
intent-to-test scores (R=0.25; R2=0.06; p=0.051). Neither MMS nor ITT scores were
significantly associated with age, gender, education level, income, marital status or presence or
absence of other chronic medical conditions. Qualitatively, patients’ intent to test was driven by
their perceptions of A) the threat of their condition and B) the utility of stress testing. Perception
of threat, in particular, perception of susceptibility to future events, was the most highly
represented factor that influenced patients’ intentions; however, all health belief model
constructs including perceptions of severity, benefits and barriers as well as the importance of
the action cue were represented.
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Conclusion:
In ED patients with ‘low-risk chest pain’ who are provided non-biased information in a DA,
MMS accounts for a small degree of variation in patients’ intent to take a stress test. The
association observed between MMS and patients’ intent to test may be related to the role MMS
plays in mediating relationships between different health belief model constructs and behavior.
PS 3-26 IMPACT AND COST-EFFECTIVENESS OF ADOPTING WHO
RECOMMENDATIONS ON CERVICAL CANCER ELIMINATION IN THE UNITED
STATES
Health Services, Outcomes and Policy Research (HSOP)
Emily A. Burger, PhD1, Megan Smith, MPH, PhD2, James Killen2, Kate Simms, PhD2, Karen
Canfell, PhD2 and Jane J Kim, MS, PhD1, (1)Center for Health Decision Science, Harvard T.H.
Chan School of Public Health, Boston, MA, (2)Cancer Council NSW, Woolloomooloo NSW,
Australia
Purpose: In May 2018, the World Health Organization (WHO) Director-General made a global
call for action towards the elimination of cervical cancer (CC) as a public health problem, which
will involve setting ambitious screening and vaccination coverage targets. The draft WHO
strategic plan for elimination proposes a CC incidence target of 4/100,000 women per annum.
We performed a comparative modeling analysis using two models from the Cancer Intervention
and Surveillance Modeling Network (CISNET) consortium to explore the timing and value of
adopting CC control targets outlined by the WHO in the USA, as well as potential other targets.
Methods: We used two independently-developed CISNET models (Harvard and Policy1Cervix) to estimate the health benefits (e.g., incidence rates) and economic consequences
associated with nine alternative CC prevention scale-up scenarios compared with a ʼstatus quo’
scenario that involved no additional interventions. Both models involved a dynamic multicohortmodeling platform to capture changes in health outcomes over time, including herd effects.
Sensitivity analysis explored the impact of alternative standard population structures, inter alia.
Results: Under status quo assumptions, both models projected that CC incidence would fall
below 4/100,000 women by 2035 (with <5 years between model predictions). Sensitivity
analysis using different population structures generated a range of approximately +/- 10 years
around these predictions. Scaling-up screening coverage to 90% was the most impactful
intervention in terms of relative cancer reductions, averting between 11% (CCNSW) and 19%
(Harvard) additional cases over 2020-2100. Although increasing female vaccination coverage to
90% was considered high-value, the decrease in CC burden was lower than increasing screening
coverage. Scaling up vaccination coverage of boys to 90% or vaccinating adults aged 26-45
years were identified as low-value interventions.
Conclusion: Under status quo assumptions, both Harvard and Policy1-Cervix found that national
CC rates may fall below 4/100,000 women by 2035, and may be expedited if improvements in
screening coverage are achieved. Both models reached consensus about low-value interventions.
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These national estimates do not apply to all subgroups of women; therefore, reaching underscreened and under-vaccinated women remain key to achieving CC elimination for all women.
PS 3-27 BUILDING AND VALIDATING REAL-WORLD CONTROL ARMS FOR
SINGLE-ARM CLINICAL TRIALS: CHALLENGES TOWARD ESTABLISHING BEST
PRACTICES
Health Services, Outcomes and Policy Research (HSOP)
Zhanglin Lin Cui, PhD, Yanping Wang, PhD, Huzhang Mao, PhD, Xiaohong Li, MS, Kristin
M. Sheffield, PhD and Douglas E Faries, PhD, Eli Lilly and Company, Indianapolis, IN
Purpose: Real-world data as external controls for single-arm clinical trials (SACT) are
increasingly used in drug development and regulatory decision-making. However, given the
challenges with building real-world controls (RWC) and potential selection bias and
confounding, it is necessary to develop best practices for this approach. This research aims to
develop best practices for building and validating the RWC and balancing the RWC and SACT
for fair comparison.
Method: We introduce processes covering selecting target patients, resolving covariate
differences between the real-world and SACT data, improving covariate overlap, and achieving
and assessing covariate balance. As ensuring the validity of RWC for SACT is critical, we
discuss steps and methods including assessing the importance of concurrency of the RWC
patients and validation options such as the use of benchmarking with historical randomized
controlled trial (RCT) data, real-world data, and even the creation of a concurrent partial control
in the SACT. A case study with RCT data and Flatiron Health electronic health records-derived
database in lung cancer is used to illustrate how to build and validate RWC. The RCT mimics an
ʼsACT’ and an ‘external control’ – where true relationship of them is ‘ignored’ for this research.
This allows us to demonstrate the quality of the RWC with a comparison of the RWC to the
actual control arm in the RCT. Entropy balancing, inverse probability weighting and propensity
score matching are presented and compared for balancing covariates prior to treatment
comparisons. Kaplan-Meier method and Cox proportional hazards regression are applied to the
reweighted or matched treatment groups to assess treatment differences in overall survival.
Result: The RWC included 705 patients who met selection criteria and the RCT control arm
included 625 patients. Baseline demographic and clinical characteristics differed significantly
between the cohorts. After covariate balancing, RWC and RCT control arm demonstrated similar
overall survival (p=0.22-0.60). Time trend was observed in the real-world data in terms of
outcome difference (p=0.002-0.02), indicating the importance of concurrency of the RWC.
Conclusion: The validity of RWC for SACT could be established after adequate target patient
selection, covariate matching and balancing, and validation test. As best practices in using
RWCs, we recommend adopting concurrent external control, improving covariate overlap,
providing validation test, and using multiple matching/re-weighting methods as sensitivity
analyses.
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PS 3-28 LIVING SYSTEMATIC REVIEWS TO SUPPORT CLINICAL DECISION
MAKING: EXPERIENCES IN CONDUCTING A LIVING SYSTEMATIC REVIEW OF
CANNABIS FOR THE TREATMENT OF PEDIATRIC EPILEPSY
Health Services, Outcomes and Policy Research (HSOP)
Jesse Elliott, MSc1, Deirdre DeJean, PhD2, Tammy Clifford, PhD1, Doug Coyle, PhD1, Beth
Potter, PhD1, Becky Skidmore, MLS3, Christine Alexander4, Alexander Repetski4, Blathnaid
McCoy, MB BCh BAO, MRCPI, CSCSN (EEG) MSc5 and George A. Wells, PhD1, (1)School of
Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada, (2)CADTH,
Ottawa, ON, Canada, (3)Independent Information Specialist, Ottawa, ON, Canada, (4)Patient
representative, Ottawa, ON, Canada, (5)Department of Paediatrics, University of Toronto,
Toronto, ON, Canada
Purpose: Systematic reviews can quickly become out of date with the publication of new
studies. Living systematic review (LSR) methodology can be used to incorporate evidence as it
becomes available in order to better inform health care decision-making. Here we provide an
example of how LSRs can provide up-to-date information about the use of cannabis for the
treatment of pediatric epilepsy, an area of active research.
Methods: LSRs comprise a baseline systematic review, followed by updates at set intervals. We
performed the initial literature search in April 2018, which was updated in October 2018 and
April 2019. Eligible studies were randomized controlled trials (RCTs) and non-randomized
studies involving children with epilepsy administered any type of cannabis-based product. The
primary outcome was seizure freedom; secondary outcomes included seizure frequency and
quality of life. Data were pooled, and risk of bias was assessed. Going forward, the literature
search will be updated every 6 months, and newly identified records will be screened for
inclusion.
Results: In this session, we will present data from the baseline review and the first two review
updates, as well as our experiences in conducting a LSR. In the baseline review, 23 studies met
the inclusion criteria; an additional 11 studies had been included as of April 2019. Data from the
RCTs suggest that cannabidiol reduces seizure frequency (median difference –20% [95%
confidence interval –27% to –13%]) with no significant effect on seizure freedom (risk
difference 5% [–1% to 11%]) or quality of life (mean difference 0.6 [–2.6 to 3.9]). We identified
35 eligible on-going clinical studies; the results from these studies will be included in subsequent
updates of this LSR as data become available.
Conclusion: Maintaining up-to-date systematic reviews is important in evidence-based decisionmaking, especially in areas with rapidly accumulating evidence. To date, few RCTs have
evaluated the use of cannabis as a treatment for pediatric epilepsy, although there are many
ongoing studies. Cannabis for pediatric epilepsy is an ideal topic for a LSR because it is a
priority for decision-making, there is little certainty in the existing evidence base, and there are
many ongoing studies. PROSPERO CRD42018084755.

E158

Medical Decision Making 40(1)

PS 3-29 LEVEL LOADING PHYSICIAN SCHEDULES IN OUTPATIENT SPECIALTY
CLINICS
Health Services, Outcomes and Policy Research (HSOP)
Bjorn Berg, Ph.D.1, Ayca Erdogan, Ph.D.2, Jennifer Mason Lobo, PhD3 and Katie Pendleton,
M.D.1, (1)University of Minnesota, Minneapolis, MN, (2)San Jose State University, San Jose,
CA, (3)University of Virginia, Charlottesville, VA
Purpose: Variability in outpatient specialty clinic schedules contributes to numerous adverse
effects including chaotic clinic settings, physician burn out, high patient waiting, and inefficient
use of resources. This research measures the benefit of level loading physician schedules in an
outpatient specialty clinic.
Method: We developed a constrained optimization model to minimize the variability in
physician schedules in an outpatient specialty clinic at the University of Minnesotaʼs Clinics and
Surgery Center. Schedule variability is defined as the variance of the number of physicians
scheduled in the clinic during each hour the clinic is open during the week. To measure the
benefit of the constrained optimization model schedule, three reference were used based on
actual week-long schedules from the outpatient specialty clinic. The three reference scenario
schedules ranged in the total number of physicians scheduled during the week between 12 and 15
physicians. Physician weekly assigned clinic hours ranged from 3 to 30 across the reference
scenarios. The outpatient specialty clinic studied is open 12 hours per day, five days per week.
We compared the variance of the number of physicians scheduled per hour resulting from the
constrained optimization schedule and the actual schedule for each of the three reference
scenarios.
Result: The schedules produced by the constrained optimization model reduced the variance of
the number of physicians scheduled per hour by 92% (1.70 to 0.14), 88% (1.98 to 0.24), and
94% (1.98 to 0.12) for the three reference scenarios compared to the actual schedules. The total
(and per physician) assigned clinic hours remained the same for each of the three reference
scenarios. The schedules produced by the constrained optimization model reduced the maximum
number of physicians scheduled at a single time of the actual schedules (four to three, five to
three, four to three) for each of the reference scenarios, respectively. The constrained
optimization schedules utilized 100% of the available clinic time compared to the reference
scenario schedules where physicians were scheduled during 87%, 92%, and 82% of the open
clinic time, respectively.
Conclusion: Constrained optimization can help to level load physician schedules in outpatient
specialty clinics where physician clinic assignments vary, thereby reducing the risk of negative
effects associated with highly variable clinic settings.
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PS 3-30 USING REAL-WORLD ELECTRONIC HEALTH RECORD DATA TO
PREDICT POSITIVE BLOOD CULTURE
Health Services, Outcomes and Policy Research (HSOP)
Hadi Beyhaghi1, Louise Zimmer1, Ellen Thiel2, Nicole Zimmerman2, Seth Toback1 and Mark
Miller3, (1)bioMerieux Inc., Durham, NC, (2)IBM Watson Health, Ann Arbor, MI,
(3)bioMerieux S.A., Marcy-l'Étoile, France
Purpose: Currently, no reliable means exist to determine which patients with suspected sepsis
have bacteremia, prior to a positive blood culture. Rapid identification of bacteremia may be
crucial in improving clinical outcomes in sepsis. We developed a predictive algorithm for blood
culture results using real-world electronic health record (EHR) data and then compared the
algorithm performance with physicians’ clinical judgment.
Methods: We used EHR data from the IBM Explorys Therapeutic Datasets covering January
2009 to July 2018 to develop the predictive algorithm. Available patient characteristics and
laboratory variables were used to fit a forward stepwise logistic regression model for the binary
outcome of a positive vs. negative blood culture using 70% randomly selected eligible
observations. The remaining 30% was used to validate model performance. Few patients were
tested with sepsis-related biomarkers (eg. procalcitonin, CRP, HLA-DR) so these were excluded
from the models. We considered the antibiotic prescription on the day of the first blood culture
draw/order as a proxy for physicians’ clinical judgment in predicting a positive blood culture.
Holding specificity constant, we compared the false negative rate of physicians’ predictions with
the corresponding rate of the algorithm to estimate the number of patients that would have
correctly received timely antibiotics if the algorithm was used in addition to physicians’ clinical
judgment.
Results: This study included 2,701 patients with at least one positive blood culture and 34,924
patients with negative blood culture results. On average, patients with a positive blood culture
were 3.3 years older [61.6 vs. 58.3 years (p<0.0001)], more likely to have type-2 diabetes (27%
vs. 23%, p<0.0001), lower blood pressure (104.1 vs.106.5, p<0.0001) and higher heart rate
(102.6 vs. 101.8 beats/minute, p<0.0001) than culture-negative patients. The regression model
resulted in a C-statistic of 0.624 (Figure), which indicated a fair fit. Antibiotic prescription on the
index date was associated with 0.72 and 0.38 sensitivity and specificity, respectively. Setting the
algorithmʼs specificity at 0.38, the sensitivity was estimated to be 0.74, which is associated with
723 (1.9%) fewer false negative patients if the algorithm had been applied to this study
population.
Conclusion: Compared to clinical judgment alone, the algorithm identified more patients who
might benefit from early antibiotic therapy. Better data sources including richer laboratory data
e.g., sepsis-related biomarkers might improve such predictive algorithms.
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PS 3-31 COLORECTAL CANCER SCREENING EVALUATION - THE IMPACT OF
ADENOMAS WITH LESS BLEEDING AND FIT ACCURACY
Health Services, Outcomes and Policy Research (HSOP)
Beate Jahn, PhD1, Gaby Sroczynski, Dr., MPH2, Annette Conrads-Frank, PhD2, Ursula Rochau,
MD, MSc2, Nikolai Muehlberger, Priv.-Doz., DVM, MPH2, Marvin Bundo, MD2, Sibylle
Puntscher, PhD2, Jovan Todorovic, MD2, Wilhelm Oberaigner, Assoc.-Prof. Priv.-Doz. Dr.2,
Timo Fischer, PhD3, Irmgard Schiller-Fruehwirth, MD3, Monika Hackl, Dr.4, Monika Ferlitsch,
MD5 and Uwe Siebert, MD, MPH, MSc, ScD6, (1)UMIT - University for Health Sciences,
Medical Informatics and Technology, Department of Public Health, Health Services Research
and HTA, Hall. i.T., Austria, ONCOTYROL- Center for Personalized Cancer Medicine,
Innsbruck, Austria, (2)UMIT - University for Health Sciences, Medical Informatics and
Technology, Institute of Public Health, Medical Decision Making and HTA, Department of
Public Health, Health Services Research and HTA, Hall i.T., Austria, (3)Main Association of
Austrian Social Security Institutions, Vienna, Austria, (4)Statistics Austria, Austrian National
Cancer Registry, Vienna, Austria, (5)Medical University of Vienna, Department of Internal
Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria, (6)UMIT University for Health Sciences, Medical Informatics and Technology, Dept. of Public Health,
Health Services Research & HTA / Harvard Univ., Dept. Health Policy & Management, Institute
for Technology Assessment, Hall i.T. / Boston, Austria
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Purpose: In organized population-based screening programs for colorectal cancer (CRC) in
Europe, the predominantly applied screening strategy includes immunochemical fecal-occult
blood test (FIT), alone or in combination with colonoscopy. Our study evaluates the long-term
effectiveness and cost effectiveness of CRC-screening strategies compared to no screening for
women and men with average CRC risk in Austria, and investigates the impact of FIT accuracy
for specific adenoma characteristics.
Methods: Four CRC-screening strategies: 1) no screening, 2) FIT: immunochemical fecal-occult
blood test (age 40-75years, annually), 3) gFOBT: guaiac-based fecal-occult blood test (age 4075years, annually), and 4) COL: colonoscopy (age 50-70years, 10-yearly) were evaluated using a
calibrated and validated decision-analytic state-transition cohort (Markov) model with a lifelong
time horizon. We assessed effectiveness in terms of life-years gained (LYG), CRC-related deaths
avoided, and CRC-cases avoided. Health economic outcomes included discounted lifetime costs
and incremental cost-effectiveness ratios (ICER). The perspective of the Austrian public health
care system was adopted. Comprehensive sensitivity analyses were performed. In a threshold
analysis for FIT sensitivity conditional on adenoma characteristics, the percentage of nonbleeding adenomas, undetectable for FIT testing, was varied.
Results: No Screening and gFOBT based screening were dominated. Most effective strategies
were FIT and COL. Moving from COL to FIT has an ICER of 15,000 EUR/LYG. Increasing the
proportion of non-bleeding adenomas, non-detectable for fecal-occult blood tests, leads to a
decreasing number of LYG, increasing costs and ICER for FIT. FIT becomes less effective than
COL in terms of CRC-cases avoided with 11% or more non-detectable adenomas and in terms of
CRC-related death with 40% or more non-detectable adenomas.
Discussion: The reduction of the conditional sensitivity of FIT in certain adenomas indicates the
high impact of conditional FIT accuracy on effectiveness and cost effectiveness. Undetected
lesions associated with no or less bleeding may in practice decrease the sensitivity for fecaloccult blood tests in persons with certain adenomas over time. Therefore, the current cohort
model assumption of independent test accuracies of consecutive annual fecal-blood tests
conditional on the disease needs to be further investigated.
Conclusion: Organized CRC-screening programs with annual FIT or 10-yearly colonoscopy are
most effective. Appropriate modeling requires considering the heterogeneity of adenoma
characteristics and conditional sensitivities of screening tests. Further clinical research on FIT
sensitivity, conditional on adenoma characteristics, is warranted.
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PS 3-32 PERSONALIZING BREAST CANCER SCREENING AND PREVENTION IN
WOMEN IN THEIR 40S SEEN IN PRIMARY CARE
Decision Psychology and Shared Decision Making (DEC)
Mara Schonberg, MD, MPH1, Maria Karamourtopoulos1, Adlin Pinheiro, MPH1, Scot B
Sternberg, MS1, Roger Davis1, Tejas S Mehta, MD MPH2, Marc Cohen, MD2, Jennifer Beach,
MD2 and Nadine Tung, MD2, (1)Beth Israel Deaconess Medical Center, Brookline, MA, (2)Beth
Israel Deaconess Medical Center, Boston, MA
Purpose: Guidelines recommend individualized breast cancer screening and prevention for
women in their 40s. We aimed to examine the effects of a personalized conversation aid (CA) on
breast cancer screening and prevention decisions among women in their 40s in a pretest-posttest
trial.
Method:
From 8/17-5/19 we contacted women 40-49 years without breast cancer scheduled to see their
primary care provider (PCP) at one Boston-based academic medical center. Participants
completed a questionnaire on their breast cancer risk factors before a visit. At the visit, women
and their PCPs received a 2-page CA that included: 1) 5-year breast cancer risk; 2) benefits and
risks of mammography; 3) whether or not breast cancer prevention medications (BCPMs) should
be discussed (e.g., 5-year risk >1.7%); 4) whether or not to consider breast MRI (e.g., lifetime
risk >25%); and 5) whether or not genetic testing should be recommended. After the visit,
women completed follow-up. Using the signed rank test we examined differences in intentions to
undergo mammography screening (0 -100), decisional conflict, and knowledge, between baseline
and follow-up and by 5-year risk (<1.1/>1.1%- the average risk of a 50 year old).
Result:
Of 558 eligible women, 343 completed baseline and 312 ([91%]) completed follow-up. Of these
312 women, 63% were non-Hispanic white, mean age was 44, 79% were college graduates, and
33% had 5-year risk >1.1%. Mean intentions to be screened were high regardless of 5-year risk
(78 vs. 84 for those with >1.1% 5-year risk) and declined significantly after receiving the CA
(p<0.001) but less so for those at higher risk (66 vs. 77). Regardless of 5-year risk, mean
decisional conflict declined by 7 points (24 to 17, p<0.001) and knowledge scores increased by
0.4 points (p<0.001); 93% found the CA helpful. Of 12 women who met criteria for discussion
of BCPMs, 7 discussed BCPMs with their PCP. Of 23 women who met criteria for breast MRI,
18 discussed breast MRI with their PCP (9 were also referred to a high-risk clinic). Of 69 women
who met criteria for genetic counseling, 36 discussed their genetic risk with their PCP and 15
were referred to genetic counseling.
Conclusion:
A personalized CA for women in their 40s may lead to more informed, value-based, and riskbased breast cancer screening and prevention.
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PS 3-33 FRAILTY IN PATIENTS UNDERGOING TRANSCATHETER AORTIC
VALVE IMPLANTATION (TAVI): A SYSTEMATIC REVIEW AND META-ANALYSIS
Health Services, Outcomes and Policy Research (HSOP)
Zhe Li, MPH1, Emily Dawson, MPH2, Jessica Moodie3, Janet E. Martin, PharmD,
MSc(HTA&M)4, Rodrigo Bagur, MD2, Davy Cheng, MD, MSc5, Bob Kiaii, MD2 and Ava JohnBaptiste, PhD4, (1)Western University, London, ON, Canada, (2)London Health Sciences
Centre, London, ON, Canada, (3)London, ON, Canada, (4)Centre for Medical Evidence,
Decision Integrity & Clinical Impact (MEDICI), Western University, London, ON, Canada,
(5)Department of Anesthesia & Perioperative Medicine, Western University, London, ON,
Canada
Purpose: The objective of this study was to review the operationalization of frailty instruments
for Transcatheter aortic valve implantation (TAVI) recipients and to determine the mortality,
clinical outcomes and change in quality of life in frail patients undergoing TAVI.
Method: We conducted a systematic review of the literature, searching PubMed, EMBASE,
PsycINFO, Cochrane Library, Web of Science and ClinicalTrial.gov for articles published in
2006 or later. We searched the abstracts of relevant conferences held in the last 3 years. We
included studies of patients with aortic stenosis, diagnosed as frail, who underwent a TAVI
procedure that reported mortality, clinical outcomes, or health-related quality of life. We
described and categorized the frailty instruments, described the frailty dimensions measured and
reported on the prevalence of frailty in each study. We also summarized the frequency of clinical
outcomes of frail patients after TAVI. We created a single pooled Kaplan-Meier curve for timeto-death by digitizing survival curves from individual studies and combining survival data in a
meta-analysis; we also performed a meta-analysis of 30-day and 1-year mortality. We explored
heterogeneity and performed sub-group analyses, where possible.
Result: We included 34 studies; 14 studies used single measures to assess frailty, and the
remaining 20 studies used multi-dimensional measures. Prevalence of frailty varied widely
across studies, ranging from 7.21% to 90.07%. Albumin was the most commonly used single
frailty measure and the Fried or modified Fried phenotype were the most common multidimensional measures. Sub-group analysis was performed, combining studies that used the Fried
or modified Fried phenotype, due to significant heterogeneity. Subgroup meta-analysis showed a
30-day mortality of 7.28% (95% CI: 5.36%-9.81%) and a 1-year mortality of 23.09% (95% CI:
19.72%-26.84%) in studies using the Fried or modified Fried frailty measure. Meta-analysis of
survival curve data suggested that survival of frail TAVI recipients at 1, 2 and 3 years was 73%,
64.5%, and 58.9% respectively.
Conclusion: Frailty instruments for TAVI recipients varied across studies, leading to a range of
frailty prevalence estimates and substantial heterogeneity. The results of this systematic review
provide clinicians, patients, and health care administrators, with the best available evidence on
the prognosis of frail patients undergoing TAVI.
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PS 3-34 BALANCING COST AND QUALITY OF HEALTHCARE IN THE US AND
DENMARK: LESSONS FOR NATIONS TRANSITIONING TO VALUE-BASED CARE
Health Services, Outcomes and Policy Research (HSOP)
Negin Fouladi, PhD, MPH, MS, University of Maryland, College Park, MD and Margit
Malmmose, PhD, MSC, Aarhus University, Aarhus V, Denmark
Purpose: Nations are increasingly having difficulties controlling rising healthcare costs and
improving population health leading to emphasis on value and quality-based care. This study
assessed barriers and facilitators to balancing cost and quality of care within the US state of
Maryland and Denmark, which have transitioned from volume to value-based care. In 2014,
Maryland implemented a unique all-payer rate setting and global budget cap model for all
hospitals, shifting payment structures from fee-for-service to efficiency and care quality. The
Danish health system has historically focused on healthcare efficiency based on resource
allocation structures, however, is redirecting efforts towards improved quality of care.
Method: Open-ended and semi-structured key-informant interviews were conducted in 2016 and
2017 among high level decision-makers in Maryland (N=21) and the Danish (N=17) healthcare
systems, including hospital, local, regional, and cross-organizational administrators and elected
officials. The interviews consisted of questions related to: (1) currently practiced and preferred
approaches to resource allocation and development and use of quality performance measures,
and (2) preferred sources, formats/styles, modes of information, and decision-making strategies
based on a shift from volume to quality-driven care.
Result: Decision-makers in Maryland expressed the need for collaboration in a changing
environment, yet increasingly rely on cost and quality outcomes data to drive decisions and note
the struggle to identify credible and useful information. Maryland decision-makers also face
challenges in regulating utilization and costs without mandated participation of physician
practices within the global budget cap model, which is perceived to be a primary driver of
healthcare utilization in the hospital sector. Similarly, decision-makers in Denmark conveyed the
importance of quantitative data to aid decisions, however, stress collaboration and dialogue as
driving factors and important sources of information. Danish decision-makers also express
challenges to wide-spread adoption of a quality-driven approach due to unsustained quality
assurance regulatory bodies.
Conclusion: The findings suggest implementation of value-based healthcare is highly driven and
influenced by availability of credible data, which may significantly impact development of
policies and innovative cost control strategies, and regulatory oversight to promote adoption of
quality measures in decision-making. Furthermore, collaboration within and across healthcare
organizations remains a key component to health system improvement as it fosters dialogue and
sharing of best practices among stakeholders.
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PS 3-35 ARE LOW AND MIDDLE-INCOME COUNTRIES PRIORITIZING HIGHVALUE HEALTHCARE INTERVENTIONS?
Health Services, Outcomes and Policy Research (HSOP)
Ashley Leech, PhD, MS1, David D. Kim, Ph.D.2, Joshua T. Cohen, PhD3 and Peter J. Neumann,
Sc.D.2, (1)Vanderbilt University School of Medicine, Nashville, TN, (2)Center for the
Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, (3)Tufts Medical
Center, Boston, MA
Purpose: Assess to what extent low and middle-income countries (LMICs) have included costsaving interventions in their national strategic health plans.
Method: We used the Tufts Medical Center Global Health Cost-Effectiveness Analysis Registry,
a continually-updated, open-source database of English-language cost-per-disability-adjusted life
year (DALY) studies, to identify analyses published in the last 10 years (2008 to 2017) of costsaving health interventions in LMICs. To assess whether countries prioritized cost-saving
interventions within their latest national health strategic plans, we identified ten countries, all in
sub-Saharan Africa, with the highest measures on the global burden of disease scale and
reviewed their national health priority plans. We identified these priority plans through country
government and international agency websites. We excluded countries for which we could not
obtain health priority plans in English or country-specific, cost-saving interventions. We
measured alignment by assessing whether cost-saving intervention areas targeted for specific
countries or diseases areas were included in country health prioritization plans.
Result: We identified 392 studies (63%) reporting 3,315 cost-per-DALY ratios, of which 207
ratios (6%) represented cost-saving interventions. Over half (53%) of these targeted sub-Saharan
Africa. Communicable, maternal, neonatal, and nutritional disorders comprised the highest
proportion (61%) of cost-saving interventions. For the ten countries we investigated in subSaharan Africa, 56% (80/142) of cost-saving interventions aligned with priorities identified in
countries’ health plans. Concordance, however, varied substantially across country and disease
area. Alignment ranged from 95% (21/22) in South Africa to 8% (1/12) in Sierra Leone. At the
intervention level, all 10 countries prioritized haemophilus influenzae vaccination, 8 of 10 (80%)
prioritized HPV, and 7 of 10 (70%) prioritized applicable HIV prevention and treatment
initiatives. Only 4 of 10 countries (40%) explicitly prioritized antenatal syphilis screening and 2
of 5 (40%) addressed neglected tropical diseases.
Conclusion: Our findings indicate substantial variation across country and disease area in
incorporating positive economic evidence into national health priority plans in sub-Saharan
Africa. Because LMICs have particularly restricted budgets, it is important to maximize health
returns per dollar spent on care. While contextual factors such as donor funding, implementation
constraints, or equity issues may play a larger role than economic evidence in decision making,
our list of cost-saving interventions can provide a good starting point for policymakers to
prioritize limited resources across LMICs.
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PS 3-36 BREAST CANCER RISK DATA IN THE ELECTRONIC HEALTH RECORD:
RESULTS FROM A MAMMOGRAPHY DECISION AID PILOT STUDY
Decision Psychology and Shared Decision Making (DEC)
Gabriel Franta, B.S.1, Alyssa Hersh, B.S.1, Ilya Ivlev, M.D., Ph.D.2, Katherine Bensching,
M.D.3, Heidi Nelson, M.D., M.P.H.4 and Karen B. Eden, Ph.D.4, (1)Oregon Health & Science
University School of Medicine, Portland, OR, (2)Kaiser Permanente Center for Health Research,
Portland, OR, (3)Oregon Health & Science University Department of Internal Medicine,
Portland, OR, (4)Pacific Northwest Evidence-Based Practice Center, Department of Medical
Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR
Purpose:
Electronic health records (EHR) contain patient health information used in clinical decisionmaking. However, it is unclear if sufficient risk data are stored and easily available to providers
at the point of care. This analysis compares the completeness of breast cancer (BC) risk data in
the EHR with the patient self-reported data collected by an online mammography screening
decision aid (MammoScreen).
Method:
A pilot study in three Oregon Health & Science University Internal Medicine clinician practices
evaluated the information captured by MammoScreen. Female patients of these practices were
invited to participate in MammoScreen using Epic-MyChart (patient portal). Self-reported BC
risk factors collected by MammoScreen were compared with data captured by the EHR. Women
were classified as average risk or above-average risk, in part using the Breast Cancer Genetics
Referral Screening Tool.
Result:
Of 339 patients who opened an Epic-MyChart invitation to use MammoScreen, 118 (34.8%)
patients completed MammoScreen. Both MammoScreen and the EHR agreed that 36 (31% of
118) women had a documented BC family history, and 38 (32% of 118) women had no BC
family history, but disagreed about the presence of BC family history in 44 (37% of 118) of the
women. Thirty-six (82% of 44) women had no information on BC family history in the EHR, of
whom six reported having BC family history on MammoScreen. Three women had BC family
history in the EHR but reported no family history on MammoScreen, and five women were
documented to have no family history in the EHR, but reported having BC family history on
MammoScreen. Some risk factors are largely unreported in the EHR, such as family history of
ovarian cancer, where 89 (75% of 118) women lacked information. Twenty-one patients were
classified as having above-average risk in either MammoScreen or the EHR; only seven (33% of
21) of these patients were classified as above-average risk in both MammoScreen and the EHR.
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Conclusion:
We found disagreements when comparing risk data in the EHR to recent self-reported BC risk
data in MammoScreen. Our analysis suggests that the EHR may not contain the most current BC
risk data. An integrated approach using data from both the EHR and MammoScreen could help
to retrieve current risk data and support decision-making regarding screening.
PS 3-37 CO-MORBIDITIES AND SEVERE ADVERSE EVENTS AMONG TREATED
AND UNTREATED VETERANS WITH OPIOID USE DISORDER IN THE VETERANS
HEALTH ADMINISTRATION
Health Services, Outcomes and Policy Research (HSOP)
Jack H. Ching, BSE, Stanford Health Policy, Stanford University, Stanford, CA, Douglas K.
Owens, MD, MS, VA Palo Alto Health Care System, Palo Alto, CA and Jodie A. Trafton, PhD,
Program Evaluation and Resource Center, Office of Mental Health and Suicide Prevention, VA
Palo Alto Health Care System, Menlo Park, CA
Purpose:
The opioid epidemic has become a national public health crisis. Understanding how best to care
for people with opioid use disorder (OUD) requires understanding the comorbid conditions and
severe adverse events (SAEs) associated with OUD. We characterized the prevalence of
comorbidities and SAEs for Veterans seen in the Veterans Health Administration (VHA) for
OUD, and examined how these vary by length of receipt of medications for addiction treatment
(MAT).
Method:
Using VHAʼs electronic health records, we identified Veterans with and without OUD, and
Veterans with OUD who received MAT between 2015-2017. OUD was defined based on
diagnosis codes associated with any care encounter. Receipt of MAT was defined as any receipt
of buprenorphine or methadone treatment in an office-based, clinic, or fee-basis setting, as well
as prescription or administration of injectable extended-release naltrexone. Among Veterans who
were diagnosed for at least three years, we identified those who (1) never received MAT, (2)
initiated MAT in 2017, and (3) received treatment for at least three years. We calculated the
prevalence of co-morbidities and SAEs for each group, computed prevalence ratios and
differences, and evaluated them using chi-squared tests.
Result:
Comorbidities related to substance use and mental health, and experience of SAEs were
significantly more prevalent in Veterans with OUD (n=68,981) compared to Veterans without
OUD (n=5,391,829). The prevalence of liver disease (21% vs. 4%), AIDS/HIV (1.4% vs. 0.4%),
depression (54% vs. 20%), alcohol abuse (41% vs. 7%), and psychoses (7% vs. 2%) were all
significantly higher. The prevalence of having care encounters related to opioid/heroin overdose
was 39 times higher (3.5% vs. 0.1%), and those related to suicide was nearly 15 times higher
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(13.5% vs. 0.9%). Compared to Veterans who never received MAT, Veterans who continuously
received MAT for at least 3 years had similar or lower prevalence of comorbid substance use and
mental health related conditions, other medical co-morbidities, and experience of SAEs within
the last year.
Conclusion:
Important comorbid conditions and SAEs are strikingly higher in Veterans with OUD than in
those without OUD. These findings have important implications for provision of comprehensive
care for patients with OUD, as care will necessarily encompass integrated management of cooccurring substance use and psychiatric conditions, in addition to targeted efforts to reduce
overdose and suicide mortality.
PS 3-38 EXAMINING PROVIDER-LEVEL VARIATION IN RATES OF
PREOPERATIVE STRESS TESTING RATES
Health Services, Outcomes and Policy Research (HSOP)
Matthew Pappas, MD, MPH, Cleveland Clinic Foundation, Center for Value-based Care
Research, Cleveland, OH and Michael Rothberg, MD, MPH, Cleveland Clinic, Cleveland, OH
Purpose:
The 2014 ACC/AHA guidelines recommend preoperative stress testing for patients whose
predicted risk of a major adverse cardiac event exceeds 1%, whose functional status is poor or
unknown, and when stress testing would change clinical management.
However, each of those three decision points likely vary by provider. Physicians may use
different risk prediction tools, which select different proportions of patients. Multiple different
methods of assessing functional status are in use, each of which appears to select different patient
populations. And the final decision point in this guideline — whether stress testing is likely to
change management — is entirely a provider-level judgment. We therefore set out to estimate
provider-level variation in rates of preoperative stress testing.
Method:
The Internal Medicine Preoperative Assessment, Consultation and Treatment (IMPACT) Center
assesses patients prior to noncardiac surgery at the Cleveland Clinic. Between 1/1/2008 and
12/31/2017, 118,552 patients were seen by 104 providers across 159,795 visits. Within that
cohort, we identified whether the patient completed cardiac stress testing in the 30 days after the
visit, including single-photon emission computed tomography, stress echocardiography, or
exercise stress testing.
Result:
The overall rate of cardiac stress testing within 30 days of preoperative clinic visit was
approximately 2.8%. We observed substantial variation in testing rates by provider, with 16% of
providers ordering stress tests at rates significantly below the mean rate, and 15% of providers
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ordering stress tests at rates significantly above the mean rate. Rates of testing by provider are
shown in the Figure. From the first to the last decile, rates of preoperative stress testing varied
from 1.6% to 5.2%, a 3.3-fold increase in rates of preoperative stress testing.
Conclusion:
In this large cohort of patients seen for preoperative risk assessment at a single health system,
rates of preoperative cardiac stress testing varied substantially and significantly by provider.
Further attention to appropriate selection criteria and the role of preoperative stress testing is
required. Provider-level interventions may be able to reduce unhelpful and low value testing.
Figure:
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PS 3-39 PILOT TESTING AND RECRUITMENT FOR A PATIENT DECISION AID
SUPPORTING SUICIDE PREVENTION COUNSELING IN THE EMERGENCY
DEPARTMENT: THE LOCK2LIVE TOOL
Health Services, Outcomes and Policy Research (HSOP)
Bonnie Siry, MS1, Chris Knoepke, PhD, MSW, LCSW2, Scott Simpson, MD3, Deb Azrael,
PhD4, Leah Adams, MPH1, Faris Omeragic, BS1, Sydney Almond, BS1 and Marian Betz, MD,
MPH1, (1)University of Colorado School of Medicine, Aurora, CO, (2)Adult and Child Center
for Health Outcomes Research and Delivery Science, University of Colorado School of
Medicine, Aurora, CO, (3)Denver Health & Hospital Authority, Denver, CO, (4)Aurora, CO
Purpose: Decision support for patients experiencing acute suicidal crises is critically
understudied. The goal of this pilot trial was to describe the research feasibility of a decision aid
for suicidal adult patients in the emergency department (ED), including challenges specific to
research regarding firearm safety and suicide prevention.
Method: We consecutively screened and enrolled patients at three EDs, randomizing patients to
receive either the “Lock to Live” decision aid (which supports decision-making about reducing
home access to firearms, medications, and other suicide methods. FIGURE 1), or an attentioncontrol educational website. Primary outcomes included recruitment and retention as well as
acceptability of this decision aid. Participants reviewed the decision aid or educational site and
then completed Decision Conflict Scale (DCS) and behavioral intent measures.
Result: We approached 844 patients across the three EDs who were being evaluated for suicide
risk. 735 patients were willing to answer more questions. 567 patients met initial eligibility
criteria (English-speaking, community-dwelling, aged 18+, cognitively able to participate), 555
of whom expressed interest in considering participation. However, only 49 patients (9%) met the
final eligibility criterion (1+ firearm at home), lower than the state firearm ownership estimate of
~34%. Of those 49 patients, 33 (67%) participated in the trial. Total DCS scores at baseline were
low and variable in both the intervention (m=12.6, SD=20.2) and control (m=9.7, SD=17.6)
arms.
Conclusion:
This population of high-risk, suicidal patients has historically been viewed as unable to
participate in either SDM or research meant to develop supportive interventions; however,
patients were interested and engaged with a decision aid about lethal means restriction. There
were several study challenges. First, there was a much lower than expected rate of reported
firearm access--many individuals may not be disclosing firearm ownership. And low decision
conflict scores suggest participants did not perceive firearm storage to be a decision within the
context of acute suicidal crisis. Despite these methodological challenges, this well-accepted tool
showed promise for helping patients reduce their risk of suicide during psychiatric crisis.
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PS 3-40 ARTIFICIAL INTELLIGENCE MAKES LIVING CLINICAL GUIDELINES
POSSIBLE WITH CONTINUAL MONITORING OF SCIENTIFIC EVIDENCE
Health Services, Outcomes and Policy Research (HSOP)
Craig Whittington, PhD, Sandra Zelman-Lewis, PhD, Steve Kanters, PhD, Todd Feinman, MD
and Michael del Aguila, PhD, Doctor Evidence, Santa Monica, CA
Purpose: Recommendations (and the underlying evidence) need to be kept up-to-date for
clinical guidelines to be reliable and valid for patients, providers, and other stakeholders. The
living guidelines model seeks to address this issue by continually and systematically updating the
evidence base and subsequent recommendations. Implementation challenges include the burden
of continuously monitoring/screening an ever-growing literature base and prioritizing clinical
questions for revisions. We aimed to evaluate whether artificial intelligence (AI) software using
natural language processing and machine learning could help overcome the barriers to living
guidelines.
Methods: DOC Search, a cloud-based AI search engine, was used to continuously monitor
literature relevant to the CHEST (American College of Chest Physicians) guideline on screening
for lung cancer. Three terms (“lung cancer”, “screening”, and “Low-Dose Computed
Tomography” [LDCT]) were used to search PubMed, ClinicalTrials.gov, and RSS feeds from
news/official organizations. Results were limited to those published since August 2017, the
previous search end date. AI-based auto-annotation tools automatically labelled terms as
interventions, characteristics, and outcomes; displayed in a co-occurrence matrix and used to
detect articles mentioning relevant terms corresponding to the key clinical questions (see Figure).
The search query was saved and configured to send weekly email alerts of all newly published
matches.
Results: The initial search (May 17, 2019) identified 203 references (81% from PubMed, and
12% from ClinicalTrials.gov, including 2 trials currently in progress). The AI software linked to
9 different taxonomies to automatically generate synonyms for each search term. A cooccurrence matrix showed that a significant number of articles mentioned both LDCT and the
primary outcomes analyzed in the guideline (other than QoL with only 4 articles). For the
comparators (chest radiograph, sputum analysis, and no screening), far fewer articles mentioned
an outcome of interest. Potential new research on biomarkers and smoking cessation was
detected. Email alerts highlighted new evidence about using AI to detect malignant lung nodules
on LDCT.
Conclusions: AI-based features, particularly auto-annotation, used in tandem with the cooccurrence matrix, provided an effective system for identifying new evidence and potential new
research. Using search engines that rely on AI to continuously monitor the literature efficiently
steers allocation of resources to recommendations most impacted by new knowledge, thereby
facilitating up-to-date and reliable living guidelines.
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Figure. DOC Search: Screening for lung cancer – search results

PS 3-41 RISK PREDICTION MODELS OF DIABETES COMPLICATIONS: A
SCOPING REVIEW
Health Services, Outcomes and Policy Research (HSOP)
Ruth Ndjaboue, PhD1, Imen Farhat, MSc1, Gerard Ngueta, PhD1, Sandrine Comeau, BSc
Cand.1, Carol-Ann Ferlatte, RN, MSc Cand.1, Thierry Provencher, BA, PhD Cand.1, Charlotte
Rochefort-Brihay, MD Cand.2, Daniel Guay3, Sasha Delorme4, Noah Ivers, MD, PhD5, Baiju
Shah, MD, PhD6, Catherine Yu, BSc, MD, FRCPC, MHSc7, Sharon E. Straus, MD, MSc,
FRCPC8 and Holly Witteman, PhD9, (1)Laval University, Quebec City, QC, Canada,
(2)Université Laval, Quebec City, QC, Canada, (3)Diabees Action Cannda, Toronto, ON,
Canada, (4)Caregiver, Regina, SK, Canada, (5)Womenʼs College Hospital, Toronto, ON,
Canada, (6)Sunnybrook Health Sciences Centre, Toronto, ON, Canada, (7)Division of
Endocrinology & Metabolism,, Quecec City, QC, Canada, (8)St. Michaelʼs Hospital, Toronto,
ON, Canada, (9)Laval University, Quebec, QC, Canada
Purpose: To review and synthesize prediction models for the risk of diabetes complications,
including physical and mental conditions.
Method: We conducted a comprehensive search for studies in Medline and Embase using
established scoping review methods. Longitudinal studies involving patients of any age and
gender with any type of diabetes were considered. We limited the search to studies of internallyor externally-validated models published between 2000 and 2018. Trained reviewers screened
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and extracted data independently. Quality of the selected models will be assessed using validated
tools and reporting standards. Because diabetes and its complications vary by age, sex/gender,
and race/ethnicity (e.g., Black, Indigenous), we assessed which models incorporated these
concepts. Along with clinicians, six patient partners were invited to help shape the search
strategy and contribute to each step of the review.
Result: We retrieved 27,511 references from Medline and Embase and retained 71 studies that
met the inclusion criteria. Studies involved people with type 1 (n=5), type 2 (n=43) or
unspecified diabetes type (n=23) in cohorts followed up from 30 days to 20 years, depending on
outcomes. We identified 131 models predicting mostly physical outcomes (n=129), namely:
cardiovascular (n=55), kidney (n=23), foot (n=18), mortality (n=17), eye (n=8), and cancer (n=4)
outcomes. The models predicting mental health outcomes (n=2) assessed the risk of dementia.
Predictors included demographic and personal characteristics, lifestyle factors, other health
factors, and lab results. Of the 76 models which included sex/gender as a candidate predictor,
seven were ultimately stratified by sex/gender. We found little data on ethnic/racial groups with
a high prevalence of diabetes, such as Black (n=1) or Indigenous/Native/Aboriginal populations
(n=0). None of the models included in this review involved people aged <18 years old. Fewer
than one in three models had a good or excellent fit (C-statistics or AUC ≥ 0.80).
Conclusion: Prediction models are increasingly being recommended for risk assessment in
treatment decision making and clinical guidelines. This review offers a synthesis of validated
risk prediction models of diabetes complications that may be helpful to identify people at higher
risk of specific complications and to enhance personalized risk communication and shared
decision making in diabetes. Our findings thus have the potential to contribute to preventing
diabetes complications.
PS 3-42 HEALTH STATUS DISCONTINUITIES IN LONGITUDINAL DATA– WHICH
“GAPS IN CARE” MATTER?
Health Services, Outcomes and Policy Research (HSOP)
Herbert Fillmore, MSW, 3M HIS, Blauvelt, NY
Purpose: About 60% of U.S. adults live with at least one chronic condition(CC). CCʼs can
eventually lead to disability and death, but many can be ameliorated with medications and
support for behavior change. Patterns in large administrative longitudinal data sets can identify
potential gaps in care based on discontinuities in documented disease status. Example: a person
has multiple claims for congestive heart failure in Year 1 but has no claims with that diagnosis in
Year 2. While discontinuity flags can be useful screens for care managers, they can also return
overwhelming numbers of potential cases. This study examines the question, which
discontinuities should be priorities for attention?
Method: We examined ~75,000 persons with CCʼs (using 3M Clinical Risk Groups(CRG) to
classify individuals into health status categories) over 4 years. Each person was enrolled in the
same commercial health plan for the 4 years and had no coordination of benefits. The source of
data was claims with at least 12 months elapsing from last date of service in the sample. Each

E174

Medical Decision Making 40(1)

person had the same chronic condition CRG listed for them in years 1 & 2. This rule established
the clear evidence that the person was treated for the chronic condition for at least 24 months.
Result: 16% of persons with multiple chronic conditions (MCC) had a
discontinuity in recorded health status in Year 3 (the absence of a previously
identified CC). During year 3, their costs were ~half the PMPM of Years 1 &
2. Among these individuals with discontinuity, 84% returned to their original MCC status in
year 4. Their costs ~doubled from Year 3 to 4, settling at a 5% higher rate than in Years 1 & 2.
Some individuals with discontinuity returned to reported chronic health status with significantly
higher costs than they had experienced in Years 1 & 2. Poorer overall health status and older age
are among the factors differentiating these individuals.
Conclusion: The problems of persons with chronic conditions are not gone when there are
discontinuities in the record... those problems will eventually require attention and may cost
more. A select group of individuals can be prioritized for follow-up when discontinuities occur
with the potential to improve care and better manage costs.
PS 3-43 INAPPROPRIATE TRIPLE THERAPY: A BUDGET IMPACT COST
CALCULATOR TO IDENTIFY AVENUES FOR POTENTIAL SAVINGS IN PATIENTS
WITH COPD
Health Services, Outcomes and Policy Research (HSOP)
Swetha Palli, MS and Jessica Franchino-Elder, PhD, Boehringer Ingelheim Pharmaceuticals,
Inc., Ridgefield, CT
Purpose: The 2018 Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommendations position long-acting muscarinic agents/long-acting beta2-agonists
(LAMA/LABA) as the preferred first-line maintenance treatment for symptomatic COPD
patients. LAMA/LABA/Inhaled Corticosteroids (“Triple Therapy [TT]”) is recommended for
those who experience further exacerbations post-LAMA/LABA treatment. Despite these
recommendations, existing literature repeatedly found TT to be potentially over-prescribed
across all COPD severities.
Method: To develop a budget impact framework and calculator for patients initiating TT and
identify avenues for potential cost savings from a payer perspective.
Result: An Excel-based budget impact model was developed. Model parameters included COPD
prevalence, receipt of maintenance therapy, including TT, as well as annual COPD related cost
burden associated with treatment regimens. Data was extracted from Government reports and
data on file (under review; being readied for peer-review). All cost data were adjusted to April
2019 US dollars using the Medical Care Component of the Consumer Price Index. A population
of 100,000 adult members was hypothesized for this model. The model framework was aimed at
finding savings via eliminating potentially unnecessary prescriptions of TT. This was patients
who received TT inconsistent with GOLD recommendations defined as patients who initiated
triple as first line maintenance therapy or whose 12-month exacerbation history classified them
as GOLD A/B. The model then calculated the incremental budget impact of shifting these

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E175

potentially inappropriately prescribed patients to LAMA/LABA therapies, by measuring permember-per-year (PMPY) costs. One-way and scenario-based sensitivity analyses were
performed to determine the robustness of the results and identify the main drivers of the results.
Conclusion: For a US Medicare-Advantage health plan with 100,000 adult members, the
incremental impact of shifting potentially inappropriate TT patients with COPD to
LAMA/LABA therapies was found to yield PMPY savings between $8.4 to $10.4. In case of a
commercial plan, these savings could range between $14.3 to $17.9 PMPY. One-way sensitivity
analyses found TT-associated annual cost burden to be the most sensitive parameter influencing
these results.
PS 3-44 DEVELOPING EVIDENCE TO INFORM A PATIENT-CENTERED VALUE
FRAMEWORK FOR MAJOR DEPRESSIVE DISORDER
Patient and Stakeholder Preferences and Engagement (PSPE)
Tara Lavelle, PhD1, Keren Ladin, PhD2, Flora Berklein, MPH1, Debra Lerner, PhD1, Steven
Kymes, PhD, MHA3, Ann Hartry, PhD3 and Joshua T. Cohen, PhD1, (1)Tufts Medical Center,
Boston, MA, (2)Tufts University, Medford, MA, (3)Lundbeck LLC, Deerfield, IL
Purpose: The goal of this study is to: (1) understand which treatment benefits patients with
major depressive disorder (MDD) regard as most important, and (2) how well these benefits are
currently reflected in the EQ-5D and SF-6D, two preference-based quality of life instruments
commonly used to estimate quality adjusted life years (QALYs) in value assessments.
Methods: We conducted semi-structured qualitative interviews with purposefully-sampled
individuals who reported both receiving a diagnosis of MDD from a medical professional and
taking a medication to treat depression in the previous 12 months. Participants were recruited
from online mental health patient networks, social media, and primary care clinics in the Greater
Boston, MA area. Interviews were conducted in English from August to December 2018.
Participants were asked to describe aspects of MDD medication treatment that are most important
to them, and factors that influenced their decisions to start, switch, or discontinue medication.
Interviews were audio-recorded, transcribed, coded, and analyzed using thematic analysis.
Results: Twenty-five (25) participants were recruited. The sample was 84% female (21/25), 76%
white (19/25) and 48% employed (12/25). The mean age was 39.3 years and mean time since
diagnosis was 11.2 years. Eighty-four percent of our sample reported at least one physical
comorbidity, most commonly high blood pressure, and 84% had at least one mental health
comorbidity (most commonly generalized anxiety disorder). Respondents prioritized a number of
desired treatment benefits that are not fully reflected in either the SF-6D or the EQ-5D,
including: regulating negative emotions, improving concentration, recovering motivation,
enjoying activities, changing patterns of negative thinking, decreasing sleep problems, increasing
feelings of self-worth, and feeling good about their lives.
Conclusions: Many treatment benefits that are prioritized by patients with MDD are not
included as constructs in the two instruments most commonly used to estimate QALYs in costeffectiveness analyses. Future research will provide guidance on how QALY measures can be
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improved for value assessments of MDD treatments, to more fully reflect the value patients place
on treatment outcomes.
PS 3-45 HUNTINGTON DISEASE COMMUNITY PERSPECTIVES ON DESIRED
CHARACTERISTICS OF DISEASE MODIFYING THERAPIES
Patient and Stakeholder Preferences and Engagement (PSPE)
Michele Gornick, PhD1, Kerry Ryan, MA2, Praveen Dayalu, MI3, Noelle Carlozzi, PhD4, Roger
Albin, MD3 and Darin Zahuranec, MD, MS5, (1)Ann Arbor, MI, (2)University of Michigan
Center for Bioethics and Social Sciences in Medicine, Ann Arbor, MI, (3)University of Michigan
Deparment of Neurology, Ann Arbor, MI, (4)University of Michigan Department of Physicial
Medicine and Rehabilitation, Ann Arbor, MI, (5)Center for Bioethics and Social Sciences in
Medicine, University of Michigan, Ann Arbor, MI
Purpose: Huntington disease (HD) is an incurable and insidiously progressive autosomal
dominant neurodegenerative disease. While disease modifying therapies (DMTs) for HD are now
entering pivotal trials, these treatments (which are designed to delay onset of HD) may also
result in prolonged survival with symptomatic disease. As such, patients with HD may face
complicated tradeoffs when considering these new potential treatments. We conducted a
preliminary assessment of the HD community views on emerging DMTs to address what patients
and families consider successful outcomes.
Methods: Semi-structured interviews were conducted with members of the HD community
(manifest HD, at-risk, and family/caregivers). Participants were asked which symptoms they
believed should be targeted with DMTs, as well as potential benefits and tradeoffs of delaying
symptom onset versus prolonging late-stage disease. Responses were organized according to
three key thematic questions: (1) What are the most important symptoms to target?; (2) How
much of a delay in disease onset is enough?; and (3) What if delay of onset also leads to
prolonging the later stages of the disease?
Results: Participants from the HD community (N=14, 57% female, age range 27-80) were
recruited from a single academic medical center. Key themes and example quotations are shown
in the Table. Respondents emphasized the need for treatments improving cognitive and/or
behavioral symptoms more so than motor symptoms. Many wanted treatments that delayed
symptom onset up to 5-10 years, though some considered shorter delays acceptable due to
potential value in advancing research to help future generations. Concern regarding potential for
prolonging later-stage symptomatic disease was variable, with some participants uncertain if they
would want a treatment that delayed onset but prolonged later-stage disease. Others stated that
any delay in onset would be desirable, regardless of potential prolongation of later stage disease.
Some mentioned that they were not concerned about prolonging later stage disease as they could
refuse treatments such as feeding tubes.
Conclusions: This pilot study demonstrates a breadth of opinions among the HD community
surrounding both the benefits and complex tradeoffs that might occur with DMTs. These
findings should be confirmed and expanded in larger samples within the HD community, to best
inform sample size and outcome measure selection for future DMT trials.
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PS 3-46 ARE INDIVIDUALS WILLING TO TRADE HEALTH FOR NON-HEALTH
VALUE DERIVING FROM GENOMIC-BASED DIAGNOSTIC INFORMATION?
Patient and Stakeholder Preferences and Engagement (PSPE)
Martin Eden, MSc1, Graeme Black, PhD2, Gavin Daker-White, PhD3 and Katherine Payne,
PhD1, (1)Manchester Centre for Health Economics, The University of Manchester, Manchester,
United Kingdom, (2)University of Manchester/Central Manchester University Hospitals NHS
Foundation Trust, Manchester, United Kingdom, (3)NIHR Greater Manchester Primary Care
Patient Safety Translational Research Centre, The University of Manchester, Manchester, United
Kingdom
Purpose: To identify if, and how, individuals’ trade-off between health and non-health outcomes
of receiving information from a genomic-based diagnostic test
Method: Informed by qualitative work, a Discrete Choice Experiment (DCE) with
accompanying training using a linear-narrative storyline was developed. The DCE was fielded in
an online-survey with supplementary background questions. People were asked to consider the
scenario of being at risk of a genetic condition, potentially diagnosed using a genomic test.
Respondents could choose from two sets of outcomes deriving from the diagnostic information
or could opt-out from having the test. Four attributes, each comprising three-levels, described
outcomes: 1) changes in health-related quality-of-life (HRQL) based on the EQ-5D-3L; 2)
improvements in informed decision-making; 3) benefit to others; 4) reductions in uncertainty. A
D-efficient design generated six choice-sets per respondent, blocked into four surveys.
A purposive sample, representative of the UK population, was recruited via an online panel.
Descriptive statistics summarised survey responses and conditional logit regression was used to
quantify preferences. Willingness-to-trade HRQL for non-health attributes with 95% confidence
intervals (CI) were calculated (delta method) and compared with minimally important
differences (MIDs) in HRQL changes.
Result: 1077 respondents (52% male, mean age 51.5) completed the DCE. Fewer than 7%
(n=71) of respondents had previously undergone genetic testing. Statistically significant
preferences, in-line with expected direction of change, were observed for all attributes. On
average, participants would give up 0.13 units of HRQL (95%CI: 0.12 to 0.14) if the test
information resulted in a unit improvement in their ability to make an informed decision.
Improvement in the testʼs ability to benefit others meant that 0.09 of HRQL (95%CI: 0.08 to
0.10) would be traded. A HRQL decrement of 0.07 (95%CI: 0.05 to 0.08) would be acceptable
for reduced uncertainty. The amount of health willing to be traded for improvements in each
non-health attribute was similar to, or exceeded, previously-estimated MID values for the EQ-5D
(mean 0.08, SD: 0.03).
Conclusion: Participants made meaningful trade-offs in health for non-health benefits of
genomic-based diagnostic information. Accounting for observed characteristics of preference
data, this quantification of value types can inform adaptations to the evaluative space used in
economic analyses of complex precision medicine interventions comprising a diagnostic
component.
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PS 3-47 VALUES CLARIFICATION AMONG PATIENTS WITH EARLY PSYCHOSIS:
LESSONS LEARNED AND IMPLICATIONS FOR SHARED DECISION MAKING
Patient and Stakeholder Preferences and Engagement (PSPE)
Elizabeth Thomas, PhD1, Alicia Lucksted, PhD2, Irene Hurford, MD3, Laura Siminoff, PhD3,
Lisa Dixon, MD4, Maria O'Connell, PhD5, John Suarez, MA6, Yaara Zisman-Ilani, PhD7 and
Mark Salzer, PhD3, (1)Temple University, Philadelphia, PA, (2)Baltimore, MD, (3)Philadelphia,
PA, (4)New York, NY, (5)New Haven, CT, (6)University of Pennsylvania, Philadelphia, PA,
(7)Temple University College of Public Health, Philadelphia, PA
Purpose: Mental health programs for patients with early psychosis, called Coordinated Specialty
Care (CSC), offer a variety of pharmacological and therapy services to help patients navigate
challenges presented by the onset of psychosis and get back on track with their life goals. These
programs seek to promote shared decision-making (SDM); however, little is known about the
specific decision-making needs of this population. The purpose of this study was to understand
not only the range of decisions faced by patients with early psychosis after enrolling in a CSC
program, but which are considered most difficult/complicated and why. As such, we expected to
gain important insights about what matters most to them.
Method: Sixteen patients with early psychosis were administered semi-structured interviews
informed by the Ottawa Decision Support Framework to capture their experience of treatment
decision-making. Interviews were audio-recorded and transcribed verbatim. Responses were
independently and inductively coded by two of the authors (ECT and JS) using the Constant
Comparison Method; differences in coding were discussed to consensus. Data analysis was
facilitated using NVivo 12 Plus.
Result: Patients identified a diversity of decision points that they faced after enrollment in CSC,
including decisions about starting and continuing CSC services; social decisions (e.g., whether to
participate in program social activities); and other decisions (e.g., setting and asking for help
with life goals). Decisions pertaining to life goals and to starting and continuing medication were
most commonly selected as the most difficult/complicated. When examining participants’
responses about what made these decisions most difficult/complicated, four themes related to
patient values arose: being successful, decision autonomy, staying well, and being like everyone
else. Patients saw their decisions as being tied to future achievements (e.g., going to college,
having a house). They wanted to make decisions without experiencing pressure from others to
make a specific choice. They emphasized the importance of maintaining health through their
decision-making. Finally, patients struggled to accept that mental health treatment could be
helpful to them, highlighting a desire to fit in with peers without mental health challenges.
Conclusion: These findings suggest that one way to attend to patient values is to understand
what makes decisions particularly difficult/complicated for them. Treatment providers might
especially explore the values reported here as they strive to support SDM within CSC.
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PS 3-48 FACTORS ASSOCIATED WITH OLDER ADULTʼs WILLINGNESS TO STOP
ASPIRIN
Patient and Stakeholder Preferences and Engagement (PSPE)
Sarah Vordenberg, PharmD, MPH and Brian J. Zikmund-Fisher, PhD, University of
Michigan, Ann Arbor, MI
Purpose: Current guidelines recommend against routine use of aspirin for primary prevention of
arteriosclerotic cardiovascular disease (ASCVD) among older adults due to the lack of net
benefit. The objective of this study was to explore factors that may influence older adultʼs
comfort with the idea of stopping aspirin.
Method: We recruited 774 adults 65 years and older through Dynata (formerly Survey Sampling
International) who were either not taking aspirin or were currently taking aspirin for the primary
prevention of ASCVD. In the web-based survey, participants read a vignette in which a
physician raised the idea of stopping aspirin and discussed the lack of benefit for primary
prevention of ASCVD and risk of bleeding. Participants reported their concern about stopping
aspirin (not at all to extremely, 7-point scale) and comfort with the idea of stopping aspirin (very
uncomfortable to very comfortable, 4-point scale). Participants also completed the validated
Maximizer-Minimizer Scale (MMS) and the Beliefs about Medicines Questionnaire (BMQ),
which includes subscales focused on harms of medications (BMQ-General) and medication
necessity and concern (BMQ-Specific). We used ordered logistic regression to examine
demographic and psychological factors associated with (1) concern about stopping aspirin and
(2) comfort with the idea of stopping aspirin.
Result: There was a broad distribution reported for concern about stopping aspirin. (Figure 1)
The following characteristics increased concern: female [OR 1.33(1.03-1.73)], Black [OR
1.65(1.13-2.39)], higher MMS score [OR 1.35(1.18-1.53)], or higher BMQ-specific scores [OR
(1.28(1.07-1.53)]. Overall, 66% of participants were somewhat or very comfortable with the idea
of stopping aspirin. Participants who identified as Black [OR 1.52 (1.03-2.24)] or had higher
BMQ-general scores [OR 1.32(1.11-1.58)] were more likely to be report being comfortable
stopping.
Conclusion: Concern about stopping aspirin varied widely in this older adult sample, and onethird of were somewhat or very uncomfortable with the idea of stopping aspirin. Although
clinical guidelines for primary prevention of ASCVD suggest that risks of aspirin may outweigh
the benefits for certain populations, efforts to decrease the inappropriate use of this over-thecounter medication will require recognizing and addressing substantial patient concerns.
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Figure 1. Frequency of concern about stopping aspirin (n=773)

PS 3-49 A PATIENT-ORIENTED APPROACH TO INFORM DESIGN OF EARLY
PHASE CLINICAL STUDIES: UNDERSTANDING THE PREFERENCES OF PEOPLE
WITH SCLERODERMA REGARDING STEM CELL TRANSPLANT
Patient and Stakeholder Preferences and Engagement (PSPE)
Magda Aguiar, PhD1, Sarah Munro, PhD2, Tiasha Burch3, Julia Kaal, MSc4, Tracey-Lea Laba,
PhD5, Nick Bansback, PhD6 and Mark Harrison, PhD1, (1)Faculty of Pharmaceutical Sciences,
University of British Columbia, Vancouver, BC, Canada, (2)Centre for Health Evaluation and
Outcome Sciences, Vancouver, BC, Canada, (3)Scleroderma Association of BC, Delta, BC,
Canada, (4)University of British Columbia, Vancouver, BC, Canada, (5)The George Institute for
Global Health, Camperdown, NSW, Australia, (6)School of Population and Public Health,
University of British Columbia; Centre for Health Evaluation and Outcome Sciences,
Vancouver, BC, Canada
Purpose: Stem cell transplant (SCT) is a new treatment for severe scleroderma offering potential
life extension and alleviation of symptoms. From the patient perspective, the decision to undergo
SCT is complex. The procedure carries risks of mortality and toxicity, and inconveniences such
as long-distance travel to a hospital offering the treatment. We are using a patient-oriented
approach, with patients and clinicians as research partners, to optimize the design of future
scleroderma clinical studies by incorporating patient priorities.
Method: We conducted a focus group with people with scleroderma of any stage, living
anywhere within British Columbia, Canada. To accommodate geographic constraints, we
allowed in person and remote participation via a web dial-in. Using a nominal group technique,
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participants were asked to list the items they find important when considering SCT. All ideas
were recorded, discussed and ranked according to importance. Group discussion about ranking
results and trade-offs followed. Focus group transcripts were analyzed by two independent
researchers and discussed with our patient partners to guarantee fair interpretation and adequate
selection of relevant attributes. The findings will inform a discrete choice experiment that will be
available in French and English, and sent to people with scleroderma in Canada.
Result: Eight people participated in the focus group, of which five participated via web dial-in.
The highest ranked factors were chances of success, survival, chemotherapy-related toxicity, and
support from multidisciplinary teams including dietary and mental health support. The final list
of attributes included: years without disease progression, risk of side effects, intensity of
chemotherapy, allied health care team, quality of life, mortality, out-of-pocket costs, distance
from home, number of people the surgeon has treated, and access to another patient with whom
the person can speak to about the treatment.
Conclusion: Patients’ preferences and care vary according to where people live. In this study,
we collected data from a diverse sample of people in BC and we found that the concerns of
people with scleroderma for SCT treatment go well beyond clinical effectiveness. Our patient
partners were key elements of the research team and supported planning, recruitment,
conceptualization of ideas and data interpretation. Knowledge regarding such concerns and the
trade-offs patients are willing to make will support better clinical study designs and potentially
improve the uptake for novel treatments.
PS 3-50 LIVER CANCER THERAPIES IN A SHARED DECISION-MAKING
PROCESS—CLINICAL OUTCOME OF THE IRALCT STUDY
Patient and Stakeholder Preferences and Engagement (PSPE)
Bennet Hensen1, Carolin Winkelmann2, Urte Kaegebein1, Thomas Neumann2, Bodo Vogt2 and
Frank Wacker1, (1)Institute for Diagnostic and Interventional Radiology, Medical School
Hanover, Hanover, Germany, (2)Chair in Empirical Economics, Otto-von-Guericke-University
Magdeburg, Magdeburg, Germany
Purpose: The IRALCT study aims to identify the relevant attributes for liver cancer therapies
that influence the therapy choice of patients and medical professionals. From the patients’ and
physicians’ perspectives, another purpose is to determine the part-worth utilities of the most
important attributes and to investigate the total utility of treatment options.
Method: To understand the factors or attributes that determine a shared decision-making process
for choices of liver cancer therapies, relevant factors were systematically identified and analyzed
during a two-phase study.
In our study, the attributes that influence the treatment choice of patients, physicians, and
medical laymen were identified. In addition, the method of maximum difference scaling was
used to determine the relevant attributes for liver cancer therapies and their decision weights. In
this context, empirical conjoint research attempts to identify patients’ and physicians’
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preferences of specific methods of treatment. The study is designed to compare the preferences
of the three different groups.
Result: The identification of the ‘most important’ attributes was based on the method of
maximum difference scaling (carried out with approx. 150 participants) using 14 attributes
identified in a pre-study. Overall, the three groups assessed the same 6 attributes as most
important: (1) recurrence rate, (2) safety of tumor resection, (3) pathological verification of
tumor resection, (4) risk for complications during surgery, (5) well-being after surgery, and (6)
degree of difficulty of the surgery. Moreover, we did not find significant differences in the
assessment of the six most important attributes between the three groups. This is important, as
the cumulative relative importance of these six attributes was about 80 percent. All other
attributes do not really have an impact on decision making.
Conclusion: Our results show that it is possible to derive preferences of patients and physicians
for the therapy choice. These preferences are very similar and stable. This is a good ground to
argue that a decision process for treatment choices can be moved away from a physician-centric
model towards shared decision making. This could improve the quality of patient care in the
sense of evidence-based medicine and shared decision-making and, thereby, increase the
satisfaction of patients and physicians. We contribute to the research stream that propose
approaches that (formally) include patients’ preferences in a shared decision-making process.
PS 3-51 INFORMATION PROCESSING AND PATIENT DECISION MAKING: A BIG
DATA APPROACH TO TREATMENT CHOICE IN PROSTATE CANCER PATIENTS
Quantitative Methods and Theoretical Developments (QMTD)
Ilona Fridman, PhD1, Vignesh Kumaresan1, Prajwal Vijendra1, Preethi Seshadri1, Samantha
Garland1, Grant Kim1, Angela Fagerlin, PhD2, Peter A. Ubel, MD1 and Marc D. Ryser, PhD,
MSc3, (1)Duke University, Durham, NC, (2)University of Utah / Salt Lake City VA, Salt Lake
City, UT, (3)Deparment of Sugery and Department of Mathematics, Duke University, Durham,
NC
Purpose: Patient preferences and choices often depend on how physicians describe available
treatment and non-cancer treatment options during patient-physician consultations. There is a
critical need to determine what factors in physician-patient conversation contribute to the
development of patients’ preferences for treatment or non-cancer treatment options. We sought
to extract the key topics present in conversations between patients with intermediate-risk prostate
cancer and their physicians to determine the influence of the conversations on final patients’
choices.
Method: We analyzed 287 clinical encounters that were audiotaped in two medical centers in the
US (2008-2012) and manually transcribed prior to analysis. We developed an automated threestage pipeline implemented in Python. First, transcripts were pre-processed using standard
natural language processing protocols (NLTK package). Second, we developed a topic model
using Latent Dirichlet Allocation (LDA) to identify the key topics of physician-patient
conversations (Gensim package). To validate the accuracy of the model, we correlated words
manually chosen for each topic with the words that the algorithm determined. Third, the topic
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distributions were used together with patient age and Gleason Score to predict patient choice
(active surveillance vs cancer treatment). The prediction was performed using the classification
algorithm XGBoost and hyperparameters were optimized using 10-fold cross-validation. Feature
extraction procedure identified which variables were most influential in predicting patient
choice.
Result: Patient median age was 62 years, 88% of them were white and 64% college educated,
Gleason score ranged between 6 and 7, and median length of the conversation was 7,226 words.
The LDA algorithms identified four topics, which we interpreted as "surgery,” “radiation,”
“active surveillance,” and other information (e.g., family history). The correlation between topics
and a predefined list of word confirmed that the algorithm accurately identified topics . XGboost
algorithm showed a moderately good performance in predicting patient choices, based on four
topics of conversations and baseline patient characteristics (accuracy=0.81, AUC = 0.74).
Through feature extraction, we found that the “active surveillance” topic had the strongest
influence on patient choice between immediate cancer treatment and active surveillance.
Conclusion: Our findings illustrate that machine learning algorithms can assist in identifying
aspects of conversations that influence patient choices. This work is especially important for
diseases where there is clinical equipoise between cancer treatment and active surveillance such
as intermediate-risk prostate cancer.
PS 3-52 AN EFFICIENT APPROACH TO QUANTIFY UNCERTAINTY IN COHORT
MODELING IN R
Quantitative Methods and Theoretical Developments (QMTD)
Alan Yang, MSc1, Eva A. Enns, MS, PhD2, Fernando Alarid-Escudero, PhD3, Hawre Jalal, MD,
PhD4, Eline Krijkamp, MSc5 and Petros Pechlivanoglou, PhD1, (1)Child Health Evaluative
Sciences, The Hospital for Sick Children, Toronto, ON, Canada, (2)Division of Health Policy
and Management, University of Minnesota School of Public Health, Minneapolis, MN, (3)Drug
Policy Program, Center for Research and Teaching in Economics, Aguascalientes, AG, Mexico,
(4)University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, (5)Erasmus
University Medical Center, Epidemiology department, Rotterdam, Netherlands
Purpose: To develop computationally efficient methods of conducting probabilistic sensitivity
analysis (PSA) in decision-analytic cohort models in R and compare them to existing methods.
Methods: We evaluated the efficiency of five methods for computing PSA results using R that
differ mainly in their handling of iterative processes: 1.The “standard” method uses two nested
“for” loops to iterate through the number of PSA simulations and over time, and performs matrix
multiplication on low-dimensional matrices at each simulation and time. 2.The “side split”
method slices a three-dimensional array (health states x health states x PSA simulations)
sideways by its longest dimension and performs matrix multiplication on larger matrices over a
smaller number of loops. 3.The “sparse matrix” method creates block diagonal matrices within a
large sparse matrix and utilizes the computation advantage of sparse matrix multiplication. 4.The
“stacking” method stacks the PSA simulation matrices before multiplying them, reducing the
number of “for” loops needed. 5.The “tensor” method uses Tensor algebra to perform three-
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dimensional array multiplication, which eliminates the use of “for” loops. In our comparisons,
we varied the number of states, cycles, and simulations in a typical PSA. We have implemented
parallel processing capabilities for these methods. Finally, we illustrate computational efficiency
against a similar implementation in Excel.
Results: The results from comparing the computation time of the five methods are shown in the
Figure. For 20,000 PSA simulations and 110 cycles, the “side split” method is the fastest until
the number of states increases beyond 13, where the “standard” method dominates the “side
split” method. The three-dimensional visualizations show that at 110 and 1,320 cycles, the “side
split” method is better than the “standard” method until the number of states reaches 12. This
holds true for a range of 1,000 to 100,000 PSA simulations. Parallel processing did not
significantly improve the results described. At 3 states, 1320 cycles and 20,000 simulations, the
“side-split” method is more than 1000 times faster than a similar implementation in Excel.
Conclusion: The “side split” method is the fastest when the number of states in the cohort model
is less than or equal to 12. Otherwise, the “standard” method is computationally superior. All
five methods implemented in R require significantly less computation time compared to methods
in Excel.
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PS 3-53 COMPARING METHODS FOR MODEL CALIBRATION WITH HIGH
UNCERTAINTY: MODELING CHOLERA IN BANGLADESH
Quantitative Methods and Theoretical Developments (QMTD)
Theresa Ryckman, Department of Health Research and Policy, Stanford University, Stanford,
CA, Stephen Luby, MD, Stanford Woods Institute for the Environment, Stanford, CA, Douglas
K. Owens, MD, MS, VA Palo Alto Health Care System, Palo Alto, CA, Eran Bendavid, MD,
MS, Stanford Health Policy, Centers for Health Policy and Primary Care and Outcomes
Research, Department of Medicine, Stanford University, Stanford, CA and Jeremy D.
Goldhaber-Fiebert, PhD, Stanford Health Policy, Centers for Health Policy and Primary Care
and Outcomes Research, Stanford University, Stanford, CA
Purpose: When published data do not match inputs needed to simulate disease natural history,
analysts may choose from several methods to calibrate simulation models to available data. We
evaluated several such methods and applied them to a cholera natural history model in
Bangladesh, where a lack of active surveillance data impedes estimation of disease burden.
Method: We built an age-stratified state-transition cohort model to simulate cholera cases and
deaths. Age-stratified parameters included cholera incidence, severity, proportion of cases
hospitalized, and treatment-dependent case fatality probabilities. We evaluated three calibration
techniques: random search, sampling importance resampling (SIR), and incremental mixture
importance sampling (IMIS). All techniques involved sampling parameters from prior
distributions, which were broad and uniform to reflect high uncertainty and allow calibration
targets to better inform posteriors. We scored parameter sets by comparing simulated
hospitalized cases and deaths against twelve targets, based on observed data. We assessed each
techniques’ performance (identification of parameters producing good fits to targets), efficiency
(time to complete), and feasibility (whether the method functions with large uncertainties and
many degrees of freedom). We also compared calibrated parameters with parameters based
purely on the literature without accounting for bias.
Result: IMIS performed the best in our context, was feasible to run, and was most efficient.
IMIS generated posterior distributions that corresponded better with observed data, after
explicitly accounting for bias. These posteriors were substantially informed compared to both
prior distributions and, often, posterior distributions from Random Search and SIR (Figure).
While each strategy took 5-7 days to run on a high-performance computing cluster, IMIS
identified almost 10,000 unique good-fitting parameter sets, whereas Random Search and SIR
identified fewer than 150. Notably, we found that calibrated incidence is considerably larger than
the literature would directly imply, as we account for cases that never make it into hospitals and
reporting systems.
Conclusion: We applied three calibration techniques to a situation with high uncertainty. IMIS
was best able to identify parameter distributions with excellent concordance to the data in a
reasonable amount of time, while adjusting for biases in passive reporting. This finding is
especially important in global settings, where data are often sparse or potentially biased and
evidence-based policy decisions are urgent.
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Figure: Comparison of Selected Posterior Parameter Estimates with Prior and LiteratureBased Distributions
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PS 3-54 METHODS FOR CHOOSING THE BEST DESIGN OF A CLINICAL TRIAL:
IMPLEMENTING EXPECTED VALUE OF SAMPLE INFORMATION AND
ADJUSTING FOR BIAS INDUCED BY A GROUP SEQUENTIAL DESIGN
Quantitative Methods and Theoretical Developments (QMTD)
Laura Flight, MMath, MSc1, Steven Julious, BSc, MSc, PhD2, Alan Brennan, BSc, MSc, PhD1
and Susan Todd, BSc, MSc, PhD3, (1)Health Economics and Decision Science, School of Health
and Related Research (ScHARR), University of Sheffield, Sheffield, United Kingdom,
(2)Medical Statistics Group, School of Health and Related Research (ScHARR), University of
Sheffield, Sheffield, United Kingdom, (3)Department of Mathematics and Statistics, University
of Reading, Reading, United Kingdom
Purpose:
A group sequential design (GSD) is a common adaptive study design. Interim analyses are
performed after groups of patients have reached the primary outcome. The interim data are
analysed and compared to pre-specified stopping rules to determine whether the trial can stop
early. Currently the choice of stopping rule and number of interim analyses does not usually
consider the expected value of sample information (EVSI). We explore how EVSI methods can
be applied to the design of GSDs, with appropriate bias adjustments made to allow for the
adaptive nature of the proposed designs.
Method:
Pilot trial data are bootstrapped 2500 times. Using estimates from each bootstrap sample a
dataset is simulated, representative of the population to be randomised in a future clinical trial.
The proposed design is applied to each simulated dataset and the parameters for a health
economic model are estimated. Parameters are both adjusted and unadjusted for the adaptive
nature of the trial. EVSI is then calculated using a non-parametric regression approach. The
expected net benefit of sampling (ENBS) is calculated by subtracting the costs of the proposed
design from the population EVSI, and compared for a range of designs. This process,
summarised in Figure 1, is applied to two case studies. Proposed designs include; a fixed sample
size design and GSDs using an O’Brien-Fleming (OBF) and Pocock (POC) stopping rules, with
up to five analyses. The optimal design has the highest ENBS.
Result:
In the first case study, the fixed sample size design had the highest EVSI and ENBS. The Pocock
stopping rule with five analyses had the highest expected sample size but a low EVSI, as trials
stopping at the earliest interim analyses provide considerably less information than the trials
continuing to the final analysis. In the case of the GSDs, there were small differences between
adjusted and unadjusted estimates of EVSI. In a second case study, we identified a scenario
where the GSD had the highest ENBS.
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Conclusion:
EVSI can be used to compare possible adaptive and non-adaptive trial designs when planning a
clinical trial. This can guide and justify the choice of trial characteristics and prevent limited
research budgets being wasted.

Figure 1 Summary of the steps required to calculate the ENBS to compare proposed trial designs
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PS 3-55 MODELING AND FORECASTING HEALTH TRAJECTORIES WITH
DYNAMICALLY ADAPTIVE PROBABILISTIC SYSTEMS
Quantitative Methods and Theoretical Developments (QMTD)
Jarrod E. Dalton, PhD1, Nikolas I. Krieger, M.S.1 and Adam T. Perzynski, PhD2, (1)Cleveland
Clinic, Cleveland, OH, (2)Case Western Reserve University at MetroHealth Medical Center,
Cleveland, OH
Purpose:
Longitudinal health data resources are increasingly being used for research, and increased use of
static prediction models has emerged as a serious threat to the validity of analyses of these vast
data resources. Static risk equations are now routinely (and inappropriately) applied to
dynamically-changing sets of risk factors. Standard system dynamics modeling techniques are
limited in that they fail to accommodate systematic variation in clinical decisions to measure (or
not measure) a particular characteristic. We propose a variant on dynamic Bayesian networks
(DBNs), called Dynamically Adaptive Probabilistic Systems (DAPS), that allows a given set of
time-varying concepts to adapt as a function of the systemʼs state. The DAPS approach includes
variables within the system only at those time points for those subsets of patients for whom
variables are likely to be measured.
Methods:
DBNs are probabilistic systems mapping vectors of monitored variables across values of discrete
time. An underlying directed acyclic graph governs the conditional independence assumptions
among the variables in the system. In DAPS, a state transition model governs the set of timevarying characteristics assumed to be endogenous to the system at a given time point. We used
the U.S. Preventive Services Task Force guidelines on cholesterol, blood pressure and glucose
screening to characterize state transitions governing monitored variable sets. Other propensitybased approaches are possible.
Results:
The Figure illustrates transitions among variable sets based on a hypothetical patients’ health
state as a function of time. Adaptation rules governing the set of variables included in the
dynamic model at a given age are shown in panel (a). Panel (b) illustrates the model architecture
for a sample female patient, for whom the initial set of monitored variables included weight and
blood pressure and for whom transitions into other monitored variable sets were made at ages 60
and 62. Open circles indicate predictions for the initial value of newly-monitored characteristics,
while solid circles indicate dynamic predictions given previous values of the characteristics.
Conclusions:
Health events can lead to structural changes in the defining characteristics of patients’
multidimensional health state. We believe DAPS can be particularly useful for developing and
simulating clinical forecasting models in which a change in health state might imply a structural
change in the set of variables that are to be modeled.
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PS 3-56 DECIDING HOW TO DECIDE: EVALUATING CHOICE FUNCTIONS FOR
TEST-AND-TREAT DECISION ANALYSES WITH PARTIALLY-IDENTIFIED
EXPECTED UTILITY
Quantitative Methods and Theoretical Developments (QMTD)
Shaun P. Forbes, AM, Rowan Iskandar, PhD and Thomas A. Trikalinos, MD, PhD, Center for
Evidence Synthesis in Health, Brown University, Providence, RI
Purpose: In the common situation where there is no perfect reference standard, we cannot attain
point identification of the sensitivity and specificity of tests; instead, we can only consistently
obtain an identification region or set. Then, mathematical modeling of the expected utility of
test-and-treat strategies must rely on partially-identified information which can only be
expressed in terms of bounds. We outline a framework for deciding between alternative test-andtreat strategies when the expected utility cannot be uniquely-identified.
Method: We construct 108 clinically-plausible testing scenarios for two tests (T1, T2) which are
determined by factorial combinations of the prevalence of disease (0.01, 0.2), covariance
between test results (0, upper-Frechet bounds), diagnostic odds ratio comparisons (1000 vs.
1000, 1000 vs. 10, and 10 vs. 10), and where on the Receiver Operating Characteristic (ROC) the
tests’ cutoffs operate (high sensitivity, high specificity, Q* index) for each test. Then we apply a
range of choice functions that encode different decision-maker attitudes (e.g., pessimism,
optimism, regret) to select the optimum out of all practically-implementable strategies for each
scenario: using no test, T1 only, T2 only, T1 or T2, T1 and T2, T1 then T2, and T2 then T1, and
then treat all or those with a positive testing result. We formulate this decision analysis as a set of
mathematical programming problems. We show that solving them is equivalent to finding the
minimum and maximum expected utility over the partially-identified region, which is a pair of
non-linear constrained optimization problems.
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Result: We organize the results by the ROC cutoffs, which were the most influential factors. To
explicate, we show results from the scenario where T1 had a high sensitivity ROC cutoff and T2
had a cutoff set at its Q* index point. In panel (a) we see that there is no obvious dominant
strategy based on the bounds of expected utility (1 = most desirable health state).
Correspondingly in panel (b) we see that the optimal strategy depends on the choice function.
Conclusion: We recast the decision analysis of a partially-identified problem as a constrained
nonlinear optimization over the partially-identified region of feasible parameters. The example
demonstrates that the optimal strategy depends on which choice function best captures the
preferred decision-making attitude. Under partial-identifiability the decisionmakers’ attitude
towards uncertainty is very important.
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PS 3-57 THE EVOLUTION OF SIMULATION MODELING IN HEALTH POLICY: A
REVIEW OF THE LITERATURE
Quantitative Methods and Theoretical Developments (QMTD)
Mohammad Jalali, PhD1, Catherine DiGennaro2, Abby Guitar3, Karen Lew3, Hazhir
Rahmandad, PhD3 and Donald Burke, MD4, (1)Harvard Medical School, MGH Institute for
Technology Assessment, Boston, MA, (2)MGH Institute for Technology Assessment, Boston,
MA, (3)MIT Sloan School of Management, Cambridge, MA, (4)University of Pittsburgh,
Pittsburgh, PA
Purpose: Increasingly complex health systems and advancing computational tools have pushed
forward the application of simulation models to inform health policy. The findings of these
models not only inform the thinking of policy makers but are also integrated into operational
policies and interventions, which have significant impacts. Hence, rigor and quality in design,
implementation, validation, reporting, and disseminating are essential to the healthy growth of
simulation modeling and its impacts; however, questions remain about the quality of many
simulation studies since quality attributes have not been formally assessed.
Method: We conducted a comprehensive review of health policy journal articles that used
simulation modeling. Through searches on PubMed and Web of Science, we found 1,613 articles
that satisfied our inclusion criteria. We performed chronological analyses and clustering based
on health research areas and simulation modeling types. We also conducted an in-depth analysis
of a random sample of 50 studies and the most-cited 50 to determine the reproducibility and
quality of the studies.
Result: We show that, over the past 50 years, the overall publication trend has been
exponentially growing, with the highest growth in dynamic modeling approaches. Through
clustering the research areas based on Medical Subject Headings (MeSH terms), we found that
diseases make up the highest fraction of articles (70%), where pathological conditions, viral
diseases, neoplasms, and cardiovascular diseases account for about one-third of the articles.
Nearly half of the 1,613 articles do not report the details of their models. In our in-depth analysis,
both samples (random and most-cited) showed significant gaps with best practice guidelines; for
instance, only seven of the twenty-six evaluation criteria were satisfied above eighty percent.
Comparing the two groups of most-cited and randomly selected articles, the majority of the
evaluation criteria did not differ, and in those that did differ, randomly selected articles often
performed better than most-cited articles.
Conclusion: Our findings indicate gaps in the breadth of health topics that are studied with a
simulation modeling approach, as well as shortcomings in the rigor of simulation modeling based
research itself. These results can be used to define specific areas of improvement in simulationbased health policy research, which can in turn more validly inform policy makers.
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PS 3-58 A NEED FOR CHANGE! A CODING FRAMEWORK FOR IMPROVING
TRANSPARENCY IN DECISION MODELING
Quantitative Methods and Theoretical Developments (QMTD)
Fernando Alarid-Escudero, PhD, Drug Policy Program, Center for Research and Teaching in
Economics, Aguascalientes, AG, Mexico, Eline Krijkamp, MSc, Erasmus University Medical
Center, Epidemiology Department, Rotterdam, Netherlands, Petros Pechlivanoglou, PhD, Child
Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, Hawre Jalal,
MD, PhD, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA and Eva A.
Enns, MS, PhD, Division of Health Policy and Management, University of Minnesota School of
Public Health, Minneapolis, MN
Purpose: The use of open-source programming languages in health decision sciences is growing
and has the potential to facilitate model transparency, reproducibility, and shareability. However,
guidance as to how to structure the required components of model building and analysis is
lacking. To address this challenge, we propose a generalizable coding framework for modelbased decision and cost-effectiveness analyses.
Methods: We designed a framework to structure and organize the implementation of decision
models in a programming language allowing for complex modeling methods to be more
transparently incorporated into decision-making. The development of this framework
encompasses a collective expertise from research and pedagogical experiences. Our framework
is based on the premise that comprehensive model-based decision and cost-effectiveness
analyses involve common components, regardless of the specific structure of the model, be it a
decision tree, Markov model, or stochastic simulation model. In developing this framework, we
strived for flexibility and generalizability to accommodate a diversity of model types and
applications. The framework provides a structure for organizing code to conduct decision
analyses, allowing for full documentation of the biological, behavioral, and mathematical
assumptions and decisions that went into the model development and analysis processes.
Results: The proposed framework consists of a set of common core decision model components
divided into five components: (1) model inputs, (2) model implementation, (3) model calibration,
(4) model validation, and (5) analysis. The first four components form the model development
phase, whereas the analysis component is the application of the final model to answer the policy
or research question of interest, conduct sensitivity analyses, assess decision uncertainty, and/or
determine the value of future research through value of information (VOI) analysis. The five
components of common decision models and their interconnectivity are shown in the Figure. We
showcase the framework through a fully functional, testbed decision model coded in R, which is
freely available on GitHub for download and easy adaptation to other applications.
Conclusions: This framework provides formal guidance for coding decision models and
facilitates the accessibility of more advanced modeling methods by a broader set of users.
Adoption of the framework will improve code readability and model-sharing, paving the way to
an ideal, open-source world.

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E195

PS 3-59 PERSONALIZED ADAPTIVE TREATMENT SELECTION FOR CHRONIC
DEPRESSION
Quantitative Methods and Theoretical Developments (QMTD)
Mutita Siriruchatanon, MS and Shan Liu, PhD, University of Washington, Seattle, WA
Purpose: There are no clear evidence-based guidelines on when/how to switch treatment in
depression. We study the treatment selection problem in chronic depression using simulated data.
The objective is to find the optimal individualized treatment sequence by creating a
computerized decision-support tool for mental healthcare providers.
Method: We formulated a treatment selection problem for chronic depression as a Markov
Decision Process (MDP) by considering four health states (i.e., three depression severity states
and death), and three treatment states (i.e. treatment 1, treatment 2, and treatment 1+2). At each
period, the decision maker can choose one of five actions (i.e., add/subtract/switch treatment, no
treatment change and monitor/not monitor in the next period). Only a monitored patientʼs
treatment can be modified in any period. After a treatment change, the patient stays on the same
treatment for a minimum holding period. The objective is to maximize the net monetary benefits
(NMB) over 48 weeks. We simulated the disease trajectories of a cohort of chronic depression
patients. We assumed patients with similar features may response similarly to the same
treatment, and categorized patients into three progression patterns (i.e., fast progressing, slow
progressing, and stable). By leveraging the subgroup treatment-effect distribution, we estimated
a unique treatment effect to establish an individualized disease progression model. We proposed
three heuristic methods to solve for the optimal treatment sequence for each patient (i.e., healthbased, one-period look ahead with/without update). The health-based method is composed of
several rules comparing a patientʼs previous and current health states. The one-period look ahead
method is based on the traditional forward iteration that considers progression uncertainties only
in the next period. The method with update will update treatment effects in every period.
Result: Health-based method provides the lowest NMB, while the one-period look ahead with
update method provides the highest NMB except in the fast progressing subgroup. Additionally,
there are high number of treatment switches by the health-based method. The look ahead method
is more conservative as most actions are to not monitor or stay on the same treatment.
Conclusion: A computerized decision-support tool for chronic depression treatment selection
shows promise to improve overall patients’ benefits.
PS 3-60 INCORPORATING MORTALITY IN HEALTH UTILITY MEASURES
Quantitative Methods and Theoretical Developments (QMTD)
Barry Dewitt, PhD, Department of Engineering & Public Policy, Carnegie Mellon University,
Pittsburgh, PA and George W Torrance, PhD, Centre for Health Economics and Policy Analysis,
McMaster University, Hamilton, ON, Canada
Purpose: Utility theory is foundational to decision analysis and choice modeling. One of its most
successful applications has been in health and medicine, where measures based on multi-attribute
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utility theory abound and are used in many different types of analyses. The creation of such
measures requires design choices that have profound effects on the final utility model, many of
which have been documented and studied in the literature. Here, we describe one design choice
that has, to the best of our knowledge, been ignored.
Method: We demonstrate that any multi-attribute decision analysis where one or more essential
outcomes cannot be described in terms of the multi-attribute space requires a design choice for
incorporating those essential outcomes. In health applications the state of being dead is such an
outcome. We derive the effect of the design choice on the resulting utility scale in a general
setting and then illustrate its impact using a widely-used health utility measure.
Result: There are two methods for incorporating the utility of dead into health utility measures.
Utility theory cannot recommend one over the other. They lead to different utility scales unless
the data used to produce the utility measure satisfy a specific polynomial of degree four. In the
Health Utilities Index Mark 3, the default method leads to a utility scale of -0.36 to 1; the
alternative (ignored) method leads to a utility scale of -0.45 to 1.
Conclusion: Incorporating the utility of dead into health utility measures requires a design
choice that has been ignored in the literature. The choice changes the resulting utility scale in
almost all cases. Its importance can vary, in part depending on the specifics of a particular
application of the health utility measure. To the best of our knowledge, utility theoretic principles
cannot guide the choice of which method to use.

PS 4-2 PRODUCING STANDARDIZED COUNTRY-LEVEL IMMUNIZATION
DELIVERY UNIT COST ESTIMATES
Applied Health Economics (AHE)
Allison Portnoy, MSPH1, Kelsey Vaughan, MSc2, Annette Özaltin, MSc2, Emma Clarke,
MPhil1, Christian Suharlim, MPH MD3, Stephen C. Resch, MPH, PHD3 and Nicolas A. Menzies,
PhD3, (1)Harvard T.H. Chan School of Public Health, Dept. of Global Health and Population,
Boston, MA, (2)ThinkWell, Washington, DC, (3)Center for Health Decision Science - Harvard
T.H. Chan School of Public Health, Boston, MA
Purpose:
To make funding and policy decisions for immunization programs, decision-makers need to
know how much these programs cost. However, many low- and middle-income countries
(LMICs) do not have immunization delivery unit cost estimates available, or have estimates that
are uncertain, unreliable, or old. While new immunization costing exercises may narrow this
evidence gap, such studies are resource-intensive and hard to implement routinely. This project
aims to produce standardized country-level estimates of routine immunization delivery unit costs
for 135 LMICs, based on a quantitative synthesis of existing evidence.
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Method:
We extracted estimates of the cost per dose for routine infant immunization services from the
Immunization Costing Action Networkʼs Immunization Delivery Cost Catalogue. We used these
data to construct a prediction model for estimating standardized immunization delivery unit
costs. A meta-regression approach was used to incorporate country-level (GDP per capita,
reported diphtheria-tetanus-pertussis (DTP3) coverage, population, and number of doses in the
routine vaccination schedule) and study-level (study year, single antigen or programmatic cost
per dose, and cost type (financial or economic)) predictors. The fitted prediction model was
weighted by sample size and used to estimate routine immunization delivery costs per dose for
each LMIC for 2009-2017.
Result:
We estimated the prediction model using the results from 62 individual studies, representing 18
countries. The fitted model demonstrated that routine costs per dose were decreasing in time (i.e.,
calendar year) and number of doses in the vaccination schedule, and increasing in DTP3
coverage. For 2017, the predicted mean economic cost per dose was $1.26 ($0.07–5.42)
compared to $1.15 ($0.06–4.97) for financial cost per dose.
Conclusion:
Immunization delivery costs are a necessary component of high-quality cost-effectiveness
models, and are also used to inform budgeting for immunization programs. Our study provides
standardized unit cost estimates that can help to expand the evidence base available in the IDCC
and improve budgeting and planning in situations where empirical cost data are unavailable.
PS 4-3 UTILITY VALUES FOR HEALTH STATES ASSOCIATED WITH DUCHENNE
MUSCULAR DYSTROPHY: A SYSTEMATIC REVIEW
Applied Health Economics (AHE)
Shelagh M. Szabo, MSc1, Ivana Audhya, MSc2, Daniel Malone, RPh, PhD, FAMCP3, David
Feeny, PhD4 and Katherine L. Gooch, PhD2, (1)Broadstreet HEOR, Vancouver, BC, Canada,
(2)Sarepta Therapeutics, Cambridge, MA, (3)College of Pharmacy, The University of Arizona,
Phoenix, AZ, (4)McMaster University, Hamilton, ON, Canada
Purpose: Duchenne muscular dystrophy (DMD) is a progressive X-linked myopathy causing
muscle wasting, early loss of ambulation, and premature death. New therapies for DMD are
under development and to accurately assess their costs and benefits, preference values for DMDrelated health states are required. As the progression of DMD begins in early childhood, the
health-related quality-of-life (HRQoL) impacts are not limited to those of the DMD patient;
caregivers and families are also affected. The objective of this review was to synthesize
published evidence on utilities for health states capturing the HRQoL impact and caregiver
burden of DMD.
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Methods: A systematic review was performed using MEDLINE and Embase. Abstract and fulltext screening and data extraction were performed in duplicate on studies reporting utilities for
DMD patients or caregivers. Data were extracted on study and patient characteristics, health
states considered, approach to measuring utility (including the Health Utilities Index Mark 3
[HUI-3] and EurQOL-5 dimensions survey [EQ-5D]) and reported utility values. Quality
appraisal of included studies was performed using a framework described by Papaionannou et al
(2013).
Results: From 888 abstracts, eight publications describing five eligible studies were identified.
DMD utility estimates were identified for a limited number of health states defined by
ambulation, ventilation, and age. Estimates of utility values ranged from 0.75 (HUI-3) for
patients with early ambulatory DMD to 0.05 (HUI-3) for DMD patients on day-and-night
ventilation; and are presented by age in Figure 1. Published caregiver utilities ranged from 0.87
(for caregivers of adult patients with DMD, measured by the EQ-5D-3L) to 0.71 (for caregivers
of predominantly childhood DMD patients, measured by the EQ-5D-3L). Both patient and
caregiver utilities tended to be lower with more severe DMD health states. Variability in utilities
was also observed based on the choice of measure, respondent type, study selection criteria, and
country. No utilities for other DMD-related health states (for example scoliosis, upper limb
function or developmental disability) were identified.
Conclusions: Published health state utilities document the substantial HRQoL impacts of DMD,
particularly as the disease progresses. Future initiatives to describe the utility of a wider range of
disease stages and health states are necessary for accurately modeling the HRQoL impact and
cost-effectiveness of therapies that have the potential to alter the course of the progression of
DMD.
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PS 4-4 COST-EFFECTIVENESS ANALYSES OF ANTIMICROBIAL RESISTANT
BACTERIA MITIGATION STRATEGIES: METHODOLOGICAL CHALLENGES AND
CONSIDERATIONS
Applied Health Economics (AHE)
Stephen Mac, Institute of Health Policy, Management and Evaluation, University of Toronto,
Toronto, ON, Canada and Beate Sander, PhD, Toronto Health Economics and Technology
Assessment (THETA) Collaborative, University Health Network, Toronto, ON, Canada
Purpose: Antimicrobial resistant (AMR) bacteria are a global threat to population health and
healthcare settings. Public health decision-makers are increasingly considering economic
evidence for infection prevention and control programs. Decision-analytic models can generate
this economic evidence while incorporating health outcomes such as quality-adjusted life years
(QALY), but model conceptualization for AMR interventions present unique challenges. Using a
cost-effectiveness analysis (CEA) of a vancomycin-resistant enterococci screening and isolation
program as a case study, we discuss key challenges and considerations.
Method: We developed an individual-level microsimulation model for a 20-bed general
medicine ward informed by local data and the literature. We incorporated a dynamic population,
which added new patients to the ward upon discharge or death, up to a total of 1,000 hospital
admissions; and dynamic transmission using a two-state dynamic transmission component. We
identified three key methodological issues: 1) selecting a time horizon for the intervention; 2)
assessing parameter uncertainty when using a dynamic population model and; 3) generalizability
to other hospitals. We estimated the programʼs cost-effectiveness from the healthcare payer
perspective over 1-year and 5-year periods.
Result: Due to stochastic events, the number of patients admitted varied and inadvertently
over/underestimated the incremental cost-effectiveness ratio (ICER). We therefore simulated the
number of admissions instead, with 1,000 simulations approximating a 1-year time horizon.
Simulation of 1,000 and 5,000 admissions resulted in ICERs of $7,850/QALY and
$50,094/QALY, respectively. At the commonly used threshold of $50,000/QALY, the time
horizon can significantly affect program value.
Deterministic sensitivity analysis was inappropriate given the non-linearity of the dynamic
transmission. Probabilistic sensitivity analysis concluded that the likelihood of the program being
cost-effective asymptotes at 51%, emphasizing the influence of stochasticity on costeffectiveness. Probabilistic scenario analyses were conducted for influential variables; an
outbreak (prevalence increased 10-times) decreased the ICER from $7,850/QALY (51% costeffective) to $2,340/QALY (56% cost-effective), reduced prevalence (by half) resulted in a
dominated program. Model generalizability would require multiple probabilistic scenario
analyses based on local input data.
Conclusion: Despite the methodological challenges of using CEAs to evaluate the value of
AMR mitigation strategies, they provide higher quality economic evidence for decision-makers
compared to simple economic evaluations (cost-analysis). CEAs provide sufficient complexity to

E200

Medical Decision Making 40(1)

model the health burden of nosocomial infections within hospital settings, while providing
timely evidence to decision-makers.
PS 4-5 A DECISION ANALYTIC MODEL OF MULTIGENE MOLECULAR
DIAGNOSTICS FOR COLORECTAL CANCER PRECISION MEDICINE
Applied Health Economics (AHE)
Amalia Issa, PhD, MPH, Personalized Medicine & Targeted Therapeutics; and Univ Science
Philadelphia, Philadelphia, PA and Vivek Chaudhari, Personalized Medicine & Targeted
Therapeutics; and University of the Sciences in Philadelphia, Philadelphia, PA
Purpose: Health economic evaluations are an important factor in evaluating the value of novel
molecular technologies. Several multi-gene expression assays are currently marketed for use as
prognostic biomarkers to detect and categorize the risk of recurrence and identify individuals in
stage II who would benefit from adjuvant chemotherapy use. However, each of these tests are
expensive and it is not known what value they add in terms of quality of life. Our purpose was to
evaluate the cost-effectiveness of using 4 molecular diagnostics for prognostic decisions for
stage II colon cancer patients.
Method: We developed a 5-year Markov model to estimate the costs and quality-adjusted lifeyears (QALYs) associated with 4 different marketed genomic tests (i.e., 12-gene assay, 18-gene
expression assay, 482-gene signature, and Immunoscore assay) for stage II colorectal cancer
treatment strategies. We used data on the clinical validity of multigene assays, costs of
treatments, adjuvant chemotherapy, costs associated with administration, adverse events,
utilities. We generated estimates of health care costs and QALYs, and the incremental costeffectiveness ratio (ICER). This study was conducted from a societal perspective, and a 3%
discount was applied. One-way sensitivity analyses were conducted, and 1,000 Monte-Carlo
simulations were performed to assess the uncertainty of the model parameters on the results of
the ICERs for the 4 tests.
Result: For 5,307 patients using the 12-gene assay, we found that the recurrence score (RS) of
780 patients (14.69%) were in the low risk group, 990 patients (18.65%) in the intermediate risk
group and 950 patients (17.90%) in the high-risk group. Use of the 12-gene assay resulted in a
33% increase in expenditures in all costs as compared with use of the 18-gene expression assay
(p<0.05). The cost of the Immunoscore test was estimated to be $23,564 as compared with the
12-gene assay guided treatment at $24,545, 18-gene assay guided treatment at $28,374, and 482gene signature guided treatment at $33,315. The use of the Immunoscore assay, 12-gene assay,
18-gene assay, and 482-gene signature resulted in gains of 3.903, 3.623, 3.677, and 3.704
QALYs respectively.
Conclusion: This study has implications for understanding how clinical decisions related to
colorectal cancer prognosis might be made in real-world clinical settings. Additionally, our
findings have important policy implications, particularly for health insurers.
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PS 4-6 THE VALUE OF METFORMIN FOR DIABETES PREVENTION TREATMENT BURDEN AS A MISSING PIECE OF THE PUZZLE
Applied Health Economics (AHE)
Natalia Olchanski, MS, David van Klaveren, PhD, Joshua T. Cohen, PhD, John B. Wong, MD
and David M Kent, MD, MS, Tufts Medical Center, Boston, MA
Purpose: Metformin is a proven effective strategy for type 2 diabetes prevention in individuals
with pre-diabetes meeting inclusion criteria for the Diabetes Prevention Program (DPP). We
estimated how costs and health benefits of metformin vary across this population, and how the
treatment burden of daily medication and its side effects affect value at the individual level.
Methods: Using microsimulation to project outcomes in the DPP trial population, we compared
metformin administration to usual care. We modeled the individualized risk of developing
diabetes and projected diabetic outcomes to yield lifetime costs and quality-adjusted life
expectancy, from which we estimated individual-level net monetary benefits (NMB) for
metformin versus usual care, assuming a base case willingness to pay of $50,000 per qualityadjusted life year. A key contribution over previous analyses is that we accounted for effect
modification of intervention effectiveness by individual diabetes risk. We further explored the
effects of patient preferences around the treatment burden of taking daily medication and the
side-effects of metformin on its NMB. We quantified these factors as disutilities, applied to the
health-related quality of life, and tested the range of 0.002 to 0.05, per published estimates.
Results: For the lowest diabetes risk quintile, metformin provided very small benefits and
increased costs compared to usual care. Metformin had a negative NMB in the lowest risk
quintile, with progressively increasing positive values in higher risk quintiles. By avoiding its
use among individuals who would not benefit, targeted administration of metformin conferred a
benefit of $500-$800 per person, depending on duration of treatment effect. Treatment burden
from daily metformin administration had a strong effect in decreasing NMB of metformin
(Figure), and the proportion of patients with positive NMB, from 75% in the base case, to 68%
with treatment burden disutility of 0.001, and 14% with treatment burden disutility of 0.05.
Conclusions: Targeting active diabetes prevention with metformin to patients at highest risk
could improve health outcomes and reduce costs compared to providing the same intervention to
a similar number of patients with pre-diabetes without targeted selection. Our results indicate
that the value of metformin is highly sensitive to individual patient preferences and perceived
burden of taking a medication daily, as well as the potential for experiencing side effects of
metformin.
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Figure:

PS 4-7 BENEFITS AND HARMS OF A PREVENTION PROGRAM FOR IODINE
DEFICIENCY DISORDERS - A DECISION-ANALYTIC MODEL
Applied Health Economics (AHE)
Monika Schaffner, MSc1, Nikolai Muehlberger, Priv.-Doz., DVM, MPH1, Annette ConradsFrank, PhD1, Vjollca Qerimi Rushaj, MPharm, Dr.sc.2, Gaby Sroczynski, Dr., MPH1, Eftychia
Koukkou, MD3, Betina Heinsbæk Thuesen, PhD4, Henry Völzke, MD5, Wilhelm Oberaigner,
Assoc.-Prof. Priv.-Doz. Dr.1, Uwe Siebert, MD, MPH, MSc, ScD6 and Ursula Rochau, MD,
MSc1, (1)UMIT - University for Health Sciences, Medical Informatics and Technology, Institute
of Public Health, Medical Decision Making and HTA, Department of Public Health, Health
Services Research and HTA, Hall i.T., Austria, (2)UMIT - University for Health Sciences, Med.
Informatics and Technology, Institute of Public Health, Medical Decision Making and HTA,
Department of Public Health, Health Services Research and HTA / Faculty of Pharmacy,
University of Skopje, Macedonia, Hall i. T., Austria, (3)Department of Endocrinology, "Elena
Venizelou", Maternity Hospital, Athens, Greece, (4)Research Centre for Prevention and Health,
The Capital Region of Denmark, Hillerod, Denmark, (5)Institute for Community Medicine,
University Medicine Greifswald, Greifswald, Germany, (6)UMIT - University for Health
Sciences, Medical Informatics and Technology, Dept. of Public Health, Health Services
Research & HTA / Harvard Univ., Dept. Health Policy & Management, Institute for Technology
Assessment, Hall i.T. / Boston, Austria
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Purpose: Iodine deficiency (ID) causes various diseases, such as thyroid disorders and mental
development disorders in children, summarized as iodine deficiency disorders (IDDs). Currently,
evidence-based information on the benefit-harm ratio of the implementation of an IDD
prevention program in Europe is lacking. We evaluated long-term benefits and harms of an IDD
prevention program for the German population with hypothetical moderate ID, as an example for
a European country.
Method: We developed a decision-analytic state-transition Markov cohort model simulating the
incidence and consequences of IDDs in the absence or presence of an IDD prevention program
(iodine fortification of salt) in an open population cohort with moderate ID using demographic
characteristics of Germany allowing the simulation of new children born into the cohort. Model
parameters were derived from literature reviews, experts’ estimations and model calibration. Our
primary net-benefit outcome was gains in quality-adjusted life years (QALYs) predicted over a
time horizon of 120 years. Additionally, we calculated cumulative disease events over time and
incremental life years. We conducted multiple deterministic one-way sensitivity analyses to
evaluate the influence of uncertainty. We evaluated face validity, internal validity and external
validity of the model.
Result: In the base-case analysis, the IDD prevention program is more beneficial than no
prevention, both in terms of QALYs and life years. Health gains predicted over a time horizon of
120 years for the open cohort consisting of the current German population of 82.2 million and
their descendants are 33.3 million QALYs or 5 million life years, respectively. Additionally,
almost 30 million cases of goiter/thyroid nodules, 1.8 million cases of intellectual disability and
50,000 cases of miscarriage/stillbirth were cumulatively avoided in the base-case analysis.
Nevertheless, prevention is not beneficial for all individuals since it can cause hyperthyroidism
(2.7 million additional cases). Results for QALY gains were robust in sensitivity analyses.
Conclusion: Based on our decision analysis, IDD prevention with iodine fortification of salt is
beneficial. It increases quality-adjusted life expectancy and avoids cases of IDDs in a European
population with moderate ID. However, our study also suggests that IDD prevention may cause
adverse health outcomes, such as a higher incidence of hyperthyroidism. Further research should
include costs for prevention and savings from reduced therapies of IDDs and evaluate cost
effectiveness of IDD prevention.
PS 4-8 DUAL ANTI-PLATELET THERAPY AFTER CORONARY STENTING IN
PATIENTS WITH ACUTE CORONARY SYNDROME (ACS): COSTS AND BENEFITS
OF SELECTING THERAPY DURATION BY INDIVIDUAL BLEEDING RISK
Applied Health Economics (AHE)
Natalia Olchanski, MS, David van Klaveren, PhD, Joshua T. Cohen, PhD and David M Kent,
MD, MS, Tufts Medical Center, Boston, MA
Purpose: While dual antiplatelet therapy (DAPT) reduces the risk of ischemic events and stent
thrombosis after a stent implantation in acute coronary syndrome (ACS) patients, it increases the
risk of bleeding events. Clinical guidelines recommend 12 months of DAPT but state that
depending on bleeding risk, either reducing therapy duration to 6 months, or extending it beyond
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12 months may be reasonable. This study evaluates the cost-effectiveness of DAPT to compare
therapy durations across patients with varying bleeding risk.
Methods: We developed a decision-analytic model to examine the costs and health outcomes, in
terms of quality-adjusted life years (QALYs), for three DAPT durations in ACS patients after
stenting procedure: 12, 24, and 6 months. We stratified patients using the precise-DAPT bleeding
risk score, and examined each strategy by bleeding risk quartile. We compare the net monetary
benefit (NMB) of selecting DAPT duration at the bleeding risk quartile level, where QALYs
were valued $100,000. We based model assumptions on published estimates for contemporary
PCI and stenting practices in the ACS patient population, and DAPT therapy with ticagrelor and
aspirin per current ESC and ACC clinical guidelines.
Results: Extending DAPT duration to 24 months increased total costs of care by $3,700-4,200
and provided a gain of 0-0.01 QALYs across all bleeding risk quartiles. In contrast, reducing
DAPT duration to 6 months lowered total care costs, but also worsened health outcomes in very
low to moderate bleeding risk patients by 0.01-0.03 QALYs. For the high bleeding risk patients,
there was no loss of QALYs. NMB are negative for extending DAPT for all and for shortening
DAPT in the two middle quartiles. Shortening DAPT has positive NMB in the very lowest and
highest risk patients (Figure).
Conclusions: Given the relatively high cost of ticagrelor in the US, and the balance of risks of
ischemic and bleeding events over time, the benefits of prolonging DAPT therapy over the
standard recommendation of 12 months may not be worth the costs. Using a predictive score for
bleeding risk to identify patients at high bleeding risk and shortening their DAPT duration does
not appear to worsen health outcomes and saves costs. For those patients at lowest risk,
shortening therapy may lower health care expenditures with a relatively minor impact on health
outcomes.
Figure:
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PS 4-10 COST-EFFECTIVENESS ANALYSIS OF PRE-ART DRUG RESISTANCE
TESTING FOR HIV-INFECTED CHILDREN IN KENYA
Applied Health Economics (AHE)
Mutita Siriruchatanon, MS1, Shan Liu, PhD1 and Horacio Duarte, MD, MS2, (1)University of
Washington, Seattle, WA, (2)University of Washington/Seattle Childrenʼs Research Institute,
Seattle, WA
Purpose: Due to the high prevalence of efavirenz-associated pretreatment drug resistance (PDR)
among HIV-infected children in resource-limited settings, use of efavirenz-based antiretroviral
therapy (ART) as the empiric initial treatment regimen contributes to high rates of virologic
failure (VF). We evaluated the cost-effectiveness of three care strategies for PDR testing in HIVinfected children initiating ART at ≥ 3 years old in Kenya.
Method: We developed a microsimulation model of disease progression and treatment in HIVinfected children in Kenya. Parameters related to CD4+ cells, mortality, clinical events, and ART
were calibrated against the survival curve of East African pre-ART HIV-infected children,
quartiles of CD4 percentage and cell count at age 5 years, and mortality rate of children
receiving ART. We simulated three care strategies for PDR testing among children ≥ 3 years old:
1) no testing (NT); 2) testing with oligonucleotide ligation assay (OLA), a low-cost point-of-care
test; and 3) testing with consensus sequencing (CS). We assumed the cost of OLA and CS were
$30 and $130, respectively, per test. This model was used to evaluate the health outcomes, costs,
and cost-effectiveness of these strategies over a 10-year time horizon. Health outcomes included
life years (LYs) and rates of opportunistic infections and viral suppression.
Result: The OLA strategy provided an additional 41 LYs at an additional cost of $176,867 per
1,000 population (an incremental cost-effectiveness ratio (ICER) of $4,352/LY gained),
compared to NT. CS provided an additional 13 LYs at an additional cost of $123,007 per 1,000
population (an ICER of $9,369/LY gained), compared to OLA. Rates of viral suppression among
NT, OLA and CS strategies were 80%, 83%, and 84%, respectively. In one-way sensitivity
analyses, cost of protease inhibitor (PI)-based ART was an important factor in the costeffectiveness of OLA. Increasing cost of PI-based ART and OLA test increased the ICER
associated with OLA, compared to NT, whereas, increasing OLA sensitivity and probability of
VF with PDR on efavirenz-based ART decreased the ICER values.
Conclusion: PDR testing with OLA is a potentially cost-effective strategy in resource-limited
settings.
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Figure 1: One-Way Sensitivity Analysis of Key Model Parameters
The horizontal bars represent the range of ICER values (OLA compared to NT) from the
tested parameters. The vertical bar represents the $4,352/LY base-case analysis ICER.

PS 4-11 THE FACE OF DIFFICULT DECISIONS: HOW CONTEXTUAL
CONSIDERATIONS AND OTHER BENEFITS ARE VIEWED IN HEALTH
TECHNOLOGY ASSESSMENT RECOMMENDATIONS IN THE USA.
Applied Health Economics (AHE)
Logan Trenaman, PhD, MSc, Division of Health Policy and Management, Department of
Public Health Sciences, University of California, Davis, Davis, CA and Jeffrey S. Hoch, PhD,
Division of Health Policy and Management, Department of Public Health Sciences, University of
California - Davis, Sacramento, CA
Purpose:
The Institute for Clinical and Economic Review (ICER) is a US, independent, non-profit,
organization which evaluates the value of drugs and other health care interventions. ICER
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convenes a council to vote on whether the intervention represents low, intermediate, or high
value, while considering: 1) comparative clinical effectiveness, 2) incremental cost-effectiveness,
3) other benefits or disadvantages, and 4) contextual considerations. This study reviewed ICER
assessments in relation to these factors to understand how they impact the value vote.
Methods:
ICER assessments published between December 2014 and April 2019 were reviewed. Data on
the assessment (e.g., date), intervention, results from incremental cost-effectiveness analyses,
and votes were extracted. Results were presented using bar charts, radar plots, and Chernoff
faces where appropriate. Two case studies (tisagenlecleucel and voretigene neparvovec) were
used to explore more deeply the relationship between different aspects of value and the vote.
Results:
31 ICER assessments were included in the review. There were 49 votes on value and 20 unique
votes on other benefits or disadvantages and contextual considerations. On average, interventions
with lower incremental cost-effectiveness ratios received a higher proportion of ‘high’ and
‘intermediate’ value votes; however, there was heterogeneity between individual assessments
(Figure 1). Of other benefits and disadvantages, reducing caregiver burden (n=159) received the
most votes (n=157) while reducing health disparities had the fewest votes (n=38). Of contextual
considerations, targeting a condition that had a severe impact on quality / length of life received
the most votes (n=197). Radar plots and Chernoff faces for interventions permitted comparisons
and demonstrated heterogeneity in the voting profiles of interventions. Two case studies
highlighted that other benefits and contextual factors can lead to either a lower (tisagenlecleucel)
or higher (voretigene neparvovec) assessment of value than suggested by cost-effectiveness
alone.
Conclusions:
While cost-effectiveness plays a key role in the value vote, other factors do appear to have an
impact. Votes on other benefits and contextual considerations highlight that few interventions
evaluated by ICER have the potential to reduce health disparities, and most target a condition for
which there is already and effective treatment. Several limitations need to be considered,
including that our findings are not causative in nature, and that data were from publically
available information and may not capture everything that discussed during the ICER
deliberation.
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PS 4-12 GOAL CONCORDANT PATIENT-CLINICIAN DYADS HAVE HIGHER ODDS
OF COMMUNICATION AROUND RHEUMATOID ARTHRITIS TREATMENT
GOALS
Decision Psychology and Shared Decision Making (DEC)
Diego Molina Ochoa, BS1, Rachel Matsumoto, MA2, Ginnifer Mastarone, PhD2, Danielle
ZuZero3, Edward Yelin, PhD4 and Jennifer L. Barton, MD5, (1)OHSU, Portland, OR, (2)VA
Portland Health Care System, Portland, OR, (3)Portland State University, Portland, OR,
(4)UCSF, San Francisco, CA, (5)Oregon Health & Science University, Portland, OR
Purpose:
Goal concordance (or agreement) between patients with chronic diseases and their clinicians is
linked to improved outcomes, however, less is known about goal communication in rheumatoid
arthritis (RA). Our objective was to explore the relationship between patient-clinician goal
concordance and actual goals discussed in clinic visits.
Method:
Patients with RA seen at one of two rheumatology clinics were enrolled in a cross-sectional
survey study. Prior to the visit, enrolled patients and their clinicians independently ranked their
top 3 goals for RA treatment. After the visit, patients completed a survey that included a question
regarding whether any of their goals were discussed during the clinic visit. Concordance was
defined as the patientʼs #1 goal being among any of the top 3 listed by the clinician. The survey
included measure of health literacy, RA medications, function, and demographics. Goal
concordance and number of goals discussed were analyzed using both descriptive statistics and
statistical analysis using an odds ratio, in which we compared goals discussed (none vs. one or
more) between concordant and non-concordant patient-clinician dyads.
Result:
Out of a total of 207 patient-clinician dyads including 15 clinicians, 178 dyads completed all
goal communication portions of the surveys. Of the patients, 58% were female, 16% Spanish
speaking, and 29% with limited health literacy. 141 dyads (79%) were goal concordant. Among
goal concordant dyads, 33% did not discuss any patient goals during the visit, while 19%
discussed 1 goal, 27% discussed 2 goals, and 21% discussed 3 goals. 57% of goal discordant
dyads did not discuss any goals, compared with 19% who discussed one goal, 16% discussed 2
goals, and 8% discussed 3 goals. Patient-clinician dyads with goal concordance had 2.63 higher
odds of discussing patient goals compared with goal discordant patient-clinician dyads
(p=0.009).
Conclusion:
Goal concordant dyads were more likely to discuss patient goals during the clinic visit compared
with discordant dyads. Future studies should examine the impact of these goal discussions and
outcomes and develop tools to promote patient-clinician communication.
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PS 4-13 CHARACTERIZING COMMUNICATION AND SHARED DECISION MAKING
DURING CARDIOVASCULAR SPECIALIST CLINIC VISITS
Decision Psychology and Shared Decision Making (DEC)
Tiffany Bellomo, B.S.1, Linda Batrow, B.A.1, Ashley Duby, M.S.1, Sandra AlAziz1 and
Matthew Corriere, MD, MS2, (1)University of Michigan, Ann Arbor, MI, (2)University of
MIchigan, Ann Arbor, MI
Purpose: Multiple instruments for assessment of shared decision-making (SDM) are available,
and many were developed and characterized in primary care environments. Patient-provider
communication during SDM in specialist clinics may differ in terms of scope, types of decisions,
and relative contributions from the clinician versus patients and family members. We conducted
a convergent parallel mixed methods study to characterize patient-clinician communication and
SDM during cardiovascular specialist clinic visits for symptomatic peripheral artery disease
(PAD), a chronic condition that affects 8.5 million Americans.
Method: Patient participants were recruited from outpatient cardiovascular center clinics at an
academic teaching hospital. Inclusion criteria were clinical diagnosis of symptomatic PAD
confirmed by physiologic testing and age>21. Visit audio recording from the time the patient
was roomed to when the clinician departed was performed using a recording device in plain
view. Audio transcripts of encounters were analyzed using qualitative methods with the
following a priori coding themes: relative contributions from patient, clinician, and family
members to total content; frequency and types of questions; interruptions; and shared decision
making based on components of the SDM-Q-9 and OPTION5 instruments. Survey data collected
included the Patient Activation Measure and the PROMIS Self-Efficacy for Managing
Symptoms. Clinical data and demographic data from both patients and clinicians were also
collected.
Result: 24 unique patients (mean age 67.7 ± 10.9, 10 women, 21 white) and 17 clinicians (all
white, 6 women) participated. Mean duration was 26.7±6.9 minutes. Clinicians accounted for
44% of discussion, followed by 39% from patients, 16% from patient family members (usually
spouses), and <1% from nurses and assistants. Patients were interrupted while speaking
18.0±12.5 times per visit. Comments and questions related to SDM accounted for <5% of overall
discussion content. Discussion of follow up was the most common dimension of SDM discussion
(42%), followed by discussion of alternative treatment options (17%), negotiation (17%),
preference elicitation (13%), and stated preferences (3%). SDM that were absent or rarely
identified included explicit disclosure of the need for a decision, partnership formulation, and
justification of team deliberation.
Conclusion: Elements of SDM were identified during most cardiovascular specialist clinic
visits, but accounted for a relatively small part of overall discussion. Observation-based
assessments may be useful for tailored training and feedback interventions to support SDM.
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PS 4-14 PATHWAYS: A FERTILITY PRESERVATION PATIENT DECISION AID
WEBSITE FOR WOMEN WITH CANCER – EFFECTIVENESS AND FEASIBILITY OF
DISSEMINATION TO NEWLY-DIAGNOSED WOMEN IN COMMUNITY CANCER
CENTERS.
Decision Psychology and Shared Decision Making (DEC)
Aubri S. Hoffman, PhD1, June Weston1, Sukhkamal Campbell, MD2, Laura Crocker1, Deborah
Holman, MSN, WHNP-BC1, Ashley J. Housten, OTD, MSCI1, Robert J. Volk, PhD1 and Terri L.
Woodard, MD2, (1)The University of Texas MD Anderson Cancer Center, Houston, TX,
(2)Baylor College of Medicine, Houston, TX
Purpose: As few as 12.2% of eligible women receive fertility preservation counseling prior to
starting cancer treatments and long-term regret and distress remain high. Challenges persist in
providing women with understandable information and decision support during the brief,
complex time between diagnosis and treatment. This study sought to test the effectiveness of
Pathways: a fertility preservation patient decision aid website for women with cancer at
improving womenʼs fertility preservation knowledge and decreasing decisional conflict. It also
assessed the feasibility of delivery to newly-diagnosed women in community cancer centers.
Method: The research team and stakeholder panel previously co-designed and pilot-tested the
Pathways website, which provides up-to-date information on fertility preservation methods
tailored to cancer type, as well as interactive features to support comprehension, values
clarification, and deliberation. The research coordinator contacted newly-diagnosed, 18-45 yearold women seen at four community cancer centers, and randomized them to receive Pathways or
a standard educational brochure. Participants completed baseline, 1 week and 2 month
questionnaires assessing their fertility preservation knowledge, decisional conflict, and decisionmaking. Analyses summarized the rates of successful delivery and mean scores at each time
point. Provider interviews assessed dissemination strategies.
Result: Women who viewed Pathways reported improved decisional conflict (22.3 vs. 0.8),
knowledge (70.8% vs. 64.8% correct) and preparation for decision making (96.9 vs. 71.8 out of
100) compared to women who viewed educational brochures. All women reported being
Mostly/Very Satisfied with their decision-making process and would recommend Pathways to
other women with cancer.
At the time of this submission, the study coordinator was able to contact 51 of 110 eligible
women before they started their cancer treatment; 18 women were interested in learning more
about fertility preservation. Reasons for declining included: pressure to start cancer treatment
urgently, feeling done with childbearing/family-building, and perceived lack of time/resources.
Providers (n = 15) recommended offering access to the Pathways website prior to the
consultation and using nurse navigators to facilitate referrals.
Conclusion: The Pathways decision aid may improve womenʼs fertility preservation knowledge
and decision-making process. Pathways was well-received; however, dissemination was lower in
community clinics than in a comprehensive cancer center and may reflect both system barriers
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and patient preferences. Early, systematic dissemination may be needed to ensure equitable
access.
PS 4-15 IMPACT OF BLOOD PRESSURE VISUALIZATION TOOL USE ON
HYPERTENSION MEDICAL DECISION MAKING
Decision Psychology and Shared Decision Making (DEC)
Tamar Wyte-Lake, DPT, MPH1, Jennifer D. Hall, MPH1, Richelle J. Koopman, MD MS2,
Shannon M. Canfield, MPH2 and Deborah J. Cohen, PhD1, (1)Oregon Health & Science
University, Portland, OR, (2)University of Missouri, Columbia, MO
Purpose: Little is known about how to optimize medical decision making when managing
patients with hypertension. We developed and implemented a tool that combines clinical and
home blood pressure (BP) readings into an EHR-embedded visualization tool. We examine how
this tool was used during primary care visits and its effect on doctor-patient communication and
hypertension management decision-making.
Method: We video recorded 89 hypertensive patient follow-up encounters with 15 physicians
between July 2018-April 2019. Encounters included recordings of home BP on paper compared
to incorporation of home BP into the EHR tool. Conversation analysis was used to analyze the
recordings.
Result: All patients recorded home BPs, 26 provided readings on paper and 56 patients had
home BPs incorporated into the visualization tool. Recording and monitoring at-home BPs
influenced patients’ awareness of their BP. Patients came to the visit with an understanding of
their BP and reflected on the fluctuations. Recording home BPs, and then seeing those readings
alongside the clinical BP readings in the visualization tool, expanded the way patients were
engaged in hypertension management decision-making. Interactions unfolded as follows. First,
physicians created a shared conversation by viewing the computer monitor with patients. Second,
physicians discussed how readings within and outside the shaded goal range were displayed.
Discussion of optimal goal ranges was particularly impactful for patients unaware of BP
guidelines. Third, the physician and patient used the tool to compare practice BP readings to
home BPs and jointly constructed an understanding of these readings overtime. For instance,
when the graph line trended above the guidelines, the physician could easily highlight the
discrepancy to the patient, prompting a BP medication adjustment discussion; when the graph
line was generally within range, the physician might interpret a few high readings as “nothing to
worry about,” and conclude treatment adjustment wasn’t needed; and evidence of low home BP
readings prompted discussion about low BP symptoms (e.g., dizziness), possibly leading to
discussion and decision to reduce medication.
Conclusion: Taking home BP prepares patients to come into their doctorʼs visit aware of and
ready to discuss their BP. Introduction of an easy to read BP visualization tool incorporating
home and clinical BPs overtime can support patient education and a more dynamic and shared
decision making and treatment process.
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PS 4-16 THE EFFECT OF SPIRITUAL, MORAL, AND EXISTENTIAL BELIEFS ON
PREFERENCES FOR END-OF-LIFE CARE
Decision Psychology and Shared Decision Making (DEC)
Aaron M. Scherer, PhD, University of Iowa, Iowa City, IA and Victoria Shaffer, PhD,
University of Missouri, Columbia, MO
Purpose: Many Americans are unable to achieve their ideal death—which for most consists of
controlling symptoms and being surrounded by their family, often in their own home. The
majority of patients in the US spend their final days in an acute care setting or in a nursing home,
and many people receive aggressive medical treatment in the weeks preceding—or even the day
of—their death. There is an urgent need to better understand preferences for end-of-life care.
Therefore, this study was designed to examine the associations between religious, spiritual, or
moral beliefs, existential concerns about death and suffering, and preferences for end-of-life
care.
Method: Participants (N=251 older adults; age 60-90) completed a web survey measuring
preferences for treatment decisions at the end of life (adapted from Bookwala et al., 2001), the
Advance Care Planning Values/Beliefs Scale, a Sanctity of Life Scale, Views of Suffering Scale,
Moral Absolutism and Exporting Scale, Multidimensional Fear of Death Scale, Duke Religiosity
Index, and additional demographic variables. Treatment preferences were assessed for 7 different
health states: current health, Alzheimerʼs disease, COPD, moderate stroke, severe stroke, colon
cancer without pain, and colon cancer with pain. Primary outcomes for each health state were
preferences associated with: 1) the use of antibiotics to treat pneumonia; 2) the use of CPR; 3)
surgical removal of gallbladder; and 4) the use of artificial feeding and fluids. We tested two
hypotheses: Greater reported religiosity and stronger moral beliefs (H1) and greater existential
concern about death and suffering (H2) will be associated with preferences for more invasive
care at the end of life.
Result: We found little support for H1. Neither the Duke Religiosity Index nor self-reported
measures of spirituality were associated with preferences for end-of-life care, P >.05. However,
the Moral Exporting subscale was a significant predictor of preference for care in all seven
health states, P <.05. Further, both the Sanctity of Life scale and the Fear of Death scale
significantly predicted preferences for end-of-life care in all health states (P <.05), providing
support for H2.
Conclusion: Greater preferences for more invasive end-of-life were associated with greater
amounts of “moral evangelism”, fear/anxiety associated with death/dying, and beliefs that all
possible medical interventions should be applied to extend life for all people.
PS 4-17 DOES GENDER TARGETING MATTER? ASSESSING THE EFFECTIVENESS
OF SPORTS TEAM METAPHORS IN A SLEEP APNEA DECISION AID
Decision Psychology and Shared Decision Making (DEC)
John Friend, PhD, University of Hawai'i at Manoa, Honolulu, HI, Logan Trenaman, PhD, MSc,
Division of Health Policy and Management, Department of Public Health Sciences, University of
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California, Davis, Davis, CA and Dana (Dane) L. Alden, PhD, University of Hawaii at Manoa,
Honolulu, HI
Purpose: Healthcare providers use decision aids (DAs) to facilitate shared decision making.
However, research shows that low interdependent men are less likely to feel prepared following
review of a generic DA. Since men place greater importance on group membership, gender
targeted decision support tools that include sports team metaphors may be more effective. To
better understand how gender-specific attitudinal factors affect the DA experience, this study
tests the impact of a generic versus gender targeted DA for sleep apnea.
Method: An online panel sample of 320 U.S. men (ages 45-66; 83% white; lower and middle
class) who have not been diagnosed with sleep apnea were randomly assigned to a generic or
targeted DA. Using the scenario method, participants imagined they have been recently
diagnosed with sleep apnea and are meeting their doctor to discuss treatment options. In
preparation, they reviewed an online sleep apnea DA and answered questions that measured
relevant outcomes. The targeted DA emphasized the collective self and relationships with groups
through the use of sports team metaphors (see figure). A one-way MANOVA with covariate
controls met all diagnostic criteria and tested the effects of gender targeting on decision
preparedness, confidence, and empowerment.
Result: The manipulation check indicated awareness of the team metaphor in the targeted group.
A majority (88%) of participants were “somewhat familiar” or “very familiar” with sleep apnea.
Participants who experienced the targeted DA reported higher levels of preparedness ( generic =
3.48/ targeted = 3.82; p ≤ .001), confidence ( generic = 7.08/ targeted = 7.41; p ≤ .037), and
empowerment ( generic = 3.75/ targeted = 3.97; p ≤ .002). Univariate analysis of these outcomes
found that the DA treatment main effect was the strongest on preparedness (η2 = .035).
Conclusion: Sleep apnea is a common sleep disorder prevalent among older men. Despite the
adverse health outcomes associated with the condition, men are more reluctant to seek care.
Therefore, the effects of gender on medical decision making need to be fully understood by
providers to improve patient engagement and increase utilization of health services. This study
demonstrates that a gender targeted DA better prepares U.S. men for a medical consultation than
a generic version. Results also suggest that sports team metaphors can be used to empower men
within the DA context.
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PS 4-18 THE DEVELOPMENT OF ELECTRONIC BRIEF ACTION PLANNING (EBAP): A SELF-MANAGEMENT SUPPORT TOOL FOR HEALTH BEHAVIOR
CHANGE
Decision
Psychology
and
Shared
Decision
Making
(DEC)
Jannat Tumpa, B.Sc, Department of Mathematics, Statistics and Computer Science, Marquette
University, Milwaukee, WI, Sheikh Ahamed, PhD, Department of Mathematics, Statistics and
Computer Science, Milwaukee, WI, Steven Cole, MD, Stony Brook University School of
Medicine and Clinical Professor of Scientific Education, Donald and Barbara Zucker School of
Medicine at Hofstra/Northwell, Stony Brook, NY and Daniel Pinto, PT, PhD, Marquette
University, Milwaukee, WI
Purpose: To create a software infrastructure for the conduct of Brief Action Planning, a
pragmatic, evidence-based, stepped-care self-management support tool.

Method: Electronic Brief Action Planning (E-BAP) uses principles of motivational interviewing
to facilitate the creation of action plans for health behaviors. We used the Django web
framework with Python 3 using a modular pattern to maintain the fidelity of the BAP process. EBAP uses eight evidence-based competencies, and prompts facilitators in recommended
language to best help patients set and achieve action plans that are SMART (Specific,
Measurable, Achievable, Relevant and Time-bound). E-BAP was created to mimic clinical care
in which users are invited to establish a plan, assess confidence in the plan, modify a plan at any
timepoint, and establish an opportunity for follow-up in which the plan will be reviewed and
revised if necessary. As a form of motivational interviewing, BAP emphasizes patient autonomy
in decision-making and E-BAP contains programming loops (see figure) for iterative plan
modification. E-BAP supports English and Spanish languages.
Result: We present the E-BAP software infrastructure as a means to enable quality improvement
efforts and create an infrastructure for both clinical care and clinical research. We present a
clinical test-use case of a previously ‘non-adherent’ patient using a traditional approach to
exercise program construction within the context of physical therapy management. Upon seeing
that the patient was not engaging in the exercise program that was created for her using a
traditional clinical paradigm, the patient was invited to utilize E-BAP to create a goal for her
health. The patient successfully completed two patient-centered action plans for physical activity
using E-BAP, a walking program and a stair climbing program. Over the course of a month
follow-up the patient modified one plan to make it more achievable and consistently successfully
achieved both self-generated physical activity plans. All plans and revisions are maintained in a
hierarchical data infrastructure for data analysis.
Conclusion: E-BAP transforms a paper-based, self-management support tool into a highly
structured and logical digital format that enables quality improvement efforts as well as
quantitative and qualitative research into the process and outcomes of care. Future work will
establish integration with provider workflow and measures of feasibility.

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E217

PS 4-19 PATIENT SEGMENTATION FRAMEWORK FOR EFFECTIVE CLINICAL
OUTREACH USING HIGH DIMENSIONAL HEALTHCARE DATA
Decision Psychology and Shared Decision Making (DEC)
Sheetal Saini, PhD, Sravya Etlapur, Jennifer Megibben, Aaron Schaffer and Erika Pabo,
Humana Inc., Louisville, KY
Purpose:
It is well documented that a small proportion of healthcare population accounts for a large
proportion of healthcare cost. The findings from the Agency for Healthcare Research and
Qualityʼs 2012 Medical Expenditure Panel Survey states that the top 5 percent of the population
ranked by their healthcare expenses accounted for 50 percent of total healthcare expenditure in
US. Overall, the top 50 percent of the population ranked by their expenditures accounted for 97.3
percent of overall healthcare costs. This demonstrates the healthcare population consists of very
diverse groups with different clinical characteristics and needs. Therefore, it is necessary to have
analytic tools to segment the population appropriately. The objective of this work was to create
an analytic framework to enable effective clinical outreach to achieve the best population health.
Methods:
The segmentation framework was built using data from individuals in a large national health plan
with Medicare Advantage coverage. Analysis was limited to MA members residing in two
markets enrolled at any point in time between July 1st, 2017 to June 30th, 2018. Firstly, a data
mart was built using patient characteristics from historical medical claims, pharmacy claims,
demographics, social determinants of health and other data sources. Secondly, factor analysis
was performed for feature reduction and correlation analysis was performed to further remove
correlated features. Next, clustering analysis was performed by using k-mean and hierarchical
clustering techniques. Finally, clustering evaluation measures such as sum of squared error,
cubic clustering criterion were used to estimate the number of clusters.
Result:
Clustering evaluation was performed to select the final set of clusters for the 147,956 patients.
We selected 5 segments as the best segments after testing for different numbers of clusters. The
first segment was assigned a label of ‘Very Unhealthy, High Risk’ (5%), the second segment was
assigned a label of ‘Unhealthy, Mostly Disabled’ (14%); the third segment was assigned a label
of ‘Moderate Unhealthy’ (22%). The fourth and fifth segments were assigned labels of ‘Healthy,
Low Socioeconomic Status’ and ‘Healthy, High Socioeconomic Status’, respectively, and these
segments included 30% and 29% of the overall population.
Conclusion:
This segmentation framework can handle high dimensional healthcare data. The output can be
used to plan effective outreach for patients, as per the key characteristics of their respective
segment.
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Figure 1. Segmentation Framework
PS 4-20 USING NARRATIVES TO DEBIAS FORECASTING ERRORS IN PEDIATRIC
TRACHEOSTOMY DECISION MAKING
Decision Psychology and Shared Decision Making (DEC)
Haoyang Yan, MS1, Patricia Deldin, PhD1, Stephanie Kukora, MD2, Kenneth Pituch, MD2,
Cynthia Arslanian-Engoren, PhD, RN1 and Brian J. Zikmund-Fisher, PhD1, (1)University of
Michigan, Ann Arbor, MI, (2)C.S. Mott Childrenʼs Hospital, Ann Arbor, MI
Purpose: Parents are sometimes faced with value-laden tracheostomy decisions, choosing
between accepting a machine-dependent life for their child or allowing death. Parents unfamiliar
with these high-stakes decisions may lack past experience and understanding of long-term
implications in order to accurately forecast possible outcomes. Overemphasis on survival and
immediate outcomes and underestimation of challenges affecting the childʼs/familyʼs long-term
quality of life (QOL) could lead to decision dissatisfaction or regret. We primarily aimed to
examine whether and how parents’ narratives of childʼs long-term quality of life and home care
challenges influence parental tracheostomy decisions.
Method: We recruited U.S. adults through Amazon Mechanical Turk who self-reported having a
child age <6 years or planning to get pregnant with spouse within the next 5 years. Participants
read a vignette that asked them to imagine participating in a physician-parent meeting about
placing a tracheostomy for their hypothetical newborn baby, who was unable to breathe without
support due to brain injury. Participants were randomized to one of the 4 conditions: 1) No
narrative information; 2) Baby QOL narratives: 2 narratives discussing childrenʼs long-term
quality of life; 3) Family QOL narratives: 2 narratives of home life challenges; 3) Baby QOL +
Family QOL: all 4 narratives. Participants decided whether or not to place a tracheostomy for the
child, forecasted potential outcomes about the babyʼs and familyʼs QOL, reported decisional
conflict and beliefs about pediatric life support decision making, and completed individual
differences scales (i.e., Medical Maximizer-Minimizer, End-of-Life Value, Consideration of
Future Consequences, Optimism), and demographics questions.
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Result: Rates of tracheostomy choice were significantly lower in the experimental conditions
(22% in Baby QOL, 38% in Family QOL, and 24% in Baby QOL + Family QOL conditions
versus 47% in No Narratives group) (N=1966). Higher ratings of future concerns, especially
concern for babyʼs QOL, predicted lower odds of choosing tracheostomy. Moreover, medical
maximizers, women, and those who value length of life tended to choose tracheostomy.
Conclusion: Our research demonstrates that narratives clarifying long-term implications of
pursuing tracheostomy have the potential to influence forecasting and decisions. Providing
narratives from other parents could be a feasible way to support parents to make informed
decisions. This type of narrative-based intervention strategy may be valuable in other situations
where forecasting errors are common.
PS 4-21 WHAT FACTORS IMPACT LUNG CANCER PATIENTS’ ROLE IN MAKING
TREATMENT DECISIONS: RESULTS FROM A NATIONAL SURVEY
Decision Psychology and Shared Decision Making (DEC)
Sarah Janse, PhD1, Upal Basu Roy, PhD, MPH2, John F P Bridges, PhD3, Andrea Ferris, MBA2
and Ellen Janssen, PhD4, (1)Ohio State University College of Medicine, Columbus, OH,
(2)LUNGevity Foundation, Bethesda, MD, (3)The Ohio State University College of Medicine,
Columbus, OH, (4)Center for Medical Technology Policy (CMTP), Baltimore, MD
Purpose: Understanding patient experiences with lung cancer can guide research, treatment, and
healthcare decisions. As part of a larger study (Project Transform) that aimed to quantify patient
experiences, we explored the decision-making style of lung cancer patients and their caregivers
and to determine what demographic and clinical factors impact these styles.
Method: Decision-making strategies were identified from patient interviews and the existing literature.
A survey incorporating preference questions on decision-making style was fielded to participants
recruited through LUNGevity Foundation. The three decision-making styles include: patient-led (you
made the decision either with little or no input from your doctors or after considering your doctors’
opinions), shared (you and your doctors made the decision together), and doctor-led (your doctors made
the decision after considering your opinion or with little or no input from you). Differences in the
strategies across demographic and clinical indicators were identified through the use of exact Chi-square
tests for categorical variables and one-way ANOVA for continuous variables.
Result: Responses were collected from 606 patients with an average age of 58.5 years, 72.4% were
female, 62% earned less than $75,000 per year, 9.6% had the equivalent of a high school degree or less,
4.1% were unemployed, and 67.6% were married or in a domestic partnership. The majority of patients
engaged in a shared decision-making strategy (57.3%), while patients were more likely to engage in
patient-led decision-making if they were younger (p = 0.014), Hispanic (p = 0.018), or had participated
in a clinical trial (p = 0.002). Patients were more likely to participate in shared decision-making role if
they were married (p < 0.001), more educated (p = 0.018), or had non-small cell lung cancer (p = 0.011).
Unemployed respondents were more likely to adopt a doctor-led decision-making strategy (p = 0.030).
Conclusion: Patients engage in different decision-making strategies when choosing lung cancer
treatments. These strategies vary across a confluence of demographic, subtype of lung cancer, and
treatment (availability of multiple treatment options as against a single one) factors. Specifically,
decision-making style was associated with age, ethnicity, marital status, education level, employment
status, LC type, and previous participation in a clinical trial. As healthcare delivery becomes more
patient-centered, greater attention to individual decision-making style will be needed.
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PS 4-22 A LINGUISTIC EXAMINATION OF INFORMATION FRAMING IN
PHYSICIAN-PATIENT CONVERSATIONS
Decision Psychology and Shared Decision Making (DEC)
Ilona Fridman, PhD1, Angela Fagerlin, PhD2, Karen Scherr, MD, PhD1, Laura Scherer, PhD3,
Dana Kanze, PhD4, Hanna Huffstetler5 and Peter A. Ubel, MD1, (1)Duke University, Durham,
NC, (2)University of Utah / Salt Lake City VA, Salt Lake City, UT, (3)University of Colorado,
Denver, CO, (4)London Business School, London, NY, United Kingdom, (5)Durham, NC
Purpose: When discussing risks and benefits with cancer patients, physicians could focus on
losses such as mortality rates and recurrence or, alternatively, gains such as survival rates and
curing cancer. Previous research has shown that the way health information is framed influences
individuals’ preferences and choices 1. We developed dictionaries for automated text analysis
and ran exploratory analysis investigating whether and when framing manifests in actual
physician-patient conversations and how often only one (gain) or another (loss) frame dominates
the conversation.
Methods: We analyzed transcribed consultations with patients who had low- or intermediaterisk prostate cancer. Using Linguistic Inquiry and Word Count (LIWC) software, we calculated
the number of words describing gains or losses. We ran a regression analysis exploring framing
in the communications.
Results: Our analysis revealed that on average, physicians use more words related to gains than
losses. Furthermore, we found that the frame of the conversation shifts depending on the type of
recommendation the physician offered during the consultation. Physicians who recommended
immediate active treatment for prostate cancer (versus active surveillance) used marginally fewer
loss words and significantly fewer words related to death. Exploratory analyses showed that
words associated with losses and death were correlated with patient choice of active treatment
(versus active surveillance).
Conclusion: The frequency of loss words in physicians’ explanations was correlated with
physicians’ recommendations and patients choices. We discuss theoretical implications and
suggest directions for further research.
PS 4-23 AN INTERACTIVE PATIENT DECISION AID IMPROVED DECISION
CONFLICT FOR WOMEN WITH MINIMALLY SUSPICIOUS BREAST IMAGING.
Decision Psychology and Shared Decision Making (DEC)
Lynn Dengel, MD, MSc, University of Virginia School of Medicine, Charlottesville, VA,
Jonathan Yoder, MSN, U.Va. School of Nursing, Charlottesville, VA and Crystal Chu, BSN,
PhD(c), University of Virginia School of Nursing, Charlottesville, VA
Purpose: To conduct a pilot study to assess the feasibility, acceptability and impact on patient
decision conflict of an interactive patient decision aid (PDA) for women presenting to a
community breast specialty clinic with minimally suspicious breast imaging.
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Methods: This study examines the feasibility, patient impact, physician review, and biopsy rate
while testing a theory-based, interactive PDA for women with minimally suspicious breast
imaging deciding between biopsy or close follow-up imaging. The study was conducted in a
private practice breast specialty clinic. Participant demographics, clinical characteristics,
Decision Making Quality Scale score (DMQS), Decisional Conflict Scale score (DCS), and
feedback regarding use of the PDA were collected. Breast specialist physicians reported
perceptions of PDA utility and implementation.
Results: 37 participants were enrolled (median age 53; median years education 16). 23/30
participants presented with BIRADs 4a imaging, 7/30 with BIRADs 4. Following utilization of
the PDA, the management recommendation was changed in 15/30 cases, 13 from observation or
neutral to recommending biopsy. Biopsy was performed at initial consultation in 19/30 cases.
Comparison of DCS scores pre-intervention (Mean = 7.5, Range = 0-30) and post-intervention
(Mean = 2.43, Range = 0-20) showed a statistically significant reduction in patient decisional
conflict (P = 0.39, 95% CI 0.41-12.59). Participants and physicians reviewed the PDA favorably
(Table 1).
Conclusions: A PDA for women with a minimally suspicious mammogram impacted provider
recommendations and decrease in patient decision conflict. Physicians and participants find this
a useful tool in informed, shared decision making that was easily integrated into clinical practice.
Table 1: Physician and participant evaluation the PDA

Physician feedback
(N=37):
PDA was helpful
Utilized PDA in
decision making
Easily incorporated
into practice workflow
Participant feedback:
(N=36)
PDA was helpful
Physician utilized
PDA in decision
making
Increased peace of
mind

Strongly
disagree

Disagree

Neutral

Agree

Strongly
agree

0
0

0
0

0
4

25
14

12
19

0

0

0

5

32

0
0

1
0

1
3

24
11

10
22

0

0

2

18

16
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PS 4-24 PERCEIVED VULNERABILITY TO DISEASE – WHAT MODERATES
PARENTS’ OPTIMISM?
Decision Psychology and Shared Decision Making (DEC)
Olivier Drouin, MD MSc MPH, Université de Montréal, Montreal, QC, Canada
Purpose: Determine if parental perception of their childʼs vulnerability to diseases is influenced
by the perceived control parents have in preventing them, and how severe the diseases are.
Method: Using Amazon mTurk, we surveyed 450 parents of children aged 0-18 years old. The
primary outcome was participants’ evaluation of their childʼs vulnerability to 10 diseases
compared to the average, using a 5-point Likert scale (from much less likely to much more likely
than average). Perceived vulnerability was then dichotomized, and participants considered
optimistic if they believed their child was less likely than average to develop each of 10 diseases:
dental caries, obesity, opioid use disorder, pneumonia, autism, leukemia, head lice, food
allergies, appendicitis, and asthma. The two independent variables were 1) the participants’
evaluation of how much control parents have in preventing each disease, on a scale from 0 (no
control at all) to 4 (a lot of control) and 2) participants’ evaluation of the severity of each disease,
on a scale from 0 to 100. Multivariable logistic regression models were created to determine the
relationship between perceived vulnerability and the two independent variables, while adjusting
for socio-demographic characteristics.
Result: Participants had a mean age of 39.5 years (s.d. 10.1); 68% were female and 61% had a
college degree. The mean age of participants’ children were 9.4 (s.d. 5.1) years old, and 49%
were girls. Level of parental optimism ranged from 36% for appendicitis to 82% for opioid use
disorder. Mean perceived control was 1.46 (SD 1.46) (range from 0.49 for leukemia to 3.02 for
obesity), and mean disease severity was 71.1 (SD 26.7) (range from 34.6 for head lice to 92.9 for
leukemia). After adjusting for socio-demographic factors, parents were more optimistic about
diseases they perceived as more controllable (OR 1.43 [95% C.I.: 1.36-1.50]). Parents also
displayed more optimism for diseases they rated as more severe (OR 1.09 [95% C.I.: 1.07-1.12]
for each 10-point increment in severity). Men, parents of older children, and college graduates
were also more likely to display optimism.
Conclusion: Parental optimism was greater for diseases perceived as being more controllable,
and more severe. Designing interventions that address low perceived vulnerability may be
important in addressing important pediatric diseases perceived as controllable and severe, such
as obesity and opioid use disorder.
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PS 4-25 MINDFULNESS AND DECISION MAKING IN THE ICU: A CONCEPTUAL
MODEL BASED ON THE HOT-COLD DECISION TRIANGLE
Decision Psychology and Shared Decision Making (DEC)
Melissa Basile, PhD1, Michael E. Wilson, MD2, Eileen Rubin, JD3, Suzanne Ardito, MA1, Parsa
Tafreshi, DO1, Abdul Khan, MPH1 and Negin Hajizadeh, MD, MPH4, (1)Northwell Health,
Manhasset, NY, (2)Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester,
MN, (3)ARDS Foundation, Northbrook, IL, (4)Hofstra Northwell School of Medicine and
Northwell Health, Manhasset, NY
Purpose: The Hot-Cold Decision Triangle (Yang) envisions decision-making as either hot-state
(driven by visceral reactions, emotions and heuristics triggered by socio-environmental context),
or cold-state, (deliberative, and guided by reasoning (Kahneman and Tversky)). By minimizing
visceral triggers, individuals may move toward more deliberative decision-making (Yang).
Mindfulness-Based Stress Reduction can train individuals to move from reactive/impulsive
decision making to more guided decision making. Signs of burnout syndrome in ICU providers
includes impulsive reactions and dehumanizing behaviors towards patients. We wondered
whether there was evidence that dehumanizing or humanizing behaviors impact ICU decision
making. We developed a conceptual model for ICU deliberative decision-making which
incorporates mindfulness training for ICU clinicians and conducted secondary analysis of data
exploring factors for humanizing and dehumanizing treatment of ICU patients to determine
whether the data supported our model.
Method: Our conceptual model suggests that ICU clinicians experiencing stress and burnout
may react viscerally and engage patients and families in dehumanizing ways. In reaction, this
may trigger visceral, less deliberative decision-making among patients and families. Cliniciandriven mindfulness interventions e.g. guided meditation, may reduce ICU-related burnout, and
minimize visceral triggers, enabling more deliberative and empathic behaviors towards patients
and families. This may facilitate patient and family-level deliberative decision-making. Applying
this conceptual model, we deductively analyzed focus group transcripts from former ICU
patients, family members, and current ICU clinicians discussing personal-level humanizing and
dehumanizing ICU experiences.
Result: We conducted 8 focus groups representing ICU patients, families, and clinical staff.
There were examples of humanizing treatment linked to shared decision-making (“For the
patients, we need to get to know them - what they would or wouldn’t want and their overall goals
in care...I feel like our responsibility is to determine what we should do based on their wishes.”).
Clinicians also discussed mindfulness interventions contributing to deliberative communication
with patients (“We just have a dark space with some soft music playing. Staff can take five
minutes from their day to center themselves, to help with their empathic responses”). Our data
showed no examples of dehumanization triggering visceral, less deliberative decision-making
among patients and families
Conclusion: Data from our focus groups suggests that humanizing behaviors improved shared
decision making. However, further studies are needed to assess whether dehumanizing treatment
results in less deliberative decision-making among patients and families.
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PS 4-26 WHAT ATTRIBUTES OF LUNG CANCER SCREENING DO INFORMED
PATIENTS VALUE AND WHAT RELATION DO THEY HAVE WITH INTENT TO
SCREEN?
Decision Psychology and Shared Decision Making (DEC)
Stephen Clark, MD1, Alison Brenner, PhD2, Michael Pignone, MD, MPH3 and Daniel Reuland,
MD, MPH1, (1)UNC Department of Medicine, Chapel Hill, NC, (2)Cecil G Sheps Center for
Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, (3)UTAustin Dell Medical School, Austin, TX
Purpose: Understanding patient values is critical for high-quality decision-making about lung
cancer screening. Little is known regarding the values screen-eligible individuals (current or
former smokers who quit >15 years ago, aged 55-80, >30 pack-years smoking) place on the
benefits and harms of screening. We assessed the importance of key screening attributes and the
attributes’ relation to participant intent to screen.
Method: We conducted an online survey where, after viewing a decision aid, respondents rated
(1-5 scale, 5=most important) six attributes (reducing: chance of death from lung cancer, risk of
being diagnosed, false positives, biopsies, complications of biopsies, and out-of-pocket costs of
work-up) and ranked their top three attributes (ranked 1-3, 1=highest). Respondents also
indicated their intent to screen (1-4 scale, 1=not likely, 4=very likely). Participants were
recruited through online US survey panels and met USPSTF guideline criteria for screening.
Result: Among 269 eligible respondents who began the survey, 185 (62.5%) completed it.
Respondents were 56.2% female, 80.5% white, 60.5% current smokers, 30.3% high school
degree or less, 62.2% annual income <$50,000, and 73.0% publicly insured. Among attributes,
reducing the chance of death rated highest overall (rating 4.3 ±1.0). Avoiding complications of
biopsies (3.7 ±1.3) and out-of-pocket costs (3.7 ±1.2) rated higher than other harms attributes
(avoiding diagnosis 3.6 ±1.1, biopsies 3.5 ±1.2, and false positives 3.3 ±1.2). Fifty-nine percent
ranked reducing mortality as most important; of the 41% ranking any of the harms most
important, the highest-ranked attribute was heterogeneous (avoiding costs 13.0%, false positives
8.1%, biopsies 7.0%, complications 6.5%, diagnosis 6.5%).
Screening intention varied, with overall mean response 2.6 ±1.1. Ninety (48.6%) indicated a
strong intention (22.2% not likely; 26.5% very likely). Respondents very likely to pursue
screening rated reducing chance of death higher than those not likely (4.9 vs 3.6, diff 1.3, 95%CI
0.9, 1.6, p<0.01) and more frequently ranked this attribute first (66.7% vs 33.3%, p=0.01). Those
not likely to screen more frequently ranked a harm attribute first: (59.5% vs 40.5%, p=0.01).
Conclusion: Overall, a slight majority of respondents valued reducing risk of death from lung
cancer as the most important attribute of the lung cancer screening decision. Those ranking a
harm first were more likely to not desire screening. Providers should elicit patient preferences for
informed decision-making about whether to screen.
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PS 4-27 ESTIMATING THE POPULATION IMPACT OF PUBLIC HEALTH
INTERVENTIONS THROUGH INTERRUPTED TIME-SERIES ANALYSIS: A CASESTUDY AND BODY OF EVIDENCE FROM THE FIELD OF VACCINOLOGY
Health Services, Outcomes and Policy Research (HSOP)
Angel Paternina-Caicedo, MD, MSc, Universidad de Cartagena, Cartagena, Colombia, Nelson
Alvis-Guzmán, PhD, MPH, MD, Universidad de Cartagena., Colombia, Colombia, Carlos
Castañeda-Orjuela, MD, MSc, Instituto Nacional de Salud, Bogota, Colombia and Fernando De
la Hoz-Restrepo, MD, MPH, PhD, Universidad Nacional de Colombia, Bogota, Colombia
Purpose: The population-level effects of mass interventions are difficult to estimate. Interrupted
time-series regression can provide trend- and seasonal-adjusted impact estimates at the
ecological level (1). We propose the use of this framework to estimate the immunization-related
reduction of burden of disease; and expand the framework beyond linear/Poisson regression to
any type of analysis that yields predictions (e.g. ARIMA). Our aim is to show unpublished and
peer-reviewed applications of interrupted time-series analysis (ITSA) in the field of vaccinology.
Methods: We collected available, countrywide, mortality microdata to estimate the impact of
immunization against measles (2), polio, diphtheria, pertussis, and tetanus from 1900-2015 in the
United States (using ITSA-ARIMA, and -Poisson regression); and rotavirus immunization (RV)
in Brazil, Colombia, Ecuador, and Mexico (ITSA-Poisson regression). We applied ITSA and
estimated the population-level reduction of burden of disease for these illnesses, expressed as
percentage reduction (100[1 – incidence-rate-ratio]), with 95% confidence intervals (95% CI).
Results: The theoretical model assumes the disease trend is targeted by the intervention (Fig.
1A), and control variables can be added to the model when estimating counterfactual scenarios.
As an application in vaccinology, we estimated in children under-5 years old from the United
States, the population-level impact of vaccines against measles (2), diphtheria (99.99%; 95% CI,
99.99 to 99.99), pertussis (99.98%; 95% CI, 99.98 to 99.98), tetanus (94%; 95% CI, 93 to 95),
and polio (99.%; 95% CI, 99 to 99) in the United States (Fig. 1B); and against rotavirus in Brazil
(19%; 95% CI, 17 to 22), Colombia (39%; 95% CI, 35 to 44), Ecuador (-26%; 95% CI, -40 to 14), and Mexico (18%; 95% CI, 15 to 20) (Fig. 1C).
Conclusions: ITSA is a useful tool to estimate reduction of disease and impact of populationlevel interventions such as immunization. The selection of disease outcomes is one of the most
important issues in ITSA, as these outcomes must closely align with disease symptomatology to
control ecological bias.
References
1. BMJ 2015;350:h2750.
2. Open Forum Infectious Diseases 2018;5(7).
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PS 4-28 REAL-WORLD RECURRENCE RATES OF COLORECTAL CANCER OVER
TIME
Health Services, Outcomes and Policy Research (HSOP)
Natalia R. Kunst, MSc, Department of Health Management and Health Economics, Faculty of
Medicine, University of Oslo, Oslo, Norway, Fernando Alarid-Escudero, PhD, Drug Policy
Program, Center for Research and Teaching in Economics, Aguascalientes, AG, Mexico, Eline
Aas, PhD, Department of Health Management and Health Economics, University of Oslo, Oslo,
Norway, Veerle Coupe, PhD, Decision Modeling Center VUmc, Amsterdam, Netherlands and
Karen M. Kuntz, ScD, Division of Health Policy and Management, University of Minnesota
School of Public Health, Minneapolis, MN
Purpose: Progress in overall care for colorectal cancer (CRC) patients has led to substantial
improvements in relative survival since the 1970s. However, there is lack of evidence of the
impact of CRC care advances on distant disease recurrence in a real-world setting. We aimed to
estimate CRC distant recurrence rates and the effectiveness of CRC care developments over time
in a real-world setting.
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Method: We modeled CRC disease progression using a continuous-time multi-state model
(msm) with three states: no evidence of disease (NED), metastatic disease (Mets), and death. We
estimated the recurrence rates using registry data from the Surveillance, Epidemiology, and End
Results (SEER) program on patients diagnosed in 1974-1983 (i.e., negligible CRC care beyond
surgical resection) and 1994-2003 (i.e., substantial CRC care progress), with a 10-year follow-up
time. Mets is a state not directly observed in SEER, from which cancer deaths are presumed to
occur; thus, we assumed that all patients dying from CRC have to go through the Mets state. Our
msm accounted for background mortality, sex, and tumor location (i.e., colon or rectum). We
expanded the msm to account for time-varying rates using a piecewise-exponential msm. We
created different msm for CRC stage II and III, and different patients’ age groups.
Result: Recurrence rates decreased in CRC diagnosed in 1994-2003 compared with 1974-1983
across all age groups and stages evaluated. The average annual recurrence rates (over 10 years
post diagnosis) of stage II CRC diagnosed in 1974-1983 ranged between 0.06-0.11 depending on
patients’ age (see Figure). For CRC stage III, the annual recurrence rates were 3 to 4 times
greater, ranging between 0.25-0.35. The risk of recurrence in stage II CRC diagnosed in 19942003 relative to 1974-1983, expressed as hazard ratios (HR), was 0.79 (CI, 0.66-0.96), 0.69 (CI,
0.64-0.74), and 0.68 (CI, 0.65-0.72) in patients aged 20-49, 50-64, and 65-79, respectively. The
relative recurrence risk in stage III CRC diagnosed in 1994-2003 was 0.59 (CI, 0.55-0.77), 0.49
(CI, 0.44-0.56), and 0.65 (CI, 0.61-0.69) in patients aged 20-49, 50-64, and 65-79, respectively.
Conclusion: Advances in CRC care over time seem to decrease stage- and age-specific CRC
recurrence rates. We propose an msm to estimate the change in recurrence rates over time using
registry data that reflects improvements in real-world patterns of CRC care.
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PS 4-29 CAN ROUTINELY COLLECTED ADMINISTRATIVE HEALTH DATA BE
USED TO IDENTIFY INDIVIDUALS AT RISK OF IMMINENT SEVERE
EXACERBATION OF COPD? A MACHINE LEARNING APPROACH
Health Services, Outcomes and Policy Research (HSOP)
Hamid Tavakoli, MD, MSc1, Wenjia Chen, PhD2, Don Sin, MD, MPH3, J Mark FitzGerald,
MD, FACP.4 and Mohsen Sadatsafavi, MD PhD1, (1)University of British Colombia, Faculty of
Pharmaceutical Sciences, Vancouver, BC, Canada, (2)University of British Columbia,Faculty of
Pharmaceutical Sciences, Vancouver, BC, Canada, (3)Faculty of Medicine, The University of
British Columbia, Vancouver, BC, Canada, (4)UBC , Department of Medicine,The Lung Centre,
Vancouver, BC, Canada
Purpose: Severe acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD) are the
most common reason for hospital admissions in Canada and many other countries. Prediction
algorithms based on machine learning of routinely collected administrative health data can
provide useful information to alert patients and care providers to take immediate action to reduce
the risk of an imminent severe exacerbation. This study aimed to examine and compare the
accuracy of different automatic prediction models on the identification of individuals at high risk
of imminent severe exacerbations.
Method: We used British Columbiaʼs administrative health databases to identify a cohort of
COPD patients based on a validated case definition. Within this cohort, we chose a random date
between January 2012 and January 2014 (training time window) as the index date. For external
validation, a new cohort was created with index dates in 2015. The assessment window was the
three-month period before, and the outcome window was the 60 days after, the index date. The
outcome was hospital admission with main discharge diagnosis of COPD. We started from a
comprehensive list of 83 variables as potential predictors. We used a variety of machine learning
algorithms, namely feature selection through lasso, risk prediction through logistic regression
(LR), neural networks (NN), gradient boosting (GB), and random forests (RF).
Result: In the training and validation, datasets 108,438 and 113,898 patients were included,
respectively. During the outcome assessment window 1,176 patients in the training set and 1,217
in the validation set were hospitalized due to COPD. In the external validation, the performance
of models measured by area under curve for receiver operating characteristic (AUC) and
precision-recall (AUPCR), and they were as follows: LR (AUC=0.80, AUCPR=0.07), NN
(AUC=0.80, AUPCR=0.07), RF :( AUC=0.80, AUPCR= 0.07) and GB (AUC=0.79, AUCPR=
0.06).
Conclusion: Algorithm based on routinely collected data can be automated to alert patients and
care providers about high-risk events. The feasibility and cost-effectiveness of implementing
such automated methods needs to be evaluated in future studies.
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PS 4-30 MANY VIEWS ON VALUE OVER TIME WITHIN AND ACROSS ACC/AHA
CLINICAL GUIDELINES
Health Services, Outcomes and Policy Research (HSOP)
Andrea Luviano, MD, MPH, Harvard T.H. Chan School of Public Health, Boston, MA and
Ankur Pandya, PhD, Center for Health Decision Science, Department of Health Policy and
Management, Harvard T.H. Chan School of Public Health, Boston, MA
Purpose: In January 2014, the American College of Cardiology/American Heart Association
(ACC/AHA) released a joint policy statement arguing for the inclusion of cost-effectiveness
analysis (CEA) and value assessments in clinical practice guidelines (Anderson et al.,
Circulation). We sought to characterize the use of value- or CEA-related terms in ACC/AHA
guidelines (for cardiovascular disease sub-conditions such as high blood pressure [HBP]) before
and after 2014 to assess the policy statementʼs impact on guideline writing.
Methods: We included ACC/AHA guidelines in our analysis based on two criteria: 1) guidelines
with a version released before and after (or during) 2014; 2) complete guidelines that were not
just an update of a previous version. For each guideline, we counted the words (total use and perpage) for selected value- or CEA-related terms: cost, economic, cost-effectiveness, efficiency,
financial, price, QALY, and value (only when related to efficiency or economics; i.e., our
analysis did not consider “cholesterol value” or “patient values” as a mention of “value”).
Results: We found five guidelines that met our inclusion criteria (see Figure caption). Summed
across guidelines, total term usage increased pre-2014 to post-2014 as did term/page (p<0.001).
Total term usage (Panel A) and term/page (Panel B) were higher post-2014 for three guidelines:
HBP (p-value for term/page before vs. after = 0.53), ventricular arrhythmias/sudden cardiac
death (VA-SCD, p<0.001), and acute ischemic stroke (AIS, p<0.001). The same metrics were
lower post-2014 for guidelines for peripheral arterial disease (PAD, p=0.01) and atrial fibrillation
(AF, p=0.80). Trends for the specific terms (such as “cost-effectiveness” or “value”) followed
these guideline-specific patterns (Panel A).
Conclusion: The impact of the 2014 policy statement did not appear to be uniform across
clinical practice guidelines for cardiovascular diseases sub-conditions. This might be influenced
by the specific authors writing each guideline. For example, two members of the writing
committee of the 2014 ACC/AHA policy statement were also authors of the 2018 VAS-SCD
guideline, which had the highest term/page rate among the guidelines we analyzed. Variation
across ACC/AHA medical guidelines, and the uneven impact of the 2014 ACC/AHA policy
statement, suggest the need to better organize existing CEA information for guidelines writers to
create recommendations that incentivize high-value (cost-effective) care, caution against the use
of low-value (cost-ineffective) care, and to identify evidence gaps for future CEA research.
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PS 4-31 CLINICAL MANIFESTATIONS AND HEALTH OUTCOMES ASSOCIATED
WITH ZIKA VIRUS INFECTIONS IN ADULTS: A SYSTEMATIC REVIEW
Health Services, Outcomes and Policy Research (HSOP)
Sheliza Halani1, Panashe Tombindo1, Ryan O'Reilly2, Joanna M. Bielecki, BSc, MISt3, Justin
Boyle1, Laura Erdman4, Rafael N. Miranda, DDS5, Shaun Morris4, Kellie Murphy6, Lauren
Ramsay1, Clare Whitehead6, Raphael Ximenes, Ph.D.7 and Beate Sander8, (1)University of
Toronto, Toronto, ON, Canada, (2)Institute of Health Policy, Management and Evaluation,
Toronto, ON, Canada, (3)Toronto Health Economics and Technology Assessment (THETA)
Collaborative, Toronto, ON, Canada, (4)Hospital for Sick Children, Toronto, ON, Canada,
(5)THETA - Toronto Health Economics and Technology Assessment Collaborative, Toronto,
ON, Canada, (6)Mount Sinai Hospital, Toronto, ON, Canada, (7)THETA - Toronto Health
Economics and Technology Assessment Collaborative / University Health Network, Toronto,
ON, Canada, (8)Institute of Health Policy, Management and Evaluation, University of Toronto;
Toronto Health Economics and Technology Assessment (THETA) Collaborative, University
Health Network; Institute for Clinical Evaluative Sciences; Public Health Ontario, Toronto, ON,
Canada
Purpose: The emergence of Zika virus (ZIKV) disease led to a substantial increase in new
research. However, a great proportion focuses on the effects on pregnant women and congenital
ZIKV. Our objective was to synthesize the literature and characterize clinical manifestations and
long-term sequelae of Zika virus (ZIKV) infection in adults.
Method: We conducted a systematic review following PRISMA guidelines (Protocol published:
PROSPERO 2018 CRD42018096558). We searched MEDLINE, Embase, PubMed,LILACS,
WHOʼs ICTRP clinical trials registries and databases through January 19, 2019 using terms
“Zika virus” and “Zika infection”. Studies reporting primary outcomes for adults (18 years and
over) were included. Case series/reports with less than 10 participants and conference
proceedings were excluded. Two reviewers independently screened articles, extracted data using
predefined data fields, and conducted the quality appraisal using Joanna Briggs Institute tools.
Conflicts were resolved by consensus or a third reviewer.
Result: We identified 8076 articles, of which 53 met inclusion criteria. Five (9%) were casecontrol, 8 (15%) cohort, 27 (51%) cross-sectional, and 13 (25%) case series. Forty studies were
from the Americas, 3 from Asia, 8 from Europe/Oceania, 1 from India, and 1 from the Middle
East. 185,728 subjects met ZIKV case definitions. The median age ranged from 29-59.5 years
and median days to develop symptoms ranged between 6-10 days. Eleven studies reported travelassociated ZIKV.
Symptoms were conjunctivitis (2866/9274), rash (7499/9861), fever (6155/9955), myalgias
(1566/7513), and arthralgias (4749/9138). Thrombocytopenia was reported in 192 of 44,105
subjects; one study noted severe thrombocytopenia in 12 of 37,878 subjects. Among 136,697
participants, neurological complications were: Guillain Barre Syndrome or GBS (1054),
encephalitis (15), transverse myelitis (11), meningitis (7), or other neurological syndromes (60).
The odds ratio of having GBS from ZIKV-positivity was noted as 2.23 (P = 0.14) in one study. A
separate study highlighted after 1 year of GBS diagnosis, 60% of subjects were healthy and 40%
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showed some disability. Mortality was noted to be 40 deaths among 55,959 ZIKV-infected
subjects. One study noted 50% co-infection with Campylobacter jejuni. 30 of 53 studies met
70% or more of quality appraisal criteria.
Conclusion: Trends of neurological complications (namely GBS) and blood cell abnormalities
such as thrombocytopenia have mirrored the surge of ZIKV cases. Mortality was less common
and often related to complications or patient comorbidities.
PS 4-32 COST EFFECTIVENESS OF POPULATION-WIDE GENOMIC SCREENING
OF FAMILIAL HYPERCHOLESTEROLEMIA: IMPORTANCE OF FH PATIENT
STATIN UPTAKE AND ACHIEVING TARGET LDL LEVELS
Health Services, Outcomes and Policy Research (HSOP)
Scott Spencer, MPA, MA1, Gregory Guzauskas, MSPH, PhD2, Marc Williams, MD3, Susan
Snyder, PhD, MBA3, Laney Jones, PharmD, MPH4, Jing Hao, PhD, MD, MS, MPH3, Dina
Hassen, MPP3, Josh Peterson, MD, MPH5 and David Veenstra, PharmD, PhD2, (1)Institute for
Public Health Genetics, University of Washington, Seattle, WA, (2)The Comparative Health
Outcomes, Policy, Economics (CHOICE) Institute, School of Pharmacy, University of
Washington, Seattle, WA, (3)Geisinger, Danville, PA, (4)Geisinger, Forty Fort, PA,
(5)Vanderbilt University, Nashville, TN
Purpose: Recent models for genomic screening of familial hypercholesterolemia (FH) have
evaluated cascade screening of high-risk patients and identified various levels of costeffectiveness. Considering that most patients with FH remain undiagnosed, a third of patients
with an FH variant are not on statin, and only half on statin are at their cholesterol goal, we
propose that evaluation of the incremental outcomes of population-wide genomic screening for
FH vs. cascade and clinical screening protocols is warranted.
Method: We developed a decision tree and 9-state Markov model evaluating the identification
of patients with an FH variant, treatment, LDL-cholesterol levels, myocardial infarction (MI),
and stroke to compare the costs, QALYs, and incremental cost-effectiveness of population-wide
FH genomic screening versus no genomic screening in a general population. The prevalence of
FH variants was 0.4%. We assumed test costs were $200. The distribution of individuals who
were previously affected by MI or stroke was determined by age-based cumulative incidences
among a general population of men and women. Distributions of individuals on/off treatment and
on/off LDL target were estimated from Abul-Husn et al. (2016) using 50,726 individuals from
the Geisinger MyCode Community Health Initiative. Costs and utility estimates were obtained
from published literature. Age-based estimates of MI, recurrent MI, stroke, and recurrent stroke
were obtained from the National Center for Health Statistics, National Heart, Lung, and Blood
Institute, the Greater Cincinnati/Northern Kentucky Stroke Study, Hospital Episode Statistics,
and the Office for National Statistics.
Result: Preliminary results indicate 0.0006 and 0.0005 QALYs were gained per screened
individual, with an incremental cost of approximately $272 and $275, producing an ICER of
approximately $447,000 and $506,000 for 35-year old men and women respectively. Incremental
QALYs were small primarily due to the low number of FH variant carriers in the general
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population. Model results were driven by the prevalence of FH variants within the general
population, number of FH patients receiving statin and reaching target, and the relative risk
reduction of MI and stroke from statin use.
Conclusion: Similar to cost-effectiveness models published for FH genomic cascade screening,
we found that population-wide FH genomic screening does not appear to be cost-effective.
However, the model indicates that data on the utilization of statins in known and unknown FH
patients will be critical for future cost-effectiveness work.
PS 4-33 THE COST-EFFECTIVENESS OF SOFOSBUVIR-VELPATASVIR IN
HEPATITIS C PATIENTS WITH DECOMPENSATED CIRRHOSIS IN CANADA
Applied Health Economics (AHE)
Jocelyn Chan, PharmD Candidate, University of Waterloo School of Pharmacy, Kitchener, ON,
Canada and William W. L. Wong, PhD, School of Pharmacy, University of Waterloo,
Kitchener, ON, Canada
Purpose: Previous analyses have determined that direct acting antivirals are cost-effective to
treat compensated cirrhotic patients with hepatitis C. Although already funded by Canadian
public payers, it is still unknown whether it is economical to reimburse direct acting antivirals
within the more advanced decompensated cirrhosis population. The objective of this study is to
determine the cost-effectiveness of sofosbuvir-velpatasvir (SOF-VEL) treatment in chronic
hepatitis C patients with decompensated cirrhosis.
Methods: A state-transition model was developed to conduct a cost-utility analysis of sofosbuvirvelpatasvir plus ribavirin treatment (Figure 1). The health states implemented reflect the natural
disease history of chronic hepatitis C. Two treatment strategies were evaluated: 1) sofosbuvirvelpatasvir plus ribavirin for 12 weeks and best supportive care; and 2) best supportive care alone.
The cohort evaluated had a mean age of 58 years, genotype 1 infection, and Child-Pugh Class B
cirrhosis with decompensated symptoms. Inputs for the model were derived from published
literature. Canadian cost estimates were used. The analysis was performed from the perspective of
the provincial government payer over a lifetime horizon using a 1.5% discount rate.
Results: Treatment with sofosbuvir-velpatasvir with ribavirin led to a 36.9% reduction in liverrelated deaths compared to best possible care alone. The SOF-VEL treatment arm also decreased
worsening to Child-Pugh C by 92.6%, decreased liver transplants by 35%, and decreased cases
of hepatocellular carcinoma by 18.7%. While sofosbuvir-velpatasvir plus ribavirin treatment for
12 weeks increased health costs by $106 175, it also provided an additional 4.92 quality adjusted
life years (QALYs) compared to best possible care. With an incremental cost effectiveness ratio
(ICER) of $21 556 per QALY, SOF-VEL plus ribavirin treatment was determined to be
economically cost-effective, at a willingness-to-pay of $50 000 per QALY.
Conclusion: This is the first cost-effectiveness analysis to confirm sofosbuvir-velpatasvir should
continue to be reimbursed in decompensated hepatitis C patients by government payers in
Canada. Other direct acting antiviral therapies indicated for decompensated patients are likely
also cost-effective, given their similar efficacies and costs.
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PS 4-34 THE RAND ALCOHOL POLICY PREDICTION MODEL
Health Services, Outcomes and Policy Research (HSOP)
Carolyn Rutter, PhD, Raffaele Vardavas, PhD, Dulani Woods, MS, Rosanna Smart, PhD and
Rosalie Pacula, PhD, RAND, Santa Monica, CA
Purpose: Describe a method for simulating monthly drinking behaviors.
Methods: The RAND Alcohol Policy Prediction (RAPP) model aims to assess the impact of
alcohol policies on consumption and downstream effects on productivity, morbidity and
mortality by simulating behaviors in agents that are representative of the U.S. population at the
State-level. To predict the population-level effects of alcohol policy, the model simulates a
population that is a mixture of birth cohorts. The RAPP model for drinking behaviors builds
primarily on data from the cohort of adolescents who participated in the 1997 National
Longitudinal Survey of Youth (NLSY97). NLSY97 data informs age at drinking initiation and
monthly consumption after initiation. Monthly consumption is simulated as three behaviors:
drinking days, binge drinking days, and drinks per drinking day. Random effects regression
models estimated from NLSY97 data are used to link behaviors to agent characteristics. Data
from the National Epidemiologic Survey on Alcohol and Related Conditions informs withinagent changes in alcohol consumption over a broader age range than observed in NLSY97. Data
from the Monitoring the Future study informs secular changes in drinking behaviors, such as age
at drinking initiation. Drinking behaviors are used to calculate daily blood alcohol content and
average consumption over variety of look-back periods, which are in turn used to simulate
outcomes from drinking.
Results: Drinking behaviors are simulated using binomial distributions, with expected values
that depend on agent characteristics (e.g., age, sex, race and ethnicity, income, motherʼs
education, enrollment in a 4-year college, State of residence, urban/rural location). Withinmonth, correlation in the three drinking behaviors is simulated using the random effects
distribution estimated from NLSY97 data, in combination with constraints on behaviors (e.g., the
number of binge drinking days cannot exceed the number of drinking days). Behaviors are
correlated across months, while maintaining correlation between behaviors, by simulating
correlated multivariate normal deviates and using an inverse cumulative distribution function
look-up to simulate behaviors. The figure shows four examples of drinking behaviors based on
this approach.
Conclusions: It is necessary to simulate drinking behaviors that are correlated across type and
over time to reduce within agent variation in alcohol consumption; Without this correlation, there
is an unrealistic variation in drinking behaviors, and this variation would reduce the simulated
impact of many policy interventions.
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PS 4-35 DEVELOPMENT AND VALIDATION OF AN ELECTRONIC CODING
ALGORITHM TO IDENTIFY ELECTIVE ORTHOPEDIC SURGERIES FROM
ADMINISTRATIVE CLAIMS DATA AND ELECTRONIC MEDICAL RECORDS
Health Services, Outcomes and Policy Research (HSOP)
John Giardina, MA1, Thomas Cha, MD, MBA2, Steven Atlas, MD2, Michael Barry, MD3,
Andrew Freiberg, MD4, Lauren Leavitt, MA2, Felisha Marques, MPH2 and Karen Sepucha,
PhD3, (1)Center for Health Decision Science, Harvard University, Boston, MA,
(2)Massachusetts General Hospital, Boston, MA, (3)Division of General Internal Medicine,
Massachusetts General Hospital, Boston, MA, (4)Zimmer Biomet, Warsaw, IN
Purpose: To develop and validate an electronic coding algorithm to identify orthopedic surgeries
that are elective and, as a result, may be appropriate for shared decision-making tools and
measurement.
Methods: An automated algorithm consisting of ICD-10 and CPT codes was developed to
identify the following combinations of surgical procedure and primary indication: (1) knee
arthroplasty to treat knee osteoarthritis (KOA); (2) hip arthroplasty to treat hip osteoarthritis
(HOA); (3) spinal surgery to treat lumbar spinal stenosis (SpS); and (4) spinal surgery to treat
lumbar herniated disc (HD). Using data drawn from administrative claims data and electronic
medical records, the algorithm attempted to identify these four situations for surgical procedures
performed by participating surgeons practicing within an integrated care network. A manual
chart review was conducted to ascertain a “gold standard” determination of the procedure and
primary indication status. The primary measures of validity for the automated algorithm were the
sensitivity and specificity of the algorithm relative to the gold standard review.
Results: Participating surgeons performed 790 procedures and 438 (57.6%) represented one of
the four procedure/indication combinations of interest, as determined by the gold standard
review. The sensitivity and specificity of the automated algorithm are presented in Table 1. The
sensitivity ranged from 0.70 (HD) to 0.92 (KOA), and the specificity ranged from 0.94 (SpS) to
0.99 (HOA, KOA). The most common reason for misclassifications for HD and SpS cases was
the incorrect assignment of the indication (e.g., case labeled HD when it was actually SpS, and
vice versa). The most common reason for misclassifications for HOA was the algorithm
excluding patients due to presence of another diagnosis (e.g. fracture or infection) in the data that
was not actually related to the procedure.
Conclusion: The automated algorithm was able to identify all four procedure/primary indication
combinations of interest with high specificity. The sensitivity for the KOA and HOA cases was
reasonably high, but additional work is needed to improve the sensitivity of the algorithm for the
spine procedures. Surgery for the four conditions included in this algorithm (KOA, HOA, SpS,
HD) is usually elective, and as a result, this algorithm could be used to efficiently identify those
patients who should have been given shared decision-making interventions.
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PS 4-36 MEASURING THE SPILLOVER EFFECTS IN CAREGIVERS OF
PRETERM/LOW BIRTHWEIGHT INFANTS: A SYSTEMATIC REVIEW
Health Services, Outcomes and Policy Research (HSOP)
Ellen Kim DeLuca, MPH, Department of Health Management and Policy, University of
Michigan, Ann Arbor, MI and Lisa A. Prosser, PhD, MS, Susan B. Meister Child Health
Evaluation and Research Center, University of Michigan, Ann Arbor, MI
Purpose: The measurement of family spillover effects has received increasing attention;
however, the magnitude and duration are not well understood and vary by condition. The
objective of this study was to characterize the psychosocial effects (which include domains that
directly and indirectly assess health) and health-related quality of life (HRQoL) of caregivers in
the context of caregiving for preterm (PT)/low birthweight (LBW) infants.
Method: We performed a systematic literature search for papers published between January 1,
1990 to October 31, 2017 in PubMed and PsycINFO. We reviewed and extracted data from each
study using a two-reader consensus process. The following inclusion criteria were employed: 1)
study was conducted in the United States; 2) caregivers of PT/LBW infants were compared to
caregivers of full-term (FT) infants; 3) no study participants were exposed to an intervention; 4)
psychosocial effects and HRQoL were measured quantitatively (i.e. no interviews or open-ended
questionnaires). Any non-English and non-peer-reviewed studies were excluded.
Result: The initial search resulted in 845 articles. Of these, 26 articles met the inclusion criteria.
24 papers measured various psychosocial domains and 2 papers measured both psychosocial
effects and HRQoL. The most common domains measured were depression, anxiety, stress, and
family impact/burden. The sample sizes of the studies ranged from a total of 34 caregivers to 393
caregivers. All articles were observational studies. 17 articles reported spillover effects for one
time period and 9 articles reported spillover effects for multiple periods. The timing of data
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collection ranged from immediately after delivery to 14 years after delivery. Overall, caregivers
of PT/LBW infants exhibited worse outcomes than caregivers of FT infants, but mostly during
the first month of the infantʼs life. However, caregivers of more high-risk infants (i.e. extremely
low birthweight infants or LBW infants with comorbidities) seem to sustain worse outcomes for
much longer – up to when the child was 14 years of age. In contrast, some studies reported more
positive outcomes among caregivers of PT/LBW infants than among caregivers of FT infants,
such as feelings of greater mastery and greater post-traumatic growth.
Conclusion: Spillover effects of caregivers for PT/LBW infants are mostly transient, with the
exception of caregivers for more high-risk infants who exhibit spillover effects for a far longer
period of time.
PS 4-37 WHAT IS THE FERTILITY COST OF GESTATIONAL TROPHOBLASTIC
NEOPLASIA SURVEILLANCE FOR WOMEN OF ADVANCED MATERNAL AGE? A
DECISION ANALYSIS
Health Services, Outcomes and Policy Research (HSOP)
Ross Harrison, MD1, Scott B. Cantor, Ph.D.1, Charlotte C. Sun, DrPH, MPH1, Mariana
Villanueva, MD2, Katherine Stewart, MD, MBA1, Terri L. Woodard, MD1, Aaron Shafer, MD1,
Karen H. Lu, MD1 and Larissa A. Meyer, MD, MPH1, (1)University of Texas MD Anderson
Cancer Center, Houston, TX, (2)UT Health, Houston, TX
Purpose:
To examine the opportunity cost of postmolar surveillance for malignant gestational
trophoblastic neoplasia (GTN) in terms of fertility outcome for women of advanced maternal age
(AMA).
Method:
A decision analytic model comparing two surveillance strategies was developed in TreeAge Pro.
The current standard-of-care of 6 months of beta-hCG surveillance after normalization of betahCG measurements (conventional) was compared against a proposed alternative consisting of
one additional beta-hCG test one month after normalization (alternate) (Figure 1). Model
parameters for GTN risk, loss of follow-up, rate of attempting pregnancy, fecundity, and
pregnancy outcome were derived from the literature. Cohorts of women aged 35-39 and 40-45
with an antecedent partial (PM) or complete molar pregnancy (CM) were simulated. A 6-month
time horizon was set. Multiple one-way and probabilistic sensitivity analyses were performed to
evaluate model inputs. The primary outcome was pregnancy rate in the alternate compared to the
conventional strategy; secondary outcomes were live births and GTN cases occurring both in and
outside of surveillance (e.g. delayed diagnosis).
Result:
Among women aged 35-39 with a CM, the pregnancy rate occurring in the alternate strategy was
higher than the conventional strategy (40.8 v. 28.8 pregnancies per 100 person-years; 28.6 v.
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20.2 live births per 100 person-years). In the alternate strategy, the incidence of GTN cases
occurring outside of surveillance was 3.4 per 1000 person-years for women with history of a CM
(conventional 1.0 per 1000 person-years). For women age 35-39 with a PM, the alternate
strategy led to similar increases in pregnancy rate to the CM cohort; the incidence of GTN cases
occurring outside of surveillance was <1 per 1000 person-years. For women aged 40-45, similar
pregnancy rates occurred between the strategies (alternate & conventional: 24.0 v. 23.5
pregnancies per 100 person-years, respectively). Multiple one-way sensitivity analyses of model
parameters showed that the rate of attempting pregnancy per month, chance of unintended
pregnancy, and fecundity accounted for most model uncertainty (50.3%, 28.6%, and 19.4%).
Conclusion:
Our model demonstrates that in women with partial moles, shorter surveillance may improve live
birth rates for those seeking fertility. Among women with complete molar pregnancies, these
findings may allow for individualized decision-making regarding the value of GTN surveillance
in the context of risk for invasive disease and desire to attempt pregnancy.
PS 4-38 AN ASSESSMENT OF VALUE FOR ROUTINE CARE IN PREGNANCY
Health Services, Outcomes and Policy Research (HSOP)
Ashley Leech, PhD, MS1, Mathias Schreiner, BS1, Michal Horný, Ph.D., MSc.2, Malavika
Prabhu, MD3 and Peter J. Neumann, Sc.D.4, (1)Vanderbilt University School of Medicine,
Nashville, TN, (2)Emory University Rollins School of Public Health, Atlanta, GA, (3)Division
of Maternal-Fetal Medicine, The Warren Alpert Medical School of Brown University,
Providence, RI, (4)Center for the Evaluation of Value and Risk in Health, Tufts Medical Center,
Boston, MA
Purpose: To assess whether the American College of Obstetricians and Gynecologists (ACOG)
guidelines for routine pregnancy reflect high value care as quantified by published cost-utility
ratios.
Method: We used the Tufts Cost-Effectiveness Analysis Registry to identify cost-utility
analyses (CUAs) for routine care in pregnancy from the past 10 years (2008 to 2017) in a US
setting. We investigated the frequency of high-value healthcare interventions across willingness
to pay thresholds between $50,000/QALY and $150,000/QALY gained, then investigated
whether CUA conclusions aligned with current ACOG recommended guidelines and
corresponding Choosing Wisely® campaign lists. We used ACOGʼs Guidelines for Perinatal
Care 8th Edition and the latest editions of Practice Bulletins 148 (Thyroid Disease in Pregnancy),
187 (Neural Tube Defects), and 205 (Vaginal Birth After Cesarean Delivery).
Result: Of 5,570 published studies and 14,606 corresponding cost-per-QALY ratios between
2008 and 2017, we identified 34 (0.61%) studies and 71 (0.49%) ratios that met our inclusion
criteria of evaluated interventions for routine pregnancy care. Labor and delivery interventions
and services for pregnancy-related infectious and parasitic disease comprised over half of the
cost-per-QALY ratios. Of the identified 71 cost-per-QALY ratios, 62 (87%) interventions were
considered high-value according to a willingness to pay threshold of $150,000/QALY gained.
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Value conclusions did not vary substantially when we used a more conservative threshold of
$50,000 (8 ratios, or 11%, had an ICER between $50,000 and $150,000/QALY gained—of
which only 1 ratio fell between $100,000 and $150,000/QALY gained). Of the 62 high-value
interventions, 40 (65%) aligned with current ACOG recommended guidelines. Of the 9 low or no
value interventions, 4 (44%) aligned with the June 2018 iteration of Choosing Wisely®
Campaignʼs list of healthcare procedures that physicians and patients should question. Moreover,
for one of the high-value interventions, Choosing Wisely® included the low-value comparator as
a questionable service.
Conclusion: Maternal morbidity and mortality rates are steadily increasing in the U.S., with a
nearly 50% increase in hospitalizations for severe maternal morbidity in the last 10 years.
Conducting CUAs and incorporating these outcomes into healthcare priority setting is critical to
ensure that resources are applied to effective prevention and treatment strategies yielding the
highest possible population health outcomes. More attention to evaluating interventions during
pregnancy and their impact on value estimates is needed.
PS 4-39 DENSE BREAST LEGISLATION DOES NOT PREPARE MOST WOMEN FOR
BREAST CANCER SCREENING DECISION-MAKING: A NATIONAL SURVEY
Health Services, Outcomes and Policy Research (HSOP)
Nancy Kressin, PhD, Christine Gunn, PhD and Tracy A. Battaglia, MD, MPH, Boston
University School of Medicine, Boston, MA
Purpose: Dense breast notification legislation aims to provide women with information to
promote informed decision-making about breast cancer screening. This study examined
differences in womenʼs knowledge, awareness, and intentions for follow-up care relative to the
presence of dense breast notification legislation and by sociodemographic characteristics.
Method: Social Science Research Solutions fields a national, weekly, dual-frame bilingual
telephone survey targeting a representative sample of the U.S. population, to which survey
questions were added in May 2018. Eligible women were aged 40 or older and reported having a
mammogram within two years. We assessed awareness of and knowledge about breast density
and plans for follow up care. We used Chi-square tests to examine outcomes by state legislation
status (whether or not density notification is mandated in a womanʼs state of residence) and
sociodemographic characteristics.
Result: 578 women were surveyed in all 50 states; 76% had heard of breast density. Awareness
did not vary by the presence of state legislation (76% vs. 75%), but differed by
sociodemographics: Those with incomes under $25,000, those who completed no more than high
school, or who were Black or Hispanic were less likely to be aware of breast density. Less than
half of women knew that breast density increases breast cancer risk, with no differences by state.
Women in states with legislation were less likely to incorrectly report that breast density relates
to how breasts feel (26% vs. 40%). When asked whether breast density makes it more difficult
for a mammogram to detect cancer, younger women, those with higher incomes, more education,
Whites and Hispanics were more likely to answer correctly. There were no statistically
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significant differences in discussing breast density with a doctor by legislation status (50% in
legislation states vs. 40% no legislation).
Conclusion: This first national survey of the effect of breast density legislation on knowledge,
awareness, and follow up care demonstrated numerous sociodemographic differences, but few
variations by state legislation status. That women in states with legislation had no significant
differences in follow up care and no greater knowledge of the effects of density on cancer risk
and mammography sensitivity suggests that current notifications may not provide the
foundational knowledge to support decision-making. Differences observed for vulnerable women
suggest that communications must address these gaps to optimize future decision-making and
clinical outcomes.
PS 4-40 AS PHYSICIANS GAIN PREOPERATIVE EXPERIENCE THEY ARE LESS
LIKELY TO ORDER PREOPERATIVE STRESS TESTING
Health Services, Outcomes and Policy Research (HSOP)
Matthew Pappas, MD, MPH, Cleveland Clinic Foundation, Center for Value-based Care
Research, Cleveland, OH and Michael Rothberg, MD, MPH, Cleveland Clinic, Cleveland, OH
Purpose:
The 2014 ACC/AHA guidelines recommend preoperative stress testing for patients whose
predicted risk of a major adverse cardiac event exceeds 1%, whose functional status is poor or
unknown, and when stress testing would change clinical management. However, each of those
three decision points likely vary by provider judgment.
Among inpatient providers, physician experience appears to be correlated with lower resource
utilization. We therefore set out to investigate whether preoperative stress testing varies as a
function of prior experience in a preoperative clinic.
Method:
The Internal Medicine Preoperative Assessment, Consultation and Treatment (IMPACT) Center
assesses patients prior to noncardiac surgery at the Cleveland Clinic. Between 1/1/2008 and
12/31/2017, 118,552 patients were seen by 104 providers across 159,795 visits. For each visit,
we calculated how many previous visits the physician had completed in the IMPACT clinic
(median: 2547, IQR: 1589-4739).
For our primary outcome variable, we identified whether the patient completed cardiac stress
testing in the 30 days after the visit, including single-photon emission computed tomography,
stress echocardiography, or exercise stress testing. We tested fixed- and random-effects models
and tested for interactions among predictors.
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Result:
The number of patients the physician had seen previously was a significant and meaningful
predictor of preoperative stress testing rates (marginal probabilities shown in Figure). A visit
with a provider who had seen 1,000 patients previously would be 1.62 times more likely to result
in a preoperative stress test compared to a visit with a physician who had seen 5,000 previous
patients. Using a random-effects model, previous provider experience explained approximately
8.7% of variation in preoperative testing rates.
Conclusion:
In this large cohort of patients seen for preoperative risk assessment at a single health system, we
have shown that as physicians gain experience in a preoperative clinic, they are less likely to
order preoperative stress testing. Among physicians seeing preoperative patients, there appears to
be an inverse relationship between previous experience and testing rates.
Figure:
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PS 4-41 IMPROVING THE VALUE OF PRIMARY CARE USING
MULTIDISCIPLINARY CARE TEAMS: BASELINE RESULTS FROM A
NORWEGIAN PILOT STUDY
Health Services, Outcomes and Policy Research (HSOP)
Kine Pedersen, PhD1, Susanna Sten-Gahmberg, PhD1, Hanna Isabel Løyland, MSc1, Ivar S.
Kristiansen, MD, PhD, MPH2, Erik Magnus Saether, PhD1 and The research team evaluating the
Norwegian multidisciplinary care teams pilot study (University of Oslo, University of Tromsø
and Oslo Economics), engaged by the Norwegian Directorate of Health., (1)Oslo Economics,
Oslo, Norway, (2)Department of Health Management and Health Economics, University of Oslo,
Oslo, Norway
Purpose: In 2018, Norwegian health authorities initiated a three-year pilot study involving
reorganizing the general practitioner (GP) services to include multidisciplinary care teams
(MCTs), consisting of a GP, a nurse and a medical secretary. 13 GP offices in nine
municipalities were enrolled. MCT-based care aims to improve health status, access and followup of patients with comprehensive needs, create more coordinated health services and improve
resource utilization. During the study period (2018-2021), the performance of MCTs will be
evaluated using a mixed-methods approach, involving registry-data, surveys and interviews with
multiple stakeholders.
Method: To establish a baseline for the pilot study and understand stakeholders’ expectations to
MCTs, in 2018, we conducted surveys among three main stakeholder-groups: 1) health personnel
at GP offices (GPs, nurses and medical secretaries) within and outside the pilot study (snowballsampling; N unknown), 2) health personnel elsewhere in the primary care sector and in
specialized care (snowball-sampling; N unknown), and 3) the general population (N=44,143).
Surveys of health personnel included work satisfaction, collaboration at the workplace and
between service providers. The survey of the general population included own health (including
EQ-5D-5L) and satisfaction with GP services.
Results: Personnel at GP offices (N=165) were satisfied with their tasks and collaboration at the
workplace, yet GPs were unhappy with their workload. 77% of GPs enrolled in MCTs expected
to improve identification and follow-up of patients with comprehensive needs. A majority also
expected improved patient satisfaction and strengthened coordination between care providers.
Two-thirds of department leaders/key clinicians in the municipalities and specialized care
(N=82) considered the coordination and collaboration with the GP services to be wellfunctioning, and more than half of these respondents expected that MCTs would improve patient
satisfaction. Respondents of the general population survey (N=8,236 (19%)) were generally
satisfied with GP services (49% were “very satisfied”).
Conclusion: GPs and other service providers expect MCTs to improve care, patient satisfaction
and coordination between care providers. These findings provide important insight to the status
and value of primary care at baseline. We will conduct repeated measurements during the study
period, and a mid-way study evaluating health personnelʼs experience with MCTs is ongoing.
This mixed-methods approach, encompassing various stakeholders, will help inform Norwegian
health authorities whether and how MCTs can play a role in the primary care services.
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PS 4-42 DISEASE SEVERITY IS ASSOCIATED WITH RESEARCH VISIT NO-SHOWS
AMONG PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERY DISEASE: AN
ARGUMENT FOR TIERED PARTICIPANT COMPENSATION STRATEGIES.
Health Services, Outcomes and Policy Research (HSOP)
Gloria Kim, MD, MPH, University of Michigan, Ann Arbor, MI, Donna Keith, MS, MHA,
Wake Forest University, Winston Salem, NC and Matthew Corriere, MD, MS, University of
MIchigan, Ann Arbor, MI
Purpose: Institutional review boards (IRBs) sometimes mandate limits on research participant
incentives and compensation to avoid undue influence, particularly when socioeconomic status
may make participation difficult to decline. People with severe disease symptoms and/or
comorbidity, however, may face greater barriers to participation that justify increased
compensation. This report describes associations between disease severity and no-show rates for
research visits among candidate participants with symptomatic peripheral artery disease (PAD),
as well as impacts of implementing a tiered compensation strategy on recruitment and
participation rates.
Method: Recruitment data for a focus group study of patients with symptomatic disease were
evaluated. Participant symptoms were characterized based on disease severity as claudication
(intermittent muscular leg pain precipitated by walking) or chronic limb threatening ischemia
(CLTI) (pain at rest, foot ulcer, or gangrene). All participants were initially offered free
transportation and a $40 cash incentive. Patients who verbally agreed to participate but missed
their scheduled research visit appointment were categorized as “no shows”. Rates of rates of
contact, recruitment, and participation stratified by disease severity were evaluated using
descriptive statistics and categorical tests.
Result: A total of 184 candidates who met the inclusion criteria were identified and had
attempted contact for recruitment. Of these, 56 (including 26 with claudication and 30 with
chronic limb-threatening ischemia) participated. Information related to screening and recruitment
is summarized in Figure 1. Reasons volunteered for non-participation included work and
personal schedule conflicts, pending procedures, lack of transportation, residence within a skilled
nursing or rehabilitation facility, and legal blindness. Patients with CLTI had a higher rate of "no
shows" (i.e., agreeing to participate in but not showing up for a scheduled focus group)
compared with those with claudication (11 versus 4). Ten of the eleven patients with CLTI who
were a no-show for their initial appointment participated in a subsequent focus group following
the targeted increase in compensation for this subgroup from $40 to $100.
Conclusion: Although limits on participant compensation protect many research candidates from
undue financial influence, lower rates of recruitment and participation may be an unintended
consequence among participants with severe disease. These observations support consideration
for tiered participant compensation structures for low-risk studies targeting participants with
severe chronic disease symptoms.
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PS 4-43 POOR NUTRITION STATUS IN OLDER ADULT OUTPATIENTS:
PREVALENCE, POPULATION CHARACTERISTICS, AND ECONOMIC BURDEN
Health Services, Outcomes and Policy Research (HSOP)
David Lanctin, MPH1, Jamie Partridge, PhD, MBA2, Kurt Hong, MD PhD FACN3, Carolyn
Kaloostian, MD MPH3 and Suela Sulo, PhD2, (1)Abbott Laboratories, Abbott Park, IL,
(2)Abbott Nutrition, Columbus, OH, (3)Los Angeles, CA
Purpose: Poor nutrition – defined as including both under-nutrition and over-nutrition – affects
over 25% of US community-dwelling adults. Without proper management, it leads to poor health
and economic outcomes. Physician offices present an opportunity for detecting and addressing
poor nutrition among community-dwellers. However, the characteristics and nutrition risk profile
of this population are poorly understood. This study explores the prevalence, characteristics, and
economic burden of Medicare community-dwellers at nutrition risk presenting to US physician
offices for outpatient care.
Method: This was a retrospective analysis of a 5% random sample of Medicare beneficiaries.
Eligible beneficiaries included in the Medicare Standard Analytic Files had at least one physician
office visit between January-June 2017, while those without continuous fee-for-service Medicare
coverage for the 2017 calendar year were excluded. Patients were classified as under-nourished
(UN), over-nourished (ON), or at normal nutrition status (NNS) based on presence of
International Classification of Diseases, Tenth Revision (ICD-10) diagnosis codes for UN or ON.
Demographics and primary diagnoses were compared between the three patient cohorts. The
economic burden was estimated by calculating the mean annual number of hospitalizations and
mean annual hospitalization costs.
Result: A total of 1,309,356 patients were included in the analysis, of which 2.2% were UN,
10.6% were ON, and 87.1% were NNS. Compared with NNS patients, ON patients were
younger (68 vs. 72 years) and living in southern geographic regions (46% vs. 40%). UN patients
were more likely to be female (65% vs. 56%), older (75 vs 72 years), and living in the south
(47% vs. 40%) (all p-values<0.0001). The most common primary diagnoses were diabetes
(13.8%) and hypertension (13.3%) for ON patients, and nutritional/endocrine/metabolic
disorders (17.0%) for UN patients. The mean number of annual hospitalizations (NNS: 0.33;
ON/UN: 0.44; p<0.0001) and mean annual hospitalization costs (NNS: $5,842; ON/UN: $7,893;
p<0.0001) were significantly higher in patients at nutrition risk.
Conclusion: Poor nutrition is common and burdensome in older community-dwelling adults
presenting to US physician offices for outpatient care. The lower prevalence observed in our
analysis suggests that poor nutrition may be under-diagnosed in US physician offices.
Implementation of nutrition screening and treatment protocols in physician offices may alleviate
the burden of poor nutrition in this population. Health policies supporting nutrition protocols for
outpatients at nutrition risk are essential.
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PS 4-44 USE OF THE ELECTRONIC HEALTH RECORD TO INCREASE PATIENT
ENGAGEMENT IN A SMOKING CESSATION PROGRAM (SCP)
Patient and Stakeholder Preferences and Engagement (PSPE)
Santanu Datta, PhD, MBA, MS, College of Public Health and Health Professions, University
of Florida, Gainesville, FL, James Davis, MD, Duke University School of Medicine, Durham,
NC and Paul Dennis, PhD, Duke University, School of Medicine, Psychiatry & Behavioral
Sciences, Behavioral Medicine, Durham, NC
Purpose: Estimate the increase in the number of smokers who attend their first smoking
cessation appointment through the use of best practice advisory (BPA) notification and
population-based outreach to augment traditional referral for smoking cessation and estimate
health and economic outcomes as a result.
Method: Retrospective database analysis was used to estimate the proportion of smokers seen at
two Duke University Primary Care and two Disadvantaged Care clinics who attended their first
smoking cessation appointment after referral via traditional referral and by BPA. Because
population-based outreach was in the process of being implemented at Duke, a pilot study (n=30)
was used to determine first appointment attendance. Then a three-state Markov model was used
to compare traditional referral vs. traditional referral plus BPA and population-based outreach.
Lifetime health care cost was estimated from the providerʼs perspective. In the model, smokers
begin in the “currently smoking” health state and decide whether to quit; first appointment
attendance was a proxy for a quit attempt. Duke SCP treats smokers using intensive counseling,
pharmacotherapy, or both. If they quit successfully they transition to the “abstinent” state. While
abstinent they could suffer remission and transition back to “currently smoking.” Some current
and former smokers die each one-year cycle and transition to the “Death” state. Costs included
labor for patient outreach, smoking cessation interventions and medical care costs. Effectiveness
measures included life expectancy and QALYs. Model parameter values were derived from the
literature. Costs (2018 $) and QALYs were discounted at 3%.
Result: Traditional referral resulted in 4.6% of Primary Care and 7.4% of Disadvantaged Care
clinic smokers attending their visit Duke SCP appointment. Attendance was estimated to
increase to 11.7% for Primary Care and 14.4% for Disadvantaged Care smokers with the
addition of the two EHR engagement methods. Among the 5,605 smokers utilizing the four
clinics, EHR use is estimated to lead to 967 life-years gained, 408 QALYs saved, and total
lifetime healthcare cost savings of about $46 million.
Conclusion: Implementation of EHR-based patient engagement methods require relatively little
upfront investment and recurring labor cost. They can be an effective complement to traditional
referrals for improving service utilization of a smoking cessation program. This, in turn, can lead
to substantial gains in health outcomes and healthcare cost savings.
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PS 4-45 PATIENT REPORTED OUTCOMES IN CLINICAL DECISION-MAKING:
PROVIDER PERSPECTIVES ON VALUE AND UTILITY
Patient and Stakeholder Preferences and Engagement (PSPE)
Jenney Lee, MA1, Cynthia LeRouge, PhD2, Courtney Segal, BA1, Elizabeth Austin, MPH1 and
Danielle Lavallee, PharmD, PhD3, (1)University of Washington, Seattle, WA, (2)Florida
International University, Miama, FL, (3)Department of Surgery, Seattle, WA
Purpose:
Patient Reported Outcomes (PROs) augment routine healthcare with direct insight into the
patient experience. Providers perceive a value for this data in its ability to enhance clinical
decision-making and patient care. Yet in order to achieve this potential, PRO data must be
delivered to providers in an accessible format. The objective of this study is to examine the
perspectives of providers as key stakeholders in the use of PRO data, to discern their stated
preferences and needs for visual displays of PRO data, and to understand the value they ascribe
to clinical integration of PROs.
Method:
As part of a larger PRO action research implementation effort, our multi-disciplinary team
performed a review of published literature on PROs. The literature was open coded; codes
emerged relating to PRO visualization content, functionality, and design. We then performed key
informant interviews with 20 providers (representing 11 medical and surgical specialties) at a
large academic medical center with experience in using PROs. Semi-structured interview guides
explored providers’ needs and preferences for PRO reporting and the values and barriers
associated with PRO integration. Interviews were recorded, transcribed, and coded using results
of the literature review as an a priori coding schema. Additional inductive codes were added as
salient topics emerged. Constant comparison methodology and 100% code review (by a noncoder) was used to establish rigor and enhance validity.
Result:
Providers reported the value of PROs increases when it aligns with measurement-based care to
provide actionable data based on validated metrics to aid decision-making and support care
coordination. Additionally, preferences and needs for PRO reporting revolved around three
domains deemed critical by providers in making PRO data clinically useful. These domains
included content (what type of data is provided), visualization design (how data is visually
represented), and functionality (which capabilities are provided).
Conclusion:
Providers perceive that PRO data has great potential to provide valuable insights about patient
health status outside of the healthcare encounter. They also state a range of preferences and
needs related to how PRO data is presented for clinical use, within the domains of content,
visualization design, and functionality. Our findings reveal core areas that provider stakeholders
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consider critical to the usefulness and usability of PRO reporting for the purposes of enhancing
patient care and clinical decision-making.
PS 4-46 PRICING TREATMENTS COST-EFFECTIVELY WHEN THEY HAVE
MULTIPLE INDICATIONS: NOT JUST A SIMPLE THRESHOLD ANALYSIS
Applied Health Economics (AHE)
Jeremy D. Goldhaber-Fiebert, PhD, Stanford Health Policy, Centers for Health Policy and
Primary Care and Outcomes Research, Stanford University, Stanford, CA, Lauren E. Cipriano,
PhD, Ivey Business School, Western University, London, ON, Canada and Jay Bhattacharya,
MD, PhD, Stanford University, Stanford, CA
Purpose: HPV vaccination of females is more cost-effective than vaccination of males.
Treatment of chronic HCV infections with advanced fibrosis is more cost-effective than without
fibrosis. Despite this, in many jurisdictions, it is not feasible to pay separate prices for the same
treatment used for different indications. When one of the indications is above the payerʼs
willingness-to-pay (WTP) threshold, what single price should be charged?
Method: We construct an analytically tractable example: a drug is produced by a single
manufacturer; a single payer considers coverage. Initially, the drug is available for a patient
population of a given size at a price that is satisfactory to the payer (i.e., below the WTP
threshold) and to the manufacturer (i.e., non-negative marginal revenues net marginal costs).
Next, the drug is shown to be effective for a second patient population of a different size, but at
the current price, it is not cost-effective. We derive optimal feasible price(s) acceptable to the
manufacturer and payer when drug prices : a) can vary by condition; b) must be the same for all
conditions.
Result: When drug prices can vary by condition, the condition-specific price is set such that the
cost per QALY gained is at the payerʼs threshold – lower for the second condition than the first
since fewer per-patient QALY are gained by this group. If the condition-specific price is below
the manufacturerʼs marginal cost, the drug is not offered for that condition. This outcome is an
equilibrium only if the payer must accurately report the number patients in the high and low
groups. If there must be one price for both conditions, then there can be a range of optimal prices
between the two prices determined in the first example that depend on the relative sizes of the
two groups. Where the price is set within this range depends on a variety of factors including
negotiating strength and the value the payer places on distribution considerations for the second
patient group – these have implications for who internalizes the cost of the single price
inefficiency.
Conclusion: Cost-effectiveness analyses often identify optimal price points based on a WTP
threshold. In cases where treatments have multiple indications, threshold price analyses depend
on additional features of patient populations and institutions.
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PS 4-47 EXAMINING THE HEALTH CARE DECISION-MAKING PREFERENCES OF
MILLENNIAL WOMEN
Patient and Stakeholder Preferences and Engagement (PSPE)
Priyanka Desai, MSPH1, Kari M. Mentzer, MA1, Donna McAlpine, PhD1, Mary Butler, PhD,
MBA1 and Cynthia Peden-McAlpine, PhD, ACNS, BC2, (1)University of Minnesota School of
Public Health, Minneapolis, MN, (2)University of Minnesota School of Nursing, Minneaplis,
MN
Purpose: To examine the health care decision-making preferences of millennial women when
considering clinical severity and available time with health care providers.
Method: We recruited 35 women residing in Minnesota and born between 1982 and 2000 to
participate in audio recorded, in-person interviews. The first section of the interview examined
previous health care decision-making experiences. The second part was a card sort exercise using
five statements reflecting passive, passive-shared, shared, active-shared, and active decisionmaking. Participants were given three scenarios with increasing severity: painful periods,
polycystic ovary syndrome (PCOS), and recurring ovarian cysts, and asked to sort the cards in
order of preference based on the scenario. For each scenario participants were asked questions
about their preferences and the role of time with health care providers. We transcribed interviews
and used transcripts for content analysis to identify common thematic elements.
Result: Participants overwhelmingly preferred an active-shared approach for the painful period
scenario. Shared decision-making was the most preferred approach for PCOS and recurring
ovarian cysts. When explaining preferences, participants discussed the tradeoff between personal
autonomy and information asymmetry, especially when treatment and management options
involved lifestyle factors. Autonomy was important regardless of participant age or health care
decision-making experiences. For more uncertain and severe situations, participants expressed a
willingness to give more power to health care providers due to their training and expertise, but
were rarely willing to cede all decision-making power. Several participants also expressed that
their preference would depend on the gender of their health care provider, preferring to make
decisions with a female provider. While participants acknowledged the value of sufficient time
with health care providers, there was not consensus regarding the role of time in health care
decision-making preferences.
Conclusion: For some health care situations, millennial women appear to prefer a more active
approach to health care decision-making where they not only participate as equals, but also act as
the final decision-maker. In addition to current efforts to implement shared decision-making,
health care organizations and providers should prepare to engage with patients who prefer an
active-shared or active model of decision-making.
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PS 4-48 PERSONALIZED DIABETES MANAGEMENT: DOES ONE SIZE FIT ALL IN
TERMS OF PATIENT VALUE?
Patient and Stakeholder Preferences and Engagement (PSPE)
Axel Mühlbacher, PhD, Christin Juhnke, B.Sc., M.A. and Andrew Sadler, M.Sc., Hochschule
Neubrandenburg, Neubrandenburg, Germany
Purpose: Personalized diabetes management can be seen as a kind of "standard process" that
provides both physicians and patients with a guideline. However, patients living with type II
diabetes differ in their preferences and values. How can these differences be analyzed and
described?
Method: A discrete choice experiment (DCE) was applied to identify preferences for a
personalized diabetes management in patients with type II diabetes mellitus. Six attributes were
included. The DCE was conducted using a fractional factorial design, and the statistical data
analysis used random effect logit and latent class models.
Result: Preference analysis of 227 patients (66.1% male) showed dominance for the attribute
"occurrence of severe hypoglycemia per year" (level difference (LD): 2,765). Preference analysis
also showed that participants weight the “risk of myocardial infarction (over 10 years)” (LD:
1.854) highest among the side effects. Within the effectiveness criterion of "change in the longterm blood glucose level (HbA1c)" a change at an initial value of 9.5% (LD: 1.146) is weighted
slightly higher than changes at 7.5% (LD: 1.141).
The latent class analysis shows three heterogeneous classes with different vlaues of the
therapeutic properties: for 1/3 of the respondents the change of the long-term blood sugar
(HbA1c value) is the top objective. Another third is solely interested in the short-term
effectiveness of the therapy in the sense of the occurrence of severe hypoglycemia per year. The
last third of the interviewees finally focuses on the follow-up with regard to cardiovascular
events. Overall, there were five structural and personality traits which have an influence on the
probability of the class membership.
Conclusion: Overall, the effectiveness of a care program is the most important from the
perspective of the patient and avoiding severe hypoglycemia has the greatest value and influence
on the choice. However, the analysis of possible subgroup differences by means of latent class
analysis, found that three preference patterns exist within the sample that vary significantly. This
raises the question on how to best tailor personalized management approaches to the preferences
and values of specific populations in order to improve the acceptability of and adherence to care
programs.
Ethical Research Declaration: The research has been conducted in accordance with the principles
of the Declaration of Helsinki of the World Medical Association.
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PS 4-49 STAKEHOLDER PERSPECTIVES ON THE IMPLEMENTATION OF
SHARED DECISION MAKING TO EMPOWER COMMERCIALLY SEXUALLY
EXPLOITED YOUTH
Patient and Stakeholder Preferences and Engagement (PSPE)
Samantha Sahl, MSW, LMSW1, Maria Isabella Pontoriero, MSW, LMSW1, Chloe Hill, MSW1
and Chris Knoepke, PhD, MSW, LCSW2, (1)New Orleans, LA, (2)Adult and Child Center for
Health Outcomes Research and Delivery Science, University of Colorado School of Medicine,
Aurora, CO
Purpose:
Commercial sexual exploitation of children (CSEC) is a prevalent problem characterized by
coercive relationships of power and control between victims and perpetrators. This traumatic loss
of autonomy and control is often compounded by service systems that act paternalistically
towards youth, failing to give them a voice or include them in treatment decisions, resulting in
common challenges of treatment non-adherence and drop-out. While integrating the voice of
CSEC youth into treatment planning decisions is easy to advocate, and recent models have
outlined possibilities for adapting shared decision making (SDM) for use in these contexts, little
is known about how to implement these models into the wide variety of venues serving CSEC
victims. The objective of this project was to explore key stakeholder perspectives on
implementing SDM into traditional service systems of intervention with CSEC youth.
Method:
Using a semi-structured interview guide and snowball sampling methods, we interviewed 16
multidisciplinary stakeholders from CSEC service organizations in New Orleans, Louisiana,
covering 1) perspectives on the inclusion of youth voice in CSEC treatment planning decisions;
and 2) suggestions for how to support the implementation of SDM to engage CSEC youth in
such decisions. All interviews were qualitatively analyzed using a combined inductive-deductive
framework.
Result:
Qualitative analyses revealed the presence of five themes across the two areas of interest,
including 1) Inclusion of Youth Voice in the Current System; 2) Importance of Including Youth
Voice; 3) Barriers to Including Youth Voice; 4) Benefits/Challenges to Applying SDM to CSEC
Treatment Decisions; and 5) Implementation Considerations. In addition to those appearing in
Table 1, representative quotes will be included and discussed.
Conclusion:
Service providers who work with CSEC youth philosophically support including youth voice in
treatment planning decisions, but lack processes and tools for doing so effectively and
consistently. While models of SDM common to other areas of medicine hold promise in
supporting stability, adherence, and the victim-centered quality of decision making, an ethical
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tension between supporting youth agency and desiring to protect them persists. Participants felt
that SDM would be most effectively implemented through policy-level mandates, training, and
fidelity monitoring to be effective in engaging juvenile justice and child welfare systems.
PS 4-50 INTENSIVE CARE UNIT EXPERIENCES OF PATIENTS AND FAMILIES
Patient and Stakeholder Preferences and Engagement (PSPE)
Jorie M. Butler, PhD, University of Utah School of Medicine, Department of Internal
Medicine, Division of Geriatrics, Salt Lake City, UT, Eliotte Hirshberg, MD, University of Utah,
Division of Pulmonary Medicine, Department of Internal Medicine, Salt Lake City, UT, Samuel
Brown, MD, MS, Division of Pulmonary Medicine, Department of Internal Medicine, University
of Utah, Salt Lake City, UT, Sarah Beesley, MD, Intermountain Healthcare, Salt Lake City, UT
and Ramona Hopkins, PhD, Psychology Department and Neuroscience Center, Provo, UT
Purpose:
The intensive care unit (ICU) is characterized by uncertainty and medical complexity. This can
be an emotionally charged environment for patients. To create a patient centered care
environment it is crucial to understand patient and family ICU experiences. This qualitative
study examines patient and family experiences during an ICU admission in a culturally diverse
population.
Method: We recruited participants age 18 years or older who had been hospitalized in the
Intensive Care Unit (ICU) or had a family member hospitalized in the ICU within the preceding
10 years. Participants were recruited from a major medical center and Community Faces of Utah
(CFU), a partnership among University of Utah, the Utah Department of Health, and five
ethnically diverse communities in the state of Utah. Community Faces of Utah is dedicated to
improving health access with local healthcare partners. We conducted four focus groups using a
semi-structured script and recorded and transcribed. Transcripts were analyzed using qualitative
analytic software NVIVO using an approach consistent with grounded theory by a health
psychologist, pulmonologist and research scientist. Member checking was conducted. Quotes
were coded and codes were combined to create themes.
Results: Codes included 1) participant experiences prior to the illness (normal), 2) the ICU
experience at large, 3) communication and decision making in the ICU 4) feelings about the ICU
experience 5) the impact of the ICU on their lives and 6) concerns about the future after critical
illness. Five main themes emerged f: 1) Personalized ICU stories - a narrative encapsulating the
experience; 2) Communication and shared decision making, 3) Adjustment to life after critical
illness. 4) Trust toward clinical team and relevance of cultural beliefs, and 5) End of life decision
making. Across themes, we observed a misalignment between the medical system and
patient/family values and priorities.
Conclusion: The five identified themes reflect the construction of a narrative around the
powerful human experience of an ICU admission. Clinical providers need to be aware of the
lasting effects of the ICU experience on patients and families. This will help personalize
communication during the ICU that can enhance patient and family centred care.
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PS 4-51 OPTIMIZING PORTFOLIOS OF RESEARCH STUDIES DESIGNED TO
INFORM ECONOMIC EVALUATIONS
Quantitative Methods and Theoretical Developments (QMTD)
Michael Fairley, MS, Department of Management Science and Engineering, Stanford University,
Stanford, CA, Lauren E. Cipriano, PhD, Ivey Business School, Western University, London,
ON, Canada and Jeremy D. Goldhaber-Fiebert, PhD, Stanford Health Policy, Centers for
Health Policy and Primary Care and Outcomes Research, Stanford University, Stanford, CA
Purpose: By including Expected Value of Sample Information (EVSI) analyses alongside costeffectiveness analyses, decision makers can assess both the value of implementing treatments as
well as value of collecting additional information to reduce decision uncertainty. Such analyses
can also determine the optimal sample size for a future research study. However, just as decision
makers must consider portfolios of implementation decisions, they must also identify the
portfolio of optimally sized research studies -- requiring consideration of nuanced trade-offs.
Methods: Under a fixed research budget, decision makers must determine which studies to fund:
additional sample size allocated for one study (concerning a given coverage decision) implies
less for others (concerning different coverage decisions). We provide a framework for
determining the optimal research portfolio and level of investment in each research study. We
construct a mathematical optimization problem where the objective is to maximize the sum of
the population expected net benefit of sampling (ENBS) for each study. We formulate the
problem as a budget-constrained mixed-integer program where decisions are whether to invest in
a study and if so at what sample size.
Results: Among studies selected for at least some investment (i.e., non-zero sample size), the
optimal sample size is at a point on each studies’ ENBS-sample size curve where the marginal
population EVSI divided by the marginal sampling cost is equal for all studies (Figure 1, points
A1 & A2). The slope of the tangent at this point is the shadow price of the research budget
constraint. Unlike standard ENBS optimization which does not incorporate an overall research
budget constraint, the typical optimal sample size we identify is smaller (compare A1 & A2, to
B1 & B2). Compared to an optimization problem in which the decision variables are only in
which studies to invest (where sample size is pre-selected at the level that maximizes ENBS for
the study), including the sample size as a decision variable can increase the number of funded
studies and overall ENBS achieved.
Conclusions: When research studies selection is considered as a portfolio, selecting sample sizes
that maximize each studies’ ENBS is not necessarily optimal. Portfolio optimization is superior
because it can yield higher total ENBS for a fixed research budget.
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PS 4-52 BAYESIAN CALIBRATION FOR THE RESEARCHING EFFECTIVE
STRATEGIES TO PREVENT OPIOID DEATH (RESPOND) MODEL
Quantitative Methods and Theoretical Developments (QMTD)
R. W. M. A. Madushani, PhD1, Jianing Wang, MS2, Shayla Nolen, MPH2, Golnaz Eftekhari
Yazdi, MSc2, Caroline Savitzky, MSW2, Jake R. Morgan, PhD, MS3, Rachel L. Epstein, MD,
MA4, Joshua A. Barocas, MD5, Benjamin P. Linas, MD, MPH2 and Laura F. White, PhD3,
(1)Boston Medical Center, Boston, MA, (2)Section of Infectious Disease, Department of
Medicine, Boston Medical Center, Boston, MA, (3)Boston University, Boston, MA,
(4)Department of Internal Medicine, Section of Infectious Diseases, Boston Medical Center,
Boston, MA, (5)Boston University School of Medicine, Boston, MA
Purpose: Simulation models of opioid use disorder (OUD) that seek to estimate population-level
outcomes must address uncertainty in both the OUD population size, and critical transition rates
between health states. We describe an approach to infer model parameters that combines the
population size estimates from “capture-recapture” analysis, with Bayesian calibration
techniques to substantially improve simulation results and quantify uncertainty.
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Methods: RESPOND is a compartmental model that simulates the population with OUD in
Massachusetts. The primary data source is the Massachusetts Public Health Data Warehouse
(PHD), a novel dataset that longitudinally links person-level MA administrative records. We
utilized capture-recapture analysis to estimate the OUD population in MA, and to quantify
uncertainty in the likelihood for model outcomes. (Barocas et al. AJPH 2018). We then
employed a Bayesian calibration approach to estimate the demographics of “arrivals” of people
with OUD, as well as standardized mortality ratios (SMR) for patients using injection and noninjection opioids . We created prior distributions of parameters governing the new OUD arrivals
using regression analysis of the age and sex characteristics of recent initiates to opioid use in the
National Survey on Drug Use and Health. We developed prior distributions of SMR using PHD.
We generated posterior samples of the Bayesian calibration using a Metropolis Hastings Markov
Chain Monte Carlo algorithm. Finally, we conducted a probabilistic sensitivity analysis (PSA)
using the prior distributions defined in the Bayesian approach. We compare model performance
using uncalibrated priors and Bayesian calibrated posteriors.
Results: The figure illustrates the Bayesian calibrated posterior distributions, the target
likelihoods, and the prior distributions from PSA of model outcomes for six different age-gender
categories in 2015. Preliminary calibration results demonstrate that for all strata except females
ages 25-45, the Bayesian calibration creates OUD population size estimates that are closer to the
target distribution of age-gender stratified OUD counts compared to PSA.
Conclusion: This analysis demonstrates the utility of combining capture recapture with Bayesian
calibration to improve the performance of simulation models of OUD. The calibrated simulation
results do not yet perfectly match empirical population estimates, but this exercise was limited to
two simulatuion parameters. Future directions will incorporate substance use transitions and
include multiple calibration targets.
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Figure. Comparison of Bayesian posteriors to target likelihoods and uncalibrated priors of model
outcomes.

PS 4-53 ARE DIFFERENCES IN CLINICAL OUTCOME BETWEEN STROKE
CENTERS EXPLAINED BY CASE-MIX, PROCESS MEASURES, AND CENTER
VOLUME?
Quantitative Methods and Theoretical Developments (QMTD)
Marzyeh Amini, MSc1, Nikki van Leeuwen, PhD1, Frank Eijkenaar, PhD2, Jan Hazelzet, MD,
PhD1, Diederik W.J. Dippel, MD, PhD3, Bob Roozenbeek, MD, PhD3, Hester F. Lingsma, PhD1
and MR CLEAN Registry Investigators, (1)Department of Public Health, Erasmus University
Medical Center, Rotterdam, Netherlands, (2)Erasmus School of Health Policy and Management,
Erasmus University, Rotterdam, Netherlands, (3)Department of Neurology, Erasmus University
Medical Center, Rotterdam, Netherlands
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Purpose:
To compare outcome between centers after endovascular treatment (EVT) for acute ischemic
stroke and assess the effect of case-mix, process measures, and center volume on between-center
differences in outcome.
Method:
All patients undergoing EVT for acute ischemic stroke between 2014 and 2017 in all centers
providing EVT were registered in the Netherlands. We analyzed between-centers differences in
functional outcome measured with the modified Rankin Scale (mRS), an ordinal measure of
disability ranging from 0 (no symptoms) to 6 (death), at 90 days after stroke with a random effect
proportional odds regression model. Patient characteristics, processes measures (time from
arrival in the emergency department (ED) of the intervention center to reperfusion and use of
general anesthesia) and center volume (number of patients treated per year) were added to the
model as independent variables. Models were compared with Akaikeʼs Information Criterion
(AIC). A lower AIC value indicates a better model fit. The between-center variance was
quantified with the variance of the random effects (tau2).
Result:
We included 3201 patients from 17 centers. Outcome varied substantially between centers (32%49% of patients with mRS 0-2). The same was true for case-mix (26%-57% predicted probability
of mRS 0-2 based on patient characteristics). Center volume ranged between 23 and 399 patients.
In terms of processes, median time from arrival in the ED to reperfusion varied 122-203 minutes
for non-transferred patients and 76-112 minutes for patients transferred from another center. The
use of general anesthesia varied from 0-99%. Significant associations with outcome were found
for time from arrival in the ED to reperfusion (OR=0.92, 95%-CI=0.89-0.96) and use of general
anesthesia (OR=0.64, 95%-CI=0.51-0.81), while center volume had no effect (OR=1.00, 95%CI=0.97-1.03). In the unadjusted model with only a random intercept for center, the betweencenter variance in outcome (tau2) was 0.031 (AIC=10829). The variance increased after adjusting
for case-mix (tau2= 0.069, AIC=9828), while adjusting for process/volume left the variance
largely unchanged (tau2=0.074, AIC=9776).
Conclusion:
Although between-center differences in functional outcome after EVT are influenced by
processes of stroke care, variation in case-mix explains between-center differences in outcome to
a much greater extent, while center volume has no clear effect. Therefore, functional outcome
may not be valid as an indicator of the quality of stroke care and have limited value for
comparing hospital performance.
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PS 4-54 QUANTIFYING THE INFORMATION PROVIDED BY MULTIPLE
DIAGNOSTIC TESTS
Quantitative Methods and Theoretical Developments (QMTD)
William Benish, MS, MD, Case Western Reserve University, Shaker Heights, OH
Purpose: Information theory functions have been used to quantify diagnostic uncertainty,
diagnostic information, and diagnostic test performance. Since more than one diagnostic test is
often required to diagnose a patientʼs condition, we extend the application of the theory to
calculate the information provided by multiple diagnostic tests.
Method: Basic information theory functions are defined on random variables. For a given
population of patients, the disease state, S, and the test result, R, for a patient randomly selected
from the population are random variables. The entropy of S, H(S), quantifies the uncertainty
about S. The mutual information between S and R, I(S;R), quantifies the expected value of the
amount of information that R will provide about S. The relative entropy function quantifies the
amount of information provided by a specific test result. We extend the mutual information and
relative entropy functions to apply to situations in which there is more than one diagnostic test.
The theory is applied to the results of a study by Anderson et al (J Thromb Haemost 2003;1:645651; see Table 1) which evaluated a clinical index and the d-dimer test in the diagnosis of deep vein
thrombosis (DVT).
Table 1 Number of patients with and without a DVT as a function of the clinical index and the ddimer test.

Clinical Index
Low risk
Moderate risk
High risk

d-dimer
+
+
+

DVT+
3
17
15
61
15
79

DVT313
113
243
93
50
55

Result: The Figure below presents pertinent equations and results. The expected values of the
information provided by the tests, even in combination, do not substantially decrease the pretest
uncertainty. For the subset of patients with a high clinical index and a negative d-dimer, the
information provided by each test performed separately is negative, indicating that the pretest
probability is a better estimate than the posttest probabilities. The clinical value of performing these
tests is in ruling out a DVT--the combination of a low clinical index and a negative d-dimer provides
0.230 bits of the 0.286 bits of information required to rule out a DVT.
Conclusion: Information theory allows for the quantification of the information provided by multiple
diagnostic tests.
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PS 4-55 OPTIMAL ALLOCATION OF CLINICAL TRIAL SAMPLE SIZE TO
SUBPOPULATIONS WITH CORRELATED PARAMETERS
Quantitative Methods and Theoretical Developments (QMTD)
Michael Fairley, MS, Department of Management Science and Engineering, Stanford University,
Stanford, CA, Lauren E. Cipriano, PhD, Ivey Business School, Western University, London,
ON, Canada and Jeremy D. Goldhaber-Fiebert, PhD, Stanford Health Policy, Centers for Health
Policy and Primary Care and Outcomes Research, Stanford University, Stanford, CA
Purpose: Recent focus on precision medicine highlights the importance of identifying
subpopulation-specific cost-effective treatments. Different levels of decision uncertainty and
correlations across subpopulations necessitate novel clinical trial designs in which allocated
sample size can vary by subpopulation.
Methods: We provide a mathematical framework for designing clinical trials to identify optimal
treatments for subpopulations when prior information indicates potential heterogeneous
treatment effects, allowing for correlation in prior uncertainty. We develop a budget-constrained,
non-linear program where the objective is to maximize the Expected Net Benefit of Sampling
(ENBS) for each subpopulation weighted by the size of the subpopulation; the decision is the
number of samples to take from each subpopulation. We incorporate correlation between
subpopulations so that sampling from one subpopulation also provides information about other
subpopulations.
Results: We provide the first-order necessary optimality conditions for the allocation of sample
size and show for subpopulations with a non-zero optimal sample size that the optimal allocation
occurs at the point where the marginal population EVSI divided by the marginal cost of sampling
is equal for all subpopulations. We derive an analytical expression for ENBS with any number of
subpopulations and treatment options when the prior and likelihood are Gaussian and the utility
function is linear. We derive an expression for the preposterior mean in terms of the prior when
there is correlation between the priors of two subpopulations. In a numerical example with two
subpopulations and a higher sampling cost for subpopulation 2 (Figure 1), we find cases where
incorporating non-zero correlation results in optimal sampling where: 1) there is a lower sample
size for the more costly subpopulation; 2) there is a lower total sample size (hence, total study
cost decreases) which can even mean decreases in sampling for the less costly subpopulation.
Hence, if one does not consider correlation, optimizing trial designs can lead to more costly trials
yielding less ENBS.
Conclusions: In the context of precision medicine, stratifying clinical trial populations and
optimizing the allocation of subpopulation-specific sample size can increase ENBS. Correlation
in prior uncertainty across subpopulations complicates this optimal allocation because
information about one subpopulation provides information about others. These findings highlight
the importance of incorporating correlations from previous studies into priors used in health
economic analyses.
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PS 4-56 AN AGENT-BASED NETWORK MODEL OF HEPATITIS C VIRUS
TRANSMISSION AMONG PEOPLE WHO INJECT DRUGS CALIBRATED TO A
HIGH-BURDEN RURAL POPULATION IN THE UNITED STATES
Quantitative Methods and Theoretical Developments (QMTD)
Lin Zhu, PhD1, Jennifer R. Havens, PhD, MPH2, Abby E. Rudolph, PhD, MPH3, April M.
Young, PhD, MPH4, Golnaz Eftekhari Yazdi, MSc5, William W. Thompson, PhD6, Liesl Hagan,
MPH6, Liisa M. Randall, PhD7, Benjamin P. Linas, MD, MPH5 and Joshua A. Salomon, Ph.D.8,
(1)Harvard T.H. Chan School of Public Health, Boston, MA, (2)Center on Drug and Alcohol
Research/Department of Behavioral Science, University of Kentucky College of Medicine,
Lexington, KY, (3)Department of Epidemiology and Biostatistics, Temple University College of
Public Health, Philadelphia, PA, (4)Department of Epidemiology, University of Kentucky
College of Public Health, Lexington, KY, (5)Section of Infectious Disease, Department of
Medicine, Boston Medical Center, Boston, MA, (6)Division of Viral Hepatitis, Centers for
Disease Control and Prevention, Atlanta, GA, (7)Bureau of Infectious Disease and Laboratory
Sciences, Massachusetts Department of Public Health, Boston, MA, (8)Center for Health Policy
and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA
Purpose: To develop an agent-based network model of hepatitis C virus (HCV) transmission
among people who inject drugs (PWID) in rural areas.
Method: Baseline data from the Social Networks among Appalachian People (SNAP) study
were used to estimate the full size and structure of a PWID network in rural Eastern Kentucky. In
the SNAP study, 503 people who use drugs (including 309 PWID) were recruited through
respondent-driven sampling (RDS) from 2008 to 2010, and followed up for two years. We
defined partnerships as “injecting together.” The reported degree distribution was adjusted to
include unreported partnerships with individuals outside the SNAP sample. We used exponential
random graph models to reconstruct the full network, which was characterized by mean degree,
transitivity (a measure of clustering), age and gender mixing. We adjusted quantitative network
features to correct for biases introduced by RDS, using methods we have developed and reported
in another study. We calibrated parameters governing injection equipment-sharing behaviors and
HCV transmission to match prevalence and incidence estimates from SNAP.
Result: The estimated PWID population size in this rural area was 790. The simulated networks
had demographics and HCV serostatus consistent with the SNAP sample, including 57% male,
mean age of 32 years, and 57% HCV-antibody positivity. The mean degree in the full network
was 2.0 overall (2.3 for males, and 1.6 for females), slightly lower than observed in SNAP due to
adjustments for unreported partnerships and RDS bias. The full simulated network appears
visually denser than the SNAP sample (figure), consistent with network expansion while
preserving adjusted density and mean degree. Calibrating to the observed incidence of 0.028 per
person-month among PWID having at least one partner, we estimated a monthly transmission
probability of 0.025 per discordant partnership. Considering the chain of onward transmission,
we estimated that each person who was infected at baseline would result in 1.6 additional
infections in the network.
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Conclusion: We developed and calibrated an agent-based network model of HCV transmission
among PWID in a rural area using a longitudinal RDS dataset with multiple empirically-derived
adjustments. The model provides a useful platform for evaluating hepatitis C prevention and
control strategies.

PS 4-57 DEVELOPING AN AGENT-BASED MODEL FOR THE ASSESSMENT OF
HEPATITIS C CONTROL STRATEGIES IN CANADA
Quantitative Methods and Theoretical Developments (QMTD)
Abdullah Hamadeh, PhD1, Zeny Feng, PhD2, Murray Krahn, MD, MSc, FRCPC3 and William
W. L. Wong, PhD1, (1)School of Pharmacy, University of Waterloo, Kitchener, ON, Canada,
(2)Department of Mathematics and Statistics, University of Guelph, Guelph, ON, Canada,
(3)Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto,
ON, Canada
Purpose: The WHO has called for a reduction in hepatitis C incidence by 90% by 2030. This
goal has been adopted by Canada. To achieve this target, birth cohort screening has been
recommended as a key strategy. However, on its own, this strategy will likely be insufficient,
and additional national efforts composed of both population-level and targeted high risk
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interventions will likely be required. The aim of this work is to identify the type and the scale of
strategies that can achieve the WHO targets.
Method: To simulate these strategies, we built an agent-based model in which disease
transmission takes place through randomly-evolving contact networks representing injectiondrug networks and sexual transmission networks. Individual agents were characterized by sex,
age, geographic location, disease state, injection drug use and sexual behavior. Over time,
infected agents’ disease states evolved according to a validated hepatitis C state transition model.
In each time step, each infected agent may infect each of its healthy partners with a probability
dependent on the two individuals’ characteristics, such as their injection drug use or sexual
behavior. Infection probabilities were calibrated by comparing the modelʼs predicted outcomes
against Ontario administrative data describing hepatitis C outcomes. Policy scenarios including
birth-cohort screening and supervised drug injection were included as initial options in the
model.
Result: Simulated estimates of chronic hepatitis C (CHC) clinical outcomes from 2000 to 2014
were consistent with observed health administrative data on CHC incidence, advanced liver
disease incidence and CHC treatment. Under the current policies of only risk-based screening
and unrestricted publicly-funded direct-acting antiviral reimbursement, between 2020 and 2030,
there was a decline in yearly CHC incidence among Ontarians born between 1964 and 1996 from
17 to 9 per 100,000 population. Over this period, the model projects a fall in the birth cohortʼs
CHC prevalence from 0.38% to 0.26%.
Conclusion: The calibrated model was able to reproduce hepatitis C health outcomes data
observed within the calibration period. Under current policies, the model predicts that the WHO
hepatitis C elimination targets will not be met. Once fully developed, the model will be able to
forecast the hepatitis C burden under both the status quo and prospective hepatitis C policy
interventions.
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PS 4-58 THE APPLICATION OF A 30-DAY PNEUMONIA READMISSION MODEL AT
AN EXTERNAL HEALTHCARE INSTITUTION
Quantitative Methods and Theoretical Developments (QMTD)
Kristin Lenoir, MPH1, Erin Barnes, MD1, Michael McCrory, MD1, Amit Saha2, Christopher
Jones1, Christopher Webb1, Alysha Taxter1, Elizabeth Halverson1, Jason Itri1, Ajay Dharod1,
Arjun Chatterjee1, Derek Richardson1 and Brian Wells, MD, PhD1, (1)Wake Forest School of
Medicine, Winston-Salem, NC, (2)Wake Forest, winston salem, NC
Purpose: Prediction models are increasingly utilized among medical institutions to target care
with the aim of reducing outcomes such as pneumonia readmissions. This is an area of focus for
the Centers for Medicare and Medicaid Services (CMS) Hospital Readmission Reduction
Program. It is unknown whether models developed at one institution will perform sufficiently at
external institutions. This abstract examines the external validity of a 30-day all-cause
pneumonia readmission model developed by investigators at the Cleveland Clinic (CC) when
applied to data at Wake Forest Baptist Health (WFBH) by two methods: the direct application of
the original equation versus refitting the model to obtain new coefficients using the same
variables.
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Method: Index pneumonia cases between 10/1/2015 and 6/1/2018 were identified by ICD-10
codes used in the CMS definition for pneumonia. Exclusion criteria encompassed <18 years old,
death during index admission, discharge to an acute care facility, or leaving against medical
advice. Variables in the CC model were extracted from the electronic health record. Data from
2015 – 5/31/2017 served as the training dataset (N=16,483) to refit variable coefficients. Model
performance was assessed in a test dataset consisting of data post 5/31/2017. Missing data were
imputed 5 times with replacement.
Result: The test dataset included 3063 admissions with 329 (10.7%) all-cause readmissions
within 30 days. The mean age of the population was 65.5 (SD 16.6), 1048 (50.8%) were females,
542 (17.8%) identified as non-white, and 63 (3.3%) were Hispanic. The international normalized
ratio variable included in the CC model was missing in ~ 96% of the WFBH data. The direct
application of the CC equation and the refit equation achieved C-statistics of 0.704 (SD 0.029)
and 0.766 (SD 0.269), respectively. The model created by refitting variables demonstrated better
calibration but both models tended to overestimate rates of readmission especially among the
highest risk group.
Conclusion: The CC equation worked well in the external dataset at WFBH. The refit model
outperformed the original equation, but there were noticeable differences in variable availability
and distributions between the two institutions. Healthcare systems need to determine if the
process of refitting is worth the additional benefit.
PS 4-59 AN EXPLORATION OF THE TRADE-OFF BETWEEN FALSE NEGATIVES
AND FALSE POSITIVES WHEN IDENTIFYING SUBGROUP EFFECTS.
Quantitative Methods and Theoretical Developments (QMTD)
Neil Hawkins, PhD1, Claudia Geue, PhD1, Jeremy Oakley, PhD2, Richard Grieve, PhD3 and
Monica Hernandez, PhD4, (1)University of Glasgow, Glasgow, United Kingdom, (2)University
of sheffield, Sheffield, United Kingdom, (3)London School of Hygiene and Tropical Medicine,
London, United Kingdom, (4)University of Sheffield, Sheffield, United Kingdom
Purpose: To comparethe performance of alternative statistical methods in terms of inference and
estimation regarding subgroup (interaction) effects amongst a set of candidate variables using
simulation studies. The simulation model was also used to evaluate the potential performance of
pre-specified subgroup analyses in example trials.
Methods: Fixed effects, random effects, lasso and mixture models were compared. The fixed
interaction effects model estimates subgroup interaction effects independently. The random
interaction effects model treats the subgroup interaction terms as a random effects and provides
shrunken estimates. Lasso regression forces certain coefficients to be set to zero so that the sum
of the absolute value of the regression coefficients is less than a fixed value.The mixture model
represents the subgroup interaction terms as a mixture of zero and non-zero values.
The models were compared in simulation studies where the true interactions effects are known.
The inferential performance of the models was assessed by estimating the probability of falsely
identifying at least one subgroup (any false positive rate) and the probability of failing to identify
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at least one positive subgroup (any false negative rate) as the threshold for accepting a subgroup
effect was varied. The bias and precision (Mean Absolute Deviation) of interaction effects were
estimated for identified subgroups. Simulations were also run based on pre-specified subgroup
analyses and power calculations from example trials.
Results: The models were compared using “ROC” curves were formed illustrating the trade-off
between the risks of accepting false subgroup effect and rejecting true subgroup effects. In terms
of inference, when true subgroup effects were relatively rare, there was evidence that the random
effects and mixture models may provide better inference than the fixed effects models. The
random and fixed effects models perform better in terms of bias and the random effects model
performs better in terms of precision.
Conclusion: There are trade-offs between the performance of the alternative models for the
identification of subgroups in terms of inference and estimation. However, for most trials the
performance of these models to reliably identify subgroup effects from a set of candidate
variables is limited in the absence of prior information.
PS 4-60 APPLICATION OF A MACHINE LEARNING MODEL TO PREDICT
SURVIVAL OUTCOMES FOR PATIENTS WITH ADVANCED RENAL CELL
CARCINOMA (ARCC) TREATED WITH NIVOLUMAB
Quantitative Methods and Theoretical Developments (QMTD)
Alind Gupta, PhD1, Paul Arora, PhD1, Darren Brenner, PhD1, Mark Edmonson-Jones, MSc2,
Elena Parkhomenko, PhD2, Warren Stevens, PhD2, Samuel Wagner, PhD3, John Borrill, MSc4
and Elise Wu, PhD3, (1)Lighthouse Outcomes, Toronto, ON, Canada, (2)PAREXEL, London,
United Kingdom, (3)Bristol-Myers Squibb, Princeton, NJ, (4)Bristol-Myers Squibb, Uxbridge,
United Kingdom
Purpose: A long-term survival (LTS) benefit of Immuno-oncology (I-O) therapies is observed
only in a subset of cancer patients. This study sought to identify possible causes of variability in
patient response to immunotherapy. A second aim was to identify patient subgroups with the
highest probability of LTS on I-O therapies without resorting to the assumptions of
independence between exposures and linear relationships imposed by traditional linear
regression models.
Method: A machine learning approach, Bayesian networks (BNs), was used for the predictive
modeling of the CheckMate 025 dataset. This was a randomized phase 3 clinical trial comparing
nivolumab to everolimus in 821 patients with previously-treated aRCC. BNs are probabilistic
models well-suited to risk modeling due to their transparency, flexibility in handling missing
data, and their ability to capture multiple statistical interactions that are difficult to model with
regression. The R package bnlearn was used to learn the BN structure from data using
bootstrapping for estimation of learned edges. These edges were then parameterized by using
Bayesian estimation. This trained BN was used to calculate prognostic rankings for variables to
predict overall survival (OS) at months 12, 24, and 36, and to identify patient profiles that were
most likely to respond to nivolumab. Classification performance of BNs was compared to Lasso-
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regularized logistic regression by calculating the area under the receiver operating characteristic
curve (AUC).
Result: BNs classified OS at month 12 with AUC of 0.74 ± 0.06, which compares favorably
with established predictive models (AUCs: 0.63-0.73). Performance was on par with state-of-theart Lasso-regularized logistic regression model across time points. Risk scores (MSKCC, Heng),
biomarkers (hemoglobin, albumin) and performance status were most prognostic of OS at month
12, with patients most likely to respond favorably having health state utility values >0.85 at
baseline. Progression, response and subsequent therapy in the time periods 13-24 and 25-36
months showed strong predictiveness on OS at months 24 and 36 respectively, compared to
baseline variables.
Conclusion: BNs were suitable for modeling interactions between variables and identified sets
of variables to be prognostic of OS in patients receiving nivolumab. Future work should use
dynamic BNs to model time-varying characteristics to improve predictive performance for
modeling the effect of I-O treatments, and incorporate real-world evidence to improve the
generalizability of results.
1A-1 INCORPORATING OUTCOMES DATA FROM LARGE REGISTRIES AND
ADMINISTRATIVE DATABASES TO IMPROVE APPROPRIATENESS CRITERIA
FOR TOTAL KNEE REPLACEMENT
Decision Psychology and Shared Decision Making (DEC)
Hassan Ghomrawi, PhD, MPH1, Daniel Riddle, PhD, PT2, Mohamed Hasan, MBBS1, Jing
Song1, Lisa Mandl, MD, MPH3, Michael Parks, MD4, Mohamed Moussa, MD5, Matthew Beal,
MD6, Linda Russell, MD7, Jason Mathias, MD, MPH1, Pamela Semanik, PhD, CPN8, Dorothy
Dunlop, PhD1, Patricia Frnaklin, MD, MBA, MPH1 and Rowland Chang, MD, MPH9,
(1)Northwestern University, Chicago, IL, (2)Virginia Commonwealth University, Richmond,
VA, (3)Hospital for Special Surgery and Weill Cornell MEdicine, New York, NY, (4)Hospital
for Special Surgery, New York, NY, (5)Kaiser Permanente, Anaheim, CA, (6)Northwestern
UNiversity, Chicago, IL, (7)Hospital for Special Surgery and Weill Cornell Medicine, New
York, NY, (8)Rush University, Chicago, IL, (9)Institute for Public Health and Medicine,
Northwestern University, Chicago, IL
Purpose: Appropriateness criteria (AC) are important tools to assess overuse and underuse of
elective surgical procedures. Numerous AC have been developed for elective total knee
replacement (TKR); however, existing AC focus on clinical presentation but do not consider
expected outcomes following surgery. With recent availability of longitudinal outcome data from
patient registries and administrative databases, we aimed to develop new AC that also included
expected outcomes.
Methods: TKR AC developed by Escobar et al. and modified by Riddle et al. are the most
widely cited AC for TKR. These AC include 16 hypothetical appropriateness scenarios based on
5 clinical factors: age, osteoarthritis radiographic severity, knee stability, symptoms severity, and
number of knee compartments with osteoarthritis). To update the AC, we expanded these
scenarios to include 3 additional outcomes-based factors: risk of serious complications (0%, 1-
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2%, 3-5%), time to revision (<5, 5-15, >15 years), and improvement in pain and function 2 years
after surgery (little, some, a lot). We also assembled a clinicians’ panel (3 orthopedic surgeons, 2
rheumatologists, 2 internists, 1 physical therapist, 1 experienced nurse practitioner) to rate the
scenarios. Scenarios identified by panel orthopedic surgeons as not clinically plausible were
excluded. Then clinically plausible scenarios were scored by all 9 panel members for
appropriateness on a 1-9 scale, and the median score for each scenario was classified into one of
3 categories: inappropriate 1-3, maybe appropriate 4-6, and appropriate 7-9. Classification and
Regression Tree (CART) analysis was applied to the TKR AC appropriateness categories to
determine the contribution of each factor to appropriateness classification.
Results: Including all possible combinations of factors resulted in 427 scenarios. After vetting
by orthopedic surgeons, 279 were deemed clinically plausible, of which 71 were considered
inappropriate, 112 maybe appropriate, and 96 appropriate. CART analyses (Figure) showed that
outcomes-based factors: improvement expected at 2 years, time to revision, symptoms, and risk
of complications were key variables that discriminated among the classifications. Terminal nodes
(grey) indicate the final distributions of ratings of appropriate (App), may be appropriate (Maybe
App), and inappropriate (Inapp). Misclassification rate was 13.4%.
Conclusions: Expected outcome data appear to be highly valued by clinicians when determining
appropriateness for TKR. How these data influence decision making of patients contemplating
TKR should be investigated further.
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1A-2 THE USE OF DIAGNOSTIC DECISION SUPPORT CAN REDUCE BIAS IN
CLINICAL DOCUMENTATION
Decision Psychology and Shared Decision Making (DEC)
Chris Tracey, MD, MSc, Brendan Delaney, MD and Olga Kostopoulou, PhD, Imperial College
London, London, United Kingdom
Purpose: The development of clinical prediction rules (CPRs) is increasingly based on primary
care data routinely documented during the clinical consultation. Relying entirely on coded data,
omitting free text, can lead to inflated positive predictive values in CPRs (Price et al. 2016). We
hypothesised that both coded and free-text data documented in the patient record can be biased
by the diagnosis that the physician gave.
Method: We performed a secondary analysis of all data items (free-text and coded) that 34
General Practitioners (GPs) documented during consultations with 12 standardized patients
(actors)(408 consultations). In half of the consultations, the GPs had used a prototype diagnostic
aid that suggests differential diagnoses at the start and facilitates coding of symptoms during the
consultation (Kostopoulou et al. 2017). The 12 patient scenarios consisted of pre-defined sets of
clinical cues and differential diagnoses. Five GPs, not involved in the original study,
independently identified the clinical cues that were consistent with each differential diagnosis.
We designated a cue as consistent with a diagnosis, if 3 out of the 5 GPs had identified it as such.
For each of the 34 GPs who took part in the original study, we estimated the proportion of data
items they had documented in the patient record that were consistent with the diagnosis that they
finally gave. We compared the total number of data documented, and the proportion of
diagnosis-consistent data documented in aided vs. unaided consultations. We employed mixed
effects linear regressions.
Results: In the aided vs. unaided consultations: 1) There was a significant overall increase in the
amount of documentation (b=3.58 [2.81-4.35] p<0.001), with more coded and fewer free-text
data items. 2) The proportion of documentation consistent with the GPʼs diagnosis was
significantly lower (b=-0.08 [-0.11 to -0.05] p<0.001), for both coded and free-text data. In 60%
of the unaided consultations, where codes had been entered, they were all consistent with the
GPʼs diagnosis.
Conclusion: A high proportion of documented data consistent with the final diagnosis suggests
bias: the GP documents preferentially data that support his/her diagnosis. Using the diagnostic
aid led to more complete and less biased documentation. This has implications for the use of
routine data in diagnostic research, and the opportunity to learn new and valid relationships
between symptoms and diagnoses.
1A-3 USING A DIAGNOSTIC AID CHANGES PHYSICIAN BEHAVIOR IN THE
CONSULTATION
Decision Psychology and Shared Decision Making (DEC)
Sonny Ramtale, MSc, Brendan Delaney, MD and Olga Kostopoulou, PhD, Imperial College
London, London, United Kingdom
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Purpose:
Decision support systems (DSS) have the potential to improve diagnosis when used during the
medical consultation. A previous study of a prototype DSS that suggests diagnoses at the start
and facilitates coding during the primary care consultation found improved diagnostic accuracy
(Kostopoulou et al. BJGP 2017). We sought to explore how the DSS influenced observable
General Practitioner (GP) behaviour.
Method:
We analysed 391 videotaped consultations of GPs and standardised patients (actors). In half of
the consultations, the GPs used the DSS, integrated with the electronic patient record. We
constructed a coding scheme for activities of interest, which went through several cycles of
refinement during discussions among the authors and a patient co-designer. For each
consultation, we created a complete timeline of events by timestamping the activities of interest
using ELAN (https://tla.mpi.nl/tools/tla-tools/elan/). We then used Fluxicon Disco
(https://fluxicon.com/), a process-modelling tool, to estimate the frequency and duration of
activities. We conducted multilevel logistic and linear regressions to compare aided (with the
DSS) with unaided consultations.
Result:
In aided consultations, GPs asked more questions (b=4.22, [2.68-5.75], p<0.0001) than in
unaided consultations. These were either closed questions or questions that required follow up
after a yes/no response; no difference was found in the number of open questions. Consultations
lasted one more minute on average (b=1.35 [0.47-2.24] p<0.003). Eye contact with the patient
was reduced by one minute on average (b=-1.02 [-1.42 to -0.63] p<0.001). There was less active
listening and more interacting with the computer when the patient was talking. GPs spent two
more minutes on average interacting with the computer (b=1.91 [1.44-2.39], p<0.001). There
was no reduction in the time spent discussing test results, diagnoses and management. Neither
the number of questions asked nor consultation length were related to diagnostic accuracy, once
case difficulty was accounted for.
Conclusion:
Using the DSS resulted in GPs asking the patient more questions; less active listening while
patients were talking; and more interaction with the computer. Increases in consultation length
were small and may reduce as GPs become familiar with the DSS. The way GPs allocated their
attention between patient and computer changed. This might have a detrimental impact on some
doctor-patient relationships, making it important to explain to patients the benefits of using
diagnostic aids during the consultation.
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1A-4 WHAT PASSED IS PAST? THE ROLE OF RECENT ADVERSE EVENTS IN
PHYSICIAN TREATMENT DECISIONS
Decision Psychology and Shared Decision Making (DEC)
Manasvini Singh, MSPH, Emory University, Atlanta, GA
Purpose: I examine how subjectivity in clinical decisions causes physicians to incorporate
clinically irrelevant information into treatment decisions, leading to unnecessary variation in care
and suboptimal patient outcomes.
Methods: First, I explore how an obstetricianʼs treatment choice is influenced by adverse
outcomes of prior patients. I use econometric techniques on inpatient EHR data (2015-2018)
from a large hospital to estimate the within-physician effect of experiencing an adverse outcome
in a patient on the likelihood of switching delivery modes on the next patient. In other words, if a
patient has an adverse outcome in delivery mode D1, I examine whether their physician is more
likely to switch to delivery mode D2 on the next patient. If so, I examine whether this switching
behavior affects quality of care and patient outcomes, both in the short- and long-run.
Second, I explore whether observed obstetrician response to prior adverse outcomes is consistent
with a standard model of Bayesian physician learning. I use computer simulations based on data
from published meta-analyses to model the delivery choices of a hypothetical Bayesian
obstetrician over time. The simulations offer testable predictions about how a physician should
respond to an adverse event if they were a rational agent, which I then formally test using EHR
data.
Results: I find that prior adverse events significantly affect physician treatment decisions. An
obstetrician is significantly more likely to switch delivery modes following an adverse patient
outcome (see attached figure), even after accounting for patient heterogeneity and physician
practice style. Moreover, immediately after an adverse event, a physician is significantly more
likely to i) switch to the inappropriate delivery mode, ii) increase treatment intensity (i.e., greater
daily inpatient charges, specialist consultations, length of stay), and iii) experience worse patient
outcomes (higher probability of adverse obstetric events, 90-day readmission). In the long run,
however, frequent switching appears to be correlated with significant improvements in the worstperforming physicians.
While these improvements suggest a learning component to observed physician switching after
adverse events, I conclude with evidence that this behavior cannot be a purely Bayesian
response, and may indicate the presence of bias in physician decision-making.
Conclusion: Policies should aim to strengthen objectivity in clinical decision-making to avoid
biases in subjective judgment, thereby enhancing quality of care and patient outcomes.
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1A-5 DIRECT OBSERVATION AND FEEDBACK IDENTIFIES AND IMPROVES
ERRORS IN CARE
Health Services, Outcomes and Policy Research (HSOP)
Alan Schwartz, PhD1, Alan Spiro, MD, MBA2, Steven Peskin, MD, MBA, FACP3, Amy BinnsCalvey1, Gunjan Sharma, PhD1 and Saul Weiner, MD1, (1)Institute for Practice and Provider
Performance Improvement, Inc., Chicago, IL, (2)Blue Health Intelligence, Chicago, IL,
(3)Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ
Purpose: Health care delivery is rarely systematically directly observed. We used feedback from
unannounced standardized patients (USPs, aka “mystery patients”) to assess and improve patient
care quality and costs.
Method: USPs made 217 visits to 59 providers in 22 practices enrolled in Horizon BCBSʼs
value-based program in New Jersey between 2017-2019 presenting 4 case scripts. In each visit,
the USP completed a checklist of guideline-based diagnostic and treatment provider behaviors;
we also coded visit audio recordings and provider notes. After two baseline visits, we delivered
feedback to providers in writing and by phone, and scheduled two follow-up visits. We
compared pre- vs. post-feedback performance using mixed logistic regression. We also identified
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a comparison group of propensity-matched practices and compared costs of actual claims for
services in the three months prior to the project and the three months 9 months later (after
feedback) in patients attributed to study vs. comparison practices who had received at least one
service associated with a focal condition (diabetes, opioid use, depression, back pain, smoking,
or cancer screening). We fitted mixed gamma regressions to per-visit claims costs and to patientlevel costs attributable to diabetes or low back pain (using Horizonʼs proprietary attribution
formulae).
Result: 46% of expected behaviors were observed in pre-intervention visits and 56% in postintervention visits (adjusted odds ratio 1.53, 95% CI 1.29-1.83, p<.0001). Significant
improvement areas included smoking cessation (24% vs. 58%, p<.001), managing chronic pain
without opioids (74% vs. 84%, p=.048), and depression screening (52% vs. 70%, p = .004).
Following feedback, providers were 39% more likely to perform expected behaviors, and 26%
less likely to document tasks they had not performed, compared with pre-feedback visits
(Figure). Total per-visit costs did not differ between study and comparison groups at prefeedback, increased in both groups from pre- to post-feedback, but increased significantly less in
the study group than comparison group (p<.001; difference-in-difference savings of $175,529).
A similar interaction was observed for patient-attributed diabetes costs; patient-attributed low
back pain costs increased more pre-to-post in the study group, apparently reflecting more use of
(costlier) non-opioid treatments such as physical therapy.
Conclusion: Direct observation of care identifies deficits in practice and documentation, and can
be used to improve both, sometimes with concomitant cost savings.
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1A-6 STRAINED AND CONSTRAINED: HOW CAPACITY CONSTRAINTS AFFECT
PHYSICIAN DECISION-MAKING IN THE ICU
Health Services, Outcomes and Policy Research (HSOP)
Manasvini Singh, MSPH and David Howard, PhD, Emory University, Atlanta, GA
Purpose: We examine how increasing ICU capacity affects: i) physician decision-making in the
ICU, and ii) patient health outcomes.
Methods: In our primary “micro” analysis, we use econometric techniques on 100% inpatient
EHR data from two hospitals (2015-2018) to estimate the causal, within-physician effect of ICU
capacity on ICU care and patient outcomes. We exploit two separate ICU expansions to study the
effects of total ICU capacity (i.e., total number of ICU beds) and temporarily available ICU
capacity (or “strain”, i.e., hourly availability of ICU beds conditional on total capacity) on a
physicianʼs ICU admission, retention, and discharge patterns. We also examine whether changes
in physician patterns as a result of the expansion improve hospital efficiency and patient welfare.
We conduct a secondary “macro” analysis to bolster the external validity of the “micro” analysis.
We use administrative data from Florida (2014-2015) to examine the relationship between
hospital-level ICU capacity constraints and ICU admission rates, where we exploit a patientʼs
differential distance (from a high ICU bed-share hospital) as an instrument for hospital selection.
Results: Physicians consistently admitted more patients to the ICU following the expansion at all
levels of ICU strain (see attached figure), even when all patients could have been accommodated
at the pre-expansion capacity level. The expansion led physicians to ration beds less and be less
sensitive to patient insurance status, but only when the ICU was relatively empty. When the ICU
was full post-expansion, physicians treated their sickest patients no differently than they had preexpansion. In other words, the greatest improvements in hospital efficiency and clinical
processes (as a result of the expansion) occurred when patients could have been admitted to the
pre-expansion ICU. Moreover, the expansions led to trivial improvements in patient outcomes,
suggesting the ICU expansion affected hospital and care processes more than it affected patient
health. Finally, the “macro” analysis generalizes this result by confirming the positive causal
relationship between physicianʼs ICU use and hospital ICU capacity.
Conclusion: The physician plays a central role in managing ICU capacity. If the physician uses
ICU resources independent of patient demand, then there is no level of ICU capacity that will
appear to fully meet ICU demand, spurring a cycle of overinvestment in ICU resources without
equivalent gains in patient welfare.
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1B-1 ESOPHAGEAL CANCER TREATMENT COSTS BY PHASE OF CARE AND
TREATMENT MODALITY, 2000-2013
Applied Health Economics (AHE)
Angela Tramontano, MPH1, Yufan Chen, MPH1, Tina Watson, BA1, Andrew Eckel, MS1, Chin
Hur, MD, MPH2 and Chung Yin Kong, PhD1, (1)Massachusetts General Hospital - Institute for
Technology Assessment, Boston, MA, (2)Columbia University Medical Center, New York, NY
Purpose: Our study estimated phase-specific treatment costs for older esophageal cancer
patients in the United States to provide accurate cost estimates for cost-effectiveness analyses.
Method: We identified esophageal cancer patients diagnosed between 2000-2011 in the
Surveillance, Epidemiology, and End Results (SEER)-Medicare database and allocated total and
patient-liability costs into the following phases of care-staging, surgery, initial, continuing, and
terminal. Esophageal cancer patients were matched to noncancer control patients from a random
sample of 5% of all Medicare enrollees. Cancer-attributable costs for each phase were then
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calculated by subtracting the matched noncancer patientʼs mean monthly phase costs from the
esophageal cancer patientʼs mean monthly phase costs. We fit linear regression models using log
transformation to determine cost by age and calendar year for each histology, stage at diagnosis,
and treatment strategy. We estimated the costs of esophageal adenocarcinoma and squamous cell
carcinoma separately and report costs estimates adjusted to 2018 U.S. dollars.
Result: Our cohort included a total of 8,061 esophageal cancer patients, with 5,044 (62.6%)
esophageal adenocarcinoma patients and 3,017 (37.4%) squamous cell carcinoma patients.
Overall, monthly cost estimates across all subgroups were high during the staging and initial
phases, decreased over the continuing phase, and increased during the six-month terminal phase,
with the highest costs in the terminal phase. The mean total costs during the surgery phase were
high, ranging from $59,494-$84,538 for esophageal adenocarcinoma stages I-III and $54,854$70,280 for squamous cell carcinoma stage I-III. For most histology and stage subgroups, mean
monthly cancer-attributable costs in the initial and continuing phases were highest for patients
who received chemoradiation and in the terminal phase were highest for those who received
radiation. The linear regression models showed that for most histology, stage and treatment
modality subgroups, cancer-attributable costs remained stable over the study period and were
unaffected by age.
Conclusion: Accurate treatment cost estimates are a necessary component of comprehensive
cost-effectiveness analyses, yet detailed, updated costs estimates are currently not available for
esophageal cancer. Our phase-specific cost estimates of different esophageal cancer treatment
modalities can be used in updated cost-effectiveness analyses to determine the benefit of
esophageal cancer interventions from a health economics point of view.
1B-2 ESTIMATES OF FIRST-YEAR QUALITY-ADJUSTED LIFE YEAR LOSS FOR
INJURIES AND POISONINGS IN THE UNITED STATES
Applied Health Economics (AHE)
William Raich1, Jennifer Baxter1, Lisa Robinson2, Jeremy D. Goldhaber-Fiebert, PhD3, Patrick
Sullivan, PhD4 and Janel Hanmer, MD, PhD5, (1)Industrial Economics, Inc., Cambridge, MA,
(2)Harvard University Center for Health Decision Science, Boston, MA, (3)Stanford Health
Policy, Centers for Health Policy and Primary Care and Outcomes Research, Stanford
University, Stanford, CA, (4)Regis University School of Pharmacy, Denver, CO, (5)The
University of Pittsburgh, Pittsburgh, PA
Purpose: Unlike chronic conditions, short-lived medical conditions like injuries may have
rapidly changing impacts on quality of life over a relatively narrow timeframe, making
estimation of their health-related quality-of-life (HRQoL) effects challenging. Our study
explores the feasibility of estimating nationally representative quality-adjusted life year (QALY)
loss from acute medical conditions, primarily injury and poisoning conditions, using data
collected in the Medical Expenditures Panel Survey (MEPS).
Methods: The study uses data from adults in the 2001-2016 MEPS Household Component.
MEPS has an overlapping cohort design where each cohort is followed for 2 years. Various types
of injury and poisoning episodes were identified using medical events and self-reported medical
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conditions which each have a specific date of occurrence. We developed regression models to
estimate injury and poisoning effects on HRQoL. Our main outcome measure was HRQoL based
on SF-6D and mapped EQ-5D scores, which also have date of completion and are elicited once
per year. Models included age group, sex, comorbidities, and measures of the occurrence of
injury or poisoning within one year of health status assessment. Alternate models considered
time-since injury trajectory specifications as well as a variety of injury categorizations and
estimators.
Results: Acute medical conditions can be identified in MEPS using medical event dates and selfreported date of injury. HRQoL decrements can be estimated using binary indicators of injury in
the prior year. When grouped into 22 broad injury categories, most injury categories, age,
comorbidity, and sex were statistically significant predictors of HRQoL scores. For broad groups
of injuries, mean first-year QALY loss ranges from 0.005 (sprains and strains of joints and
adjacent muscles, n = 7,067) to 0.109 (injury to nerves and spinal cord, n = 71). Estimates were
substantially less precise when the 185 injuries are coded separately using more specific threedigit ICD-9 codes.
Figure 1. Estimates of First-Year QALY Loss

Conclusion: The study explores the feasibility of identifying a wide variety of acute injury and
poisoning conditions and estimating their associated QALY loss in a nationally representative,
community-based sample. The results suggest that this novel approach to identifying acute
conditions may be feasible for broad categories of conditions, however, precise estimates may be
limited for rare and less aggregated conditions in the U.S. adult population.
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1B-3 PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF EXPANDING
THE CURRENT ACIP RECOMMENDATION FOR NONAVALENT HPV VACCINE
TO ROUTINELY VACCINATING 9-45 YEAR OLD PERSONS
Applied Health Economics (AHE)
Vincent Daniels, PhD, Vimalanand S. Prabhu, B.E, M.Mgmt, Ph.D., Cody Palmer, PhD,
Salome Samant, MBBS, Craig Roberts, MPA, PharmD, MBA, Smita Kothari, PhD and Elamin
H. Elbasha, PhD, Merck & Co., Inc., Kenilworth, NJ
Purpose:
In the United States, the Advisory Committee for Immunization Practice (ACIP) recommends
routine human papillomavirus (HPV) vaccination at age 11-12 years. ACIP also recommends
vaccinating females through 26 years and males through 21 years. Children 9-10 years-old, and
males 22-26 years-old may be vaccinated (status quo). In 2018, the FDA granted use of the
9vHPV vaccine through age 45 years for males and females (expanded vaccination). We
assessed the public health impact and cost-effectiveness of expanded vaccination compared with
status quo.
Methods: A published and validated non-linear, deterministic, mathematical model of the
transmission dynamics of HPV infection and disease in an age-structured population was used to
estimate disease outcomes, pre-vaccination age of acquisition of HPV infection, quality-adjusted
life years (QALY), costs, and incremental cost-effectiveness ratio (ICER) of expanded
vaccination compared with status quo. Historical vaccination coverage was estimated using NISTEEN survey data. Costs were estimated from a payer perspective (2018 USD). We built
historical vaccine coverage (HVC) from 2006-2018, adopted a 100-year time horizon (outcomes
calculated from 2019), and 3% annual discount rate (future costs/benefits. Scenario analyses
conducted included restricting upper age limit of expanded vaccination in 5-year increments and
reducing duration of expanded vaccination to 10 years (from 100 years). Sensitivity analysis
included using NHANES data for HVC.
Results: The pre-vaccination median age of acquisition of HPV infection was estimated to be
25–26 years old. Expanded vaccination would prevent 29,016 HPV-related cancers, 151,946
CIN1 cases, 224,614 CIN2/3 cases, 1,516,614 genital wart cases, and 9,613 deaths compared
with status quo over 100 years, with an ICER of $117,500/QALY (Table 1). The ICERs for
restricting the upper age limit to 35 years, and 10-year catch-up were $93,500/QALY, and
$100,400/QALY, respectively. The ICER using NHANES data for HVC was $73,500/QALY.
Conclusions: The results show that expanded vaccination of males and females 9-45 years-old is
expected to provide significant public health benefits in the US. The economic value of the
vaccine is sensitive to the underlying assumption regarding HVC, the upper age limit of the
expanded vaccination program, and the duration of the catch-up program. Given the high
estimated median age of HPV infection, a substantial burden of HPV among 27-45 year-olds can
be averted through expanded vaccination of 9-45 year-olds in the US.
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1B-4 A POPULATION-BASED MATCHED COHORT STUDY EVALUATING THE
HEALTHCARE COSTS OF HEPATITIS B VIRUS (HBV) IN ONTARIO, CANADA
Applied Health Economics (AHE)
Natasha Nanwa, PhD1, Jeffrey Kwong, MD, MSc, CCFP, FRCPC2, Jordan J. Feld, MD, MPH3,
Fangyun Wu2 and Beate Sander, PhD4, (1)Toronto Health Economics and Technology
Assessment (THETA) Collaborative, Toronto, ON, Canada, (2)ICES, Toronto, ON, Canada,
(3)Toronto Centre for Liver Disease, University Health Network, Toronto, ON, Canada,
(4)Toronto Health Economics and Technology Assessment (THETA) Collaborative, University
Health Network, Toronto, ON, Canada
Purpose: To determine healthcare costs attributable to HBV from the Ontario Ministry of Health
and Long-Term care perspective.
Methods: Using a matched-cohort incidence-based cost-of-illness approach, we identified HBVinfected subjects from January 1, 2004 to December 31, 2014 using Public Health Ontario
laboratory data, linked to population-based Ontario health administrative data. Infected subjects
were defined as having positive HBV surface antigen, DNA, or e-antigen. The index date
corresponded to the date of the first positive specimen. We organized our cohort into three
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groups: no HBV-related complication; HBV-related complication prior to index date; and HBVrelated complication post index date. We adopted the phase-of-care approach to calculate costs
(2017 Canadian dollars) for six phases: 1) pre-diagnosis; 2) initial care; 3) continuing care; 4)
HBV-related complication; 5) continuing care for HBV-related complication; and 6) final care.
We hard matched on sex, age group, index year, rurality, neighbourhood income quintile,
resource utilization bands (co-morbidities measure), and immigrant status (post 1985) at the
initial and final phases. We calculated mean attributable phase-specific costs and combined them
with crude survival data to determine 1-, 5-, and 10-year costs. We stratified costs by age group,
sex, immigrant status, and acute/chronic infection.
Results: We identified 41,469 infected subjects. Mean age was 44 (standard deviation=±15,
median=43) years old, majority were male (55%), immigrant (58%), moderate user of the
healthcare system (45%), urban resident (96%), and among lowest income quintile (27%). Eight
percent had a HBV-related complication prior to the index date and 12% had a HBV-related
complication post index date. Our match rates were 89-93% for initial care and 100% for final
care across groups. Mean attributable phase-specific costs ranged from -$27-$19 for prediagnosis, $167-$1,062 for initial care, $53-$407 for continuing care, $1,033 for HBV-related
complication, $304 for continuing care for HBV-related complication, and $2,552-$4,281 for
final care. Across groups, mean cumulative 1-, 5-, and 10-year costs ranged between $253$3,066, $3,067-$20,349, and $6,128-$38,968, respectively. Infected subjects with HBV-related
complication prior to index date had the highest 10-year costs. Costs were higher among males,
long-term Ontario residents, those aged ≤19 years, and those with chronic infection.
Conclusions: HBV has a long-term impact on healthcare costs. Our study quantifies the burden
of HBV and aids decision-making on strategies that may mitigate this costly infectious disease.
1B-5 DO DECISION TREE-BASED COST-EFFECTIVENESS MODELS OF
HEREDITARY BREAST AND OVARIAN CANCER (HBOC) SCREENING
INTRODUCE A TIME CRUNCH? A COMPARISON OF MODELING APPROACHES
Health Services, Outcomes and Policy Research (HSOP)
Gregory Guzauskas, MSPH, PhD1, Josh Peterson, MD, MPH2, Marc Williams, MD3, Scott
Spencer, MPA, MA4, Jing Hao, PhD, MD, MS, MPH3, Susan Snyder, PhD, MBA3, Dina Hassen,
MPP3 and David Veenstra, PharmD, PhD1, (1)The Comparative Health Outcomes, Policy,
Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, WA,
(2)Vanderbilt University, Nashville, TN, (3)Geisinger, Danville, PA, (4)Institute for Public
Health Genetics, University of Washington, Seattle, WA
Purpose: Previous cost-effectiveness models of genomic screening for HBOC in unselected
women, which have reported cost-effective results for genomic versus family history-based
screening, have utilized decision trees to model lifetime cancer risk and lifetime risk-reducing
mastectomy and salpingo-oophorectomy (RRM/RRSO) uptake. We propose that this model
structure oversimplifies the decision problem by failing to account for multiple competing risks
over a patientʼs lifetime.
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Method: We developed a 9-state Markov model to compare the costs, QALYs, and incremental
cost-effectiveness of genomic screening versus family history screening in an unselected
population. HBOC variant prevalence was 0.5%. The age at which women elected to undergo
RRM and/or RRSO was determined by a prospective cohort study of 1,499 women with
inherited BRCA1/2 mutations. Age-based cancer incidence was stratified by gene variant.
Estimates of risk reduction from RRM/RRSO, mortality, prophylaxis uptake, cancer onset, the
costs of prophylactic procedures and cancer, and health state utilities were obtained from
published sources. We assumed a test cost of $200, and included a 1-year disutility (0.05) for a
positive screening result. To understand our results within the context of previous findings, we
reproduced and compared the decision trees of two published HBOC screening models that
concluded genomic screening was cost-effective, using consistent parameterization among the
three models.
Result: We estimated that screening resulted in 0.001 QALYs (95% CR: 0.0002 to 0.0010)
gained per woman screened at an incremental cost of $200 (95% CR: $170 to $240) for 30-yearolds (ICER = $317,000). In comparison, two previous studies reported slightly higher
incremental costs ($243 and $400) and higher incremental QALYs (0.008 and 0.012). These
differences appear to arise primarily from previous models’ utilization of confounder-controlled
estimates of lifetime cancer risk and RRM/RRSO uptake within a simple decision tree
framework, whereas our Markovian approach accounted for competing risks over a patient
lifetime. We also identified results in one of the models that lacked face validity.
Conclusion: Our model incorporated age-related impacts of (1) gradual uptake of prophylactic
surgery and (2) cancer incidence. Contrary to previous cost-effectiveness models, we found that
general population screening for HBOC alone does not appear to be cost-effective at accepted
cost-effectiveness thresholds of <$150,000/QALY. Nonetheless, the value of population-wide
genomic screening should be assessed within the context of a broader screening panel.
1B-6 ESTIMATE OF UNITED STATES ANTIHYPERTENSIVE MEDICATION COSTS
USING DATA FROM THREE PUBLICLY AVAILABLE SOURCES
Health Services, Outcomes and Policy Research (HSOP)
Gabriel Tajeu, DrPH, MPH1, Natalia Ruiz-Negron, PharmD2, Jordan King, PharmD, MS2,
Richard Nelson, PhD, MS2, Andrew Moran, MD, MPH3 and Brandon Bellows, PharmD, MS3,
(1)Temple University, Philadelphia, PA, (2)University of Utah, Salt Lake City, UT, (3)Columbia
University, New York, NY
Purpose: To estimate utilization-weighted annual costs of standard doses of antihypertensive
medications using data from three different publicly available sources.
Methods: First, we calculated average per-unit costs for all US guideline-recommended
antihypertensive medications using Medicare Part D drug spending data, Medicaid National
Average Drug Acquisition Cost (NADAC) plus a dispensing fee, and Medical Expenditure Panel
Survey (MEPS) all payer expenditures with and without patient out-of-pocket costs. Second, we
multiplied these per-unit costs by the average number of daily doses from MEPS then by 365
days to estimate an average annual cost. Then, we estimated nationally representative costs of

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E283

taking one, two, three, or four antihypertensives by weighting the estimated annual average costs
based on utilization in the National Health and Nutrition Examination Survey data. Finally, we
estimated 10-year treatment costs assuming perfect adherence for each data source. We
simulated a 1,000-iteration probabilistic sensitivity analysis using gamma distributions for each
number of medications used. All cost data were from 2015. Costs were discounted 3% annually
and are reported in 2015 USD.
Results: Average annual antihypertensive costs ranged from $154 to $665 for one to four
classes, respectively, using Medicare, $166 to $728 using NADAC, $187 to $833 using MEPS
without patient out-of-pocket costs, and $247 to $1,081 using MEPS with patient out-of-pocket
costs. These differences became more prominent in the 10-year probabilistic sensitivity analysis;
ranging from $1,317 to $5,682 using Medicare, $1,418 to $6,223 using NADAC, $1,593 to
$7,099 using MEPS without out-of-pocket costs, and $2,106 to $9,241 using MEPS including
patient out-of-pocket costs (Table).
Conclusions: Antihypertensive costs varied considerably when using Medicare, NADAC, and
MEPS data. The data sources differ in the costs included (i.e., acquisition costs only to all payer
costs), how frequently they are updated (i.e., weekly to yearly with a lag), and in the populations
represented (i.e., low socioeconomic status, older adults, and nationally representative).
Modelers should carefully consider which data source to use when deriving costs for costeffectiveness studies to ensure they reflect the goals of the analysis and incorporate all
components of medication costs.

2D-1 DISCORDANCE IN DECISION MAKING AND ITS ASSOCIATION WITH
PSYCHOLOGICAL DISTRESS AND PERCEIVED QUALITY OF CARE OF
ADVANCED CANCER PATIENTS
Decision Psychology and Shared Decision Making (DEC)
Semra Ozdemir, PhD1, Yubing Tian1, Chetna Malhotra, MBBS, MD, MPH1, Eric A.
Finkelstein, PhD, MHA1 and COMPASS Writing Group, (1)Duke-NUS Medical School,
Singapore, Singapore
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Purpose: To investigate discordance between reported experience of and preference for
participation in decision making among patients with advanced cancer, and its association with
psychological distress and perceived quality of care.
Method: We used baseline survey data from Cost of Medical Care of Patients with Advanced
Serious Illness in Singapore (COMPASS) study interviewing 599 patients with Stage IV solid
malignancy. Stuart-Maxwell tests compared patients’ reported experience of and their preference
for participation in treatment decisions. Univariate and multivariate ordinary least squares
regression models examined the associations of psychological distress (Hospital Anxiety and
Depression Scale), and perceived quality of care (in terms of physician communication, nursing
care and care coordination) with discordance in decision making.
Result: Patients’ most commonly reported experience was making decisions together with their
family and physicians (25%), making decisions after considering their familyʼs and physicians’
opinions (18%) and making decisions alone (13%). Patient preference for treatment decisions
followed a similar pattern. Discordance between the two was observed in 16% of patients. A
greater proportion of patients experienced making treatment decisions by themselves, after
considering their familyʼs and physicians’ opinions, than the proportion who preferred this
method (18% vs 16%; p value = 0.041). A smaller proportion of patients experienced no role in
decision making than the proportion who preferred this process (15% vs 17%; p value = 0.040).
Univariate models reveal that patients facing discordance reported greater anxiety (p value =
0.013), lower perceived physician communication (p value = 0.024), lower perceived quality of
care coordination (p value = 0.000), and lower perceived quality of care overall (p value =
0.025), relative to patients with concordance. Multivariate models reveal that the direction of
discordance matters. Only patients who experienced less involvement than they preferred
confirmed findings from univariate models and were associated with higher depression scores (p
value = 0.037).
Conclusion: Discordance between reported experience of and preference for participation in
decision making was associated with higher psychological distress and poorer perceived quality
of care in advanced cancer patients. Findings suggest that physicians should first assess to what
extent patients would like to be involved in their treatment decisions.
2D-2 MEASURING THE QUALITY OF DECISIONS FOR ELECTIVE ORTHOPEDIC
PROCEDURES ACROSS A LARGE HEALTHCARE SYSTEM
Decision Psychology and Shared Decision Making (DEC)
Karen Sepucha, PhD1, Thomas Cha, MD, MBA2, Felisha Marques, MPH2, KD Valentine,
PhD1, Lauren Leavitt, MA2, Adam Licurse, MD3, John Giardina, MA4, Steven Atlas, MD2 and
Partners Healthcare System Orthopedics and Neurosurgery Collaborative, (1)Division of General
Internal Medicine, Massachusetts General Hospital, Boston, MA, (2)Massachusetts General
Hospital, Boston, MA, (3)Brigham and Womenʼs Hospital, Harvard Medical School, Boston,
MA, (4)Center for Health Decision Science, Harvard University, Boston, MA
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Purpose:
This study assessed the quality of surgical decision making for elective hip and knee replacement
and spine surgery at four hospitals across Partners HealthCare System.
Method:
Patients undergoing elective hip or knee replacement for osteoarthritis (OA), or spine surgery for
lumbar herniated disc (HD) or spinal stenosis (SS) with 36 participating surgeons were invited to
complete a post-operative survey via mail. Median time between surgery and survey completion
was 155 days (IQR=30). Two NQF endorsed measures were used to assess the quality of
decisions. The Shared Decision Making Process (SDMP) is a 4-item scale (scores ranging 0-4)
with higher scores indicating more shared decision making. The Informed, Patient-Centered
(IPC) surgery score is a binary indicator derived from responses to 5 multiple-choice knowledge
items and one treatment preference item. Patients made an IPC decision if they met or exceeded
established knowledge thresholds and had a clear preference for surgery. Analyses adjusted for
clustering of patients within surgeons.
Result:
646/875 surveys (73.9% response rate) were returned with sufficient responses for analysis. The
sample was female (51%), white (94%), with an average age of 65 (SD=11). OA patients had
lower SDMP scores than spine patients (MOA=2.53, SDOA=1.15; MS=3.11, SDS=1.07; b=-0.57,
p<.001). As age increased, SDMP tended to decrease (b=-0.01, p=0.03). The hospital, patient
sex, age, and race were not predictive of SDMP scores (all ps>0.28). Patients who had OA
surgery were more likely to make IPC decisions (OA=69%, Spine=14%; OR=14.62, p<0.001).
Both knowledge scores (mean=72% for OA vs. mean=36% for spine) and surgical preference
(84% for OA vs. 67% for spine) were lower for spine. Additionally, males (50% v.47%;
OR=1.58, p =0.01), and white patients (59% v. 41%; OR=1.8, p =0.047), were more likely to
make IPC decisions, and as age increased, likelihood of IPC decisions decreased (OR=0.98, p
=0.03). The hospital was not predictive of IPC decisions (all ps>0.17).
Conclusion:
Spine surgery patients reported more shared decision making in pre-operative conversations, but
OA surgery patients were more likely to make informed, patient centered decisions. These
findings may reflect a more complex decision-making process for spine surgery. Strategies to
successfully implement shared decision making into clinical practice may need to vary based on
the specific disease as well as the patient characteristics.
2D-3 BARRIERS TO GOAL-CONCORDANT CARE AT END OF LIFE: FINDINGS
FROM INTERVIEWS WITH CAREGIVERS OF PATIENTS WITH CANCER
Patient and Stakeholder Preferences and Engagement (PSPE)
Cara McDermott, PharmD, PhD1, Marlaine Figueroa Gray, PhD2, J. Randall Curtis, MD,
MPH3, Cossette Woo, MSW3 and Ruth Engelberg, PhD3, (1)University of Washington/Fred
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Hutch, Seattle, WA, (2)Kaiser Permanente Washington Health Research Institute, Seattle, WA,
(3)University of Washington, Seattle, WA
Purpose: To understand caregiver perspectives of barriers to goal-concordant care at end of life,
with goal concordance defined as patient and caregiver values and preferences regarding anticancer therapies.
Method: From October-December 2017, we conducted semi-structured phone interviews with
35 adults who were primary caregivers for a patient who died with cancer between JulyDecember 2016. We asked if care received at end of life was aligned with patient and family
goals for care. Interviews were audio recorded. Two analysts coded transcripts using qualitative
content analysis and summarized results according to major emergent themes.
Result: Patient were 30-88 years old, caregivers 34-85. Most caregivers were white (91%),
female (63%), and spouses (89%). Barriers to goal-concordant end-of-life care included: 1)
Misaligned values for care: “The doctors are saying... do another round of chemo and sheʼs
saying no...I know I'm going to die. And taking this drug that you're offering me is not going to
help;” “When they were giving him chemo...they knew it wasn't doing any good (and) that we
needed to talk some more, but it was too late.” 2) Clinical momentum: “After 15 years of always
choosing treatment, it was hard to change the perspective and pattern...[to clinicians] I
would...slow down...making it very, very clear to caregivers and patients that they’re at a turning
point.” 3) Hope for a cure: “Maybe if I just would have left [patient on life support]]...a little
longer, maybe there would have been a miracle;” “As a family we were grabbing at straws trying
to help him.” 4) Decision making with incomplete information: “In hindsight I wish that she
hadn’t had the final chemotherapy [but] the oncologist didn’t warn us that it might be hard for
her to tolerate;” “To healthcare providers...don’t make a value judgement about what you should
tell them and what you shouldn’t.”
Conclusion: In this qualitative study of caregivers of patients with cancer, caregivers reported
four key barriers to patients receiving goal-concordant care at end of life. Future research is
needed on how to best communicate risks and potential benefits of anti-cancer therapies in the
context of patientʼs informed goals, especially in the age of immunotherapy, so patients and
families can make informed decisions aligned with their values and goals for care throughout
their course of treatment.
2D-4 PATIENT PREFERENCES FOR SECOND-LINE MEDICATIONS TO MANAGE
TYPE 2 DIABETES MELLITUS
Patient and Stakeholder Preferences and Engagement (PSPE)
Semra Ozdemir, PhD1, Drishti Baid1, Naina Verghese1, Amanda Yun Rui Lam2, Phong Ching
Lee2, Lim Adoree Yi Ying2, Ling Zhu2, Eric A. Finkelstein, PhD, MHA1 and Su-Yen Goh2,
(1)Duke-NUS Medical School, Singapore, Singapore, (2)Singapore General Hospital, Singapore,
Singapore
Purpose: The objective of this paper is to use a discrete choice experiment (DCE) to quantify
patients’ willingness to accept greater urinary and genital tract infections (UGTI) risk in
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exchange for benefits associated with second-line treatments to manage type 2 diabetes mellitus
(T2DM).
Method: Patients who were at least 21 years old, diagnosed with T2DM, and currently on
Metformin or Metformin plus sulphonylurea (first-line treatments), were recruited from
outpatient diabetes clinics and newspaper advertisements. Patients were asked to choose between
two hypothetical medications defined by 6 attributes in each DCE choice task: years of
medication effectiveness for controlling blood glucose, weight reduction, UGTI risk,
hospitalisation due to heart failure risk, mortality risk, and out of pocket medication cost per
month. Weight loss and risk attributes were defined within 1 year of starting medication. A Defficient design was created in SAS and 5 blocks of 10 tasks were randomly assigned to patients.
Results were analysed using latent class logistic regression models. Model fit was assessed using
AIC and hold-out task predictions.
Result: After dropping those who failed the monotonicity test (N=12), a 2-class latent class
model was identified as the fit for the responses from 147 patients. The first group (54% of the
sample), termed as “survival-conscious”, were willing to accept a 42% and 14% UGTI risk in
exchange for a reduction from 6% to 1% in mortality risk (p<0.05) and hospitalization risk
(p<0.10), respectively. The second class, termed as “UGTI-risk-conscious” were willing to
accept a much smaller (5% and 6%) UGTI risk in exchange for the same reductions in mortality
(p<0.05) and hospitalization risks (p<0.01), respectively. Patients with prior diagnosis of a heart
problem were more likely to be in the survival-conscious group (p=0.05). Patients with
household income below the sample median were more likely to be in the UGTI-risk-conscious
group (p<0.05). Neither gender nor past experience with UGTI was a significant predictor of
class membership.
Conclusion: Findings suggest that half of the patients were primarily concerned with mortality
and hospitalization risks as compared to UGTI risk and other medication attributes. Physicians
should assess how patients weigh different types of risks and benefits associated with secondline T2DM treatments when making treatment recommendations for these patients.
2D-5 DIABETES GUIDELINE FRAMEWORKS FOR INDIVIDUALIZING GLYCEMIC
TARGETS – WHAT DO PATIENTS THINK?
Patient and Stakeholder Preferences and Engagement (PSPE)
Nancy Schoenborn, MD, MHS1, Norah Crossnohere, MHS2, John F P Bridges, PhD3, Craig
Pollack, MD, MHS1, Scott Pilla, MD, MHS1 and Cynthia Boyd, MD, MPH1, (1)Johns Hopkins
University, Baltimore, MD, (2)Johns Hopkins University Bloomberg School of Public Health,
Baltimore, MD, (3)The Ohio State University College of Medicine, Columbus, OH
Purpose: Diabetes guidelines recommend considering specific factors, such as diabetes duration
and life expectancy, to individualize treatment in older adults. The individualized glycemic target
then, in turn, informs decisions around whether to intensify or de-intensify medication regimens.
How older adults with diabetes perceive these factors used to individualize glycemic targets and
decide on medication (de)intensification is unknown. This study aimed to examine how older
adults perceive factors used in diabetes guidelines for individualizing glycemic targets
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Methods: Adults 65+ with type 2 diabetes (n=1364) from a nationally representative online
panel were invited to participate in a cross-sectional survey. We randomized participants to
vignettes about adding or stopping diabetes medicines. We assessed the importance of seven
factors - diabetes duration, established diabetes complications, other health conditions, life
expectancy, risk of side effects, cost, and treatment effort – in these treatment decisions using
yes/no responses and the best-worst scaling method to quantify the factors’ relative importance.
All participants then answered questions on how different levels of each factor related to
aggressiveness of diabetes treatment.
Results: The sample included 818 participants (response rate 60.0%) with mean age 74.0 years.
In the decision to add a diabetes medicine, 48.8%-62.8% of participants considered the factors
important. In contrast, only 8.4%-37.7% of participants considered the factors important in the
decision to stop a diabetes medicine. In both decisions, participants perceived the risk of side
effects as the most important factor. Opposite to guideline recommendations, most participants
believed that patients with longer disease duration, more established complications, and more
other health conditions should receive more aggressive diabetes treatment.
Conclusions: Older adults may not consider guideline factors used to individualize diabetes
treatment as important, especially for stopping a medicine, and have misperceptions about their
intended effect per guidelines. Developing strategies to communicate the rationales behind
individualized diabetes treatment to patients and to effectively engage patients in these treatment
decisions are important next steps.
2D-6 ARE PRIORITIZED HEALTHCARE GOALS OF SERIOUSLY ILL
OUTPATIENTS ACCURATELY IDENTIFIED BY THEIR CLINICIANS?
Patient and Stakeholder Preferences and Engagement (PSPE)
Matthew Modes, Ruth Engelberg, Lois Downey, Lyndia Brumback, Elizabeth Nielsen, J.
Randall Curtis and Erin Kross, University of Washington, Seattle, WA
Purpose:
To estimate the proportion of seriously ill patients with a prioritized healthcare goal that have
their goal accurately identified by their clinician and investigate patient- and clinician-level
factors as well as communication processes associated with patients whose goals are accurately
identified.
Method:
We conducted an analysis of a cluster-randomized trial testing a communication intervention
designed to facilitate goals-of-care discussions for patients with serious illness. Data were
collected from patient and clinician surveys at enrollment and within two weeks after the target
clinic visit. On those latter surveys, patients identified their prioritized healthcare goal, selecting
between extending life despite the risk of increased discomfort versus relief of discomfort
despite the possibility of shortened life. Patients could also choose “not sure”. Clinicians
identified their patientʼs top priority using the same three options. Among patients who
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prioritized a goal, we estimated the proportion of patients whose goal was accurately identified
by their clinician using a marginal intercept-only model with logit link. To examine associations
we ran a multivariate marginal model with logit link. These modeling strategies account for
clinicians having multiple patients in the study.
Result:
338 patients (mean age 74 years, 81% white/non-Hispanic, 49% female) and 114 clinicians
(mean age 47 years, 76% white/non-Hispanic, 51% female) answered the question about
prioritized healthcare goal. There was a mean of 3 patients per clinician. Seventeen percent
(n=56) of patients prioritized extending life, 58% (n=196) prioritized relief of discomfort, and
25% (n=86) were unsure of their top priority. Clinicians believed 37% (n=124) of those same
patients would prioritize extending life, 50% (n=168) would prioritize relief of discomfort, and
14% (n=46) expressed uncertainty about their patients’ goal (Figure). Of the 252 patients who
specified a healthcare goal, 60% (95% CI 53%-66%) had their goal accurately identified by their
clinician. In a multivariate model, patients whose goal was accurately identified by their clinician
were more likely to be older (OR 1.03 per year, 95% CI 1.00-1.05) and have the same goal on
enrollment and on after clinic visit surveys (OR 2.42, 95% CI 1.22-4.81).
Conclusion:
Healthcare goals of seriously ill patients are often not accurately identified by their clinician.
Improving clinician understanding of patient goals may be a target for future interventions
designed to increase delivery of goal-concordant care.
2E-1 ADAPTIVE GUIDELINES FOR THE TREATMENT OF GONORRHEA
INFECTION TO INCREASE THE EFFECTIVE LIFESPAN OF ANTIBIOTICS IN THE
CONTEXT OF RISING ANTIMICROBIAL RESISTANCE: A MATHEMATICAL
MODELING STUDY
Health Services, Outcomes and Policy Research (HSOP)
Reza Yaesoubi, PhD1, Ted Cohen, DPH, MD, MPH1, Katherine Hsu2, Thomas Gift, PhD3,
Harrell Chesson, PhD4, Joshua Salomon, Ph.D.5 and Yonatan Grad, M.D., Ph.D.6, (1)Yale
School of Public Health, New Haven, CT, (2)Massachusetts Department of Public Health,
Boston, MA, (3)Center for Disease Control and Prevention, Atlanta, GA, (4)Centers for Disease
Control and Prevention, Atlanta, GA, (5)Center for Health Policy and Center for Primary Care
and Outcomes Research, Stanford, CA, (6)Harvard TH Chan School of Public Health, Boston,
MA
Purpose: The rise of gonococcal antimicrobial resistance highlights the need for strategies that
extend the clinically useful lifespan of antibiotics. As there is limited evidence to support the
current practice of switching empiric first-line antibiotic when resistance exceeds 5% in the
population, our objective was to compare the impact of alternative strategies on the overall
burden of gonorrhea and the effective lifespans of antibiotics.
Methods:
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We developed and calibrated a mathematical model of gonococcal transmission to describe the
key characteristics of gonorrhea epidemics among men who have sex with men (MSM) in the
U.S., including the disease prevalence and incidence, and the emergence of resistance to the
antimicrobial drugs used for the treatment of gonorrhea infection. We used this model to
evaluate whether the current practice of switching first-line empiric antibiotics when resistance,
measured annually, exceeds a predefined threshold (the ‘Threshold’ strategy in Table) is
outperformed by policies that i) increase the frequency of drug resistance surveys (the
‘Threshold-Quarterly’ strategy), and ii) increase the frequency and size of drug resistance
surveys and incorporate information on the trend in the percentage of isolates that are resistant
(the ‘Enhanced Threshold+Trend’ strategy).
Results: We found that compared to the current practice, the ‘Threshold-Quarterly’ and
‘Enhanced Threshold+Trend’ strategies could increase the effective life of first-line therapy
drugs by 0.94 and 1.13 years, respectively, without increasing the number of gonorrhea cases
(Figure). This is equivalent to successfully treating an additional 4,476 and 5,381 gonorrhea
cases with the first-line therapy drugs each year without worsening the burden of gonorrhea
among the MSM population.
Conclusions: Our results suggest that use of data from surveillance programs could be expanded
to prolong the clinical effectiveness of antibiotics without increasing the burden of disease. This
highlights the importance of maintaining effective surveillance systems and the engagement of
policy makers to translate surveillance findings into timely and effective decisions.
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2E-2 IS NETFLIX THE ANSWER? OPERATIONALIZING THE SUBSCRIPTION
MODEL FOR HEPATITIS C THERAPIES
Health Services, Outcomes and Policy Research (HSOP)
Taruja Karmarkar, MHS, PhD1, Gillian D. Sanders, PhD2, Marianne Hamilton-Lopez, PhD,
MPA3, Gregory Daniel, PhD, MPH3 and Mark McClellan, MD, PhD3, (1)Duke-Margolis Center
for Health Policy / National Pharmaceutical Council, Washington, DC, (2)Duke University
School of Medicine, Durham, NC, (3)Duke-Margolis Center for Health Policy, Washington, DC
Purpose: Subscription, or ‘Netflix’, models have been proposed to enhance access to effective,
high-cost prescription drugs such as those for Hepatitis C (HCV). However, these models have
not yet been successfully implemented, and their likely impact and factors influencing their
success have not been fully described.
Methods: We outlined a framework of approaches, building upon current state efforts, to
implement a subscription payment for HCV treatment. This includes a baseline annual fee plus
possible bonuses linked to shared savings from curing patients. We used a forecasting model to
simulate the potential impact of the reforms over a five-year time horizon, including the
epidemiological benefits and cost consequences of increased coverage capacity. Finally, we
explored the potential role of manufacturer incentives related to treatment goals. Input
parameters were derived from the literature and assumptions were tested using sensitivity
analyses.
Results: A range of barriers to treatment, coupled with asymptomatic disease, have contributed
to a large prevalent HCV population and a continuing burden of HCV complications. Our
simulated population assumed 10,000 prevalent cases of HCV in year one. With the subscription
model, more patients can be treated sooner (Table 1) than with fee for service (FFS) programs.
When facing FFS costs, the payer could treat 1,000 patients (at an assumed $25,000/unit) each
year while in the subscription model, treatment increased (2,500 at 1 year) and continued to rise
over time. We saw a large difference by year five– 5,000 patients were treated in the FFS system
while approximately 8,750 patients were treated in the subscription arrangement. Varying the
coverage capacity of the plan demonstrated a similarly widening gap over five years. Other
variations include an annual expenditure cap to shared savings linked to achieving health
improvement goals. Providing manufacturers the opportunity to share in savings generated from
the subscription model may motivate their participation and create additional impact in these
arrangements.
Conclusions: While the subscription model enables additional treatment, provider and public
health capacity and provider and beneficiary incentives also influence the impact of a
subscription model. Aligning incentives across the payer, manufacturer, providers and patients
can result in more patients being treated earlier. As states consider this model for their HCV
populations, we highlight the financial resources and data capabilities necessary to make this
arrangement successful.
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2E-3 LARGE SCALE EMPIRICAL EVALUATION OF MACHINE LEARNING FOR
SEMI-AUTOMATING CITATION SCREENING IN SYSTEMATIC REVIEWS
Health Services, Outcomes and Policy Research (HSOP)
Thomas Trikalinos, MD, PhD1, Byron Wallace, PhD2, Jens Jap3, Birol Senturk3, Gaelen Adam,
MLIS, MPH3, Bryant Smith, MPH4, Christopher Schmid, PhD3, Ethan Balk, MD, MS4 and
Shaun P. Forbes, AM3, (1)Brown University Center for Evidence Synthesis in Health,
Providence, RI, (2)Khoury College of Computer Sciences, Northeastern University, Boston, MA,
(3)Center for Evidence Synthesis in Health, Brown University, Providence, RI, (4)Center for
Evidence Synthesis in Health, Providence, RI
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Purpose: As the demand for current and well-conducted systematic reviews increases and the
literature continues to grow it is important to identify efficiencies, including through semiautomating citation screening. We report the largest, to our knowledge, empirical evaluation of
using machine learning to semi-automate citation screening in systematic reviews. To stimulate
further research, we make all data and analyses publicly available.
Methods: Among the citation screening projects included in our open-source and access
AbstrackrTM webtool for which we could obtain permission, we selected fully double-screened
datasets for systematic reviews in health, provided that they comprised at least 2500 citations,
and that we knew which citations were included in the completed review. We then examined the
utility of using machine learning to exclude ‘irrelevant’ citations.
Our learner comprises (i) an ensemble of 33 support vector machines that classify citations into
‘relevant’/’irrelevant’ based on bag-of-words representations of their title, abstract, and
keywords, and (ii) a sequential sampling design that selects the subset of citations on which we
train the classifier ensemble. For each project we constructed learning curves of the yield
(fraction of finally eligible citations in the review that were identified) and burden (fraction of
citations that a human has to read) for classifiers trained with increasing numbers of citations.
We also report these metrics were we to stop training the learner at 50% of the sample or at 2500
citations, whichever is smaller.
Results: We included 24 projects (median size 3334 citations, range 2525-29257). On average,
8.2% of citations were ‘relevant’ and 0.6% were finally eligible. The Figure shows yield and
burden curves in a topic. Were we to stop training the learner at 50% of the sample or by 2500
citations, the median yield (25th to 75th percentile) would be 98% (83%, 100%); the median
burden would be 44% (28%, 50%); and, in 20 of the 24 projects, we would miss at most one
citation or 1% of the citations that were finally included in the systematic review.
Conclusions: Machine learning can help make citation screening more efficient. The
performance of the current system may be appropriate for rapid and scoping reviews. We hope
that, by sharing our data and analyses, further research using better text representations and
stronger classification algorithms will greatly improve performance.
2E-4 ESTIMATING THE TRUE VALUE OF NEW ONCOLOGY TREATMENTS:
IMPROVED TWO-STAGE ESTIMATION TO ADJUST FOR TREATMENT
SWITCHING IN RANDOMISED TRIALS
Quantitative Methods and Theoretical Developments (QMTD)
Nicholas Latimer, PhD, School of Health and Related Research, The University of Sheffield,
Sheffield, United Kingdom, Ian White, University College London, London, United Kingdom,
Kate Tilling, University of Bristol, Bristol, United Kingdom and Uwe Siebert, MD, MPH, MSc,
ScD, UMIT - University for Health Sciences, Medical Informatics and Technology, Dept. of
Public Health, Health Services Research & HTA / Harvard Univ., Dept. Health Policy &
Management, Institute for Technology Assessment, Hall i.T. / Boston, Austria
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Purpose:
In oncology trials, control group patients often switch onto the experimental treatment during
follow-up, usually after disease progression. In this case, an intention-to-treat (ITT) analysis will
not address the policy question of interest – that of whether the new treatment represents an
effective and cost-effective use of health care resources, compared to the standard treatment.
Alternative methods are required to estimate the true value of new treatments, enabling efficient
medical decision making. Rank preserving structural failure time models (RPSFTM), inverse
probability of censoring weights (IPCW) and two-stage estimation (TSE) have often been used
to adjust for switching to inform treatment reimbursement policy decisions. TSE has been
applied using a simple approach (TSEsimp): in a case where switching occurs after disease
progression, the post-progression treatment effect in switchers is estimated using a simple
regression model comparing survival in control group switchers and non-switchers and then
untreated survival times are derived. This assumes that there is no time-dependent confounding
between the time of disease progression and the time of switch. This is problematic if there is a
delay between progression and switch. We introduce TSEgest, which uses structural nested
models and g-estimation to account for time-dependent confounding, and compare it to
TSEsimp, RPSFTM and IPCW.
Method:
We simulated scenarios where control group patients could switch onto the experimental
treatment after disease progression, with and without time-dependent confounding being present.
We varied switching proportions, treatment effects and censoring proportions. We assessed
adjustment methods according to their estimation of control group restricted mean survival times
(RMST) that would have been observed in the absence of switching. We knew the true RMST
because we simulated the data.
Result:
TSEgest, TSEsimp, RPSFTM and IPCW all performed well in scenarios with no time-dependent
confounding, resulting in RMST estimates that were much closer to the truth than estimates from
an ITT analysis. TSEgest, RPSFTM and IPCW also performed well in scenarios with timedependent confounding, but TSEsimp resulted in substantial bias. IPCW was prone to bias when
maximum weights were high and RPSFTM is known to be sensitive to the common treatment
effect assumption.
Conclusion:
TSEgest represents a useful addition to the collection of methods that may be considered when
adjusting for treatment switching in trials in order to address policy-relevant questions.
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2E-5 ‘DAMPACK’: A FLEXIBLE R PACKAGE FOR ANALYZING AND
VISUALIZING COST-EFFECTIVENESS ANALYSIS RESULTS
Quantitative Methods and Theoretical Developments (QMTD)
Eva A. Enns, MS, PhD1, Caleb Easterly, BA1, Szu-Yu Zoe Kao, MA1, Eline Krijkamp, MSc2,
Petros Pechlivanoglou, PhD3, Hawre Jalal, MD, PhD4 and Fernando Alarid-Escudero, PhD5,
(1)Division of Health Policy and Management, University of Minnesota School of Public Health,
Minneapolis, MN, (2)Erasmus University Medical Center, Epidemiology Department,
Rotterdam, Netherlands, (3)Child Health Evaluative Sciences, The Hospital for Sick Children,
Toronto, ON, Canada, (4)University of Pittsburgh Graduate School of Public Health, Pittsburgh,
PA, (5)Drug Policy Program, Center for Research and Teaching in Economics, Aguascalientes,
AG, Mexico
Purpose: To improve the accessibility, transparency, and reproducibility of state-of-the-art costeffectiveness analysis (CEA) methods for users and developers of decision-analytic models.
Methods: We developed the R package ‘dampack’ (Decision-Analytic Modeling Package) to analyze and
visualize CEA results with expanded functionality over similar existing packages. Using standard CEA
outputs exported from a model developed in any software, ‘dampack’ facilitates both basic and advanced
calculations of CEA results crucial for informing decision making. Users can input results into ‘dampack’
in one of two ways: as a probabilistic sensitivity analysis (PSA) dataset or as deterministic results (e.g.,
expected costs and effectiveness of each strategy). The package can be used to identify dominated
strategies, calculate incremental cost-effectiveness ratios, plot the efficient frontier, and visualize one- and
two-way sensitivity analyses. Additionally, for PSA datasets, ‘dampack’ users can construct costeffectiveness acceptability and expected loss curves and compute the expected value of perfect, partial,
and sample information. Sensitivity and value of information analysis functionality are implemented
using linear meta-models based on the PSA samples. We also designed ‘dampack’ to deliver
customizable, publication-quality figures for all analyses. The source code of the ‘dampack’ package is
freely available, allowing users to easily customize and extend its functionality. To demonstrate the
functionality of ‘dampack’, we analyzed the PSA outputs from a previously published evaluation of the
cost-effectiveness of different treatment strategies for Clostridioides difficile (C. diff). The PSA compared
48 treatment strategies, sampling 10,000 sets of 51 parameters.
Results: CEA results generated by ‘dampack’ from the C. diff PSA are shown in the 4-panel figure. The
cost-effectiveness plot highlights the six strategies on the efficient frontier, while also indicating strongly
and weakly dominated strategies. One-way sensitivity analysis plots show how the optimal strategy
changes as model parameters are varied individually. PSA results are additionally summarized through
cost-effectiveness acceptability and expected loss curves. For each, ‘dampack’ also plots the frontier,
indicating the optimal strategy in expectation at each willingness-to-pay threshold.
Conclusion: ‘dampack’ is a powerful and flexible package for the analysis and visualization of CEA
results. It can summarize key CEA results, even when comparing a large number of strategies. With userfriendly and computationally efficient implementations, ‘dampack’ also facilitates the use of state-of-theart economic evaluation methods, such as value of information analysis, to a broader user-base.
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2E-6 ESTIMATION AND CORRECTION OF BIAS IN NETWORK SIMULATIONS
BASED ON RESPONDENT-DRIVEN SAMPLING DATA
Quantitative Methods and Theoretical Developments (QMTD)
Lin Zhu, PhD1, Nicolas A. Menzies, PhD2, Jianing Wang, MS3, Benjamin P. Linas, MD, MPH3,
Steven M. Goodreau, PhD4 and Joshua A. Salomon, Ph.D.5, (1)Harvard T.H. Chan School of
Public Health, Boston, MA, (2)Center for Health Decision Science - Harvard T.H. Chan School
of Public Health, Boston, MA, (3)Section of Infectious Disease, Department of Medicine,
Boston Medical Center, Boston, MA, (4)University of Washington, Seattle, WA, (5)Center for
Health Policy and Center for Primary Care and Outcomes Research, Stanford University,
Stanford, CA
Purpose: Data collected using respondent-driven sampling (RDS) often inform network
simulations for infectious disease policy models. In this study, we examine systematic biases in
conventional methods for estimating network statistics from RDS data, and propose an approach
for correcting these biases.
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Method: We developed a platform to simulate network structures and the data generation
mechanisms produced by RDS. We first used exponential random graph models to generate
multiple ‘original’ networks with different values of network statistics. RDS was then simulated
on each original network to generate a sample network, based on varying values for an additional
set of parameters reflecting RDS design factors. We compared several different network
statistics including density/mean degree, homophily, and transitivity between the sample
networks and the original networks to identify biases. We used generalized linear models to
correct these biases by predicting the true statistics of the original network from the observed
statistics of the sample network and known sample design features.
Result: Network density estimates calculated from RDS data overestimated the original
densities, with median error of 80%. Networks reconstructed directly from RDS-based densities
were visibly different from the original networks (figure). Mean degrees were overestimated
from RDS data, with median error of 10%. However, if only ties connecting to another sampled
individual were counted in the sample degree, the sample estimate was biased downward, with
median error of 60%. Homophily estimates from RDS data overestimated the original homophily
when preferential recruitment occurred, with median error of 10%. Transitivity was
underestimated from RDS data, with median error of 50%. Key predictors of bias in various
network statistics included original network size, sample size, proportion of the sample from
partner-referral, and number of coupons. After applying corrections based on our predictive
models, the median errors were reduced to 0 for all network statistics, and the visible match to
the original networks improved substantially (figure).
Conclusion: Conventional methods for analyzing RDS data can introduce bias in the estimation
of network statistics. Adjustments to network generating statistics derived using predictive
models can substantially improve validity of simulated networks in terms of density, and can
reduce bias in replicating mean degree, homophily, and transitivity from the original network.
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2F-2 HEALTH AND ECONOMIC IMPACT OF HPV TESTING COMPARED TO
CYTOLOGY
Applied Health Economics (AHE)
Dave Martin, PhD1, Jean-François Laprise, PhD1, Mélanie Drolet, PhD1, Marie-Helène
Mayrand, M.D., F.R.C.S.C., PHD2, Chantal Sauvageau, M.D.3 and Marc Brisson, PhD4,
(1)Centre de recherche du CHU de Québec—Université Laval, Axe santé des populations et
pratiques optimales en santé, Québec, QC, Canada, (2)Centre de recherche du CHUM, Montréal,
QC, Canada, (3)Institut national de santé publique du Québec, Québec, QC, Canada,
(4)Department of Infectious Disease Epidemiology, Imperial College, London, United Kingdom
Purpose:
To examine the effectiveness/cost-effectiveness of primary HPV testing compared to cytologybased screening in the context of high HPV vaccination coverage in Canada.
Method:
We used HPV-ADVISE, an individual-based transmission-dynamic model of multi-type HPV
infection and disease calibrated to Canadian data. We compared primary HPV testing to
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cytology-based screening in the era of HPV vaccination. For primary HPV testing scenarios
(Cobas 4800 test & triage of HPV-positive women by cytology), we varied the age at start of
screening (25, 30 or 35 years old) and screening intervals (5 or 10 years). For cytology, we
reproduced the Canadian cytology recommendations: age at start of screening=21 years old and
screening interval=2-3 years. For HPV vaccination, we reproduced Quebecʼs vaccination
program: coverage=80%, start of vaccination=2008, gender-neutral 9-valent vaccination. In
sensitivity analyses we varied the 1) triage of HPV-positive women: cytology vs genotyping and
2) types included in the HPV test: Cobas 4800 types vs all oncogenic types. We used a health
care provider perspective, 3% discount rate, and 2018-2050 time horizon. Predictions are annual
averages for Quebec population (10 million).
Result:
Switching from cytology-based screening to primary HPV testing was predicted to produce
substantial cost savings (CA$16-25 million/year on average), and a decrease in negative
colposcopies (i.e. normal colposcopy follow-ups; 3600/year on average). The only HPV testing
scenario which led to a lower cancer incidence than cytology was screening starting at 25 years
old with a 5-year interval. All other HPV testing scenarios led to a predicted increase in cancer
incidence. The most cost-effective HPV testing scenario was screening starting at 30 years old
with a 10-year interval. HPV testing with genotyping triage had a negligible impact on cancer
incidence and costs but increased the number of negative colposcopies compared to HPV testing
with cytology triage. The inclusion of all oncogenic types in the HPV test reduced the long-term
cancer incidence for all scenarios, reaching values similar to cytology-based screening.
Conclusion:
Switching from the current cytology-based screening to primary HPV testing is predicted to
produce substantial cost savings assuming there is a good adherence to the recommended
screening interval. Most primary HPV testing scenarios, including the most cost-effective, could
lead to a slight increase in cancer incidence, unless additional HPV types are included in the test
2F-3 ELICITING PREFERENCES FOR CANCER SCREENING TESTS:
COMPARISON OF A DISCRETE CHOICE EXPERIMENT, A THRESHOLD
TECHNIQUE EXPERIMENT, AND AN INDIVIDUAL DIFFERENCE MEASURE.
Patient and Stakeholder Preferences and Engagement (PSPE)
KD Valentine, PhD, Massachusetts General Hospital, Boston, MA, Victoria Shaffer, PhD,
University of Missouri, Columbia, MO and Brett Hauber, PhD, RTI Health Solutions, Research
Triangle Park, NC
Purpose: To extend our understanding of the association between three methods of preference
elicitation—discrete choice experiments (DCE), threshold techniques (TT), and a new individual
difference measure—and to evaluate their ability to predict desire for cancer screening with an
unbeneficial test.
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Methods: 300 undergraduate students completed the DCE, the TT, and the items for the
Evaluating Screening Tests for Cancer: Attributes People Emphasize (ESCAPE) scale. The
ESCAPE scale measures the importance of accuracy (false positives, false negatives), benefits
(live saved), familiarity, cost, and personal preference matching for a cancer screening test. The
measures of accuracy, benefit, familiarity, and cost were translated into attributes for participants
to consider within the DCE and TT (See Table below). Next, participants were told about a
hypothetical test screening for breast (women) or prostate (men) cancer with no mortality benefit
and were asked if they wanted this test.
Results: Risk threshold values for DCE and TT were largely uncorrelated (max r=.23 between
DCE false negative threshold and TT false negative threshold). The largest association was
between the ESCAPE cost subscale and the TT cost threshold (r=-.35, indicating that those who
reported cost as being a more important consideration were more likely to not be willing to pay
more for an increasingly beneficial test). Additionally, 54.8% of our sample stated they wanted
to receive the unbeneficial screening test but none of the preference measures successfully
predicted this choice (all ps>.14).
Conclusions: These three methods of measuring preference resulted in categorically different
preference estimates for the same participant. Further, none of these preference elicitation
methods were capable of predicting screening test choice. These results suggest a violation of the
principle of procedure invariance that underlies models of rational choice. This calls into
question the assumption underlying these techniques—that patients have stable, measurable
preferences regarding attributes of health states previously unexperienced. This study suggests
that we need to explore whether these potential differences can be explained by differences in the
assumptions underlying the methods as decision making on the individual and aggregate levels
may be informed by these and similar types of preference elicitation methods.
Attribute
Benefit
Accuracy
Accuracy
Cost
Familiarity

Levels in DCE
0-1-2
5%-25%-50%
5%-25%-50%
$0--$100-$3,000
Unfamiliar-Familiar-Very familiar

Values (Ranges) in TT
0 v. 1
5%-100%
5%-100%
$0-$3,200
Always Familiar

2F-4 PRIORITIZING CANCER SCREENINGS IN WOMEN WITH RESTRICTIVE
PREFERENCES: A HOLISTIC APPROACH
Health Services, Outcomes and Policy Research (HSOP)
Glen Taksler, PhD1, Elisabeth Peterse, PhD2, Isarah Willems, BSc2, Kevin ten Haaf, PhD2, Erik
Jansen, MSc3, Inge M.C.M. de Kok, PhD2, Nicolien T. van Ravesteyn, PhD2, Harry J. de
Koning, MD, PhD3 and Iris Lansdorp-Vogelaar, PhD2, (1)Medicine Institute and Department of
Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, (2)Department of Public Health,
Erasmus University Medical Center, Rotterdam, Netherlands, (3)Department of Public Health,
Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
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Purpose: Women often prioritize breast and cervical cancer screenings but hesitate to obtain
colorectal and lung cancer screenings. We evaluated how providers might best advise women on
strategies to prevent overall cancer-specific mortality while still limiting screenings to 1-2 per
year.
Method: We modeled a cohort of females aged ≥50 y in the general US population, utilizing 4
validated microsimulation models developed through the National Cancer Instituteʼs Cancer
Intervention and Surveillance Network (CISNET). We examined 45 strategies combining breast,
cervical (PAP/HPV co-testing), colorectal (colonoscopy, fecal immunochemical testing [FIT])
and/or lung cancer screenings where women obtained some, but not all, US Preventive Services
Task Force (USPSTF)-recommended screenings. The primary outcome was life-years gained
from cancer screenings relative to full compliance with USPSTF recommendations (“optimal
benefits”). Finally, based on prior work suggesting higher adherence rates when fewer screenings
are recommended, we evaluated the increase in adherence needed to each strategy for life-years
gained to equal USPSTF recommendations. Results were stratified by lung cancer screening
eligibility (“eligible/ineligible”).
Result: It was possible to reduce cancer screening intensity to just 1 test/year in women
ineligible for lung cancer screening and 2 tests/year in eligible women, while maintaining up to
94% and 97% of optimal benefits, respectively. Highly-ranked strategies screened for a variety
of cancers, even if less often than USPSTF-recommended. For example, among ineligible
women willing to obtain just 1 screening/year, a strategy of annual FIT (no other screenings)
provided 52% of optimal benefits but alternating FIT and mammography (i.e., biennial FIT
instead of annual USPSTF recommendation) conferred nearly twice the share of optimal benefits
(86%). Among eligible women, lung cancer screening was essential; strategies omitting it
provided ≤25% of optimal benefits. The top-ranked strategy with 2 screenings/year was annual
lung, alternate FIT and breast, but skip mammography when due for PAP/HPV (97% of optimal
benefits). If women were 4% more likely to adhere to this less-intensive strategy than USPSTF
recommendations, then life-years gained would exceed the optimal (USPSTF-recommended)
strategy.
Conclusion: Women who do not want all guideline-recommended cancer screenings may be
able to reduce screening intensity with minimal impact on overall benefits. However, colorectal
cancer screening and (if eligible) lung cancer screening were essential. Providers might consider
these results as part of a holistic cancer screening discussion.
2F-5 PROSTATE CANCER MORTALITY AND METASTASIS UNDER DIFFERENT
BIOPSY FREQUENCIES IN NORTH AMERICAN ACTIVE SURVEILLANCE
COHORTS
Health Services, Outcomes and Policy Research (HSOP)
Jane Lange, PhD and Ruth Etzioni, PhD, Fred Hutchinson Cancer Research Center, Seattle,
WA
Purpose: Active surveillance (AS) is an accepted means of managing low-risk prostate cancer.
Due to rarity of downstream events, data from existing AS cohorts cannot yet address how
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differences in surveillance intensity affect metastasis and mortality. This study projects the
comparative benefits of different AS schedules in men diagnosed with Gleason Score (GS) 6 or
below with risk profiles similar to those in North American AS cohorts.
Method: We simulated times of GS upgrading based on AS data from the University of Toronto
(UT), Johns Hopkins University (JHU), University of California, San Francisco (UCSF) and the
Canary Pass Active Surveillance Cohort (PASS). Times to metastasis and prostate cancer death,
informed by models of the Scandinavian Prostate Cancer Group 4 trial, were projected under
biopsy surveillance schedules ranging from watchful waiting (WW) to annual biopsies.
Outcomes included risk of metastasis and death, remaining life years (LYs), and quality adjusted
life years (QALYs).
Result: Compared to WW, annual surveillance biopsies reduced the risk of prostate cancer
metastasis (death) at 20 years by 1.4-3.3% (death 1.0-2.4%) and 5 year biopsies by 1.0-2.4%
(death .6-1.6%). There was little difference between annual and five year biopsy schedules in
terms of LYs (range of differences 0.04-0.16), and QALYs (range -0.09-0.02).
Conclusion: In men diagnosed with GS< 6, biopsying every 3-4 years appears is an acceptable
alternative to more frequent biopsies. Reducing surveillance intensity for those with low risk of
progression reduces the number of biopsies while preserving the benefit of more frequent
schedules.
2F-6 OVARIAN SURVEILLANCE IN POST-MENOPAUSAL WOMEN WITH
INCIDENTAL OVARIAN CYSTS: PROJECTED OUTCOMES BY AGE AND
COMORBIDITY LEVEL
Health Services, Outcomes and Policy Research (HSOP)
Claudia L. Seguin, BA1, Anna P. Lietz, BA1, Jason D. Wright, MD2, Alexi A. Wright, MD,
MPH3, Amy B. Knudsen, PhD1 and Pari V. Pandharipande, MD, MPH1, (1)Institute for
Technology Assessment, Massachusetts General Hospital, Boston, MA, (2)Division of
Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University
College of Physicians and Surgeons, New York, NY, (3)Dana-Farber Cancer Institute,
Gynecologic Oncology Outcomes Research, Boston, MA
Purpose: Detection of small, simple ovarian cysts on imaging tests performed for unrelated
reasons is common. Ongoing surveillance of these “incidental” cysts is often pursued, though
their presence has not been shown to increase cancer risk. Our purpose was to determine the
effects on life expectancy (LE) of imaging-based ovarian surveillance in post-menopausal
women of varied age and comorbidity level, under different assumptions about cancer risk and
detection.
Method: We developed a decision-analytic Markov model to evaluate LE benefits. Hypothetical
cohorts of post-menopausal women with simple ovarian cysts were evaluated, with varied age
(66-80 years) and comorbidity level (none, mild, moderate, severe). For each cohort, we
compared LE in “follow-up” and “no follow-up” strategies. Follow-up entailed five years of
imaging surveillance. In keeping with current evidence, we did not assume increased cancer risk
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in patients with cysts. However, incident ovarian cancers could be detected during surveillance.
In the base-case, to estimate theoretical, maximal LE gains from follow-up, we invoked the
hypothetical assumption of “perfect” ovarian cancer detection and treatment during surveillance
(i.e., cure without surgical risks). We varied key assumptions to determine effects on our results,
including those pertaining to test performance for cancer detection, cancer risks, and surgical
mortality.
Result: In the base-case, projected LE gains from follow-up were limited: 66, 70, 75, and 80year-olds with no comorbidities gained 15.2, 14.2, 11.8, and 8.8 days, respectively (Figure).
With severe comorbidities, corresponding estimates were 10.0, 8.6, 6.6, and 4.6 days. With
reduced test sensitivity of 50% for cancer detection, LE gains decreased to 10.4 days for 66-yearolds with no comorbidities, and 2.7 days for 80-year-olds with severe comorbidities. When we
assumed ovarian cancer risk for women with cysts was 1.1 times that of women without cysts,
LE gains increased modestly (16.7 days for 66-year-olds with no comorbidities, and 5.1 days for
80-year-olds with severe comorbidities). Across cohorts and analyses, LE gains increased as the
number of test-positive results (true- or false-positive) increased, because the benefits of
oophorectomy – i.e., lifelong ovarian cancer risk elimination – outweighed the harms associated
with the highest assumed surgical mortality risks.
Conclusion: Even with “perfect” ovarian cancer detection and treatment, surveillance of postmenopausal women with simple ovarian cysts affords limited benefits, particularly in women
with advanced age and comorbidities.
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3G-1 CONSIDERING BREAST RECONSTRUCTION AFTER MASTECTOMY:
DEVELOPMENT AND PILOT TESTING A PATIENT DECISION AID VIDEO AND
WORKBOOK
Decision Psychology and Shared Decision Making (DEC)
Aubri S. Hoffman, PhD1, Scott B. Cantor, Ph.D.2, Michelle Fingeret, PhD1, Ashley J. Housten,
OTD, MSCI1, Summer Hanson, MD, PhD1, Alina Bennett, PhD1, Jordan Pietz1, Jennifer
McGee1, Robert J. Volk, PhD1 and Gregory Reece, MD1, (1)The University of Texas MD
Anderson Cancer Center, Houston, TX, (2)University of Texas MD Anderson Cancer Center,
Houston, TX
Purpose: We engaged patients, survivors, providers, and stakeholders in a user-centered design
process to develop, iteratively refine, and pilot test a patient decision aid video and workbook
about breast reconstruction after mastectomy.
Method: Working with a stakeholder advisory panel, we followed a modified user-centered
design process, including an environmental scan of existing tools, literature review, and care
pathway mapping, to identify decision support needs and potential design strategies. Next, we
engaged survivors and providers/stakeholders in iterative reviews of proposed content and
storyboards (paper mock-ups) to create a prototype. We then piloted tested the prototype with
patients who were 6 months - 3 years post-mastectomy and had considered reconstruction using
cognitive interviews and pre/post-decision aid questionnaires assessing acceptability and
feasibility of delivery.
Result:
Development: Five survivors and 17 providers/stakeholders revised the content and storyboards
in six iterative cycles to produce a 24-minute video containing five content modules, 60 custom
graphics, and 26 custom medical illustrations. The video introduces the breast reconstruction
process and compares the risks and benefits of three key decisions: reconstruction vs. no
reconstruction, immediate vs. delayed, and tissue- vs. implant-based reconstruction. Survivors
proposed and co-developed a workbook that summarizes the video and adds Tips from Patients
& Nurses, Myths & Facts, side-by-side comparison charts, a glossary, and a Personal Decisionmaking Worksheet that assesses knowledge, decision-making values, and treatment preferences.
Pilot Test: After viewing the decision aid video and workbook, patients scored 97.5% correct
responses on the knowledge test. Wide variation was observed in decision-making values (i.e.,
what women considered important in their decisions). Twenty patients and 20
providers/stakeholders provided >80% positive acceptability ratings and 100% reported that it
would be helpful. They recommended making it available at multiple time points (postdiagnosis, pre/during/post-consultation) in multiple formats (website, email, computer), with an
emphasis on viewing at home prior to the consultation.
Conclusion: The Considering Breast Reconstruction After Mastectomy patient decision aid
video and workbook are acceptable to patients and providers, and show potential for supporting
informed decision making. Delivery prior to the initial plastic surgery consultation was well-
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supported as a way to give women time to process the information and prepare to talk with the
surgical team about their options. The Personal Decision Worksheet shows potential for
assessing patients’ knowledge and personal decision-making values.
3G-2 A MIXED-METHODS HYBRID EFFECTIVENESS-IMPLEMENTATION STUDY
OF AN ONLINE BREAST CANCER SCREENING DECISION AID DESIGNED TO
FACILITATE INFORMED DECISION-MAKING FOR LOW-TO-AVERAGE RISK
WOMEN IN THEIR 40S
Decision Psychology and Shared Decision Making (DEC)
Erin Hahn, PhD, MPH1, Elena Elkin, PhD2, Corrine Munoz-Plaza, MPH1, Yi-Lin Wu, MS1,
Dana Pounds, MS1, Su Wu, MPH3, Viviann Soto1, Corrina Wood, MD4, Steven Farr, MD4,
Yung-Mee Park, MD5, Michael Gould, MD1 and Margaret M. Polaneczky, MD6, (1)Kaiser
Permanente Southern California, Pasadena, CA, (2)Memorial Sloan-Kettering Cancer Center,
New York, NY, (3)Childrenʼs Hospital of Los Angeles, Los Angeles, CA, (4)Kaiser Permanente
Southern California, Long Beach, CA, (5)Kaiser Permanente Southern California, Harbor City,
CA, (6)Weill Cornell Medical College, New York, NY
Purpose: Conflicting guidelines for breast cancer screening in women aged 40-49 have led to
confusion about initiation and frequency of mammography. Breast Screening Decisions (BSD) is
a web-based decision aid designed to facilitate informed decision-making; BSD supported
informed decision-making in a prospective single-arm trial in an academic setting. We designed
a randomized, hybrid effectiveness-implementation study to evaluate BSD in a community
setting, Kaiser Permanente Southern California.
Method: We recruited female English-speaking patients aged 40-49 at low-to-average risk for
breast cancer. Intervention participants were invited to use BSD and controls were provided an epamphlet on mammography risks and benefits. Both groups completed a survey on decisional
conflict, risk of breast cancer, mammography risks and benefits, and decisional satisfaction. We
had 80% power to detect a difference on the O’Connor decisional conflict scale (DCS) of 0.4
with 98 patients per group and 0.5 with 66; scores below 25 are associated with informed
decisions. We used content analysis to evaluate free-text responses to open-ended questions on
screening concerns. We conducted qualitative interviews with primary care clinician leaders to
determine feasibility of large-scale implementation.
Result: We contacted 1,184 women; 198 agreed to participate. The sample was diverse: 34%
Black, 29% Hispanic, 22% White, and 10% Asian. We randomized 99 to each arm; there were
no significant differences between the groups on mean age (44 vs. 45, p=0.31) or race/ethnicity
(p=0.25). In the intervention group, 70 used BSD (71%) and 57 completed the survey; 87
controls (88%) viewed the e-pamphlet and completed the survey. We found no significant
differences for DCS (mean score 18 intervention vs. 20 controls). A higher proportion of
intervention participants reported decisional satisfaction (72% vs. 60%, p=0.02), strongly agreed
that they have a choice to regarding mammography initiation (50% vs. 39%, p=0.05), correctly
estimated their risk of developing breast cancer in the next 10 years as low (31% vs. 11%,
p=0.02), and were unsure about the benefits of mammography (31% vs. 20%, p=0.03). Content
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analysis revealed a need for better information on screening options and risks. We conducted 11
interviews; participants found BSD implementation highly feasible and scalable.
Conclusion: BSD provided important education on options and risks for screening and improved
decisional satisfaction. Our results provide valuable insights into facilitating informed decisionmaking when facing conflicting recommendations.
3G-3 A RANDOMIZED CONTROLLED TRIAL OF A CPR VIDEO DECISION AID
AND VALUES CLARIFICATION TOOLS FOR HOSPITALIZED PATIENTS WITH A
HIGH RISK OF DEATH
Decision Psychology and Shared Decision Making (DEC)
Daniel Kobewka, MD MSc1, Nick Bansback, PhD2, Peter Dodek, MD MHSc3, Daren Heyland,
MD, PhD4, Alan Forster, MD MSc5, Aman Nijjar, MD MPH3, Jamie C. Brehaut, PhD1 and John
You, MD MSc6, (1)Ottawa Hospital Research Institute, Ottawa, ON, Canada, (2)School of
Population and Public Health, University of British Columbia; Centre for Health Evaluation and
Outcome Sciences, Vancouver, BC, Canada, (3)University of British Columbia, Vancouver, BC,
Canada, (4)Queenʼs University, Kingston, ON, Canada, (5)The Ottawa Hospital, Ottawa, ON,
Canada, (6)Mc Master University, Hamilton, ON, Canada
Purpose:
Our objective was to determine if a video decision aid about cardio pulmonary resuscitation
(CPR) combined with 2 values tools that help patients reflect on what is important to them would
change decisions that seriously ill patients in hospital make about CPR.
Method:
We performed a randomized controlled trial on general internal medicine and neurology wards at
2 tertiary care academic teaching hospitals. Patients were eligible if they had > 10% risk of death
in the next 1-year as determined by a validated logistic regression model and were currently
going to receive CPR if their heart stopped in hospital. Patients were randomized to usual care or
to receive a suite of decision support tools that included 2 values tools to help patients reflect on
what is most important to them in the context of serious illness and a CPR video decision aid.
Intervention patients received a “Dear Doctor Letter” to give to their doctor in hospital that
summarized their responses to the values tools and their wishes regarding CPR. The primary
outcome was the order for CPR in the medical record 14 days after the intervention. Secondary
outcomes were the stated CPR preference, decision conflict and satisfaction with decision
making.
Result:
There were 631 were eligible patients, 200 of whom were consented and enrolled. Enrolled
patients had a mean age of 76.9 years old, were 60.3% male and had a mean 1-year predicted
mortality of 25%. The intervention and control groups were similar across all baseline
characteristics. At 14 days after the intervention 70/100 (70%) patients in the control group and
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72/99 (72.7%) (P=0.89) patients in the intervention group had an order in the medical record to
receive CPR. There were no statistically significant differences in decisional conflict or
satisfaction with decision making between groups although patients in the intervention group did
know more about CPR than patients in the control group.
Conclusion:
A CPR video decision aid used with 2 values clarification tools did not change peopleʼs
decisions about CPR as recorded in the medical record. More work is needed to understand why
patients with a high risk of death choose to receive a medical treatment with a low probability of
benefit and large potential harms.
3G-4 EVALUATING AN INTERACTIVE PATIENT DECISION AID FOR PEOPLE
WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
Decision Psychology and Shared Decision Making (DEC)
Judy Chiu, MPH1, Robert Carruthers, MD2, Rebecca Metcalfe, BA Hons., MA2, Emmanuelle
Lapointe, MD3, Alice Schabas, MD2, Marilyn Lenzen, Patient Partner2, Larry D. Lynd, PhD4,
Anthony Traboulsee, MD2 and Nick Bansback, PhD5, (1)Centre for Health Evaluation and
Outcome Sciences, Vancouver, BC, Canada, (2)University of British Columbia, Vancouver, BC,
Canada, (3)Université de Sherbrooke, Sherbrooke, QC, Canada, (4)Faculty of Pharmaceutical
Sciences, University of British Columbia, Vancouver, BC, Canada, (5)School of Population and
Public Health, University of British Columbia; Centre for Health Evaluation and Outcome
Sciences, Vancouver, BC, Canada
Purpose: We sought to develop and test an interactive patient decision aid (PtDA) that helps
patients with relapsing remitting multiple sclerosis (RRMS) make informed, and value-based
choices between the seven available first-line disease modifying therapies (DMTs) in British
Columbia, Canada.
Methods: We developed a web-based prototype PtDA following the IPDAS guidelines for
development. The PtDA was informed by extensive mixed methods research in which patients
reported feeling overwhelmed by the number of DMTs. They wanted a tool that would improve
their knowledge and help them discuss treatment options with their neurologist. We
consequently developed the PtDA to simplify decisions by first grouping beta-interferon drugs,
and second, using a values clarification exercise to order DMTs such that those that best matched
the patientʼs values were presented first. We tested the preliminary effectiveness of the PtDA in
participants recruited from the University of British Columbiaʼs MS Clinic. Data were analyzed
descriptively. T-tests compared participant decisional conflict and knowledge scores before and
after completing the PtDA.
Results: 49 participants were recruited into the study. Most participants were female (81%), 40
years of age or younger (65%), and had experienced MS for less than 4 years (52%). Mean
decisional conflict improved from 1.64 (SD = 1.31) to 2.70 (SD = 1.23; p < 0.001), where a
score of 4 represents no conflict. Participants’ knowledge of MS and MS treatments also
significantly increased; before using the PtDA, the mean number of correct responses was 3.14
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(SD = 1.04) compared to 5.39 (SD = 1.41; p < 0.001). About half of the participants made a
‘high quality decision’, defined by scoring >=4 on the knowledge test, and choosing the option
that best matched their values on the PtDA. Of the 15 participants that have completed the 6month follow-up, 11 (73%) are adherent to the medication choice they made with their
neurologist.
Conclusions: This mixed methods study has led to the development of a PtDA that can support
patients with RRMS as they make treatment decisions. Future studies will assess the feasibility
of implementation and the impact of the PtDA on both the timely treatment initiation and longerterm adherence.
3G-5 ADAPTATION OF A TRAUMATIC BRAIN INJURY GOALS-OF-CARE
DECISION AID FOR SURROGATE DECISION-MAKERS TO HEMORRHAGIC AND
ISCHEMIC STROKE WITH ACCEPTABILITY AND USABILITY TESTING
Decision Psychology and Shared Decision Making (DEC)
Kelsey Goostrey, BS1, David Hwang, MD2, Christopher Lee, MS3, Kelsey Jones, BS3, Thomas
Quinn, MD4, Jesse Moskowitz, MD5, Jolanda Pach2, Andrea Knies, cand.med.2, Lori Shutter,
MD6, Robert Goldberg, PhD7, Kathleen M. Mazor, EdD8 and Susanne Muehlschlegel, MD,
MPH1, (1)Department of Neurology, University of Massachusetts Medical School, Worcester,
MA, (2)Department of Neurology, Yale School of Medicine, New Haven, CT, (3)University of
Massachusetts Medical School, Worcester, MA, (4)Department of Internal Medicine, Beth Israel
Deaconess Medical Center, Harvard Medical School, Boston, MA, (5)Department of Psychiatry,
Brown University, Providence, RI, (6)University of Pittsburgh School of Medicine, Pittsburgh,
PA, (7)Department of Population and Quantitative Health Sciences, University of Massachusetts
Medical School, Worcester, MA, (8)Meyers Primary Care Institute and Dept of Internal
Medicine, University of Massachusetts Medical School, Worcester, MA
Purpose: Major professional critical care societies recommend shared decision-making using
decision aids (DAs) to reduce surrogate decisions incongruent with patient values and
preferences and decisional conflict. No DAs currently exist for any decisions in the neurologic
intensive care unit (neuroICU), including goals-of-care decisions, despite an alarming variability
in rates of withdrawal-of-life-sustaining treatments across stroke and trauma centers. Using
multilevel input from 88 stakeholders, we recently developed a goals-of-care DA for critically-ill
traumatic brain injury (TBI) patients that meets international DA standards. We aimed to adapt
this DA to intracerebral hemorrhage (ICH) and hemispheric acute ischemic stroke (AIS) to
widen its applicability and fulfill a need expressed by surrogate decision-makers of stroke
patients.
Methods: First, we adapted the existing goals-of-care DA by replacing the TBI prognostication
model with disease-specific outcome models as recommended by DA quality-standards. We
selected the validated 12-month ICH-model and 12-month hemicraniectomy trial outcome data
for AIS because they include validated long-term outcome assessments. Next, we performed
acceptability and usability testing of both DAs using validated scales in family members
recruited from two academic neuroICU waiting rooms.
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Result: We successfully modified the DAs and created new icon-arrays to optimize the display
of predicted probabilities and uncertainties, as has been shown in risk communication studies.
Twenty family members from two centers participated in acceptability and usability testing.
Median usage time was 22±7 minutes. Usability was very good (mean System-Usability-Scalescore =77/100). 89% of participants graded the DA content as good or excellent and ≥90% rated
it favorably for information amount, balance and comprehensibility.
Conclusion: We developed three goals-of-care DAs for surrogates of critically ill TBI, ICH and
AIS patients that include disease specific icon-arrays to communicate outcome probabilities
meeting international DA standards. Feasibility testing of all three DAs is ongoing, in
preparation for a future multicenter comparative-effectiveness trial. Our rigorous development
process following international DA standards may serve as a template for other neuroICU DAs.
3G-6 DEVELOPMENT OF A TAILORED LIFE-SUSTAINING TREATMENT
DECISION SUPPORT TOOL FOR STROKE SURROGATE DECISION MAKERS
Decision Psychology and Shared Decision Making (DEC)
Emily Chen, MA1, Cynthia Arslanian-Engoren, PhD, RN2, William Newhouse, BS, AAS3, Diane
Egleston, MPH3, Savina Sahgal2, Aneesha Yande2, Angela Fagerlin, PhD4 and Darin
Zahuranec, MD, MS1, (1)Center for Bioethics and Social Sciences in Medicine, University of
Michigan, Ann Arbor, MI, (2)University of Michigan, Ann Arbor, MI, (3)Center for Health
Communications Research, University of Michigan, Ann Arbor, MI, (4)University of Utah / Salt
Lake City VA, Salt Lake City, UT
Purpose: There are limited tools available to support surrogate decision makers facing lifesustaining treatment decisions during an acute hospitalization. We describe the development of
Understanding Stroke, an interactive tailored web-based decision support tool for surrogates of
stroke patients.
Methods: A Patient and Family Advisory Council assisted our multidisciplinary team in
development of the tool. Five stakeholder focus groups (7 stroke survivors, 8 family members,
15 providers) were conducted to obtain feedback on presentation of prognostic information,
items to include in a values clarification exercise, as well as general wording recommendations.
A card sorting exercise was conducted with 24 participants to refine the most important elements
to include in a values clarification exercise. Tool content was developed by a multidisciplinary
team using an iterative process, and two rounds of usability testing (7 participants) were
conducted to ensure the interface supports human computer interaction standards.
Results: Understanding Stroke was designed for use on a tablet or computer during the first 5
days of the hospitalization, with patient-specific data pre-loaded by the study team. To make the
tool broadly applicable, the decision was framed around overall goals of treatment (life
prolonging treatment, basic treatment, or comfort measures only) rather than a specific individual
treatment or procedure. Focus group participants generally preferred a pie chart for presentation
of ordinal prognostic data (Figure, Panel A) and supported the plan to give surrogates the option
whether or not to view individualized numeric prognostic information. The values clarification
exercise asked the surrogate to think about situations in which their loved one might consider
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stopping treatment to extend life and instead consider comfort measures, with the final ranking
of item importance from the card-sort exercise shown in the Figure, Panel B. Usability testing
was generally positive, with minor modifications made to improve content clarity, task
completion and overall navigability of the website. An overview of the final tool elements is
shown in the Figure, Panel C.
Conclusions: We successfully developed a novel web-based decision support tool for stroke
surrogate decision makers facing decisions on life-sustaining treatments during the acute
hospitalization. The tool is currently undergoing pilot testing in a pre-post study design of 50
stroke surrogate decision makers to assess acceptability, usability, decisional self-efficacy, and
impact on knowledge of stroke outcomes.
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3H-1 PRISM: DECISION-ANALYTIC MODELS ON THE CLOUD
Decision Psychology and Shared Decision Making (DEC)
Mohsen Sadatsafavi, MD PhD and Amin Adibi, MSc, Collaboration for Outcomes Research and
Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver,
BC, Canada
Purpose: Complex decision analytics and clinical prediction models often require complicated
software and hardware set up to run and do not have a standardized input/output language. As
such, they are often inaccessible to the wider community even when they are open-source. The
PRogrammable Interface for Statistical/Simulation Models (PRISM) seeks to remove this barrier
by enabling cloud-based remote access to such models.
Methods: Standardized model input and output functions were designed using a layered
approach, starting from a minimal set of functions (e.g., running a model with its default
parameters) to more complex functions (e.g., for probabilistic sensitivity analysis). Modelspecific bridge wrapper functions were created to translate standardized PRISM commands to
model-specific functions. API-enabled models were wrapped in Docker containers and hosted on
The University of British Columbiaʼs cloud-based container management system.
Results: The core component of PRISM is a web-enabled API that standardizes access to
models. The current implementation of PRISM is capable of hosting models developed in R and
can be accessed through a wide range of programming languages. A permanent implementation
of PRISM on a scalable computational platform is available on http://prism.resp.core.ubc.ca. The
basic features of the API are demonstrated through two case studies. An R package and a
Microsoft Excel™ template are provided to facilitate client access to existing and future models
hosted on the platform.
Conclusions: PRISM facilitate access to models by diverse end-users and alleviates the clients’
concerns about the computational and software resources required for running the models.
PRISM empowers patients, physicians, policy-makers, and advocacy groups by allowing them to
examine models more closely and provide critical feedback. Standardization of the platforms of
this type can have far-reaching benefits in terms of more uptake among the end-users, integration
of models into electronic medical records, and facilitating meta-modeling approaches.
3H-2 TRIMODAL THERAPY VERSUS RADICAL CYSTECTOMY FOR MUSCLE
INVASIVE BLADDER CANCER – A MARKOV MICROSIMULATION MODEL
Health Services, Outcomes and Policy Research (HSOP)
Diana Magee, MD, MPH1, Douglas Cheung, MD, MBA1, Amanda Hird, MD1, Srikala Sridhar,
MD, MSc2, Padraig Warde, MD3, Charles Catton, MD3, Alejandro Berlin, MD3, Peter Chung,
MD3, Alexandre Zlotta, MD, PhD4, Neil Fleshner, MD, MPH1 and Girish Kulkarni, MD, PhD5,
(1)University of Toronto, Toronto, ON, Canada, (2)Division of Medical Oncology, Department
of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada,
(3)Department of Radiation Oncology, University Health Network, University of Toronto,
Toronto, ON, Canada, (4)Division of Urology, Department of Surgery, University Health

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E313

Network, University of Toronto, Toronto, ON, Canada, (5)University of Toronto and University
Health Network, Division of Urology, Department of Surgery, Toronto, ON, Canada
Purpose: Radical cystectomy (RC) is the historically accepted gold standard treatment for
muscle invasive bladder cancer (MIBC), but trimodal therapy (TMT) has emerged as a valid
therapeutic option. These two modalities however have not been directly compared. Therefore,
we created a decision model assessing the effectiveness of TMT and RC using decision analysis
methods.
Method: A two-dimensional Markov microsimulation model was constructed using TreeAge
Pro to compare RC and TMT for patients with newly diagnosed MIBC (Figure 1). Model
probabilities and utilities were derived from published literature. Our primary outcome was
quality adjusted life expectancy (QALE). Secondary outcomes included crude life expectancy
(LE), and bladder cancer recurrences in the TMT arm. Markov cycle length was dynamic to
mimic actual clinical practice. The base case for our model was an adult patient with MIBC
(pT2-4 N0 M0) considered appropriate for either RC or TMT. Individual level sampling was
completed for age, gender, and reconstruction type (ileal conduit vs neobladder) assigned in the
RC arm.
Results: TMT was the preferred modality with an estimated mean QALE of 7.49 (95%CI: 6.897.86) versus 7.41 (95%CI: 6.95-7.86) for RC but mean LE for patients treated with TMT was
lower (10.21 years, 95%CI: 9.3-10.7) compared with RC (10.74 years, 95%CI: 10.0-11.4). A
sensitivity analysis evaluating the impact of age showed that younger patients treated with RC
had greater QALE and longer LE than those treated with TMT. However, inverse findings were
observed for elderly patients. Overall, 39.4% of patients in the TMT arm experienced a bladder
recurrence with 27% undergoing a salvage cystectomy.
Conclusion: Our study suggests that RC provides more unadjusted life years than TMT (0.53
years), but lower quality of life (-0.08). Differences in treatment preference were dependent on
age. The younger patients are, the more likely they are to benefit from the oncological control
derived from RC.
3H-3 MICROSIMULATION ANALYSIS TO EVALUATE THE COMPARATIVE
EFFECTIVENESS OF STRATEGIES TO IMPROVE OUTCOMES IN ARGENTINAʼs
COLORECTAL CANCER SCREENING PROGRAM
Health Services, Outcomes and Policy Research (HSOP)
Anna P. Lietz, BA1, Fernando Alarid-Escudero, PhD2, Santiago Melendi, MD, MSc3, Vilma
Irazola, MD, PhD, MPH3, Karen M. Kuntz, ScD4 and Amy Knudsen, PhD1, (1)Institute for
Technology Assessment, Massachusetts General Hospital, Boston, MA, (2)Drug Policy Program,
Center for Research and Teaching in Economics, Aguascalientes, AG, Mexico, (3)Institute for
Clinical Effectiveness and Health Policy, Buenos Aires, Argentina, (4)Division of Health Policy
and Management, University of Minnesota School of Public Health, Minneapolis, MN
Purpose: Screening uptake and adherence with diagnostic follow-up in Argentinaʼs nation-wide
fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening program are very low.
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We used simulation modeling to evaluate which aspect of the screening program – improved
uptake or increased adherence with follow-up – would yield the largest reduction in the burden
of CRC.
Method: We adapted SimCRC, an established microsimulation model of CRC for the US, to
reflect Argentinaʼs observed CRC epidemiological outcomes (e.g., adenoma prevalence, CRC
incidence, CRC stage distribution, CRC survival by tumor location, and life expectancy). We
then used the adapted model to estimate the number of FIT screening tests, diagnostic and
surveillance colonoscopy tests, CRC cases, CRC deaths, and life-years under alternative
scenarios for uptake and adherence with follow-up in Argentinaʼs screening program. Outcomes
from all scenarios were compared to the status quo scenario: 10% program uptake among adults
aged ≥50 years and 30% adherence with diagnostic follow-up of positive FITs. Outcomes are
expressed per 1,000 Argentinian 50-year-olds.
Result: Compared with no screening, the model estimated that Argentinaʼs current screening
program prevents 1 CRC death and yields 7 life-years gained (LYG) per 1,000 50-year-olds.
Under the status quo, 47 out of every 1,000 Argentinian 50-year-olds will be diagnosed with
CRC in their lifetimes and 29 will die from the disease. Increasing program uptake from 10% to
30% of eligible 50-year-olds would prevent 1 CRC death and result in 14 LYG (Table). Gains
from increasing adherence with follow-up from 30% to 70% would be similar (1 CRC death
prevented, 11 LYG), although they could be achieved at a substantially smaller increase in the
number of screening-related resources (89 vs. 1,379 additional FITs and 75 vs. 90 additional
diagnostic colonoscopies).
Conclusion: Increasing adherence to diagnostic follow-up yields similar reductions in the
number of CRC deaths when compared to increasing screening uptake but requires considerably
fewer screening-related procedures. The Argentinian National Cancer Institute may use these
findings to guide changes to the countryʼs CRC screening program and establish priorities for
future cancer-control interventions.
3H-4 ESTIMATING THE CLINICAL AND ECONOMIC BURDEN OF COPD USING
PREDICTION AND SIMULATION MODELING
Health Services, Outcomes and Policy Research (HSOP)
Elizabeth Bond, MPH1, Lusine Abrahamyan, MD, PhD2, Murray Krahn, MD, MSc, FRCPC3,
Kaviul Anam, MSc2, Rajibul Mian, PhD4, Nicholas Mitsakakis, PhD5, Mohsen Sadatsafavi, MD
PhD6, Teresa To, PhD7, Andrea Gershon, MD8 and Petros Pechlivanoglou, PhD1, (1)Child
Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, (2)University
of Toronto, Toronto, ON, Canada, (3)Toronto Health Economics and Technology Assessment
(THETA) Collaborative, Toronto, ON, Canada, (4)McMaster University, Hamilton, ON,
Canada, (5)Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada,
(6)University of British Colombia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada,
(7)The Hospital for Sick Children, Toronto, ON, Canada, (8)Sunnybrook Health Sciences
Centre, Toronto, ON, Canada
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Purpose: To identify patient-level predictors of healthcare resource utilization and costs and to
estimate long-term burden for patients with Chronic Obstructive Pulmonary Disease (COPD).
Methods: We conducted a retrospective cohort analysis using administrative and survey data for
17,791 patients with COPD in Ontario, Canada, who were followed from 2001-2014. We
considered the following events, health states and outcomes: alive post-COPD diagnosis, COPDrelated and non-COPD-related emergency department (ED) visits, COPD-related and nonCOPD-related hospitalizations, all-cause mortality, as well as healthcare costs broken-down into
30-day periods. This analysis involved 1) estimation and prediction of ED visits, hospitalizations
and mortality and 2) estimation and prediction of healthcare costs for patients in the community
setting, during hospitalization and six months prior to death.
In order to estimate healthcare resource use, we first fitted a multi-state regression model with
six health states and 17 transitions. Subsequently, we fitted cost-prediction models stratified by
health state. Model estimates from the above models were fed into a COPD microsimulation
model. Patient-level characteristics were varied to allow quantification of the impact of
covariates of interest (e.g. smoking) on hospitalizations, ED visits, mortality and healthcare
costs. Recurrent events from the simulation were quantified by Mean Cumulative Counts
(MCC), terminal events were quantified by cumulative incidence and survival, and costs were
calculated as mean cumulative costs.
Results: Using simulation modeling to estimate the relative difference on outcomes on smokers
vs. non-smokers, the cumulative incidence of all-cause mortality at fourteen years for smokers
was 0.22 (95% CI: 0.20, 0.24) and 0.18 (95% CI: 0.16, 0.20) for non-smokers. At five years
post-diagnosis, smokers averaged 0.64 (95% CI: 0.60, 0.68) COPD-related ED visits, while nonsmokers averaged 0.44 (95% CI: 0.40, 0.48) COPD-related ED visits. The mean cost of a
simulated COPD patient over 14 years was $39,150, while the median cost was $14,190.
Conclusions: We showed that by combining novel methods such as multistate modeling,
prediction modeling and microsimulation, with administrative data we can estimate clinical and
economic disease burden for the overall population as well as directly assess the disease burden
across subgroups (e.g. smokers). We identified that smokers used more healthcare resources for
COPD-related reasons, and had a shorter life expectancy compared to non-smokers.
3H-5 PROJECTING THE AGE DISTRIBUTION OF PEOPLE RECEIVING HIV CARE
IN THE UNITED STATES: A SIMULATION STUDY
Quantitative Methods and Theoretical Developments (QMTD)
Parastu Kasaie, PhD, Elizabeth Humes, Jinbing Zhang and Keri Althoff, The Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD
Purpose: With improvements in earlier HIV diagnosis and effective use of antiretroviral
treatment (ART), adults are aging with HIV in the United States (US). Given heterogeneities in
the rates of HIV transmission and access to care by age, sex, race and transmission category, the
projected age distribution of adults in HIV care over the next decade is unclear.
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Methods: The PEARL model (ProjEcting Age, multimoRbidity, and poLypharmacy in adults
with HIV) is an individual-based simulation model of HIV care in the US. Simulated individuals
are characterized by age, race, sex and HIV risk category. The risk groups are mutually exclusive
and include men who have sex with men (MSM), injection drug users (IDUs) and those with
heterosexual contact. The model is calibrated against observed data from the North American
AIDS Cohort Collaboration on Research and Design (NA-ACCORD) and US Centers for
Disease Control (CDC) and Preventionʼs HIV surveillance reports from 2009 to 2015.
Results: We project a gradual increase in the median [interquartile range] age from 46 [39-53]
years in 2010 to 56 [42-66] years in 2030. This aging pattern is heterogenous by risk-category,
with the median age changing from 45 [38-51] to 52 [39-64] years among MSM, 45 [38-52] to
60 [50-67] years among those with heterosexual risk and 51 [45-56] to 66 [54-72] years among
IDUs during 2010-30. Additional heterogeneities are projected by sex and race in each subpopulation (Figure1). Limitations include the assumption that trends in a) HIV treatment and b)
the number of new ART initiations (from the CDC) from 2009-2015 (prior to the “Treat All”
era) will both persist to 2030.
Conclusions: Despite higher rates of new HIV infections in younger adults and earlier HIV
diagnosis, the overall age of US population receiving HIV care is projected to increase over the
next decade, likely due to the increased life expectancy and decreased transmissibility among
those with suppressed HIV RNA in the “Treat All” era. However, there are differences in the age
distribution by sex, race, and risk categories which may impact multimorbidity burden among
adults with HIV.

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E317

3I-1 AFRICAN AMERICAN PARTICIPANTS EXPERIENCE GREATER PAIN
SEVERITY AND PAIN INTERFERENCE COMPARED TO NON-HISPANIC WHITES
IN A LARGE SCALE VIRTUAL STUDY ON CHRONIC PAIN
Health Services, Outcomes and Policy Research (HSOP)
Christian J. Cerrada, PhD, Caroline Tai, PhD, Shefali Kumar, MPH, Kelly Scherer, BS, Raul
Eulogio, BS, Ernesto Ramirez, PhD, Luca Foschini, PhD and Jessie Juusola, PhD, Evidation
Health, San Mateo, CA
Purpose: Previous research has shown that African Americans report higher levels of pain
severity and disability associated with chronic pain compared to Non-Hispanic Whites (NHW)
using self-reported data. In this analysis, we aimed to further explore racial disparities in the
subjective experience of pain using objectively measured behavioral data among individuals with
chronic pain.
Method: Individuals with self-reported moderate to severe chronic pain (n=5,832) and no
chronic pain (n=4,204) were eligible to enroll in a currently ongoing, prospective 1-year, virtual
study. To understand the association between self-reported pain and behavioral data, we
conducted two separate multivariable linear regressions using study baseline survey data and
behavioral data 30 days prior to enrollment. The dependent variables were 1) pain severity and 2)
pain interference (on a scale from 0-10) using questions adapted from the Brief Pain InventoryShort Form for the chronic pain subgroup. A race variable was constructed from a list of race and
ethnicity categories. Analysis was restricted to participants with no more than 7 consecutive days
of missing activity data. Models were adjusted for person-level median daily step count
aggregated over the month prior to enrollment. Age, sex, education, income, and BMI were
included as additional covariates.
Result: Among chronic pain participants, 2,021 had sufficient activity data for analysis (NHW =
1,734; African American = 79; biracial African American = 35, other race = 173). Relative to
NHW participants, African Americans reported significantly greater average pain severity
(β=.81, p=<.001) and pain interference (β=.46, p=.042), adjusting for median daily step count
and additional covariates. Median daily step count was negatively associated with pain severity
(β=-2.3e-5, p<.01) and pain interference (β=-6.2e-5, p<.001), adjusting for race and additional
covariates.
Conclusion: Holding objectively measured activity levels constant, African Americans with
chronic pain reported greater levels of pain severity and pain interference compared to NHWs.
Our findings add to a growing body of evidence indicating that African Americans are
disproportionately burdened by chronic pain above and beyond their activity levels. Elevated
levels of pain severity may contribute to poor symptom management observed in the literature
among this population. Future analysis will further examine the utility of novel, behavioral data
as a potential digital measure for pain severity and burden among diverse individuals with
chronic pain.
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3I-2 ATTRIBUTING BENEFITS OF HIV INTERVENTIONS PORTFOLIOS TO
PREVENTION AND TREATMENT EFFECTS
Health Services, Outcomes and Policy Research (HSOP)
Eva A. Enns, MS, PhD, Division of Health Policy and Management, University of Minnesota
School of Public Health, Minneapolis, MN and Horacio A. Duarte, MD, MS, Seattle Childrenʼs
Hospital, Seattle, WA
Purpose: The best allocation between HIV prevention and treatment is an ongoing debate.
Treatment-as-prevention complicates this question, as antiretroviral therapy (ART) confers
treatment benefits to people living with HIV, while also reducing infectivity (preventing onward
transmission). The net benefits of intervention portfolios are measured in terms of qualityadjusted life-years (QALYs) gained in a population; however, understanding to whom benefits
accrue may be important in assessing the equity and impact of HIV intervention investments.
Methods: We derived equations to calculate the proportion of model-predicted QALY
improvements resulting from prevention versus treatment effects. The equations integrate
infections averted with changes in quality-adjusted life-expectancy (QALE) with and without
infection. To accurately account for the impact of delayed, but not entirely averted, infections,
we present equations stratified by age and time. Let NI(a,t) be the number and QI(a,t) the
remaining QALE of individuals infected at age a and time t, while Q0(a,t) is remaining QALE at
age a and time t without infection, under the status quo. Corresponding variables with
intervention are denoted with a prime. For a population aged a in [a0,aM] and an intervention
simulated over t in [0,T], QALYs gained due to prevention are calculated according to equation
1, while treatment benefits are calculated as equation 2. We implemented a simple
compartmental HIV model to evaluate the impact of increasing ART coverage (modeled as
increasing ART initiation rates) over a 10-year time horizon. We evaluated the benefits of ART
scale-up alone and in combination with pre-exposure prophylaxis (PrEP), a medication taken by
uninfected individuals to prevent HIV acquisition.
Results: In an initial population of 1,000 with 12% HIV prevalence, the proportion of QALYs
gained due to prevention increased with ART scale-up (Table 1). At status quo ART coverage,
our equations correctly calculated that PrEP uptake yields 100% of benefits from prevention.
PrEP in combination with ART scale-up yielded more QALYs than scale-up alone; the
proportion due to prevention was also greater, but this initially decreased before increasing again
once sufficiently high ART initiation was achieved.
Conclusions: The proportion of benefit arising due to the prevention versus treatment effects of
HIV interventions changes with intervention intensity. Our equations facilitate the calculation of
benefits, accounting for potentially complex, time-varying effects of delayed infection in
addition to averted infections.
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3I-3 SO A V-BID, CEA, AND DCE WALK INTO A BAR…QUANTIFYING CONSUMER
TRADE-OFFS FOR VALUE-BASED HEALTH INSURANCE
Health Services, Outcomes and Policy Research (HSOP)
Ankur Pandya, PhD, Center for Health Decision Science, Department of Health Policy and
Management, Harvard T.H. Chan School of Public Health, Boston, MA, Kai Yeung, PhD,
PharmD, Seattle, WA and Davene R. Wright, PhD, University of Washington, Seattle, WA
Purpose: Cost-effectiveness analysis (CEA) can be incorporated into U.S. health policy by tying
prescription drug copayment tiers to CEA results (a form of value-based insurance design [VBID]), where patients face higher copayments for low-value (cost-ineffective) drugs and
relatively lower copayments for high-value (cost-effective) drugs. In 2010, Premera Blue Cross
piloted such a policy, and found using CEA-based tiers decreased pharmacy spending by 11%,
but increased patient copayments. Therefore, we aimed to quantify consumer preferences for
CEA-based V-BID designs assuming plan pharmacy savings would be passed onto consumers
via lower premiums.
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Method: We performed a discrete choice experiment (DCE) with U.S. private health insurance
consumers aged 26-62 years (n=364). To capture the key trade-offs between CEA-based V-BID
designs and more typical insurance options, we included the following attributes in our DCE: (1)
copayment structure (6 options: all drugs have $10, $30 or $60 copayment, or high-value/lowvalue combinations of $10/$30, $10/$60, $10/$100); (2) premium reduction (0-10%); and (3)
chance of needing a drug in the low-value tier over next three years (1-25%). Using these
attributes, we generated a balanced set of plan designs representing hypothetical premium
savings and copayment tiers using a fractional factorial design. In ten choice questions,
respondents chose their preferred option from a pair of plan choices. We collected contextual
data on demographics and other factors that could affect insurance choices, such as whether
respondents had a family- or individual-level health plan or chronic health conditions. We
analyzed data using a hierarchical Bayesian model.
Results: The copayment structure was the primary driver of preferences, accounting for 44% of
respondents’ decisions, followed by premium reduction (32%) and chance of needing a lowvalue drug (24%). Respondents generally preferred lower copayment structures (all drugs with
$10 copayment most preferred), but preferred the high-value/low-value combination of $10/$60
to all drug copayment of $30, and a $10/$100 combination to all drug copayment of $60. On
average respondents would require a $260 (individual-level health insurance) or $740 (familylevel) annual premium reduction to choose the $10/$100 copayment formulary.
Conclusions: Consumer preferences are sensitive to copayment structure, but consumers are
willing to make trade-offs for sufficient premium reductions. Future research should assess the
impact of CEA-based V-BID on plan uptake, beneficiary satisfaction, and actual premium
spending for beneficiaries and health plans.
3I-4 ESTIMATING COST-EFFECTIVENESS THRESHOLDS FOR 174 COUNTRIES: A
PRELIMINARY EMPIRICAL STUDY TO INFORM HEALTH DECISION-MAKING.
Health Services, Outcomes and Policy Research (HSOP)
Angel Paternina-Caicedo, MD, MSc, Universidad de Cartagena, Cartagena, Colombia
Purpose: Only a few countries have guidelines on cost-effectiveness thresholds (CET) in the
medical decision-making process. Claxton et al.(1) estimated CET for 2008 in UK, and Woods et
al.(2) extrapolated the Claxton et al. methods in world countries for 2013. However, the
extrapolation required several strong assumptions and some issues remain unresolved. The aim
of this analysis is to provide empirical CETs for world countries, under some assumptions.
Methods: This study quantifies the health-investment per disability-adjusted life-year lost
(DALY) in each world country from 2001-2015. This analysis assumes that CET is the average
investment each country is currently paying for one unit of DALY (health-investment per
DALY). The investment (health expenditures of the gross-domestic-product) was collected from
World Bank databases and DALYs from the Global Burden of Disease (GBD) study, for each
country. This study did not use quality-adjusted life-years because this utility construct does not
allow a systematic estimation across countries, populations, and cultures without significant
additional resources, unavailable now. Other important assumptions of the proposed CETs are:

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E321

1) DALYs from GBD represent all spectrum of disease; 2) the effect of each monetary unit is
cross-sectional and lasts one year; and 3) the health-investment each country is making can come
from any source (public/private, or domestic/external).
Results: According to the assumptions of this study, the country with the largest CET is
Switzerland (current US$ 48,817 for 2015), followed (in descending order) by Australia,
Luxembourg, United States and Norway. The CET in all countries for 2015 and 2001 is shown in
Fig. 1 A-B, respectively. The CET is listed in Fig. 1C for the 20 most populous world countries.
The CET was lower than per-capita gross-domestic-product in all countries, ranging from 5-64%
of per-capita gross-domestic-product for 2015.
Conclusions: CETs in this study are the average health-investment per DALY each country is
making now. An intervention with a cost per DALY greater than the country-specific CET,
means the country will potentially pay more than current investments in health. The present
CETs may help guide health policy in countries worldwide.
References
1. Methods for the estimation of the NICE cost-effectiveness threshold. CHE Research Paper 81,
University of York, 2013.
2. Value in Heath 2016;19(8):929.
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3I-5 VALIDATION OF A NEIGHBORHOOD RISK INDEX OF THE SOCIAL
DETERMINANTS OF HEALTH
Health Services, Outcomes and Policy Research (HSOP)
Kristen Berg, PhD1, Jarrod E. Dalton, PhD2, Douglas Gunzler, PhD3, Claudia J. Coulton,
Ph.D.4, Darcy Freedman, PhD4, Nik Krieger, MS2, Neal V. Dawson, MD5 and Adam T.
Perzynski, PhD5, (1)Case Western Reserve University at MetroHealth, Cleveland, OH,
(2)Cleveland Clinic, Cleveland, OH, (3)CWRU at MetroHealth, Cleveland, OH, (4)Case
Western Reserve University, Cleveland, OH, (5)Case Western Reserve University at
MetroHealth Medical Center, Cleveland, OH
Purpose: Measures of neighborhood (area-based) social determinants of health (SDH) have
shown prognostic value for informing preventive screening decisions, intermediate and primary
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outcomes models, care utilization and treatment decisions. Given growing interest in using SDH
measures it is critically important to evaluate construct validity. We examined configural,
temporal and spatial invariance of a commonly used index of area deprivation.
Method: Data for all United States Census Tracts (N=73,056) from the 2012 and 2017 American
Community Survey were compiled into constituent items of the Area Deprivation Index:
percentage of owner-occupied housing, households with no vehicle, families in poverty, people
living below 150% of the federal poverty level, children in single-parent households, people
unemployed, people with white-collar jobs, people with < 9th-grade education, people with at
least a high-school education, and households with over one person per room; ratio of those
making under $10,000 to those making over $50,000; and median mortgage, house value, rent,
and household income (Singh, 1993; Kind, 2018). Multi-group exploratory and confirmatory
factor analysis models were estimated to evaluate (i) configural invariance (whether the index is
unidimensional) (ii) temporal invariance (measurement structure and weights are equivalent
across time periods and (iii) spatial invariance (measurement equivalence for heterogeneous
regions and communities).
Results: Exploratory factor analysis results indicated a three factor structure (71.38% variance
explained) to be superior to a unidimensional structure (46.51% variance explained) with
economic inequality, financial strength, and education forming the three factors. The three
dimensional factor structure fit the data better on the Comparative Fit Index (CFI) in both 2012
(CFI=.85) and 2017 (CFI=.84) as compared to the unidimensional model (CFI=.48). Evaluation
of temporal noninvariance of the economic inequality factor indicated equivalence of
measurement structure and weights across time (Δ CFI<.01). Evaluation of spatial equivalence
between New York and Wisconsin indicated partial invariance; namely, percentage of
households with no vehicle is more strongly related to economic inequality in Wisconsin than in
New York.
Conclusion: A commonly used SDH index fails standard tests of construct validity. Models
incorporating neighborhood SDH concepts should include more robust multidimensional
measures, and investigate the influence of distinct dimensions of SDH on clinical outcomes.
Further, clinical care decisions may be best informed by integrating regionally-relevant SDH
measures.
4J-1 ANALYSIS OF OBSERVED AND PATIENT-REPORTED SHARED DECISION
MAKING WHEN USING ENCOUNTER DECISION AIDS FOR BREAST CANCER
SURGERY CHOICES
Decision Psychology and Shared Decision Making (DEC)
Renata W Yen, MPH, Marie-Anne Durand, PhD MSc MPhil, Camille Harris, Sarah Cohen,
Abigail Ward, A. James O'Malley, PhD and Glyn J. Elwyn, MD, MSc, PhD, The Dartmouth
Institute for Health Policy & Clinical Practice, Lebanon, NH
Purpose: Observer OPTION-5 measures the extent to which shared decision making (SDM)
occurs in the consultation and collaboRATE measures patient-reported SDM following a
consultation. We aimed to determine whether 1) a text-based (Option Grid) or picture-based
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(Picture Option Grid) encounter decision aid increased observed SDM when compared to usual
care during early-stage breast cancer surgical encounters, 2) there was a correlation between
observed and patient-reported SDM in each group, and 3) observed SDM varied by patientʼs
socioeconomic status (SES).
Method: As part of a comparative effectiveness trial, we randomized surgeons to: 1) Option
Grid, 2) Picture Option Grid, or 3) usual care and audio recorded their encounters with adult
women with early-stage breast cancer who consented to being audio recorded. Two trained raters
independently scored all recorded consultations using OPTION-5. Descriptive statistics, simple
and multilevel linear regressions compared OPTION-5 and collaboRATE scores across arms and
by SES. Mixed-effects multilevel analyses evaluated the influence of surgeon, clinic, and site
clusters as well as surgeon learning effects and SES on OPTION-5 scores.
Result: We analyzed 311 recordings (Option Grid = 40, Picture Option Grid = 147, usual care =
127). OPTION-5 scores were higher in the Option Grid arm (73.2/100) and Picture Option Grid
arm (56.3/100) compared to usual care (40.6/100) (p<.0001). When adjusting for surgeon, clinic,
and site clusters, Option Grid and Picture Option Grid were associated with higher OPTION-5
scores (21.92 [95% CI 7.78-36.06]; 18.63 [95% CI 2.28-34.99], respectively). These results held
constant when adjusting for SES (21.80 [95% CI 7.83-35.77]; 18.79 [95% CI 2.72-34.86]) and
surgeon learning effects (21.50 [95% CI 7.56-35.43]; 19.13 [95% CI 2.84-35.41]).
CollaboRATE scores varied by arm (Option Grid = 79%, Picture Option Grid = 80%, usual care
= 57%, p<.001). High collaboRATE scores were associated with a 7.21 improvement in
OPTION-5 (rpb = 0.126, 95% CI 0.69-13.73).
Conclusion: The use of Option Grid and Picture Option Grid by surgeons in their consultations
with patients led to significantly higher observed and patient-reported SDM. This held after
adjusting for surgeon, clinic, and site as well as surgeon learning effects and SES.
4J-2 FEARFUL EVENTS ARE FAR AWAY: TIME PERCEPTION IN INDIVIDUALS
WHO ENGAGE IN HEALTHY AND UNHEALTHY BEHAVIORS
Decision Psychology and Shared Decision Making (DEC)
Dario Monzani, PhD, Department of Oncology and Hemato-Oncology, University of Milan,
Milan, Italy, Luca Pancani, PhD, Department of Psychology, University of Milan-Bicocca,
Milan, Italy, Patrice Rusconi, Ph.D., School of Psychology, University of Surrey, Guildford,
United Kingdom and Gabriella Pravettoni, PhD, Applied Research Division for Cognitive and
Psychological Science, IEO, European Institute of Oncology IRCCS, Milan, Italy
Purpose: The aim of this study was to investigate peopleʼs time perception of benefits and costs
associated with four types of health-related behaviors: smoking, alcohol consumption, physical
activity, and fruit and vegetable intake.
Methods: Two samples from Italy (N = 214) and the UK (N = 151) filled in an online
questionnaire created on Qualtrics. Participants were asked about their current habits in each of
the four behaviors. Then, they were presented with five positive (e.g., ‘having a satisfying social
life’) and five negative (e.g., ‘having high blood pressure’) events and asked about their own
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perceived risk (‘the likelihood that each of these events will occur at some time in your life’) and
affect (‘how much you are afraid of or hopeful that each of these events will occur at some time
in your life’). Finally, time perception was measured by asking participants to estimate how long
they thought it would take for each event to occur in the life of an 18-years-old person who: (1)
starts smoking every day, (2) drinks spirits every day, (3) stops exercising, and (4) stops eating
fruits and vegetables.
Results: Mixed models were run on participants’ time estimates. The results showed significant
interactions between perceived risk and affect for each of the four health-related behaviors we
considered. Highly negative affect (feeling fear) produced a ceiling effect, whereby participants
tended to postpone the events associated with the health-related behaviors. This effect was
relatively independent of their perceived (low or high) probability of occurrence and their current
behaviour (healthy or unhealthy). For positive affect (high hope), participants tended to perceive
the events closer in time, especially when their perceived probability was high.
Conclusions: These results show that affect played a greater role than risk in participants’ time
estimates. When the level of fear about an event was high, participants postponed the occurrence
of the event later in time. This could have a negative impact on healthy-related behaviors, such
as engaging in healthier habits and screening for diseases. These time distortions can inform the
design of interventions to make peopleʼs perceptions of the risks of unhealthy behaviors more
adequate.
4J-3 VALUE ATTRIBUTION IN ONCOLOGICAL PATIENTS DECIDING ABOUT
RISK REDUCING MASTECTOMY
Decision Psychology and Shared Decision Making (DEC)
Ketti Mazzocco, PhD1, Marianna Masiero, PhD2, Dario Monzani, PhD1, Federica Toscano3,
Ludovica Scotto, MA3, Derna Busacchio, MA3, Serena Oliveri, PhD1 and Gabriella Pravettoni,
PhD1, (1)Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy,
(2)Department of Biomedical and Clinical Science - University of Milan, Milan, Italy,
(3)Applied Research Division for Cognitive and Psychological Science, IEO, European Institute
of Oncology IRCCS, Milan, Italy
Purpose: The study aims to investigate differences in objective-subjective risk perception in
women with breast cancer (BC) and BRCA mutation and to identify the decisional expected
outcomes (EO) patients considered when deciding whether or not to undergo risk-reducing
mastectomy (RRM).
Method: BC patients admitted to the European Institute of Oncology entered the onco-genetic
program for genetic mutation assessment (N=172; mean age=45.46). Decisional counseling was
provided to support patients’ decision on whether or not to undergo RRM.During the decisional
counseling patients had to build a decision tree (DT) whose branches were 1) RRM and 2) active
surveillance (AS). While constructing the DT, patients had to explicit the outcomes they would
expect for each option and the subjective value attributed to each outcome on a scale from 0 to
10 (0 to -10 in case the outcome was a loss). Objective and subjective cancer risk perception was
assessed, as well the DT perceived utility.
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Result: Results showed a significant difference between objective and subjective risk (M=64.4
and M=71.2 respectively; p<.01). Cluster analysis was performed to define groups of patients by
mapping similarities or dissimilarities on how EOs were evaluated. Reported EOs were classified
in the following categories: emotion, cancer risk, femininity, treatment implication, prevention,
and quality of life. Eight clusters were identified relative to the value attributed to the EOs of
RRM. Reduction of negative emotions and of cancer risk were indicated as pivotal outcomes in
the majority of clusters. However, in two clusters reduction of negative emotions and cancer risk
respectively were not considered at all. In only two clusters femininity and treatment
implications were evaluated as salient outcomes. Relative to AS seven clusters were identified,
with a majority of them presenting negative emotions as central outcome. Risk of cancer was
relevant in two clusters, while femininity was considered in only three clusters. Finally, 67% of
patients reported that DT improved their decision awareness.
Conclusion: Results showed different mental representations of the same decisional problem in
different patients. Patients can be grouped depending on specific outcomes they expect,
confirming the need to understand the complexity of patients’ preferences and to find solutions
to reduce such complexity. DT can help physicians and patients improve awareness toward
priorities and values and enhance confidence in the decision.
4J-4 IMPACT OF LUNG CANCER ETIOLOGY ON STIGMATIZING AND
SCREENING INTENTIONS: AN EXPERIMENTAL STUDY
Decision Psychology and Shared Decision Making (DEC)
Aaron M. Scherer, PhD1, Mark Vander Weg, PhD2, Tanner J. Caverly, MD3 and Richard M.
Hoffman, MD, MPH1, (1)University of Iowa, Iowa City, IA, (2)VA Iowa City Health Care
System, Comprehensive Access & Delivery Research and Evaluation (CADRE) Center, Iowa
City, IA, (3)University of Michigan, Ann Arbor, MI
Purpose: Lung cancer is the leading cause of cancer mortality in the US. Prior research has
provided evidence that concern about being stigmatized is a barrier to lung cancer screening. The
objectives of the current study were to provide novel tests for 1) a relationship between lung
cancer patient stigmatization and personal willingness to engage in lung cancer screening and 2)
the impact of the etiology of a patientʼs lung cancer on these measures.
Methods: A national, demographically representative sample of 1,866 U.S. participants were
recruited through Qualtrics Research Services and randomized to read 1 of 3 vignettes about a
lung cancer patient. The vignettes were identical apart from the reported cause of the lung
cancer: 1)smoking; 2)asbestos exposure; or 3)unknown cause.
Participants completed measures of patient stigmatization, willingness to engage in screening
activities if the participant thought they might have lung cancer, and smoking status. Participants
who did not complete the study (n=560) or answer the smoking items (n=119) were dropped
from our analyses, for a final sample size of 1,187.
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We dichotomized participants into never-smokers (n=706) and current/past smokers (n=481) and
created aggregate scores for the 8 stigmatization items (Cronbachʼs α=0.85) and 4 screening
willingness items (Cronbachʼs α=0.90).
Results: Greater stigmatization of the patient was associated with decreased participant
willingness to be screened (r=-0.26, p<.001).
Patient stigmatization (Figure 1) was highest when the reported cause of the cancer was
smoking, followed by asbestos, and the unknown cause (p<.001). Current/past smokers had
lower patient stigmatization compared to never-smokers (p=.049).
Current/past smokers were less willing to be screened compared to never-smokers (p=.005).
While there was no significant impact of cancer cause condition (p=.686), it did significantly
interact with smoking status (p<.001). Specifically, screening willingness was highest in the
unknown cause condition and lowest in the asbestos condition for never-smokers, while
current/past smokers exhibited the reverse pattern (Figure 1).
Conclusion: Our study provides the first evidence for an association between the expression of
lung cancer stigmatization and personal screening willingness, both of which were impacted by
the etiology of a patientʼs lung cancer and the observerʼs smoking status. Additional research is
needed to expand on these results in order to develop effective interventions to reduce lung
cancer stigmatization and increase lung cancer screening rates.
4J-5 UNDERSTANDING MEDICAL MAXIMIZING-MINIMIZING PREFERENCES
Decision Psychology and Shared Decision Making (DEC)
Laura Scherer, PhD, University of Colorado, Denver, CO and Niraj Patel, MA, University of
Missouri, Columbia, MO
Purpose: The Medical Maximizer-Minimizer Scale (MMS) assesses patient preferences for
active vs. passive approaches to healthcare, and predicts healthcare utilization and patient
preferences in a variety of healthcare contexts. However, the antecedents or causes of
maximizing-minimizing orientations are not well understood. Prior research has shown small or
no correlation between the MMS and health status or healthcare access, but moderate
associations with health anxiety, suggesting that maximizing might be driven by health anxiety
more-so than objective health. The purpose of the present study was to further elucidate
maximizing-minimizing preferences by examining the MMSʼs association with trust and
reasoning skills; namely, healthcare system distrust, belief in science, scientific reasoning, and
reliance on intuitive vs. reflective modes of thought.
Methods: 1061 men and women age 18-73 (M=32, SD=12; 73% White) completed an online
survey. The MMS (Scherer et al., 2016) was assessed along with validated measures of
healthcare system distrust (Shea et al., 2008), belief in science (Farias et al., 2013), scientific
reasoning (Drummond & Fischhoff, 2017), and the Rational-Experiential Inventory (Epstein et
al., 1996), which includes Need for Cognition (NFC) and Faith in Intuition (FI).
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Results: There was no association between the MMS and the NFC and FI, ps>.09. However,
maximizers expressed less healthcare system distrust (r=-.28, p<.001), greater belief in science
(r=.25, p<.001), and worse scientific reasoning skill (r=-.29, p<.001) relative to minimizers.
Scientific reasoning was uncorrelated with belief in science and distrust, rs<.01, ps>.81.
Stepwise linear regression including age, sex and education as covariates showed that distrust,
belief in science and scientific reasoning were each uniquely predictive of the MMS (all p<.001)
and explained 18% of the variance in MMS after accounting for covariates (R2=.18).
Conclusions: Maximizers and minimizers are equally likely to rely on intuitive vs. reflective
modes of thought, but maximizers possess worse scientific reasoning skills than minimizers.
Maximizers also express greater trust the healthcare system and belief in science than
minimizers. Although these results are correlational and cannot establish causality, they suggest
that some maximizers have faith in science but do not understand it well, which can potentially
explain their greater likelihood of pursuing low-benefit medical interventions. By contrast,
minimizers are more distrusting, but are better scientific reasoners, suggesting that minimizers
might be more likely than maximizers to be informed skeptics.
4J-6 WHEN DOES THE INCREMENTAL RISK FORMAT AID INFORMED MEDICAL
DECISIONS? THE ROLE OF LEARNING, FEEDBACK, AND NUMBER OF
TREATMENT OPTIONS
Decision Psychology and Shared Decision Making (DEC)
Kevin E. Tiede, Felicia Ripke, Nicole Degen and Wolfgang Gaissmaier, PhD, University of
Konstanz, Konstanz, Germany
Purpose: Informed medical decisions require understanding the benefits and risks of treatments.
This entails comparing treatment outcomes to a control group. The incremental risk format has
been recommended as it highlights these differences between treatment and control, rather than
presenting treatment and control outcomes separately (total risk format). Because research on
this format is scarce, we investigated when the incremental risk format aids understanding.
Method: In two experiments, participants received information about medical treatments, either
as incremental or total risk format. We assessed gist and verbatim knowledge and evaluations of
the formats. Study 1 (N = 99) consisted of only one trial with medical information and
additionally assessed recall. Study 2 (N = 222) assessed learning across multiple trials and
additionally varied the presence of feedback and the number of treatment options.
Result: In Study 1, the incremental risk format (vs. total risk format) led to worse knowledge,
recall, and evaluations. In Study 2, participants learned to understand the incremental risk format
over time, resulting in comparable verbatim knowledge and evaluations as the total risk format,
and in even better gist knowledge. Feedback and number of treatment options did not moderate
the effect of risk format.
Conclusion: The incremental risk format was initially less understandable than the total risk
format. After a short learning period, however, the incremental risk format resulted in better gist
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knowledge and was comparable otherwise, which suggests that participants had to get used to
that format. This has important implications for the study of new formats.
4K-1 A VALUE OF INFORMATION ANALYSIS FOR A TRIAL EVALUATING
SALVAGE SURGERY FOR RECURRENT COLORECTAL CANCER
Applied Health Economics (AHE)
Jonah Popp, PhD, Brown University, Providence, RI
Purpose: The results of three recent randomized control trials (RCT) have cast doubt on the
value of intensive post-diagnosis extracolonic follow up of non-metastatic colorectal cancer
(CRC) patients. Skeptics argue early detection of recurrence confers no survival benefit because
aggressively treating recurrence with salvage surgery is not beneficial to patients. We have
previously shown that, if intensive extracolonic surveillance is beneficial to patients in virtue of
an increase in the rate of salvage surgery for recurrence, the benefit would be very small on
average and could not plausibly be estimated precisely from a RCT comparing surveillance
strategies. Rather a RCT directly evaluating curative resection of recurrence would be necessary.
To evaluate the potential value of such a trial, we conducted a value of information analysis.
Method: We used a previously-developed model of the natural history process of CRC
extracolonic recurrence overlain with surveillance, treatment of recurrence, and treatmentdependent mortality. We estimated the per-patient and population expected value of sample
information (EVSI) associated with a trial randomizing CRC patients with asymptomatic
‘resectable’ recurrence to curative resection or conservative treatment. We assumed the endpoint
would be a risk-difference (RD) in 10-year overall survival (an increase in ‘cured’ patients). We
placed a beta-mixture prior on this parameter, with one beta distribution parameterized from
observational data (the ‘optimistic case’) and the other representing a skepticʼs view. To estimate
the EVSI, we used a nonparametric regression meta-modeling approach with an embedded
MCMC sampling step to estimate the posterior mean of the RD parameter. We estimated the
EVSI with respect to the number of patients randomized to each treatment arm (from n = 50-350,
in increments of 50). We performed these calculations assuming WTP values of $50,000,
$100,000, and $150,000 (2017 $US) per life-year. We took a societal perspective and used a
lifetime time horizon (discount rate=3%).
Result: The figure below presents the preliminary per-patient results of the analyses. If 10,000
US CRC patients were affected per year for 10 years, the population-level EVSI (WTP = $100k)
would range from about 20-45 million dollars at the sample sizes considered.
Conclusion: It appears unlikely that an RCT evaluating salvage surgery for CRC recurrence
would be worth the investment assuming 15 post-operative CRC patients are needed per patient
randomized.
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4K-2 PRIORITIZING FUTURE RESEARCH TO INFORM EVIDENCE-BASED
GUIDELINES FOR ANTIBIOTIC PROPHYLAXIS FOR DENTAL PATIENTS WITH A
HISTORY OF TOTAL KNEE ARTHROPLASTY
Applied Health Economics (AHE)
Karen Kuntz, ScD1, Fernando Alarid-Escudero, PhD2 and Daniel Skaar, DDS, MS, MBA1,
(1)University of Minnesota, Minneapolis, MN, (2)Drug Policy Program, Center for Research and
Teaching in Economics (CIDE), Aguascalientes, AG, Mexico
Purpose: Clinical guidelines for recommending antibiotic prophylaxis (AP) before dental
procedures to prevent periprosthetic joint infection (PJI) following total knee arthroplasty (TKA)
have been hampered by the lack of prospective randomized controlled trials (RCTs). Over the
past two decades guidance has ranged from lifetime AP, to limited AP, to no AP. We conducted
value-of-information (VOI) analyses to quantify the value of potential additional research and
reducing decision uncertainty regarding the cost-effectiveness of AP strategies for dental patients
with a history of TKA.
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Method: We used a previously developed Markov model to estimate the expected net benefit of
sampling for three AP strategies for TKA patients: No AP, 2-year AP, lifetime AP. We assigned
distributions to all of the uncertain parameters and conducted a probabilistic sensitivity analysis
(PSA) to evaluate decision uncertainty. We used the PSA dataset to conduct VOI analyses to
determine the value of conducting further research, particularly an RCT to determine the
effectiveness of AP strategies. We used a linear regression meta-modeling approach to calculate
population expected value of partial perfect information (EVPPI), and a Gaussian approximation
to calculate population expected value of sample information (EVSI) and subtracted the cost for
research to obtain the expected net benefit of sampling (ENBS). We then obtained the optimal
sample size for each study design as the sample at which ENBS is maximized.
Result: The PSA showed that no AP had the highest expected net benefit and a 58% probability
of being cost effective at a $100,000 per quality-adjusted life year (QALY) cost-effectiveness
threshold and 2-year AP had a 39% probability. EVPPI for parameters related to AP efficacy and
PJI risk was $33.7 million for a cost-effectiveness threshold of $100,000 per QALY. We found
that the optimal sample size for an RCT to determine the efficacy of AP and the risk of dentalrelated PJI would require approximately 430 patients per arm. By comparison, frequentist sample
size estimates (using a 0.05 type I error and 80% power) were over 1 million subjects per arm.
Conclusion: Because of the uncertainties associated with AP guidelines for dental patients post
TKA, we found that that it would be of value to conduct an RCT to better inform evidence-based
guidelines with sample size calculations smaller than using a traditional frequentist approach.
4K-3 APPLICATION OF VALUE OF INFORMATION ANALYSES IN INFORMING
RESEARCH INVESTMENT PLANS FOR FUTURE CONGENITAL
CYTOMEGALOVIRUS VACCINE CANDIDATES
Health Services, Outcomes and Policy Research (HSOP)
Yao-Hsuan Chen, PhD1, John Cook, PhD2, Anushua Sinha, MD, MPH3, Manpreet Kaur, MS2
and Elamin H. Elbasha, PhD1, (1)Merck & Co., Inc., Kenilworth, NJ, (2)Complete HEOR
Solutions, North Wales, PA, (3)Merck & Co., Inc, Kenilworth, NJ
Purpose:
A human cytomegalovirus (CMV) vaccine was identified as one of seven priority vaccines for
development by Institute of Medicine in 20001, but substantial uncertainties in the congenital
CMV (cCMV) epidemiology, natural history of disease, and economic evaluation of candidate
CMV vaccines need to be addressed.
Method:
We developed a CMV state-transition model to estimate disease burden as well as costs
associated with CMV transmission and performed Value of Information (VOI) analyses with the
model to inform prioritization decisions on research investments among clinical, epidemiologic,
and outcome research studies. The model was developed to follow the remaining lifetime of
adolescent females and their infants in the U.S. population. Relevant health states were stratified
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by CMV infection status, pregnancy status, cCMV infection status, and cCMV-related sequelae.
Five potential vaccination strategies were evaluated: no vaccination; routine vaccination without
boosters and with boosters if required; selective vaccination without boosters and with boosters
if required. Model inputs were obtained from the published literature. We used Microsoft Excel
to develop the model and conduct Expected Value of Perfect Information (EVPI), Expected
Value of Partial Perfect Information (EVPPI), and Expected Value of Sample Information
(EVSI) analyses.
Result:
Among the vaccination strategies considered, routine vaccination with boosters (if required) is
the most effective and provides the greatest value. The estimated EVPI is $51.41 per eligible
female adolescent from the payerʼs perspective. With 95 model parameters grouped into 9
mutually exclusive sets, 4 sets have relatively higher aggregated EVPPI across a wide range of
WTP values compared to the other 5 sets (Figure 1-a). Within the identified influential parameter
sets, EVPPI analysis identified 5 significant parameters (Figure 1-b); the parameter “primary
infection during pregnancy if susceptible” was the most influential and should be the focus of
future research with a study design of at most 500 subjects (Figure 1-c).
Conclusion:
Our study suggests that a hypothetical cCMV vaccine may be cost-effective in the U.S. when
implemented as part of a routine vaccination strategy for adolescent females without or, if
required, with boosters. Given parameter uncertainty, efforts should be taken to minimize their
impact on future CMV vaccination recommendations. With limited resources for research, VOI
analyses point to prioritizing studies that explore the risk of primary CMV infection during
pregnancy.
Reference:
https://www.nap.edu/catalog/5501/vaccines-for-the-21st-century-a-tool-for-decisionmaking
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4K-4 THE VALUE OF (BIASED) INFORMATION
Quantitative Methods and Theoretical Developments (QMTD)
Katherine Lofgren, MPH, Harvard University, Cambridge, MA, Laura Hatfield, PhD, Health
Care Policy, Harvard Medical School, Boston, MA and Ariel Stern, PhD, Harvard Business
School, Boston, MA
Purpose:
Value of information (VOI) typically assumes that current and future observed patient outcomes
are random samples from the same underlying population. However, in many contexts, that
assumption may be violated. For example, in the Food and Drug Administrationʼs accelerated
approval pathway, drugs are initially approved on proxy outcomes (like tumor size). Proxy
outcomes are typically easier to demonstrate a drug-response compared to patient survival.
Importantly, regulators have the authority to stipulate outcomes in post-market studies for
accelerated approval drugs. Here we ask: What is the expected difference in the value of sample
information when an optimal follow-up study reports a proxy vs. true outcome of interest?
Method:
We conducted a VOI analysis to estimate the expected net monetary benefit of a future study
measuring a proxy outcome compared to a true outcome of interest. The proxy is biased in favor
of a treatment effect. In our simulated scenarios, we consider cases where initial and future
evidence is both unbiased and biased (Figure). In our empiric analysis of the FDAʼs required
confirmatory studies following accelerated approval we extend this research to a context with
real-world regulatory policy implications.
Result:
In one illustrative case where the first evidence available between two treatment choices was
generated from a study size of 125 patients, if the results were an unbiased sample of the true
outcome of interest, the optimal future study size was 891 patients with a per person expected
value of information of 1897 USD. When the initial study is biased in favor of the novel therapy,
the value of additional information on the true outcome of interest decreases to 1278 USD per
person. Expected value further decreases when both current and future information is a biased
proxy to 1026 USD per person despite the optimal sample size staying relatively stable.
Conclusion:
The majority of post-market studies of accelerated approval drugs report proxy outcomes. Our
results suggest this is a sub-optimal regulatory strategy. Although this work is framed in terms of
data collection on proxy versus true outcomes, the results have implications across VOI analyses.
In any context where study results are potentially biased population samples, VOI results that do
not account for information bias may be inaccurate.
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Figure: Schematic of simulation scenarios and relevance to the FDA accelerated approval
pathway

4K-5 THE MAXIMUM VALUE OF HETEROGENEITY FOR UNKNOWN
SUBGROUPS
Quantitative Methods and Theoretical Developments (QMTD)
Anna Heath, PhD, University of Toronto, Toronto, ON, Canada and Petros Pechlivanoglou,
PhD, Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada
Background: Clinical care is moving away from a “one size fits all” approach towards treatment
decisions that are made by reflecting individual patient response, needs, preferences and risk.
Research into personalised treatment strategies tries to identify subgroups in the population,
distinguished by a currently unknown marker, that would benefit from an alternative treatment
compared to the population level optimal treatment. Before investigating these markers, it is
important to assess whether research in this area has the potential to generate value. The Value of
Heterogeneity [1] assesses the value of personalising care based on a set of known patient level
characteristics but has not been extended to the case where the subgroup structure is unknown.
Thus, we extend the Value of Heterogeneity so it is relevant to settings where the subgroup
structure is unknown.
Purpose: We highlight the importance of accounting for the counterfactual, i.e. the benefit a
patient would have experienced had they received an alternative treatment, when valuing
personalised treatments. We develop a set of new measures to assess the maximum value that
could be generated by personalising care at the population level (maximum Value of
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Heterogeneity, mVoH) and demonstrate how this measure can determine the potential value of
personalised treatments.
Methods: Using a previously published example [2], we explore how assumptions about the
correlation between the net benefit across different treatments for a single patient alter the
mVoH. If this correlation is not defined, then an unspecified assumption is implicitly made about
the correlation structure.
Results: The Figure demonstrates that mVoH varies between $0 and $3,500, depending on the
assumed value for the correlation between the individual level net benefits. As the correlation
decreases, the mVoH increases implying that personalising treatment has a greater potential to
generate value at the population level.
Conclusions: Calculating the mVoH while correctly accounting for the counterfactual is the first
element of a comprehensive value of heterogeneity framework to guide research prioritization in
personalised medicine. This method highlights areas with the greatest potential to generate value
from personalised treatment decisions.
[1] Espinoza, M. et al, Medical Decision Making 34(8):951-964 (2014)
[2] Ades, A. et al, Medical Decision Making 24(2):207-227 (2004)

Figure 1: The mVoH plotted against the correlation between the individual-level net benefit for
our example.

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E337

4K-6 CALCULATING THE EXPECTED VALUE OF SAMPLE INFORMATION IN
PRACTICE: CONSIDERATIONS FROM THREE CASE STUDIES
Quantitative Methods and Theoretical Developments (QMTD)
Anna Heath, PhD, The Hospital for Sick Children, Toronto, ON, Canada, Natalia R. Kunst,
MSc, Department of Health Management and Health Economics, Faculty of Medicine,
University of Oslo, Oslo, Norway, Christopher Jackson, PhD, MRC Biostatistics Unit,
University of Cambridge, Cambridge, United Kingdom, Mark Strong, PhD, School of Health
and Related Research (ScHARR), University of Sheffield, Sheffield, United Kingdom, Fernando
Alarid-Escudero, PhD, Drug Policy Program, Center for Research and Teaching in Economics,
Aguascalientes, AG, Mexico, Jeremy D. Goldhaber-Fiebert, PhD, Stanford Health Policy,
Centers for Health Policy and Primary Care and Outcomes Research, Stanford University,
Stanford, CA, Gianluca Baio, PhD, University College London, London, United Kingdom,
Nicolas A. Menzies, PhD, Harvard TH Chan School of Public Health, Dept. of Global Health
and Population, Boston, MA and Hawre Jalal, MD, PhD, University of Pittsburgh Graduate
School of Public Health, Pittsburgh, PA
Purpose: Determining the potential value of future research is key to improving policy-making.
The Expected Value of Sample Information (EVSI) quantifies the expected value of a proposed
study and can be used to optimize research study design. Estimating EVSI using the standard
nested Monte Carlo (nMC) algorithm has a notoriously high computational burden. Recently,
efficient methods to approximate EVSI have been developed. However, their relative advantages
and disadvantages have not been compared. Members of the Collaborative Network for Value of
Information (ConVOI), including the developers of the four efficient approximation methods
considered in this abstract, compared these methods to inform choices about their use in practice.
Methods: Four EVSI approximation methods (developed by Strong et al. [1], Menzies [2], Jalal
and Alarid-Escudero [3], and Heath et al. [4]) were compared using three case studies. The
examples were chosen to represent a range of real-world contexts, including observational and
randomized studies, a range of proposed study outcomes (e.g., survival, quality of life), and the
possibility of missing data in a proposed study. We compared the computational speed and
precision for each case study.
Results: The four approximation methods were substantially faster than the nMC methods,
requiring between 1.48 minutes and 8.2 hours instead of 7 to 22 weeks. All approximation
methods achieved EVSI estimates that had acceptable precision. EVSI estimates for the first case
study with 95% uncertainty intervals are shown in Figure. Similar results were observed in case
studies 2 and 3. Variations in relative performance of the methods depended on features of the
specific problem, including the number of different sample sizes considered and the
computational cost of the underlying health economic model.
Conclusion: EVSI can be computed efficiently using these four approximation methods in range
of realistic examples. None of these approximation methods is generally superior to the others
and they all give reasonable EVSI estimates in a reasonable amount of time.
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Figure: EVSI estimates with 95% uncertainty intervals for the four methods with a black vertical
line displaying the nMC estimate.

[1] M. Strong, et al. Medical Decision Making, 35(5):570–583 (2015)
[2] N. Menzies. Medical Decision Making, 36(3):308–320 (2016)
[3] H. Jalal and F. Alarid-Escudero. Medical Decision Making, 38(2):174–188 (2018)
[4] A. Heath et al. Medical Decision Making. In press.
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4L-1 INOCULATING AGAINST FLU VACCINE MISINFORMATION: A TEST OF 3
INTERVENTIONS
Decision Psychology and Shared Decision Making (DEC)
Niraj Patel, MA1, Laura Scherer, PhD2 and Victoria Shaffer, PhD1, (1)University of Missouri,
Columbia, MO, (2)University of Colorado, Denver, CO
Purpose: Many people believe that the influenza vaccine can cause influenza illness, and this
myth may be one reason for low vaccination rates. Correcting this misperception is important,
but misinformation corrections are rarely completely effective at changing beliefs. Information
corrections can be less memorable than misinformation, and corrections can leave people with
incomplete mental models (e.g., fail to explain how a person could become sick with flu-like
illness after receiving the vaccine). We therefore tested three interventions to reduce beliefs in
this vaccine myth: a basic message, an explanatory message, and a narrative message.
Methods: 1061 men and women age 18-73 (M=32, SD=12; 73% White) completed an online
survey. Participants first reported their belief that the flu vaccine causes the flu (Time 1). Then
they were randomized to one of four conditions: Control (no correction), basic CDC statement
that the flu vaccine does not cause the flu, a more thorough CDC explanation of why a person
might get sick after the vaccine, or a narrative that contained all aforementioned information.
After the intervention, participants reported their belief in the myth and vaccination intentions
(Time 2). Next, participants were exposed to further misinformation in the form of short stories
suggesting that the flu vaccine does cause the flu. Then participants stated their beliefs and
intentions again (Time 3).
Results: A 4 (Condition) × 2 (Time: Time 1 vs. Time 2) ANOVA on myth beliefs revealed a 2way interaction, F(3, 1036)=5.50, p<.001. All interventions increased rejection of the myth to
approximately the same extent (ps<.001, ds=.46-.57) whereas there was no change in the control
condition (p=.10; see Figure below). An interaction also emerged comparing Time 2 vs. Time 3
(F(3, 1037)=3.42, p=.017); the additional misinformation decreased myth rejection in all
conditions at Time 3 relative to Time 2, but the effect was smaller for the thorough correction
and narrative (ds=.16, .28) versus the control and basic correction (ds=.40, .40). No intervention
affected vaccination intentions.
Conclusions: Both basic and more explanatory corrections reduced beliefs in the flu vaccine
myth, but more explanatory corrections may be more effective at inoculating against further
misinformation. Vaccination intentions were unaffected by the interventions, indicating that
other concerns or perceived barriers may drive intentions.
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4L-2 PATIENT-CLINICIAN COMMUNICATION AND LONGITUDINAL PATIENTCENTERED OUTCOMES AMONG STAGE I NON-SMALL CELL LUNG CANCER
PATIENTS: A PROSPECTIVE COHORT STUDY
Health Services, Outcomes and Policy Research (HSOP)
Shannon Nugent, PhD1, Charles Thomas, Jr., MD2, Donald Sullivan, MD, MA, MCR3 and
Christopher Slatore, MD, MS3, (1)VA Portland Health Care System, Center to Improve Veteran
Involvement in Care, Portland, OR, (2)Department of Radiation Medicine, Knight Cancer
Institute, Oregon Health & Science University, Portland, OR, (3)Oregon Health & Science
University, Portland, OR
Purpose: Among patients (pts) with early stage non-small cell lung cancer (NSCLC), we sought
to evaluate the association of patient-clinician communication (PCC) with patient - centered
outcomes (treatment self-efficacy, decisional conflict, and anxiety). We hypothesized that high
quality PCC would be associated with higher treatment self-efficacy, lower decisional conflict,
and lower anxiety.
Method: We included pts with stage I NSCLC who were treated at seven, diverse healthcare
centers in Portland, Oregon. We prospectively examined communication-related outcomes at
five time points after cancer diagnosis: prior to treatment, during treatment, 4-6 weeks after
treatment, 6-months and 12-months post-treatment. We used validated measures to examine
PCC, treatment self-efficacy, decisional conflict, and anxiety. Three separate mixed model
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analyses that each adjusted for relevant sociodemographic and clinical variables examined the
relationship between PCC and (1) treatment self-efficacy, (2) decisional conflict, and (3) anxiety
across time.
Result: The analytic cohort included 131 individuals, 57 who received surgical resection and 74
who received stereotactic body radiation therapy (SBRT). The sample was mostly white (92%),
males (62%), with a mean age of 70.7 ± SD 8.1 years, who were former smokers (73%). High
quality PCC was related to higher treatment self-efficacy (coeff = 0.12 [95% CI = 0.06 - 0.19])
and lower decisional conflict (coeff = 5.49 [95% CI = 3.06 – 7.92]) but not anxiety (coeff = 1.36
[95% CI = -0.58 - 3.30]) over time. Higher anxiety was associated with surgery (coeff = 5.21
[95% CI = 1.25 – 9.17]).
Conclusion: High quality PCC appears to be associated with less decisional conflict and greater
treatment related self-efficacy, though not associated with anxiety over time. Surgical resection
was associated with higher anxiety over time. High quality patient-clinician communication may
be an important determinant of certain patient - centered outcomes. Communication is a
modifiable clinician behavior that may enhance important components of self-efficacy such as
patient understanding and participation in treatment.
4L-3 A METACOGNITIVE CONFIDENCE CALIBRATION TOOL TO HELP
MEDICAL STUDENTS SCAFFOLD DIAGNOSTIC REASONING IN DECISION
MAKING DURING HIGH FIDELITY PATIENT SIMULATIONS
Decision Psychology and Shared Decision Making (DEC)
Luciana S. Garbayo, MD, PhD1, David Harris2, Steve Fiore2 and Jonathan Kibble2,
(1)University of Central Florida, Orlando, FL, (2)Orlando, FL
Purpose: 1) Help novice students scaffold problem-solving, engage safely in the deliberate
practice of diagnostic reasoning and decision-making in real-time, 2) Assess how accurately
students gather and apply data in medical reasoning and treatment during HFPS, 3) Identify
students scientific misconceptions related to the HFPS case, 4) Provide a stimulus to promote
student metacognitive processing, self-assessment and self-efficacy, 5) Facilitate the explicit
calibration of student confidence in deliberate reasoning with patient outcomes and team medical
decision-making.
Method: Mixed method; metacognitive calibration self-assessing (MCC) survey tool applied to
high fidelity patient simulation (HFPS); N=80, 20 teams of 6 medical students; Semi-structured
interviews with faculty N=5
Result: When compared against the faculty rubric, the mean correct student response rate ranged
from 23-74 % ,whereas the self-assessment of confidence ranged from 71-86 %. This result
revealed overconfidence bias in novice students regarding the correctness of wrong responses.
The most common misconception identified was inverting cause and effect: that metabolic
acidosis was pointed as the cause of the patientʼs problems, rather than a consequence of
untreated diabetes mellitus. The most common treatment error was overtreatment, with
unnecessary added medication. Semi-structured interviews with faculty facilitators suggested the
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MCC tool improved team process by slowing students down, required to think through their
answers and that overall the tool improved their critical thinking.
Conclusion: This study demonstrated the feasibility of using a metacognitive confidence
calibration tool to assist novice students in learning safely to make deliberate diagnostic
reasoning and medical decisions on patient care in real time during complex simulations, while
observing objectively their levels of psychological confidence against patient outcomes. We
suggest several uses for this new self-assessment instrument.
Table 1. Student Accuracy and Confidence Levels
Median
ITEM Accuracy
(%)

Mean
Range
of
Accuracy
Accuracy (%)
SD, %)

1
2
3

0-67
0-67
0-67

53 ± 18
40 ± 17
34 ± 19

Mean
Range
of Confidence
Confidence (%)
(± SD, %)
86* (p=0.000) 57 – 100
86 ± 10
86* (p=0.000) 43 – 100
81 ± 11
71* (p=0.000) 43 – 100
75 ± 13

0-100
0-100

74 ± 44
23 ± 42

71 (p=0.530) 29 – 100
71* (p=0.000) 29 – 100

4
5
6

50
33
33
N/A
narrative
answers
100
0

Median
(± Confidence
(%)

72 ± 16
71 ± 17

4L-4 AGREEMENT BETWEEN UROLOGISTS AND RADIATION ONCOLOGISTS'
PROSTATE CANCER TREATMENT RECOMMENDATIONS
Decision Psychology and Shared Decision Making (DEC)
Angela Fagerlin, PhD1, Xuechen Wang2, Karen Scherr, MD, PhD3, Rebecca Delaney, PhD1,
Brittany Sisco-Taylor, PhD1, Benjamin Haaland, PhD2, Valerie C. Kahn, MPH4 and Peter A.
Ubel, MD3, (1)University of Utah, Salt Lake City, UT, (2)University of Utah, SALT LAKE
CITY, UT, (3)Duke University, Durham, NC, (4)University of Michigan, Ann Arbor, MI
Purpose: Previous research has shown urologists’ and radiation oncologists’ recommendations
for a hypothetical patient and the treatment they believe offers better survival are closely aligned
with their specialty. We compared urologists’ and radiation oncologists’ actual treatment
recommendations for the same patient and examined whose recommendation patients followed.
Methods: 108 patients with Gleason 6-7 prostate cancer were recorded during consultations with
both a urologist and a radiation oncologist. We coded urologists and radiation oncologists’
highest-scoring recommendations into a not mutually exclusive, overall recommendation for
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each patient (providers could recommended multiple options equally). Data on treatment
received was obtained from electronic medical records. We examined agreement rates among
recommendations using a Kappa test. We used multinomial logistical regression to examine
factors that predicted whose recommendation patients were more likely to follow, including
which specialist was seen first, length of consultation, and strength of recommendation.
Results: 40% of patients had Gleason 6 prostate cancer. The figure shows percent of each type
of recommendation for urologists and radiation oncologists. Urologists typically recommended
active treatment (69% of cases), listing surgery as the only recommendation in 49% of cases.
Radiation oncologists recommended active treatment similarly (64%), but only radiation in 19%
of cases. The rate of agreement between providers was 30.6% (kappa 0.18, p<0.001, 95%CI
0.08-0.28).
Examination of the treatment received showed that when the specialists agreed, patients followed
recommendations 55% of the time. When there was disagreement, patients followed urologist,
radiation oncologist, and neither recommendation 38.7%, 22.7%, and 38.7% of the time,
respectively. Whether patients followed urologist or radiation oncologist recommendations was
not predicted by the doctor seen first, how long they spent with each, or patients’ perceptions of
strength of recommendations (pʼs>0.05).
Conclusions: Our results suggest urologists and radiation oncologists rarely agree in
recommendations for the same patient , and even when they do, patients often chose a different
treatment.
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4L-5 WHAT ARE FAMILIES’ DECISIONAL NEEDS WHEN CONSIDERING
NEWBORN FEEDING OPTIONS? USING VALUE PROPOSITION AND DECISION
MAPPING STRATEGIES TO DEVELOP SHARED DECISION-MAKING
INTERVENTIONS
Decision Psychology and Shared Decision Making (DEC)
Sarah Munro, PhD, University of British Columbia; Centre for Health Evaluation and Outcome
Sciences, Vancouver, BC, Canada, Julie Sou, MSc, Centre for Health Evaluation and Outcome
Sciences, Vancouver, BC, Canada and Nick Bansback, PhD, School of Population and Public
Health, University of British Columbia; Centre for Health Evaluation and Outcome Sciences,
Vancouver, BC, Canada
Purpose:
Shared decision-making (SDM) interventions should be developed using a systematic,
transparent process. One core activity is to identify users’ decision-making needs at the outset.
There are few reported methods for engaging patients and health care professionals in that
process. We aimed to identify decision-making needs using two mapping techniques to inform
the scope and design of an SDM intervention for early newborn feeding choices involving breast
and formula feeding.
Method:
We used two design thinking techniques. 1) Value proposition mapping is a strategy for
designing interventions that deliver benefit and value to the user, and improve the quality of their
work (e.g. decision-making). 2) Decision mapping is a method of identifying and illustrating the
different choices a patient faces in their care pathway. A multidisciplinary advisory group
involving 17 stakeholders met five times from December 2018 to May 2019 in British Columbia,
Canada. Stakeholders represented government, health authorities, patients, midwives, physicians,
nurses, dieticians, and researchers. We conducted iterative cycles of moderated discussion,
mapping, and revision. Each version of the map was dated for an audit trail. The maps were
discussed and revised until no new insights arose.
Result:
Decision mapping resulted in a visual timeline of newborn feeding decision points across the
period from early pregnancy until the newborn is 6 months of age. Families’ decisional needs
varied based on delayed versus urgent decisions (considering feeding options versus making a
choice during a feeding crisis). Value proposition mapping identified the context of family and
health care professional decisional needs at each stage of the timeline: the key audience, their
decision-making tasks, potential benefits/harms of the tasks, and strategies to increase benefit
and reduce harm. Mapping results suggested that health care professionals should monitoring
newborn feeding choices over the perinatal period, screen for unresolved needs, and provide
support as social, emotional, and physiological challenges arise.

Abstracts: SMDM 41st Annual Meeting; Portland, Oregon

E345

Conclusion:
Mapping techniques are a potential strategy for identifying decisional needs and engaging
patients and health care professionals as equal partners in the development of SDM
interventions. Health care professionals require skills in identifying families’ decisional needs
and tailoring their SDM support to match those needs during different perinatal timepoints. Next,
our team will adapt an SDM skills training program for health care professionals to support
newborn feeding choices.
4L-6 IMPACT OF THE 2009 U.S. PREVENTIVE SERVICES TASK FORCE
MAMMOGRAPHY SCREENING RECOMMENDATIONS: ARE PHYSICIANS
ENGAGING IN SHARED DECISION MAKING?
Decision Psychology and Shared Decision Making (DEC)
Kathryn Martinez, PhD, MPH1, Abhishek Deshpande, MD, PhD2 and Michael Rothberg, MD,
MPH1, (1)Cleveland Clinic, Cleveland, OH, (2)Center for Value Based Care Research, Medicine
Institute, Cleveland Clinic, Cleveland, OH
Purpose: In 2009 the U.S. Preventive Services Task Force recommended shared decision
making (SDM) for mammography for average risk women aged 40-49 years. Population-based
studies show screening rates remained largely static, suggesting that SDM is not taking place.
Yet nothing is known about how individual physicians altered their screening behavior following
the guideline change.
Method: We performed a retrospective cohort study in a large health system. Physicians were
included if they had ≥20 encounters with eligible women in the period before (2006-2008) and
after (2011-2015) guideline change. Eligible women were mammography-naïve, aged 40 to 49
years with no personal history of breast cancer or breast biopsy, with a primary care appointment
between 2006 and 2015. Mixed effects logistic regression was used to assess the odds of a
woman receiving screening post 2009, accounting for clustering by physician. To assess changes
in individual physician screening behavior, each physicianʼs pre-2009 screening rate decile was
included as a predictor. Patient characteristics included race, marital status, insurance type, and
median household income quartile. Physician characteristics included gender, age, and specialty.
Result: Between 2006 and 2015, 53,695 unique patients were seen by112 study-eligible
physicians. In the pre-2009 period, physicians saw 20,781 patients, 50% of whom received
mammography. In the post 2009 period, these physicians saw 12,649 patients of whom 36%
received mammography. In the mixed effects model of the odds of a patient receiving
mammography post 2009, patient factors associated with mammography were black race versus
white (Adjusted odds ratio (AOR):1.49; 95%CI:1.28-1.73) and highest income quartile versus
lowest (AOR:1.16;95%CI:1.03-1.36). Having a female physician was also associated with higher
odds of screening (AOR:1.31:95%CI: 1.08-1.60). The strongest predictor of mammography
receipt was their physicianʼs pre-2009 screening rate (AOR:4.21 per decile;95%CI:2.19-8.07).
The post-2009 screening rate was 45% for physicians in the health system before 2009 compared
to 33% among those newly practicing after 2009.
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Conclusion: For patients, the strongest predictor of mammography receipt after 2009 was
having a physician with a higher pre-2009 screening rate. Physicians in our study are therefore
not routinely participating in SDM. While these physicians’ screening behaviors declined
modestly after 2009, the overall reduction in screening was mostly the result of new physicians
with lower rates who entered the health system after 2009.
5M-1 GIST INFERENCE SCORES PREDICT COMPREHENSION, RECALL, AND
KNOWLEDGE OF CANCER TEXTS.
Decision Psychology and Shared Decision Making (DEC)
Christopher R. Wolfe, Ph.D.1, Mitchell Dandignac, MA1, Vasanthi Kalidindi, BA1, Chase
Tirey, BA1 and Valerie F. Reyna, PhD2, (1)Miami University, Oxford, OH, (2)Cornell
University, Ithaca, NY
Purpose: Gist Inference Scores (GIS) are used to analyze observable characteristics of texts that
promote inferences about a textʼs bottom-line meaning that are most useful in decision-making.
Following Fuzzy-Trace Theory, two behavioral studies tested whether GIS for texts about cancer
predict comprehension, knowledge, and recall of decision-critical propositions.
Methods: We used the discourse technology Coh-Matrix to determine GIS (high and low) of
texts about cancer and different treatment options. Then we studied the behavioral outcomes of
randomly assigning participants to read High-GIS or Low-GIS cancer texts. In Study 1, two pairs
of texts about breast cancer covering the same content were created, and one of each pair was
edited to be one standard deviation higher than the other on GIS (while remaining less than onehalf standard deviation different on all other variables). Participants were randomly assigned to
read one of the four texts then given tests of foundational knowledge and gist comprehension,
which were validated in previously-published research. In Study 2, participants were randomly
assigned to read a text about Soft Tissue Sarcoma from the National Cancer Institute that was
either high-GIS (for physicians) or a low-GIS (for patients) and then ask to write what they
remembered (free recall).
Results: In Study 1, for one pair of texts, the High GIS mean percent correct on the knowledge
test was 80% and the Low GIS mean percent correct was 73%, F(1,80)=6.36, p=0.014. On the
other pair of texts, we found that reading High GIS texts produced comprehension scores that
were significantly higher than reading Low GIS texts, F(1,87)=4.44, p=0.038. In Study 2, for the
High GIS text, 41% of the propositions that were recalled were identified a priori as central to
decision-making, compared to 29% for those participants randomly assigned to the Low GIS
text, F(1,172)=9.82, p<0.002.
Conclusions: Gist Inference Scores applied to texts – both those created for research to tightly
control for content, as well as “authentic” texts from the National Cancer Institute web site –
predicted comprehension, recall, and knowledge about cancer and treatment options. These
results, which were predicted by Fuzzy-Trace Theory, provide evidence of the efficacy of GIS in
identifying characteristics of didactic texts about cancer that are most likely to be useful for
decision-making by helping readers develop appropriate gist inferences.
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5M-2 THE EFFECT OF DATA VISUALIZATION ON JUDGMENTS OF
HYPERTENSION CONTROL: COMPARING PATIENTS AND PHYSICIANS
Decision Psychology and Shared Decision Making (DEC)
Victoria Shaffer, PhD1, Pete Wegier, PhD2, KD Valentine, PhD3, Sean Duan, BS1, Jeffery L.
Belden, MD1, Shannon M. Canfield, MPH1, Sonal J. Patil, MD1, Mihail Popescu, PhD1, Linsey
M. Steege, PhD4, Akskay Jain, MS1 and Richelle J. Koopman, MD MS1, (1)University of
Missouri, Columbia, MO, (2)Sinai Health System, Toronto, ON, Canada, (3)Division of General
Internal Medicine, Massachusetts General Hospital, Boston, MA, (4)University of Wisconsin,
Madison, WI
Purpose: Uncontrolled hypertension is a significant health problem in the US, though multiple
drugs exist to effectively treat the disease. Shared data visualizations may help overcome clinical
inertia by improving judgments about hypertension control. As part of a larger project
developing data visualizations for the electronic medical record to support shared decision
making for hypertension management, we compared patient and physician judgments of
hypertension control using different types of data visualization.
Method: Participants (N=1,079 patients with hypertension and N=54 physicians) viewed graphs
depicting blood pressure (BP) data for fictitious patients. For each graph, participants rated
hypertension control and perceived need for medication change. Using a within subjects design,
patients evaluated 12 graphs that varied in systolic BP mean (130, 145 mmHg) and standard
deviation (15, 25 mmHg) with three different forms of data visualization that displayed 30 BP
values over a three-month period: 1) Data Table; 2) Line Graph of raw data; 3) Graph with
Smoothing Line (generated by a non-robust LOESS function). Physicians evaluated the same
graphs but with only two different forms of data visualization: 1) Line Graph of raw data or 2)
Graph with Smoothing Line (8 graphs total). Patient numeracy, health literacy, and graph literacy
were also measured.
Results: We observed main effects of BP mean, BP standard deviation, and data visualization
type on all outcome measures in both the patient and physician samples; P < .05. Both samples
deemed hypertension to be less controlled for visualizations with higher mean values and larger
standard deviations. Visualization type also significantly impacted perceptions of hypertension
control in both samples. The raw data displays were perceived to be less well controlled by
physicians and patients than displays that utilized a smoothing function. However, there were
significant interactions between visualization type and patient numeracy, health literacy, and
graph literacy; see Figure 1. Generally, there was a much greater effect of visualization type for
patients with greater numeracy and literacy.
Conclusions: Visualizations employing the use of a LOESS smoothing function led to
judgments by patients and physicians that were better calibrated with clinical guidelines. The
effect was largest for patients with greater numeracy and literacy, suggesting that visualization
type matters most for patients who have the ability to extract complex information from data.
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5M-3 BEING OBJECTIVELY NUMERATE IS NOT ENOUGH: GOOD MEDICAL
OUTCOMES DEPEND ON NUMERIC CONFIDENCE IN LUPUS PATIENTS
Decision Psychology and Shared Decision Making (DEC)
Ellen Peters, PhD1, Mary Kate Tompkins, PhD1, Stacy Ardoin, MD MS2, Brittany ShootsReinhard, PhD1 and Alexa Meara, MD MS2, (1)Ohio State University, Columbus, OH, (2)The
Ohio State University Wexner Medical Center, Department of Internal Medicine, Division of
Rheumatology, Columbus, OH
Purpose: Effective management of chronic health conditions such as systemic lupus
erythematosus (SLE) requires patients to understand and use numeric information relevant to
their disease and treatments and to engage continuously in numeracy-related healthy behaviors.
We proposed and tested a novel interaction between objective numeracy and numeric selfefficacy (confidence) and questioned the “more is better” mantra of prior numeracy and selfefficacy research.
Methods: SLE patients ≥ 18 years provided consent including permission to access their medical
records. They completed measures including objective numeracy, numeric confidence, health
literacy, patient activation, and demographics. Lupus disease activity was assessed at clinic visits
with the Systemic Lupus Erythematous Disease Activity Index 2000 (SLEDAI). This wellvalidated composite disease activity score uses weighted physician-observed clinical variables
and laboratory data of nine organ systems. Data were analyzed from patients (N=91) who
completed all measures and had an up-to-date SLEDAI score.
Results: Among patients with more numeric confidence, having greater objective numeracy was
associated with lower SLEDAI scores (less disease activity, b(SE)=−0.66(0.29), p=.023).
However, objective-numeracy effects were nonsignificant among those with less numeric
confidence (b(SE) =0.14(0.27), p = .61). Based on this model, a patient higher in numeric
confidence (+1SD) was predicted to have a 44% chance of high disease activity indicative of
needing more treatment (SLEDAI score>=6) if she scored a 0 on objective numeracy and only
7% if she had the highest score.
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Conclusions: Results supported our hypothesis that objective numeracy interacts with numeric
confidence to predict a clinical outcome (SLE disease activity). Although medical and
psychological studies demonstrate that greater self-efficacy leads to better performance and
outcomes, these confidence benefits accrued only among those with greater objective skills.
Those with high objective numeracy and high numeric confidence had the best outcomes.
Patients who lacked objective numeracy skills but had high numeric confidence had the highest
disease activity scores, presumably because they persisted in doing numeric tasks critical to their
health but made mistakes that went unnoticed. Thus, having high numeric self-efficacy is
insufficient and may be harmful when ability is low. Similarly, having high objective numeracy
does not guarantee good outcomes. The benefits of objective numeracy did not accrue among
those who were not numerically confident.
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5M-4 A FUZZY-TRACE THEORY OF FLU VACCINATION: GIST, RISK, AND
CONSPIRACY
Decision Psychology and Shared Decision Making (DEC)
Valerie F. Reyna, PhD1, Michelle Galindez, BS1, Christian Ong1, Priscila Brust-Renck, PhD2,
Annabel Grossman1, David Garavito, MA1 and Nnamdi Igwe1, (1)Cornell University, Ithaca,
NY, (2)Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Purpose: The purpose was to assess relationships among constructs introduced in fuzzy-trace
theory to explain flu vaccination and conspiracy theories.
Methods: We recruited 770 adults of whom 386 responded to a 51-item knowledge scale (0-4
agreement ratings). Measures also included: 11-item quantitative risk of illness/death from
vaccination (0-100%; QRVax), 7-item quantitative risk of illness/death from not vaccinating (0100%; QRNotVax), 8-item gist of the risk of illness/death from vaccination (low = 0, medium =
1, high = 2; GistVax), 7-item gist of the risk of illness/death from not vaccinating (low = 0,
medium = 1, high = 2; GistNotVax), gist principles (simple pro-vaccination social/moral values;
0-4 rating), 5-item perceived behavioral control (0-4 rating; PBC), 8-item metabeliefs in
conspiracies (0-4). Outcomes included self-reported vaccination in the past year (yes/no) and 6item intentions-to-vaccinate scale (0-4 rating). Reliabilities were good to excellent.
Results: Proportion vaccinated in the past year was 54.6% (nationally representative sample was
44.9% for 2018-2019) and mean intentions fell near the midpoint (2.48). Knowledge scores were
65.2% of ideal ratings (agreement with true items as true and false as false). Perceived risk of
vaccinating was generally low (QRVax = 16.3%; GistVax = .39) and of not vaccinating
approached “medium” (QRNotVax = 29.3%; GistNotVax = .67). Agreement with conspiracy
theories (1.33) was low. Measures exhibited wide variability, however, and correlated in
predicted ways: Endorsing vaccine conspiracy theories was negatively correlated with
knowledge (-.645), perceived control (-.511), and gist principles (-.453) and positively correlated
with perceived quantitative risk (.351) and gist risk (.432) of vaccinating; endorsement did not
correlate significantly with the perceived risk of not vaccinating. However, risk of not
vaccinating did correlate with past vaccination (.204 GistNotVax; .250 QRNotVax) and
intentions to vaccinate (.260 GistNotVax; .256 QRNotVax). Conspiracy theories were associated
with lower vaccination rates (-.185) and intentions (-.397). Gist principles predicted vaccination
(.432) and intentions (.748), and remained significant in logistic and linear regressions
respectively, controlling for knowledge and other gist measures.
Conclusions: Conspiracy theorists perceived greater risk from vaccination (and lower control)
and were less likely to report vaccinating (or intentions to vaccinate), whereas vaccinators
perceived greater risk from not vaccinating. The greatest predictor of past vaccination and
intentions was affirmation of simple social and moral values, such as not hurting other people.
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5M-5 BACKFIRE EFFECTS FROM COMMUNICATING INFORMATION ABOUT
INFECTIOUS DISEASE POLICY EFFICACY AND HARMS: AN EXPERIMENTAL
STUDY
Health Services, Outcomes and Policy Research (HSOP)
Aaron M. Scherer, PhD1, Megan Knaus, MPH2, Victoria Shaffer, PhD3, Angela Fagerlin, PhD4,
Laura D. Scherer, PhD5 and Brian J. Zikmund-Fisher, PhD2, (1)University of Iowa, Iowa City,
IA, (2)University of Michigan, Ann Arbor, MI, (3)University of Missouri, Columbia, MO,
(4)University of Utah / Salt Lake City VA, Salt Lake City, UT, (5)University of ColoradoDenver, Denver, CO
Purpose: Successful governmental responses to infectious disease outbreaks require public
support for implementation of evidence-based prevention and control policies. Yet little is
known about the factors that influence such support. Previous studies from our group have
demonstrated that a majority of the public support implementing ineffective policies (e.g., travel
ban into the U.S.) in response to a hypothetical pandemic influenza outbreak. Here, we test
whether receiving information indicating that a policy may be ineffective and/or harmful reduces
support for the policy.
Methods: Participants (N=3,238) from a national online panel read a vignette in which a Centers
for Disease Control and Prevention (CDC) spokesperson discussed proposed legislation for a
travel ban to prevent a pandemic influenza outbreak from reaching the U.S. Participants were
randomized to 1 of 4 conditions where the CDC spokesperson 1) did not discuss policy efficacy
or harmfulness information or alternately highlighted that scientific studies have found that travel
bans to prevent the spread of influenza are 2) ineffective, 3) harmful, or 4) both. Outcome
measures were:
1)Support for implementing 5 proposed policies: travel ban, monitoring, and 3 types of
quarantines (“Strongly oppose-1” to “Strongly support-7”)
2)Confidence in the CDC to prevent an infectious disease outbreak in the U.S. (“Not at all
confident-1” to “Very confident-7”)
3)General trust in the CDC (“Not at all-1” to “Completely-7”)
Results: As anticipated, support for the travel ban policy was significantly reduced when
information was provided indicating that travel ban policies are ineffective and/or harmful
compared to the “No Information” condition, F(3,3214)=19.49, p<.001, η2=.02 (Figure 1).
However, there were unexpected backfire effects when considering aggregate measures of
support for the non-travel ban policies (monitoring and 3 quarantine policies; Cronbachʼs
α=0.86) and the CDC (combined confidence and trust; Cronbachʼs α=0.78). Specifically, when
efficacy and/or harm information was included, support was significantly lower for both the nontravel ban policies, F(3,3214)=17.26, p<.001, η2=.02, and CDC, F(3,3214)=16.89, p<.001,
η2=.02 (Figure 1).
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Conclusions: Communicating information that a proposed policy may be ineffective or harmful
could successfully decrease support for that policy, but it may also have unintended
consequences on support for other policies and the government. Additional research is needed to
determine how to effectively decrease public support for ineffective policies without also
inducing backfire effects.
5N-1 COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMBINATION
THERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NONSQUAMOUS
NON-SMALL CELL LUNG CANCER IN THE UNITED STATES
Applied Health Economics (AHE)
Steven Criss, BS1, Meghan Mooradian, MD2, Tina Watson, BA1, Justin Gainor, MD2, Kerry
Reynolds, MD2 and Chung Yin Kong, PhD1, (1)Massachusetts General Hospital - Institute for
Technology Assessment, Boston, MA, (2)Massachusetts General Hospital Cancer Center,
Boston, MA
Purpose:
Immune checkpoint inhibitor combination therapy has recently become the standard of care for
first-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC). The
implications of these first-line treatments are considerable, given the potential population of
patients eligible to receive them and their high cost. The most recently approved combination—
atezolizumab plus bevacizumab, carboplatin, and paclitaxel (BCP)—has yet to be investigated
using cost-effectiveness analysis.
Method:
We developed a primary microsimulation model to assess atezolizumab combination versus BCP
in the first line from the healthcare sector perspective. A secondary model was developed to
assess these treatments along with pembrolizumab combination and platinum doublet
chemotherapy. Treatment strategies were based on those from the IMpower150 and KEYNOTE189 clinical trials. Incremental cost-effectiveness ratios (ICER) were compared to a willingnessto-pay threshold of $100,000/quality-adjusted life-year (QALY).
Both progression-free survival and overall survival projections were modeled using KaplanMeier estimates from the clinical trials, followed by exponential functions fitted to the KaplanMeier survival curves. Overall survival projections were also subsequently modeled using
Surveillance, Epidemiology, and End Results program mortality risk estimates after year five.
Costs related to cancer treatment in our analysis included drug acquisition, therapy
administration, treatment of major adverse events, follow-up scans, monthly supportive care, and
death costs.
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Result:
Treating with BCP in the first line resulted in a mean cost of $108,713 and mean QALYs of
1.59. Atezolizumab plus BCP resulted in a mean cost of $230,539 and mean QALYs of 2.20, for
an estimated ICER of $200,170/QALY.
In the secondary model, pembrolizumab combination therapy resulted in a mean cost of
$222,347 and mean QALYs of 2.55. Pembrolizumab combination dominated atezolizumab plus
BCP, leading to an ICER of $118,328/QALY between pembrolizumab combination and BCP.
Conclusion:
Our primary model estimated that atezolizumab combination would not be a cost-effective
option at a willingness-to-pay threshold of $100,000/QALY. Pembrolizumab combination
represented a better tradeoff than atezolizumab combination between incremental cost and
quality-adjusted survival in our secondary model analysis, though it was also not cost-effective at
the willingness-to-pay threshold. Price reductions remain the most pragmatic solution for the
poor cost-effectiveness of these immune checkpoint inhibitors in the treatment of metastatic
nonsquamous NSCLC.
5N-2 COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION IN US
UNDERSERVED AND GENERAL POPULATION SENIORS: EFFECTS OF
ALTERNATIVE POLICIES AND UPTAKE IMPROVEMENT PROGRAMS
Applied Health Economics (AHE)
Kenneth J. Smith, MD, MS1, Angela Wateska, MPH2, Mary Patricia Nowalk, PhD, RD3,
Chyongchiou Jeng Lin, PhD3 and Richard K. Zimmerman, MD, MPH, MS2, (1)University of
Pittsburgh, Section of Decision Sciences, Pittsburgh, PA, (2)University of Pittsburgh School of
Medicine, Pittsburgh, PA, (3)University of Pittsburgh, School of Medicine, Dept of Family
Medicine, Pittsburgh, PA
Purpose:
Vaccination recommendations for US adults ≥65-years-old include both pneumococcal
polysaccharide vaccine (PPSV) and pneumococcal conjugate vaccine (PCV), but are being reevaluated; adult PCV may be unnecessary due to herd immunity from routine childhood PCV
use. We compared the cost-effectiveness of current recommendations, alternative policies, and
vaccine uptake intervention programs in general and underserved minority populations, due to
greater risk and less vaccine uptake in the underserved.
Method:
A Markov model estimated the cost-effectiveness of pneumococcal vaccination strategies,
including no vaccination, current US adult recommendations, and an alternative strategy (PPSV
for all and PCV added for the immunocompromised), in ≥65-year-olds, without and with
intervention programs (absolute uptake increase 12.3%, costing $1.78/eligible patient) to
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increase vaccination uptake. Strategies were separately examined in US general and black
population cohorts; black race was a proxy for underserved minorities. Populations were
segmented based on health status from US databases; CDC data populated age-, race-, and health
status-specific pneumococcal illness rates. Vaccine effectiveness came from trial data and Delphi
panel estimates. Scenarios examined differing PPSV effectiveness assumptions. Analyses took a
healthcare perspective over a lifetime horizon, discounting 3%/year.
Result:
The alternative strategy, with or without an intervention program, had the lowest ICERs in both
populations, though never <$100,000/QALY gained (Table); current recommendations
(with/without a program) were economically unfavorable in all analyses. Increasing the most
uncertain influential parameter, hospitalized nonbacteremic pneumonia risk, made current
recommendations less unfavorable, but never <$197,000/QALY in any scenario; other 1-way
sensitivity analyses were similarly robust. Probabilistic sensitivity analyses confirmed results,
with current recommendations rarely favored at acceptability thresholds <$500,000/QALY
gained.
Conclusion:
Current pneumococcal vaccination recommendations for US seniors are economically
unfavorable compared to an alternative strategy. The alternative policy with an uptake program
may be economically reasonable in black populations, and worth considering as a populationwide recommendation if mitigating racial disparities is a priority.

No vaccination
Alternative strategy*
Alternative strategy w/program
Current recommendations w/program

ICER
(/QALY)
$120,685
$156,311
$813,864

General Population
No vaccination
Alternative strategy
Alternative strategy w/program
Current recommendations w/program

$226,733
$287,328
$765,018

Black Population

*Alternative strategy = PPSV for all, adding PCV for
immunocompromised
Current recommendations with no program dominated in both
populations
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5N-3 IMPACT OF TREATING ORAL DISEASE ON PREVENTING VASCULAR
DISEASES: A MODEL-BASED COST-EFFECTIVENESS ANALYSIS OF
PERIODONTAL TREATMENT AMONG DIABETICS
Health Services, Outcomes and Policy Research (HSOP)
Sung Eun Choi, PhD, Department of Oral Health Policy and Epidemiology, Harvard School of
Dental Medicine, Boston, MA, Corneliu Sima, DMD, Department of Oral Medicine, Infection
and Immunity, Harvard School of Dental Medicine, Boston, MA and Ankur Pandya, PhD,
Center for Health Decision Science, Department of Health Policy and Management, Harvard
T.H. Chan School of Public Health, Boston, MA
Purpose:
Recent studies have shown that treating chronic periodontitis, a serious gum disease, can
improve glycemic control (reduced hemoglobin A1c) in diabetic patients, thus lowering the risk
of type II diabetes (T2D)-related microvascular diseases, and reducing the risk of cardiovascular
disease events. In light of these developments, some payers have started covering nonsurgical
periodontal treatment for those with chronic conditions, such as diabetes. We sought to identify
the cost-effectiveness of expanding periodontal treatment coverage among diabetic patients in
the US.
Methods:
Using data from a randomized trial of periodontal treatment (cost=$368 in first year, $290/year
in subsequent years) among diabetic patients, and health risk factors data from the nationallyrepresentative National Health and Nutrition Examination Survey (2009-2016), we constructed a
microsimulation model of periodontal disease and seven associated health outcomes: T2D, T2Drelated microvascular disease (retinopathy, neuropathy, nephropathy), cardiovascular diseases
(myocardial infarction, stroke), and tooth loss. We identified under which circumstances
expanding periodontal treatment (from the observed treatment rate of 27% to 88% [the
proportion of T2D patients seeing a physician]) would be cost effective (lifetime quality-adjusted
life years [QALYs] using a 3% annual discount rate) in the general diabetic population and
among sub-groups. We performed probabilistic and deterministic sensitivity analyses to estimate
95% confidence intervals and identify key drivers of model-based results.
Results:
Compared to status quo, expanding periodontal treatment coverage among diabetic patients to
88% would be expected to avert tooth loss by 33.0% (95%CI: -38.7,-25.3), and microvascular
diseases by 20.8% (-31.8,-9.3), 18.7% (-33.8,-3.8), and 19.2% (-35.6,-4.8) for nephropathy,
neuropathy, and retinopathy, respectively (Figure). Providing periodontal treatment to diabetic
patients would be cost saving from a societal perspective at a total savings of $706 (-809,-602)
with an estimated gain of 0.43 (0.35,0.51) QALYs per capita among the target population. Longterm reductions in tooth loss and microvascular disease risk drove the differences in lifetime
costs (relative to cardiovascular disease reductions). The largest relative benefits were observed
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among non-Hispanic Blacks and Mexican Americans given their high baseline risk of T2D and
periodontitis.
Conclusion:
Providing periodontal treatment to diabetic patients with periodontitis would be expected to
significantly reduce tooth loss and T2D-related microvascular diseases via improved glycemic
control. Encouraging diabetic patients with poor oral health conditions to receive periodontal
treatment would improve health outcomes and still be cost-saving.
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5N-4 COST-EFFECTIVENESS OF THE PALLIATIVE CARE IN HEART FAILURE
TRIAL
Health Services, Outcomes and Policy Research (HSOP)
Brystana G. Kaufman, PhD, MSPH1, Bradi Granger, PhD, MSN1, Jie-Lena Sun, MS2, Gillian
D. Sanders, PhD1, Donald Taylor, PhD1, Joseph Rogers, MD3, James Tulsky, MD4, Daniel Mark,
MD2 and Robert Mentz, MD2, (1)Margolis Center for Health Policy, Duke University, Durham,
NC, (2)Duke Clinical Research Institute, Durham, NC, (3)Duke University School of Medicine,
Durham, NC, (4)Harvard Medical School, Boston, MA
Purpose: In a randomized control trial, Palliative Care in Heart Failure (PAL-HF) increased
heart failure (HF) related quality of life, and a meta-analysis found that palliative care (PC)
reduced hospitalizations in HF patients. Cost-effectiveness of PC interventions in HF is
unknown; using the PAL-HF dataset, we evaluated whether PC in this setting met a standard
threshold for cost-effectiveness.
Methods: We developed a Markov model which simulated monthly outcomes expected with and
without the PAL-HF intervention for a cohort of 1000 patients over 36 months based on
observations from PAL-HF and supplemented with meta-analyses and Medicare administrative
data. Outcomes included hospitalization, place of death, Medicare expenditures, quality adjusted
life years (QALYs), and incremental cost-effectiveness ratios (ICER). Treatment effects included
previously published EQ-5D utility gains for other HF palliative care trials, and in a sensitivity
analysis, risk ratios associated with non-CV hospitalization. Due to the uncertainty in
effectiveness estimates, a threshold analyses was used to evaluate cost-effectiveness at $50,000
willingness-to-pay per QALY over the range of estimates. A Monte Carlo probabilistic
sensitivity analysis with 1000 simulations was used to generate a cost-effectiveness acceptability
curve.
Results: Overall mortality rates were the same between the studyʼs PC and control arms with
897 of 1000 patients having died at 36 months and 16.8% of patients (n=168) having died in the
hospital. In base case analysis, at an estimated $100 program cost per month, the PC scenario
resulted in an incremental gain of 0.07 QALYs and an incremental cost of $1,325 per patient for
an ICER of $20,000/QALY. Using the threshold of $50,000/QALY and base case effectiveness
assumptions, an intervention cost of up to $250 per month is considered cost-effective. Of 1000
simulations, the PC intervention had a 94% probability of being cost-effective at $50,000 WTP
threshold (Figure 1). In a sensitivity analysis assuming PAL-HF reduced non-CV
hospitalizations by 42%, a cost of up to $500 per month is considered cost-effective and 260
admissions were prevented.
Conclusions: PC interventions in HF have a high probability of cost-effectiveness and the
potential for cost-savings by reducing hospitalizations. Improving estimates for effects on
utilization is unlikely to improve decision-making. The threshold for cost-effectiveness is
sensitive to the utility gain, and research is needed to improve identification of patients likely to
benefit from palliative services.
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5N-5 USUAL CARE IS COMPARATIVELY MORE EFFECTIVE AND MORE COSTEFFECTIVE THAN ZULRESSO (BREXANOLONE), A NEW $34K INFUSION FOR
POSTPARTUM DEPRESSION
Health Services, Outcomes and Policy Research (HSOP)
Helen Newton, MPH1, Catherine Saunders, MPH1 and Anna Tosteson, ScD2, (1)The Dartmouth
Institute for Health Policy & Clinical Practice, Lebanon, NH, (2)The Dartmouth Institute for
Health Policy and Clinical Practice; Geisel School of Medicine at Dartmouth, Lebanon, NH
Purpose: One in nine women in the U.S. experience postpartum depression. Prevalence is more
pronounced among Medicaid-insured women. Postpartum depression is disabling and costs an
estimated $5.7 billion from lost work and productivity alone. The Food and Drug Administration
(FDA) approved Zulresso (Brexanolone) as an inpatient infusion treatment for women with
severe postpartum depression in March 2019. We aimed to determine if Zulresso is a costeffective treatment for Medicaid patients with severe postpartum depression, which has not been
addressed to date.
Methods: We evaluated the cost-effectiveness of Zulresso compared to usual care - oral
antidepressants - using a Markov decision model over a 2-year time horizon. Effectiveness data
came from systematic reviews, when possible, or randomized trials. We estimated the cost of
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hospitalization, antidepressant prescriptions, and productivity loss in U.S. 2019 dollars for
postpartum women insured by Medicaid using the Medical Expenditure Panel Survey 2013-2016
and used projections from Sage Therapeutics to estimate the cost of Zulresso treatment. We used
published health utilities for managed and unmanaged depression and estimated disutility for
hospitalization without infant with input from patient and clinical stakeholders. We performed
sensitivity analyses on all probabilities and utilities included in our model.
Results: Without disutility for hospitalization included, Zulresso yielded 1.67 quality-adjusted
life years (QALYs) compared to 1.62 QALYs for usual care. After including disutility for
hospitalization, the usual care arm yielded 1.74 quality QALYs, compared to 0.38 QALYs for
the Zulresso arm. Usual care had an expected cost of $6,790 over 2 years, whereas Zulressoʼs
cost was $35,850 over 2 years, which when not considering the disutility for hospitalization
generated an ICER of $581,214 per QALY. Limitations of our analysis include assumptions
about the generalizability of data concerning general major depressive disorder for the
postpartum major depression population and the applicability of our disutilities for
hospitalization to individual women. Additional sensitivity analyses examining use of Zulresso
while rooming infants with mothers, which may also impact the utility of hospitalization, will be
available before October.
Conclusions: Zulresso is neither cost-effective nor comparatively effective compared to usual
care after adding the disutility for hospitalization without an infant. If mothers roomed with their
infants while receiving treatment, this calculus might change.
5N-6 COST-EFFECTIVENESS OF POST-TREATMENT FOLLOW-UP AND
SECONDARY PREVENTION OF TUBERCULOSIS IN A HIGH-INCIDENCE
SETTING – A MODEL-BASED ANALYSIS
Health Services, Outcomes and Policy Research (HSOP)
Florian Marx, MD, MSc1, Ted Cohen, DPH, MD, MPH2, Nicolas Menzies, PhD3, Joshua
Salomon, Ph.D.4 and Reza Yaesoubi, PhD2, (1)DST-NRF South African Centre of Excellence
in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch, South Africa, (2)Yale
School of Public Health, New Haven, CT, (3)Center for Health Decision Science - Harvard T.H.
Chan School of Public Health, Boston, MA, (4)Center for Health Policy and Center for Primary
Care and Outcomes Research, Stanford, CA
Purpose: In tuberculosis (TB) high-incidence settings, previously treated people remain at high
risk of recurrent TB and contribute substantially to overall disease burden. Recent modeling
studies suggest that active case finding and secondary isoniazid preventive therapy (IPT) targeted
to previously treated individuals could accelerate declines in TB incidence and mortality.
Whether these targeted, resource-intensive interventions are cost-effective has not been
established.
Methods: We developed a transmission dynamic model of the TB/HIV co-epidemic among
individuals with and without a history of TB treatment in a high-incidence community in
suburban Cape Town, South Africa. The model was calibrated to local demography, TB and HIV
prevalence, TB case notifications and TB control program data. We used this model to project
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the disability-adjusted life-years (DALYs) averted and costs associated with annual follow-up
examinations and secondary IPT among individuals completing TB treatment. Costs were
estimated in 2018 US dollars from a South Africa health system perspective and included
expenses for diagnosis and treatment of TB. Total costs and health outcomes were calculated
over a 10-year horizon using a 3% discount rate. For primary analysis, we assumed that 75% of
individuals completing TB treatment would agree to participate in the interventions, and that on
average 15% of those currently enrolled drop out per year.
Results: We estimated that a combination of follow-up examinations and secondary IPT during
the first-year post treatment would avert 2,233 DALYs (95% uncertainty interval: [−1,387,
7,672]) over a 10-year period and would be cost saving compared to current control efforts.
Sustained annual follow-up of previously treated individuals and continuous secondary IPT
would avert an additional 1,402 [-1,597, 5,330] DALYs over 10 years at an expected cost of
USD 151.3 per DALY averted. Strategies of follow-up without secondary IPT were dominated
(Table). Sensitivity analyses suggested that lower uptake of interventions and higher drop-out
post treatment reduced the overall health benefit but did not change the comparative costeffectiveness of these targeted interventions.
Conclusions: In this high-incidence setting, post-treatment follow-up and secondary preventive
therapy can accelerate declines in TB incidence and potentially save resources for TB control.
Feasibility of implementing these strategies should be considered given their potential to
accelerate declines in TB incidence in settings most severely affected by the disease.
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5O-1 INCREASING UTILIZATION OF DECEASED DONOR KIDNEYS: MODELING
COSTS AND OUTCOMES USING KIDNEYS FROM HCV-INFECTED DONORS FOR
TRANSPLANTATION INTO HCV-UNINFECTED RECIPIENTS
Applied Health Economics (AHE)
Mark Eckman, MD, MS, E. Steve Woodle, MD, Charuhas Thakar, MD, Rita Alloway, PharmD
and Kenneth Sherman, MD, PhD, University of Cincinnati, Cincinnati, OH
Purpose: Fewer than 4% of patients with end stage renal disease (ESRD) receive kidney
transplants. Kidneys from deceased donors with chronic hepatitis C virus (HCV) infection are
routinely discarded. Highly effective antiviral agents are now available to treat chronic hepatitis
C infection. Our objective was to examine the cost-effectiveness of transplanting HCV-infected
kidneys into HCV-uninfected recipients.
Method: We constructed a 31 state Markov transition decision model to examine strategies of 1)
transplantation with an HCV-uninfected kidney; versus 2) transplantation with an HCV-infected
kidney followed by HCV treatment. Data sources included MEDLINE searches, bibliographies
from relevant English language articles, and United States Renal Data System. Target population
was ESRD patients receiving hemodialysis who are on kidney transplant waiting lists. We used a
lifetime time horizon and took a health care system perspective. Outcome measures included
effectiveness measured in quality-adjusted life years (QALYs), and costs measured in 2018 U.S.
dollars.
Result: In our base case analysis, transplantation with an HCV-infected kidney was more
effective and less costly than transplantation with an HCV-uninfected kidney because of the
longer waiting times for HCV-uninfected kidneys, the substantial excess mortality risk while
receiving dialysis, and the high efficacy of direct acting antiviral agents for HCV infection.
Transplantation with an HCV-infected kidney was preferred in sensitivity analyses of multiple
model parameters. The strategy remained “cost-effective” unless waiting list time for an HCVinfected kidney exceeded 1.5 years compared with the base case value of 0.63 years. Over
10,000 iterations, transplanting with HCV-infected kidneys was less costly and more effective,
i.e., it dominated transplanting with HCV-uninfected kidneys 71% of the time and was costsaving or had an ICER less than $50,000/QALY 96% of the time.
Conclusion: Transplanting kidneys from HCV-infected donors into HCV-uninfected patients
increased quality-adjusted life expectancy and reduced costs compared with a strategy of
transplanting kidneys from HCV-uninfected donors.
5O-2 USING METAMODELING TO APPROXIMATE COST-EFFECTIVENESS
ACCEPTABILITY CURVES OF COST-EFFECTIVENESS ANALYSIS
Quantitative Methods and Theoretical Developments (QMTD)
Jingyi Xie and Qiushi Chen, PhD, Department of Industrial and Manufacturing Engineering,
Pennsylvania State University, University Park, PA
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Purpose: Cost-effectiveness Acceptability Curves (CEACs) based on probabilistic sensitivity
analysis (PSA) are commonly used to represent the model uncertainty in cost-effectiveness
analysis. Conducting PSA for complex simulation models could be computationally challenging.
Metamodeling is a commonly used approach to simplify the model representation and to reduce
the computation burden, which has been found useful in sensitivity/threshold analysis and value
of information analysis. The objective of this study is to explore whether metamodels can be
used to represent the model uncertainty and approximate CEACs in cost-effectiveness analysis.
Method: We adapted the microsimulation model from a tutorial example in the literature
(Krijkamp et al. 2018). Ten model parameters (utilities, transition probabilities, and costs) were
sampled from recommended statistical distributions. To develop metamodels for the original
microsimulation model, we trained two classes of commonly used metamodels, linear regression
models (with up to second-order polynomials) and neural networks, on independent training sets
of 5000 or fewer PSA samples. Using an independent testing set of 10,000 PSA samples, we
calculated the “true” CEAC as the gold standard, and metamodel-based CEACs based on
predicted model outcomes by metamodels. We compared the metamodel-based CEAC with the
true CEAC, and defined the approximation error as the maximum absolute value of the
differences between the two curves over a willingness-to-pay range $0-$150,000 per qualityadjusted life-years. We repeated the analysis for 20 times to account for sampling randomness.
We further extended the analysis with two comparators to three comparators.
Result: In our base case analysis with two comparators, we found that linear metamodel
generated CEACs with an average approximation error 0.024 (95% CI: 0.021-0.026) compared
with the true CEAC (Figure 1). Introducing nonlinearity in metamodel reduced the
approximation error: The linear model with second-order polynomials resulted in error 0.007
(0.006-0.009), and neural network metamodel resulted in error 0.008 (0.006-0.009). With fewer
training samples, the approximation error increased slightly. Metamodels achieved
approximation error below 0.05 when as few as 500 training samples were used. Metamodels
showed similar performance of approximating CEACs in the cases with three comparators.
Conclusion: We demonstrated that metamodels could closely reproduce the CEAC results of
cost-effectiveness analysis in this case study. Metamodeling is a promising approach to
effectively reduce the computational burden of calculating CEAC from PSA for complex
simulation models.
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5O-3 THE EFFECT OF PHARMACARE PLAN G COVERAGE EXPANSION IN
BRITISH COLUMBIA ON OPIOID AGONIST TREATMENT INITIATION AND
RETENTION.
Applied Health Economics (AHE)
Natt Hongdilokkul, PhD, Emanuel Krebs, M.A., Xiao Zang, MSc, Charlie Zhou, MSc, Fahmida
Homayra, MSc, Jeong Eun Min, MSc and Bohdan Nosyk, PhD, Health Economic Research Unit
at the BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
Purpose: Opioid agonist treatment (OAT) is the evidence-based standard of care for people with
opioid use disorder (PWOUD). OAT medications reduce the risk of mortality by 2.4 times
through reductions in illicit drug use, consequently also reducing the risk of infectious disease
transmission and criminal activity. To combat the opioid crisis in British Columbia (BC), full
coverage for OAT was expanded to low-income PWOUD under BC PharmaCare Plan G on
February 1st, 2017. Given the mixed evidence on whether coverage expansion in the US
increases numbers of prescription for OAT, we aimed to determine the effect of BC PharmaCare
Plan G coverage expansion on OAT initiation and retention.
Method: We defined a cohort of all BC residents with an indication of an OUD using four
linked health administrative databases: BC PharmaNet (drug dispensations, Pharmacare Plan
coverage, and out-of-pocking spending), the Discharge Abstract Database (records of
hospitalizations), Medical Services Plan (physician billing records), and BC Vital Statistics
(deaths and underlying causes). We executed a difference-in-difference-in-differences analysis in
which we compared outcomes of the beneficiaries during the policy change interval (04/01/201611/30/2017) with those of an intratemporal control (non-beneficiaries within the same interval)
and intertemporal control (both groups observed during the historical control interval:
08/01/2014-03/31/2016), adjusting for individual characteristics, OAT regimen type and
prescriber characteristics. We assessed the robustness of our results with a test for the parallel
trends assumption, placebo tests, and an event study.
Result: Among the 48,556 individuals included in our analysis, 25,910 (53.3%) individuals
received OAT during the post-intervention period and 4,721 (9.7%) enrolled in Plan G. We
found Plan G coverage expansion did not have a significant effect on OAT initiation but
significantly increased OAT retention. Specifically, coverage expansion decreased the number of
days off OAT by 3.8% (95% CI: 1.6%, 6.1%) and decreased the number of OAT episode
discontinuations by 8.9% (5.8%, 17.2%). These effects were stronger among individuals who
experienced more than one OAT episode, received Buprenorphine/Naloxone, and were
diagnosed with mental health disorders. Results were upheld over all robustness checks.
Conclusion: Reducing out-of-pocket spending improves OAT retention. The limited effect on
initiation may be attributable to a lack of client focus in the policyʼs implementation, or it may
indicate the reduced expenditures are an insufficient incentive to commence treatment.
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5O-5 A POPULATION SIMULATION MODEL FOR OPIOID POLICYMAKING IN
MASSACHUSETTS
Health Services, Outcomes and Policy Research (HSOP)
Shayla Nolen, MPH1, Laura F. White, PhD2, Jianing Wang, MS1, Golnaz Eftekhari Yazdi,
MSc1, R.W.M.a Madushani, PhD1, Caroline Savitzky, MSW1, Sean Murphy, PhD3, Jake R.
Morgan, PhD, MS2, Rachel L. Epstein, MD, MA4, Bruce R. Schackman, PhD3, Joshua A.
Barocas, MD5, Alexander Y. Walley, MD, MSc6 and Benjamin P. Linas, MD, MPH1, (1)Section
of Infectious Disease, Department of Medicine, Boston Medical Center, Boston, MA, (2)Boston
University, Boston, MA, (3)Department of Healthcare Policy & Research, Weill Cornell Medical
College, New York, NY, (4)Department of Internal Medicine, Section of Infectious Diseases,
Boston Medical Center, Boston, MA, (5)Boston University School of Medicine, Boston, MA,
(6)Department of Medicine, Section of General Internal Medicine, Boston Medical Center,
Boston, MA
Purpose: US opioid overdose crisis-related policies are frequently made at the state level. To
inform policy priorities, we developed a simulation of opioid use disorder (OUD) in
Massachusetts (MA). We compare simulation outcomes to historic MA data and demonstrate
potential model applications by simulating two hypothetical interventions.
Methods: The Researching Effective Strategies to Prevent Opioid Death (RESPOND) model is a
compartmental simulation of the MA OUD population. The simulation is stratified by current
opioid use (active vs. non-active) and route of administration (injection vs. non-injection), with
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bilateral movement between states. RESPOND has treatment seeking rates for inpatient opioid
detoxification and outpatient medication for OUD (MOUDs: buprenorphine-naloxone, extendedrelease naltrexone, or methadone). The primary data source is the Massachusetts Public Health
Data Warehouse (PHD), a longitudinal dataset that links person-level administrative records. We
utilized capture-recapture analysis to estimate the MA OUD population (Barocas et al. AJPH
2018). Urine toxicology data from National Drug Abuse Treatment Clinical Trials Network
studies inform opioid relapse and remission rates. We developed feasible ranges around
uncertain model parameters including: arrival rates of new OUD in the simulation, transitions in
substance use behaviors, and overdose rates. We then varied parameter values through their
feasible ranges to fit the simulation to counts of the alive population with OUD and fatal
overdoses 2013-2015. We simulated 1) doubling the rate of treatment seeking for MOUD
treatment, and 2) increasing retention on MOUDs by 25%. We estimated the population-level
impact of each intervention on overdose rates over a three-year time-horizon.
Results: The calibrated model accurately matched the MA OUD population in 2013-2015 with a
percent error of -2.7% in 2015 (model simulation: 264,496; capture-recapture estimate: 271,903).
In each calendar year of the simulation, the projected fatal overdose rate was within the 95%
confidence interval of the observed data. Doubling the rate of MOUD treatment
initiation decreased the three-year fatal overdose rate by 6.7% in comparison to the base case
simulation (4.9 per 1,000 PY and 5.3 per 1,000 PY, respectively). Increasing retention on
MOUDs decreased the fatal overdose rate by 5.7% (IR=5.0 per 1,000 PY).
Conclusion: The RESPOND model accurately estimates MA state-specific OUD and fatal
overdose prevalence and is useful for developing treatment priorities for reducing statewide
overdose fatality.
Figure. Projected Fatal Overdose Rates
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5O-6 THE IMPACT OF ALTERNATIVE SPECIFICATIONS OF UNCERTAINTY
RELATING TO EXTRAPOLATION IN DECISION MODELS
Applied Health Economics (AHE)
Doug Coyle, PhD, School of Epidemiology and Public Health, University of Ottawa, Ottawa,
ON, Canada and Kathryn Coyle, BScPharm, MSc, Health Economics Research Group, Brunel
University London, Middlesex, United Kingdom
Purpose:
In economic evaluation, extrapolation is frequently required to allow estimation of unobserved
data based on the relationship between observations relating to a specific parameter and time:
e.g. transition probabilities and treatmentʼs relative effectiveness may be based on short term
clinical trial data. Currently, it is frequently assumed, implicitly, that the uncertainty for the
period with no observed data can be represented by the uncertainty in observed data. This
approach contradicts standard mathematics where the uncertainty around unobserved data should
always be considered greater than observed data. The study evaluates the impact of alternative
approaches to representing the uncertainty around unobserved/extrapolated data with respect to
incremental outcomes and value of information (VoI).
Method:
A simple three state (Moderate, Severe, Dead) Markov model was developed. Extrapolation was
required for the probability of progression to severe disease without treatment and the relative
effect of treatment on progression; both based on a one year clinical trial. In the base case
analysis, the same parameters and uncertainty for both periods was adopted. Three alternative
assumptions were considered relating to the uncertainty in the unobserved period: the same
variance but distinct parameters for each period; a higher variance for the set relating to the
unobserved period; and a variance for the unobserved period which increases with time from the
observed period.
Result:
Regardless of the alternative assumption adopted; the incremental QALYs (0.78, 0.75, 0.75),
incremental costs ($29,276, $28,899, $28,912) and ICER ($37,347, $38,567, $38,559) for the
new treatment from probabilistic analysis were similar to the base case (0.79, $29,389, $37,150).
However, the EVPPI for the clinical trial data was $2,253 per person in the base case; but ranged
from $5 to $186 under the alternative scenarios. With the alternative scenarios, the EVPPI for the
unobserved period ranged from $1,738 to $3,255.
Conclusion:
Economic evaluation which incorporates VoI frequently conclude that the greatest information
value relates to estimates of transition probabilities and clinical effectiveness. However, such
analyses do not distinguish between observed and unobserved periods and are therefore falsely
concluding that “more of the same” clinical data are required. When uncertainty over unobserved
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and observed data are correctly quantified, VoI techniques can demonstrate that there is limited
value to such studies and further studies relating to the unobserved periods are required.
TRA-1-1 DID WE MAKE THE RIGHT DECISION? PARENTS NAVIGATION OF
CRITICAL TREATMENT DECISION(S) FOR THEIR FETUS/NEONATE DIAGNOSED
WITH A LIFE-THREATENING CONGENITAL HEART DEFECT
Decision Psychology and Shared Decision Making (DEC)
Rebecca Delaney, PhD1, Nelangi Pinto, MD, MS1, Elissa Ozanne, PhD1, Heather Coulter,
M.Ed2, Louisa Stark, PhD2, Michelle Karasawa, M.S.1, Angira Patel, MD, MPH3, Mary
Donofrio, MD4, Michelle Steltzer, MSN, APRN, CPNP, AC/PC3, Mingfen Xu, M.S.N.5 and
Angela Fagerlin, PhD6, (1)University of Utah, Salt Lake City, UT, (2)University of Utah Health
Center for Clinical & Translational Science, Salt Lake City, UT, (3)Ann & Robert H. Lurie
Childrenʼs Hospital of Chicago, Chicago, IL, (4)Childrenʼs National Health System,
Washington, DC, (5)Duke University School of Medicine, Durham, NC, (6)University of Utah /
Salt Lake City VA, Salt Lake City, UT
Purpose: Parents of a fetus/neonate diagnosed with a complex, life-threatening congenital heart
defect (cCHD) must make unexpected and challenging medical decisions choosing between
termination, palliative/comfort care, or surgery. The purpose of this qualitative study is to
understand parental experiences and decision-making processes surrounding the initial treatment
decision.
Method: Parents of a fetus/neonate diagnosed with cCHD from four sites across the U.S.
(Chicago, Durham, Salt Lake City, and Washington, DC) were recruited 6 months to 5 years
post-diagnosis. Ten focus groups, lasting approximately 2 hours, were conducted with parents of
a child with cCHD who chose termination or palliative care (5 groups) or surgical intervention (5
groups) to gain insight into experiences around diagnosis, treatment decisions, outcomes, and
daily life. Participants (n=56) were, on average, 34 years old (range= 20-52 years; SD=5.1), 45
were female and 11 were male; 89% identified themselves as White. Focus groups were audiorecorded, transcribed, coded by independent raters and content analyzed to identify prominent
themes.
Result: Key guiding principles in the decision-making process differed among parents. Some
parents reported that their “gut feelings” or religious or spiritual beliefs guided treatment
decisions; while others focused on measurable outcomes (e.g., survival rates). The impact on
quality of life for the child, their other children, and family was another key factor in decisions.
The main barriers parents reported regarding the decision-making process included: 1) difficultly
processing information under emotional circumstances, 2) the need to learn exceedingly complex
information in a short amount of time, and 3) challenges finding quality information. Parents also
reported inconsistencies in treatment options providers discussed, with little to no discussion for
some options and other options presented that did not align with parents’ values.
Conclusion: Parents have trouble processing and understanding important information to make
complex treatment decisions, especially in their distressed state. There is also variability in how
parents make treatment decisions and how treatment options are presented by providers.
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Therefore, we believe that the development of decision support tools and strategies would benefit
parents to ensure that they are informed and help them navigate the challenging decision-making
process. Future work should include developing decision support tools that address barriers to
decision making and help identify parents’ values as a method for improving the medical
decision-making process for cCHD.
TRA-1-2 DETERMINING THE COST-EFFECTIVENESS OF HIV PREVENTION AND
CARE INTERVENTIONS DELIVERED AT PLAUSIBLE SCALE ACROSS SIX U.S.
CITIES: THE IMPACT OF LOCALIZED IMPLEMENTATION
Applied Health Economics (AHE)
Emanuel Krebs, M.A.1, Xiao Zang, MSc1, Benjamin Enns, M.A.1, Czarina Behrends, PhD2,
Carlos Del Rio, MD3, Julia Dombrowski, MD4, Daniel Feaster, PhD5, Kelly Anne Gebo, M.D.,
M.P.H6, Matthew Golden, MD7, Reuben Granich, PhD8, Brandon Marshall, PhD9, Lisa Metsch,
PhD10, Bruce R. Schackman, PhD11, Steven Shoptaw, PhD12, Steffanie Strathdee, PhD13, Bohdan
Nosyk, PhD1 and the Localized Economic Modeling Study Group, (1)Health Economic Research
Unit at the BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, (2)Department of
Healthcare Policy and Research, Weill Cornell Medical College, New York, NY, (3)Hubert
Department of Global Health, Emory Center for AIDS Research, Rollins School of Public Health
of Emory University, Atlanta, GA, (4)Department of Medicine, Division of Allergy and
Infectious Disease, University of Washington, Seattle, WA, (5)Department of Public Health
Sciences, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, (6)Division
of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore,
MD, (7)Department of Medicine/ Division of Allergy & Infectious Disease, adjunct in
Epidemiology, Seattle, WA, (8)Independent Public Health Consultant, Washington, DC,
(9)Brown University School of Public Health, Providence, RI, (10)Department of Sociomedical
Sciences, Mailman School of Public Health, Columbia University, New York, NY,
(11)Department of Healthcare Policy & Research, Weill Cornell Medical College, New York,
NY, (12)School of Medicine, University of California Los Angeles, Los Angeles, CA,
(13)School of Medicine, University of California San Diego Department of Medicine, La Jolla,
CA
Purpose: The President of the United States recently announced the intention to eliminate the
domestic HIV epidemic within 10 years. While effective interventions to reduce the public health
burden of HIV/AIDS are available, these interventions vary substantially in their ability to
deliver value at different levels of scale and in different epidemiological contexts. Our objective
was to determine the cost-effectiveness of HIV treatment and prevention interventions
implemented at plausible scales of delivery in six US cities with diverse HIV microepidemics.
Method: We identified and estimated costs, effectiveness and plausible scale of delivery for 16
evidence-based interventions from the US CDCʼs Compendium of Evidence-Based Interventions
and Best Practices for HIV Prevention and from the published literature. Using a dynamic HIV
transmission model calibrated for Atlanta, Baltimore, Los Angeles (LA), Miami, New York City
(NYC) and Seattle, we estimated averted HIV infections, quality-adjusted life-years (QALYs),
total costs and incremental cost-effectiveness ratios (ICERs) (healthcare perspective; 3% annual
discount rate, 2018$US), for each intervention and city compared to the status quo over a 20-
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year time horizon. Interventions were implemented at plausible scale for a 10-year period. We
performed probabilistic sensitivity analysis using the 2,000 best-fitting calibrated parameter sets
from 10,000 calibration runs, sampling all non-calibrated parameters simultaneously.
Result: We synthesized evidence from 11 peer-reviewed publications, 12 public health and
surveillance reports and 3 publicly available data sets to derive a plausible scale of delivery for
each intervention. We found that increased HIV testing was cost-saving across all cities but
Seattle (Figure 1). Increased medication for opioid use disorders was cost-effective across all
cities, whereas expansion of syringe service programs was cost-saving in Miami and costeffective in Atlanta ($12,000/QALY) and Los Angeles ($22,000/QALY). Targeted pre-exposure
prophylaxis for high-risk men who have sex with men was cost-saving in Miami and costeffective in Atlanta ($6,000/QALY), Baltimore ($8,000/QALY) and LA ($86,000/QALY).
Among ART engagement and re-engagement interventions, those improving ART initiation
provided greater value within each city (ICERs ranged from $24,000/QALY in Baltimore to
$108,000/QALY in LA). No single intervention was projected to reduce HIV incidence by more
than 10.1% in any city.
Conclusion: While a number of HIV interventions could provide substantial value, coordinated,
context-specific combination implementation strategies will be required to meet the newlyestablished national targets for HIV elimination.
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TRA-1-3 IDENTIFYING CITY-LEVEL COMBINATION IMPLEMENTATION
STRATEGIES TO ‘END THE HIV EPIDEMIC IN THE US’: A CASE STUDY USING
ECONOMIC MODELING ACROSS 6 CITIES
Applied Health Economics (AHE)
Bohdan Nosyk, PhD1, Xiao Zang, MSc1, Emanuel Krebs, M.A.1, Benjamin Enns, M.A.1 and
Localized HIV modeling study group, (1)Health Economic Research Unit at the BC Centre for
Excellence in HIV/AIDS, Vancouver, BC, Canada
Purpose: The HIV epidemic in the United States is a collection of diverse local microepidemics,
concentrated primarily in urban centers. Targeted, context-specific strategies will be required to
realize the newly-announced national targets to reduce HIV incidence by 90% within 10 years.
We aim to identify optimal combination implementation strategies to reduce the public health
burden of HIV/AIDS in six US cities comprising 24.1% of all PLHIV in the US.
Methods: Using a dynamic HIV transmission model calibrated with the best-available evidence
on epidemiological and structural conditions for Atlanta, Baltimore, Los Angeles (LA), Miami,
New York City (NYC) and Seattle, we assessed all practical combinations of 16 evidence-based
interventions from the US CDCʼs Compendium of Evidence-Based Interventions and Best
Practices for HIV Prevention and from the published literature. We then estimated health
production functions, representing optimal combination implementation strategies (OCIS)
providing the greatest health benefits for a range of investment levels. Interventions were
implemented at what we estimated to be a plausible scale of delivery (based on best publiclyavailable evidence) and sustained for a period of 10 years, with outcomes evaluated over 20
years to capture long-term individual health benefits and 2nd-order transmission effects. We
estimated averted HIV infections, quality-adjusted life-years (QALYs), total costs and
incremental cost-effectiveness ratios (ICERs) (healthcare perspective; 3% annual discount rate,
2018$US). We performed probabilistic sensitivity analysis to quantify the uncertainty in our
recommended combination implementation strategies.
Results: We assessed 17,279 unique combinations of interventions within each city, identifying
the most cost-effective OCIS compared to the next-most-costly OCIS. The most cost-effective
OCISs contained between 8 (Seattle) and 12 (Atlanta and Miami) interventions. These strategies
produced QALY gains of between 2006 (Seattle) and 22,107 (LA) over the study time horizon at
ICERs ranging from cost-saving (Miami) to 94,846/QALY (Seattle). In no city however were
these strategies estimated to reduce incidence by more than 48.7% (NYC) within 10 years.
Conclusion: An unprecedented effort will be required to bridge the implementation gap in
delivering evidence-based interventions at elevated scale to meet the newly-established national
targets for HIV elimination.

E374

Medical Decision Making 40(1)

TRA-1-4 DIVERSION PROGRAMS FOR LOW-LEVEL DRUG OFFENDERS: HEALTH
OUTCOMES AND COST-EFFECTIVENESS
Applied Health Economics (AHE)
Margaret L. Brandeau, PhD, Department of Management Science and Engineering, Stanford
University, Stanford, CA and Cora Bernard, PhD, Stanford University, Stanford, CA
Purpose: Cycles of incarceration, drug abuse, and poverty undermine ongoing public health
efforts to reduce overdose deaths and the spread of infectious disease in vulnerable populations.
Jail diversion programs aim to divert low-level drug offenders toward community care resources,
avoiding criminal justice costs and disruptions in treatment for HIV, hepatitis C virus (HCV),
and drug abuse. We sought to assess the health benefits and cost-effectiveness of a jail diversion
program for low-level drug offenders.
Methods: We developed a dynamic transmission microsimulation model that captured the
spread of HIV and HCV infections and incarceration and treatment systems as well as preexisting interventions such as needle and syringe programs and opiate agonist therapy, calibrated
to King County, Washington. We considered an adult population of people who inject drugs
(PWID), people who use drugs but do not inject (PWUD), men who have sex with men, and
lower-risk heterosexuals. We projected discounted lifetime costs and quality-adjusted life years
(QALYs) over a ten-year time horizon with and without a jail diversion program and calculated
resulting incremental cost-effectiveness ratios (ICERs) from the health system and societal
perspectives. We also tracked HIV and HCV infections, overdose deaths, and jail population
size.
Results: Over ten years, the program reduced HIV and HCV incidence by 3.4% and 3.3%,
respectively, overdose deaths among people who inject drugs by 10.0%, and jail population size
by 6.3%. When considering healthcare costs only, the program cost $25,500/QALY gained.
Including savings from reduced incarceration (societal perspective) improved the ICER to
$6,200/QALY gained. Sensitivity analysis indicated that cost-effectiveness depends on diversion
program participants accessing community programs such as needle and syringe programs,
substance abuse treatment, and HIV and HCV treatment.
Conclusions: Diversion programs for low-level drug offenders are likely to be cost-effective,
generating savings in the criminal justice system while only moderately increasing healthcare
costs. Such programs have the potential not only to reduce incarceration and its associated costs
but also to avert overdose deaths and improve quality of life for PWID and PWUD, as well as
the broader population (through reduced HIV and HCV transmission). The spread of infectious
disease and the global overcrowding of jails and prisons suggest that, more than ever, effective,
cost-effective, and innovative approaches are required to address these crises.
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TRA-2-1 REPLICATING TEMPORAL OUTCOMES OF AN OPIOID POLICY
SIMULATION MODEL VIA META-MODELING: A DEEP LEARNING APPROACH
Quantitative Methods and Theoretical Developments (QMTD)
Ozden Dalgic, PhD1, Peter Mueller, PhD1, Qiushi Chen, PhD2, Marc LaRochelle, MD3, Anna P.
Lietz, BA4, Claudia Seguin, BA4, Mohammad Jalali, PhD1, Kenneth Freedberg, MD5, Sarah
Wakeman, MD5, Pari Pandharipande, MD, MPH1, Amy Knudsen, PhD1 and Jagpreet Chhatwal,
PhD1, (1)Institute for Technology Assessment, Massachusetts General Hospital, Harvard
Medical School, Boston, MA, (2)Harold and Inge Marcus Department of Industrial and
Manufacturing Engineering, Penn State University, State College, PA, (3)Clinical Addiction
Research and Education Unit, Section of General Internal Medicine, Department of Medicine,
Boston University School of Medicine and Boston Medical Center, Boston, MA, (4)Institute for
Technology Assessment, Massachusetts General Hospital, Boston, MA, (5)Massachusetts
General Hospital, Harvard Medical School, Boston, MA
Purpose: Meta-modeling is an approach for approximating a complex and computationally
intensive simulation model with a “statistical” representation, which can facilitate generating
model outcomes in real time (e.g., for value of information analyses or online decision-support
tools). Though traditional statistical or machine learning methods can generate meta-models of
simpler models, they may fail to capture complex simulation dynamics. Our objective was to
assess how well meta-models using an advanced machine learning approach like deep learning
can replicate temporal outcomes of a complex simulation model.
Method: We created a meta-model of a previously-validated system dynamics model, Opioid
Policy Model (OPyM), that simulates the trajectory of opioid overdose crisis in the United State
from 2002 to 2025. For that purpose, we generated 10,000 simulation outcomes using different
input parameters from OPyM for training the meta-model and another 1,000 for testing the metamodel. We built a deep neural network (DNN) as a deep learning algorithm that included one
input layer (with 17 nodes), four hidden layers (with 32-256 nodes), and one output layer (with
24 nodes). For comparison, we also built two traditional machine learning algorithms: linear
regression (LR) and random forests (RF). By design, DDN and RF may utilize the interrelation
among temporal outcomes to increase their estimation accuracy, whereas LR considers outcome
of each year separately.
Result: Using DNN, we replicated temporal trends in four outcomes: overdose deaths, number
of people using opioids non-medically without opioid use disorder (OUD), those with a
prescription OUD, and those using illicit opioids (Figure1) with OPyM predictions. The mean
absolute percentage error ranged from 0%-3.6% for DNN, 1.6%-45.4% for LR, and 0.3-15.1%
for RF.
Conclusion: An advanced deep-learning algorithm like deep neural networks can closely
replicate temporal outcomes of a complex dynamic simulation model. The resulting meta-model
can be used to generate results in real-time and can facilitate the value of information analysis or
development of an interactive decision-support tool.
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TRA-2-2 NAFLD SIMULATOR: AN INTERACTIVE SIMULATION TOOL FOR
LONG-TERM OUTCOMES OF NON-ALCOHOLIC FATTY LIVER DISEASE
Health Services, Outcomes and Policy Research (HSOP)
Ozden Dalgic, PhD1, Sumeyye Samur, PhD1, Kathleen Corey, MD, MPH2, Emily Bethea, MD3,
Wanyi Chen, PhD1, Rohit Loomba, MD, MHSc4 and Jagpreet Chhatwal, PhD1, (1)Institute for
Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston,
MA, (2)Harvard Medical School, Boston, MA, (3)Liver Center and Gastrointestinal Division,
Massachusetts General Hospital, Boston, MA, (4)University of California San Diego, La Jolla,
CA
Purpose: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease
worldwide, with an estimated prevalence ranging from 25% to 40%. Non-alcoholic
steatohepatitis (NASH), an aggressive form of NAFLD, is projected to become the leading
indication of liver transplantation in the US by 2020. Several potential drugs for NAFLD/NASH
treatment are in early stages of development; however, long-term outcomes of these treatments
will not be known for decades. Our aim was to predict long-term outcomes of NAFLD/NASH
and develop an open-access, interactive tool for patients and providers that help them understand
the long-term adverse outcomes associated with NAFLD.
Methods: We developed an individual-level state-transition model to simulate the life course of
NAFLD patients as they progressed through the different stages of the natural history. Transition
probabilities were derived from published meta-analyses, observational studies, and clinical
trials. Unknown model parameters were estimated through calibration process—we used
simulated annealing for calibration such that model-predicted 20-year survival (equivalent to
139,163 person-years data) matched closely with the outcomes of a large observational study.
Using the calibrated model, we generated 10 million simulated NASH patient profiles and their
outcomes, which were then used it to create an interactive, web-based tool, NAFLD Simulator.
NAFLD Simulator allows users to enter patient demographics and current NAFLD stage, and
predicts survival, mortality due to liver, non-liver, and background and causes, cumulative risk
of hepatocellular carcinoma and cirrhosis.
Results: Figure 1 compares the estimated outcomes for a 50-year old patient having NASH
fibrosis stages F1, F2, F3 and F4. For instance, the 10-year survival in patients with NASH F1,
F2, F3, and F4 was 93%, 91%, 86%, and 69%, respectively. The 10-year non-liver-related
mortality in these patients was 2%, 4%, 8%, and 12%, respectively; and the corresponding liverrelated mortality was 0%, 0.01%, 0.06 and 13.5, respectively. The model also estimated the 10year risk of developing hepatocellular carcinoma increases from 0.6% to 8.8% if patients
progress from F3 to F4 stage.
Conclusions: NAFLD Simulator can closely replicate the outcomes of a large observational
study and provides an innovative platform to disseminate the long-term risk associated with
NAFLD and NASH to patients and providers.
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TRA-2-3 PREDICTING THE EFFECTIVENESS OF INTERVENTIONS FOR
INFECTIOUS DISEASE CONTROL: THE ROLE OF MODEL STRUCTURE
Quantitative Methods and Theoretical Developments (QMTD)
Giovanni Malloy, Stanford University Department of Management Science & Engineering,
Stanford, CA, Jeremy D. Goldhaber-Fiebert, PhD, Stanford Health Policy, Centers for Health
Policy and Primary Care and Outcomes Research, Stanford University, Stanford, CA, Eva A.
Enns, MS, PhD, Division of Health Policy and Management, University of Minnesota School of
Public Health, Minneapolis, MN and Margaret L. Brandeau, PhD, Department of Management
Science and Engineering, Stanford University, Stanford, CA
Purpose: Many infectious disease policy decisions hinge on estimates of magnitudes and rates
of intervention impacts. These impacts are often estimated using dynamic transmission models.
We aim to characterize how the choice of model can influence estimates of intervention impacts
over both short- and long-term time horizons.
Methods: We characterize dynamic transmission models along two dimensions: 1)
homogeneous vs. heterogeneous levels of individual risk behaviors; and 2) contact network vs.
mass-action mixing model of transmission. We define the reference model as a contact network
with heterogeneous risk levels. We use this model to simulate the long-term equilibrium disease
prevalence. We then define simpler models on one or both dimensions, calibrating to the same
long-term equilibrium prevalence as the reference model. We conduct a structural sensitivity
analysis considering an intervention with 100% coverage that reduces the probability of
transmission per contact by 50%. We measure long-term intervention impacts over 5,000 days.
Results: The stable equilibrium disease prevalence of the mass-action mixing model with
heterogeneous risk levels reaches 0% by 5,000 days (Panel 1), while that of the network model
with heterogeneous risk levels reaches 0.9% (Panel 2). The mass-action mixing model predicts a
larger magnitude of intervention impact because an intervention affects the entire population
uniformly. Each model reaches stable disease prevalence at different rates: the mass-action
mixing model with heterogeneous risk reaches an overall disease prevalence of under 0.01%
after 1,550 days, whereas the network model with heterogeneous risk reaches an overall disease
prevalence of 0.9% after 4,450 days. The rate of intervention impact is slower in the network
model because the intervention must propagate via individuals. Finally, 5,000 days after
intervention, in the mass-action mixing model the prevalence among both risk groups decreases
by 100% and in the network model, prevalence among high-risk individuals decreases by 95%
and among low-risk individuals decreases by 89%.
Conclusions: Despite producing equivalent results in the absence of intervention, different
models can lead to different estimates of magnitudes and rates of intervention impact. Our results
highlight the importance of choices regarding model structure and complexity when estimating
intervention impacts. By abstracting away the underlying contact network structure, simpler
mass-action mixing models can greatly overestimate the population health impacts of
interventions as well as the speed of those impacts.
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TRA-2-4 CALIBRATION TO CROSS-SECTIONAL DATA WHEN BIRTH COHORT
TRENDS EXIST AS EXEMPLIFIED BY MODELS OF HEAVY DRINKING IN CHINA:
CONSISTENCY WITH CALIBRATION TARGETS DESPITE MARKEDLY
DIFFERENT PARAMETERS AND FUTURE PROJECTIONS
Quantitative Methods and Theoretical Developments (QMTD)
Kyueun Lee, Stanford University, Stanford, CA, Joshua Salomon, Ph.D., Center for Health
Policy and Center for Primary Care and Outcomes Research, Stanford, CA and Jeremy D.
Goldhaber-Fiebert, PhD, Stanford Health Policy, Centers for Health Policy and Primary Care
and Outcomes Research, Stanford University, Stanford, CA
Purpose:
Calibration infers parameter values that generate model estimates consistent with observed data,
enabling credible future projections and policy evaluation. Current modeling studies frequently
employ cross-sectional data as calibration targets, assuming no cohort trends in risk behaviors or
disease natural history. Using the example of high-risk drinking in China, we illustrate how this
assumption can lead to drastically different calibrated parameters, future burden projections, and
intervention effect estimates when compared to calibration that employs cohort-specific
parameters.
Methods:
We modeled heavy drinking among Chinese men using a 4-state Markov model: never-heavy
drinkers, heavy-drinkers, non-heavy drinkers, and dead. For birth cohort (BC) calibration, we
used longitudinal data (1993-2011) from Chinese Nutrition and Surveys as targets and calibrated
age-specific rates of initiating/resuming and stopping drinking in each cohort. Cross-sectional
(CS) calibration used 1-year cross-sectional data as targets. We measured each calibration
methodʼs performance (sum of squared errors, SSE) to predict heavy drinking prevalence in
2015. We also compared the change in prevalence when a mitigation policy halted a birth
cohortʼs initiation and resumption of heavy drinking from 2015 through 2027 using BC- or CSderived parameters.
Results:
Both BC and CS calibration methods generated age-specific heavy drinking prevalence
concordant with past observations. Notably, the scale and age-patterns of quitting rates differed
between BC and CS calibration (Panels A1, A2). BC calibrated models performed better in
projecting prevalence in 2015 (SSE = 0.62) than CS calibration for any year (SSE varying from
0.80 to 7.58). While CS calibration for the most recent year had better fit than CS calibration for
other years, temporal proximity did not monotonically predict projective validity (Panel B). All
the models that used CS calibration estimated intervention effects that were >2 times larger than
with BC calibration (Panel C) because BC calibration projected slowly declining prevalence even
in the absence of intervention. Notably, even CS calibration to 2011 data, which had projective
validity similar to BC calibration, projected substantially larger policy effects (Panel C).
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Conclusions:
Calibration to cross-sectional data is often necessitated when cohort-specific data are
unavailable. Even when cross-sectional calibration generates estimates consistent with past and
near future observations, it can still produce divergent future projections and intervention effect
estimates when secular trends exist. If cross-sectional calibration is necessary, cohort
assumptions should be carefully evaluated.

